data_1ps2_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1ps2 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.1 m . . . . . 0 CA--C 1.531 0.248 0 CA-C-O 121.139 0.495 . . . . 1.0 109.715 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 75.1 m -113.22 -14.19 12.89 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.498 -0.751 . . . . 1.0 109.594 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.8 t -71.19 96.44 1.38 Allowed 'General case' 0 CA--C 1.53 0.211 0 O-C-N 121.286 -0.884 . . . . 1.0 109.658 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 39.4 t -119.35 168.98 11.01 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 O-C-N 121.465 -0.772 . . . . 1.0 109.074 179.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.21 121.27 73.53 Favored Pre-proline 0 CA--C 1.542 0.65 0 O-C-N 121.386 -0.821 . . . . 1.0 109.17 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_exo -36.95 -47.43 1.46 Allowed 'Trans proline' 0 N--CA 1.49 1.281 0 C-N-CA 124.917 3.745 . . . . 1.0 111.334 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -75.88 -39.44 56.44 Favored 'General case' 0 N--CA 1.463 0.208 0 O-C-N 121.466 -0.771 . . . . 1.0 109.745 -179.775 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -84.33 38.38 0.67 Allowed 'General case' 0 N--CA 1.462 0.162 0 O-C-N 121.399 -0.813 . . . . 1.0 109.565 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 18.6 mtt180 -104.82 145.64 30.1 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.446 -0.784 . . . . 1.0 109.407 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 10.1 mp0 -94.69 120.6 35.17 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 121.542 -0.724 . . . . 1.0 109.36 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -63.63 120.34 11.59 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.457 -0.777 . . . . 1.0 109.817 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.412 ' HA ' ' CE2' ' A' ' 46' ' ' TYR . 44.3 t -94.65 -17.77 21.97 Favored 'General case' 0 CA--C 1.535 0.385 0 O-C-N 121.574 -0.704 . . . . 1.0 109.329 179.716 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 177.15 175.44 44.43 Favored Glycine 0 CA--C 1.529 0.939 0 N-CA-C 109.404 -1.479 . . . . 1.0 109.404 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.424 ' CE2' HG11 ' A' ' 22' ' ' VAL . 9.5 p90 -64.61 167.95 7.84 Favored Pre-proline 0 CA--C 1.538 0.512 0 O-C-N 121.383 -1.069 . . . . 1.0 109.063 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.33 -31.36 1.25 Allowed 'Trans proline' 0 N--CA 1.483 0.905 0 C-N-CA 124.341 3.361 . . . . 1.0 110.643 -178.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.75 -7.91 6.95 Favored Glycine 0 CA--C 1.537 1.438 0 N-CA-C 110.294 -1.122 . . . . 1.0 110.294 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.424 HG11 ' CE2' ' A' ' 19' ' ' PHE . 17.4 m -60.17 -178.97 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 O-C-N 121.208 -1.172 . . . . 1.0 109.742 179.762 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 12.0 p -138.5 155.08 73.88 Favored Pre-proline 0 CA--C 1.536 0.43 0 O-C-N 121.513 -0.742 . . . . 1.0 109.276 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -36.05 -36.45 0.2 Allowed 'Trans proline' 0 N--CA 1.488 1.187 1 C-N-CA 125.368 4.045 . . . . 1.0 111.316 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 42.1 t -73.99 -46.07 46.1 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.405 -0.809 . . . . 1.0 109.874 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 38.0 mt-30 -60.57 -48.63 80.91 Favored 'General case' 0 N--CA 1.464 0.258 0 O-C-N 121.468 -0.77 . . . . 1.0 109.988 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.7 t -65.11 -27.73 68.95 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.409 -0.807 . . . . 1.0 109.497 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.34 -5.26 58.42 Favored 'General case' 0 CA--C 1.535 0.38 0 O-C-N 121.547 -0.721 . . . . 1.0 109.846 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.0 t-20 -70.83 -49.45 46.17 Favored 'General case' 0 N--CA 1.463 0.181 0 O-C-N 121.408 -0.808 . . . . 1.0 109.363 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.448 ' HG2' ' H ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -83.64 -44.7 14.27 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.534 -0.729 . . . . 1.0 109.432 179.889 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.448 ' H ' ' HG2' ' A' ' 30' ' ' LYS . . . 125.65 32.45 0.76 Allowed Glycine 0 CA--C 1.531 1.075 0 N-CA-C 109.958 -1.257 . . . . 1.0 109.958 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.5 m -92.26 144.7 25.13 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.43 -1.041 . . . . 1.0 109.301 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.402 ' O ' ' CD1' ' A' ' 45' ' ' PHE . 60.0 m -66.51 115.4 6.35 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.462 -0.774 . . . . 1.0 109.516 -179.814 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -94.6 132.01 39.76 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.38 -0.825 . . . . 1.0 109.33 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -144.2 111.12 5.74 Favored 'General case' 0 CA--C 1.53 0.19 0 O-C-N 121.425 -0.797 . . . . 1.0 109.481 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.425 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.0 p-10 -115.34 70.42 0.74 Allowed 'General case' 0 CA--C 1.534 0.334 0 O-C-N 121.509 -0.745 . . . . 1.0 109.414 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 43.9 p -114.45 -39.35 3.84 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.429 -0.794 . . . . 1.0 109.471 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.9 t -111.95 167.93 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 O-C-N 121.519 -0.738 . . . . 1.0 109.401 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.41 ' C ' ' H ' ' A' ' 41' ' ' VAL . 4.9 ttm180 -113.31 175.99 5.22 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.432 -0.793 . . . . 1.0 109.432 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.51 -37.33 2.25 Favored Glycine 0 CA--C 1.53 0.996 0 N-CA-C 109.41 -1.476 . . . . 1.0 109.41 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.41 ' H ' ' C ' ' A' ' 39' ' ' ARG . 28.9 m -94.66 170.39 8.16 Favored Pre-proline 0 CA--C 1.536 0.431 0 O-C-N 121.571 -0.958 . . . . 1.0 109.174 179.808 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_endo -85.68 139.31 6.57 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 124.628 3.552 . . . . 1.0 109.937 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.425 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 11.2 m0 -89.22 -41.05 12.44 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 121.502 -0.749 . . . . 1.0 110.028 -179.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 18.5 t -89.31 107.43 19.06 Favored 'General case' 0 N--CA 1.465 0.309 0 O-C-N 121.426 -0.797 . . . . 1.0 109.719 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.417 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 9.5 p90 -135.05 173.81 11.31 Favored 'General case' 0 CA--C 1.537 0.479 0 O-C-N 121.346 -0.846 . . . . 1.0 109.633 179.59 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.417 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 90.8 m-85 -82.11 167.38 31.04 Favored Pre-proline 0 CA--C 1.536 0.419 0 O-C-N 121.493 -0.755 . . . . 1.0 109.716 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -89.65 161.52 5.26 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 124.998 3.799 . . . . 1.0 110.424 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 . . . . . 0 CA--C 1.531 0.216 0 O-C-N 121.549 -0.719 . . . . 1.0 109.388 179.949 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.53 0.181 0 N-CA-C 109.383 -0.599 . . . . 1.0 109.383 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.4 ' HB3' ' CZ ' ' A' ' 45' ' ' PHE . 62.8 m -125.91 31.49 5.46 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.488 -0.758 . . . . 1.0 109.022 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.414 ' H ' HG21 ' A' ' 8' ' ' THR . 5.1 t -96.08 118.9 33.58 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.657 -0.652 . . . . 1.0 109.556 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 34.2 t -149.92 156.21 7.24 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.206 0 O-C-N 121.495 -0.753 . . . . 1.0 109.236 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -74.07 136.72 76.04 Favored Pre-proline 0 CA--C 1.54 0.59 0 O-C-N 121.482 -0.761 . . . . 1.0 109.308 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -35.05 -41.05 0.28 Allowed 'Trans proline' 0 N--CA 1.488 1.171 1 C-N-CA 125.361 4.041 . . . . 1.0 111.305 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.7 mtt180 -80.95 -44.61 17.95 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.543 -0.723 . . . . 1.0 109.759 -179.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -74.56 10.46 1.34 Allowed 'General case' 0 CA--C 1.533 0.326 0 O-C-N 121.417 -0.802 . . . . 1.0 109.975 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 24.2 mtt180 -81.25 124.37 29.26 Favored 'General case' 0 CA--C 1.529 0.164 0 O-C-N 121.34 -0.85 . . . . 1.0 109.361 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 25.5 mm100 -92.56 126.76 37.79 Favored 'General case' 0 N--CA 1.463 0.197 0 O-C-N 121.463 -0.773 . . . . 1.0 109.025 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.2 t-20 -72.23 116.68 12.95 Favored 'General case' 0 CA--C 1.532 0.286 0 O-C-N 121.604 -0.685 . . . . 1.0 109.942 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -83.55 -6.97 59.6 Favored 'General case' 0 CA--C 1.537 0.447 0 O-C-N 121.53 -0.731 . . . . 1.0 109.208 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.84 170.0 37.42 Favored Glycine 0 CA--C 1.532 1.097 0 N-CA-C 108.353 -1.899 . . . . 1.0 108.353 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD2' HG11 ' A' ' 22' ' ' VAL . 7.5 p90 -62.52 168.33 4.35 Favored Pre-proline 0 CA--C 1.54 0.56 0 O-C-N 121.208 -1.172 . . . . 1.0 109.043 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -81.36 -30.25 1.61 Allowed 'Trans proline' 0 N--CA 1.481 0.785 0 C-N-CA 124.304 3.336 . . . . 1.0 110.677 -178.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.23 -6.82 8.12 Favored Glycine 0 CA--C 1.536 1.374 0 N-CA-C 110.052 -1.219 . . . . 1.0 110.052 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.431 HG11 ' CD2' ' A' ' 19' ' ' PHE . 29.2 m -60.25 -176.31 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 O-C-N 121.157 -1.202 . . . . 1.0 109.816 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 10.6 p -137.38 155.95 75.36 Favored Pre-proline 0 CA--C 1.535 0.368 0 O-C-N 121.51 -0.744 . . . . 1.0 109.13 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_exo -37.47 -42.24 1.08 Allowed 'Trans proline' 0 N--CA 1.488 1.176 0 C-N-CA 125.188 3.926 . . . . 1.0 111.001 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 80.3 p -69.45 -42.76 74.51 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.524 -0.735 . . . . 1.0 110.118 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -65.61 -53.92 34.91 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.401 -0.812 . . . . 1.0 109.909 -179.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 18.9 t -62.04 -19.71 63.17 Favored 'General case' 0 CA--C 1.534 0.357 0 O-C-N 121.409 -0.807 . . . . 1.0 109.934 -179.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -100.54 -3.56 30.41 Favored 'General case' 0 CA--C 1.535 0.378 0 O-C-N 121.356 -0.84 . . . . 1.0 110.154 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -73.78 -44.07 57.09 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.395 -0.815 . . . . 1.0 109.855 -179.476 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.9 tttm -86.26 -41.39 14.64 Favored 'General case' 0 N--CA 1.462 0.154 0 O-C-N 121.43 -0.794 . . . . 1.0 109.662 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 127.27 19.71 1.88 Allowed Glycine 0 CA--C 1.53 1.031 0 N-CA-C 109.473 -1.451 . . . . 1.0 109.473 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 60.8 m -77.39 140.42 39.91 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.43 -1.041 . . . . 1.0 109.028 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 84.5 m -66.87 123.09 19.2 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.414 -0.803 . . . . 1.0 109.647 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -96.51 147.78 23.49 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.439 -0.788 . . . . 1.0 109.162 179.653 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -161.72 135.12 6.38 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.384 -0.822 . . . . 1.0 109.486 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -133.17 38.24 3.34 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.515 -0.741 . . . . 1.0 109.471 179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 59.9 p -72.05 -58.7 3.22 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.48 -0.763 . . . . 1.0 109.541 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.0 t -110.07 138.12 39.26 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 O-C-N 121.429 -0.794 . . . . 1.0 109.408 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -83.62 178.03 8.15 Favored 'General case' 0 CA--C 1.53 0.19 0 O-C-N 121.496 -0.752 . . . . 1.0 109.247 179.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.56 -45.73 3.15 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 109.339 -1.504 . . . . 1.0 109.339 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 26.7 m -84.43 157.33 61.84 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.647 -0.914 . . . . 1.0 109.325 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -59.63 129.24 30.06 Favored 'Trans proline' 0 N--CA 1.488 1.164 0 C-N-CA 124.164 3.243 . . . . 1.0 110.308 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . . . . . . . . . 40.4 m0 -87.27 -45.87 10.22 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.521 -0.737 . . . . 1.0 109.173 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 27.4 t -89.92 110.42 21.37 Favored 'General case' 0 CA--C 1.534 0.338 0 O-C-N 121.493 -0.755 . . . . 1.0 108.978 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.433 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 5.2 p90 -134.1 175.87 9.09 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 121.302 -0.874 . . . . 1.0 110.257 -179.371 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.41 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 21.5 m-85 -82.18 171.33 12.18 Favored Pre-proline 0 CA--C 1.537 0.47 0 O-C-N 121.523 -0.735 . . . . 1.0 109.522 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -90.84 -166.39 0.19 Allowed 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 124.939 3.759 . . . . 1.0 110.102 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.4 m120 . . . . . 0 N--CA 1.463 0.192 0 O-C-N 121.478 -0.763 . . . . 1.0 109.509 179.943 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.7 m . . . . . 0 CA--C 1.532 0.263 0 N-CA-C 109.763 -0.458 . . . . 1.0 109.763 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 90.5 m -89.62 -15.82 31.91 Favored 'General case' 0 CA--C 1.533 0.326 0 O-C-N 121.311 -0.868 . . . . 1.0 109.493 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.8 t -71.31 112.45 7.45 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.429 -0.795 . . . . 1.0 109.907 -179.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 42.0 t -127.87 167.33 23.08 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.264 0 N-CA-C 108.84 -0.8 . . . . 1.0 108.84 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -71.67 125.41 91.7 Favored Pre-proline 0 CA--C 1.542 0.644 0 O-C-N 121.36 -0.838 . . . . 1.0 109.118 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_exo -36.84 -50.36 1.43 Allowed 'Trans proline' 0 N--CA 1.489 1.263 0 C-N-CA 124.899 3.732 . . . . 1.0 111.209 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 18.7 ptt180 -73.8 -38.86 64.48 Favored 'General case' 0 N--CA 1.463 0.195 0 O-C-N 121.487 -0.758 . . . . 1.0 109.763 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -92.29 43.03 1.12 Allowed 'General case' 0 CA--C 1.532 0.253 0 O-C-N 121.405 -0.81 . . . . 1.0 109.574 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 15.0 mtt180 -105.71 131.98 52.4 Favored 'General case' 0 CA--C 1.531 0.235 0 O-C-N 121.405 -0.81 . . . . 1.0 109.437 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -79.57 107.64 12.5 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 108.557 -0.905 . . . . 1.0 108.557 179.456 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 29.5 t30 -61.98 108.54 1.06 Allowed 'General case' 0 N--CA 1.464 0.245 0 O-C-N 121.557 -0.714 . . . . 1.0 110.085 -179.336 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.5 t -76.78 -21.75 54.71 Favored 'General case' 0 CA--C 1.533 0.318 0 O-C-N 121.5 -0.75 . . . . 1.0 109.229 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -175.46 179.56 46.6 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 109.145 -1.582 . . . . 1.0 109.145 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.433 ' CD2' HG12 ' A' ' 22' ' ' VAL . 8.9 p90 -64.81 167.49 9.13 Favored Pre-proline 0 CA--C 1.538 0.489 0 O-C-N 121.398 -1.06 . . . . 1.0 109.0 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -81.19 -30.93 1.42 Allowed 'Trans proline' 0 N--CA 1.482 0.806 0 C-N-CA 124.351 3.367 . . . . 1.0 110.715 -178.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.84 -8.41 7.89 Favored Glycine 0 CA--C 1.537 1.457 0 N-CA-C 110.305 -1.118 . . . . 1.0 110.305 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.433 HG12 ' CD2' ' A' ' 19' ' ' PHE . 25.7 m -60.62 -171.21 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 O-C-N 121.194 -1.18 . . . . 1.0 109.864 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.448 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 19.9 p -150.09 157.27 37.64 Favored Pre-proline 0 CA--C 1.534 0.361 0 N-CA-C 109.18 -0.674 . . . . 1.0 109.18 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_exo -34.91 -36.37 0.12 Allowed 'Trans proline' 0 N--CA 1.488 1.193 1 C-N-CA 125.599 4.199 . . . . 1.0 111.383 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.4 t -76.41 -47.21 23.93 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.434 -0.791 . . . . 1.0 109.865 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLN . . . . . 0.448 ' HB2' ' H ' ' A' ' 23' ' ' THR . 2.2 mm100 -60.93 -44.05 97.76 Favored 'General case' 0 N--CA 1.465 0.293 0 O-C-N 121.433 -0.792 . . . . 1.0 109.925 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 7.5 t -64.72 -33.4 75.87 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.443 -0.786 . . . . 1.0 109.346 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.48 -5.55 59.28 Favored 'General case' 0 CA--C 1.534 0.358 0 O-C-N 121.556 -0.715 . . . . 1.0 109.935 179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 12.2 t-20 -64.84 -32.6 74.37 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.32 -0.862 . . . . 1.0 109.618 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.3 mtmm -105.79 -39.52 6.02 Favored 'General case' 0 C--N 1.332 -0.183 0 O-C-N 121.456 -0.777 . . . . 1.0 109.403 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 125.6 27.55 1.16 Allowed Glycine 0 CA--C 1.53 1.012 0 N-CA-C 109.862 -1.295 . . . . 1.0 109.862 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.8 m -91.09 147.69 22.89 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.326 -1.103 . . . . 1.0 109.16 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.429 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 57.4 m -70.33 139.6 52.06 Favored 'General case' 0 CA--C 1.532 0.266 0 O-C-N 121.371 -0.831 . . . . 1.0 109.333 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -119.21 119.7 34.87 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.463 -0.773 . . . . 1.0 109.332 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -132.67 120.1 21.29 Favored 'General case' 0 CA--C 1.529 0.167 0 O-C-N 121.533 -0.729 . . . . 1.0 109.667 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.41 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.0 p-10 -116.32 77.27 1.08 Allowed 'General case' 0 N--CA 1.463 0.197 0 O-C-N 121.442 -0.786 . . . . 1.0 109.233 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 82.2 p -114.54 -38.37 4.05 Favored 'General case' 0 CA--C 1.53 0.183 0 O-C-N 121.446 -0.784 . . . . 1.0 109.543 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 38.3 t -117.36 148.51 20.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.205 0 O-C-N 121.442 -0.786 . . . . 1.0 109.411 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 22.5 mtp180 -94.65 -179.08 4.76 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.5 -0.75 . . . . 1.0 109.5 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.07 6.71 13.89 Favored Glycine 0 CA--C 1.532 1.149 0 N-CA-C 109.992 -1.243 . . . . 1.0 109.992 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.0 m -130.59 169.35 13.81 Favored Pre-proline 0 CA--C 1.536 0.415 0 O-C-N 121.359 -1.083 . . . . 1.0 109.203 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -87.74 130.03 2.63 Favored 'Trans proline' 0 N--CA 1.48 0.708 0 C-N-CA 124.693 3.595 . . . . 1.0 110.117 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.41 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.3 m0 -91.95 -47.83 7.09 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.505 -0.747 . . . . 1.0 109.733 -179.567 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 18.6 t -78.07 107.81 10.9 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 121.527 -0.733 . . . . 1.0 109.646 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.429 ' CE1' ' HB2' ' A' ' 33' ' ' CYS . 3.3 p90 -139.42 -175.93 4.36 Favored 'General case' 0 N--CA 1.465 0.314 0 O-C-N 121.515 -0.74 . . . . 1.0 109.393 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -91.57 163.85 26.68 Favored Pre-proline 0 CA--C 1.537 0.477 0 O-C-N 121.411 -0.806 . . . . 1.0 110.029 -179.404 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -90.18 172.84 3.5 Favored 'Trans proline' 0 C--N 1.352 0.744 0 C-N-CA 124.97 3.78 . . . . 1.0 110.718 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 . . . . . 0 CA--C 1.531 0.217 0 O-C-N 121.433 -0.792 . . . . 1.0 109.412 179.944 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.4 m . . . . . 0 CA--C 1.53 0.176 0 CA-C-O 121.153 0.501 . . . . 1.0 110.161 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 96.2 m -108.54 -18.14 13.8 Favored 'General case' 0 CA--C 1.536 0.408 0 O-C-N 121.503 -0.748 . . . . 1.0 109.184 179.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.2 t -70.15 108.35 4.09 Favored 'General case' 0 CA--C 1.533 0.297 0 O-C-N 121.106 -0.996 . . . . 1.0 109.329 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.446 HG23 HD21 ' A' ' 48' ' ' ASN . 26.7 t -132.99 173.46 14.8 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.248 0 O-C-N 121.334 -0.854 . . . . 1.0 109.323 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.432 ' H ' ' CG1' ' A' ' 9' ' ' VAL . . . -69.14 122.81 86.62 Favored Pre-proline 0 CA--C 1.539 0.542 0 O-C-N 121.461 -0.774 . . . . 1.0 109.235 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -37.62 -33.92 0.24 Allowed 'Trans proline' 0 N--CA 1.488 1.198 0 C-N-CA 124.774 3.65 . . . . 1.0 111.229 -179.799 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 15.2 ptt180 -78.55 -46.88 18.42 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.469 -0.769 . . . . 1.0 109.766 -179.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 21.0 mm-40 -82.73 40.97 0.7 Allowed 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.405 -0.809 . . . . 1.0 109.434 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 54.0 mtt180 -104.1 142.95 33.57 Favored 'General case' 0 C--N 1.331 -0.214 0 O-C-N 121.526 -0.734 . . . . 1.0 109.569 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 mm-40 -92.59 111.33 22.88 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.426 -0.796 . . . . 1.0 109.195 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -60.33 110.34 1.22 Allowed 'General case' 0 CA--C 1.533 0.303 0 O-C-N 121.362 -0.836 . . . . 1.0 110.121 -179.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.4 t -86.65 -16.4 36.74 Favored 'General case' 0 CA--C 1.533 0.323 0 O-C-N 121.485 -0.76 . . . . 1.0 109.442 179.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.64 179.28 44.19 Favored Glycine 0 CA--C 1.531 1.075 0 N-CA-C 109.506 -1.438 . . . . 1.0 109.506 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.425 ' CE2' HG11 ' A' ' 22' ' ' VAL . 9.6 p90 -65.13 168.0 8.56 Favored Pre-proline 0 CA--C 1.538 0.492 0 O-C-N 121.468 -1.019 . . . . 1.0 109.018 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.43 -30.98 1.32 Allowed 'Trans proline' 0 N--CA 1.484 0.918 0 C-N-CA 124.4 3.4 . . . . 1.0 110.671 -178.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.42 -10.28 7.51 Favored Glycine 0 CA--C 1.537 1.41 0 N-CA-C 110.356 -1.098 . . . . 1.0 110.356 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.425 HG11 ' CE2' ' A' ' 19' ' ' PHE . 18.0 m -60.74 169.71 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 O-C-N 121.205 -1.174 . . . . 1.0 109.611 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 29.2 p -128.35 155.45 78.45 Favored Pre-proline 0 CA--C 1.535 0.387 0 O-C-N 121.517 -0.739 . . . . 1.0 109.38 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_exo -36.33 -37.35 0.26 Allowed 'Trans proline' 0 N--CA 1.489 1.237 1 C-N-CA 125.341 4.027 . . . . 1.0 111.186 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 4.5 m -69.91 -47.38 62.69 Favored 'General case' 0 N--CA 1.463 0.206 0 O-C-N 121.351 -0.843 . . . . 1.0 109.79 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 7.5 mm100 -61.49 -49.88 75.0 Favored 'General case' 0 CA--C 1.533 0.302 0 O-C-N 121.41 -0.806 . . . . 1.0 109.842 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.8 t -64.97 -27.49 68.87 Favored 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.431 -0.793 . . . . 1.0 109.439 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.29 -8.91 57.38 Favored 'General case' 0 CA--C 1.534 0.344 0 O-C-N 121.5 -0.75 . . . . 1.0 109.821 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -91.38 -28.0 17.98 Favored 'General case' 0 CA--C 1.529 0.14 0 O-C-N 121.37 -0.831 . . . . 1.0 109.405 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -89.65 -29.15 19.0 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.471 -0.768 . . . . 1.0 109.441 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.04 45.64 2.02 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 109.771 -1.332 . . . . 1.0 109.771 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 2.0 m -121.42 142.95 49.52 Favored 'General case' 0 N--CA 1.465 0.29 0 O-C-N 121.496 -1.002 . . . . 1.0 109.303 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 46.8 m -63.32 113.66 3.35 Favored 'General case' 0 N--CA 1.466 0.332 0 O-C-N 121.4 -0.812 . . . . 1.0 109.39 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 48.7 t80 -90.36 137.19 32.55 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.43 -0.794 . . . . 1.0 109.126 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -151.02 106.86 3.41 Favored 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.47 -0.769 . . . . 1.0 109.676 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.425 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 2.1 p30 -107.09 48.55 0.83 Allowed 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.491 -0.756 . . . . 1.0 109.245 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 16.8 p -81.34 -52.28 7.46 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.519 -0.738 . . . . 1.0 109.361 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.8 t -114.14 145.39 20.03 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 O-C-N 121.589 -0.694 . . . . 1.0 109.383 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -88.35 179.66 6.29 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.539 -0.726 . . . . 1.0 109.449 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.45 -49.91 4.12 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 109.278 -1.529 . . . . 1.0 109.278 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 27.6 m -79.79 171.16 13.15 Favored Pre-proline 0 CA--C 1.538 0.502 0 O-C-N 121.588 -0.948 . . . . 1.0 109.041 179.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -84.17 127.41 3.99 Favored 'Trans proline' 0 N--CA 1.48 0.724 0 C-N-CA 124.383 3.389 . . . . 1.0 110.003 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.425 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 11.0 m0 -82.83 -39.85 21.12 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.594 -0.691 . . . . 1.0 110.104 -179.129 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.5 t -89.46 108.38 19.61 Favored 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.325 -0.859 . . . . 1.0 109.597 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.426 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 15.0 p90 -135.92 175.9 9.17 Favored 'General case' 0 CA--C 1.538 0.496 0 O-C-N 121.438 -0.789 . . . . 1.0 109.58 179.647 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.426 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 37.5 m-85 -84.61 166.99 29.45 Favored Pre-proline 0 CA--C 1.536 0.422 0 O-C-N 121.274 -0.891 . . . . 1.0 110.061 -179.539 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -88.92 159.7 6.01 Favored 'Trans proline' 0 C--N 1.353 0.779 0 C-N-CA 124.868 3.712 . . . . 1.0 110.538 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.446 HD21 HG23 ' A' ' 9' ' ' VAL . 59.7 m-80 . . . . . 0 CA--C 1.531 0.242 0 O-C-N 121.525 -0.734 . . . . 1.0 109.406 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.5 m . . . . . 0 CA--C 1.531 0.219 0 CA-C-O 121.184 0.516 . . . . 1.0 110.016 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 98.6 m -104.02 45.33 0.97 Allowed 'General case' 0 CA--C 1.534 0.358 0 O-C-N 121.429 -0.794 . . . . 1.0 108.934 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.8 t -110.83 108.98 18.99 Favored 'General case' 0 CA--C 1.532 0.262 0 O-C-N 121.19 -0.944 . . . . 1.0 109.877 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 38.5 t -135.39 160.9 40.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 O-C-N 121.441 -0.787 . . . . 1.0 109.114 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -79.55 115.59 54.54 Favored Pre-proline 0 CA--C 1.541 0.606 0 O-C-N 121.434 -0.791 . . . . 1.0 109.382 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -38.23 -28.79 0.13 Allowed 'Trans proline' 0 N--CA 1.49 1.277 0 C-N-CA 124.664 3.576 . . . . 1.0 111.108 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 -66.94 -64.92 0.75 Allowed 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.489 -0.757 . . . . 1.0 109.691 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -90.56 44.4 1.2 Allowed 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.499 -0.751 . . . . 1.0 109.542 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 21.7 mtt180 -86.11 143.16 28.19 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.476 -0.765 . . . . 1.0 109.516 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -92.87 108.1 19.73 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 109.021 -0.733 . . . . 1.0 109.021 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -62.49 122.59 16.15 Favored 'General case' 0 CA--C 1.532 0.278 0 O-C-N 121.517 -0.739 . . . . 1.0 109.984 -179.709 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 t -88.94 -13.33 39.25 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 109.06 -0.718 . . . . 1.0 109.06 179.434 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 177.28 177.54 46.25 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 108.645 -1.782 . . . . 1.0 108.645 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.433 ' CE2' HG11 ' A' ' 22' ' ' VAL . 8.2 p90 -64.35 167.62 8.08 Favored Pre-proline 0 CA--C 1.54 0.585 0 O-C-N 121.24 -1.153 . . . . 1.0 109.064 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -81.22 -30.38 1.62 Allowed 'Trans proline' 0 N--CA 1.483 0.858 0 C-N-CA 124.347 3.365 . . . . 1.0 110.84 -178.684 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.92 -10.16 8.28 Favored Glycine 0 CA--C 1.537 1.423 0 N-CA-C 110.192 -1.163 . . . . 1.0 110.192 179.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.433 HG11 ' CE2' ' A' ' 19' ' ' PHE . 23.6 m -62.01 169.14 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 O-C-N 121.257 -1.143 . . . . 1.0 109.727 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 71.8 p -127.41 157.52 72.52 Favored Pre-proline 0 CA--C 1.534 0.361 0 N-CA-C 108.702 -0.851 . . . . 1.0 108.702 179.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -34.88 -36.12 0.12 Allowed 'Trans proline' 0 N--CA 1.489 1.255 1 C-N-CA 125.364 4.043 . . . . 1.0 111.315 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.7 p -72.83 -48.37 38.3 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.469 -0.769 . . . . 1.0 109.931 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 53.1 mt-30 -65.17 -44.01 89.89 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.542 -0.724 . . . . 1.0 110.07 -179.634 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 9.1 t -61.3 -31.85 71.7 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 121.303 -0.873 . . . . 1.0 109.855 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.19 -1.5 48.17 Favored 'General case' 0 CA--C 1.535 0.373 0 O-C-N 121.433 -0.792 . . . . 1.0 110.137 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -69.95 -28.49 65.61 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 121.349 -0.845 . . . . 1.0 110.255 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.29 -36.9 5.68 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 121.249 -0.907 . . . . 1.0 109.857 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 126.76 55.71 0.14 Allowed Glycine 0 CA--C 1.531 1.057 0 N-CA-C 109.959 -1.256 . . . . 1.0 109.959 179.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 36.9 m -120.98 137.3 54.7 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.398 -1.06 . . . . 1.0 108.725 179.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 53.0 m -69.42 122.75 19.58 Favored 'General case' 0 N--CA 1.466 0.374 0 O-C-N 121.326 -0.859 . . . . 1.0 109.418 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 34.9 t80 -93.48 140.1 29.97 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.493 -0.754 . . . . 1.0 109.002 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -152.76 112.4 3.91 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.379 -0.825 . . . . 1.0 109.737 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.427 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 11.5 p30 -113.76 76.12 0.96 Allowed 'General case' 0 N--CA 1.464 0.253 0 O-C-N 121.474 -0.766 . . . . 1.0 109.446 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.8 p -115.39 -29.95 6.39 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.507 -0.746 . . . . 1.0 109.635 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.4 t -124.44 154.43 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 O-C-N 121.503 -0.748 . . . . 1.0 109.501 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 41.8 mtm-85 -99.29 178.95 4.74 Favored 'General case' 0 CA--C 1.53 0.184 0 O-C-N 121.532 -0.73 . . . . 1.0 109.357 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 62.14 11.21 31.41 Favored Glycine 0 CA--C 1.533 1.206 0 N-CA-C 109.919 -1.272 . . . . 1.0 109.919 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.9 m -134.64 169.27 14.3 Favored Pre-proline 0 CA--C 1.535 0.404 0 O-C-N 121.357 -1.084 . . . . 1.0 109.182 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -87.64 122.44 1.69 Allowed 'Trans proline' 0 C--N 1.351 0.692 0 C-N-CA 124.825 3.683 . . . . 1.0 110.213 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.427 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.7 m0 -82.71 -32.68 27.89 Favored 'General case' 0 N--CA 1.463 0.216 0 O-C-N 121.478 -0.764 . . . . 1.0 109.44 -179.618 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 11.0 t -89.36 107.97 19.37 Favored 'General case' 0 CA--C 1.535 0.372 0 O-C-N 121.532 -0.73 . . . . 1.0 109.207 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.413 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 4.7 p90 -137.4 -179.32 5.66 Favored 'General case' 0 CA--C 1.539 0.524 0 O-C-N 121.263 -0.898 . . . . 1.0 110.33 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.409 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 10.5 m-85 -84.41 169.32 17.11 Favored Pre-proline 0 CA--C 1.539 0.524 0 O-C-N 121.519 -0.738 . . . . 1.0 110.097 -179.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_endo -90.89 170.23 3.46 Favored 'Trans proline' 0 C--N 1.353 0.767 0 C-N-CA 125.204 3.936 . . . . 1.0 110.888 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.6 m120 . . . . . 0 CA--C 1.531 0.249 0 N-CA-C 108.445 -0.946 . . . . 1.0 108.445 179.224 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 m . . . . . 0 CA--C 1.53 0.185 0 CA-C-O 121.283 0.563 . . . . 1.0 109.485 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.434 ' O ' ' CE2' ' A' ' 45' ' ' PHE . 11.2 m -111.05 -24.57 10.26 Favored 'General case' 0 C--N 1.332 -0.16 0 O-C-N 121.544 -0.723 . . . . 1.0 109.449 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 t -68.9 146.31 52.92 Favored 'General case' 0 N--CA 1.464 0.24 0 O-C-N 121.475 -0.766 . . . . 1.0 110.739 -178.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.494 ' CG1' ' H ' ' A' ' 10' ' ' ALA . 25.2 t -140.32 178.9 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 108.308 -0.997 . . . . 1.0 108.308 179.616 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.494 ' H ' ' CG1' ' A' ' 9' ' ' VAL . . . -61.95 110.54 3.32 Favored Pre-proline 0 CA--C 1.541 0.603 0 O-C-N 121.216 -0.927 . . . . 1.0 109.717 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -39.75 -31.32 0.43 Allowed 'Trans proline' 0 N--CA 1.489 1.222 0 C-N-CA 124.607 3.538 . . . . 1.0 111.194 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 8.7 mtt-85 -84.19 -39.61 19.16 Favored 'General case' 0 N--CA 1.464 0.273 0 O-C-N 121.39 -0.819 . . . . 1.0 109.979 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -103.58 50.82 0.8 Allowed 'General case' 0 CA--C 1.532 0.282 0 O-C-N 121.385 -0.822 . . . . 1.0 109.348 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 50.0 mtt180 -91.35 136.39 33.14 Favored 'General case' 0 N--CA 1.464 0.239 0 O-C-N 121.457 -0.777 . . . . 1.0 109.726 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -79.92 104.21 10.34 Favored 'General case' 0 CA--C 1.53 0.182 0 O-C-N 121.586 -0.696 . . . . 1.0 109.249 179.724 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 11.5 t-20 -62.84 116.5 5.31 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.48 -0.763 . . . . 1.0 109.899 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.0 t -92.55 -9.97 39.29 Favored 'General case' 0 CA--C 1.536 0.422 0 O-C-N 121.555 -0.716 . . . . 1.0 109.521 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.91 173.57 33.69 Favored Glycine 0 CA--C 1.529 0.957 0 N-CA-C 109.206 -1.557 . . . . 1.0 109.206 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.436 ' CD2' HG12 ' A' ' 22' ' ' VAL . 8.9 p90 -65.51 167.74 9.99 Favored Pre-proline 0 CA--C 1.539 0.544 0 O-C-N 121.43 -1.041 . . . . 1.0 108.971 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.67 -30.37 1.45 Allowed 'Trans proline' 0 N--CA 1.484 0.922 0 C-N-CA 124.305 3.337 . . . . 1.0 110.832 -178.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.29 -10.71 7.83 Favored Glycine 0 CA--C 1.537 1.441 0 N-CA-C 110.324 -1.11 . . . . 1.0 110.324 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.436 HG12 ' CD2' ' A' ' 19' ' ' PHE . 20.3 m -60.54 -171.94 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 O-C-N 121.294 -1.121 . . . . 1.0 109.723 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -146.63 157.25 48.2 Favored Pre-proline 0 CA--C 1.535 0.379 0 O-C-N 121.584 -0.697 . . . . 1.0 109.25 179.809 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -34.71 -31.93 0.07 OUTLIER 'Trans proline' 0 N--CA 1.489 1.207 1 C-N-CA 125.588 4.192 . . . . 1.0 111.36 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 76.8 p -75.3 -50.22 16.71 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.475 -0.766 . . . . 1.0 109.872 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 38.0 mt-30 -61.57 -48.02 82.88 Favored 'General case' 0 N--CA 1.465 0.291 0 O-C-N 121.44 -0.788 . . . . 1.0 109.811 -179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.9 t -64.69 -28.4 69.57 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.392 -0.818 . . . . 1.0 109.558 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -87.95 -4.96 58.77 Favored 'General case' 0 CA--C 1.534 0.353 0 O-C-N 121.57 -0.706 . . . . 1.0 110.012 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -75.01 -30.1 61.03 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.318 -0.864 . . . . 1.0 109.73 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.5 mmtp -102.82 -40.43 6.56 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.453 -0.779 . . . . 1.0 109.466 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 118.23 39.27 0.75 Allowed Glycine 0 CA--C 1.529 0.944 0 N-CA-C 109.419 -1.472 . . . . 1.0 109.419 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 48.7 m -101.94 139.7 37.22 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.567 -0.96 . . . . 1.0 109.189 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 84.6 m -65.37 116.51 6.76 Favored 'General case' 0 N--CA 1.464 0.255 0 O-C-N 121.523 -0.736 . . . . 1.0 109.927 -179.374 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 34.2 t80 -92.74 121.14 33.84 Favored 'General case' 0 C--N 1.333 -0.141 0 N-CA-C 109.042 -0.725 . . . . 1.0 109.042 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 26.8 t0 -134.15 118.48 17.72 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.391 -0.818 . . . . 1.0 109.518 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.429 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 7.0 p-10 -110.91 64.55 0.61 Allowed 'General case' 0 CA--C 1.533 0.298 0 O-C-N 121.526 -0.734 . . . . 1.0 109.236 179.866 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 27.0 p -114.26 -49.71 2.83 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.392 -0.817 . . . . 1.0 109.489 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.3 t -100.22 133.6 42.69 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 O-C-N 121.404 -0.81 . . . . 1.0 109.507 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.428 ' HG3' ' H ' ' A' ' 40' ' ' GLY . 2.3 tpt180 -85.13 176.17 8.55 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.571 -0.706 . . . . 1.0 109.553 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.428 ' H ' ' HG3' ' A' ' 39' ' ' ARG . . . 80.89 -48.43 3.74 Favored Glycine 0 CA--C 1.529 0.908 0 N-CA-C 109.447 -1.461 . . . . 1.0 109.447 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.3 m -81.4 169.75 17.86 Favored Pre-proline 0 CA--C 1.536 0.437 0 O-C-N 121.511 -0.993 . . . . 1.0 109.215 179.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -86.55 124.37 2.3 Favored 'Trans proline' 0 C--N 1.35 0.628 0 C-N-CA 124.757 3.638 . . . . 1.0 110.157 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.429 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 16.9 m0 -67.28 -37.61 83.7 Favored 'General case' 0 CA--C 1.53 0.192 0 O-C-N 121.554 -0.716 . . . . 1.0 109.522 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 11.1 t -87.86 109.25 19.62 Favored 'General case' 0 C--O 1.233 0.195 0 O-C-N 121.399 -0.813 . . . . 1.0 108.961 179.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.434 ' CE2' ' O ' ' A' ' 7' ' ' CYS . 1.3 p90 -149.3 178.44 8.76 Favored 'General case' 0 CA--C 1.537 0.454 0 O-C-N 121.454 -0.779 . . . . 1.0 109.832 -179.512 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 29.8 m-85 -83.78 170.28 14.59 Favored Pre-proline 0 CA--C 1.538 0.498 0 O-C-N 121.485 -0.759 . . . . 1.0 109.942 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -93.83 -168.32 0.18 Allowed 'Trans proline' 0 C--N 1.35 0.641 1 C-N-CA 125.357 4.038 . . . . 1.0 111.39 -179.45 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.5 m120 . . . . . 0 C--N 1.33 -0.241 0 N-CA-C 107.902 -1.148 . . . . 1.0 107.902 179.364 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 CA--C 1.53 0.208 0 CA-C-O 121.139 0.495 . . . . 1.0 109.733 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 80.6 m -97.31 45.84 1.04 Allowed 'General case' 0 CA--C 1.532 0.287 0 O-C-N 121.51 -0.743 . . . . 1.0 108.998 179.445 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.6 t -123.79 83.5 2.15 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.178 -0.951 . . . . 1.0 109.848 -179.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 38.2 t -109.5 172.03 2.46 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 N-CA-C 108.85 -0.796 . . . . 1.0 108.85 179.449 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -73.15 131.76 83.04 Favored Pre-proline 0 CA--C 1.541 0.597 0 O-C-N 121.323 -0.861 . . . . 1.0 109.272 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -36.87 -38.75 0.39 Allowed 'Trans proline' 0 N--CA 1.488 1.156 0 C-N-CA 125.103 3.869 . . . . 1.0 111.351 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.7 mpp_? -82.01 -40.28 22.34 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 121.433 -0.792 . . . . 1.0 109.944 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 29.6 mt-10 -86.24 42.68 1.01 Allowed 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.277 -0.89 . . . . 1.0 109.671 -179.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 37.9 mtt180 -101.51 151.34 22.08 Favored 'General case' 0 N--CA 1.464 0.232 0 O-C-N 121.409 -0.807 . . . . 1.0 109.627 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -104.68 105.6 15.76 Favored 'General case' 0 N--CA 1.462 0.172 0 O-C-N 121.345 -0.847 . . . . 1.0 109.06 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -57.32 118.69 5.38 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 121.235 -0.916 . . . . 1.0 110.305 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -94.13 -18.85 21.35 Favored 'General case' 0 CA--C 1.534 0.348 0 O-C-N 121.515 -0.741 . . . . 1.0 109.345 179.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -171.88 176.82 44.9 Favored Glycine 0 CA--C 1.53 1.017 0 N-CA-C 109.059 -1.616 . . . . 1.0 109.059 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.429 ' CE2' HG11 ' A' ' 22' ' ' VAL . 8.3 p90 -66.12 167.16 12.91 Favored Pre-proline 0 CA--C 1.539 0.526 0 O-C-N 121.374 -1.074 . . . . 1.0 108.815 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.97 -30.16 1.41 Allowed 'Trans proline' 0 N--CA 1.482 0.828 0 C-N-CA 124.537 3.491 . . . . 1.0 110.906 -178.604 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -57.8 -11.86 9.12 Favored Glycine 0 CA--C 1.536 1.39 0 N-CA-C 110.323 -1.111 . . . . 1.0 110.323 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.429 HG11 ' CE2' ' A' ' 19' ' ' PHE . 20.9 m -61.06 -172.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 O-C-N 121.302 -1.116 . . . . 1.0 109.932 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.495 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 59.9 p -145.15 157.64 53.21 Favored Pre-proline 0 CA--C 1.535 0.37 0 N-CA-C 108.913 -0.773 . . . . 1.0 108.913 179.709 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -35.07 -39.75 0.22 Allowed 'Trans proline' 0 N--CA 1.489 1.212 1 C-N-CA 125.484 4.123 . . . . 1.0 111.378 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.1 p -74.08 -46.63 41.77 Favored 'General case' 0 CA--C 1.532 0.288 0 O-C-N 121.462 -0.774 . . . . 1.0 109.903 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLN . . . . . 0.495 ' HB2' ' H ' ' A' ' 23' ' ' THR . 32.4 mt-30 -61.26 -53.07 61.49 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 121.447 -0.783 . . . . 1.0 109.975 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 23.1 t -61.66 -26.41 68.0 Favored 'General case' 0 CA--C 1.533 0.322 0 O-C-N 121.298 -0.877 . . . . 1.0 109.719 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -90.01 -6.69 55.33 Favored 'General case' 0 CA--C 1.535 0.386 0 O-C-N 121.504 -0.748 . . . . 1.0 110.08 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 15.5 t-20 -78.96 -45.38 20.49 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.29 -0.882 . . . . 1.0 109.535 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.1 mtmm -72.36 -45.85 58.03 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.483 -0.761 . . . . 1.0 109.526 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 125.26 27.03 1.25 Allowed Glycine 0 CA--C 1.529 0.939 0 N-CA-C 109.197 -1.561 . . . . 1.0 109.197 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 26.4 m -99.52 145.29 27.65 Favored 'General case' 0 CA--C 1.532 0.276 0 O-C-N 121.685 -0.891 . . . . 1.0 108.696 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 35.9 m -68.58 128.92 38.35 Favored 'General case' 0 N--CA 1.465 0.321 0 O-C-N 121.307 -0.871 . . . . 1.0 109.42 -179.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -97.82 138.09 35.69 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.511 -0.743 . . . . 1.0 109.067 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 13.6 t0 -157.63 89.25 1.02 Allowed 'General case' 0 N--CA 1.463 0.183 0 O-C-N 121.521 -0.737 . . . . 1.0 109.512 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.415 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 38.2 p-10 -103.05 78.68 1.67 Allowed 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.539 -0.725 . . . . 1.0 109.472 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 76.6 p -113.85 -23.15 9.79 Favored 'General case' 0 CA--C 1.534 0.334 0 O-C-N 121.383 -0.823 . . . . 1.0 109.709 -179.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.8 t -127.6 165.54 26.35 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 O-C-N 121.451 -0.78 . . . . 1.0 109.645 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.447 ' CD ' ' H ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER -107.03 175.05 5.63 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 109.097 -0.705 . . . . 1.0 109.097 179.812 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.447 ' H ' ' CD ' ' A' ' 39' ' ' ARG . . . 72.17 -8.07 7.13 Favored Glycine 0 CA--C 1.533 1.173 0 N-CA-C 109.954 -1.258 . . . . 1.0 109.954 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.421 ' H ' ' C ' ' A' ' 39' ' ' ARG . 30.9 m -121.52 170.08 8.12 Favored Pre-proline 0 CA--C 1.537 0.461 0 O-C-N 121.317 -1.108 . . . . 1.0 109.051 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -86.53 127.75 2.85 Favored 'Trans proline' 0 N--CA 1.48 0.694 0 C-N-CA 124.585 3.523 . . . . 1.0 110.209 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.415 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.4 m0 -82.49 -39.36 22.57 Favored 'General case' 0 N--CA 1.464 0.264 0 O-C-N 121.586 -0.696 . . . . 1.0 109.28 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.1 t -88.14 117.49 27.06 Favored 'General case' 0 N--CA 1.466 0.329 0 O-C-N 121.508 -0.745 . . . . 1.0 109.113 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.419 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 5.2 p90 -145.18 173.14 12.19 Favored 'General case' 0 CA--C 1.537 0.463 0 O-C-N 121.328 -0.857 . . . . 1.0 110.34 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.408 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 14.3 m-85 -79.53 172.78 9.0 Favored Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 121.473 -0.767 . . . . 1.0 109.496 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo -90.37 160.53 4.54 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 125.087 3.858 . . . . 1.0 110.252 179.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 8.2 m-20 . . . . . 0 CA--C 1.53 0.195 0 O-C-N 121.485 -0.759 . . . . 1.0 109.492 -179.955 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 CA--C 1.532 0.256 0 N-CA-C 109.502 -0.555 . . . . 1.0 109.502 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 63.9 m -105.61 -20.56 13.43 Favored 'General case' 0 CA--C 1.533 0.316 0 O-C-N 121.601 -0.687 . . . . 1.0 109.478 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.8 t -70.05 104.78 2.66 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.322 -0.861 . . . . 1.0 109.538 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 36.2 t -131.66 170.66 19.39 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 O-C-N 121.607 -0.683 . . . . 1.0 109.186 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.77 126.52 91.86 Favored Pre-proline 0 CA--C 1.539 0.535 0 O-C-N 121.448 -0.782 . . . . 1.0 109.22 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_exo -37.74 -40.02 0.88 Allowed 'Trans proline' 0 N--CA 1.49 1.268 0 C-N-CA 124.926 3.751 . . . . 1.0 111.126 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.9 mtm-85 -76.6 -41.73 45.08 Favored 'General case' 0 CA--C 1.532 0.254 0 O-C-N 121.4 -0.812 . . . . 1.0 109.886 -179.425 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -81.88 40.52 0.61 Allowed 'General case' 0 C--N 1.331 -0.213 0 O-C-N 121.451 -0.78 . . . . 1.0 109.561 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 55.3 mtt180 -108.09 133.49 52.31 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.47 -0.769 . . . . 1.0 109.556 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 22.6 mm-40 -90.65 117.71 29.52 Favored 'General case' 0 N--CA 1.464 0.227 0 O-C-N 121.438 -0.789 . . . . 1.0 109.367 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -61.31 115.36 3.78 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.453 -0.779 . . . . 1.0 109.992 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.4 t -93.47 -20.39 20.33 Favored 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.605 -0.685 . . . . 1.0 109.324 179.614 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.52 170.58 37.19 Favored Glycine 0 CA--C 1.529 0.958 0 N-CA-C 109.494 -1.442 . . . . 1.0 109.494 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CE2' ' CG1' ' A' ' 22' ' ' VAL . 19.8 p90 -64.85 148.77 97.14 Favored Pre-proline 0 CA--C 1.538 0.505 0 O-C-N 121.435 -1.038 . . . . 1.0 109.263 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -65.43 -28.69 54.07 Favored 'Trans proline' 0 N--CA 1.489 1.232 0 C-N-CA 124.053 3.169 . . . . 1.0 110.704 -178.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -55.04 -15.62 7.1 Favored Glycine 0 CA--C 1.536 1.355 0 N-CA-C 110.649 -0.981 . . . . 1.0 110.649 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.431 ' CG1' ' CE2' ' A' ' 19' ' ' PHE . 30.2 m -64.01 178.26 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 O-C-N 121.389 -1.065 . . . . 1.0 109.505 179.816 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.1 p -132.03 156.4 80.15 Favored Pre-proline 0 CA--C 1.536 0.427 0 O-C-N 121.543 -0.723 . . . . 1.0 109.313 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -34.49 -33.03 0.07 OUTLIER 'Trans proline' 0 N--CA 1.489 1.206 1 C-N-CA 125.587 4.192 . . . . 1.0 111.293 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 2.6 m -71.83 -49.96 33.83 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.472 -0.767 . . . . 1.0 109.962 -179.554 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 13.2 mm-40 -63.39 -49.93 71.89 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.403 -0.81 . . . . 1.0 109.73 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.6 t -63.16 -21.34 66.14 Favored 'General case' 0 CA--C 1.533 0.306 0 O-C-N 121.518 -0.739 . . . . 1.0 109.829 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.0 -11.06 27.06 Favored 'General case' 0 CA--C 1.535 0.399 0 O-C-N 121.416 -0.802 . . . . 1.0 109.916 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -71.38 -35.96 71.27 Favored 'General case' 0 N--CA 1.463 0.205 0 O-C-N 121.331 -0.856 . . . . 1.0 109.56 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.8 tttp -92.07 -42.68 9.82 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.44 -0.787 . . . . 1.0 109.447 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 122.33 38.05 0.61 Allowed Glycine 0 CA--C 1.528 0.849 0 N-CA-C 109.526 -1.43 . . . . 1.0 109.526 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.8 m -105.59 145.34 31.12 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.493 -1.004 . . . . 1.0 109.114 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 61.4 m -68.5 127.48 33.14 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.557 -0.714 . . . . 1.0 109.54 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 51.1 t80 -104.12 109.39 21.16 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 121.507 -0.746 . . . . 1.0 109.25 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -120.81 102.98 8.74 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.575 -0.703 . . . . 1.0 109.564 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.431 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.8 p-10 -108.08 59.49 0.61 Allowed 'General case' 0 CA--C 1.532 0.267 0 O-C-N 121.527 -0.733 . . . . 1.0 109.291 179.742 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.5 p -112.28 -42.1 3.78 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.364 -0.835 . . . . 1.0 109.454 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.2 t -96.71 155.09 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 O-C-N 121.481 -0.762 . . . . 1.0 109.483 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.405 ' C ' ' H ' ' A' ' 41' ' ' VAL . 0.8 OUTLIER -108.03 165.05 11.75 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.529 -0.732 . . . . 1.0 109.449 -179.991 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.4 -32.6 2.82 Favored Glycine 0 CA--C 1.53 1.009 0 N-CA-C 109.096 -1.602 . . . . 1.0 109.096 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.405 ' H ' ' C ' ' A' ' 39' ' ' ARG . 26.8 m -91.34 171.85 7.45 Favored Pre-proline 0 CA--C 1.538 0.502 0 O-C-N 121.619 -0.93 . . . . 1.0 109.041 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . 0.402 ' CD ' ' HB ' ' A' ' 41' ' ' VAL . 11.4 Cg_endo -85.97 138.68 6.01 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 124.411 3.407 . . . . 1.0 109.706 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.431 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 30.6 m0 -87.36 -46.06 10.0 Favored 'General case' 0 CA--C 1.531 0.239 0 O-C-N 121.481 -0.762 . . . . 1.0 110.466 -179.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 14.9 t -89.04 109.51 20.34 Favored 'General case' 0 CA--C 1.532 0.276 0 O-C-N 121.242 -0.911 . . . . 1.0 109.953 -179.503 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.415 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 5.6 p90 -137.38 -178.97 5.46 Favored 'General case' 0 CA--C 1.537 0.474 0 O-C-N 121.387 -0.821 . . . . 1.0 109.448 179.365 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.415 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 43.9 m-85 -90.48 165.27 23.74 Favored Pre-proline 0 CA--C 1.536 0.422 0 O-C-N 121.328 -0.857 . . . . 1.0 109.512 -179.798 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -90.86 175.59 2.49 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 124.95 3.767 . . . . 1.0 110.502 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 67.8 m-80 . . . . . 0 CA--C 1.529 0.165 0 N-CA-C 109.291 -0.633 . . . . 1.0 109.291 179.866 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 4.7 t . . . . . 0 CA--C 1.532 0.265 0 N-CA-C 109.316 -0.624 . . . . 1.0 109.316 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 72.2 m -108.43 -20.97 12.94 Favored 'General case' 0 CA--C 1.534 0.345 0 O-C-N 121.46 -0.775 . . . . 1.0 109.644 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.5 t -70.03 102.98 2.15 Favored 'General case' 0 CA--C 1.53 0.211 0 O-C-N 121.489 -0.757 . . . . 1.0 109.892 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.0 t -114.53 171.44 4.32 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 O-C-N 121.346 -0.846 . . . . 1.0 108.936 179.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -78.39 119.5 77.54 Favored Pre-proline 0 CA--C 1.541 0.622 0 O-C-N 121.417 -0.802 . . . . 1.0 109.542 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_exo -37.93 -38.84 0.77 Allowed 'Trans proline' 0 N--CA 1.489 1.258 0 C-N-CA 124.757 3.638 . . . . 1.0 111.205 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 18.6 mmm-85 -77.01 -42.65 37.76 Favored 'General case' 0 N--CA 1.464 0.237 0 O-C-N 121.494 -0.754 . . . . 1.0 109.889 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -102.53 50.03 0.83 Allowed 'General case' 0 CA--C 1.532 0.286 0 O-C-N 121.375 -0.828 . . . . 1.0 109.508 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 26.7 mtt180 -94.04 147.77 22.81 Favored 'General case' 0 N--CA 1.463 0.223 0 O-C-N 121.379 -0.826 . . . . 1.0 109.704 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 54.1 mm-40 -91.6 107.26 19.09 Favored 'General case' 0 CA--C 1.53 0.196 0 O-C-N 121.474 -0.766 . . . . 1.0 109.166 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 30.2 t-20 -63.76 123.06 17.92 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 121.513 -0.742 . . . . 1.0 109.819 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 38.1 t -100.9 -18.34 16.4 Favored 'General case' 0 CA--C 1.534 0.329 0 O-C-N 121.53 -0.731 . . . . 1.0 109.505 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 175.94 -177.13 47.67 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 109.276 -1.53 . . . . 1.0 109.276 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.428 ' CE2' HG11 ' A' ' 22' ' ' VAL . 9.1 p90 -65.73 167.87 10.13 Favored Pre-proline 0 CA--C 1.538 0.492 0 O-C-N 121.395 -1.062 . . . . 1.0 108.822 179.732 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.81 -30.4 1.39 Allowed 'Trans proline' 0 N--CA 1.483 0.888 0 C-N-CA 124.374 3.383 . . . . 1.0 110.794 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -56.96 -12.58 7.23 Favored Glycine 0 CA--C 1.537 1.458 0 N-CA-C 110.357 -1.097 . . . . 1.0 110.357 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.428 HG11 ' CE2' ' A' ' 19' ' ' PHE . 23.0 m -61.05 170.37 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 O-C-N 121.3 -1.117 . . . . 1.0 109.627 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.7 p -133.97 154.51 80.33 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.555 -0.716 . . . . 1.0 109.172 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.406 ' HD3' ' CZ ' ' A' ' 34' ' ' PHE . 16.8 Cg_exo -34.58 -31.87 0.06 OUTLIER 'Trans proline' 0 N--CA 1.488 1.195 1 C-N-CA 125.594 4.196 . . . . 1.0 111.355 179.956 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.6 m -75.53 -51.24 13.39 Favored 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.439 -0.788 . . . . 1.0 109.608 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 15.6 mt-30 -62.79 -43.37 98.98 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.427 -0.796 . . . . 1.0 109.721 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 10.1 t -64.54 -29.14 70.17 Favored 'General case' 0 N--CA 1.464 0.235 0 O-C-N 121.474 -0.766 . . . . 1.0 109.422 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.98 -11.15 56.13 Favored 'General case' 0 CA--C 1.533 0.315 0 O-C-N 121.604 -0.685 . . . . 1.0 109.756 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -88.24 -26.04 22.55 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.359 -0.838 . . . . 1.0 109.531 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 9.6 tttp -89.39 -32.06 17.46 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.419 -0.801 . . . . 1.0 109.407 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.41 43.43 1.36 Allowed Glycine 0 CA--C 1.53 0.985 0 N-CA-C 109.633 -1.387 . . . . 1.0 109.633 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.9 m -129.46 150.36 50.84 Favored 'General case' 0 CA--C 1.53 0.191 0 O-C-N 121.47 -1.018 . . . . 1.0 109.461 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.42 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 62.5 m -72.91 134.77 44.92 Favored 'General case' 0 CA--C 1.529 0.173 0 O-C-N 121.412 -0.805 . . . . 1.0 109.5 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.406 ' CZ ' ' HD3' ' A' ' 24' ' ' PRO . 57.1 t80 -107.87 125.13 51.1 Favored 'General case' 0 CA--C 1.53 0.175 0 O-C-N 121.488 -0.758 . . . . 1.0 109.233 179.689 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 16.2 t0 -138.54 117.84 12.77 Favored 'General case' 0 CA--C 1.53 0.179 0 O-C-N 121.457 -0.777 . . . . 1.0 109.527 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.42 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 14.1 p30 -113.55 66.06 0.66 Allowed 'General case' 0 N--CA 1.464 0.256 0 O-C-N 121.547 -0.721 . . . . 1.0 109.368 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.9 p -97.62 -69.82 0.74 Allowed 'General case' 0 CA--C 1.531 0.235 0 O-C-N 121.358 -0.839 . . . . 1.0 109.522 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 38.2 t -96.46 155.19 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 O-C-N 121.458 -0.776 . . . . 1.0 109.452 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.476 ' CG ' ' H ' ' A' ' 40' ' ' GLY . 13.7 ttp-105 -93.9 178.34 5.7 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 121.504 -0.748 . . . . 1.0 109.395 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.476 ' H ' ' CG ' ' A' ' 39' ' ' ARG . . . 81.3 -43.62 2.92 Favored Glycine 0 CA--C 1.529 0.918 0 N-CA-C 109.472 -1.451 . . . . 1.0 109.472 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.2 m -85.52 169.66 15.31 Favored Pre-proline 0 CA--C 1.537 0.444 0 O-C-N 121.538 -0.978 . . . . 1.0 109.197 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -87.22 136.46 4.06 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 124.77 3.647 . . . . 1.0 110.139 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.42 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 11.6 m0 -86.72 -50.55 6.69 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.526 -0.734 . . . . 1.0 109.569 -179.742 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.2 t -77.28 103.69 7.36 Favored 'General case' 0 N--CA 1.463 0.224 0 O-C-N 121.488 -0.758 . . . . 1.0 109.505 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.42 ' CE1' ' HB2' ' A' ' 33' ' ' CYS . 4.8 p90 -135.82 -178.99 5.38 Favored 'General case' 0 N--CA 1.465 0.316 0 O-C-N 121.489 -0.757 . . . . 1.0 109.523 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 65.1 m-85 -93.75 164.31 21.23 Favored Pre-proline 0 CA--C 1.534 0.357 0 O-C-N 121.436 -0.79 . . . . 1.0 109.652 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -91.11 -165.34 0.16 Allowed 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 125.045 3.83 . . . . 1.0 110.406 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 17.9 m-80 . . . . . 0 CA--C 1.53 0.207 0 O-C-N 121.505 -0.747 . . . . 1.0 109.441 -179.991 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 CA--C 1.53 0.191 0 N-CA-C 109.303 -0.629 . . . . 1.0 109.303 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.9 m -105.21 28.87 6.88 Favored 'General case' 0 C--N 1.33 -0.249 0 O-C-N 121.611 -0.681 . . . . 1.0 109.316 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.2 t -80.51 118.29 21.98 Favored 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.406 -0.809 . . . . 1.0 109.508 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 36.4 t -149.47 154.18 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 O-C-N 121.57 -0.706 . . . . 1.0 109.349 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -83.1 146.38 51.41 Favored Pre-proline 0 CA--C 1.537 0.472 0 O-C-N 121.472 -0.768 . . . . 1.0 109.353 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_exo -34.48 -62.19 0.21 Allowed 'Trans proline' 0 N--CA 1.489 1.235 1 C-N-CA 125.571 4.18 . . . . 1.0 111.388 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.52 -29.88 65.29 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.383 -0.823 . . . . 1.0 109.856 -179.649 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -80.62 3.7 21.06 Favored 'General case' 0 CA--C 1.535 0.39 0 O-C-N 121.394 -0.816 . . . . 1.0 109.932 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 48.8 mtt180 -73.86 129.71 38.45 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.396 -0.815 . . . . 1.0 109.56 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.4 mm-40 -88.08 108.98 19.51 Favored 'General case' 0 N--CA 1.463 0.212 0 N-CA-C 109.03 -0.73 . . . . 1.0 109.03 179.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 32.9 t-20 -59.22 105.8 0.37 Allowed 'General case' 0 CA--C 1.534 0.328 0 O-C-N 121.396 -0.815 . . . . 1.0 110.391 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 t -85.53 -15.22 43.43 Favored 'General case' 0 CA--C 1.535 0.391 0 O-C-N 121.489 -0.757 . . . . 1.0 109.02 179.361 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 178.57 165.28 32.89 Favored Glycine 0 CA--C 1.529 0.96 0 N-CA-C 108.99 -1.644 . . . . 1.0 108.99 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.425 ' CD2' HG11 ' A' ' 22' ' ' VAL . 7.1 p90 -59.41 168.91 1.49 Allowed Pre-proline 0 CA--C 1.541 0.634 0 O-C-N 121.355 -1.085 . . . . 1.0 109.276 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.5 Cg_endo -80.51 -30.93 1.74 Allowed 'Trans proline' 0 N--CA 1.482 0.834 0 C-N-CA 124.112 3.208 . . . . 1.0 110.662 -178.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.43 -6.33 7.93 Favored Glycine 0 CA--C 1.537 1.408 0 N-CA-C 110.05 -1.22 . . . . 1.0 110.05 179.332 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.425 HG11 ' CD2' ' A' ' 19' ' ' PHE . 24.7 m -59.71 -172.79 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 O-C-N 121.079 -1.248 . . . . 1.0 109.894 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.1 p -143.63 152.79 57.21 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.639 -0.663 . . . . 1.0 109.298 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -34.98 -33.31 0.08 OUTLIER 'Trans proline' 0 N--CA 1.488 1.174 1 C-N-CA 125.396 4.064 . . . . 1.0 111.437 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 9.3 t -76.37 -48.99 18.0 Favored 'General case' 0 CA--C 1.532 0.282 0 O-C-N 121.451 -0.781 . . . . 1.0 109.865 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 66.2 mt-30 -62.71 -41.17 99.0 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.45 -0.781 . . . . 1.0 109.782 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.3 t -69.09 -27.61 65.75 Favored 'General case' 0 CA--C 1.532 0.25 0 O-C-N 121.468 -0.77 . . . . 1.0 109.465 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.48 -5.77 53.7 Favored 'General case' 0 CA--C 1.536 0.424 0 O-C-N 121.546 -0.721 . . . . 1.0 109.941 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -63.03 -51.12 67.97 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.351 -0.843 . . . . 1.0 109.617 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.83 -40.54 13.07 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.466 -0.771 . . . . 1.0 109.403 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 126.91 21.44 1.72 Allowed Glycine 0 CA--C 1.531 1.074 0 N-CA-C 109.806 -1.318 . . . . 1.0 109.806 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 14.9 m -75.93 136.65 40.08 Favored 'General case' 0 N--CA 1.464 0.268 0 O-C-N 121.466 -1.02 . . . . 1.0 108.76 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 62.0 m -65.2 141.0 58.81 Favored 'General case' 0 CA--C 1.531 0.213 0 O-C-N 121.375 -0.828 . . . . 1.0 109.444 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 35' ' ' ASP . 15.2 t80 -111.22 143.17 42.4 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.448 -0.782 . . . . 1.0 109.17 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . 0.443 ' N ' ' CD1' ' A' ' 34' ' ' PHE . 24.8 t70 -162.21 116.19 1.82 Allowed 'General case' 0 CA--C 1.531 0.242 0 O-C-N 121.392 -0.818 . . . . 1.0 109.62 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.432 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 16.0 p30 -105.71 63.17 0.67 Allowed 'General case' 0 CA--C 1.533 0.295 0 O-C-N 121.574 -0.704 . . . . 1.0 109.478 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.6 p -87.19 -58.18 2.68 Favored 'General case' 0 CA--C 1.531 0.242 0 O-C-N 121.417 -0.802 . . . . 1.0 109.512 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 37.5 t -119.74 146.56 24.3 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 O-C-N 121.496 -0.753 . . . . 1.0 109.427 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 1.4 ptm180 -84.15 -174.94 5.56 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 121.496 -0.752 . . . . 1.0 109.358 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.89 -42.93 2.55 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 109.213 -1.555 . . . . 1.0 109.213 -179.706 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.7 m -91.23 170.08 10.35 Favored Pre-proline 0 CA--C 1.534 0.354 0 O-C-N 121.489 -1.006 . . . . 1.0 108.981 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_endo -86.64 119.51 1.64 Allowed 'Trans proline' 0 C--N 1.35 0.621 0 C-N-CA 124.479 3.453 . . . . 1.0 110.049 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.432 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.9 m0 -72.69 -29.25 63.24 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 109.173 -0.677 . . . . 1.0 109.173 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 12.6 t -89.66 99.38 12.39 Favored 'General case' 0 CA--C 1.533 0.31 0 N-CA-C 109.158 -0.682 . . . . 1.0 109.158 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.402 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 4.3 p90 -128.91 173.99 9.9 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 121.241 -0.912 . . . . 1.0 110.083 -179.619 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.402 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 19.8 m-85 -78.67 170.91 14.05 Favored Pre-proline 0 CA--C 1.536 0.424 0 O-C-N 121.415 -0.803 . . . . 1.0 109.543 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -89.81 -178.63 1.67 Allowed 'Trans proline' 0 C--N 1.351 0.662 0 C-N-CA 125.137 3.891 . . . . 1.0 110.304 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.8 m120 . . . . . 0 CA--C 1.531 0.243 0 O-C-N 121.441 -0.787 . . . . 1.0 109.303 179.957 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.0 m . . . . . 0 CA--C 1.531 0.233 0 CA-C-O 121.243 0.544 . . . . 1.0 109.76 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.2 m -119.67 46.07 2.01 Favored 'General case' 0 CA--C 1.532 0.273 0 O-C-N 121.528 -0.733 . . . . 1.0 109.131 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.3 t -128.79 80.85 1.99 Allowed 'General case' 0 CA--C 1.532 0.269 0 O-C-N 121.423 -0.798 . . . . 1.0 109.469 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.401 ' CG1' ' N ' ' A' ' 10' ' ' ALA . 38.0 t -102.42 170.16 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 O-C-N 121.367 -0.833 . . . . 1.0 109.332 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.401 ' N ' ' CG1' ' A' ' 9' ' ' VAL . . . -71.79 134.99 83.43 Favored Pre-proline 0 CA--C 1.539 0.547 0 O-C-N 121.52 -0.738 . . . . 1.0 109.202 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_exo -35.87 -31.13 0.08 OUTLIER 'Trans proline' 0 N--CA 1.489 1.226 0 C-N-CA 125.202 3.934 . . . . 1.0 111.554 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.409 ' H ' ' HG2' ' A' ' 12' ' ' ARG . 10.5 ptp180 -84.25 -44.75 13.57 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.392 -0.817 . . . . 1.0 110.171 -179.402 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -79.07 39.81 0.39 Allowed 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.357 -0.839 . . . . 1.0 109.653 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 63.9 mtt180 -111.22 121.46 45.33 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.391 -0.818 . . . . 1.0 109.754 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.478 ' H ' ' NE2' ' A' ' 15' ' ' GLN . 1.3 pm0 -90.16 125.21 35.38 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.488 -0.757 . . . . 1.0 108.993 179.391 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -65.0 127.56 32.1 Favored 'General case' 0 CA--C 1.534 0.347 0 O-C-N 121.454 -0.779 . . . . 1.0 110.7 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -98.16 -26.67 14.49 Favored 'General case' 0 CA--C 1.534 0.335 0 N-CA-C 108.371 -0.974 . . . . 1.0 108.371 178.714 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -165.47 171.62 40.78 Favored Glycine 0 CA--C 1.53 1.012 0 N-CA-C 108.701 -1.76 . . . . 1.0 108.701 179.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CE2' HG11 ' A' ' 22' ' ' VAL . 7.9 p90 -62.73 167.62 5.54 Favored Pre-proline 0 CA--C 1.54 0.586 0 O-C-N 121.174 -1.192 . . . . 1.0 109.153 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.21 -30.86 1.44 Allowed 'Trans proline' 0 N--CA 1.483 0.875 0 C-N-CA 124.375 3.384 . . . . 1.0 110.771 -178.642 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.28 -9.91 9.29 Favored Glycine 0 CA--C 1.538 1.479 0 N-CA-C 110.104 -1.198 . . . . 1.0 110.104 179.443 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.432 HG11 ' CE2' ' A' ' 19' ' ' PHE . 23.4 m -60.09 169.66 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 O-C-N 121.282 -1.128 . . . . 1.0 109.721 179.802 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.472 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 38.1 p -128.55 157.89 73.56 Favored Pre-proline 0 CA--C 1.536 0.409 0 N-CA-C 109.083 -0.71 . . . . 1.0 109.083 179.608 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -36.03 -34.03 0.13 Allowed 'Trans proline' 0 N--CA 1.488 1.157 1 C-N-CA 125.364 4.042 . . . . 1.0 111.176 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 33.7 p -79.25 -45.81 19.04 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.442 -0.786 . . . . 1.0 109.965 -179.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLN . . . . . 0.472 ' HB2' ' H ' ' A' ' 23' ' ' THR . 25.7 mt-30 -62.42 -52.5 63.32 Favored 'General case' 0 N--CA 1.465 0.304 0 O-C-N 121.476 -0.765 . . . . 1.0 109.853 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 10.4 t -62.0 -33.97 75.32 Favored 'General case' 0 CA--C 1.533 0.311 0 O-C-N 121.483 -0.761 . . . . 1.0 109.765 -179.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.6 -3.13 58.31 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.336 -0.852 . . . . 1.0 110.03 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -79.08 -46.65 17.64 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.319 -0.863 . . . . 1.0 109.834 -179.593 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.2 tttt -78.82 -48.5 14.64 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 121.431 -0.793 . . . . 1.0 109.544 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 132.58 21.41 0.92 Allowed Glycine 0 CA--C 1.531 1.052 0 N-CA-C 110.281 -1.127 . . . . 1.0 110.281 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 39.9 m -91.48 138.74 31.33 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 121.246 -1.149 . . . . 1.0 108.746 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.7 m -65.17 128.04 34.19 Favored 'General case' 0 N--CA 1.464 0.242 0 O-C-N 121.303 -0.873 . . . . 1.0 109.729 -179.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 64.4 t80 -97.57 143.3 28.4 Favored 'General case' 0 C--O 1.234 0.266 0 O-C-N 121.541 -0.724 . . . . 1.0 109.155 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -152.72 103.54 2.79 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 121.363 -0.836 . . . . 1.0 109.645 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.421 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 9.5 p-10 -109.02 82.56 1.61 Allowed 'General case' 0 CA--C 1.531 0.216 0 O-C-N 121.55 -0.719 . . . . 1.0 109.426 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 49.1 p -118.63 -35.03 3.82 Favored 'General case' 0 N--CA 1.463 0.218 0 O-C-N 121.421 -0.799 . . . . 1.0 109.601 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.6 t -128.97 150.15 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 O-C-N 121.458 -0.776 . . . . 1.0 109.396 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 22.3 ttt180 -87.08 168.18 13.52 Favored 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.468 -0.77 . . . . 1.0 109.384 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.43 -52.03 4.58 Favored Glycine 0 CA--C 1.529 0.907 0 N-CA-C 109.529 -1.428 . . . . 1.0 109.529 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 27.6 m -74.14 169.2 20.21 Favored Pre-proline 0 CA--C 1.536 0.419 0 O-C-N 121.551 -0.97 . . . . 1.0 109.324 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_endo -88.92 130.43 2.15 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 124.883 3.722 . . . . 1.0 110.219 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.421 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 7.7 m0 -87.95 -36.44 17.09 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.423 -0.798 . . . . 1.0 109.509 -179.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 8.0 t -89.44 102.96 15.63 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 109.144 -0.687 . . . . 1.0 109.144 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.406 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 3.6 p90 -134.55 174.23 10.78 Favored 'General case' 0 CA--C 1.538 0.497 0 O-C-N 121.304 -0.873 . . . . 1.0 110.083 -179.414 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.406 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 45.3 m-85 -76.6 170.5 15.87 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 121.435 -0.791 . . . . 1.0 109.495 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_endo -90.18 161.83 4.73 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 124.928 3.752 . . . . 1.0 110.454 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 . . . . . 0 N--CA 1.463 0.194 0 O-C-N 121.569 -0.707 . . . . 1.0 109.384 179.974 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 31.7 m . . . . . 0 CA--C 1.531 0.248 0 N-CA-C 109.193 -0.669 . . . . 1.0 109.193 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.3 m -124.67 -6.23 7.48 Favored 'General case' 0 CA--C 1.535 0.393 0 O-C-N 121.446 -0.783 . . . . 1.0 109.92 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.6 t -70.17 126.94 31.11 Favored 'General case' 0 N--CA 1.463 0.215 0 O-C-N 121.215 -0.928 . . . . 1.0 109.434 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.434 ' CG1' ' H ' ' A' ' 10' ' ' ALA . 26.0 t -142.34 173.64 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 O-C-N 121.513 -0.742 . . . . 1.0 109.37 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.434 ' H ' ' CG1' ' A' ' 9' ' ' VAL . . . -77.96 136.84 61.89 Favored Pre-proline 0 CA--C 1.54 0.595 0 O-C-N 121.477 -0.764 . . . . 1.0 109.566 -179.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_exo -36.0 -38.24 0.27 Allowed 'Trans proline' 0 N--CA 1.489 1.216 1 C-N-CA 125.314 4.01 . . . . 1.0 111.442 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 40.4 mtp85 -85.11 -39.97 17.31 Favored 'General case' 0 N--CA 1.465 0.321 0 O-C-N 121.362 -0.836 . . . . 1.0 110.02 -179.282 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -79.11 39.67 0.39 Allowed 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.427 -0.795 . . . . 1.0 109.671 -179.624 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 39.3 mtt180 -107.8 125.91 52.0 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.464 -0.772 . . . . 1.0 109.672 179.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.0 mp0 -94.76 113.13 24.86 Favored 'General case' 0 CA--C 1.532 0.284 0 O-C-N 121.472 -0.768 . . . . 1.0 109.224 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -59.74 126.17 26.53 Favored 'General case' 0 CA--C 1.533 0.314 0 O-C-N 121.411 -0.805 . . . . 1.0 110.252 -179.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -98.58 -18.63 18.03 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 121.565 -0.71 . . . . 1.0 109.094 179.582 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -173.21 176.67 45.89 Favored Glycine 0 CA--C 1.529 0.935 0 N-CA-C 108.834 -1.706 . . . . 1.0 108.834 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CD2' HG12 ' A' ' 22' ' ' VAL . 9.4 p90 -65.87 167.34 11.83 Favored Pre-proline 0 CA--C 1.538 0.491 0 O-C-N 121.289 -1.124 . . . . 1.0 108.923 179.771 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.55 -29.46 1.83 Allowed 'Trans proline' 0 N--CA 1.483 0.894 0 C-N-CA 124.492 3.461 . . . . 1.0 110.897 -178.528 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.43 -11.58 10.34 Favored Glycine 0 CA--C 1.538 1.474 0 N-CA-C 110.192 -1.163 . . . . 1.0 110.192 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.432 HG12 ' CD2' ' A' ' 19' ' ' PHE . 22.7 m -61.06 -171.8 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 O-C-N 121.354 -1.086 . . . . 1.0 109.72 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 43.3 p -147.1 152.52 43.59 Favored Pre-proline 0 CA--C 1.535 0.393 0 O-C-N 121.527 -0.733 . . . . 1.0 109.168 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_exo -35.15 -31.43 0.07 OUTLIER 'Trans proline' 0 N--CA 1.488 1.187 1 C-N-CA 125.575 4.183 . . . . 1.0 111.224 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 78.9 p -77.21 -51.21 11.33 Favored 'General case' 0 CA--C 1.532 0.271 0 O-C-N 121.491 -0.756 . . . . 1.0 109.752 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 68.8 mt-30 -63.08 -46.93 85.11 Favored 'General case' 0 N--CA 1.464 0.252 0 O-C-N 121.493 -0.755 . . . . 1.0 109.97 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 13.1 t -62.36 -33.15 74.15 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 121.419 -0.8 . . . . 1.0 109.82 -179.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.84 -3.96 58.61 Favored 'General case' 0 CA--C 1.534 0.346 0 O-C-N 121.444 -0.785 . . . . 1.0 110.056 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -79.73 -39.31 31.4 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.37 -0.831 . . . . 1.0 109.809 -179.534 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 35.4 mtmt -85.18 -46.58 10.95 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.396 -0.815 . . . . 1.0 109.938 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 137.91 11.58 0.93 Allowed Glycine 0 CA--C 1.533 1.174 0 N-CA-C 110.246 -1.141 . . . . 1.0 110.246 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 35.0 m -86.91 136.88 32.79 Favored 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.353 -1.086 . . . . 1.0 108.71 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.6 m -69.7 126.08 28.64 Favored 'General case' 0 N--CA 1.465 0.302 0 O-C-N 121.249 -0.907 . . . . 1.0 109.924 -179.704 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.424 ' CE1' ' HB2' ' A' ' 43' ' ' TRP . 50.3 t80 -94.79 147.34 23.44 Favored 'General case' 0 CA--C 1.531 0.22 0 N-CA-C 109.156 -0.683 . . . . 1.0 109.156 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -154.04 96.31 1.94 Allowed 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.454 -0.779 . . . . 1.0 109.631 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.41 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 6.7 p-10 -104.48 70.64 0.96 Allowed 'General case' 0 CA--C 1.533 0.299 0 O-C-N 121.523 -0.736 . . . . 1.0 109.25 179.821 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 18.2 p -117.64 -42.47 2.86 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.356 -0.84 . . . . 1.0 109.407 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 37.4 t -111.2 159.23 11.32 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 O-C-N 121.438 -0.789 . . . . 1.0 109.415 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 16.4 ttp-105 -100.33 170.37 8.47 Favored 'General case' 0 C--O 1.233 0.201 0 O-C-N 121.412 -0.805 . . . . 1.0 109.425 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.46 -58.29 5.0 Favored Glycine 0 CA--C 1.529 0.922 0 N-CA-C 109.511 -1.436 . . . . 1.0 109.511 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.5 m -70.23 169.25 14.13 Favored Pre-proline 0 CA--C 1.537 0.448 0 O-C-N 121.491 -1.006 . . . . 1.0 109.233 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -87.39 127.11 2.38 Favored 'Trans proline' 0 C--N 1.352 0.72 0 C-N-CA 124.721 3.614 . . . . 1.0 110.15 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.424 ' HB2' ' CE1' ' A' ' 34' ' ' PHE . 11.2 m0 -73.62 -43.45 59.55 Favored 'General case' 0 N--CA 1.464 0.248 0 O-C-N 121.593 -0.692 . . . . 1.0 109.603 -179.665 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 12.3 t -88.3 110.99 21.2 Favored 'General case' 0 CA--C 1.535 0.382 0 O-C-N 121.452 -0.78 . . . . 1.0 109.578 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.401 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 4.2 p90 -141.89 175.9 9.36 Favored 'General case' 0 CA--C 1.538 0.507 0 O-C-N 121.353 -0.842 . . . . 1.0 109.974 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.401 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 18.1 m-85 -74.83 171.43 11.63 Favored Pre-proline 0 CA--C 1.536 0.432 0 O-C-N 121.472 -0.767 . . . . 1.0 109.889 -179.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -94.42 -178.82 0.64 Allowed 'Trans proline' 0 C--N 1.351 0.691 1 C-N-CA 125.336 4.024 . . . . 1.0 110.919 -179.647 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.423 HD21 ' CG2' ' A' ' 9' ' ' VAL . 19.4 m-20 . . . . . 0 CA--C 1.531 0.222 0 O-C-N 121.602 -0.687 . . . . 1.0 109.214 179.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.6 m . . . . . 0 C--O 1.233 0.191 0 N-CA-C 109.574 -0.528 . . . . 1.0 109.574 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 77.6 m -110.51 34.68 3.81 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.523 -0.736 . . . . 1.0 109.229 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.0 t -91.96 125.64 36.73 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.507 -0.745 . . . . 1.0 109.677 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 38.7 t -146.88 163.7 8.02 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 109.085 -0.709 . . . . 1.0 109.085 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -78.59 136.59 59.46 Favored Pre-proline 0 CA--C 1.541 0.624 0 O-C-N 121.467 -0.771 . . . . 1.0 109.233 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_exo -34.74 -57.81 0.4 Allowed 'Trans proline' 0 N--CA 1.488 1.196 1 C-N-CA 125.457 4.105 . . . . 1.0 111.416 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.2 mmt180 -74.49 -32.28 62.49 Favored 'General case' 0 N--CA 1.463 0.194 0 O-C-N 121.488 -0.758 . . . . 1.0 109.895 -179.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -83.05 21.93 1.01 Allowed 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.348 -0.845 . . . . 1.0 109.73 -179.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 69.0 mtt180 -89.98 126.03 35.6 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.444 -0.785 . . . . 1.0 109.418 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -89.01 121.42 31.35 Favored 'General case' 0 CA--C 1.53 0.197 0 O-C-N 121.52 -0.738 . . . . 1.0 109.092 179.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -69.04 118.61 12.16 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.421 -0.799 . . . . 1.0 109.484 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -88.29 -24.16 23.26 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.48 -0.762 . . . . 1.0 109.065 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -169.74 173.79 43.95 Favored Glycine 0 CA--C 1.529 0.914 0 N-CA-C 109.085 -1.606 . . . . 1.0 109.085 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.433 ' CD2' HG12 ' A' ' 22' ' ' VAL . 8.5 p90 -66.5 167.59 12.57 Favored Pre-proline 0 CA--C 1.538 0.493 0 O-C-N 121.439 -1.036 . . . . 1.0 108.924 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -82.09 -30.21 1.35 Allowed 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 124.441 3.427 . . . . 1.0 110.801 -178.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.05 -11.33 8.57 Favored Glycine 0 CA--C 1.537 1.46 0 N-CA-C 110.329 -1.108 . . . . 1.0 110.329 179.593 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.433 HG12 ' CD2' ' A' ' 19' ' ' PHE . 22.3 m -60.73 -169.98 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 O-C-N 121.334 -1.098 . . . . 1.0 109.702 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.445 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 12.8 p -140.85 156.13 68.83 Favored Pre-proline 0 CA--C 1.534 0.356 0 N-CA-C 109.096 -0.705 . . . . 1.0 109.096 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_exo -38.16 -36.23 0.49 Allowed 'Trans proline' 0 N--CA 1.487 1.143 0 C-N-CA 125.14 3.893 . . . . 1.0 110.998 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.3 t -75.98 -41.46 51.29 Favored 'General case' 0 CA--C 1.532 0.273 0 O-C-N 121.557 -0.714 . . . . 1.0 110.141 -179.473 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLN . . . . . 0.445 ' HB2' ' H ' ' A' ' 23' ' ' THR . 5.1 mt-30 -65.2 -50.79 64.51 Favored 'General case' 0 CA--C 1.532 0.261 0 O-C-N 121.431 -0.793 . . . . 1.0 110.002 -179.638 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 11.4 t -61.67 -32.3 72.47 Favored 'General case' 0 CA--C 1.533 0.319 0 O-C-N 121.335 -0.853 . . . . 1.0 109.914 -179.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -89.18 -3.93 58.42 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 121.497 -0.752 . . . . 1.0 110.109 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 41.6 t-20 -73.8 -53.55 10.01 Favored 'General case' 0 N--CA 1.464 0.245 0 O-C-N 121.392 -0.818 . . . . 1.0 109.523 -179.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.2 mttt -73.19 -48.09 38.18 Favored 'General case' 0 C--N 1.332 -0.182 0 O-C-N 121.515 -0.74 . . . . 1.0 109.375 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 136.8 15.67 0.82 Allowed Glycine 0 CA--C 1.532 1.119 0 N-CA-C 109.647 -1.381 . . . . 1.0 109.647 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 36.4 m -82.12 140.61 33.7 Favored 'General case' 0 N--CA 1.463 0.218 0 O-C-N 121.345 -1.091 . . . . 1.0 108.731 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 69.3 m -71.5 123.27 22.05 Favored 'General case' 0 C--N 1.332 -0.189 0 O-C-N 121.368 -0.833 . . . . 1.0 109.66 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 37.0 t80 -94.71 142.72 27.13 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.46 -0.775 . . . . 1.0 109.169 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -160.45 98.96 1.28 Allowed 'General case' 0 C--O 1.233 0.194 0 O-C-N 121.513 -0.742 . . . . 1.0 109.47 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.435 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.0 p-10 -107.44 76.28 1.07 Allowed 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.457 -0.777 . . . . 1.0 109.486 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 70.1 p -120.15 -38.54 2.91 Favored 'General case' 0 CA--C 1.533 0.291 0 O-C-N 121.468 -0.77 . . . . 1.0 109.654 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.8 t -110.75 144.5 18.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 O-C-N 121.397 -0.815 . . . . 1.0 109.7 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.2 mmt180 -88.69 177.16 6.82 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.547 -0.721 . . . . 1.0 109.487 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.71 -62.57 4.36 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 109.092 -1.603 . . . . 1.0 109.092 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 28.7 m -73.1 170.23 14.61 Favored Pre-proline 0 CA--C 1.536 0.406 0 O-C-N 121.63 -0.924 . . . . 1.0 109.096 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -84.34 150.76 11.95 Favored 'Trans proline' 0 C--N 1.351 0.662 0 C-N-CA 124.366 3.377 . . . . 1.0 109.901 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.435 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 7.8 m0 -94.68 -40.58 9.73 Favored 'General case' 0 N--CA 1.465 0.284 0 O-C-N 121.545 -0.722 . . . . 1.0 109.639 -179.218 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 22.7 t -90.29 105.55 17.89 Favored 'General case' 0 CA--C 1.534 0.364 0 O-C-N 121.416 -0.802 . . . . 1.0 109.448 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.433 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 4.9 p90 -128.99 179.26 5.84 Favored 'General case' 0 CA--C 1.534 0.338 0 O-C-N 121.395 -0.816 . . . . 1.0 109.9 -179.863 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.401 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 17.8 m-85 -80.97 170.71 14.48 Favored Pre-proline 0 CA--C 1.538 0.482 0 O-C-N 121.391 -0.818 . . . . 1.0 109.835 -179.596 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -90.58 169.6 3.83 Favored 'Trans proline' 0 C--N 1.352 0.736 0 C-N-CA 124.981 3.787 . . . . 1.0 110.58 179.798 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.2 m120 . . . . . 0 CA--C 1.531 0.215 0 O-C-N 121.469 -0.77 . . . . 1.0 109.011 179.726 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.3 m . . . . . 0 CA--C 1.531 0.249 0 CA-C-O 121.19 0.519 . . . . 1.0 109.625 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 75.8 m -110.73 13.67 22.37 Favored 'General case' 0 CA--C 1.534 0.346 0 O-C-N 121.482 -0.761 . . . . 1.0 109.623 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.4 t -93.97 104.69 16.73 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.444 -0.785 . . . . 1.0 109.565 -179.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 38.6 t -123.4 164.43 21.11 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 O-C-N 121.557 -0.714 . . . . 1.0 109.29 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -69.4 121.96 83.92 Favored Pre-proline 0 CA--C 1.54 0.569 0 O-C-N 121.434 -0.791 . . . . 1.0 109.155 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_exo -38.36 -28.22 0.12 Allowed 'Trans proline' 0 N--CA 1.49 1.29 0 C-N-CA 124.749 3.633 . . . . 1.0 111.357 -179.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 64.8 mtt180 -84.25 -41.26 17.09 Favored 'General case' 0 CA--C 1.533 0.292 0 O-C-N 121.37 -0.831 . . . . 1.0 110.171 -179.252 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 15.0 mm-40 -92.43 44.88 1.17 Allowed 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.45 -0.781 . . . . 1.0 109.748 -179.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 19.3 mtt180 -106.81 141.63 37.73 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.332 -0.855 . . . . 1.0 109.603 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 16.5 mt-30 -111.11 126.67 55.08 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 108.918 -0.771 . . . . 1.0 108.918 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -67.73 117.32 9.49 Favored 'General case' 0 CA--C 1.532 0.285 0 O-C-N 121.427 -0.796 . . . . 1.0 110.673 -178.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.44 ' H ' ' HA ' ' A' ' 45' ' ' PHE . 3.0 t -72.64 -31.32 65.03 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 108.665 -0.865 . . . . 1.0 108.665 178.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -152.88 178.92 29.73 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 109.306 -1.517 . . . . 1.0 109.306 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.436 ' CD2' HG12 ' A' ' 22' ' ' VAL . 6.6 p90 -62.03 169.28 2.89 Favored Pre-proline 0 CA--C 1.541 0.634 0 O-C-N 121.387 -1.067 . . . . 1.0 108.889 179.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -80.43 -31.92 1.44 Allowed 'Trans proline' 0 N--CA 1.482 0.838 0 C-N-CA 124.044 3.163 . . . . 1.0 110.762 -178.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.2 -3.21 6.24 Favored Glycine 0 CA--C 1.537 1.423 0 N-CA-C 110.196 -1.161 . . . . 1.0 110.196 179.704 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.436 HG12 ' CD2' ' A' ' 19' ' ' PHE . 21.9 m -62.82 170.73 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 O-C-N 121.148 -1.207 . . . . 1.0 109.686 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.8 p -130.21 155.72 80.41 Favored Pre-proline 0 CA--C 1.534 0.361 0 N-CA-C 108.962 -0.755 . . . . 1.0 108.962 179.714 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -35.95 -38.7 0.28 Allowed 'Trans proline' 0 N--CA 1.488 1.18 0 C-N-CA 125.254 3.969 . . . . 1.0 111.188 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 79.4 p -70.9 -46.23 62.91 Favored 'General case' 0 CA--C 1.533 0.291 0 O-C-N 121.447 -0.783 . . . . 1.0 110.043 -179.583 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -62.19 -49.1 77.12 Favored 'General case' 0 N--CA 1.465 0.321 0 O-C-N 121.366 -0.834 . . . . 1.0 110.024 -179.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 7.2 t -62.54 -25.12 67.88 Favored 'General case' 0 CA--C 1.533 0.297 0 O-C-N 121.407 -0.808 . . . . 1.0 109.808 -179.715 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -95.95 -5.32 41.62 Favored 'General case' 0 CA--C 1.534 0.363 0 O-C-N 121.391 -0.818 . . . . 1.0 110.309 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -98.11 -23.39 15.75 Favored 'General case' 0 N--CA 1.465 0.281 0 O-C-N 121.223 -0.923 . . . . 1.0 109.726 -179.619 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.1 mmtm -91.41 -15.2 29.29 Favored 'General case' 0 CA--C 1.533 0.289 0 O-C-N 121.311 -0.868 . . . . 1.0 109.736 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.99 14.81 41.29 Favored Glycine 0 CA--C 1.532 1.143 0 N-CA-C 109.988 -1.245 . . . . 1.0 109.988 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 56.3 m -94.3 148.52 22.13 Favored 'General case' 0 N--CA 1.465 0.298 0 O-C-N 121.402 -1.058 . . . . 1.0 108.808 179.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.431 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 58.4 m -80.7 126.71 31.63 Favored 'General case' 0 CA--C 1.532 0.267 0 O-C-N 121.343 -0.848 . . . . 1.0 109.713 -179.638 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -98.84 128.13 44.96 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 108.799 -0.815 . . . . 1.0 108.799 179.334 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -141.38 117.32 10.5 Favored 'General case' 0 N--CA 1.464 0.256 0 O-C-N 121.465 -0.772 . . . . 1.0 109.864 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.428 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 7.2 p-10 -112.14 72.92 0.79 Allowed 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.594 -0.691 . . . . 1.0 109.21 179.513 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.1 p -104.08 -61.92 1.38 Allowed 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.368 -0.832 . . . . 1.0 109.619 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.6 t -103.5 154.72 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 O-C-N 121.451 -0.781 . . . . 1.0 109.415 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.94 171.85 8.85 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.479 -0.763 . . . . 1.0 109.487 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.08 -49.64 4.15 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 109.477 -1.449 . . . . 1.0 109.477 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.7 m -73.81 169.36 19.06 Favored Pre-proline 0 CA--C 1.536 0.422 0 O-C-N 121.553 -0.969 . . . . 1.0 109.333 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_endo -89.08 127.1 1.74 Allowed 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 124.838 3.692 . . . . 1.0 109.901 179.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.428 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 13.6 m0 -77.27 -51.5 10.8 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.51 -0.744 . . . . 1.0 109.367 -179.719 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 5.2 t -74.88 111.63 10.28 Favored 'General case' 0 CA--C 1.531 0.241 0 N-CA-C 108.616 -0.883 . . . . 1.0 108.616 179.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.44 ' HA ' ' H ' ' A' ' 17' ' ' CYS . 2.3 p90 -140.86 175.32 9.71 Favored 'General case' 0 N--CA 1.468 0.429 0 O-C-N 121.449 -0.782 . . . . 1.0 110.185 -179.686 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 41.7 m-85 -74.17 160.55 81.3 Favored Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 121.405 -0.81 . . . . 1.0 110.128 -179.243 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -90.03 174.32 3.23 Favored 'Trans proline' 0 C--N 1.352 0.74 0 C-N-CA 124.96 3.774 . . . . 1.0 110.401 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 4.0 m120 . . . . . 0 CA--C 1.53 0.203 0 O-C-N 121.541 -0.724 . . . . 1.0 109.491 179.867 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.7 m . . . . . 0 CA--C 1.53 0.209 0 N-CA-C 109.402 -0.592 . . . . 1.0 109.402 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 73.1 m -86.95 11.97 12.27 Favored 'General case' 0 CA--C 1.534 0.35 0 O-C-N 121.544 -0.722 . . . . 1.0 109.641 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.4 t -85.41 117.96 24.65 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.257 -0.902 . . . . 1.0 109.677 -179.77 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 37.7 t -140.95 168.24 16.5 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 O-C-N 121.419 -0.8 . . . . 1.0 109.126 179.649 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -84.42 138.32 38.82 Favored Pre-proline 0 CA--C 1.538 0.487 0 O-C-N 121.351 -0.843 . . . . 1.0 109.439 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_exo -34.75 -40.38 0.22 Allowed 'Trans proline' 0 N--CA 1.489 1.222 1 C-N-CA 125.511 4.141 . . . . 1.0 111.276 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 25.7 mtt85 -85.26 -46.57 10.9 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.472 -0.767 . . . . 1.0 109.699 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -67.31 -5.0 12.33 Favored 'General case' 0 CA--C 1.534 0.328 0 O-C-N 121.505 -0.747 . . . . 1.0 110.023 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.8 mtt180 -70.38 126.11 28.72 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.36 -0.838 . . . . 1.0 109.52 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 11.2 mm100 -87.07 123.09 31.76 Favored 'General case' 0 C--N 1.332 -0.168 0 O-C-N 121.478 -0.764 . . . . 1.0 109.252 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -65.7 111.39 3.18 Favored 'General case' 0 N--CA 1.464 0.238 0 O-C-N 121.559 -0.713 . . . . 1.0 109.745 -179.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 41.8 t -82.04 -16.42 50.23 Favored 'General case' 0 CA--C 1.534 0.351 0 O-C-N 121.431 -0.793 . . . . 1.0 109.339 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.59 179.08 44.01 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 109.061 -1.615 . . . . 1.0 109.061 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.422 ' CE2' HG11 ' A' ' 22' ' ' VAL . 8.2 p90 -65.04 167.73 9.01 Favored Pre-proline 0 CA--C 1.539 0.548 0 O-C-N 121.306 -1.114 . . . . 1.0 108.838 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.54 -30.59 1.42 Allowed 'Trans proline' 0 N--CA 1.482 0.814 0 C-N-CA 124.39 3.393 . . . . 1.0 110.881 -178.658 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.62 -8.77 7.9 Favored Glycine 0 CA--C 1.537 1.441 0 N-CA-C 110.25 -1.14 . . . . 1.0 110.25 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.422 HG11 ' CE2' ' A' ' 19' ' ' PHE . 20.0 m -61.16 177.24 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 O-C-N 121.228 -1.16 . . . . 1.0 109.669 179.766 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.0 p -138.89 156.24 72.73 Favored Pre-proline 0 CA--C 1.535 0.389 0 O-C-N 121.54 -0.725 . . . . 1.0 109.225 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -34.91 -32.04 0.07 OUTLIER 'Trans proline' 0 N--CA 1.487 1.12 1 C-N-CA 125.56 4.174 . . . . 1.0 111.171 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 1.8 m -72.12 -51.94 19.08 Favored 'General case' 0 CA--C 1.532 0.281 0 O-C-N 121.419 -0.801 . . . . 1.0 109.614 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 52.3 mt-30 -62.78 -46.01 90.0 Favored 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.47 -0.769 . . . . 1.0 109.772 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.2 t -64.59 -23.8 67.38 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.401 -0.812 . . . . 1.0 109.563 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -94.12 -7.12 43.37 Favored 'General case' 0 CA--C 1.535 0.399 0 O-C-N 121.383 -0.823 . . . . 1.0 109.881 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -73.38 -39.26 65.27 Favored 'General case' 0 CA--C 1.532 0.281 0 O-C-N 121.269 -0.895 . . . . 1.0 109.418 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -92.49 -38.39 11.98 Favored 'General case' 0 N--CA 1.462 0.171 0 O-C-N 121.523 -0.736 . . . . 1.0 109.425 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 113.95 37.93 1.21 Allowed Glycine 0 CA--C 1.53 1.024 0 N-CA-C 109.631 -1.388 . . . . 1.0 109.631 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.8 m -97.52 145.01 26.65 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.472 -1.017 . . . . 1.0 109.273 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.404 ' O ' ' CD1' ' A' ' 45' ' ' PHE . 58.4 m -68.28 119.56 13.02 Favored 'General case' 0 CA--C 1.532 0.267 0 O-C-N 121.398 -0.814 . . . . 1.0 109.426 -179.677 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 43.7 t80 -92.02 146.85 23.41 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.386 -0.821 . . . . 1.0 109.258 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 10.6 t0 -162.12 110.43 1.41 Allowed 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.353 -0.842 . . . . 1.0 109.537 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.423 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 13.6 p30 -110.63 70.77 0.73 Allowed 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.501 -0.749 . . . . 1.0 109.442 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.8 p -111.82 -53.31 2.72 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.403 -0.811 . . . . 1.0 109.737 -179.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 35.6 t -96.3 159.38 2.98 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 O-C-N 121.341 -0.849 . . . . 1.0 109.639 -179.692 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.2 mmm180 -103.82 169.13 8.69 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 121.473 -0.767 . . . . 1.0 109.263 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.75 -42.63 2.49 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 109.355 -1.498 . . . . 1.0 109.355 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.4 m -80.34 169.68 18.77 Favored Pre-proline 0 CA--C 1.537 0.466 0 O-C-N 121.538 -0.978 . . . . 1.0 109.082 179.768 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -87.3 131.77 3.05 Favored 'Trans proline' 0 C--N 1.351 0.682 0 C-N-CA 124.712 3.608 . . . . 1.0 110.011 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.423 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 15.3 m0 -80.15 -39.45 29.34 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.46 -0.775 . . . . 1.0 109.738 -179.482 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 16.0 t -90.01 107.78 19.32 Favored 'General case' 0 CA--C 1.534 0.338 0 O-C-N 121.412 -0.805 . . . . 1.0 109.486 179.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.423 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 5.6 p90 -133.52 175.9 9.01 Favored 'General case' 0 CA--C 1.536 0.412 0 O-C-N 121.452 -0.78 . . . . 1.0 109.757 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.406 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 31.9 m-85 -85.34 170.84 12.09 Favored Pre-proline 0 CA--C 1.537 0.462 0 O-C-N 121.532 -0.73 . . . . 1.0 109.351 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -90.96 177.06 2.15 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 124.968 3.779 . . . . 1.0 110.39 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.2 m120 . . . . . 0 CA--C 1.53 0.188 0 O-C-N 121.569 -0.707 . . . . 1.0 109.597 179.953 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.463 0.175 0 N-CA-C 109.327 -0.62 . . . . 1.0 109.327 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 62.3 m -114.9 28.24 8.85 Favored 'General case' 0 C--O 1.232 0.15 0 O-C-N 121.496 -0.752 . . . . 1.0 109.326 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.6 t -95.39 122.82 38.51 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.362 -0.836 . . . . 1.0 109.586 -179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.3 t -147.11 167.67 5.5 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.198 0 O-C-N 121.5 -0.75 . . . . 1.0 109.283 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -76.66 124.97 87.83 Favored Pre-proline 0 CA--C 1.541 0.609 0 O-C-N 121.438 -0.789 . . . . 1.0 109.354 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_exo -36.87 -50.37 1.45 Allowed 'Trans proline' 0 N--CA 1.49 1.302 0 C-N-CA 124.922 3.748 . . . . 1.0 111.242 -179.675 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.6 mtp180 -70.21 -49.12 53.38 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.458 -0.776 . . . . 1.0 109.652 -179.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 25.0 mt-10 -82.61 40.36 0.66 Allowed 'General case' 0 CA--C 1.53 0.211 0 O-C-N 121.46 -0.775 . . . . 1.0 109.52 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 26.2 mtt180 -92.4 139.34 30.7 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.473 -0.767 . . . . 1.0 109.476 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -85.46 108.48 17.91 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.522 -0.736 . . . . 1.0 109.162 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -64.59 120.48 12.43 Favored 'General case' 0 CA--C 1.532 0.275 0 O-C-N 121.485 -0.759 . . . . 1.0 109.668 -179.72 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 28.2 t -95.75 -19.48 19.63 Favored 'General case' 0 CA--C 1.534 0.327 0 O-C-N 121.586 -0.696 . . . . 1.0 109.456 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 175.3 -179.03 46.79 Favored Glycine 0 CA--C 1.528 0.871 0 N-CA-C 109.232 -1.547 . . . . 1.0 109.232 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.427 ' CD2' HG12 ' A' ' 22' ' ' VAL . 9.1 p90 -65.72 167.97 9.84 Favored Pre-proline 0 CA--C 1.537 0.455 0 O-C-N 121.369 -1.077 . . . . 1.0 108.929 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.68 -30.15 1.53 Allowed 'Trans proline' 0 N--CA 1.483 0.902 0 C-N-CA 124.418 3.412 . . . . 1.0 110.809 -178.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -57.16 -12.16 7.4 Favored Glycine 0 CA--C 1.536 1.401 0 N-CA-C 110.401 -1.079 . . . . 1.0 110.401 179.597 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.427 HG12 ' CD2' ' A' ' 19' ' ' PHE . 24.2 m -61.3 162.92 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 O-C-N 121.253 -1.145 . . . . 1.0 109.641 179.694 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.4 p -121.6 154.75 60.05 Favored Pre-proline 0 CA--C 1.534 0.35 0 O-C-N 121.505 -0.747 . . . . 1.0 109.311 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.0 Cg_exo -35.8 -38.75 0.27 Allowed 'Trans proline' 0 N--CA 1.487 1.119 1 C-N-CA 125.479 4.12 . . . . 1.0 111.258 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 1.9 p -69.91 -48.08 59.97 Favored 'General case' 0 N--CA 1.463 0.213 0 O-C-N 121.511 -0.743 . . . . 1.0 109.791 -179.826 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -62.72 -46.15 89.42 Favored 'General case' 0 CA--C 1.533 0.322 0 O-C-N 121.4 -0.813 . . . . 1.0 109.749 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 17.3 t -64.59 -26.79 68.56 Favored 'General case' 0 CA--C 1.531 0.213 0 O-C-N 121.431 -0.793 . . . . 1.0 109.368 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.56 -8.85 54.06 Favored 'General case' 0 CA--C 1.532 0.271 0 O-C-N 121.562 -0.711 . . . . 1.0 109.811 179.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -77.94 -38.42 45.46 Favored 'General case' 0 CA--C 1.53 0.18 0 O-C-N 121.245 -0.91 . . . . 1.0 109.373 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.4 mmtt -83.69 -41.44 17.72 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 121.429 -0.794 . . . . 1.0 109.41 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 118.07 38.45 0.81 Allowed Glycine 0 CA--C 1.531 1.055 0 N-CA-C 109.569 -1.412 . . . . 1.0 109.569 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.7 m -112.61 147.97 35.56 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.606 -0.938 . . . . 1.0 109.485 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 66.4 m -69.5 125.14 25.82 Favored 'General case' 0 CA--C 1.529 0.163 0 O-C-N 121.477 -0.765 . . . . 1.0 109.36 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -99.1 143.13 29.71 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.508 -0.745 . . . . 1.0 109.367 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -157.0 113.9 3.06 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 121.529 -0.732 . . . . 1.0 109.503 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.413 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.9 p-10 -111.54 60.27 0.62 Allowed 'General case' 0 CA--C 1.533 0.321 0 O-C-N 121.492 -0.755 . . . . 1.0 109.39 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 67.7 p -99.8 -56.64 2.33 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.356 -0.84 . . . . 1.0 109.569 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.5 t -98.23 161.88 2.87 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.22 0 O-C-N 121.485 -0.76 . . . . 1.0 109.425 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 4.0 mpt_? -104.95 173.59 6.24 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.506 -0.746 . . . . 1.0 109.448 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.31 -45.53 3.06 Favored Glycine 0 CA--C 1.529 0.936 0 N-CA-C 109.477 -1.449 . . . . 1.0 109.477 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.6 m -79.37 169.52 20.01 Favored Pre-proline 0 CA--C 1.536 0.413 0 O-C-N 121.56 -0.965 . . . . 1.0 109.321 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -87.42 127.84 2.47 Favored 'Trans proline' 0 C--N 1.35 0.657 0 C-N-CA 124.805 3.67 . . . . 1.0 109.987 179.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.413 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 16.6 m0 -74.6 -38.54 62.58 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.457 -0.777 . . . . 1.0 109.918 -179.439 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 8.3 t -89.59 109.15 20.13 Favored 'General case' 0 CA--C 1.533 0.318 0 O-C-N 121.352 -0.842 . . . . 1.0 109.609 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.419 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 4.9 p90 -135.65 -178.69 5.24 Favored 'General case' 0 CA--C 1.535 0.397 0 O-C-N 121.415 -0.803 . . . . 1.0 109.463 179.708 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.402 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 18.6 m-85 -90.68 167.1 17.17 Favored Pre-proline 0 CA--C 1.536 0.426 0 O-C-N 121.487 -0.758 . . . . 1.0 109.592 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -91.23 148.65 3.66 Favored 'Trans proline' 0 C--N 1.35 0.628 0 C-N-CA 124.998 3.799 . . . . 1.0 110.461 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.6 m120 . . . . . 0 C--N 1.332 -0.173 0 N-CA-C 109.126 -0.694 . . . . 1.0 109.126 179.664 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.531 0.247 0 N-CA-C 109.53 -0.545 . . . . 1.0 109.53 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 74.0 m -107.04 19.98 19.67 Favored 'General case' 0 CA--C 1.532 0.277 0 O-C-N 121.539 -0.725 . . . . 1.0 109.548 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.8 t -82.89 94.87 7.79 Favored 'General case' 0 CA--C 1.532 0.286 0 O-C-N 121.456 -0.777 . . . . 1.0 109.749 -179.628 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 39.8 t -122.16 155.04 26.95 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 O-C-N 121.526 -0.734 . . . . 1.0 109.035 179.639 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -81.23 137.49 49.08 Favored Pre-proline 0 CA--C 1.539 0.533 0 O-C-N 121.387 -0.82 . . . . 1.0 109.378 -179.731 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_exo -35.39 -36.41 0.15 Allowed 'Trans proline' 0 N--CA 1.488 1.159 1 C-N-CA 125.398 4.065 . . . . 1.0 111.266 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 19.6 mtp180 -74.47 -49.91 20.4 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.529 -0.732 . . . . 1.0 109.674 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 7.7 mm-40 -81.38 27.64 0.41 Allowed 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.481 -0.762 . . . . 1.0 109.808 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 32.2 mtt180 -100.73 146.31 27.38 Favored 'General case' 0 N--CA 1.464 0.23 0 O-C-N 121.433 -0.792 . . . . 1.0 109.418 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 16.7 mt-30 -120.38 154.76 34.65 Favored 'General case' 0 C--N 1.332 -0.194 0 O-C-N 121.518 -0.739 . . . . 1.0 109.297 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -80.32 125.15 29.53 Favored 'General case' 0 CA--C 1.53 0.197 0 O-C-N 121.498 -0.751 . . . . 1.0 109.132 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -98.62 -23.71 15.37 Favored 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.455 -0.778 . . . . 1.0 109.303 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -167.13 -179.81 40.35 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 109.021 -1.632 . . . . 1.0 109.021 179.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.455 ' CE2' ' CG1' ' A' ' 22' ' ' VAL . 7.8 p90 -67.68 167.17 17.31 Favored Pre-proline 0 CA--C 1.537 0.471 0 O-C-N 121.348 -1.09 . . . . 1.0 108.826 179.81 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -82.31 -29.57 1.48 Allowed 'Trans proline' 0 N--CA 1.483 0.908 0 C-N-CA 124.551 3.501 . . . . 1.0 110.914 -178.576 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -55.6 -15.34 8.52 Favored Glycine 0 CA--C 1.535 1.324 0 N-CA-C 110.35 -1.1 . . . . 1.0 110.35 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.455 ' CG1' ' CE2' ' A' ' 19' ' ' PHE . 22.6 m -63.22 151.55 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 O-C-N 121.326 -1.103 . . . . 1.0 109.543 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.495 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 73.0 p -99.7 154.64 37.16 Favored Pre-proline 0 CA--C 1.536 0.422 0 N-CA-C 108.99 -0.745 . . . . 1.0 108.99 179.311 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -33.18 -55.68 0.38 Allowed 'Trans proline' 0 N--CA 1.487 1.113 1 C-N-CA 125.797 4.332 . . . . 1.0 111.862 -179.454 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 67.6 m -80.12 -27.38 39.15 Favored 'General case' 0 N--CA 1.464 0.245 0 O-C-N 121.43 -0.793 . . . . 1.0 110.565 -179.041 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLN . . . . . 0.495 ' HB2' ' H ' ' A' ' 23' ' ' THR . 10.5 mt-30 -61.46 -54.51 42.44 Favored 'General case' 0 N--CA 1.466 0.353 0 O-C-N 121.287 -0.883 . . . . 1.0 110.332 -179.47 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -77.5 -27.2 51.77 Favored 'General case' 0 CA--C 1.534 0.333 0 O-C-N 121.393 -0.817 . . . . 1.0 109.886 -179.261 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.72 -5.01 57.73 Favored 'General case' 0 CA--C 1.534 0.365 0 O-C-N 121.422 -0.799 . . . . 1.0 110.113 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -106.8 -4.39 19.36 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.316 -0.865 . . . . 1.0 109.8 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.1 tttt -89.9 -46.69 8.37 Favored 'General case' 0 CA--C 1.533 0.289 0 O-C-N 121.269 -0.895 . . . . 1.0 109.196 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 151.22 19.14 0.06 OUTLIER Glycine 0 CA--C 1.531 1.054 0 N-CA-C 109.528 -1.429 . . . . 1.0 109.528 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 85.6 m -119.17 148.96 42.51 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.423 -1.045 . . . . 1.0 109.285 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 55.9 m -77.49 115.63 17.41 Favored 'General case' 0 N--CA 1.463 0.221 0 O-C-N 121.557 -0.715 . . . . 1.0 109.083 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.436 ' CD1' ' N ' ' A' ' 35' ' ' ASP . 46.5 t80 -89.95 152.37 21.24 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.446 -0.784 . . . . 1.0 109.722 -179.618 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . 0.436 ' N ' ' CD1' ' A' ' 34' ' ' PHE . 28.5 t70 -165.29 118.7 1.21 Allowed 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.589 -0.694 . . . . 1.0 109.309 179.724 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -120.34 51.54 1.21 Allowed 'General case' 0 CA--C 1.534 0.329 0 O-C-N 121.532 -0.73 . . . . 1.0 109.547 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.467 ' H ' ' HG1' ' A' ' 37' ' ' THR . 0.9 OUTLIER -99.77 -15.59 18.4 Favored 'General case' 0 CA--C 1.533 0.317 0 O-C-N 121.308 -0.87 . . . . 1.0 109.937 -179.856 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 37.3 t -129.71 161.02 40.1 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.222 0 O-C-N 121.335 -0.853 . . . . 1.0 109.625 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 79.5 mtt85 -111.89 166.96 10.75 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.516 -0.74 . . . . 1.0 109.379 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.55 -41.99 2.38 Favored Glycine 0 CA--C 1.53 0.986 0 N-CA-C 109.234 -1.546 . . . . 1.0 109.234 -179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 28.9 m -81.1 170.63 14.75 Favored Pre-proline 0 CA--C 1.537 0.478 0 O-C-N 121.587 -0.949 . . . . 1.0 109.049 179.73 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -85.87 126.31 2.89 Favored 'Trans proline' 0 C--N 1.352 0.744 0 C-N-CA 124.539 3.493 . . . . 1.0 110.018 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . . . . . . . . . 33.8 m0 -75.41 -37.6 60.35 Favored 'General case' 0 N--CA 1.462 0.169 0 O-C-N 121.429 -0.794 . . . . 1.0 109.91 -179.536 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 6.5 t -90.08 113.99 25.82 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.415 -0.803 . . . . 1.0 109.539 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.416 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 5.7 p90 -140.02 170.91 14.98 Favored 'General case' 0 CA--C 1.536 0.424 0 O-C-N 121.388 -0.82 . . . . 1.0 110.025 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 61.8 m-85 -77.06 170.59 15.6 Favored Pre-proline 0 CA--C 1.537 0.443 0 O-C-N 121.674 -0.641 . . . . 1.0 109.419 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -88.18 173.12 4.92 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 124.829 3.686 . . . . 1.0 110.415 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.5 m120 . . . . . 0 CA--C 1.531 0.215 0 O-C-N 121.664 -0.647 . . . . 1.0 109.346 179.905 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.7 m . . . . . 0 C--O 1.233 0.198 0 CA-C-O 121.302 0.572 . . . . 1.0 109.953 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 86.2 m -108.07 -18.53 13.76 Favored 'General case' 0 CA--C 1.534 0.336 0 O-C-N 121.444 -0.785 . . . . 1.0 109.216 179.337 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.1 t -68.78 101.42 1.33 Allowed 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.201 -0.937 . . . . 1.0 109.521 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.406 HG22 HD21 ' A' ' 48' ' ' ASN . 38.6 t -121.82 171.16 11.02 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 O-C-N 121.575 -0.703 . . . . 1.0 109.233 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.4 ' N ' ' CG1' ' A' ' 9' ' ' VAL . . . -67.99 129.17 93.25 Favored Pre-proline 0 CA--C 1.539 0.541 0 O-C-N 121.355 -0.84 . . . . 1.0 109.483 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -36.95 -50.21 1.48 Allowed 'Trans proline' 0 N--CA 1.49 1.281 0 C-N-CA 125.027 3.818 . . . . 1.0 111.227 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -70.75 -39.55 73.21 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.502 -0.749 . . . . 1.0 109.833 -179.591 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -81.42 29.24 0.37 Allowed 'General case' 0 CA--C 1.532 0.254 0 O-C-N 121.529 -0.732 . . . . 1.0 109.716 -179.72 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 37.9 mtt180 -101.41 120.63 40.57 Favored 'General case' 0 N--CA 1.464 0.248 0 O-C-N 121.417 -0.802 . . . . 1.0 109.368 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 -79.86 121.43 25.4 Favored 'General case' 0 CA--C 1.531 0.216 0 O-C-N 121.491 -0.756 . . . . 1.0 109.261 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -63.91 121.4 13.98 Favored 'General case' 0 CA--C 1.532 0.261 0 O-C-N 121.517 -0.74 . . . . 1.0 109.911 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.3 t -93.73 -20.33 20.23 Favored 'General case' 0 CA--C 1.534 0.351 0 O-C-N 121.562 -0.711 . . . . 1.0 109.272 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 179.57 177.23 47.71 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 109.178 -1.569 . . . . 1.0 109.178 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.433 ' CD2' HG12 ' A' ' 22' ' ' VAL . 8.8 p90 -65.01 167.7 9.0 Favored Pre-proline 0 CA--C 1.538 0.516 0 O-C-N 121.446 -1.032 . . . . 1.0 108.885 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.58 -30.67 1.38 Allowed 'Trans proline' 0 N--CA 1.481 0.777 0 C-N-CA 124.45 3.433 . . . . 1.0 110.802 -178.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.46 -10.04 7.22 Favored Glycine 0 CA--C 1.537 1.454 0 N-CA-C 110.307 -1.117 . . . . 1.0 110.307 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.433 HG12 ' CD2' ' A' ' 19' ' ' PHE . 24.2 m -60.66 -174.74 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 O-C-N 121.231 -1.158 . . . . 1.0 109.531 179.763 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.1 p -143.74 153.72 58.28 Favored Pre-proline 0 CA--C 1.537 0.45 0 O-C-N 121.515 -0.741 . . . . 1.0 109.285 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -35.85 -36.97 0.2 Allowed 'Trans proline' 0 N--CA 1.487 1.134 1 C-N-CA 125.32 4.013 . . . . 1.0 111.382 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.6 t -73.73 -47.34 40.04 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.442 -0.786 . . . . 1.0 109.756 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 45.0 mt-30 -61.65 -44.73 96.42 Favored 'General case' 0 N--CA 1.466 0.327 0 O-C-N 121.436 -0.79 . . . . 1.0 109.674 -179.831 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 8.5 t -65.34 -32.63 74.37 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 121.486 -0.758 . . . . 1.0 109.382 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.6 -4.16 59.08 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 121.615 -0.678 . . . . 1.0 109.938 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -86.22 -23.55 26.39 Favored 'General case' 0 N--CA 1.464 0.258 0 O-C-N 121.218 -0.926 . . . . 1.0 109.636 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.3 tppp? -101.41 -34.94 9.38 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.379 -0.826 . . . . 1.0 109.315 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 111.49 53.62 0.52 Allowed Glycine 0 CA--C 1.529 0.955 0 N-CA-C 109.414 -1.475 . . . . 1.0 109.414 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.7 m -128.7 139.24 52.33 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.544 -0.974 . . . . 1.0 109.363 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.404 ' O ' ' CD1' ' A' ' 45' ' ' PHE . 56.0 m -61.47 119.8 9.27 Favored 'General case' 0 N--CA 1.468 0.448 0 O-C-N 121.462 -0.774 . . . . 1.0 109.964 -179.344 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -101.51 121.56 42.19 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.423 -0.798 . . . . 1.0 109.192 179.623 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 22.5 t0 -134.6 114.24 12.57 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.493 -0.754 . . . . 1.0 109.61 -179.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.415 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 5.8 p-10 -112.0 54.82 0.69 Allowed 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.503 -0.748 . . . . 1.0 109.156 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 39.3 p -104.01 -31.27 9.79 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.377 -0.827 . . . . 1.0 109.61 -179.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 34.9 t -114.88 151.76 16.58 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 O-C-N 121.406 -0.809 . . . . 1.0 109.478 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.403 ' C ' ' H ' ' A' ' 41' ' ' VAL . 21.7 mtm-85 -101.77 165.65 11.09 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 121.497 -0.752 . . . . 1.0 109.471 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.54 -33.79 2.52 Favored Glycine 0 CA--C 1.53 1.017 0 N-CA-C 109.457 -1.457 . . . . 1.0 109.457 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.403 ' H ' ' C ' ' A' ' 39' ' ' ARG . 28.5 m -88.13 169.99 12.52 Favored Pre-proline 0 CA--C 1.537 0.473 0 O-C-N 121.521 -0.988 . . . . 1.0 109.222 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -86.63 123.57 2.15 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 124.724 3.616 . . . . 1.0 110.04 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.415 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 23.9 m0 -75.3 -43.93 48.34 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.555 -0.716 . . . . 1.0 109.873 -179.515 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.6 t -88.8 109.11 19.91 Favored 'General case' 0 CA--C 1.535 0.365 0 O-C-N 121.328 -0.857 . . . . 1.0 109.915 -179.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.428 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 7.1 p90 -138.9 177.33 7.97 Favored 'General case' 0 CA--C 1.537 0.453 0 O-C-N 121.461 -0.775 . . . . 1.0 109.547 179.259 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.428 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 70.6 m-85 -78.78 169.32 21.22 Favored Pre-proline 0 CA--C 1.537 0.463 0 O-C-N 121.271 -0.893 . . . . 1.0 109.975 -179.568 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -92.34 167.69 2.86 Favored 'Trans proline' 0 C--N 1.352 0.711 0 C-N-CA 125.047 3.831 . . . . 1.0 110.582 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.406 HD21 HG22 ' A' ' 9' ' ' VAL . 23.1 m-20 . . . . . 0 N--CA 1.463 0.222 0 O-C-N 121.466 -0.771 . . . . 1.0 109.273 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.53 0.208 0 CA-C-O 121.148 0.499 . . . . 1.0 109.667 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.5 m -117.18 46.18 1.74 Allowed 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.463 -0.773 . . . . 1.0 109.314 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.9 t -131.01 106.89 8.7 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.517 -0.739 . . . . 1.0 109.369 179.82 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.438 ' CG1' ' H ' ' A' ' 10' ' ' ALA . 21.7 t -125.09 174.09 9.82 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 O-C-N 121.369 -0.832 . . . . 1.0 109.34 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.438 ' H ' ' CG1' ' A' ' 9' ' ' VAL . . . -74.92 140.33 74.0 Favored Pre-proline 0 CA--C 1.538 0.508 0 O-C-N 121.479 -0.763 . . . . 1.0 109.57 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_exo -34.81 -61.24 0.25 Allowed 'Trans proline' 0 N--CA 1.488 1.171 1 C-N-CA 125.484 4.122 . . . . 1.0 111.566 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -69.93 -29.95 67.22 Favored 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.476 -0.765 . . . . 1.0 110.107 -179.287 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -85.29 36.62 0.64 Allowed 'General case' 0 N--CA 1.464 0.252 0 O-C-N 121.289 -0.882 . . . . 1.0 109.642 -179.736 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 50.4 mtt180 -108.1 142.94 37.54 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.508 -0.745 . . . . 1.0 109.435 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -102.35 115.02 29.71 Favored 'General case' 0 N--CA 1.463 0.195 0 O-C-N 121.547 -0.721 . . . . 1.0 109.399 179.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 48.9 t30 -61.06 118.7 7.1 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 121.391 -0.818 . . . . 1.0 109.784 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 t -94.51 -18.85 21.06 Favored 'General case' 0 CA--C 1.534 0.352 0 O-C-N 121.463 -0.773 . . . . 1.0 109.247 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.43 178.2 47.8 Favored Glycine 0 CA--C 1.53 0.976 0 N-CA-C 108.967 -1.653 . . . . 1.0 108.967 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.445 ' CE2' ' CG1' ' A' ' 22' ' ' VAL . 8.5 p90 -65.92 167.81 10.68 Favored Pre-proline 0 CA--C 1.539 0.542 0 O-C-N 121.369 -1.077 . . . . 1.0 108.799 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -82.12 -30.09 1.38 Allowed 'Trans proline' 0 N--CA 1.483 0.855 0 C-N-CA 124.38 3.387 . . . . 1.0 110.992 -178.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -56.62 -13.73 8.33 Favored Glycine 0 CA--C 1.536 1.358 0 N-CA-C 110.36 -1.096 . . . . 1.0 110.36 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.445 ' CG1' ' CE2' ' A' ' 19' ' ' PHE . 20.4 m -60.7 173.54 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 O-C-N 121.239 -1.153 . . . . 1.0 109.768 179.849 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 73.6 p -131.84 155.7 81.06 Favored Pre-proline 0 CA--C 1.534 0.339 0 O-C-N 121.524 -0.735 . . . . 1.0 109.143 179.773 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -35.74 -33.82 0.12 Allowed 'Trans proline' 0 N--CA 1.49 1.267 1 C-N-CA 125.354 4.036 . . . . 1.0 111.233 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 39.7 m -75.68 -47.74 24.98 Favored 'General case' 0 CA--C 1.532 0.253 0 O-C-N 121.396 -0.815 . . . . 1.0 109.956 -179.622 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -65.3 -47.25 77.25 Favored 'General case' 0 CA--C 1.533 0.307 0 O-C-N 121.468 -0.77 . . . . 1.0 109.85 -179.689 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 11.2 t -62.48 -29.86 70.84 Favored 'General case' 0 N--CA 1.464 0.269 0 O-C-N 121.408 -0.808 . . . . 1.0 109.796 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -90.52 -9.79 45.95 Favored 'General case' 0 N--CA 1.465 0.281 0 O-C-N 121.464 -0.772 . . . . 1.0 110.098 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -93.03 -5.09 51.33 Favored 'General case' 0 CA--C 1.534 0.34 0 O-C-N 121.224 -0.923 . . . . 1.0 110.028 -179.762 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 51.9 mttp -109.52 -27.28 9.51 Favored 'General case' 0 N--CA 1.464 0.246 0 O-C-N 121.337 -0.852 . . . . 1.0 109.544 -179.794 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.08 22.66 5.83 Favored Glycine 0 CA--C 1.53 0.993 0 N-CA-C 109.568 -1.413 . . . . 1.0 109.568 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 22.8 m -112.74 137.21 51.38 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.469 -1.018 . . . . 1.0 108.564 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.6 m -72.85 133.87 44.62 Favored 'General case' 0 N--CA 1.463 0.222 0 O-C-N 121.316 -0.865 . . . . 1.0 109.735 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -101.68 139.63 37.07 Favored 'General case' 0 C--O 1.232 0.163 0 O-C-N 121.626 -0.671 . . . . 1.0 109.223 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -148.62 102.39 3.3 Favored 'General case' 0 N--CA 1.463 0.202 0 O-C-N 121.306 -0.871 . . . . 1.0 109.591 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.423 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 7.0 p-10 -104.9 73.93 1.1 Allowed 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.525 -0.735 . . . . 1.0 109.294 179.83 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.429 ' HG1' ' N ' ' A' ' 38' ' ' VAL . 30.6 p -118.66 -43.6 2.68 Favored 'General case' 0 CA--C 1.53 0.177 0 O-C-N 121.43 -0.794 . . . . 1.0 109.494 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.429 ' N ' ' HG1' ' A' ' 37' ' ' THR . 38.2 t -110.81 153.06 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 O-C-N 121.467 -0.771 . . . . 1.0 109.287 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 7.8 mtt-85 -101.11 172.51 6.97 Favored 'General case' 0 CA--C 1.532 0.271 0 O-C-N 121.545 -0.722 . . . . 1.0 109.337 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.72 -31.14 3.06 Favored Glycine 0 CA--C 1.529 0.917 0 N-CA-C 109.501 -1.44 . . . . 1.0 109.501 -179.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.6 m -99.83 170.55 6.61 Favored Pre-proline 0 CA--C 1.537 0.478 0 O-C-N 121.501 -1.0 . . . . 1.0 109.129 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -85.64 126.41 3.01 Favored 'Trans proline' 0 N--CA 1.479 0.654 0 C-N-CA 124.506 3.471 . . . . 1.0 110.036 179.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.423 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 10.0 m0 -77.64 -38.89 46.91 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.555 -0.715 . . . . 1.0 109.837 -179.356 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 28.1 t -89.44 103.84 16.45 Favored 'General case' 0 CA--C 1.534 0.357 0 O-C-N 121.385 -0.822 . . . . 1.0 109.566 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.406 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 5.1 p90 -132.87 177.42 7.66 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.259 -0.901 . . . . 1.0 109.881 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' TYR . . . . . 0.406 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 32.2 m-85 -74.1 169.81 17.44 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 121.61 -0.681 . . . . 1.0 109.684 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -93.35 173.16 1.85 Allowed 'Trans proline' 0 C--N 1.35 0.643 0 C-N-CA 125.217 3.944 . . . . 1.0 110.612 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 . . . . . 0 CA--C 1.531 0.241 0 O-C-N 121.54 -0.725 . . . . 1.0 109.38 179.989 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 . . . . . 0 CA--C 1.531 0.232 0 N-CA-C 109.414 -0.587 . . . . 1.0 109.414 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -165.0 166.45 19.33 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.495 -0.753 . . . . 1.0 109.535 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -110.56 171.26 7.56 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.487 -0.758 . . . . 1.0 109.385 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 15.6 p -132.31 144.09 50.33 Favored 'General case' 0 CA--C 1.529 0.165 0 O-C-N 121.531 -0.73 . . . . 1.0 109.56 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -84.41 137.5 33.35 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.559 -0.713 . . . . 1.0 109.141 179.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.1 m -149.62 124.34 9.83 Favored 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.575 -0.703 . . . . 1.0 109.715 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 75.1 m -113.22 -14.19 12.89 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.498 -0.751 . . . . 1.0 109.594 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.8 t -71.19 96.44 1.38 Allowed 'General case' 0 CA--C 1.53 0.211 0 O-C-N 121.286 -0.884 . . . . 1.0 109.658 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 39.4 t -119.35 168.98 11.01 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 O-C-N 121.465 -0.772 . . . . 1.0 109.074 179.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.21 121.27 73.53 Favored Pre-proline 0 CA--C 1.542 0.65 0 O-C-N 121.386 -0.821 . . . . 1.0 109.17 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_exo -36.95 -47.43 1.46 Allowed 'Trans proline' 0 N--CA 1.49 1.281 0 C-N-CA 124.917 3.745 . . . . 1.0 111.334 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -75.88 -39.44 56.44 Favored 'General case' 0 N--CA 1.463 0.208 0 O-C-N 121.466 -0.771 . . . . 1.0 109.745 -179.775 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -84.33 38.38 0.67 Allowed 'General case' 0 N--CA 1.462 0.162 0 O-C-N 121.399 -0.813 . . . . 1.0 109.565 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 18.6 mtt180 -104.82 145.64 30.1 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.446 -0.784 . . . . 1.0 109.407 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 10.1 mp0 -94.69 120.6 35.17 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 121.542 -0.724 . . . . 1.0 109.36 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -63.63 120.34 11.59 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.457 -0.777 . . . . 1.0 109.817 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.412 ' HA ' ' CE2' ' A' ' 46' ' ' TYR . 44.3 t -94.65 -17.77 21.97 Favored 'General case' 0 CA--C 1.535 0.385 0 O-C-N 121.574 -0.704 . . . . 1.0 109.329 179.716 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 177.15 175.44 44.43 Favored Glycine 0 CA--C 1.529 0.939 0 N-CA-C 109.404 -1.479 . . . . 1.0 109.404 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.424 ' CE2' HG11 ' A' ' 22' ' ' VAL . 9.5 p90 -64.61 167.95 7.84 Favored Pre-proline 0 CA--C 1.538 0.512 0 O-C-N 121.383 -1.069 . . . . 1.0 109.063 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.33 -31.36 1.25 Allowed 'Trans proline' 0 N--CA 1.483 0.905 0 C-N-CA 124.341 3.361 . . . . 1.0 110.643 -178.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.75 -7.91 6.95 Favored Glycine 0 CA--C 1.537 1.438 0 N-CA-C 110.294 -1.122 . . . . 1.0 110.294 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.424 HG11 ' CE2' ' A' ' 19' ' ' PHE . 17.4 m -60.17 -178.97 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 O-C-N 121.208 -1.172 . . . . 1.0 109.742 179.762 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 12.0 p -138.5 155.08 73.88 Favored Pre-proline 0 CA--C 1.536 0.43 0 O-C-N 121.513 -0.742 . . . . 1.0 109.276 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -36.05 -36.45 0.2 Allowed 'Trans proline' 0 N--CA 1.488 1.187 1 C-N-CA 125.368 4.045 . . . . 1.0 111.316 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 42.1 t -73.99 -46.07 46.1 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.405 -0.809 . . . . 1.0 109.874 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 38.0 mt-30 -60.57 -48.63 80.91 Favored 'General case' 0 N--CA 1.464 0.258 0 O-C-N 121.468 -0.77 . . . . 1.0 109.988 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.7 t -65.11 -27.73 68.95 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.409 -0.807 . . . . 1.0 109.497 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.34 -5.26 58.42 Favored 'General case' 0 CA--C 1.535 0.38 0 O-C-N 121.547 -0.721 . . . . 1.0 109.846 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.0 t-20 -70.83 -49.45 46.17 Favored 'General case' 0 N--CA 1.463 0.181 0 O-C-N 121.408 -0.808 . . . . 1.0 109.363 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.448 ' HG2' ' H ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -83.64 -44.7 14.27 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.534 -0.729 . . . . 1.0 109.432 179.889 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.448 ' H ' ' HG2' ' A' ' 30' ' ' LYS . . . 125.65 32.45 0.76 Allowed Glycine 0 CA--C 1.531 1.075 0 N-CA-C 109.958 -1.257 . . . . 1.0 109.958 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.5 m -92.26 144.7 25.13 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.43 -1.041 . . . . 1.0 109.301 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.402 ' O ' ' CD1' ' A' ' 45' ' ' PHE . 60.0 m -66.51 115.4 6.35 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.462 -0.774 . . . . 1.0 109.516 -179.814 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -94.6 132.01 39.76 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.38 -0.825 . . . . 1.0 109.33 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -144.2 111.12 5.74 Favored 'General case' 0 CA--C 1.53 0.19 0 O-C-N 121.425 -0.797 . . . . 1.0 109.481 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.425 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.0 p-10 -115.34 70.42 0.74 Allowed 'General case' 0 CA--C 1.534 0.334 0 O-C-N 121.509 -0.745 . . . . 1.0 109.414 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 43.9 p -114.45 -39.35 3.84 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.429 -0.794 . . . . 1.0 109.471 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.9 t -111.95 167.93 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 O-C-N 121.519 -0.738 . . . . 1.0 109.401 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.41 ' C ' ' H ' ' A' ' 41' ' ' VAL . 4.9 ttm180 -113.31 175.99 5.22 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.432 -0.793 . . . . 1.0 109.432 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.51 -37.33 2.25 Favored Glycine 0 CA--C 1.53 0.996 0 N-CA-C 109.41 -1.476 . . . . 1.0 109.41 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.41 ' H ' ' C ' ' A' ' 39' ' ' ARG . 28.9 m -94.66 170.39 8.16 Favored Pre-proline 0 CA--C 1.536 0.431 0 O-C-N 121.571 -0.958 . . . . 1.0 109.174 179.808 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_endo -85.68 139.31 6.57 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 124.628 3.552 . . . . 1.0 109.937 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.425 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 11.2 m0 -89.22 -41.05 12.44 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 121.502 -0.749 . . . . 1.0 110.028 -179.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 18.5 t -89.31 107.43 19.06 Favored 'General case' 0 N--CA 1.465 0.309 0 O-C-N 121.426 -0.797 . . . . 1.0 109.719 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.417 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 9.5 p90 -135.05 173.81 11.31 Favored 'General case' 0 CA--C 1.537 0.479 0 O-C-N 121.346 -0.846 . . . . 1.0 109.633 179.59 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.417 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 90.8 m-85 -82.11 167.38 31.04 Favored Pre-proline 0 CA--C 1.536 0.419 0 O-C-N 121.493 -0.755 . . . . 1.0 109.716 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -89.65 161.52 5.26 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 124.998 3.799 . . . . 1.0 110.424 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -136.62 100.09 4.24 Favored 'General case' 0 CA--C 1.531 0.216 0 O-C-N 121.549 -0.719 . . . . 1.0 109.388 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 41.3 p -77.68 116.04 17.91 Favored 'General case' 0 CA--C 1.53 0.209 0 O-C-N 121.503 -0.748 . . . . 1.0 109.476 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 60.2 mt -98.82 144.49 11.66 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 O-C-N 121.527 -0.733 . . . . 1.0 109.374 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -80.94 130.05 34.84 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.479 -0.763 . . . . 1.0 109.528 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 27.9 m -126.85 79.38 72.44 Favored Pre-proline 0 CA--C 1.539 0.532 0 O-C-N 121.421 -0.799 . . . . 1.0 109.456 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.434 ' N ' ' CD ' ' A' ' 54' ' ' PRO . 16.7 Cg_exo -34.85 -46.59 0.59 Allowed 'Trans proline' 0 N--CA 1.487 1.127 0 C-N-CA 125.214 3.943 . . . . 1.0 111.862 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . 0.434 ' CD ' ' N ' ' A' ' 53' ' ' PRO . 19.3 Cg_endo -91.28 121.43 0.68 Allowed 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 124.737 3.625 . . . . 1.0 110.418 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.0 tt0 -80.26 141.59 35.4 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.457 -0.777 . . . . 1.0 109.412 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -103.09 175.08 5.59 Favored 'General case' 0 N--CA 1.463 0.199 0 O-C-N 121.499 -0.751 . . . . 1.0 109.463 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -108.76 141.96 40.0 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.569 -0.707 . . . . 1.0 109.452 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.7 p -134.46 179.32 6.35 Favored 'General case' 0 CA--C 1.53 0.189 0 O-C-N 121.526 -0.734 . . . . 1.0 109.473 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -76.47 137.7 39.83 Favored 'General case' 0 N--CA 1.463 0.177 0 O-C-N 121.501 -0.749 . . . . 1.0 109.455 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 25.9 t80 . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.983 -1.008 . . . . 1.0 109.417 -179.964 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 . . . . . 0 CA--C 1.529 0.162 0 N-CA-C 109.419 -0.585 . . . . 1.0 109.419 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -158.79 33.69 0.22 Allowed 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.392 -0.818 . . . . 1.0 109.491 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 9.7 mp0 -85.67 102.66 13.79 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.497 -0.752 . . . . 1.0 109.5 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 17.0 p -146.83 -168.2 2.97 Favored 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.575 -0.703 . . . . 1.0 109.404 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -86.39 137.24 32.72 Favored 'General case' 0 CA--C 1.531 0.213 0 O-C-N 121.462 -0.774 . . . . 1.0 109.441 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -128.11 146.74 50.6 Favored 'General case' 0 CA--C 1.53 0.181 0 O-C-N 121.544 -0.722 . . . . 1.0 109.383 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.4 ' HB3' ' CZ ' ' A' ' 45' ' ' PHE . 62.8 m -125.91 31.49 5.46 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.488 -0.758 . . . . 1.0 109.022 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.414 ' H ' HG21 ' A' ' 8' ' ' THR . 5.1 t -96.08 118.9 33.58 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.657 -0.652 . . . . 1.0 109.556 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 34.2 t -149.92 156.21 7.24 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.206 0 O-C-N 121.495 -0.753 . . . . 1.0 109.236 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -74.07 136.72 76.04 Favored Pre-proline 0 CA--C 1.54 0.59 0 O-C-N 121.482 -0.761 . . . . 1.0 109.308 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -35.05 -41.05 0.28 Allowed 'Trans proline' 0 N--CA 1.488 1.171 1 C-N-CA 125.361 4.041 . . . . 1.0 111.305 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.7 mtt180 -80.95 -44.61 17.95 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.543 -0.723 . . . . 1.0 109.759 -179.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -74.56 10.46 1.34 Allowed 'General case' 0 CA--C 1.533 0.326 0 O-C-N 121.417 -0.802 . . . . 1.0 109.975 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 24.2 mtt180 -81.25 124.37 29.26 Favored 'General case' 0 CA--C 1.529 0.164 0 O-C-N 121.34 -0.85 . . . . 1.0 109.361 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 25.5 mm100 -92.56 126.76 37.79 Favored 'General case' 0 N--CA 1.463 0.197 0 O-C-N 121.463 -0.773 . . . . 1.0 109.025 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.2 t-20 -72.23 116.68 12.95 Favored 'General case' 0 CA--C 1.532 0.286 0 O-C-N 121.604 -0.685 . . . . 1.0 109.942 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -83.55 -6.97 59.6 Favored 'General case' 0 CA--C 1.537 0.447 0 O-C-N 121.53 -0.731 . . . . 1.0 109.208 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.84 170.0 37.42 Favored Glycine 0 CA--C 1.532 1.097 0 N-CA-C 108.353 -1.899 . . . . 1.0 108.353 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD2' HG11 ' A' ' 22' ' ' VAL . 7.5 p90 -62.52 168.33 4.35 Favored Pre-proline 0 CA--C 1.54 0.56 0 O-C-N 121.208 -1.172 . . . . 1.0 109.043 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -81.36 -30.25 1.61 Allowed 'Trans proline' 0 N--CA 1.481 0.785 0 C-N-CA 124.304 3.336 . . . . 1.0 110.677 -178.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.23 -6.82 8.12 Favored Glycine 0 CA--C 1.536 1.374 0 N-CA-C 110.052 -1.219 . . . . 1.0 110.052 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.431 HG11 ' CD2' ' A' ' 19' ' ' PHE . 29.2 m -60.25 -176.31 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 O-C-N 121.157 -1.202 . . . . 1.0 109.816 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 10.6 p -137.38 155.95 75.36 Favored Pre-proline 0 CA--C 1.535 0.368 0 O-C-N 121.51 -0.744 . . . . 1.0 109.13 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_exo -37.47 -42.24 1.08 Allowed 'Trans proline' 0 N--CA 1.488 1.176 0 C-N-CA 125.188 3.926 . . . . 1.0 111.001 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 80.3 p -69.45 -42.76 74.51 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.524 -0.735 . . . . 1.0 110.118 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -65.61 -53.92 34.91 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.401 -0.812 . . . . 1.0 109.909 -179.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 18.9 t -62.04 -19.71 63.17 Favored 'General case' 0 CA--C 1.534 0.357 0 O-C-N 121.409 -0.807 . . . . 1.0 109.934 -179.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -100.54 -3.56 30.41 Favored 'General case' 0 CA--C 1.535 0.378 0 O-C-N 121.356 -0.84 . . . . 1.0 110.154 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -73.78 -44.07 57.09 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.395 -0.815 . . . . 1.0 109.855 -179.476 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.9 tttm -86.26 -41.39 14.64 Favored 'General case' 0 N--CA 1.462 0.154 0 O-C-N 121.43 -0.794 . . . . 1.0 109.662 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 127.27 19.71 1.88 Allowed Glycine 0 CA--C 1.53 1.031 0 N-CA-C 109.473 -1.451 . . . . 1.0 109.473 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 60.8 m -77.39 140.42 39.91 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.43 -1.041 . . . . 1.0 109.028 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 84.5 m -66.87 123.09 19.2 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.414 -0.803 . . . . 1.0 109.647 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -96.51 147.78 23.49 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.439 -0.788 . . . . 1.0 109.162 179.653 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -161.72 135.12 6.38 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.384 -0.822 . . . . 1.0 109.486 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -133.17 38.24 3.34 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.515 -0.741 . . . . 1.0 109.471 179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 59.9 p -72.05 -58.7 3.22 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.48 -0.763 . . . . 1.0 109.541 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.0 t -110.07 138.12 39.26 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 O-C-N 121.429 -0.794 . . . . 1.0 109.408 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -83.62 178.03 8.15 Favored 'General case' 0 CA--C 1.53 0.19 0 O-C-N 121.496 -0.752 . . . . 1.0 109.247 179.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.56 -45.73 3.15 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 109.339 -1.504 . . . . 1.0 109.339 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 26.7 m -84.43 157.33 61.84 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.647 -0.914 . . . . 1.0 109.325 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -59.63 129.24 30.06 Favored 'Trans proline' 0 N--CA 1.488 1.164 0 C-N-CA 124.164 3.243 . . . . 1.0 110.308 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . . . . . . . . . 40.4 m0 -87.27 -45.87 10.22 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.521 -0.737 . . . . 1.0 109.173 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 27.4 t -89.92 110.42 21.37 Favored 'General case' 0 CA--C 1.534 0.338 0 O-C-N 121.493 -0.755 . . . . 1.0 108.978 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.433 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 5.2 p90 -134.1 175.87 9.09 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 121.302 -0.874 . . . . 1.0 110.257 -179.371 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.41 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 21.5 m-85 -82.18 171.33 12.18 Favored Pre-proline 0 CA--C 1.537 0.47 0 O-C-N 121.523 -0.735 . . . . 1.0 109.522 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -90.84 -166.39 0.19 Allowed 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 124.939 3.759 . . . . 1.0 110.102 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -158.42 100.51 1.66 Allowed 'General case' 0 N--CA 1.463 0.192 0 O-C-N 121.478 -0.763 . . . . 1.0 109.509 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 33.5 p -80.7 97.89 7.48 Favored 'General case' 0 CA--C 1.532 0.265 0 O-C-N 121.429 -0.795 . . . . 1.0 109.306 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 63.4 mt -136.92 165.08 28.89 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 O-C-N 121.443 -0.786 . . . . 1.0 109.374 -179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -107.29 -166.66 1.18 Allowed 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.433 -0.792 . . . . 1.0 109.443 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.1 m -130.8 160.36 66.89 Favored Pre-proline 0 CA--C 1.536 0.427 0 O-C-N 121.502 -0.749 . . . . 1.0 109.379 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -91.59 154.46 3.54 Favored 'Trans proline' 0 CA--C 1.537 0.642 0 C-N-CA 124.956 3.77 . . . . 1.0 110.359 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -34.47 -46.33 0.52 Allowed 'Trans proline' 0 N--CA 1.489 1.234 1 C-N-CA 125.567 4.178 . . . . 1.0 111.18 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -134.63 165.73 24.56 Favored 'General case' 0 CA--C 1.53 0.209 0 O-C-N 121.532 -0.73 . . . . 1.0 109.382 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -111.46 117.47 33.12 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.436 -0.79 . . . . 1.0 109.37 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -143.84 108.13 4.79 Favored 'General case' 0 N--CA 1.463 0.215 0 O-C-N 121.47 -0.769 . . . . 1.0 109.409 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.7 m -141.7 122.23 14.16 Favored 'General case' 0 CA--C 1.53 0.196 0 O-C-N 121.521 -0.737 . . . . 1.0 109.466 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 20.2 tp10 -128.08 110.43 12.47 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.455 -0.778 . . . . 1.0 109.501 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 41.8 t80 . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.018 -0.991 . . . . 1.0 109.412 -179.964 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 . . . . . 0 CA--C 1.53 0.182 0 N-CA-C 109.478 -0.564 . . . . 1.0 109.478 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -117.49 88.42 2.91 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 121.483 -0.76 . . . . 1.0 109.507 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 2.5 mp0 -82.0 165.08 21.0 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.52 -0.737 . . . . 1.0 109.352 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.13 157.44 43.12 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.486 -0.759 . . . . 1.0 109.409 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -75.37 171.29 14.49 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 121.494 -0.754 . . . . 1.0 109.459 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.7 m -150.27 93.79 2.04 Favored 'General case' 0 CA--C 1.532 0.263 0 O-C-N 121.51 -0.744 . . . . 1.0 109.763 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 90.5 m -89.62 -15.82 31.91 Favored 'General case' 0 CA--C 1.533 0.326 0 O-C-N 121.311 -0.868 . . . . 1.0 109.493 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.8 t -71.31 112.45 7.45 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.429 -0.795 . . . . 1.0 109.907 -179.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 42.0 t -127.87 167.33 23.08 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.264 0 N-CA-C 108.84 -0.8 . . . . 1.0 108.84 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -71.67 125.41 91.7 Favored Pre-proline 0 CA--C 1.542 0.644 0 O-C-N 121.36 -0.838 . . . . 1.0 109.118 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_exo -36.84 -50.36 1.43 Allowed 'Trans proline' 0 N--CA 1.489 1.263 0 C-N-CA 124.899 3.732 . . . . 1.0 111.209 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 18.7 ptt180 -73.8 -38.86 64.48 Favored 'General case' 0 N--CA 1.463 0.195 0 O-C-N 121.487 -0.758 . . . . 1.0 109.763 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -92.29 43.03 1.12 Allowed 'General case' 0 CA--C 1.532 0.253 0 O-C-N 121.405 -0.81 . . . . 1.0 109.574 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 15.0 mtt180 -105.71 131.98 52.4 Favored 'General case' 0 CA--C 1.531 0.235 0 O-C-N 121.405 -0.81 . . . . 1.0 109.437 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -79.57 107.64 12.5 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 108.557 -0.905 . . . . 1.0 108.557 179.456 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 29.5 t30 -61.98 108.54 1.06 Allowed 'General case' 0 N--CA 1.464 0.245 0 O-C-N 121.557 -0.714 . . . . 1.0 110.085 -179.336 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 49.5 t -76.78 -21.75 54.71 Favored 'General case' 0 CA--C 1.533 0.318 0 O-C-N 121.5 -0.75 . . . . 1.0 109.229 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -175.46 179.56 46.6 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 109.145 -1.582 . . . . 1.0 109.145 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.433 ' CD2' HG12 ' A' ' 22' ' ' VAL . 8.9 p90 -64.81 167.49 9.13 Favored Pre-proline 0 CA--C 1.538 0.489 0 O-C-N 121.398 -1.06 . . . . 1.0 109.0 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -81.19 -30.93 1.42 Allowed 'Trans proline' 0 N--CA 1.482 0.806 0 C-N-CA 124.351 3.367 . . . . 1.0 110.715 -178.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.84 -8.41 7.89 Favored Glycine 0 CA--C 1.537 1.457 0 N-CA-C 110.305 -1.118 . . . . 1.0 110.305 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.433 HG12 ' CD2' ' A' ' 19' ' ' PHE . 25.7 m -60.62 -171.21 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 O-C-N 121.194 -1.18 . . . . 1.0 109.864 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.448 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 19.9 p -150.09 157.27 37.64 Favored Pre-proline 0 CA--C 1.534 0.361 0 N-CA-C 109.18 -0.674 . . . . 1.0 109.18 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_exo -34.91 -36.37 0.12 Allowed 'Trans proline' 0 N--CA 1.488 1.193 1 C-N-CA 125.599 4.199 . . . . 1.0 111.383 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.4 t -76.41 -47.21 23.93 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.434 -0.791 . . . . 1.0 109.865 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLN . . . . . 0.448 ' HB2' ' H ' ' A' ' 23' ' ' THR . 2.2 mm100 -60.93 -44.05 97.76 Favored 'General case' 0 N--CA 1.465 0.293 0 O-C-N 121.433 -0.792 . . . . 1.0 109.925 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 7.5 t -64.72 -33.4 75.87 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.443 -0.786 . . . . 1.0 109.346 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.48 -5.55 59.28 Favored 'General case' 0 CA--C 1.534 0.358 0 O-C-N 121.556 -0.715 . . . . 1.0 109.935 179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 12.2 t-20 -64.84 -32.6 74.37 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.32 -0.862 . . . . 1.0 109.618 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.3 mtmm -105.79 -39.52 6.02 Favored 'General case' 0 C--N 1.332 -0.183 0 O-C-N 121.456 -0.777 . . . . 1.0 109.403 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 125.6 27.55 1.16 Allowed Glycine 0 CA--C 1.53 1.012 0 N-CA-C 109.862 -1.295 . . . . 1.0 109.862 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.8 m -91.09 147.69 22.89 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.326 -1.103 . . . . 1.0 109.16 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.429 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 57.4 m -70.33 139.6 52.06 Favored 'General case' 0 CA--C 1.532 0.266 0 O-C-N 121.371 -0.831 . . . . 1.0 109.333 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -119.21 119.7 34.87 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.463 -0.773 . . . . 1.0 109.332 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -132.67 120.1 21.29 Favored 'General case' 0 CA--C 1.529 0.167 0 O-C-N 121.533 -0.729 . . . . 1.0 109.667 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.41 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.0 p-10 -116.32 77.27 1.08 Allowed 'General case' 0 N--CA 1.463 0.197 0 O-C-N 121.442 -0.786 . . . . 1.0 109.233 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 82.2 p -114.54 -38.37 4.05 Favored 'General case' 0 CA--C 1.53 0.183 0 O-C-N 121.446 -0.784 . . . . 1.0 109.543 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 38.3 t -117.36 148.51 20.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.205 0 O-C-N 121.442 -0.786 . . . . 1.0 109.411 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 22.5 mtp180 -94.65 -179.08 4.76 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.5 -0.75 . . . . 1.0 109.5 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.07 6.71 13.89 Favored Glycine 0 CA--C 1.532 1.149 0 N-CA-C 109.992 -1.243 . . . . 1.0 109.992 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.0 m -130.59 169.35 13.81 Favored Pre-proline 0 CA--C 1.536 0.415 0 O-C-N 121.359 -1.083 . . . . 1.0 109.203 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -87.74 130.03 2.63 Favored 'Trans proline' 0 N--CA 1.48 0.708 0 C-N-CA 124.693 3.595 . . . . 1.0 110.117 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.41 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.3 m0 -91.95 -47.83 7.09 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.505 -0.747 . . . . 1.0 109.733 -179.567 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 18.6 t -78.07 107.81 10.9 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 121.527 -0.733 . . . . 1.0 109.646 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.429 ' CE1' ' HB2' ' A' ' 33' ' ' CYS . 3.3 p90 -139.42 -175.93 4.36 Favored 'General case' 0 N--CA 1.465 0.314 0 O-C-N 121.515 -0.74 . . . . 1.0 109.393 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -91.57 163.85 26.68 Favored Pre-proline 0 CA--C 1.537 0.477 0 O-C-N 121.411 -0.806 . . . . 1.0 110.029 -179.404 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -90.18 172.84 3.5 Favored 'Trans proline' 0 C--N 1.352 0.744 0 C-N-CA 124.97 3.78 . . . . 1.0 110.718 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -143.35 86.38 1.9 Allowed 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.433 -0.792 . . . . 1.0 109.412 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 34.2 p -67.43 131.59 45.99 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.465 -0.772 . . . . 1.0 109.417 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 54.7 mt -118.8 140.36 42.86 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 O-C-N 121.412 -0.805 . . . . 1.0 109.306 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -143.08 166.62 24.17 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.443 -0.786 . . . . 1.0 109.518 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.8 m -69.79 111.07 7.79 Favored Pre-proline 0 CA--C 1.539 0.546 0 O-C-N 121.543 -0.723 . . . . 1.0 109.462 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -93.3 176.88 1.39 Allowed 'Trans proline' 0 C--N 1.353 0.768 0 C-N-CA 124.755 3.637 . . . . 1.0 110.44 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . 0.438 ' HD2' ' H ' ' A' ' 55' ' ' GLU . 18.7 Cg_endo -92.11 -54.77 0.02 OUTLIER 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 125.177 3.918 . . . . 1.0 110.175 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.438 ' H ' ' HD2' ' A' ' 54' ' ' PRO . 1.1 mt-10 -137.71 101.68 4.53 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.547 -0.721 . . . . 1.0 109.331 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -88.45 108.17 19.24 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.487 -0.758 . . . . 1.0 109.59 -179.813 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 -147.16 134.35 20.52 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.567 -0.708 . . . . 1.0 109.271 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 72.6 m -137.1 172.82 12.43 Favored 'General case' 0 N--CA 1.464 0.228 0 O-C-N 121.542 -0.724 . . . . 1.0 109.461 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 14.6 tm-20 -96.6 119.79 35.73 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.499 -0.751 . . . . 1.0 109.43 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.929 -1.034 . . . . 1.0 109.495 179.909 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 . . . . . 0 CA--C 1.531 0.216 0 N-CA-C 109.498 -0.556 . . . . 1.0 109.498 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -155.65 37.59 0.37 Allowed 'General case' 0 N--CA 1.463 0.195 0 O-C-N 121.479 -0.763 . . . . 1.0 109.581 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 14.9 mp0 -84.33 113.76 21.37 Favored 'General case' 0 CA--C 1.53 0.175 0 O-C-N 121.351 -0.843 . . . . 1.0 109.347 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 75.8 p -108.94 133.51 52.85 Favored 'General case' 0 C--N 1.332 -0.189 0 O-C-N 121.449 -0.782 . . . . 1.0 109.563 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -85.59 133.43 34.05 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.863 -0.792 . . . . 1.0 108.863 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.4 m -150.23 114.1 5.05 Favored 'General case' 0 CA--C 1.53 0.176 0 O-C-N 121.469 -0.769 . . . . 1.0 110.161 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 96.2 m -108.54 -18.14 13.8 Favored 'General case' 0 CA--C 1.536 0.408 0 O-C-N 121.503 -0.748 . . . . 1.0 109.184 179.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.2 t -70.15 108.35 4.09 Favored 'General case' 0 CA--C 1.533 0.297 0 O-C-N 121.106 -0.996 . . . . 1.0 109.329 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.446 HG23 HD21 ' A' ' 48' ' ' ASN . 26.7 t -132.99 173.46 14.8 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.248 0 O-C-N 121.334 -0.854 . . . . 1.0 109.323 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.432 ' H ' ' CG1' ' A' ' 9' ' ' VAL . . . -69.14 122.81 86.62 Favored Pre-proline 0 CA--C 1.539 0.542 0 O-C-N 121.461 -0.774 . . . . 1.0 109.235 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -37.62 -33.92 0.24 Allowed 'Trans proline' 0 N--CA 1.488 1.198 0 C-N-CA 124.774 3.65 . . . . 1.0 111.229 -179.799 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 15.2 ptt180 -78.55 -46.88 18.42 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.469 -0.769 . . . . 1.0 109.766 -179.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 21.0 mm-40 -82.73 40.97 0.7 Allowed 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.405 -0.809 . . . . 1.0 109.434 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 54.0 mtt180 -104.1 142.95 33.57 Favored 'General case' 0 C--N 1.331 -0.214 0 O-C-N 121.526 -0.734 . . . . 1.0 109.569 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 mm-40 -92.59 111.33 22.88 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.426 -0.796 . . . . 1.0 109.195 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -60.33 110.34 1.22 Allowed 'General case' 0 CA--C 1.533 0.303 0 O-C-N 121.362 -0.836 . . . . 1.0 110.121 -179.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.4 t -86.65 -16.4 36.74 Favored 'General case' 0 CA--C 1.533 0.323 0 O-C-N 121.485 -0.76 . . . . 1.0 109.442 179.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.64 179.28 44.19 Favored Glycine 0 CA--C 1.531 1.075 0 N-CA-C 109.506 -1.438 . . . . 1.0 109.506 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.425 ' CE2' HG11 ' A' ' 22' ' ' VAL . 9.6 p90 -65.13 168.0 8.56 Favored Pre-proline 0 CA--C 1.538 0.492 0 O-C-N 121.468 -1.019 . . . . 1.0 109.018 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.43 -30.98 1.32 Allowed 'Trans proline' 0 N--CA 1.484 0.918 0 C-N-CA 124.4 3.4 . . . . 1.0 110.671 -178.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.42 -10.28 7.51 Favored Glycine 0 CA--C 1.537 1.41 0 N-CA-C 110.356 -1.098 . . . . 1.0 110.356 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.425 HG11 ' CE2' ' A' ' 19' ' ' PHE . 18.0 m -60.74 169.71 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 O-C-N 121.205 -1.174 . . . . 1.0 109.611 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 29.2 p -128.35 155.45 78.45 Favored Pre-proline 0 CA--C 1.535 0.387 0 O-C-N 121.517 -0.739 . . . . 1.0 109.38 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_exo -36.33 -37.35 0.26 Allowed 'Trans proline' 0 N--CA 1.489 1.237 1 C-N-CA 125.341 4.027 . . . . 1.0 111.186 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 4.5 m -69.91 -47.38 62.69 Favored 'General case' 0 N--CA 1.463 0.206 0 O-C-N 121.351 -0.843 . . . . 1.0 109.79 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 7.5 mm100 -61.49 -49.88 75.0 Favored 'General case' 0 CA--C 1.533 0.302 0 O-C-N 121.41 -0.806 . . . . 1.0 109.842 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.8 t -64.97 -27.49 68.87 Favored 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.431 -0.793 . . . . 1.0 109.439 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.29 -8.91 57.38 Favored 'General case' 0 CA--C 1.534 0.344 0 O-C-N 121.5 -0.75 . . . . 1.0 109.821 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -91.38 -28.0 17.98 Favored 'General case' 0 CA--C 1.529 0.14 0 O-C-N 121.37 -0.831 . . . . 1.0 109.405 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -89.65 -29.15 19.0 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.471 -0.768 . . . . 1.0 109.441 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.04 45.64 2.02 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 109.771 -1.332 . . . . 1.0 109.771 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 2.0 m -121.42 142.95 49.52 Favored 'General case' 0 N--CA 1.465 0.29 0 O-C-N 121.496 -1.002 . . . . 1.0 109.303 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 46.8 m -63.32 113.66 3.35 Favored 'General case' 0 N--CA 1.466 0.332 0 O-C-N 121.4 -0.812 . . . . 1.0 109.39 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 48.7 t80 -90.36 137.19 32.55 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.43 -0.794 . . . . 1.0 109.126 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -151.02 106.86 3.41 Favored 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.47 -0.769 . . . . 1.0 109.676 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.425 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 2.1 p30 -107.09 48.55 0.83 Allowed 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.491 -0.756 . . . . 1.0 109.245 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 16.8 p -81.34 -52.28 7.46 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.519 -0.738 . . . . 1.0 109.361 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.8 t -114.14 145.39 20.03 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 O-C-N 121.589 -0.694 . . . . 1.0 109.383 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -88.35 179.66 6.29 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.539 -0.726 . . . . 1.0 109.449 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.45 -49.91 4.12 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 109.278 -1.529 . . . . 1.0 109.278 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 27.6 m -79.79 171.16 13.15 Favored Pre-proline 0 CA--C 1.538 0.502 0 O-C-N 121.588 -0.948 . . . . 1.0 109.041 179.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -84.17 127.41 3.99 Favored 'Trans proline' 0 N--CA 1.48 0.724 0 C-N-CA 124.383 3.389 . . . . 1.0 110.003 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.425 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 11.0 m0 -82.83 -39.85 21.12 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.594 -0.691 . . . . 1.0 110.104 -179.129 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.5 t -89.46 108.38 19.61 Favored 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.325 -0.859 . . . . 1.0 109.597 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.426 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 15.0 p90 -135.92 175.9 9.17 Favored 'General case' 0 CA--C 1.538 0.496 0 O-C-N 121.438 -0.789 . . . . 1.0 109.58 179.647 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.426 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 37.5 m-85 -84.61 166.99 29.45 Favored Pre-proline 0 CA--C 1.536 0.422 0 O-C-N 121.274 -0.891 . . . . 1.0 110.061 -179.539 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -88.92 159.7 6.01 Favored 'Trans proline' 0 C--N 1.353 0.779 0 C-N-CA 124.868 3.712 . . . . 1.0 110.538 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.446 HD21 HG23 ' A' ' 9' ' ' VAL . 59.7 m-80 -132.77 84.85 2.17 Favored 'General case' 0 CA--C 1.531 0.242 0 O-C-N 121.525 -0.734 . . . . 1.0 109.406 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.4 p -88.64 122.57 32.22 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.508 -0.745 . . . . 1.0 109.377 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 64.7 mt -94.54 145.01 8.6 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 O-C-N 121.472 -0.767 . . . . 1.0 109.264 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -155.14 173.27 16.84 Favored 'General case' 0 CA--C 1.529 0.171 0 O-C-N 121.546 -0.721 . . . . 1.0 109.494 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.2 m -139.18 88.02 13.41 Favored Pre-proline 0 CA--C 1.535 0.366 0 O-C-N 121.559 -0.713 . . . . 1.0 109.573 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -91.42 169.03 3.32 Favored 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 125.139 3.892 . . . . 1.0 110.283 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . 0.473 ' HD2' ' H ' ' A' ' 55' ' ' GLU . 19.1 Cg_endo -91.39 -23.75 0.44 Allowed 'Trans proline' 0 C--N 1.349 0.602 0 C-N-CA 125.123 3.882 . . . . 1.0 110.305 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.473 ' H ' ' HD2' ' A' ' 54' ' ' PRO . 15.2 mt-10 -131.93 178.47 6.75 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.482 -0.761 . . . . 1.0 109.472 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -125.77 153.08 44.51 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 121.463 -0.773 . . . . 1.0 109.445 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -146.14 120.55 9.66 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.515 -0.74 . . . . 1.0 109.421 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -96.93 152.18 18.96 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.511 -0.743 . . . . 1.0 109.392 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -100.39 153.56 19.23 Favored 'General case' 0 CA--C 1.53 0.189 0 O-C-N 121.449 -0.782 . . . . 1.0 109.456 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 41.9 p90 . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.894 -1.05 . . . . 1.0 109.516 180.0 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 . . . . . 0 CA--C 1.531 0.216 0 N-CA-C 109.465 -0.569 . . . . 1.0 109.465 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -160.2 84.75 0.72 Allowed 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.558 -0.714 . . . . 1.0 109.475 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -91.29 101.15 13.86 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.57 -0.706 . . . . 1.0 109.442 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -165.15 -170.06 1.81 Allowed 'General case' 0 N--CA 1.465 0.278 0 O-C-N 121.472 -0.767 . . . . 1.0 109.602 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -91.29 152.92 20.29 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.511 -0.743 . . . . 1.0 109.226 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.5 m -150.5 125.45 9.86 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.42 -0.8 . . . . 1.0 110.016 -179.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 98.6 m -104.02 45.33 0.97 Allowed 'General case' 0 CA--C 1.534 0.358 0 O-C-N 121.429 -0.794 . . . . 1.0 108.934 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.8 t -110.83 108.98 18.99 Favored 'General case' 0 CA--C 1.532 0.262 0 O-C-N 121.19 -0.944 . . . . 1.0 109.877 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 38.5 t -135.39 160.9 40.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 O-C-N 121.441 -0.787 . . . . 1.0 109.114 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -79.55 115.59 54.54 Favored Pre-proline 0 CA--C 1.541 0.606 0 O-C-N 121.434 -0.791 . . . . 1.0 109.382 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -38.23 -28.79 0.13 Allowed 'Trans proline' 0 N--CA 1.49 1.277 0 C-N-CA 124.664 3.576 . . . . 1.0 111.108 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 -66.94 -64.92 0.75 Allowed 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.489 -0.757 . . . . 1.0 109.691 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -90.56 44.4 1.2 Allowed 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.499 -0.751 . . . . 1.0 109.542 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 21.7 mtt180 -86.11 143.16 28.19 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.476 -0.765 . . . . 1.0 109.516 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -92.87 108.1 19.73 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 109.021 -0.733 . . . . 1.0 109.021 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -62.49 122.59 16.15 Favored 'General case' 0 CA--C 1.532 0.278 0 O-C-N 121.517 -0.739 . . . . 1.0 109.984 -179.709 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 t -88.94 -13.33 39.25 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 109.06 -0.718 . . . . 1.0 109.06 179.434 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 177.28 177.54 46.25 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 108.645 -1.782 . . . . 1.0 108.645 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.433 ' CE2' HG11 ' A' ' 22' ' ' VAL . 8.2 p90 -64.35 167.62 8.08 Favored Pre-proline 0 CA--C 1.54 0.585 0 O-C-N 121.24 -1.153 . . . . 1.0 109.064 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -81.22 -30.38 1.62 Allowed 'Trans proline' 0 N--CA 1.483 0.858 0 C-N-CA 124.347 3.365 . . . . 1.0 110.84 -178.684 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.92 -10.16 8.28 Favored Glycine 0 CA--C 1.537 1.423 0 N-CA-C 110.192 -1.163 . . . . 1.0 110.192 179.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.433 HG11 ' CE2' ' A' ' 19' ' ' PHE . 23.6 m -62.01 169.14 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 O-C-N 121.257 -1.143 . . . . 1.0 109.727 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 71.8 p -127.41 157.52 72.52 Favored Pre-proline 0 CA--C 1.534 0.361 0 N-CA-C 108.702 -0.851 . . . . 1.0 108.702 179.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -34.88 -36.12 0.12 Allowed 'Trans proline' 0 N--CA 1.489 1.255 1 C-N-CA 125.364 4.043 . . . . 1.0 111.315 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.7 p -72.83 -48.37 38.3 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.469 -0.769 . . . . 1.0 109.931 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 53.1 mt-30 -65.17 -44.01 89.89 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.542 -0.724 . . . . 1.0 110.07 -179.634 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 9.1 t -61.3 -31.85 71.7 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 121.303 -0.873 . . . . 1.0 109.855 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.19 -1.5 48.17 Favored 'General case' 0 CA--C 1.535 0.373 0 O-C-N 121.433 -0.792 . . . . 1.0 110.137 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -69.95 -28.49 65.61 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 121.349 -0.845 . . . . 1.0 110.255 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.29 -36.9 5.68 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 121.249 -0.907 . . . . 1.0 109.857 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 126.76 55.71 0.14 Allowed Glycine 0 CA--C 1.531 1.057 0 N-CA-C 109.959 -1.256 . . . . 1.0 109.959 179.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 36.9 m -120.98 137.3 54.7 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.398 -1.06 . . . . 1.0 108.725 179.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 53.0 m -69.42 122.75 19.58 Favored 'General case' 0 N--CA 1.466 0.374 0 O-C-N 121.326 -0.859 . . . . 1.0 109.418 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 34.9 t80 -93.48 140.1 29.97 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.493 -0.754 . . . . 1.0 109.002 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -152.76 112.4 3.91 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.379 -0.825 . . . . 1.0 109.737 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.427 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 11.5 p30 -113.76 76.12 0.96 Allowed 'General case' 0 N--CA 1.464 0.253 0 O-C-N 121.474 -0.766 . . . . 1.0 109.446 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.8 p -115.39 -29.95 6.39 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.507 -0.746 . . . . 1.0 109.635 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.4 t -124.44 154.43 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 O-C-N 121.503 -0.748 . . . . 1.0 109.501 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 41.8 mtm-85 -99.29 178.95 4.74 Favored 'General case' 0 CA--C 1.53 0.184 0 O-C-N 121.532 -0.73 . . . . 1.0 109.357 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 62.14 11.21 31.41 Favored Glycine 0 CA--C 1.533 1.206 0 N-CA-C 109.919 -1.272 . . . . 1.0 109.919 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.9 m -134.64 169.27 14.3 Favored Pre-proline 0 CA--C 1.535 0.404 0 O-C-N 121.357 -1.084 . . . . 1.0 109.182 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -87.64 122.44 1.69 Allowed 'Trans proline' 0 C--N 1.351 0.692 0 C-N-CA 124.825 3.683 . . . . 1.0 110.213 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.427 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.7 m0 -82.71 -32.68 27.89 Favored 'General case' 0 N--CA 1.463 0.216 0 O-C-N 121.478 -0.764 . . . . 1.0 109.44 -179.618 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 11.0 t -89.36 107.97 19.37 Favored 'General case' 0 CA--C 1.535 0.372 0 O-C-N 121.532 -0.73 . . . . 1.0 109.207 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.413 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 4.7 p90 -137.4 -179.32 5.66 Favored 'General case' 0 CA--C 1.539 0.524 0 O-C-N 121.263 -0.898 . . . . 1.0 110.33 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.409 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 10.5 m-85 -84.41 169.32 17.11 Favored Pre-proline 0 CA--C 1.539 0.524 0 O-C-N 121.519 -0.738 . . . . 1.0 110.097 -179.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_endo -90.89 170.23 3.46 Favored 'Trans proline' 0 C--N 1.353 0.767 0 C-N-CA 125.204 3.936 . . . . 1.0 110.888 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -132.44 79.75 1.87 Allowed 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 108.445 -0.946 . . . . 1.0 108.445 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 56.5 p -72.19 145.61 47.91 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.526 -0.734 . . . . 1.0 110.322 -179.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 42.5 mt -121.41 146.28 26.69 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 N-CA-C 108.764 -0.828 . . . . 1.0 108.764 179.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -154.51 -168.19 2.84 Favored 'General case' 0 N--CA 1.464 0.242 0 O-C-N 121.453 -0.779 . . . . 1.0 109.684 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.4 m -84.5 160.78 55.85 Favored Pre-proline 0 CA--C 1.536 0.421 0 O-C-N 121.589 -0.694 . . . . 1.0 109.348 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -90.72 106.85 0.31 Allowed 'Trans proline' 0 CA--C 1.539 0.734 0 C-N-CA 124.943 3.762 . . . . 1.0 110.151 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_endo -89.19 -160.32 0.1 OUTLIER 'Trans proline' 0 C--N 1.353 0.778 0 C-N-CA 124.734 3.623 . . . . 1.0 110.344 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 -78.14 135.52 37.68 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.428 -0.795 . . . . 1.0 109.586 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -107.28 117.08 33.14 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.508 -0.745 . . . . 1.0 109.369 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -108.18 157.64 18.14 Favored 'General case' 0 CA--C 1.53 0.205 0 O-C-N 121.529 -0.732 . . . . 1.0 109.498 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.0 p -139.18 109.27 6.39 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.547 -0.721 . . . . 1.0 109.348 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 11.9 mm-40 -132.63 106.49 7.83 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.553 -0.717 . . . . 1.0 109.418 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 8.7 t80 . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.032 -0.985 . . . . 1.0 109.412 -179.995 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 . . . . . 0 CA--C 1.532 0.281 0 N-CA-C 109.369 -0.604 . . . . 1.0 109.369 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -166.59 70.61 0.12 Allowed 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.494 -0.754 . . . . 1.0 109.367 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 10.9 mp0 -147.02 94.36 2.4 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.384 -0.823 . . . . 1.0 109.3 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -171.77 -165.75 0.39 Allowed 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.447 -0.783 . . . . 1.0 109.321 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -108.97 124.43 50.68 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.489 -0.757 . . . . 1.0 109.145 179.523 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.457 ' H ' HG23 ' A' ' 49' ' ' THR . 1.2 m -139.39 147.39 41.41 Favored 'General case' 0 CA--C 1.53 0.185 0 O-C-N 121.518 -0.739 . . . . 1.0 109.485 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.434 ' O ' ' CE2' ' A' ' 45' ' ' PHE . 11.2 m -111.05 -24.57 10.26 Favored 'General case' 0 C--N 1.332 -0.16 0 O-C-N 121.544 -0.723 . . . . 1.0 109.449 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.9 t -68.9 146.31 52.92 Favored 'General case' 0 N--CA 1.464 0.24 0 O-C-N 121.475 -0.766 . . . . 1.0 110.739 -178.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.494 ' CG1' ' H ' ' A' ' 10' ' ' ALA . 25.2 t -140.32 178.9 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 108.308 -0.997 . . . . 1.0 108.308 179.616 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.494 ' H ' ' CG1' ' A' ' 9' ' ' VAL . . . -61.95 110.54 3.32 Favored Pre-proline 0 CA--C 1.541 0.603 0 O-C-N 121.216 -0.927 . . . . 1.0 109.717 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -39.75 -31.32 0.43 Allowed 'Trans proline' 0 N--CA 1.489 1.222 0 C-N-CA 124.607 3.538 . . . . 1.0 111.194 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 8.7 mtt-85 -84.19 -39.61 19.16 Favored 'General case' 0 N--CA 1.464 0.273 0 O-C-N 121.39 -0.819 . . . . 1.0 109.979 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -103.58 50.82 0.8 Allowed 'General case' 0 CA--C 1.532 0.282 0 O-C-N 121.385 -0.822 . . . . 1.0 109.348 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 50.0 mtt180 -91.35 136.39 33.14 Favored 'General case' 0 N--CA 1.464 0.239 0 O-C-N 121.457 -0.777 . . . . 1.0 109.726 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -79.92 104.21 10.34 Favored 'General case' 0 CA--C 1.53 0.182 0 O-C-N 121.586 -0.696 . . . . 1.0 109.249 179.724 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 11.5 t-20 -62.84 116.5 5.31 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.48 -0.763 . . . . 1.0 109.899 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.0 t -92.55 -9.97 39.29 Favored 'General case' 0 CA--C 1.536 0.422 0 O-C-N 121.555 -0.716 . . . . 1.0 109.521 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.91 173.57 33.69 Favored Glycine 0 CA--C 1.529 0.957 0 N-CA-C 109.206 -1.557 . . . . 1.0 109.206 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.436 ' CD2' HG12 ' A' ' 22' ' ' VAL . 8.9 p90 -65.51 167.74 9.99 Favored Pre-proline 0 CA--C 1.539 0.544 0 O-C-N 121.43 -1.041 . . . . 1.0 108.971 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.67 -30.37 1.45 Allowed 'Trans proline' 0 N--CA 1.484 0.922 0 C-N-CA 124.305 3.337 . . . . 1.0 110.832 -178.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.29 -10.71 7.83 Favored Glycine 0 CA--C 1.537 1.441 0 N-CA-C 110.324 -1.11 . . . . 1.0 110.324 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.436 HG12 ' CD2' ' A' ' 19' ' ' PHE . 20.3 m -60.54 -171.94 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 O-C-N 121.294 -1.121 . . . . 1.0 109.723 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -146.63 157.25 48.2 Favored Pre-proline 0 CA--C 1.535 0.379 0 O-C-N 121.584 -0.697 . . . . 1.0 109.25 179.809 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -34.71 -31.93 0.07 OUTLIER 'Trans proline' 0 N--CA 1.489 1.207 1 C-N-CA 125.588 4.192 . . . . 1.0 111.36 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 76.8 p -75.3 -50.22 16.71 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.475 -0.766 . . . . 1.0 109.872 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 38.0 mt-30 -61.57 -48.02 82.88 Favored 'General case' 0 N--CA 1.465 0.291 0 O-C-N 121.44 -0.788 . . . . 1.0 109.811 -179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.9 t -64.69 -28.4 69.57 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.392 -0.818 . . . . 1.0 109.558 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -87.95 -4.96 58.77 Favored 'General case' 0 CA--C 1.534 0.353 0 O-C-N 121.57 -0.706 . . . . 1.0 110.012 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -75.01 -30.1 61.03 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.318 -0.864 . . . . 1.0 109.73 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.5 mmtp -102.82 -40.43 6.56 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.453 -0.779 . . . . 1.0 109.466 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 118.23 39.27 0.75 Allowed Glycine 0 CA--C 1.529 0.944 0 N-CA-C 109.419 -1.472 . . . . 1.0 109.419 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 48.7 m -101.94 139.7 37.22 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.567 -0.96 . . . . 1.0 109.189 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 84.6 m -65.37 116.51 6.76 Favored 'General case' 0 N--CA 1.464 0.255 0 O-C-N 121.523 -0.736 . . . . 1.0 109.927 -179.374 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 34.2 t80 -92.74 121.14 33.84 Favored 'General case' 0 C--N 1.333 -0.141 0 N-CA-C 109.042 -0.725 . . . . 1.0 109.042 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 26.8 t0 -134.15 118.48 17.72 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.391 -0.818 . . . . 1.0 109.518 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.429 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 7.0 p-10 -110.91 64.55 0.61 Allowed 'General case' 0 CA--C 1.533 0.298 0 O-C-N 121.526 -0.734 . . . . 1.0 109.236 179.866 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 27.0 p -114.26 -49.71 2.83 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.392 -0.817 . . . . 1.0 109.489 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.3 t -100.22 133.6 42.69 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 O-C-N 121.404 -0.81 . . . . 1.0 109.507 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.428 ' HG3' ' H ' ' A' ' 40' ' ' GLY . 2.3 tpt180 -85.13 176.17 8.55 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.571 -0.706 . . . . 1.0 109.553 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.428 ' H ' ' HG3' ' A' ' 39' ' ' ARG . . . 80.89 -48.43 3.74 Favored Glycine 0 CA--C 1.529 0.908 0 N-CA-C 109.447 -1.461 . . . . 1.0 109.447 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.3 m -81.4 169.75 17.86 Favored Pre-proline 0 CA--C 1.536 0.437 0 O-C-N 121.511 -0.993 . . . . 1.0 109.215 179.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -86.55 124.37 2.3 Favored 'Trans proline' 0 C--N 1.35 0.628 0 C-N-CA 124.757 3.638 . . . . 1.0 110.157 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.429 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 16.9 m0 -67.28 -37.61 83.7 Favored 'General case' 0 CA--C 1.53 0.192 0 O-C-N 121.554 -0.716 . . . . 1.0 109.522 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 11.1 t -87.86 109.25 19.62 Favored 'General case' 0 C--O 1.233 0.195 0 O-C-N 121.399 -0.813 . . . . 1.0 108.961 179.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.434 ' CE2' ' O ' ' A' ' 7' ' ' CYS . 1.3 p90 -149.3 178.44 8.76 Favored 'General case' 0 CA--C 1.537 0.454 0 O-C-N 121.454 -0.779 . . . . 1.0 109.832 -179.512 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 29.8 m-85 -83.78 170.28 14.59 Favored Pre-proline 0 CA--C 1.538 0.498 0 O-C-N 121.485 -0.759 . . . . 1.0 109.942 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -93.83 -168.32 0.18 Allowed 'Trans proline' 0 C--N 1.35 0.641 1 C-N-CA 125.357 4.038 . . . . 1.0 111.39 -179.45 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -168.79 79.22 0.13 Allowed 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 107.902 -1.148 . . . . 1.0 107.902 179.364 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.457 HG23 ' H ' ' A' ' 6' ' ' THR . 48.4 p -98.5 137.29 37.39 Favored 'General case' 0 C--N 1.33 -0.247 0 O-C-N 121.641 -0.662 . . . . 1.0 110.004 -178.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 30.3 mt -90.5 170.23 1.26 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 108.275 -1.009 . . . . 1.0 108.275 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -80.13 175.41 10.67 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.265 -0.897 . . . . 1.0 110.062 -179.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 29.1 m -121.78 157.94 55.83 Favored Pre-proline 0 CA--C 1.537 0.451 0 O-C-N 121.598 -0.689 . . . . 1.0 109.793 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.447 ' N ' ' HD2' ' A' ' 54' ' ' PRO . 3.0 Cg_exo -38.47 -60.18 0.5 Allowed 'Trans proline' 0 N--CA 1.486 1.049 0 C-N-CA 125.186 3.924 . . . . 1.0 111.311 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . 0.447 ' HD2' ' N ' ' A' ' 53' ' ' PRO . 22.7 Cg_exo -33.63 128.05 0.15 Allowed 'Trans proline' 0 N--CA 1.491 1.347 0 C-N-CA 125.261 3.974 . . . . 1.0 111.511 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -76.62 135.32 39.17 Favored 'General case' 0 N--CA 1.462 0.162 0 O-C-N 121.566 -0.709 . . . . 1.0 109.511 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -122.96 147.94 46.05 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.433 -0.792 . . . . 1.0 109.422 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -102.09 139.9 37.1 Favored 'General case' 0 CA--C 1.532 0.27 0 O-C-N 121.465 -0.772 . . . . 1.0 109.52 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 7.9 m -72.06 122.98 21.85 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.558 -0.714 . . . . 1.0 109.409 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 -146.94 117.76 7.62 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.474 -0.766 . . . . 1.0 109.537 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 117.976 -1.012 . . . . 1.0 109.228 179.942 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 . . . . . 0 CA--C 1.531 0.217 0 N-CA-C 109.458 -0.571 . . . . 1.0 109.458 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -85.82 108.49 18.14 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.481 -0.762 . . . . 1.0 109.52 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 25.0 mt-30 -145.5 127.73 15.75 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.455 -0.778 . . . . 1.0 109.341 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.8 p -126.22 172.95 9.63 Favored 'General case' 0 N--CA 1.464 0.232 0 O-C-N 121.422 -0.798 . . . . 1.0 109.621 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -89.27 133.92 34.26 Favored 'General case' 0 N--CA 1.462 0.153 0 O-C-N 121.497 -0.752 . . . . 1.0 109.367 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -146.76 108.26 4.29 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.514 -0.742 . . . . 1.0 109.733 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 80.6 m -97.31 45.84 1.04 Allowed 'General case' 0 CA--C 1.532 0.287 0 O-C-N 121.51 -0.743 . . . . 1.0 108.998 179.445 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.6 t -123.79 83.5 2.15 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.178 -0.951 . . . . 1.0 109.848 -179.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 38.2 t -109.5 172.03 2.46 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 N-CA-C 108.85 -0.796 . . . . 1.0 108.85 179.449 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -73.15 131.76 83.04 Favored Pre-proline 0 CA--C 1.541 0.597 0 O-C-N 121.323 -0.861 . . . . 1.0 109.272 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -36.87 -38.75 0.39 Allowed 'Trans proline' 0 N--CA 1.488 1.156 0 C-N-CA 125.103 3.869 . . . . 1.0 111.351 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.7 mpp_? -82.01 -40.28 22.34 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 121.433 -0.792 . . . . 1.0 109.944 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 29.6 mt-10 -86.24 42.68 1.01 Allowed 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.277 -0.89 . . . . 1.0 109.671 -179.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 37.9 mtt180 -101.51 151.34 22.08 Favored 'General case' 0 N--CA 1.464 0.232 0 O-C-N 121.409 -0.807 . . . . 1.0 109.627 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -104.68 105.6 15.76 Favored 'General case' 0 N--CA 1.462 0.172 0 O-C-N 121.345 -0.847 . . . . 1.0 109.06 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -57.32 118.69 5.38 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 121.235 -0.916 . . . . 1.0 110.305 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -94.13 -18.85 21.35 Favored 'General case' 0 CA--C 1.534 0.348 0 O-C-N 121.515 -0.741 . . . . 1.0 109.345 179.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -171.88 176.82 44.9 Favored Glycine 0 CA--C 1.53 1.017 0 N-CA-C 109.059 -1.616 . . . . 1.0 109.059 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.429 ' CE2' HG11 ' A' ' 22' ' ' VAL . 8.3 p90 -66.12 167.16 12.91 Favored Pre-proline 0 CA--C 1.539 0.526 0 O-C-N 121.374 -1.074 . . . . 1.0 108.815 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.97 -30.16 1.41 Allowed 'Trans proline' 0 N--CA 1.482 0.828 0 C-N-CA 124.537 3.491 . . . . 1.0 110.906 -178.604 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -57.8 -11.86 9.12 Favored Glycine 0 CA--C 1.536 1.39 0 N-CA-C 110.323 -1.111 . . . . 1.0 110.323 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.429 HG11 ' CE2' ' A' ' 19' ' ' PHE . 20.9 m -61.06 -172.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 O-C-N 121.302 -1.116 . . . . 1.0 109.932 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.495 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 59.9 p -145.15 157.64 53.21 Favored Pre-proline 0 CA--C 1.535 0.37 0 N-CA-C 108.913 -0.773 . . . . 1.0 108.913 179.709 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -35.07 -39.75 0.22 Allowed 'Trans proline' 0 N--CA 1.489 1.212 1 C-N-CA 125.484 4.123 . . . . 1.0 111.378 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.1 p -74.08 -46.63 41.77 Favored 'General case' 0 CA--C 1.532 0.288 0 O-C-N 121.462 -0.774 . . . . 1.0 109.903 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLN . . . . . 0.495 ' HB2' ' H ' ' A' ' 23' ' ' THR . 32.4 mt-30 -61.26 -53.07 61.49 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 121.447 -0.783 . . . . 1.0 109.975 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 23.1 t -61.66 -26.41 68.0 Favored 'General case' 0 CA--C 1.533 0.322 0 O-C-N 121.298 -0.877 . . . . 1.0 109.719 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -90.01 -6.69 55.33 Favored 'General case' 0 CA--C 1.535 0.386 0 O-C-N 121.504 -0.748 . . . . 1.0 110.08 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 15.5 t-20 -78.96 -45.38 20.49 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.29 -0.882 . . . . 1.0 109.535 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.1 mtmm -72.36 -45.85 58.03 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.483 -0.761 . . . . 1.0 109.526 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 125.26 27.03 1.25 Allowed Glycine 0 CA--C 1.529 0.939 0 N-CA-C 109.197 -1.561 . . . . 1.0 109.197 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 26.4 m -99.52 145.29 27.65 Favored 'General case' 0 CA--C 1.532 0.276 0 O-C-N 121.685 -0.891 . . . . 1.0 108.696 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 35.9 m -68.58 128.92 38.35 Favored 'General case' 0 N--CA 1.465 0.321 0 O-C-N 121.307 -0.871 . . . . 1.0 109.42 -179.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -97.82 138.09 35.69 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.511 -0.743 . . . . 1.0 109.067 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 13.6 t0 -157.63 89.25 1.02 Allowed 'General case' 0 N--CA 1.463 0.183 0 O-C-N 121.521 -0.737 . . . . 1.0 109.512 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.415 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 38.2 p-10 -103.05 78.68 1.67 Allowed 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.539 -0.725 . . . . 1.0 109.472 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 76.6 p -113.85 -23.15 9.79 Favored 'General case' 0 CA--C 1.534 0.334 0 O-C-N 121.383 -0.823 . . . . 1.0 109.709 -179.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.8 t -127.6 165.54 26.35 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 O-C-N 121.451 -0.78 . . . . 1.0 109.645 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.447 ' CD ' ' H ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER -107.03 175.05 5.63 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 109.097 -0.705 . . . . 1.0 109.097 179.812 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.447 ' H ' ' CD ' ' A' ' 39' ' ' ARG . . . 72.17 -8.07 7.13 Favored Glycine 0 CA--C 1.533 1.173 0 N-CA-C 109.954 -1.258 . . . . 1.0 109.954 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.421 ' H ' ' C ' ' A' ' 39' ' ' ARG . 30.9 m -121.52 170.08 8.12 Favored Pre-proline 0 CA--C 1.537 0.461 0 O-C-N 121.317 -1.108 . . . . 1.0 109.051 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -86.53 127.75 2.85 Favored 'Trans proline' 0 N--CA 1.48 0.694 0 C-N-CA 124.585 3.523 . . . . 1.0 110.209 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.415 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.4 m0 -82.49 -39.36 22.57 Favored 'General case' 0 N--CA 1.464 0.264 0 O-C-N 121.586 -0.696 . . . . 1.0 109.28 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.1 t -88.14 117.49 27.06 Favored 'General case' 0 N--CA 1.466 0.329 0 O-C-N 121.508 -0.745 . . . . 1.0 109.113 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.419 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 5.2 p90 -145.18 173.14 12.19 Favored 'General case' 0 CA--C 1.537 0.463 0 O-C-N 121.328 -0.857 . . . . 1.0 110.34 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.408 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 14.3 m-85 -79.53 172.78 9.0 Favored Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 121.473 -0.767 . . . . 1.0 109.496 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo -90.37 160.53 4.54 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 125.087 3.858 . . . . 1.0 110.252 179.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 8.2 m-20 -135.57 106.11 6.48 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.485 -0.759 . . . . 1.0 109.492 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 65.0 p -86.9 88.24 7.65 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 121.457 -0.777 . . . . 1.0 109.535 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.456 HG22 HD11 ' A' ' 50' ' ' ILE . 62.6 mt -104.18 155.69 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 O-C-N 121.461 -0.774 . . . . 1.0 109.257 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -82.69 137.45 34.44 Favored 'General case' 0 CA--C 1.53 0.202 0 O-C-N 121.497 -0.752 . . . . 1.0 109.482 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 31.0 m -114.12 79.69 5.1 Favored Pre-proline 0 CA--C 1.537 0.461 0 O-C-N 121.509 -0.744 . . . . 1.0 109.411 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.447 ' N ' ' HD2' ' A' ' 54' ' ' PRO . 7.2 Cg_exo -37.34 -59.68 0.47 Allowed 'Trans proline' 0 N--CA 1.486 1.086 0 C-N-CA 125.128 3.885 . . . . 1.0 111.345 -179.845 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . 0.447 ' HD2' ' N ' ' A' ' 53' ' ' PRO . 15.3 Cg_exo -37.47 154.6 0.03 OUTLIER 'Trans proline' 0 N--CA 1.49 1.291 0 C-N-CA 124.785 3.657 . . . . 1.0 111.014 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -77.86 156.31 30.47 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.489 -0.757 . . . . 1.0 109.408 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -69.88 144.66 52.43 Favored 'General case' 0 CA--C 1.53 0.202 0 O-C-N 121.417 -0.802 . . . . 1.0 109.42 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 30.8 mt-10 -145.21 108.68 4.64 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 121.472 -0.768 . . . . 1.0 109.473 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 22.9 t -118.49 119.93 36.01 Favored 'General case' 0 N--CA 1.463 0.186 0 O-C-N 121.46 -0.775 . . . . 1.0 109.388 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -87.37 101.61 13.73 Favored 'General case' 0 N--CA 1.463 0.202 0 O-C-N 121.44 -0.787 . . . . 1.0 109.523 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 40.5 t80 . . . . . 0 C--O 1.221 -0.408 0 CA-C-O 117.965 -1.017 . . . . 1.0 109.386 -179.954 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.531 0.212 0 N-CA-C 109.413 -0.588 . . . . 1.0 109.413 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -81.28 23.32 0.61 Allowed 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.545 -0.722 . . . . 1.0 109.578 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -102.37 111.3 23.54 Favored 'General case' 0 CA--C 1.53 0.196 0 O-C-N 121.441 -0.787 . . . . 1.0 109.478 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.4 p -92.88 174.83 7.04 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.456 -0.778 . . . . 1.0 109.503 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 -77.7 145.01 36.85 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.46 -0.775 . . . . 1.0 109.459 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 m -143.09 125.12 15.25 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.528 -0.733 . . . . 1.0 109.502 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 63.9 m -105.61 -20.56 13.43 Favored 'General case' 0 CA--C 1.533 0.316 0 O-C-N 121.601 -0.687 . . . . 1.0 109.478 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.8 t -70.05 104.78 2.66 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.322 -0.861 . . . . 1.0 109.538 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 36.2 t -131.66 170.66 19.39 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 O-C-N 121.607 -0.683 . . . . 1.0 109.186 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.77 126.52 91.86 Favored Pre-proline 0 CA--C 1.539 0.535 0 O-C-N 121.448 -0.782 . . . . 1.0 109.22 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_exo -37.74 -40.02 0.88 Allowed 'Trans proline' 0 N--CA 1.49 1.268 0 C-N-CA 124.926 3.751 . . . . 1.0 111.126 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.9 mtm-85 -76.6 -41.73 45.08 Favored 'General case' 0 CA--C 1.532 0.254 0 O-C-N 121.4 -0.812 . . . . 1.0 109.886 -179.425 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -81.88 40.52 0.61 Allowed 'General case' 0 C--N 1.331 -0.213 0 O-C-N 121.451 -0.78 . . . . 1.0 109.561 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 55.3 mtt180 -108.09 133.49 52.31 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.47 -0.769 . . . . 1.0 109.556 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 22.6 mm-40 -90.65 117.71 29.52 Favored 'General case' 0 N--CA 1.464 0.227 0 O-C-N 121.438 -0.789 . . . . 1.0 109.367 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -61.31 115.36 3.78 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.453 -0.779 . . . . 1.0 109.992 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.4 t -93.47 -20.39 20.33 Favored 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.605 -0.685 . . . . 1.0 109.324 179.614 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.52 170.58 37.19 Favored Glycine 0 CA--C 1.529 0.958 0 N-CA-C 109.494 -1.442 . . . . 1.0 109.494 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CE2' ' CG1' ' A' ' 22' ' ' VAL . 19.8 p90 -64.85 148.77 97.14 Favored Pre-proline 0 CA--C 1.538 0.505 0 O-C-N 121.435 -1.038 . . . . 1.0 109.263 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -65.43 -28.69 54.07 Favored 'Trans proline' 0 N--CA 1.489 1.232 0 C-N-CA 124.053 3.169 . . . . 1.0 110.704 -178.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -55.04 -15.62 7.1 Favored Glycine 0 CA--C 1.536 1.355 0 N-CA-C 110.649 -0.981 . . . . 1.0 110.649 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.431 ' CG1' ' CE2' ' A' ' 19' ' ' PHE . 30.2 m -64.01 178.26 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 O-C-N 121.389 -1.065 . . . . 1.0 109.505 179.816 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.1 p -132.03 156.4 80.15 Favored Pre-proline 0 CA--C 1.536 0.427 0 O-C-N 121.543 -0.723 . . . . 1.0 109.313 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -34.49 -33.03 0.07 OUTLIER 'Trans proline' 0 N--CA 1.489 1.206 1 C-N-CA 125.587 4.192 . . . . 1.0 111.293 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 2.6 m -71.83 -49.96 33.83 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.472 -0.767 . . . . 1.0 109.962 -179.554 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 13.2 mm-40 -63.39 -49.93 71.89 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.403 -0.81 . . . . 1.0 109.73 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.6 t -63.16 -21.34 66.14 Favored 'General case' 0 CA--C 1.533 0.306 0 O-C-N 121.518 -0.739 . . . . 1.0 109.829 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.0 -11.06 27.06 Favored 'General case' 0 CA--C 1.535 0.399 0 O-C-N 121.416 -0.802 . . . . 1.0 109.916 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -71.38 -35.96 71.27 Favored 'General case' 0 N--CA 1.463 0.205 0 O-C-N 121.331 -0.856 . . . . 1.0 109.56 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.8 tttp -92.07 -42.68 9.82 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.44 -0.787 . . . . 1.0 109.447 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 122.33 38.05 0.61 Allowed Glycine 0 CA--C 1.528 0.849 0 N-CA-C 109.526 -1.43 . . . . 1.0 109.526 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.8 m -105.59 145.34 31.12 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.493 -1.004 . . . . 1.0 109.114 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 61.4 m -68.5 127.48 33.14 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.557 -0.714 . . . . 1.0 109.54 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 51.1 t80 -104.12 109.39 21.16 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 121.507 -0.746 . . . . 1.0 109.25 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -120.81 102.98 8.74 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.575 -0.703 . . . . 1.0 109.564 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.431 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.8 p-10 -108.08 59.49 0.61 Allowed 'General case' 0 CA--C 1.532 0.267 0 O-C-N 121.527 -0.733 . . . . 1.0 109.291 179.742 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.5 p -112.28 -42.1 3.78 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.364 -0.835 . . . . 1.0 109.454 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.2 t -96.71 155.09 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 O-C-N 121.481 -0.762 . . . . 1.0 109.483 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.405 ' C ' ' H ' ' A' ' 41' ' ' VAL . 0.8 OUTLIER -108.03 165.05 11.75 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.529 -0.732 . . . . 1.0 109.449 -179.991 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.4 -32.6 2.82 Favored Glycine 0 CA--C 1.53 1.009 0 N-CA-C 109.096 -1.602 . . . . 1.0 109.096 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.405 ' H ' ' C ' ' A' ' 39' ' ' ARG . 26.8 m -91.34 171.85 7.45 Favored Pre-proline 0 CA--C 1.538 0.502 0 O-C-N 121.619 -0.93 . . . . 1.0 109.041 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . 0.402 ' CD ' ' HB ' ' A' ' 41' ' ' VAL . 11.4 Cg_endo -85.97 138.68 6.01 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 124.411 3.407 . . . . 1.0 109.706 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.431 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 30.6 m0 -87.36 -46.06 10.0 Favored 'General case' 0 CA--C 1.531 0.239 0 O-C-N 121.481 -0.762 . . . . 1.0 110.466 -179.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 14.9 t -89.04 109.51 20.34 Favored 'General case' 0 CA--C 1.532 0.276 0 O-C-N 121.242 -0.911 . . . . 1.0 109.953 -179.503 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.415 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 5.6 p90 -137.38 -178.97 5.46 Favored 'General case' 0 CA--C 1.537 0.474 0 O-C-N 121.387 -0.821 . . . . 1.0 109.448 179.365 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.415 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 43.9 m-85 -90.48 165.27 23.74 Favored Pre-proline 0 CA--C 1.536 0.422 0 O-C-N 121.328 -0.857 . . . . 1.0 109.512 -179.798 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -90.86 175.59 2.49 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 124.95 3.767 . . . . 1.0 110.502 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 67.8 m-80 -153.1 105.19 2.88 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 109.291 -0.633 . . . . 1.0 109.291 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 30.7 p -65.9 92.89 0.17 Allowed 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.479 -0.763 . . . . 1.0 109.349 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.46 HD11 HG22 ' A' ' 50' ' ' ILE . 63.2 mt -139.87 162.43 25.62 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 O-C-N 121.561 -0.712 . . . . 1.0 109.315 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -101.82 130.82 48.36 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.459 -0.776 . . . . 1.0 109.36 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.9 m -144.56 155.59 56.83 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.548 -0.72 . . . . 1.0 109.446 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -38.85 162.27 0.02 OUTLIER 'Trans proline' 0 N--CA 1.488 1.152 0 C-N-CA 125.249 3.966 . . . . 1.0 110.852 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -90.68 -72.91 0.0 OUTLIER 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 124.888 3.725 . . . . 1.0 110.311 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 65.5 mt-10 -78.08 127.8 32.86 Favored 'General case' 0 CA--C 1.532 0.26 0 O-C-N 121.599 -0.688 . . . . 1.0 109.383 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -86.2 129.91 34.69 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 121.595 -0.69 . . . . 1.0 109.413 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.453 ' HG2' ' H ' ' A' ' 58' ' ' SER . 8.2 tt0 -76.78 164.41 25.87 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.522 -0.736 . . . . 1.0 109.405 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' SER . . . . . 0.453 ' H ' ' HG2' ' A' ' 57' ' ' GLU . 57.8 m -145.75 159.63 42.9 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.462 -0.774 . . . . 1.0 109.44 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 28.3 mm-40 -105.31 146.2 29.7 Favored 'General case' 0 CA--C 1.532 0.254 0 O-C-N 121.538 -0.726 . . . . 1.0 109.474 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 117.986 -1.007 . . . . 1.0 109.43 -179.97 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.531 0.243 0 N-CA-C 109.531 -0.544 . . . . 1.0 109.531 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -149.47 85.51 1.45 Allowed 'General case' 0 CA--C 1.531 0.213 0 O-C-N 121.42 -0.8 . . . . 1.0 109.394 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 -124.38 118.56 26.97 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.51 -0.744 . . . . 1.0 109.459 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -87.4 172.94 9.45 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.528 -0.732 . . . . 1.0 109.489 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.8 mt-10 -93.55 144.94 24.9 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.477 -0.764 . . . . 1.0 109.64 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 4.7 t -115.74 148.02 40.26 Favored 'General case' 0 CA--C 1.532 0.265 0 O-C-N 121.549 -0.72 . . . . 1.0 109.316 179.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 72.2 m -108.43 -20.97 12.94 Favored 'General case' 0 CA--C 1.534 0.345 0 O-C-N 121.46 -0.775 . . . . 1.0 109.644 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.5 t -70.03 102.98 2.15 Favored 'General case' 0 CA--C 1.53 0.211 0 O-C-N 121.489 -0.757 . . . . 1.0 109.892 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.0 t -114.53 171.44 4.32 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 O-C-N 121.346 -0.846 . . . . 1.0 108.936 179.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -78.39 119.5 77.54 Favored Pre-proline 0 CA--C 1.541 0.622 0 O-C-N 121.417 -0.802 . . . . 1.0 109.542 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_exo -37.93 -38.84 0.77 Allowed 'Trans proline' 0 N--CA 1.489 1.258 0 C-N-CA 124.757 3.638 . . . . 1.0 111.205 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 18.6 mmm-85 -77.01 -42.65 37.76 Favored 'General case' 0 N--CA 1.464 0.237 0 O-C-N 121.494 -0.754 . . . . 1.0 109.889 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -102.53 50.03 0.83 Allowed 'General case' 0 CA--C 1.532 0.286 0 O-C-N 121.375 -0.828 . . . . 1.0 109.508 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 26.7 mtt180 -94.04 147.77 22.81 Favored 'General case' 0 N--CA 1.463 0.223 0 O-C-N 121.379 -0.826 . . . . 1.0 109.704 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 54.1 mm-40 -91.6 107.26 19.09 Favored 'General case' 0 CA--C 1.53 0.196 0 O-C-N 121.474 -0.766 . . . . 1.0 109.166 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 30.2 t-20 -63.76 123.06 17.92 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 121.513 -0.742 . . . . 1.0 109.819 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 38.1 t -100.9 -18.34 16.4 Favored 'General case' 0 CA--C 1.534 0.329 0 O-C-N 121.53 -0.731 . . . . 1.0 109.505 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 175.94 -177.13 47.67 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 109.276 -1.53 . . . . 1.0 109.276 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.428 ' CE2' HG11 ' A' ' 22' ' ' VAL . 9.1 p90 -65.73 167.87 10.13 Favored Pre-proline 0 CA--C 1.538 0.492 0 O-C-N 121.395 -1.062 . . . . 1.0 108.822 179.732 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.81 -30.4 1.39 Allowed 'Trans proline' 0 N--CA 1.483 0.888 0 C-N-CA 124.374 3.383 . . . . 1.0 110.794 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -56.96 -12.58 7.23 Favored Glycine 0 CA--C 1.537 1.458 0 N-CA-C 110.357 -1.097 . . . . 1.0 110.357 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.428 HG11 ' CE2' ' A' ' 19' ' ' PHE . 23.0 m -61.05 170.37 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 O-C-N 121.3 -1.117 . . . . 1.0 109.627 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.7 p -133.97 154.51 80.33 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.555 -0.716 . . . . 1.0 109.172 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.406 ' HD3' ' CZ ' ' A' ' 34' ' ' PHE . 16.8 Cg_exo -34.58 -31.87 0.06 OUTLIER 'Trans proline' 0 N--CA 1.488 1.195 1 C-N-CA 125.594 4.196 . . . . 1.0 111.355 179.956 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.6 m -75.53 -51.24 13.39 Favored 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.439 -0.788 . . . . 1.0 109.608 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 15.6 mt-30 -62.79 -43.37 98.98 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.427 -0.796 . . . . 1.0 109.721 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 10.1 t -64.54 -29.14 70.17 Favored 'General case' 0 N--CA 1.464 0.235 0 O-C-N 121.474 -0.766 . . . . 1.0 109.422 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.98 -11.15 56.13 Favored 'General case' 0 CA--C 1.533 0.315 0 O-C-N 121.604 -0.685 . . . . 1.0 109.756 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -88.24 -26.04 22.55 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.359 -0.838 . . . . 1.0 109.531 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 9.6 tttp -89.39 -32.06 17.46 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.419 -0.801 . . . . 1.0 109.407 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.41 43.43 1.36 Allowed Glycine 0 CA--C 1.53 0.985 0 N-CA-C 109.633 -1.387 . . . . 1.0 109.633 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.9 m -129.46 150.36 50.84 Favored 'General case' 0 CA--C 1.53 0.191 0 O-C-N 121.47 -1.018 . . . . 1.0 109.461 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.42 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 62.5 m -72.91 134.77 44.92 Favored 'General case' 0 CA--C 1.529 0.173 0 O-C-N 121.412 -0.805 . . . . 1.0 109.5 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.406 ' CZ ' ' HD3' ' A' ' 24' ' ' PRO . 57.1 t80 -107.87 125.13 51.1 Favored 'General case' 0 CA--C 1.53 0.175 0 O-C-N 121.488 -0.758 . . . . 1.0 109.233 179.689 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 16.2 t0 -138.54 117.84 12.77 Favored 'General case' 0 CA--C 1.53 0.179 0 O-C-N 121.457 -0.777 . . . . 1.0 109.527 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.42 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 14.1 p30 -113.55 66.06 0.66 Allowed 'General case' 0 N--CA 1.464 0.256 0 O-C-N 121.547 -0.721 . . . . 1.0 109.368 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.9 p -97.62 -69.82 0.74 Allowed 'General case' 0 CA--C 1.531 0.235 0 O-C-N 121.358 -0.839 . . . . 1.0 109.522 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 38.2 t -96.46 155.19 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 O-C-N 121.458 -0.776 . . . . 1.0 109.452 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.476 ' CG ' ' H ' ' A' ' 40' ' ' GLY . 13.7 ttp-105 -93.9 178.34 5.7 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 121.504 -0.748 . . . . 1.0 109.395 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.476 ' H ' ' CG ' ' A' ' 39' ' ' ARG . . . 81.3 -43.62 2.92 Favored Glycine 0 CA--C 1.529 0.918 0 N-CA-C 109.472 -1.451 . . . . 1.0 109.472 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.2 m -85.52 169.66 15.31 Favored Pre-proline 0 CA--C 1.537 0.444 0 O-C-N 121.538 -0.978 . . . . 1.0 109.197 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -87.22 136.46 4.06 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 124.77 3.647 . . . . 1.0 110.139 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.42 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 11.6 m0 -86.72 -50.55 6.69 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.526 -0.734 . . . . 1.0 109.569 -179.742 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.2 t -77.28 103.69 7.36 Favored 'General case' 0 N--CA 1.463 0.224 0 O-C-N 121.488 -0.758 . . . . 1.0 109.505 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.42 ' CE1' ' HB2' ' A' ' 33' ' ' CYS . 4.8 p90 -135.82 -178.99 5.38 Favored 'General case' 0 N--CA 1.465 0.316 0 O-C-N 121.489 -0.757 . . . . 1.0 109.523 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 65.1 m-85 -93.75 164.31 21.23 Favored Pre-proline 0 CA--C 1.534 0.357 0 O-C-N 121.436 -0.79 . . . . 1.0 109.652 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -91.11 -165.34 0.16 Allowed 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 125.045 3.83 . . . . 1.0 110.406 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 17.9 m-80 -157.5 118.51 3.57 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.505 -0.747 . . . . 1.0 109.441 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 1.3 p -66.8 96.61 0.42 Allowed 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.454 -0.779 . . . . 1.0 109.51 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 60.8 mt -129.04 170.21 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 O-C-N 121.463 -0.773 . . . . 1.0 109.285 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -74.86 -173.1 1.78 Allowed 'General case' 0 CA--C 1.53 0.209 0 O-C-N 121.504 -0.747 . . . . 1.0 109.292 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.2 m -88.09 143.12 32.51 Favored Pre-proline 0 CA--C 1.538 0.487 0 O-C-N 121.433 -0.792 . . . . 1.0 109.443 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_exo -35.65 154.03 0.02 OUTLIER 'Trans proline' 0 N--CA 1.489 1.215 1 C-N-CA 125.38 4.053 . . . . 1.0 111.083 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -34.7 -53.46 0.63 Allowed 'Trans proline' 0 N--CA 1.487 1.101 1 C-N-CA 125.646 4.231 . . . . 1.0 111.133 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -127.36 155.31 43.79 Favored 'General case' 0 CA--C 1.53 0.182 0 O-C-N 121.544 -0.723 . . . . 1.0 109.368 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -97.04 101.44 13.02 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.478 -0.764 . . . . 1.0 109.459 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -148.53 104.16 3.47 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.535 -0.728 . . . . 1.0 109.418 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.4 p -144.86 138.89 27.32 Favored 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.553 -0.717 . . . . 1.0 109.456 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -105.6 153.43 21.8 Favored 'General case' 0 CA--C 1.53 0.202 0 O-C-N 121.542 -0.724 . . . . 1.0 109.437 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.02 -0.991 . . . . 1.0 109.439 179.958 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 . . . . . 0 CA--C 1.53 0.206 0 N-CA-C 109.419 -0.585 . . . . 1.0 109.419 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -166.25 39.26 0.05 Allowed 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.508 -0.745 . . . . 1.0 109.429 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -105.34 138.17 41.97 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.436 -0.79 . . . . 1.0 109.495 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 20.7 p -142.54 174.77 10.33 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.518 -0.739 . . . . 1.0 109.531 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 6.5 mm-40 -87.6 142.68 27.66 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.518 -0.739 . . . . 1.0 109.414 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.3 m -135.68 134.63 39.36 Favored 'General case' 0 CA--C 1.53 0.191 0 O-C-N 121.565 -0.709 . . . . 1.0 109.303 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.9 m -105.21 28.87 6.88 Favored 'General case' 0 C--N 1.33 -0.249 0 O-C-N 121.611 -0.681 . . . . 1.0 109.316 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.2 t -80.51 118.29 21.98 Favored 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.406 -0.809 . . . . 1.0 109.508 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 36.4 t -149.47 154.18 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 O-C-N 121.57 -0.706 . . . . 1.0 109.349 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -83.1 146.38 51.41 Favored Pre-proline 0 CA--C 1.537 0.472 0 O-C-N 121.472 -0.768 . . . . 1.0 109.353 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_exo -34.48 -62.19 0.21 Allowed 'Trans proline' 0 N--CA 1.489 1.235 1 C-N-CA 125.571 4.18 . . . . 1.0 111.388 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.52 -29.88 65.29 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.383 -0.823 . . . . 1.0 109.856 -179.649 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -80.62 3.7 21.06 Favored 'General case' 0 CA--C 1.535 0.39 0 O-C-N 121.394 -0.816 . . . . 1.0 109.932 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 48.8 mtt180 -73.86 129.71 38.45 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.396 -0.815 . . . . 1.0 109.56 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.4 mm-40 -88.08 108.98 19.51 Favored 'General case' 0 N--CA 1.463 0.212 0 N-CA-C 109.03 -0.73 . . . . 1.0 109.03 179.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 32.9 t-20 -59.22 105.8 0.37 Allowed 'General case' 0 CA--C 1.534 0.328 0 O-C-N 121.396 -0.815 . . . . 1.0 110.391 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 t -85.53 -15.22 43.43 Favored 'General case' 0 CA--C 1.535 0.391 0 O-C-N 121.489 -0.757 . . . . 1.0 109.02 179.361 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 178.57 165.28 32.89 Favored Glycine 0 CA--C 1.529 0.96 0 N-CA-C 108.99 -1.644 . . . . 1.0 108.99 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.425 ' CD2' HG11 ' A' ' 22' ' ' VAL . 7.1 p90 -59.41 168.91 1.49 Allowed Pre-proline 0 CA--C 1.541 0.634 0 O-C-N 121.355 -1.085 . . . . 1.0 109.276 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.5 Cg_endo -80.51 -30.93 1.74 Allowed 'Trans proline' 0 N--CA 1.482 0.834 0 C-N-CA 124.112 3.208 . . . . 1.0 110.662 -178.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.43 -6.33 7.93 Favored Glycine 0 CA--C 1.537 1.408 0 N-CA-C 110.05 -1.22 . . . . 1.0 110.05 179.332 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.425 HG11 ' CD2' ' A' ' 19' ' ' PHE . 24.7 m -59.71 -172.79 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 O-C-N 121.079 -1.248 . . . . 1.0 109.894 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.1 p -143.63 152.79 57.21 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.639 -0.663 . . . . 1.0 109.298 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -34.98 -33.31 0.08 OUTLIER 'Trans proline' 0 N--CA 1.488 1.174 1 C-N-CA 125.396 4.064 . . . . 1.0 111.437 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 9.3 t -76.37 -48.99 18.0 Favored 'General case' 0 CA--C 1.532 0.282 0 O-C-N 121.451 -0.781 . . . . 1.0 109.865 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 66.2 mt-30 -62.71 -41.17 99.0 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.45 -0.781 . . . . 1.0 109.782 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.3 t -69.09 -27.61 65.75 Favored 'General case' 0 CA--C 1.532 0.25 0 O-C-N 121.468 -0.77 . . . . 1.0 109.465 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.48 -5.77 53.7 Favored 'General case' 0 CA--C 1.536 0.424 0 O-C-N 121.546 -0.721 . . . . 1.0 109.941 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -63.03 -51.12 67.97 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.351 -0.843 . . . . 1.0 109.617 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.83 -40.54 13.07 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.466 -0.771 . . . . 1.0 109.403 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 126.91 21.44 1.72 Allowed Glycine 0 CA--C 1.531 1.074 0 N-CA-C 109.806 -1.318 . . . . 1.0 109.806 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 14.9 m -75.93 136.65 40.08 Favored 'General case' 0 N--CA 1.464 0.268 0 O-C-N 121.466 -1.02 . . . . 1.0 108.76 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 62.0 m -65.2 141.0 58.81 Favored 'General case' 0 CA--C 1.531 0.213 0 O-C-N 121.375 -0.828 . . . . 1.0 109.444 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 35' ' ' ASP . 15.2 t80 -111.22 143.17 42.4 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.448 -0.782 . . . . 1.0 109.17 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . 0.443 ' N ' ' CD1' ' A' ' 34' ' ' PHE . 24.8 t70 -162.21 116.19 1.82 Allowed 'General case' 0 CA--C 1.531 0.242 0 O-C-N 121.392 -0.818 . . . . 1.0 109.62 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.432 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 16.0 p30 -105.71 63.17 0.67 Allowed 'General case' 0 CA--C 1.533 0.295 0 O-C-N 121.574 -0.704 . . . . 1.0 109.478 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.6 p -87.19 -58.18 2.68 Favored 'General case' 0 CA--C 1.531 0.242 0 O-C-N 121.417 -0.802 . . . . 1.0 109.512 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 37.5 t -119.74 146.56 24.3 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 O-C-N 121.496 -0.753 . . . . 1.0 109.427 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 1.4 ptm180 -84.15 -174.94 5.56 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 121.496 -0.752 . . . . 1.0 109.358 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.89 -42.93 2.55 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 109.213 -1.555 . . . . 1.0 109.213 -179.706 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.7 m -91.23 170.08 10.35 Favored Pre-proline 0 CA--C 1.534 0.354 0 O-C-N 121.489 -1.006 . . . . 1.0 108.981 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_endo -86.64 119.51 1.64 Allowed 'Trans proline' 0 C--N 1.35 0.621 0 C-N-CA 124.479 3.453 . . . . 1.0 110.049 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.432 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.9 m0 -72.69 -29.25 63.24 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 109.173 -0.677 . . . . 1.0 109.173 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 12.6 t -89.66 99.38 12.39 Favored 'General case' 0 CA--C 1.533 0.31 0 N-CA-C 109.158 -0.682 . . . . 1.0 109.158 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.402 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 4.3 p90 -128.91 173.99 9.9 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 121.241 -0.912 . . . . 1.0 110.083 -179.619 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.402 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 19.8 m-85 -78.67 170.91 14.05 Favored Pre-proline 0 CA--C 1.536 0.424 0 O-C-N 121.415 -0.803 . . . . 1.0 109.543 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -89.81 -178.63 1.67 Allowed 'Trans proline' 0 C--N 1.351 0.662 0 C-N-CA 125.137 3.891 . . . . 1.0 110.304 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -143.85 108.64 4.91 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.441 -0.787 . . . . 1.0 109.303 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 1.3 p -76.88 104.27 7.28 Favored 'General case' 0 N--CA 1.464 0.263 0 O-C-N 121.53 -0.731 . . . . 1.0 109.533 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 62.4 mt -127.47 150.54 33.4 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.222 0 O-C-N 121.502 -0.749 . . . . 1.0 109.298 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -80.73 175.44 10.67 Favored 'General case' 0 CA--C 1.53 0.181 0 O-C-N 121.484 -0.76 . . . . 1.0 109.428 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.3 m -140.75 90.65 9.61 Favored Pre-proline 0 CA--C 1.535 0.394 0 O-C-N 121.509 -0.744 . . . . 1.0 109.503 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -91.55 163.93 3.52 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 125.118 3.879 . . . . 1.0 110.305 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . 0.462 ' HD2' ' H ' ' A' ' 55' ' ' GLU . 21.8 Cg_endo -92.79 -21.28 0.44 Allowed 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 125.054 3.836 . . . . 1.0 110.359 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.462 ' H ' ' HD2' ' A' ' 54' ' ' PRO . 0.5 OUTLIER -98.84 150.49 21.82 Favored 'General case' 0 N--CA 1.463 0.211 0 O-C-N 121.52 -0.738 . . . . 1.0 109.571 -179.944 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 2.5 pm0 -112.34 148.69 33.71 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.577 -0.702 . . . . 1.0 109.358 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -90.13 165.23 14.1 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.461 -0.774 . . . . 1.0 109.465 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 7.9 m -75.0 111.3 10.07 Favored 'General case' 0 C--O 1.233 0.198 0 O-C-N 121.482 -0.761 . . . . 1.0 109.401 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 -118.56 166.78 12.29 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.5 -0.75 . . . . 1.0 109.416 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.047 -0.978 . . . . 1.0 109.417 179.986 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 46.9 mm-40 . . . . . 0 CA--C 1.531 0.221 0 N-CA-C 109.397 -0.594 . . . . 1.0 109.397 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -116.48 111.92 20.66 Favored 'General case' 0 N--CA 1.462 0.172 0 O-C-N 121.503 -0.748 . . . . 1.0 109.554 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 25.2 mt-30 -89.89 158.0 17.63 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.399 -0.813 . . . . 1.0 109.482 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 55.8 p -112.78 177.62 4.57 Favored 'General case' 0 CA--C 1.531 0.235 0 O-C-N 121.516 -0.74 . . . . 1.0 109.314 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -86.02 129.68 34.76 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.508 -0.745 . . . . 1.0 109.26 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.0 m -149.23 113.69 5.28 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.45 -0.781 . . . . 1.0 109.76 -179.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.2 m -119.67 46.07 2.01 Favored 'General case' 0 CA--C 1.532 0.273 0 O-C-N 121.528 -0.733 . . . . 1.0 109.131 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.3 t -128.79 80.85 1.99 Allowed 'General case' 0 CA--C 1.532 0.269 0 O-C-N 121.423 -0.798 . . . . 1.0 109.469 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.401 ' CG1' ' N ' ' A' ' 10' ' ' ALA . 38.0 t -102.42 170.16 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 O-C-N 121.367 -0.833 . . . . 1.0 109.332 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.401 ' N ' ' CG1' ' A' ' 9' ' ' VAL . . . -71.79 134.99 83.43 Favored Pre-proline 0 CA--C 1.539 0.547 0 O-C-N 121.52 -0.738 . . . . 1.0 109.202 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_exo -35.87 -31.13 0.08 OUTLIER 'Trans proline' 0 N--CA 1.489 1.226 0 C-N-CA 125.202 3.934 . . . . 1.0 111.554 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.409 ' H ' ' HG2' ' A' ' 12' ' ' ARG . 10.5 ptp180 -84.25 -44.75 13.57 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.392 -0.817 . . . . 1.0 110.171 -179.402 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -79.07 39.81 0.39 Allowed 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.357 -0.839 . . . . 1.0 109.653 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 63.9 mtt180 -111.22 121.46 45.33 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.391 -0.818 . . . . 1.0 109.754 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.478 ' H ' ' NE2' ' A' ' 15' ' ' GLN . 1.3 pm0 -90.16 125.21 35.38 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.488 -0.757 . . . . 1.0 108.993 179.391 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -65.0 127.56 32.1 Favored 'General case' 0 CA--C 1.534 0.347 0 O-C-N 121.454 -0.779 . . . . 1.0 110.7 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -98.16 -26.67 14.49 Favored 'General case' 0 CA--C 1.534 0.335 0 N-CA-C 108.371 -0.974 . . . . 1.0 108.371 178.714 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -165.47 171.62 40.78 Favored Glycine 0 CA--C 1.53 1.012 0 N-CA-C 108.701 -1.76 . . . . 1.0 108.701 179.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CE2' HG11 ' A' ' 22' ' ' VAL . 7.9 p90 -62.73 167.62 5.54 Favored Pre-proline 0 CA--C 1.54 0.586 0 O-C-N 121.174 -1.192 . . . . 1.0 109.153 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.21 -30.86 1.44 Allowed 'Trans proline' 0 N--CA 1.483 0.875 0 C-N-CA 124.375 3.384 . . . . 1.0 110.771 -178.642 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.28 -9.91 9.29 Favored Glycine 0 CA--C 1.538 1.479 0 N-CA-C 110.104 -1.198 . . . . 1.0 110.104 179.443 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.432 HG11 ' CE2' ' A' ' 19' ' ' PHE . 23.4 m -60.09 169.66 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 O-C-N 121.282 -1.128 . . . . 1.0 109.721 179.802 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.472 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 38.1 p -128.55 157.89 73.56 Favored Pre-proline 0 CA--C 1.536 0.409 0 N-CA-C 109.083 -0.71 . . . . 1.0 109.083 179.608 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -36.03 -34.03 0.13 Allowed 'Trans proline' 0 N--CA 1.488 1.157 1 C-N-CA 125.364 4.042 . . . . 1.0 111.176 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 33.7 p -79.25 -45.81 19.04 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.442 -0.786 . . . . 1.0 109.965 -179.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLN . . . . . 0.472 ' HB2' ' H ' ' A' ' 23' ' ' THR . 25.7 mt-30 -62.42 -52.5 63.32 Favored 'General case' 0 N--CA 1.465 0.304 0 O-C-N 121.476 -0.765 . . . . 1.0 109.853 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 10.4 t -62.0 -33.97 75.32 Favored 'General case' 0 CA--C 1.533 0.311 0 O-C-N 121.483 -0.761 . . . . 1.0 109.765 -179.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.6 -3.13 58.31 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.336 -0.852 . . . . 1.0 110.03 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -79.08 -46.65 17.64 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.319 -0.863 . . . . 1.0 109.834 -179.593 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.2 tttt -78.82 -48.5 14.64 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 121.431 -0.793 . . . . 1.0 109.544 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 132.58 21.41 0.92 Allowed Glycine 0 CA--C 1.531 1.052 0 N-CA-C 110.281 -1.127 . . . . 1.0 110.281 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 39.9 m -91.48 138.74 31.33 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 121.246 -1.149 . . . . 1.0 108.746 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.7 m -65.17 128.04 34.19 Favored 'General case' 0 N--CA 1.464 0.242 0 O-C-N 121.303 -0.873 . . . . 1.0 109.729 -179.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 64.4 t80 -97.57 143.3 28.4 Favored 'General case' 0 C--O 1.234 0.266 0 O-C-N 121.541 -0.724 . . . . 1.0 109.155 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -152.72 103.54 2.79 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 121.363 -0.836 . . . . 1.0 109.645 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.421 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 9.5 p-10 -109.02 82.56 1.61 Allowed 'General case' 0 CA--C 1.531 0.216 0 O-C-N 121.55 -0.719 . . . . 1.0 109.426 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 49.1 p -118.63 -35.03 3.82 Favored 'General case' 0 N--CA 1.463 0.218 0 O-C-N 121.421 -0.799 . . . . 1.0 109.601 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.6 t -128.97 150.15 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 O-C-N 121.458 -0.776 . . . . 1.0 109.396 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 22.3 ttt180 -87.08 168.18 13.52 Favored 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.468 -0.77 . . . . 1.0 109.384 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.43 -52.03 4.58 Favored Glycine 0 CA--C 1.529 0.907 0 N-CA-C 109.529 -1.428 . . . . 1.0 109.529 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 27.6 m -74.14 169.2 20.21 Favored Pre-proline 0 CA--C 1.536 0.419 0 O-C-N 121.551 -0.97 . . . . 1.0 109.324 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_endo -88.92 130.43 2.15 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 124.883 3.722 . . . . 1.0 110.219 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.421 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 7.7 m0 -87.95 -36.44 17.09 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.423 -0.798 . . . . 1.0 109.509 -179.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 8.0 t -89.44 102.96 15.63 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 109.144 -0.687 . . . . 1.0 109.144 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.406 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 3.6 p90 -134.55 174.23 10.78 Favored 'General case' 0 CA--C 1.538 0.497 0 O-C-N 121.304 -0.873 . . . . 1.0 110.083 -179.414 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.406 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 45.3 m-85 -76.6 170.5 15.87 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 121.435 -0.791 . . . . 1.0 109.495 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_endo -90.18 161.83 4.73 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 124.928 3.752 . . . . 1.0 110.454 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -136.16 107.43 6.82 Favored 'General case' 0 N--CA 1.463 0.194 0 O-C-N 121.569 -0.707 . . . . 1.0 109.384 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 62.4 p -81.71 107.45 14.46 Favored 'General case' 0 C--N 1.332 -0.182 0 O-C-N 121.504 -0.747 . . . . 1.0 109.444 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 57.9 mt -128.34 155.76 40.21 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 O-C-N 121.412 -0.805 . . . . 1.0 109.307 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -78.14 107.93 11.07 Favored 'General case' 0 CA--C 1.53 0.209 0 O-C-N 121.41 -0.806 . . . . 1.0 109.524 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.8 m -131.24 147.96 68.27 Favored Pre-proline 0 CA--C 1.537 0.475 0 O-C-N 121.514 -0.741 . . . . 1.0 109.537 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.458 ' N ' ' HD2' ' A' ' 54' ' ' PRO . 6.6 Cg_exo -37.54 -59.72 0.48 Allowed 'Trans proline' 0 N--CA 1.486 1.051 0 C-N-CA 125.218 3.945 . . . . 1.0 111.374 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . 0.458 ' HD2' ' N ' ' A' ' 53' ' ' PRO . 21.1 Cg_exo -33.76 131.14 0.15 Allowed 'Trans proline' 0 C--N 1.363 1.329 0 C-N-CA 125.228 3.952 . . . . 1.0 111.547 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -76.22 175.09 9.34 Favored 'General case' 0 CA--C 1.532 0.27 0 O-C-N 121.523 -0.736 . . . . 1.0 109.496 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -115.17 161.49 18.34 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.528 -0.733 . . . . 1.0 109.487 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 20.4 mm-40 -108.01 118.42 36.7 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.474 -0.766 . . . . 1.0 109.537 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 60.3 p -103.77 134.32 47.28 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.519 -0.738 . . . . 1.0 109.407 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -95.0 151.01 19.53 Favored 'General case' 0 N--CA 1.463 0.214 0 O-C-N 121.517 -0.74 . . . . 1.0 109.436 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.952 -1.023 . . . . 1.0 109.389 179.95 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 . . . . . 0 C--O 1.232 0.173 0 N-CA-C 109.485 -0.561 . . . . 1.0 109.485 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -144.41 48.62 1.35 Allowed 'General case' 0 CA--C 1.533 0.31 0 O-C-N 121.485 -0.759 . . . . 1.0 109.266 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -100.76 96.85 7.59 Favored 'General case' 0 C--N 1.331 -0.215 0 O-C-N 121.521 -0.737 . . . . 1.0 109.378 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -160.01 -177.37 6.26 Favored 'General case' 0 CA--C 1.532 0.25 0 O-C-N 121.414 -0.804 . . . . 1.0 109.482 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -89.55 135.21 33.73 Favored 'General case' 0 CA--C 1.531 0.242 0 O-C-N 121.482 -0.761 . . . . 1.0 109.549 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 31.7 m -127.97 132.73 49.17 Favored 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.479 -0.763 . . . . 1.0 109.193 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.3 m -124.67 -6.23 7.48 Favored 'General case' 0 CA--C 1.535 0.393 0 O-C-N 121.446 -0.783 . . . . 1.0 109.92 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.6 t -70.17 126.94 31.11 Favored 'General case' 0 N--CA 1.463 0.215 0 O-C-N 121.215 -0.928 . . . . 1.0 109.434 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.434 ' CG1' ' H ' ' A' ' 10' ' ' ALA . 26.0 t -142.34 173.64 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 O-C-N 121.513 -0.742 . . . . 1.0 109.37 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.434 ' H ' ' CG1' ' A' ' 9' ' ' VAL . . . -77.96 136.84 61.89 Favored Pre-proline 0 CA--C 1.54 0.595 0 O-C-N 121.477 -0.764 . . . . 1.0 109.566 -179.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_exo -36.0 -38.24 0.27 Allowed 'Trans proline' 0 N--CA 1.489 1.216 1 C-N-CA 125.314 4.01 . . . . 1.0 111.442 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 40.4 mtp85 -85.11 -39.97 17.31 Favored 'General case' 0 N--CA 1.465 0.321 0 O-C-N 121.362 -0.836 . . . . 1.0 110.02 -179.282 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -79.11 39.67 0.39 Allowed 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.427 -0.795 . . . . 1.0 109.671 -179.624 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 39.3 mtt180 -107.8 125.91 52.0 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.464 -0.772 . . . . 1.0 109.672 179.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.0 mp0 -94.76 113.13 24.86 Favored 'General case' 0 CA--C 1.532 0.284 0 O-C-N 121.472 -0.768 . . . . 1.0 109.224 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -59.74 126.17 26.53 Favored 'General case' 0 CA--C 1.533 0.314 0 O-C-N 121.411 -0.805 . . . . 1.0 110.252 -179.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -98.58 -18.63 18.03 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 121.565 -0.71 . . . . 1.0 109.094 179.582 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -173.21 176.67 45.89 Favored Glycine 0 CA--C 1.529 0.935 0 N-CA-C 108.834 -1.706 . . . . 1.0 108.834 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CD2' HG12 ' A' ' 22' ' ' VAL . 9.4 p90 -65.87 167.34 11.83 Favored Pre-proline 0 CA--C 1.538 0.491 0 O-C-N 121.289 -1.124 . . . . 1.0 108.923 179.771 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.55 -29.46 1.83 Allowed 'Trans proline' 0 N--CA 1.483 0.894 0 C-N-CA 124.492 3.461 . . . . 1.0 110.897 -178.528 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.43 -11.58 10.34 Favored Glycine 0 CA--C 1.538 1.474 0 N-CA-C 110.192 -1.163 . . . . 1.0 110.192 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.432 HG12 ' CD2' ' A' ' 19' ' ' PHE . 22.7 m -61.06 -171.8 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 O-C-N 121.354 -1.086 . . . . 1.0 109.72 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 43.3 p -147.1 152.52 43.59 Favored Pre-proline 0 CA--C 1.535 0.393 0 O-C-N 121.527 -0.733 . . . . 1.0 109.168 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_exo -35.15 -31.43 0.07 OUTLIER 'Trans proline' 0 N--CA 1.488 1.187 1 C-N-CA 125.575 4.183 . . . . 1.0 111.224 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 78.9 p -77.21 -51.21 11.33 Favored 'General case' 0 CA--C 1.532 0.271 0 O-C-N 121.491 -0.756 . . . . 1.0 109.752 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 68.8 mt-30 -63.08 -46.93 85.11 Favored 'General case' 0 N--CA 1.464 0.252 0 O-C-N 121.493 -0.755 . . . . 1.0 109.97 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 13.1 t -62.36 -33.15 74.15 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 121.419 -0.8 . . . . 1.0 109.82 -179.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.84 -3.96 58.61 Favored 'General case' 0 CA--C 1.534 0.346 0 O-C-N 121.444 -0.785 . . . . 1.0 110.056 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -79.73 -39.31 31.4 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.37 -0.831 . . . . 1.0 109.809 -179.534 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 35.4 mtmt -85.18 -46.58 10.95 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.396 -0.815 . . . . 1.0 109.938 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 137.91 11.58 0.93 Allowed Glycine 0 CA--C 1.533 1.174 0 N-CA-C 110.246 -1.141 . . . . 1.0 110.246 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 35.0 m -86.91 136.88 32.79 Favored 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.353 -1.086 . . . . 1.0 108.71 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.6 m -69.7 126.08 28.64 Favored 'General case' 0 N--CA 1.465 0.302 0 O-C-N 121.249 -0.907 . . . . 1.0 109.924 -179.704 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.424 ' CE1' ' HB2' ' A' ' 43' ' ' TRP . 50.3 t80 -94.79 147.34 23.44 Favored 'General case' 0 CA--C 1.531 0.22 0 N-CA-C 109.156 -0.683 . . . . 1.0 109.156 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -154.04 96.31 1.94 Allowed 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.454 -0.779 . . . . 1.0 109.631 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.41 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 6.7 p-10 -104.48 70.64 0.96 Allowed 'General case' 0 CA--C 1.533 0.299 0 O-C-N 121.523 -0.736 . . . . 1.0 109.25 179.821 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 18.2 p -117.64 -42.47 2.86 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.356 -0.84 . . . . 1.0 109.407 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 37.4 t -111.2 159.23 11.32 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 O-C-N 121.438 -0.789 . . . . 1.0 109.415 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 16.4 ttp-105 -100.33 170.37 8.47 Favored 'General case' 0 C--O 1.233 0.201 0 O-C-N 121.412 -0.805 . . . . 1.0 109.425 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.46 -58.29 5.0 Favored Glycine 0 CA--C 1.529 0.922 0 N-CA-C 109.511 -1.436 . . . . 1.0 109.511 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.5 m -70.23 169.25 14.13 Favored Pre-proline 0 CA--C 1.537 0.448 0 O-C-N 121.491 -1.006 . . . . 1.0 109.233 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -87.39 127.11 2.38 Favored 'Trans proline' 0 C--N 1.352 0.72 0 C-N-CA 124.721 3.614 . . . . 1.0 110.15 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.424 ' HB2' ' CE1' ' A' ' 34' ' ' PHE . 11.2 m0 -73.62 -43.45 59.55 Favored 'General case' 0 N--CA 1.464 0.248 0 O-C-N 121.593 -0.692 . . . . 1.0 109.603 -179.665 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 12.3 t -88.3 110.99 21.2 Favored 'General case' 0 CA--C 1.535 0.382 0 O-C-N 121.452 -0.78 . . . . 1.0 109.578 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.401 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 4.2 p90 -141.89 175.9 9.36 Favored 'General case' 0 CA--C 1.538 0.507 0 O-C-N 121.353 -0.842 . . . . 1.0 109.974 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.401 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 18.1 m-85 -74.83 171.43 11.63 Favored Pre-proline 0 CA--C 1.536 0.432 0 O-C-N 121.472 -0.767 . . . . 1.0 109.889 -179.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -94.42 -178.82 0.64 Allowed 'Trans proline' 0 C--N 1.351 0.691 1 C-N-CA 125.336 4.024 . . . . 1.0 110.919 -179.647 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.423 HD21 ' CG2' ' A' ' 9' ' ' VAL . 19.4 m-20 -158.29 82.84 0.84 Allowed 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.602 -0.687 . . . . 1.0 109.214 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 56.4 p -76.67 135.09 39.11 Favored 'General case' 0 N--CA 1.464 0.231 0 O-C-N 121.416 -0.803 . . . . 1.0 109.582 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 38.1 mt -121.85 157.5 25.87 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 O-C-N 121.511 -0.743 . . . . 1.0 109.345 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -164.82 151.25 10.53 Favored 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.53 -0.731 . . . . 1.0 109.285 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 29.5 m -80.35 140.54 52.52 Favored Pre-proline 0 CA--C 1.537 0.463 0 O-C-N 121.38 -0.825 . . . . 1.0 109.439 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -34.83 91.09 0.01 OUTLIER 'Trans proline' 0 N--CA 1.487 1.143 1 C-N-CA 125.485 4.124 . . . . 1.0 111.325 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -92.2 -67.66 0.01 OUTLIER 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 125.094 3.862 . . . . 1.0 110.297 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -147.15 128.98 15.31 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.486 -0.759 . . . . 1.0 109.378 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -82.19 164.18 21.41 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.485 -0.759 . . . . 1.0 109.428 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 1.8 tp10 -127.7 103.72 7.46 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.439 -0.788 . . . . 1.0 109.493 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.5 p -97.41 126.8 42.89 Favored 'General case' 0 CA--C 1.53 0.191 0 O-C-N 121.539 -0.725 . . . . 1.0 109.387 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -136.02 106.81 6.59 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.399 -0.813 . . . . 1.0 109.367 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.419 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 20.5 p90 . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 117.996 -1.002 . . . . 1.0 109.507 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 . . . . . 0 CA--C 1.531 0.216 0 N-CA-C 109.329 -0.619 . . . . 1.0 109.329 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -146.93 83.72 1.59 Allowed 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.522 -0.736 . . . . 1.0 109.371 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -136.87 101.82 4.7 Favored 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.521 -0.737 . . . . 1.0 109.394 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 61.8 p -124.55 140.96 52.46 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 121.506 -0.746 . . . . 1.0 109.494 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 9.8 mp0 -109.73 139.88 44.26 Favored 'General case' 0 CA--C 1.531 0.246 0 O-C-N 121.565 -0.709 . . . . 1.0 109.422 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.6 m -150.01 137.07 19.51 Favored 'General case' 0 C--O 1.233 0.191 0 O-C-N 121.543 -0.723 . . . . 1.0 109.574 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 77.6 m -110.51 34.68 3.81 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.523 -0.736 . . . . 1.0 109.229 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.0 t -91.96 125.64 36.73 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.507 -0.745 . . . . 1.0 109.677 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 38.7 t -146.88 163.7 8.02 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 109.085 -0.709 . . . . 1.0 109.085 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -78.59 136.59 59.46 Favored Pre-proline 0 CA--C 1.541 0.624 0 O-C-N 121.467 -0.771 . . . . 1.0 109.233 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_exo -34.74 -57.81 0.4 Allowed 'Trans proline' 0 N--CA 1.488 1.196 1 C-N-CA 125.457 4.105 . . . . 1.0 111.416 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.2 mmt180 -74.49 -32.28 62.49 Favored 'General case' 0 N--CA 1.463 0.194 0 O-C-N 121.488 -0.758 . . . . 1.0 109.895 -179.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -83.05 21.93 1.01 Allowed 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.348 -0.845 . . . . 1.0 109.73 -179.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 69.0 mtt180 -89.98 126.03 35.6 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.444 -0.785 . . . . 1.0 109.418 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -89.01 121.42 31.35 Favored 'General case' 0 CA--C 1.53 0.197 0 O-C-N 121.52 -0.738 . . . . 1.0 109.092 179.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -69.04 118.61 12.16 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.421 -0.799 . . . . 1.0 109.484 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -88.29 -24.16 23.26 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.48 -0.762 . . . . 1.0 109.065 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -169.74 173.79 43.95 Favored Glycine 0 CA--C 1.529 0.914 0 N-CA-C 109.085 -1.606 . . . . 1.0 109.085 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.433 ' CD2' HG12 ' A' ' 22' ' ' VAL . 8.5 p90 -66.5 167.59 12.57 Favored Pre-proline 0 CA--C 1.538 0.493 0 O-C-N 121.439 -1.036 . . . . 1.0 108.924 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -82.09 -30.21 1.35 Allowed 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 124.441 3.427 . . . . 1.0 110.801 -178.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.05 -11.33 8.57 Favored Glycine 0 CA--C 1.537 1.46 0 N-CA-C 110.329 -1.108 . . . . 1.0 110.329 179.593 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.433 HG12 ' CD2' ' A' ' 19' ' ' PHE . 22.3 m -60.73 -169.98 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 O-C-N 121.334 -1.098 . . . . 1.0 109.702 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.445 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 12.8 p -140.85 156.13 68.83 Favored Pre-proline 0 CA--C 1.534 0.356 0 N-CA-C 109.096 -0.705 . . . . 1.0 109.096 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_exo -38.16 -36.23 0.49 Allowed 'Trans proline' 0 N--CA 1.487 1.143 0 C-N-CA 125.14 3.893 . . . . 1.0 110.998 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.3 t -75.98 -41.46 51.29 Favored 'General case' 0 CA--C 1.532 0.273 0 O-C-N 121.557 -0.714 . . . . 1.0 110.141 -179.473 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLN . . . . . 0.445 ' HB2' ' H ' ' A' ' 23' ' ' THR . 5.1 mt-30 -65.2 -50.79 64.51 Favored 'General case' 0 CA--C 1.532 0.261 0 O-C-N 121.431 -0.793 . . . . 1.0 110.002 -179.638 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 11.4 t -61.67 -32.3 72.47 Favored 'General case' 0 CA--C 1.533 0.319 0 O-C-N 121.335 -0.853 . . . . 1.0 109.914 -179.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -89.18 -3.93 58.42 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 121.497 -0.752 . . . . 1.0 110.109 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 41.6 t-20 -73.8 -53.55 10.01 Favored 'General case' 0 N--CA 1.464 0.245 0 O-C-N 121.392 -0.818 . . . . 1.0 109.523 -179.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.2 mttt -73.19 -48.09 38.18 Favored 'General case' 0 C--N 1.332 -0.182 0 O-C-N 121.515 -0.74 . . . . 1.0 109.375 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 136.8 15.67 0.82 Allowed Glycine 0 CA--C 1.532 1.119 0 N-CA-C 109.647 -1.381 . . . . 1.0 109.647 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 36.4 m -82.12 140.61 33.7 Favored 'General case' 0 N--CA 1.463 0.218 0 O-C-N 121.345 -1.091 . . . . 1.0 108.731 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 69.3 m -71.5 123.27 22.05 Favored 'General case' 0 C--N 1.332 -0.189 0 O-C-N 121.368 -0.833 . . . . 1.0 109.66 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 37.0 t80 -94.71 142.72 27.13 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.46 -0.775 . . . . 1.0 109.169 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -160.45 98.96 1.28 Allowed 'General case' 0 C--O 1.233 0.194 0 O-C-N 121.513 -0.742 . . . . 1.0 109.47 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.435 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.0 p-10 -107.44 76.28 1.07 Allowed 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.457 -0.777 . . . . 1.0 109.486 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 70.1 p -120.15 -38.54 2.91 Favored 'General case' 0 CA--C 1.533 0.291 0 O-C-N 121.468 -0.77 . . . . 1.0 109.654 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.8 t -110.75 144.5 18.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 O-C-N 121.397 -0.815 . . . . 1.0 109.7 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.2 mmt180 -88.69 177.16 6.82 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.547 -0.721 . . . . 1.0 109.487 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.71 -62.57 4.36 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 109.092 -1.603 . . . . 1.0 109.092 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 28.7 m -73.1 170.23 14.61 Favored Pre-proline 0 CA--C 1.536 0.406 0 O-C-N 121.63 -0.924 . . . . 1.0 109.096 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -84.34 150.76 11.95 Favored 'Trans proline' 0 C--N 1.351 0.662 0 C-N-CA 124.366 3.377 . . . . 1.0 109.901 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.435 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 7.8 m0 -94.68 -40.58 9.73 Favored 'General case' 0 N--CA 1.465 0.284 0 O-C-N 121.545 -0.722 . . . . 1.0 109.639 -179.218 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 22.7 t -90.29 105.55 17.89 Favored 'General case' 0 CA--C 1.534 0.364 0 O-C-N 121.416 -0.802 . . . . 1.0 109.448 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.433 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 4.9 p90 -128.99 179.26 5.84 Favored 'General case' 0 CA--C 1.534 0.338 0 O-C-N 121.395 -0.816 . . . . 1.0 109.9 -179.863 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.401 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 17.8 m-85 -80.97 170.71 14.48 Favored Pre-proline 0 CA--C 1.538 0.482 0 O-C-N 121.391 -0.818 . . . . 1.0 109.835 -179.596 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -90.58 169.6 3.83 Favored 'Trans proline' 0 C--N 1.352 0.736 0 C-N-CA 124.981 3.787 . . . . 1.0 110.58 179.798 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -141.3 79.77 1.7 Allowed 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.469 -0.77 . . . . 1.0 109.011 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 68.5 p -88.65 140.68 29.2 Favored 'General case' 0 CA--C 1.529 0.168 0 O-C-N 121.479 -0.763 . . . . 1.0 109.702 -179.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 41.9 mt -100.17 149.58 5.89 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 N-CA-C 108.963 -0.754 . . . . 1.0 108.963 179.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -136.14 172.88 12.36 Favored 'General case' 0 CA--C 1.53 0.179 0 O-C-N 121.397 -0.815 . . . . 1.0 109.888 -179.762 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.429 ' H ' HG21 ' A' ' 52' ' ' VAL . 31.6 m -108.67 79.77 1.1 Allowed Pre-proline 0 CA--C 1.538 0.507 0 O-C-N 121.619 -0.676 . . . . 1.0 109.344 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.46 ' N ' ' HD2' ' A' ' 54' ' ' PRO . 9.8 Cg_exo -35.56 -59.14 0.39 Allowed 'Trans proline' 0 N--CA 1.487 1.137 0 C-N-CA 125.234 3.956 . . . . 1.0 111.583 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . 0.46 ' HD2' ' N ' ' A' ' 53' ' ' PRO . 20.9 Cg_exo -33.83 -51.89 0.54 Allowed 'Trans proline' 0 N--CA 1.49 1.277 0 C-N-CA 125.253 3.969 . . . . 1.0 111.479 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -107.53 118.43 36.7 Favored 'General case' 0 N--CA 1.463 0.203 0 O-C-N 121.501 -0.749 . . . . 1.0 109.394 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -138.76 109.49 6.66 Favored 'General case' 0 N--CA 1.464 0.226 0 O-C-N 121.472 -0.768 . . . . 1.0 109.414 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -141.18 150.53 42.85 Favored 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.527 -0.733 . . . . 1.0 109.33 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 16.5 p -141.27 152.68 44.71 Favored 'General case' 0 CA--C 1.531 0.246 0 O-C-N 121.547 -0.721 . . . . 1.0 109.445 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 9.1 tt0 -75.11 166.92 22.9 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.527 -0.733 . . . . 1.0 109.438 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 4.6 t80 . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.934 -1.031 . . . . 1.0 109.462 -179.995 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 . . . . . 0 CA--C 1.532 0.256 0 CA-C-O 121.353 0.597 . . . . 1.0 109.406 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -120.72 -169.46 1.82 Allowed 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.349 -0.844 . . . . 1.0 109.381 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 26.0 mt-30 -111.87 99.3 8.01 Favored 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.432 -0.793 . . . . 1.0 109.447 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 15.3 p -155.56 158.73 38.9 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.444 -0.785 . . . . 1.0 109.367 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -67.1 146.59 54.13 Favored 'General case' 0 C--N 1.331 -0.201 0 O-C-N 121.568 -0.708 . . . . 1.0 109.393 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.3 m -132.24 124.64 29.34 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.462 -0.774 . . . . 1.0 109.625 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 75.8 m -110.73 13.67 22.37 Favored 'General case' 0 CA--C 1.534 0.346 0 O-C-N 121.482 -0.761 . . . . 1.0 109.623 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.4 t -93.97 104.69 16.73 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.444 -0.785 . . . . 1.0 109.565 -179.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 38.6 t -123.4 164.43 21.11 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 O-C-N 121.557 -0.714 . . . . 1.0 109.29 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -69.4 121.96 83.92 Favored Pre-proline 0 CA--C 1.54 0.569 0 O-C-N 121.434 -0.791 . . . . 1.0 109.155 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_exo -38.36 -28.22 0.12 Allowed 'Trans proline' 0 N--CA 1.49 1.29 0 C-N-CA 124.749 3.633 . . . . 1.0 111.357 -179.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 64.8 mtt180 -84.25 -41.26 17.09 Favored 'General case' 0 CA--C 1.533 0.292 0 O-C-N 121.37 -0.831 . . . . 1.0 110.171 -179.252 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 15.0 mm-40 -92.43 44.88 1.17 Allowed 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.45 -0.781 . . . . 1.0 109.748 -179.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 19.3 mtt180 -106.81 141.63 37.73 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.332 -0.855 . . . . 1.0 109.603 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 16.5 mt-30 -111.11 126.67 55.08 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 108.918 -0.771 . . . . 1.0 108.918 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -67.73 117.32 9.49 Favored 'General case' 0 CA--C 1.532 0.285 0 O-C-N 121.427 -0.796 . . . . 1.0 110.673 -178.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.44 ' H ' ' HA ' ' A' ' 45' ' ' PHE . 3.0 t -72.64 -31.32 65.03 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 108.665 -0.865 . . . . 1.0 108.665 178.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -152.88 178.92 29.73 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 109.306 -1.517 . . . . 1.0 109.306 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.436 ' CD2' HG12 ' A' ' 22' ' ' VAL . 6.6 p90 -62.03 169.28 2.89 Favored Pre-proline 0 CA--C 1.541 0.634 0 O-C-N 121.387 -1.067 . . . . 1.0 108.889 179.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -80.43 -31.92 1.44 Allowed 'Trans proline' 0 N--CA 1.482 0.838 0 C-N-CA 124.044 3.163 . . . . 1.0 110.762 -178.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.2 -3.21 6.24 Favored Glycine 0 CA--C 1.537 1.423 0 N-CA-C 110.196 -1.161 . . . . 1.0 110.196 179.704 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.436 HG12 ' CD2' ' A' ' 19' ' ' PHE . 21.9 m -62.82 170.73 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 O-C-N 121.148 -1.207 . . . . 1.0 109.686 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.8 p -130.21 155.72 80.41 Favored Pre-proline 0 CA--C 1.534 0.361 0 N-CA-C 108.962 -0.755 . . . . 1.0 108.962 179.714 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -35.95 -38.7 0.28 Allowed 'Trans proline' 0 N--CA 1.488 1.18 0 C-N-CA 125.254 3.969 . . . . 1.0 111.188 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 79.4 p -70.9 -46.23 62.91 Favored 'General case' 0 CA--C 1.533 0.291 0 O-C-N 121.447 -0.783 . . . . 1.0 110.043 -179.583 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -62.19 -49.1 77.12 Favored 'General case' 0 N--CA 1.465 0.321 0 O-C-N 121.366 -0.834 . . . . 1.0 110.024 -179.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 7.2 t -62.54 -25.12 67.88 Favored 'General case' 0 CA--C 1.533 0.297 0 O-C-N 121.407 -0.808 . . . . 1.0 109.808 -179.715 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -95.95 -5.32 41.62 Favored 'General case' 0 CA--C 1.534 0.363 0 O-C-N 121.391 -0.818 . . . . 1.0 110.309 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -98.11 -23.39 15.75 Favored 'General case' 0 N--CA 1.465 0.281 0 O-C-N 121.223 -0.923 . . . . 1.0 109.726 -179.619 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.1 mmtm -91.41 -15.2 29.29 Favored 'General case' 0 CA--C 1.533 0.289 0 O-C-N 121.311 -0.868 . . . . 1.0 109.736 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.99 14.81 41.29 Favored Glycine 0 CA--C 1.532 1.143 0 N-CA-C 109.988 -1.245 . . . . 1.0 109.988 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 56.3 m -94.3 148.52 22.13 Favored 'General case' 0 N--CA 1.465 0.298 0 O-C-N 121.402 -1.058 . . . . 1.0 108.808 179.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.431 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 58.4 m -80.7 126.71 31.63 Favored 'General case' 0 CA--C 1.532 0.267 0 O-C-N 121.343 -0.848 . . . . 1.0 109.713 -179.638 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -98.84 128.13 44.96 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 108.799 -0.815 . . . . 1.0 108.799 179.334 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -141.38 117.32 10.5 Favored 'General case' 0 N--CA 1.464 0.256 0 O-C-N 121.465 -0.772 . . . . 1.0 109.864 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.428 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 7.2 p-10 -112.14 72.92 0.79 Allowed 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.594 -0.691 . . . . 1.0 109.21 179.513 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.1 p -104.08 -61.92 1.38 Allowed 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.368 -0.832 . . . . 1.0 109.619 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.6 t -103.5 154.72 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 O-C-N 121.451 -0.781 . . . . 1.0 109.415 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.94 171.85 8.85 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.479 -0.763 . . . . 1.0 109.487 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.08 -49.64 4.15 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 109.477 -1.449 . . . . 1.0 109.477 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.7 m -73.81 169.36 19.06 Favored Pre-proline 0 CA--C 1.536 0.422 0 O-C-N 121.553 -0.969 . . . . 1.0 109.333 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_endo -89.08 127.1 1.74 Allowed 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 124.838 3.692 . . . . 1.0 109.901 179.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.428 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 13.6 m0 -77.27 -51.5 10.8 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.51 -0.744 . . . . 1.0 109.367 -179.719 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 5.2 t -74.88 111.63 10.28 Favored 'General case' 0 CA--C 1.531 0.241 0 N-CA-C 108.616 -0.883 . . . . 1.0 108.616 179.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.44 ' HA ' ' H ' ' A' ' 17' ' ' CYS . 2.3 p90 -140.86 175.32 9.71 Favored 'General case' 0 N--CA 1.468 0.429 0 O-C-N 121.449 -0.782 . . . . 1.0 110.185 -179.686 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 41.7 m-85 -74.17 160.55 81.3 Favored Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 121.405 -0.81 . . . . 1.0 110.128 -179.243 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -90.03 174.32 3.23 Favored 'Trans proline' 0 C--N 1.352 0.74 0 C-N-CA 124.96 3.774 . . . . 1.0 110.401 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -132.82 92.18 3.01 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 121.541 -0.724 . . . . 1.0 109.491 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 12.0 p -86.55 94.99 9.59 Favored 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.449 -0.782 . . . . 1.0 109.259 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 36.1 mt -118.66 146.52 23.14 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 O-C-N 121.475 -0.765 . . . . 1.0 109.394 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -110.3 154.78 22.99 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 121.465 -0.772 . . . . 1.0 109.404 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.0 m -139.84 92.44 9.94 Favored Pre-proline 0 CA--C 1.537 0.455 0 O-C-N 121.446 -0.784 . . . . 1.0 109.479 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -91.48 175.06 2.33 Favored 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 125.059 3.84 . . . . 1.0 110.299 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -91.47 -4.48 4.17 Favored 'Trans proline' 0 C--N 1.35 0.645 0 C-N-CA 125.006 3.804 . . . . 1.0 110.616 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 22.0 mt-10 -113.77 114.93 27.0 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.432 -0.792 . . . . 1.0 109.422 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -86.83 110.04 19.69 Favored 'General case' 0 C--N 1.332 -0.178 0 O-C-N 121.465 -0.772 . . . . 1.0 109.484 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.415 ' HG2' ' H ' ' A' ' 58' ' ' SER . 7.3 tt0 -141.38 173.99 10.97 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 121.433 -0.792 . . . . 1.0 109.474 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' SER . . . . . 0.415 ' H ' ' HG2' ' A' ' 57' ' ' GLU . 1.5 m -79.31 116.88 19.83 Favored 'General case' 0 CA--C 1.531 0.216 0 O-C-N 121.534 -0.729 . . . . 1.0 109.451 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -146.49 159.77 42.97 Favored 'General case' 0 N--CA 1.463 0.204 0 O-C-N 121.602 -0.686 . . . . 1.0 109.418 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.053 -0.975 . . . . 1.0 109.465 179.97 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 . . . . . 0 CA--C 1.529 0.171 0 N-CA-C 109.382 -0.599 . . . . 1.0 109.382 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -155.89 20.55 0.38 Allowed 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.423 -0.798 . . . . 1.0 109.68 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 62.0 mm-40 -146.52 95.56 2.62 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.384 -0.822 . . . . 1.0 109.395 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -161.52 -165.38 1.28 Allowed 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.556 -0.715 . . . . 1.0 109.492 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -103.0 132.13 49.48 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.536 -0.727 . . . . 1.0 109.2 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.7 m -150.26 146.13 26.61 Favored 'General case' 0 CA--C 1.53 0.209 0 O-C-N 121.403 -0.811 . . . . 1.0 109.402 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 73.1 m -86.95 11.97 12.27 Favored 'General case' 0 CA--C 1.534 0.35 0 O-C-N 121.544 -0.722 . . . . 1.0 109.641 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.4 t -85.41 117.96 24.65 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.257 -0.902 . . . . 1.0 109.677 -179.77 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 37.7 t -140.95 168.24 16.5 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 O-C-N 121.419 -0.8 . . . . 1.0 109.126 179.649 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -84.42 138.32 38.82 Favored Pre-proline 0 CA--C 1.538 0.487 0 O-C-N 121.351 -0.843 . . . . 1.0 109.439 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_exo -34.75 -40.38 0.22 Allowed 'Trans proline' 0 N--CA 1.489 1.222 1 C-N-CA 125.511 4.141 . . . . 1.0 111.276 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 25.7 mtt85 -85.26 -46.57 10.9 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.472 -0.767 . . . . 1.0 109.699 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -67.31 -5.0 12.33 Favored 'General case' 0 CA--C 1.534 0.328 0 O-C-N 121.505 -0.747 . . . . 1.0 110.023 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.8 mtt180 -70.38 126.11 28.72 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.36 -0.838 . . . . 1.0 109.52 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 11.2 mm100 -87.07 123.09 31.76 Favored 'General case' 0 C--N 1.332 -0.168 0 O-C-N 121.478 -0.764 . . . . 1.0 109.252 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -65.7 111.39 3.18 Favored 'General case' 0 N--CA 1.464 0.238 0 O-C-N 121.559 -0.713 . . . . 1.0 109.745 -179.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 41.8 t -82.04 -16.42 50.23 Favored 'General case' 0 CA--C 1.534 0.351 0 O-C-N 121.431 -0.793 . . . . 1.0 109.339 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.59 179.08 44.01 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 109.061 -1.615 . . . . 1.0 109.061 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.422 ' CE2' HG11 ' A' ' 22' ' ' VAL . 8.2 p90 -65.04 167.73 9.01 Favored Pre-proline 0 CA--C 1.539 0.548 0 O-C-N 121.306 -1.114 . . . . 1.0 108.838 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.54 -30.59 1.42 Allowed 'Trans proline' 0 N--CA 1.482 0.814 0 C-N-CA 124.39 3.393 . . . . 1.0 110.881 -178.658 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.62 -8.77 7.9 Favored Glycine 0 CA--C 1.537 1.441 0 N-CA-C 110.25 -1.14 . . . . 1.0 110.25 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.422 HG11 ' CE2' ' A' ' 19' ' ' PHE . 20.0 m -61.16 177.24 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 O-C-N 121.228 -1.16 . . . . 1.0 109.669 179.766 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.0 p -138.89 156.24 72.73 Favored Pre-proline 0 CA--C 1.535 0.389 0 O-C-N 121.54 -0.725 . . . . 1.0 109.225 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -34.91 -32.04 0.07 OUTLIER 'Trans proline' 0 N--CA 1.487 1.12 1 C-N-CA 125.56 4.174 . . . . 1.0 111.171 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 1.8 m -72.12 -51.94 19.08 Favored 'General case' 0 CA--C 1.532 0.281 0 O-C-N 121.419 -0.801 . . . . 1.0 109.614 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 52.3 mt-30 -62.78 -46.01 90.0 Favored 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.47 -0.769 . . . . 1.0 109.772 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.2 t -64.59 -23.8 67.38 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.401 -0.812 . . . . 1.0 109.563 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -94.12 -7.12 43.37 Favored 'General case' 0 CA--C 1.535 0.399 0 O-C-N 121.383 -0.823 . . . . 1.0 109.881 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -73.38 -39.26 65.27 Favored 'General case' 0 CA--C 1.532 0.281 0 O-C-N 121.269 -0.895 . . . . 1.0 109.418 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -92.49 -38.39 11.98 Favored 'General case' 0 N--CA 1.462 0.171 0 O-C-N 121.523 -0.736 . . . . 1.0 109.425 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 113.95 37.93 1.21 Allowed Glycine 0 CA--C 1.53 1.024 0 N-CA-C 109.631 -1.388 . . . . 1.0 109.631 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.8 m -97.52 145.01 26.65 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.472 -1.017 . . . . 1.0 109.273 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.404 ' O ' ' CD1' ' A' ' 45' ' ' PHE . 58.4 m -68.28 119.56 13.02 Favored 'General case' 0 CA--C 1.532 0.267 0 O-C-N 121.398 -0.814 . . . . 1.0 109.426 -179.677 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 43.7 t80 -92.02 146.85 23.41 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.386 -0.821 . . . . 1.0 109.258 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 10.6 t0 -162.12 110.43 1.41 Allowed 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.353 -0.842 . . . . 1.0 109.537 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.423 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 13.6 p30 -110.63 70.77 0.73 Allowed 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.501 -0.749 . . . . 1.0 109.442 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.8 p -111.82 -53.31 2.72 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.403 -0.811 . . . . 1.0 109.737 -179.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 35.6 t -96.3 159.38 2.98 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 O-C-N 121.341 -0.849 . . . . 1.0 109.639 -179.692 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.2 mmm180 -103.82 169.13 8.69 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 121.473 -0.767 . . . . 1.0 109.263 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.75 -42.63 2.49 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 109.355 -1.498 . . . . 1.0 109.355 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.4 m -80.34 169.68 18.77 Favored Pre-proline 0 CA--C 1.537 0.466 0 O-C-N 121.538 -0.978 . . . . 1.0 109.082 179.768 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -87.3 131.77 3.05 Favored 'Trans proline' 0 C--N 1.351 0.682 0 C-N-CA 124.712 3.608 . . . . 1.0 110.011 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.423 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 15.3 m0 -80.15 -39.45 29.34 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.46 -0.775 . . . . 1.0 109.738 -179.482 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 16.0 t -90.01 107.78 19.32 Favored 'General case' 0 CA--C 1.534 0.338 0 O-C-N 121.412 -0.805 . . . . 1.0 109.486 179.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.423 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 5.6 p90 -133.52 175.9 9.01 Favored 'General case' 0 CA--C 1.536 0.412 0 O-C-N 121.452 -0.78 . . . . 1.0 109.757 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.406 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 31.9 m-85 -85.34 170.84 12.09 Favored Pre-proline 0 CA--C 1.537 0.462 0 O-C-N 121.532 -0.73 . . . . 1.0 109.351 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -90.96 177.06 2.15 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 124.968 3.779 . . . . 1.0 110.39 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -123.08 99.92 6.61 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.569 -0.707 . . . . 1.0 109.597 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 55.3 p -105.36 92.36 4.17 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.461 -0.775 . . . . 1.0 109.393 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 57.3 mt -111.27 141.46 26.57 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.276 0 O-C-N 121.496 -0.752 . . . . 1.0 109.365 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -155.2 128.84 8.54 Favored 'General case' 0 CA--C 1.53 0.179 0 O-C-N 121.566 -0.709 . . . . 1.0 109.461 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.9 m -150.22 79.58 7.47 Favored Pre-proline 0 CA--C 1.536 0.438 0 O-C-N 121.506 -0.746 . . . . 1.0 109.54 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.438 ' N ' ' CD ' ' A' ' 54' ' ' PRO . 16.8 Cg_exo -35.0 -46.56 0.61 Allowed 'Trans proline' 0 N--CA 1.487 1.14 1 C-N-CA 125.355 4.036 . . . . 1.0 111.795 179.972 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . 0.438 ' CD ' ' N ' ' A' ' 53' ' ' PRO . 17.3 Cg_endo -90.6 -160.23 0.09 OUTLIER 'Trans proline' 0 C--N 1.354 0.843 0 C-N-CA 124.593 3.529 . . . . 1.0 110.427 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -69.96 162.61 27.74 Favored 'General case' 0 N--CA 1.465 0.276 0 O-C-N 121.469 -0.77 . . . . 1.0 109.503 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -72.14 -179.85 3.01 Favored 'General case' 0 CA--C 1.529 0.166 0 O-C-N 121.527 -0.733 . . . . 1.0 109.571 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 13.9 pm0 -110.71 153.03 25.85 Favored 'General case' 0 C--O 1.233 0.209 0 O-C-N 121.464 -0.773 . . . . 1.0 109.438 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 6.0 m -99.01 164.45 12.17 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.449 -0.782 . . . . 1.0 109.377 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -81.2 104.16 11.48 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.436 -0.79 . . . . 1.0 109.475 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 54.8 m-85 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.003 -0.999 . . . . 1.0 109.417 -179.964 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 11.0 pm0 . . . . . 0 CA--C 1.53 0.187 0 N-CA-C 109.379 -0.601 . . . . 1.0 109.379 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.78 77.07 1.05 Allowed 'General case' 0 CA--C 1.531 0.226 0 O-C-N 121.52 -0.737 . . . . 1.0 109.491 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 9.9 mp0 -143.45 170.79 15.13 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.477 -0.765 . . . . 1.0 109.346 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -147.94 176.21 10.35 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.519 -0.738 . . . . 1.0 109.395 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -90.51 139.38 30.75 Favored 'General case' 0 CA--C 1.529 0.153 0 O-C-N 121.564 -0.71 . . . . 1.0 109.41 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.66 155.33 48.38 Favored 'General case' 0 N--CA 1.463 0.175 0 O-C-N 121.495 -0.753 . . . . 1.0 109.327 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 62.3 m -114.9 28.24 8.85 Favored 'General case' 0 C--O 1.232 0.15 0 O-C-N 121.496 -0.752 . . . . 1.0 109.326 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.6 t -95.39 122.82 38.51 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.362 -0.836 . . . . 1.0 109.586 -179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.3 t -147.11 167.67 5.5 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.198 0 O-C-N 121.5 -0.75 . . . . 1.0 109.283 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -76.66 124.97 87.83 Favored Pre-proline 0 CA--C 1.541 0.609 0 O-C-N 121.438 -0.789 . . . . 1.0 109.354 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_exo -36.87 -50.37 1.45 Allowed 'Trans proline' 0 N--CA 1.49 1.302 0 C-N-CA 124.922 3.748 . . . . 1.0 111.242 -179.675 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.6 mtp180 -70.21 -49.12 53.38 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.458 -0.776 . . . . 1.0 109.652 -179.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 25.0 mt-10 -82.61 40.36 0.66 Allowed 'General case' 0 CA--C 1.53 0.211 0 O-C-N 121.46 -0.775 . . . . 1.0 109.52 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 26.2 mtt180 -92.4 139.34 30.7 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.473 -0.767 . . . . 1.0 109.476 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -85.46 108.48 17.91 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.522 -0.736 . . . . 1.0 109.162 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -64.59 120.48 12.43 Favored 'General case' 0 CA--C 1.532 0.275 0 O-C-N 121.485 -0.759 . . . . 1.0 109.668 -179.72 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 28.2 t -95.75 -19.48 19.63 Favored 'General case' 0 CA--C 1.534 0.327 0 O-C-N 121.586 -0.696 . . . . 1.0 109.456 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 175.3 -179.03 46.79 Favored Glycine 0 CA--C 1.528 0.871 0 N-CA-C 109.232 -1.547 . . . . 1.0 109.232 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.427 ' CD2' HG12 ' A' ' 22' ' ' VAL . 9.1 p90 -65.72 167.97 9.84 Favored Pre-proline 0 CA--C 1.537 0.455 0 O-C-N 121.369 -1.077 . . . . 1.0 108.929 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.68 -30.15 1.53 Allowed 'Trans proline' 0 N--CA 1.483 0.902 0 C-N-CA 124.418 3.412 . . . . 1.0 110.809 -178.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -57.16 -12.16 7.4 Favored Glycine 0 CA--C 1.536 1.401 0 N-CA-C 110.401 -1.079 . . . . 1.0 110.401 179.597 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.427 HG12 ' CD2' ' A' ' 19' ' ' PHE . 24.2 m -61.3 162.92 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 O-C-N 121.253 -1.145 . . . . 1.0 109.641 179.694 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.4 p -121.6 154.75 60.05 Favored Pre-proline 0 CA--C 1.534 0.35 0 O-C-N 121.505 -0.747 . . . . 1.0 109.311 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.0 Cg_exo -35.8 -38.75 0.27 Allowed 'Trans proline' 0 N--CA 1.487 1.119 1 C-N-CA 125.479 4.12 . . . . 1.0 111.258 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 1.9 p -69.91 -48.08 59.97 Favored 'General case' 0 N--CA 1.463 0.213 0 O-C-N 121.511 -0.743 . . . . 1.0 109.791 -179.826 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -62.72 -46.15 89.42 Favored 'General case' 0 CA--C 1.533 0.322 0 O-C-N 121.4 -0.813 . . . . 1.0 109.749 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 17.3 t -64.59 -26.79 68.56 Favored 'General case' 0 CA--C 1.531 0.213 0 O-C-N 121.431 -0.793 . . . . 1.0 109.368 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.56 -8.85 54.06 Favored 'General case' 0 CA--C 1.532 0.271 0 O-C-N 121.562 -0.711 . . . . 1.0 109.811 179.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -77.94 -38.42 45.46 Favored 'General case' 0 CA--C 1.53 0.18 0 O-C-N 121.245 -0.91 . . . . 1.0 109.373 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.4 mmtt -83.69 -41.44 17.72 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 121.429 -0.794 . . . . 1.0 109.41 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 118.07 38.45 0.81 Allowed Glycine 0 CA--C 1.531 1.055 0 N-CA-C 109.569 -1.412 . . . . 1.0 109.569 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.7 m -112.61 147.97 35.56 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.606 -0.938 . . . . 1.0 109.485 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 66.4 m -69.5 125.14 25.82 Favored 'General case' 0 CA--C 1.529 0.163 0 O-C-N 121.477 -0.765 . . . . 1.0 109.36 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -99.1 143.13 29.71 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.508 -0.745 . . . . 1.0 109.367 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -157.0 113.9 3.06 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 121.529 -0.732 . . . . 1.0 109.503 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.413 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.9 p-10 -111.54 60.27 0.62 Allowed 'General case' 0 CA--C 1.533 0.321 0 O-C-N 121.492 -0.755 . . . . 1.0 109.39 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 67.7 p -99.8 -56.64 2.33 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.356 -0.84 . . . . 1.0 109.569 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.5 t -98.23 161.88 2.87 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.22 0 O-C-N 121.485 -0.76 . . . . 1.0 109.425 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 4.0 mpt_? -104.95 173.59 6.24 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.506 -0.746 . . . . 1.0 109.448 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.31 -45.53 3.06 Favored Glycine 0 CA--C 1.529 0.936 0 N-CA-C 109.477 -1.449 . . . . 1.0 109.477 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.6 m -79.37 169.52 20.01 Favored Pre-proline 0 CA--C 1.536 0.413 0 O-C-N 121.56 -0.965 . . . . 1.0 109.321 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -87.42 127.84 2.47 Favored 'Trans proline' 0 C--N 1.35 0.657 0 C-N-CA 124.805 3.67 . . . . 1.0 109.987 179.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.413 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 16.6 m0 -74.6 -38.54 62.58 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.457 -0.777 . . . . 1.0 109.918 -179.439 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 8.3 t -89.59 109.15 20.13 Favored 'General case' 0 CA--C 1.533 0.318 0 O-C-N 121.352 -0.842 . . . . 1.0 109.609 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.419 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 4.9 p90 -135.65 -178.69 5.24 Favored 'General case' 0 CA--C 1.535 0.397 0 O-C-N 121.415 -0.803 . . . . 1.0 109.463 179.708 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.402 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 18.6 m-85 -90.68 167.1 17.17 Favored Pre-proline 0 CA--C 1.536 0.426 0 O-C-N 121.487 -0.758 . . . . 1.0 109.592 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -91.23 148.65 3.66 Favored 'Trans proline' 0 C--N 1.35 0.628 0 C-N-CA 124.998 3.799 . . . . 1.0 110.461 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -123.77 101.2 7.15 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 109.126 -0.694 . . . . 1.0 109.126 179.664 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.4 p -61.94 98.3 0.1 Allowed 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.409 -0.807 . . . . 1.0 109.856 -179.635 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 48.1 mt -131.46 156.24 42.47 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 O-C-N 121.554 -0.716 . . . . 1.0 109.158 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -127.7 151.59 48.78 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.388 -0.82 . . . . 1.0 109.537 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.4 m -131.11 147.36 65.96 Favored Pre-proline 0 CA--C 1.534 0.364 0 O-C-N 121.584 -0.697 . . . . 1.0 109.465 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.439 ' N ' ' HD2' ' A' ' 54' ' ' PRO . 4.7 Cg_exo -38.17 -60.17 0.48 Allowed 'Trans proline' 0 N--CA 1.486 1.038 0 C-N-CA 125.172 3.915 . . . . 1.0 111.233 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . 0.439 ' HD2' ' N ' ' A' ' 53' ' ' PRO . 14.6 Cg_exo -37.31 157.31 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.378 0 C-N-CA 124.892 3.728 . . . . 1.0 111.02 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -114.2 145.87 41.12 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.504 -0.748 . . . . 1.0 109.381 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -107.01 118.06 35.69 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 121.547 -0.72 . . . . 1.0 109.416 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -138.65 151.2 47.01 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.46 -0.775 . . . . 1.0 109.415 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.5 p -76.02 130.79 38.93 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.39 -0.819 . . . . 1.0 109.453 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -142.85 153.79 43.52 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.508 -0.745 . . . . 1.0 109.468 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 7.5 t80 . . . . . 0 C--O 1.221 -0.412 0 CA-C-O 118.019 -0.991 . . . . 1.0 109.47 179.997 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 . . . . . 0 CA--C 1.53 0.194 0 N-CA-C 109.433 -0.58 . . . . 1.0 109.433 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -96.84 99.49 11.06 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 121.533 -0.729 . . . . 1.0 109.438 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 7.9 mm-40 -137.31 131.34 32.09 Favored 'General case' 0 CA--C 1.53 0.189 0 O-C-N 121.482 -0.761 . . . . 1.0 109.436 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.3 p -144.3 -179.3 6.44 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.442 -0.786 . . . . 1.0 109.433 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -110.06 127.39 54.82 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 121.481 -0.762 . . . . 1.0 109.44 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.31 144.0 25.26 Favored 'General case' 0 CA--C 1.531 0.247 0 O-C-N 121.446 -0.784 . . . . 1.0 109.53 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 74.0 m -107.04 19.98 19.67 Favored 'General case' 0 CA--C 1.532 0.277 0 O-C-N 121.539 -0.725 . . . . 1.0 109.548 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.8 t -82.89 94.87 7.79 Favored 'General case' 0 CA--C 1.532 0.286 0 O-C-N 121.456 -0.777 . . . . 1.0 109.749 -179.628 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 39.8 t -122.16 155.04 26.95 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 O-C-N 121.526 -0.734 . . . . 1.0 109.035 179.639 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -81.23 137.49 49.08 Favored Pre-proline 0 CA--C 1.539 0.533 0 O-C-N 121.387 -0.82 . . . . 1.0 109.378 -179.731 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_exo -35.39 -36.41 0.15 Allowed 'Trans proline' 0 N--CA 1.488 1.159 1 C-N-CA 125.398 4.065 . . . . 1.0 111.266 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 19.6 mtp180 -74.47 -49.91 20.4 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.529 -0.732 . . . . 1.0 109.674 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 7.7 mm-40 -81.38 27.64 0.41 Allowed 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.481 -0.762 . . . . 1.0 109.808 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 32.2 mtt180 -100.73 146.31 27.38 Favored 'General case' 0 N--CA 1.464 0.23 0 O-C-N 121.433 -0.792 . . . . 1.0 109.418 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 16.7 mt-30 -120.38 154.76 34.65 Favored 'General case' 0 C--N 1.332 -0.194 0 O-C-N 121.518 -0.739 . . . . 1.0 109.297 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -80.32 125.15 29.53 Favored 'General case' 0 CA--C 1.53 0.197 0 O-C-N 121.498 -0.751 . . . . 1.0 109.132 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -98.62 -23.71 15.37 Favored 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.455 -0.778 . . . . 1.0 109.303 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -167.13 -179.81 40.35 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 109.021 -1.632 . . . . 1.0 109.021 179.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.455 ' CE2' ' CG1' ' A' ' 22' ' ' VAL . 7.8 p90 -67.68 167.17 17.31 Favored Pre-proline 0 CA--C 1.537 0.471 0 O-C-N 121.348 -1.09 . . . . 1.0 108.826 179.81 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -82.31 -29.57 1.48 Allowed 'Trans proline' 0 N--CA 1.483 0.908 0 C-N-CA 124.551 3.501 . . . . 1.0 110.914 -178.576 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -55.6 -15.34 8.52 Favored Glycine 0 CA--C 1.535 1.324 0 N-CA-C 110.35 -1.1 . . . . 1.0 110.35 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.455 ' CG1' ' CE2' ' A' ' 19' ' ' PHE . 22.6 m -63.22 151.55 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 O-C-N 121.326 -1.103 . . . . 1.0 109.543 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.495 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 73.0 p -99.7 154.64 37.16 Favored Pre-proline 0 CA--C 1.536 0.422 0 N-CA-C 108.99 -0.745 . . . . 1.0 108.99 179.311 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -33.18 -55.68 0.38 Allowed 'Trans proline' 0 N--CA 1.487 1.113 1 C-N-CA 125.797 4.332 . . . . 1.0 111.862 -179.454 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 67.6 m -80.12 -27.38 39.15 Favored 'General case' 0 N--CA 1.464 0.245 0 O-C-N 121.43 -0.793 . . . . 1.0 110.565 -179.041 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLN . . . . . 0.495 ' HB2' ' H ' ' A' ' 23' ' ' THR . 10.5 mt-30 -61.46 -54.51 42.44 Favored 'General case' 0 N--CA 1.466 0.353 0 O-C-N 121.287 -0.883 . . . . 1.0 110.332 -179.47 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -77.5 -27.2 51.77 Favored 'General case' 0 CA--C 1.534 0.333 0 O-C-N 121.393 -0.817 . . . . 1.0 109.886 -179.261 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.72 -5.01 57.73 Favored 'General case' 0 CA--C 1.534 0.365 0 O-C-N 121.422 -0.799 . . . . 1.0 110.113 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -106.8 -4.39 19.36 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.316 -0.865 . . . . 1.0 109.8 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.1 tttt -89.9 -46.69 8.37 Favored 'General case' 0 CA--C 1.533 0.289 0 O-C-N 121.269 -0.895 . . . . 1.0 109.196 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 151.22 19.14 0.06 OUTLIER Glycine 0 CA--C 1.531 1.054 0 N-CA-C 109.528 -1.429 . . . . 1.0 109.528 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 85.6 m -119.17 148.96 42.51 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.423 -1.045 . . . . 1.0 109.285 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 55.9 m -77.49 115.63 17.41 Favored 'General case' 0 N--CA 1.463 0.221 0 O-C-N 121.557 -0.715 . . . . 1.0 109.083 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.436 ' CD1' ' N ' ' A' ' 35' ' ' ASP . 46.5 t80 -89.95 152.37 21.24 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.446 -0.784 . . . . 1.0 109.722 -179.618 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . 0.436 ' N ' ' CD1' ' A' ' 34' ' ' PHE . 28.5 t70 -165.29 118.7 1.21 Allowed 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.589 -0.694 . . . . 1.0 109.309 179.724 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -120.34 51.54 1.21 Allowed 'General case' 0 CA--C 1.534 0.329 0 O-C-N 121.532 -0.73 . . . . 1.0 109.547 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.467 ' H ' ' HG1' ' A' ' 37' ' ' THR . 0.9 OUTLIER -99.77 -15.59 18.4 Favored 'General case' 0 CA--C 1.533 0.317 0 O-C-N 121.308 -0.87 . . . . 1.0 109.937 -179.856 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 37.3 t -129.71 161.02 40.1 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.222 0 O-C-N 121.335 -0.853 . . . . 1.0 109.625 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 79.5 mtt85 -111.89 166.96 10.75 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.516 -0.74 . . . . 1.0 109.379 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.55 -41.99 2.38 Favored Glycine 0 CA--C 1.53 0.986 0 N-CA-C 109.234 -1.546 . . . . 1.0 109.234 -179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 28.9 m -81.1 170.63 14.75 Favored Pre-proline 0 CA--C 1.537 0.478 0 O-C-N 121.587 -0.949 . . . . 1.0 109.049 179.73 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -85.87 126.31 2.89 Favored 'Trans proline' 0 C--N 1.352 0.744 0 C-N-CA 124.539 3.493 . . . . 1.0 110.018 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . . . . . . . . . 33.8 m0 -75.41 -37.6 60.35 Favored 'General case' 0 N--CA 1.462 0.169 0 O-C-N 121.429 -0.794 . . . . 1.0 109.91 -179.536 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 6.5 t -90.08 113.99 25.82 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.415 -0.803 . . . . 1.0 109.539 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.416 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 5.7 p90 -140.02 170.91 14.98 Favored 'General case' 0 CA--C 1.536 0.424 0 O-C-N 121.388 -0.82 . . . . 1.0 110.025 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 61.8 m-85 -77.06 170.59 15.6 Favored Pre-proline 0 CA--C 1.537 0.443 0 O-C-N 121.674 -0.641 . . . . 1.0 109.419 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -88.18 173.12 4.92 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 124.829 3.686 . . . . 1.0 110.415 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -148.09 107.11 3.85 Favored 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.664 -0.647 . . . . 1.0 109.346 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 24.2 p -77.05 84.73 3.56 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.483 -0.76 . . . . 1.0 109.485 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 48.0 mt -96.91 168.71 1.54 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 O-C-N 121.523 -0.735 . . . . 1.0 109.298 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -75.39 -177.91 3.78 Favored 'General case' 0 N--CA 1.463 0.179 0 O-C-N 121.473 -0.767 . . . . 1.0 109.422 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.0 m -148.71 100.31 3.51 Favored Pre-proline 0 CA--C 1.539 0.543 0 O-C-N 121.451 -0.781 . . . . 1.0 109.538 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -49.66 -178.43 0.01 OUTLIER 'Trans proline' 0 N--CA 1.488 1.181 0 C-N-CA 123.948 3.099 . . . . 1.0 110.209 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -87.42 42.88 0.85 Allowed 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 124.729 3.619 . . . . 1.0 110.281 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 32.3 mt-10 -112.75 118.65 35.57 Favored 'General case' 0 CA--C 1.53 0.202 0 O-C-N 121.479 -0.763 . . . . 1.0 109.265 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 51.0 mt-10 -126.73 135.91 51.73 Favored 'General case' 0 N--CA 1.463 0.193 0 O-C-N 121.475 -0.765 . . . . 1.0 109.617 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 33.3 mt-10 -148.78 110.5 4.51 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.536 -0.727 . . . . 1.0 109.364 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 90.8 p -80.96 110.37 16.43 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 121.443 -0.786 . . . . 1.0 109.531 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 13.3 tt0 -139.86 169.04 18.45 Favored 'General case' 0 N--CA 1.463 0.198 0 O-C-N 121.515 -0.741 . . . . 1.0 109.39 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.954 -1.022 . . . . 1.0 109.374 -179.934 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 13.5 tt0 . . . . . 0 CA--C 1.53 0.211 0 N-CA-C 109.413 -0.588 . . . . 1.0 109.413 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -115.23 139.57 49.83 Favored 'General case' 0 CA--C 1.531 0.223 0 O-C-N 121.454 -0.779 . . . . 1.0 109.553 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -123.25 108.93 13.33 Favored 'General case' 0 N--CA 1.463 0.211 0 O-C-N 121.483 -0.76 . . . . 1.0 109.442 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 30.7 p -155.1 161.71 41.2 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.563 -0.711 . . . . 1.0 109.57 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -67.57 156.87 35.73 Favored 'General case' 0 CA--C 1.53 0.184 0 O-C-N 121.425 -0.797 . . . . 1.0 109.005 179.654 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.7 m -149.28 116.36 6.03 Favored 'General case' 0 C--O 1.233 0.198 0 O-C-N 121.404 -0.81 . . . . 1.0 109.953 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 86.2 m -108.07 -18.53 13.76 Favored 'General case' 0 CA--C 1.534 0.336 0 O-C-N 121.444 -0.785 . . . . 1.0 109.216 179.337 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.1 t -68.78 101.42 1.33 Allowed 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.201 -0.937 . . . . 1.0 109.521 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.406 HG22 HD21 ' A' ' 48' ' ' ASN . 38.6 t -121.82 171.16 11.02 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 O-C-N 121.575 -0.703 . . . . 1.0 109.233 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.4 ' N ' ' CG1' ' A' ' 9' ' ' VAL . . . -67.99 129.17 93.25 Favored Pre-proline 0 CA--C 1.539 0.541 0 O-C-N 121.355 -0.84 . . . . 1.0 109.483 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -36.95 -50.21 1.48 Allowed 'Trans proline' 0 N--CA 1.49 1.281 0 C-N-CA 125.027 3.818 . . . . 1.0 111.227 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -70.75 -39.55 73.21 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.502 -0.749 . . . . 1.0 109.833 -179.591 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -81.42 29.24 0.37 Allowed 'General case' 0 CA--C 1.532 0.254 0 O-C-N 121.529 -0.732 . . . . 1.0 109.716 -179.72 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 37.9 mtt180 -101.41 120.63 40.57 Favored 'General case' 0 N--CA 1.464 0.248 0 O-C-N 121.417 -0.802 . . . . 1.0 109.368 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 -79.86 121.43 25.4 Favored 'General case' 0 CA--C 1.531 0.216 0 O-C-N 121.491 -0.756 . . . . 1.0 109.261 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -63.91 121.4 13.98 Favored 'General case' 0 CA--C 1.532 0.261 0 O-C-N 121.517 -0.74 . . . . 1.0 109.911 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.3 t -93.73 -20.33 20.23 Favored 'General case' 0 CA--C 1.534 0.351 0 O-C-N 121.562 -0.711 . . . . 1.0 109.272 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 179.57 177.23 47.71 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 109.178 -1.569 . . . . 1.0 109.178 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.433 ' CD2' HG12 ' A' ' 22' ' ' VAL . 8.8 p90 -65.01 167.7 9.0 Favored Pre-proline 0 CA--C 1.538 0.516 0 O-C-N 121.446 -1.032 . . . . 1.0 108.885 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.58 -30.67 1.38 Allowed 'Trans proline' 0 N--CA 1.481 0.777 0 C-N-CA 124.45 3.433 . . . . 1.0 110.802 -178.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.46 -10.04 7.22 Favored Glycine 0 CA--C 1.537 1.454 0 N-CA-C 110.307 -1.117 . . . . 1.0 110.307 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.433 HG12 ' CD2' ' A' ' 19' ' ' PHE . 24.2 m -60.66 -174.74 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 O-C-N 121.231 -1.158 . . . . 1.0 109.531 179.763 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.1 p -143.74 153.72 58.28 Favored Pre-proline 0 CA--C 1.537 0.45 0 O-C-N 121.515 -0.741 . . . . 1.0 109.285 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -35.85 -36.97 0.2 Allowed 'Trans proline' 0 N--CA 1.487 1.134 1 C-N-CA 125.32 4.013 . . . . 1.0 111.382 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.6 t -73.73 -47.34 40.04 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.442 -0.786 . . . . 1.0 109.756 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 45.0 mt-30 -61.65 -44.73 96.42 Favored 'General case' 0 N--CA 1.466 0.327 0 O-C-N 121.436 -0.79 . . . . 1.0 109.674 -179.831 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 8.5 t -65.34 -32.63 74.37 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 121.486 -0.758 . . . . 1.0 109.382 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.6 -4.16 59.08 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 121.615 -0.678 . . . . 1.0 109.938 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -86.22 -23.55 26.39 Favored 'General case' 0 N--CA 1.464 0.258 0 O-C-N 121.218 -0.926 . . . . 1.0 109.636 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.3 tppp? -101.41 -34.94 9.38 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.379 -0.826 . . . . 1.0 109.315 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 111.49 53.62 0.52 Allowed Glycine 0 CA--C 1.529 0.955 0 N-CA-C 109.414 -1.475 . . . . 1.0 109.414 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.7 m -128.7 139.24 52.33 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.544 -0.974 . . . . 1.0 109.363 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.404 ' O ' ' CD1' ' A' ' 45' ' ' PHE . 56.0 m -61.47 119.8 9.27 Favored 'General case' 0 N--CA 1.468 0.448 0 O-C-N 121.462 -0.774 . . . . 1.0 109.964 -179.344 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -101.51 121.56 42.19 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.423 -0.798 . . . . 1.0 109.192 179.623 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 22.5 t0 -134.6 114.24 12.57 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.493 -0.754 . . . . 1.0 109.61 -179.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.415 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 5.8 p-10 -112.0 54.82 0.69 Allowed 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.503 -0.748 . . . . 1.0 109.156 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 39.3 p -104.01 -31.27 9.79 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.377 -0.827 . . . . 1.0 109.61 -179.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 34.9 t -114.88 151.76 16.58 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 O-C-N 121.406 -0.809 . . . . 1.0 109.478 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.403 ' C ' ' H ' ' A' ' 41' ' ' VAL . 21.7 mtm-85 -101.77 165.65 11.09 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 121.497 -0.752 . . . . 1.0 109.471 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.54 -33.79 2.52 Favored Glycine 0 CA--C 1.53 1.017 0 N-CA-C 109.457 -1.457 . . . . 1.0 109.457 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.403 ' H ' ' C ' ' A' ' 39' ' ' ARG . 28.5 m -88.13 169.99 12.52 Favored Pre-proline 0 CA--C 1.537 0.473 0 O-C-N 121.521 -0.988 . . . . 1.0 109.222 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -86.63 123.57 2.15 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 124.724 3.616 . . . . 1.0 110.04 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.415 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 23.9 m0 -75.3 -43.93 48.34 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.555 -0.716 . . . . 1.0 109.873 -179.515 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.6 t -88.8 109.11 19.91 Favored 'General case' 0 CA--C 1.535 0.365 0 O-C-N 121.328 -0.857 . . . . 1.0 109.915 -179.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.428 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 7.1 p90 -138.9 177.33 7.97 Favored 'General case' 0 CA--C 1.537 0.453 0 O-C-N 121.461 -0.775 . . . . 1.0 109.547 179.259 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.428 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 70.6 m-85 -78.78 169.32 21.22 Favored Pre-proline 0 CA--C 1.537 0.463 0 O-C-N 121.271 -0.893 . . . . 1.0 109.975 -179.568 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -92.34 167.69 2.86 Favored 'Trans proline' 0 C--N 1.352 0.711 0 C-N-CA 125.047 3.831 . . . . 1.0 110.582 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.406 HD21 HG22 ' A' ' 9' ' ' VAL . 23.1 m-20 -146.99 80.75 1.54 Allowed 'General case' 0 N--CA 1.463 0.222 0 O-C-N 121.466 -0.771 . . . . 1.0 109.273 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 17.8 p -75.09 121.37 21.94 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 121.377 -0.827 . . . . 1.0 109.683 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 58.7 mt -99.93 141.56 16.84 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 O-C-N 121.484 -0.76 . . . . 1.0 109.201 179.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -163.52 173.72 12.73 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.51 -0.744 . . . . 1.0 109.591 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.8 m -78.23 152.03 78.75 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.509 -0.744 . . . . 1.0 109.42 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -34.38 91.07 0.01 OUTLIER 'Trans proline' 0 N--CA 1.489 1.235 1 C-N-CA 125.568 4.179 . . . . 1.0 111.201 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -91.63 -159.34 0.08 OUTLIER 'Trans proline' 0 C--N 1.351 0.67 0 C-N-CA 125.038 3.825 . . . . 1.0 110.272 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -103.99 161.79 13.68 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.453 -0.78 . . . . 1.0 109.471 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -97.73 120.83 38.81 Favored 'General case' 0 CA--C 1.529 0.158 0 O-C-N 121.505 -0.747 . . . . 1.0 109.462 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.42 ' HG3' ' H ' ' A' ' 58' ' ' SER . 0.9 OUTLIER -137.62 175.52 9.52 Favored 'General case' 0 N--CA 1.462 0.162 0 O-C-N 121.427 -0.795 . . . . 1.0 109.467 -179.961 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' SER . . . . . 0.42 ' H ' ' HG3' ' A' ' 57' ' ' GLU . 58.1 m -134.17 150.9 51.12 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.493 -0.754 . . . . 1.0 109.351 -179.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -147.17 175.6 10.6 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.509 -0.744 . . . . 1.0 109.362 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 40.4 m-85 . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 117.997 -1.002 . . . . 1.0 109.467 179.996 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 . . . . . 0 CA--C 1.53 0.208 0 N-CA-C 109.358 -0.608 . . . . 1.0 109.358 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -144.33 175.76 9.86 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.484 -0.76 . . . . 1.0 109.448 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 4.0 mp0 -102.23 119.38 38.71 Favored 'General case' 0 CA--C 1.53 0.205 0 O-C-N 121.503 -0.748 . . . . 1.0 109.536 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.7 p -143.37 -169.39 3.04 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.491 -0.756 . . . . 1.0 109.435 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -65.02 148.53 51.49 Favored 'General case' 0 CA--C 1.532 0.263 0 O-C-N 121.413 -0.804 . . . . 1.0 109.267 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -137.01 126.19 24.64 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.515 -0.74 . . . . 1.0 109.667 -179.809 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.5 m -117.18 46.18 1.74 Allowed 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.463 -0.773 . . . . 1.0 109.314 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.9 t -131.01 106.89 8.7 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.517 -0.739 . . . . 1.0 109.369 179.82 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.438 ' CG1' ' H ' ' A' ' 10' ' ' ALA . 21.7 t -125.09 174.09 9.82 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 O-C-N 121.369 -0.832 . . . . 1.0 109.34 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.438 ' H ' ' CG1' ' A' ' 9' ' ' VAL . . . -74.92 140.33 74.0 Favored Pre-proline 0 CA--C 1.538 0.508 0 O-C-N 121.479 -0.763 . . . . 1.0 109.57 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_exo -34.81 -61.24 0.25 Allowed 'Trans proline' 0 N--CA 1.488 1.171 1 C-N-CA 125.484 4.122 . . . . 1.0 111.566 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -69.93 -29.95 67.22 Favored 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.476 -0.765 . . . . 1.0 110.107 -179.287 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -85.29 36.62 0.64 Allowed 'General case' 0 N--CA 1.464 0.252 0 O-C-N 121.289 -0.882 . . . . 1.0 109.642 -179.736 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 50.4 mtt180 -108.1 142.94 37.54 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.508 -0.745 . . . . 1.0 109.435 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -102.35 115.02 29.71 Favored 'General case' 0 N--CA 1.463 0.195 0 O-C-N 121.547 -0.721 . . . . 1.0 109.399 179.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 48.9 t30 -61.06 118.7 7.1 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 121.391 -0.818 . . . . 1.0 109.784 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 t -94.51 -18.85 21.06 Favored 'General case' 0 CA--C 1.534 0.352 0 O-C-N 121.463 -0.773 . . . . 1.0 109.247 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.43 178.2 47.8 Favored Glycine 0 CA--C 1.53 0.976 0 N-CA-C 108.967 -1.653 . . . . 1.0 108.967 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.445 ' CE2' ' CG1' ' A' ' 22' ' ' VAL . 8.5 p90 -65.92 167.81 10.68 Favored Pre-proline 0 CA--C 1.539 0.542 0 O-C-N 121.369 -1.077 . . . . 1.0 108.799 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -82.12 -30.09 1.38 Allowed 'Trans proline' 0 N--CA 1.483 0.855 0 C-N-CA 124.38 3.387 . . . . 1.0 110.992 -178.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -56.62 -13.73 8.33 Favored Glycine 0 CA--C 1.536 1.358 0 N-CA-C 110.36 -1.096 . . . . 1.0 110.36 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.445 ' CG1' ' CE2' ' A' ' 19' ' ' PHE . 20.4 m -60.7 173.54 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 O-C-N 121.239 -1.153 . . . . 1.0 109.768 179.849 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 73.6 p -131.84 155.7 81.06 Favored Pre-proline 0 CA--C 1.534 0.339 0 O-C-N 121.524 -0.735 . . . . 1.0 109.143 179.773 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -35.74 -33.82 0.12 Allowed 'Trans proline' 0 N--CA 1.49 1.267 1 C-N-CA 125.354 4.036 . . . . 1.0 111.233 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 39.7 m -75.68 -47.74 24.98 Favored 'General case' 0 CA--C 1.532 0.253 0 O-C-N 121.396 -0.815 . . . . 1.0 109.956 -179.622 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -65.3 -47.25 77.25 Favored 'General case' 0 CA--C 1.533 0.307 0 O-C-N 121.468 -0.77 . . . . 1.0 109.85 -179.689 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 11.2 t -62.48 -29.86 70.84 Favored 'General case' 0 N--CA 1.464 0.269 0 O-C-N 121.408 -0.808 . . . . 1.0 109.796 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -90.52 -9.79 45.95 Favored 'General case' 0 N--CA 1.465 0.281 0 O-C-N 121.464 -0.772 . . . . 1.0 110.098 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -93.03 -5.09 51.33 Favored 'General case' 0 CA--C 1.534 0.34 0 O-C-N 121.224 -0.923 . . . . 1.0 110.028 -179.762 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 51.9 mttp -109.52 -27.28 9.51 Favored 'General case' 0 N--CA 1.464 0.246 0 O-C-N 121.337 -0.852 . . . . 1.0 109.544 -179.794 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.08 22.66 5.83 Favored Glycine 0 CA--C 1.53 0.993 0 N-CA-C 109.568 -1.413 . . . . 1.0 109.568 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 22.8 m -112.74 137.21 51.38 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.469 -1.018 . . . . 1.0 108.564 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.6 m -72.85 133.87 44.62 Favored 'General case' 0 N--CA 1.463 0.222 0 O-C-N 121.316 -0.865 . . . . 1.0 109.735 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -101.68 139.63 37.07 Favored 'General case' 0 C--O 1.232 0.163 0 O-C-N 121.626 -0.671 . . . . 1.0 109.223 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -148.62 102.39 3.3 Favored 'General case' 0 N--CA 1.463 0.202 0 O-C-N 121.306 -0.871 . . . . 1.0 109.591 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.423 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 7.0 p-10 -104.9 73.93 1.1 Allowed 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.525 -0.735 . . . . 1.0 109.294 179.83 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.429 ' HG1' ' N ' ' A' ' 38' ' ' VAL . 30.6 p -118.66 -43.6 2.68 Favored 'General case' 0 CA--C 1.53 0.177 0 O-C-N 121.43 -0.794 . . . . 1.0 109.494 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.429 ' N ' ' HG1' ' A' ' 37' ' ' THR . 38.2 t -110.81 153.06 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 O-C-N 121.467 -0.771 . . . . 1.0 109.287 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 7.8 mtt-85 -101.11 172.51 6.97 Favored 'General case' 0 CA--C 1.532 0.271 0 O-C-N 121.545 -0.722 . . . . 1.0 109.337 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.72 -31.14 3.06 Favored Glycine 0 CA--C 1.529 0.917 0 N-CA-C 109.501 -1.44 . . . . 1.0 109.501 -179.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.6 m -99.83 170.55 6.61 Favored Pre-proline 0 CA--C 1.537 0.478 0 O-C-N 121.501 -1.0 . . . . 1.0 109.129 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -85.64 126.41 3.01 Favored 'Trans proline' 0 N--CA 1.479 0.654 0 C-N-CA 124.506 3.471 . . . . 1.0 110.036 179.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.423 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 10.0 m0 -77.64 -38.89 46.91 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.555 -0.715 . . . . 1.0 109.837 -179.356 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 28.1 t -89.44 103.84 16.45 Favored 'General case' 0 CA--C 1.534 0.357 0 O-C-N 121.385 -0.822 . . . . 1.0 109.566 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.406 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 5.1 p90 -132.87 177.42 7.66 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.259 -0.901 . . . . 1.0 109.881 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' TYR . . . . . 0.406 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 32.2 m-85 -74.1 169.81 17.44 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 121.61 -0.681 . . . . 1.0 109.684 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -93.35 173.16 1.85 Allowed 'Trans proline' 0 C--N 1.35 0.643 0 C-N-CA 125.217 3.944 . . . . 1.0 110.612 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -141.51 95.04 2.76 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.54 -0.725 . . . . 1.0 109.38 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 77.7 p -76.72 132.87 39.56 Favored 'General case' 0 CA--C 1.53 0.191 0 O-C-N 121.47 -0.769 . . . . 1.0 109.452 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 63.0 mt -128.26 142.29 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 O-C-N 121.361 -0.837 . . . . 1.0 109.323 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -162.12 -177.26 5.63 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.456 -0.777 . . . . 1.0 109.421 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 29.8 m -93.01 141.41 24.06 Favored Pre-proline 0 CA--C 1.537 0.46 0 O-C-N 121.522 -0.737 . . . . 1.0 109.302 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.438 ' N ' ' HD2' ' A' ' 54' ' ' PRO . 3.0 Cg_exo -39.13 -60.39 0.51 Allowed 'Trans proline' 0 N--CA 1.488 1.172 0 C-N-CA 124.96 3.773 . . . . 1.0 111.179 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . 0.438 ' HD2' ' N ' ' A' ' 53' ' ' PRO . 16.0 Cg_exo -36.36 -69.77 0.07 OUTLIER 'Trans proline' 0 N--CA 1.49 1.294 0 C-N-CA 124.95 3.767 . . . . 1.0 111.215 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -73.46 167.16 21.86 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 121.473 -0.767 . . . . 1.0 109.494 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -140.81 135.92 31.92 Favored 'General case' 0 CA--C 1.53 0.176 0 O-C-N 121.495 -0.753 . . . . 1.0 109.404 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -102.72 132.47 48.84 Favored 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.527 -0.733 . . . . 1.0 109.467 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 13.8 p -92.16 156.69 17.16 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 121.45 -0.781 . . . . 1.0 109.444 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -130.6 136.06 48.5 Favored 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.518 -0.739 . . . . 1.0 109.491 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 44.1 t80 . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.976 -1.011 . . . . 1.0 109.443 -179.964 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.1 m . . . . . 0 CA--C 1.531 0.248 0 CA-C-O 121.139 0.495 . . . . 1.0 109.715 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 75.1 m -113.22 -14.19 12.89 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.498 -0.751 . . . . 1.0 109.594 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.548 HG23 ' O ' ' A' ' 8' ' ' THR . 2.8 t -71.19 96.44 1.38 Allowed 'General case' 0 CA--C 1.53 0.211 0 O-C-N 121.286 -0.884 . . . . 1.0 109.658 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.584 HG12 ' N ' ' A' ' 10' ' ' ALA . 39.4 t -119.35 168.98 11.01 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 O-C-N 121.465 -0.772 . . . . 1.0 109.074 179.7 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.891 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -65.21 121.27 73.53 Favored Pre-proline 0 CA--C 1.542 0.65 0 O-C-N 121.386 -0.821 . . . . 1.0 109.17 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.419 ' HD2' ' HA ' ' A' ' 10' ' ' ALA . 19.1 Cg_exo -36.95 -47.43 1.46 Allowed 'Trans proline' 0 N--CA 1.49 1.281 0 C-N-CA 124.917 3.745 . . . . 1.0 111.334 -179.559 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -75.88 -39.44 56.44 Favored 'General case' 0 N--CA 1.463 0.208 0 O-C-N 121.466 -0.771 . . . . 1.0 109.745 -179.775 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.891 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 28.0 mt-10 -84.33 38.38 0.67 Allowed 'General case' 0 N--CA 1.462 0.162 0 O-C-N 121.399 -0.813 . . . . 1.0 109.565 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 18.6 mtt180 -104.82 145.64 30.1 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.446 -0.784 . . . . 1.0 109.407 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 10.1 mp0 -94.69 120.6 35.17 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 121.542 -0.724 . . . . 1.0 109.36 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 62.7 t30 -63.63 120.34 11.59 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.457 -0.777 . . . . 1.0 109.817 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.42 ' HA ' ' CE2' ' A' ' 46' ' ' TYR . 44.3 t -94.65 -17.77 21.97 Favored 'General case' 0 CA--C 1.535 0.385 0 O-C-N 121.574 -0.704 . . . . 1.0 109.329 179.716 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 177.15 175.44 44.43 Favored Glycine 0 CA--C 1.529 0.939 0 N-CA-C 109.404 -1.479 . . . . 1.0 109.404 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.567 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.5 p90 -64.61 167.95 7.84 Favored Pre-proline 0 CA--C 1.538 0.512 0 O-C-N 121.383 -1.069 . . . . 1.0 109.063 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.33 -31.36 1.25 Allowed 'Trans proline' 0 N--CA 1.483 0.905 0 C-N-CA 124.341 3.361 . . . . 1.0 110.643 -178.837 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.75 -7.91 6.95 Favored Glycine 0 CA--C 1.537 1.438 0 N-CA-C 110.294 -1.122 . . . . 1.0 110.294 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.567 HG22 ' O ' ' A' ' 19' ' ' PHE . 17.4 m -60.17 -178.97 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 O-C-N 121.208 -1.172 . . . . 1.0 109.742 179.762 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.433 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 12.0 p -138.5 155.08 73.88 Favored Pre-proline 0 CA--C 1.536 0.43 0 O-C-N 121.513 -0.742 . . . . 1.0 109.276 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -36.05 -36.45 0.2 Allowed 'Trans proline' 0 N--CA 1.488 1.187 1 C-N-CA 125.368 4.045 . . . . 1.0 111.316 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 42.1 t -73.99 -46.07 46.1 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.405 -0.809 . . . . 1.0 109.874 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLN . . . . . 0.433 ' HB2' ' H ' ' A' ' 23' ' ' THR . 38.0 mt-30 -60.57 -48.63 80.91 Favored 'General case' 0 N--CA 1.464 0.258 0 O-C-N 121.468 -0.77 . . . . 1.0 109.988 -179.808 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.7 t -65.11 -27.73 68.95 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.409 -0.807 . . . . 1.0 109.497 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.34 -5.26 58.42 Favored 'General case' 0 CA--C 1.535 0.38 0 O-C-N 121.547 -0.721 . . . . 1.0 109.846 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.0 t-20 -70.83 -49.45 46.17 Favored 'General case' 0 N--CA 1.463 0.181 0 O-C-N 121.408 -0.808 . . . . 1.0 109.363 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.441 ' HG2' ' H ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -83.64 -44.7 14.27 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.534 -0.729 . . . . 1.0 109.432 179.889 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.441 ' H ' ' HG2' ' A' ' 30' ' ' LYS . . . 125.65 32.45 0.76 Allowed Glycine 0 CA--C 1.531 1.075 0 N-CA-C 109.958 -1.257 . . . . 1.0 109.958 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.5 m -92.26 144.7 25.13 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.43 -1.041 . . . . 1.0 109.301 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.402 ' O ' ' CD1' ' A' ' 45' ' ' PHE . 60.0 m -66.51 115.4 6.35 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.462 -0.774 . . . . 1.0 109.516 -179.814 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -94.6 132.01 39.76 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.38 -0.825 . . . . 1.0 109.33 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -144.2 111.12 5.74 Favored 'General case' 0 CA--C 1.53 0.19 0 O-C-N 121.425 -0.797 . . . . 1.0 109.481 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.434 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.0 p-10 -115.34 70.42 0.74 Allowed 'General case' 0 CA--C 1.534 0.334 0 O-C-N 121.509 -0.745 . . . . 1.0 109.414 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 43.9 p -114.45 -39.35 3.84 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.429 -0.794 . . . . 1.0 109.471 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.577 HG12 ' N ' ' A' ' 39' ' ' ARG . 39.9 t -111.95 167.93 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 O-C-N 121.519 -0.738 . . . . 1.0 109.401 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.577 ' N ' HG12 ' A' ' 38' ' ' VAL . 4.9 ttm180 -113.31 175.99 5.22 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.432 -0.793 . . . . 1.0 109.432 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.51 -37.33 2.25 Favored Glycine 0 CA--C 1.53 0.996 0 N-CA-C 109.41 -1.476 . . . . 1.0 109.41 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 28.9 m -94.66 170.39 8.16 Favored Pre-proline 0 CA--C 1.536 0.431 0 O-C-N 121.571 -0.958 . . . . 1.0 109.174 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_endo -85.68 139.31 6.57 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 124.628 3.552 . . . . 1.0 109.937 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.434 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 11.2 m0 -89.22 -41.05 12.44 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 121.502 -0.749 . . . . 1.0 110.028 -179.304 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 18.5 t -89.31 107.43 19.06 Favored 'General case' 0 N--CA 1.465 0.309 0 O-C-N 121.426 -0.797 . . . . 1.0 109.719 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.417 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 9.5 p90 -135.05 173.81 11.31 Favored 'General case' 0 CA--C 1.537 0.479 0 O-C-N 121.346 -0.846 . . . . 1.0 109.633 179.59 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.42 ' CE2' ' HA ' ' A' ' 17' ' ' CYS . 90.8 m-85 -82.11 167.38 31.04 Favored Pre-proline 0 CA--C 1.536 0.419 0 O-C-N 121.493 -0.755 . . . . 1.0 109.716 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -89.65 161.52 5.26 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 124.998 3.799 . . . . 1.0 110.424 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 . . . . . 0 CA--C 1.531 0.216 0 O-C-N 121.549 -0.719 . . . . 1.0 109.388 179.949 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.569 HG22 HG22 ' A' ' 8' ' ' THR . 0.8 OUTLIER . . . . . 0 CA--C 1.53 0.181 0 N-CA-C 109.383 -0.599 . . . . 1.0 109.383 . . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.411 ' HB3' ' CZ ' ' A' ' 45' ' ' PHE . 62.8 m -125.91 31.49 5.46 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.488 -0.758 . . . . 1.0 109.022 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.569 HG22 HG22 ' A' ' 6' ' ' THR . 5.1 t -96.08 118.9 33.58 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.657 -0.652 . . . . 1.0 109.556 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.435 HG11 ' O ' ' A' ' 13' ' ' GLU . 34.2 t -149.92 156.21 7.24 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.206 0 O-C-N 121.495 -0.753 . . . . 1.0 109.236 179.828 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -74.07 136.72 76.04 Favored Pre-proline 0 CA--C 1.54 0.59 0 O-C-N 121.482 -0.761 . . . . 1.0 109.308 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -35.05 -41.05 0.28 Allowed 'Trans proline' 0 N--CA 1.488 1.171 1 C-N-CA 125.361 4.041 . . . . 1.0 111.305 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.7 mtt180 -80.95 -44.61 17.95 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.543 -0.723 . . . . 1.0 109.759 -179.784 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.435 ' O ' HG11 ' A' ' 9' ' ' VAL . 19.9 mt-10 -74.56 10.46 1.34 Allowed 'General case' 0 CA--C 1.533 0.326 0 O-C-N 121.417 -0.802 . . . . 1.0 109.975 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 24.2 mtt180 -81.25 124.37 29.26 Favored 'General case' 0 CA--C 1.529 0.164 0 O-C-N 121.34 -0.85 . . . . 1.0 109.361 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 25.5 mm100 -92.56 126.76 37.79 Favored 'General case' 0 N--CA 1.463 0.197 0 O-C-N 121.463 -0.773 . . . . 1.0 109.025 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.2 t-20 -72.23 116.68 12.95 Favored 'General case' 0 CA--C 1.532 0.286 0 O-C-N 121.604 -0.685 . . . . 1.0 109.942 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -83.55 -6.97 59.6 Favored 'General case' 0 CA--C 1.537 0.447 0 O-C-N 121.53 -0.731 . . . . 1.0 109.208 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.84 170.0 37.42 Favored Glycine 0 CA--C 1.532 1.097 0 N-CA-C 108.353 -1.899 . . . . 1.0 108.353 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.442 ' O ' HG22 ' A' ' 22' ' ' VAL . 7.5 p90 -62.52 168.33 4.35 Favored Pre-proline 0 CA--C 1.54 0.56 0 O-C-N 121.208 -1.172 . . . . 1.0 109.043 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -81.36 -30.25 1.61 Allowed 'Trans proline' 0 N--CA 1.481 0.785 0 C-N-CA 124.304 3.336 . . . . 1.0 110.677 -178.648 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.23 -6.82 8.12 Favored Glycine 0 CA--C 1.536 1.374 0 N-CA-C 110.052 -1.219 . . . . 1.0 110.052 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.442 HG22 ' O ' ' A' ' 19' ' ' PHE . 29.2 m -60.25 -176.31 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 O-C-N 121.157 -1.202 . . . . 1.0 109.816 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.419 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 10.6 p -137.38 155.95 75.36 Favored Pre-proline 0 CA--C 1.535 0.368 0 O-C-N 121.51 -0.744 . . . . 1.0 109.13 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_exo -37.47 -42.24 1.08 Allowed 'Trans proline' 0 N--CA 1.488 1.176 0 C-N-CA 125.188 3.926 . . . . 1.0 111.001 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 80.3 p -69.45 -42.76 74.51 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.524 -0.735 . . . . 1.0 110.118 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLN . . . . . 0.419 ' HB2' ' H ' ' A' ' 23' ' ' THR . 13.9 mm100 -65.61 -53.92 34.91 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.401 -0.812 . . . . 1.0 109.909 -179.562 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 18.9 t -62.04 -19.71 63.17 Favored 'General case' 0 CA--C 1.534 0.357 0 O-C-N 121.409 -0.807 . . . . 1.0 109.934 -179.687 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -100.54 -3.56 30.41 Favored 'General case' 0 CA--C 1.535 0.378 0 O-C-N 121.356 -0.84 . . . . 1.0 110.154 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -73.78 -44.07 57.09 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.395 -0.815 . . . . 1.0 109.855 -179.476 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.9 tttm -86.26 -41.39 14.64 Favored 'General case' 0 N--CA 1.462 0.154 0 O-C-N 121.43 -0.794 . . . . 1.0 109.662 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 127.27 19.71 1.88 Allowed Glycine 0 CA--C 1.53 1.031 0 N-CA-C 109.473 -1.451 . . . . 1.0 109.473 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 60.8 m -77.39 140.42 39.91 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.43 -1.041 . . . . 1.0 109.028 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 84.5 m -66.87 123.09 19.2 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.414 -0.803 . . . . 1.0 109.647 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -96.51 147.78 23.49 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.439 -0.788 . . . . 1.0 109.162 179.653 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -161.72 135.12 6.38 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.384 -0.822 . . . . 1.0 109.486 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -133.17 38.24 3.34 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.515 -0.741 . . . . 1.0 109.471 179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 59.9 p -72.05 -58.7 3.22 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.48 -0.763 . . . . 1.0 109.541 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.0 t -110.07 138.12 39.26 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 O-C-N 121.429 -0.794 . . . . 1.0 109.408 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -83.62 178.03 8.15 Favored 'General case' 0 CA--C 1.53 0.19 0 O-C-N 121.496 -0.752 . . . . 1.0 109.247 179.808 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.56 -45.73 3.15 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 109.339 -1.504 . . . . 1.0 109.339 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.414 HG22 ' H ' ' A' ' 41' ' ' VAL . 26.7 m -84.43 157.33 61.84 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.647 -0.914 . . . . 1.0 109.325 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -59.63 129.24 30.06 Favored 'Trans proline' 0 N--CA 1.488 1.164 0 C-N-CA 124.164 3.243 . . . . 1.0 110.308 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' TRP . . . . . . . . . . . . . 40.4 m0 -87.27 -45.87 10.22 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.521 -0.737 . . . . 1.0 109.173 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 27.4 t -89.92 110.42 21.37 Favored 'General case' 0 CA--C 1.534 0.338 0 O-C-N 121.493 -0.755 . . . . 1.0 108.978 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.433 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 5.2 p90 -134.1 175.87 9.09 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 121.302 -0.874 . . . . 1.0 110.257 -179.371 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.41 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 21.5 m-85 -82.18 171.33 12.18 Favored Pre-proline 0 CA--C 1.537 0.47 0 O-C-N 121.523 -0.735 . . . . 1.0 109.522 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -90.84 -166.39 0.19 Allowed 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 124.939 3.759 . . . . 1.0 110.102 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.4 m120 . . . . . 0 N--CA 1.463 0.192 0 O-C-N 121.478 -0.763 . . . . 1.0 109.509 179.943 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.7 m . . . . . 0 CA--C 1.532 0.263 0 N-CA-C 109.763 -0.458 . . . . 1.0 109.763 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 90.5 m -89.62 -15.82 31.91 Favored 'General case' 0 CA--C 1.533 0.326 0 O-C-N 121.311 -0.868 . . . . 1.0 109.493 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.56 HG23 ' O ' ' A' ' 8' ' ' THR . 4.8 t -71.31 112.45 7.45 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.429 -0.795 . . . . 1.0 109.907 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.552 HG12 ' N ' ' A' ' 10' ' ' ALA . 42.0 t -127.87 167.33 23.08 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.264 0 N-CA-C 108.84 -0.8 . . . . 1.0 108.84 179.626 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.758 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -71.67 125.41 91.7 Favored Pre-proline 0 CA--C 1.542 0.644 0 O-C-N 121.36 -0.838 . . . . 1.0 109.118 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.425 ' HB3' HG11 ' A' ' 41' ' ' VAL . 18.7 Cg_exo -36.84 -50.36 1.43 Allowed 'Trans proline' 0 N--CA 1.489 1.263 0 C-N-CA 124.899 3.732 . . . . 1.0 111.209 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.401 ' H ' ' HG2' ' A' ' 12' ' ' ARG . 18.7 ptt180 -73.8 -38.86 64.48 Favored 'General case' 0 N--CA 1.463 0.195 0 O-C-N 121.487 -0.758 . . . . 1.0 109.763 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.758 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 20.3 mt-10 -92.29 43.03 1.12 Allowed 'General case' 0 CA--C 1.532 0.253 0 O-C-N 121.405 -0.81 . . . . 1.0 109.574 -179.689 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 15.0 mtt180 -105.71 131.98 52.4 Favored 'General case' 0 CA--C 1.531 0.235 0 O-C-N 121.405 -0.81 . . . . 1.0 109.437 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -79.57 107.64 12.5 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 108.557 -0.905 . . . . 1.0 108.557 179.456 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 29.5 t30 -61.98 108.54 1.06 Allowed 'General case' 0 N--CA 1.464 0.245 0 O-C-N 121.557 -0.714 . . . . 1.0 110.085 -179.336 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.461 ' H ' ' HA ' ' A' ' 45' ' ' PHE . 49.5 t -76.78 -21.75 54.71 Favored 'General case' 0 CA--C 1.533 0.318 0 O-C-N 121.5 -0.75 . . . . 1.0 109.229 179.426 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -175.46 179.56 46.6 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 109.145 -1.582 . . . . 1.0 109.145 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.528 ' CD2' HG13 ' A' ' 22' ' ' VAL . 8.9 p90 -64.81 167.49 9.13 Favored Pre-proline 0 CA--C 1.538 0.489 0 O-C-N 121.398 -1.06 . . . . 1.0 109.0 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -81.19 -30.93 1.42 Allowed 'Trans proline' 0 N--CA 1.482 0.806 0 C-N-CA 124.351 3.367 . . . . 1.0 110.715 -178.75 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.84 -8.41 7.89 Favored Glycine 0 CA--C 1.537 1.457 0 N-CA-C 110.305 -1.118 . . . . 1.0 110.305 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.528 HG13 ' CD2' ' A' ' 19' ' ' PHE . 25.7 m -60.62 -171.21 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 O-C-N 121.194 -1.18 . . . . 1.0 109.864 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.51 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 19.9 p -150.09 157.27 37.64 Favored Pre-proline 0 CA--C 1.534 0.361 0 N-CA-C 109.18 -0.674 . . . . 1.0 109.18 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_exo -34.91 -36.37 0.12 Allowed 'Trans proline' 0 N--CA 1.488 1.193 1 C-N-CA 125.599 4.199 . . . . 1.0 111.383 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.4 t -76.41 -47.21 23.93 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.434 -0.791 . . . . 1.0 109.865 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLN . . . . . 0.51 ' HB2' ' H ' ' A' ' 23' ' ' THR . 2.2 mm100 -60.93 -44.05 97.76 Favored 'General case' 0 N--CA 1.465 0.293 0 O-C-N 121.433 -0.792 . . . . 1.0 109.925 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 7.5 t -64.72 -33.4 75.87 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.443 -0.786 . . . . 1.0 109.346 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.48 -5.55 59.28 Favored 'General case' 0 CA--C 1.534 0.358 0 O-C-N 121.556 -0.715 . . . . 1.0 109.935 179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 12.2 t-20 -64.84 -32.6 74.37 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.32 -0.862 . . . . 1.0 109.618 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.3 mtmm -105.79 -39.52 6.02 Favored 'General case' 0 C--N 1.332 -0.183 0 O-C-N 121.456 -0.777 . . . . 1.0 109.403 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 125.6 27.55 1.16 Allowed Glycine 0 CA--C 1.53 1.012 0 N-CA-C 109.862 -1.295 . . . . 1.0 109.862 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.8 m -91.09 147.69 22.89 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.326 -1.103 . . . . 1.0 109.16 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.455 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 57.4 m -70.33 139.6 52.06 Favored 'General case' 0 CA--C 1.532 0.266 0 O-C-N 121.371 -0.831 . . . . 1.0 109.333 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -119.21 119.7 34.87 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.463 -0.773 . . . . 1.0 109.332 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -132.67 120.1 21.29 Favored 'General case' 0 CA--C 1.529 0.167 0 O-C-N 121.533 -0.729 . . . . 1.0 109.667 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.419 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.0 p-10 -116.32 77.27 1.08 Allowed 'General case' 0 N--CA 1.463 0.197 0 O-C-N 121.442 -0.786 . . . . 1.0 109.233 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 82.2 p -114.54 -38.37 4.05 Favored 'General case' 0 CA--C 1.53 0.183 0 O-C-N 121.446 -0.784 . . . . 1.0 109.543 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 38.3 t -117.36 148.51 20.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.205 0 O-C-N 121.442 -0.786 . . . . 1.0 109.411 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 22.5 mtp180 -94.65 -179.08 4.76 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.5 -0.75 . . . . 1.0 109.5 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.07 6.71 13.89 Favored Glycine 0 CA--C 1.532 1.149 0 N-CA-C 109.992 -1.243 . . . . 1.0 109.992 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.425 HG11 ' HB3' ' A' ' 11' ' ' PRO . 30.0 m -130.59 169.35 13.81 Favored Pre-proline 0 CA--C 1.536 0.415 0 O-C-N 121.359 -1.083 . . . . 1.0 109.203 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -87.74 130.03 2.63 Favored 'Trans proline' 0 N--CA 1.48 0.708 0 C-N-CA 124.693 3.595 . . . . 1.0 110.117 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.419 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.3 m0 -91.95 -47.83 7.09 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.505 -0.747 . . . . 1.0 109.733 -179.567 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 18.6 t -78.07 107.81 10.9 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 121.527 -0.733 . . . . 1.0 109.646 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.461 ' HA ' ' H ' ' A' ' 17' ' ' CYS . 3.3 p90 -139.42 -175.93 4.36 Favored 'General case' 0 N--CA 1.465 0.314 0 O-C-N 121.515 -0.74 . . . . 1.0 109.393 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -91.57 163.85 26.68 Favored Pre-proline 0 CA--C 1.537 0.477 0 O-C-N 121.411 -0.806 . . . . 1.0 110.029 -179.404 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -90.18 172.84 3.5 Favored 'Trans proline' 0 C--N 1.352 0.744 0 C-N-CA 124.97 3.78 . . . . 1.0 110.718 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 . . . . . 0 CA--C 1.531 0.217 0 O-C-N 121.433 -0.792 . . . . 1.0 109.412 179.944 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.4 m . . . . . 0 CA--C 1.53 0.176 0 CA-C-O 121.153 0.501 . . . . 1.0 110.161 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 96.2 m -108.54 -18.14 13.8 Favored 'General case' 0 CA--C 1.536 0.408 0 O-C-N 121.503 -0.748 . . . . 1.0 109.184 179.136 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.596 HG23 ' O ' ' A' ' 8' ' ' THR . 5.2 t -70.15 108.35 4.09 Favored 'General case' 0 CA--C 1.533 0.297 0 O-C-N 121.106 -0.996 . . . . 1.0 109.329 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.632 HG12 ' N ' ' A' ' 10' ' ' ALA . 26.7 t -132.99 173.46 14.8 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.248 0 O-C-N 121.334 -0.854 . . . . 1.0 109.323 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.632 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -69.14 122.81 86.62 Favored Pre-proline 0 CA--C 1.539 0.542 0 O-C-N 121.461 -0.774 . . . . 1.0 109.235 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.559 ' HB3' HG11 ' A' ' 41' ' ' VAL . 18.3 Cg_exo -37.62 -33.92 0.24 Allowed 'Trans proline' 0 N--CA 1.488 1.198 0 C-N-CA 124.774 3.65 . . . . 1.0 111.229 -179.799 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 15.2 ptt180 -78.55 -46.88 18.42 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.469 -0.769 . . . . 1.0 109.766 -179.703 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 21.0 mm-40 -82.73 40.97 0.7 Allowed 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.405 -0.809 . . . . 1.0 109.434 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 54.0 mtt180 -104.1 142.95 33.57 Favored 'General case' 0 C--N 1.331 -0.214 0 O-C-N 121.526 -0.734 . . . . 1.0 109.569 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 12.2 mm100 -92.59 111.33 22.88 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.426 -0.796 . . . . 1.0 109.195 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -60.33 110.34 1.22 Allowed 'General case' 0 CA--C 1.533 0.303 0 O-C-N 121.362 -0.836 . . . . 1.0 110.121 -179.704 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.4 t -86.65 -16.4 36.74 Favored 'General case' 0 CA--C 1.533 0.323 0 O-C-N 121.485 -0.76 . . . . 1.0 109.442 179.763 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.64 179.28 44.19 Favored Glycine 0 CA--C 1.531 1.075 0 N-CA-C 109.506 -1.438 . . . . 1.0 109.506 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.592 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.6 p90 -65.13 168.0 8.56 Favored Pre-proline 0 CA--C 1.538 0.492 0 O-C-N 121.468 -1.019 . . . . 1.0 109.018 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.43 -30.98 1.32 Allowed 'Trans proline' 0 N--CA 1.484 0.918 0 C-N-CA 124.4 3.4 . . . . 1.0 110.671 -178.714 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.42 -10.28 7.51 Favored Glycine 0 CA--C 1.537 1.41 0 N-CA-C 110.356 -1.098 . . . . 1.0 110.356 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.592 HG22 ' O ' ' A' ' 19' ' ' PHE . 18.0 m -60.74 169.71 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 O-C-N 121.205 -1.174 . . . . 1.0 109.611 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 29.2 p -128.35 155.45 78.45 Favored Pre-proline 0 CA--C 1.535 0.387 0 O-C-N 121.517 -0.739 . . . . 1.0 109.38 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_exo -36.33 -37.35 0.26 Allowed 'Trans proline' 0 N--CA 1.489 1.237 1 C-N-CA 125.341 4.027 . . . . 1.0 111.186 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 4.5 m -69.91 -47.38 62.69 Favored 'General case' 0 N--CA 1.463 0.206 0 O-C-N 121.351 -0.843 . . . . 1.0 109.79 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 7.5 mm100 -61.49 -49.88 75.0 Favored 'General case' 0 CA--C 1.533 0.302 0 O-C-N 121.41 -0.806 . . . . 1.0 109.842 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.8 t -64.97 -27.49 68.87 Favored 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.431 -0.793 . . . . 1.0 109.439 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.29 -8.91 57.38 Favored 'General case' 0 CA--C 1.534 0.344 0 O-C-N 121.5 -0.75 . . . . 1.0 109.821 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -91.38 -28.0 17.98 Favored 'General case' 0 CA--C 1.529 0.14 0 O-C-N 121.37 -0.831 . . . . 1.0 109.405 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -89.65 -29.15 19.0 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.471 -0.768 . . . . 1.0 109.441 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.04 45.64 2.02 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 109.771 -1.332 . . . . 1.0 109.771 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 2.0 m -121.42 142.95 49.52 Favored 'General case' 0 N--CA 1.465 0.29 0 O-C-N 121.496 -1.002 . . . . 1.0 109.303 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 46.8 m -63.32 113.66 3.35 Favored 'General case' 0 N--CA 1.466 0.332 0 O-C-N 121.4 -0.812 . . . . 1.0 109.39 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 48.7 t80 -90.36 137.19 32.55 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.43 -0.794 . . . . 1.0 109.126 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -151.02 106.86 3.41 Favored 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.47 -0.769 . . . . 1.0 109.676 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.435 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 2.1 p30 -107.09 48.55 0.83 Allowed 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.491 -0.756 . . . . 1.0 109.245 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 16.8 p -81.34 -52.28 7.46 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.519 -0.738 . . . . 1.0 109.361 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.8 t -114.14 145.39 20.03 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 O-C-N 121.589 -0.694 . . . . 1.0 109.383 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -88.35 179.66 6.29 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.539 -0.726 . . . . 1.0 109.449 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.45 -49.91 4.12 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 109.278 -1.529 . . . . 1.0 109.278 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.559 HG11 ' HB3' ' A' ' 11' ' ' PRO . 27.6 m -79.79 171.16 13.15 Favored Pre-proline 0 CA--C 1.538 0.502 0 O-C-N 121.588 -0.948 . . . . 1.0 109.041 179.632 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' PRO . . . . . 0.409 ' CD ' ' HB ' ' A' ' 41' ' ' VAL . 11.2 Cg_endo -84.17 127.41 3.99 Favored 'Trans proline' 0 N--CA 1.48 0.724 0 C-N-CA 124.383 3.389 . . . . 1.0 110.003 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.435 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 11.0 m0 -82.83 -39.85 21.12 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.594 -0.691 . . . . 1.0 110.104 -179.129 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.5 t -89.46 108.38 19.61 Favored 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.325 -0.859 . . . . 1.0 109.597 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.426 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 15.0 p90 -135.92 175.9 9.17 Favored 'General case' 0 CA--C 1.538 0.496 0 O-C-N 121.438 -0.789 . . . . 1.0 109.58 179.647 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.426 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 37.5 m-85 -84.61 166.99 29.45 Favored Pre-proline 0 CA--C 1.536 0.422 0 O-C-N 121.274 -0.891 . . . . 1.0 110.061 -179.539 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -88.92 159.7 6.01 Favored 'Trans proline' 0 C--N 1.353 0.779 0 C-N-CA 124.868 3.712 . . . . 1.0 110.538 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 19.9 m120 . . . . . 0 CA--C 1.531 0.242 0 O-C-N 121.525 -0.734 . . . . 1.0 109.406 -179.883 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.774 HG22 HG22 ' A' ' 8' ' ' THR . 1.5 m . . . . . 0 CA--C 1.531 0.219 0 CA-C-O 121.184 0.516 . . . . 1.0 110.016 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 98.6 m -104.02 45.33 0.97 Allowed 'General case' 0 CA--C 1.534 0.358 0 O-C-N 121.429 -0.794 . . . . 1.0 108.934 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.774 HG22 HG22 ' A' ' 6' ' ' THR . 5.8 t -110.83 108.98 18.99 Favored 'General case' 0 CA--C 1.532 0.262 0 O-C-N 121.19 -0.944 . . . . 1.0 109.877 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.46 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.5 t -135.39 160.9 40.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 O-C-N 121.441 -0.787 . . . . 1.0 109.114 179.802 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.46 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -79.55 115.59 54.54 Favored Pre-proline 0 CA--C 1.541 0.606 0 O-C-N 121.434 -0.791 . . . . 1.0 109.382 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -38.23 -28.79 0.13 Allowed 'Trans proline' 0 N--CA 1.49 1.277 0 C-N-CA 124.664 3.576 . . . . 1.0 111.108 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 -66.94 -64.92 0.75 Allowed 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.489 -0.757 . . . . 1.0 109.691 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -90.56 44.4 1.2 Allowed 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.499 -0.751 . . . . 1.0 109.542 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 21.7 mtt180 -86.11 143.16 28.19 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.476 -0.765 . . . . 1.0 109.516 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -92.87 108.1 19.73 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 109.021 -0.733 . . . . 1.0 109.021 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -62.49 122.59 16.15 Favored 'General case' 0 CA--C 1.532 0.278 0 O-C-N 121.517 -0.739 . . . . 1.0 109.984 -179.709 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 t -88.94 -13.33 39.25 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 109.06 -0.718 . . . . 1.0 109.06 179.434 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 177.28 177.54 46.25 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 108.645 -1.782 . . . . 1.0 108.645 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.6 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.2 p90 -64.35 167.62 8.08 Favored Pre-proline 0 CA--C 1.54 0.585 0 O-C-N 121.24 -1.153 . . . . 1.0 109.064 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -81.22 -30.38 1.62 Allowed 'Trans proline' 0 N--CA 1.483 0.858 0 C-N-CA 124.347 3.365 . . . . 1.0 110.84 -178.684 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.92 -10.16 8.28 Favored Glycine 0 CA--C 1.537 1.423 0 N-CA-C 110.192 -1.163 . . . . 1.0 110.192 179.528 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.6 HG22 ' O ' ' A' ' 19' ' ' PHE . 23.6 m -62.01 169.14 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 O-C-N 121.257 -1.143 . . . . 1.0 109.727 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 71.8 p -127.41 157.52 72.52 Favored Pre-proline 0 CA--C 1.534 0.361 0 N-CA-C 108.702 -0.851 . . . . 1.0 108.702 179.553 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -34.88 -36.12 0.12 Allowed 'Trans proline' 0 N--CA 1.489 1.255 1 C-N-CA 125.364 4.043 . . . . 1.0 111.315 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.7 p -72.83 -48.37 38.3 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.469 -0.769 . . . . 1.0 109.931 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 53.1 mt-30 -65.17 -44.01 89.89 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.542 -0.724 . . . . 1.0 110.07 -179.634 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 9.1 t -61.3 -31.85 71.7 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 121.303 -0.873 . . . . 1.0 109.855 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.19 -1.5 48.17 Favored 'General case' 0 CA--C 1.535 0.373 0 O-C-N 121.433 -0.792 . . . . 1.0 110.137 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -69.95 -28.49 65.61 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 121.349 -0.845 . . . . 1.0 110.255 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.29 -36.9 5.68 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 121.249 -0.907 . . . . 1.0 109.857 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 126.76 55.71 0.14 Allowed Glycine 0 CA--C 1.531 1.057 0 N-CA-C 109.959 -1.256 . . . . 1.0 109.959 179.826 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 36.9 m -120.98 137.3 54.7 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.398 -1.06 . . . . 1.0 108.725 179.701 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 53.0 m -69.42 122.75 19.58 Favored 'General case' 0 N--CA 1.466 0.374 0 O-C-N 121.326 -0.859 . . . . 1.0 109.418 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 34.9 t80 -93.48 140.1 29.97 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.493 -0.754 . . . . 1.0 109.002 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -152.76 112.4 3.91 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.379 -0.825 . . . . 1.0 109.737 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.44 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 11.5 p30 -113.76 76.12 0.96 Allowed 'General case' 0 N--CA 1.464 0.253 0 O-C-N 121.474 -0.766 . . . . 1.0 109.446 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.8 p -115.39 -29.95 6.39 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.507 -0.746 . . . . 1.0 109.635 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.4 t -124.44 154.43 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 O-C-N 121.503 -0.748 . . . . 1.0 109.501 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 41.8 mtm-85 -99.29 178.95 4.74 Favored 'General case' 0 CA--C 1.53 0.184 0 O-C-N 121.532 -0.73 . . . . 1.0 109.357 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 62.14 11.21 31.41 Favored Glycine 0 CA--C 1.533 1.206 0 N-CA-C 109.919 -1.272 . . . . 1.0 109.919 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.9 m -134.64 169.27 14.3 Favored Pre-proline 0 CA--C 1.535 0.404 0 O-C-N 121.357 -1.084 . . . . 1.0 109.182 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -87.64 122.44 1.69 Allowed 'Trans proline' 0 C--N 1.351 0.692 0 C-N-CA 124.825 3.683 . . . . 1.0 110.213 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.44 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.7 m0 -82.71 -32.68 27.89 Favored 'General case' 0 N--CA 1.463 0.216 0 O-C-N 121.478 -0.764 . . . . 1.0 109.44 -179.618 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 11.0 t -89.36 107.97 19.37 Favored 'General case' 0 CA--C 1.535 0.372 0 O-C-N 121.532 -0.73 . . . . 1.0 109.207 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.413 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 4.7 p90 -137.4 -179.32 5.66 Favored 'General case' 0 CA--C 1.539 0.524 0 O-C-N 121.263 -0.898 . . . . 1.0 110.33 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.409 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 10.5 m-85 -84.41 169.32 17.11 Favored Pre-proline 0 CA--C 1.539 0.524 0 O-C-N 121.519 -0.738 . . . . 1.0 110.097 -179.539 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_endo -90.89 170.23 3.46 Favored 'Trans proline' 0 C--N 1.353 0.767 0 C-N-CA 125.204 3.936 . . . . 1.0 110.888 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.6 m120 . . . . . 0 CA--C 1.531 0.249 0 N-CA-C 108.445 -0.946 . . . . 1.0 108.445 179.224 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.688 HG22 HG22 ' A' ' 8' ' ' THR . 1.2 m . . . . . 0 CA--C 1.53 0.185 0 CA-C-O 121.283 0.563 . . . . 1.0 109.485 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.434 ' O ' ' CE2' ' A' ' 45' ' ' PHE . 11.2 m -111.05 -24.57 10.26 Favored 'General case' 0 C--N 1.332 -0.16 0 O-C-N 121.544 -0.723 . . . . 1.0 109.449 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.688 HG22 HG22 ' A' ' 6' ' ' THR . 3.9 t -68.9 146.31 52.92 Favored 'General case' 0 N--CA 1.464 0.24 0 O-C-N 121.475 -0.766 . . . . 1.0 110.739 -178.745 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.738 HG12 ' H ' ' A' ' 10' ' ' ALA . 25.2 t -140.32 178.9 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 108.308 -0.997 . . . . 1.0 108.308 179.616 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.738 ' H ' HG12 ' A' ' 9' ' ' VAL . . . -61.95 110.54 3.32 Favored Pre-proline 0 CA--C 1.541 0.603 0 O-C-N 121.216 -0.927 . . . . 1.0 109.717 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -39.75 -31.32 0.43 Allowed 'Trans proline' 0 N--CA 1.489 1.222 0 C-N-CA 124.607 3.538 . . . . 1.0 111.194 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 8.7 mtt-85 -84.19 -39.61 19.16 Favored 'General case' 0 N--CA 1.464 0.273 0 O-C-N 121.39 -0.819 . . . . 1.0 109.979 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -103.58 50.82 0.8 Allowed 'General case' 0 CA--C 1.532 0.282 0 O-C-N 121.385 -0.822 . . . . 1.0 109.348 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 50.0 mtt180 -91.35 136.39 33.14 Favored 'General case' 0 N--CA 1.464 0.239 0 O-C-N 121.457 -0.777 . . . . 1.0 109.726 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -79.92 104.21 10.34 Favored 'General case' 0 CA--C 1.53 0.182 0 O-C-N 121.586 -0.696 . . . . 1.0 109.249 179.724 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 11.5 t-20 -62.84 116.5 5.31 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.48 -0.763 . . . . 1.0 109.899 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.0 t -92.55 -9.97 39.29 Favored 'General case' 0 CA--C 1.536 0.422 0 O-C-N 121.555 -0.716 . . . . 1.0 109.521 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.91 173.57 33.69 Favored Glycine 0 CA--C 1.529 0.957 0 N-CA-C 109.206 -1.557 . . . . 1.0 109.206 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.557 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.9 p90 -65.51 167.74 9.99 Favored Pre-proline 0 CA--C 1.539 0.544 0 O-C-N 121.43 -1.041 . . . . 1.0 108.971 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.67 -30.37 1.45 Allowed 'Trans proline' 0 N--CA 1.484 0.922 0 C-N-CA 124.305 3.337 . . . . 1.0 110.832 -178.774 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.29 -10.71 7.83 Favored Glycine 0 CA--C 1.537 1.441 0 N-CA-C 110.324 -1.11 . . . . 1.0 110.324 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.557 HG22 ' O ' ' A' ' 19' ' ' PHE . 20.3 m -60.54 -171.94 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 O-C-N 121.294 -1.121 . . . . 1.0 109.723 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -146.63 157.25 48.2 Favored Pre-proline 0 CA--C 1.535 0.379 0 O-C-N 121.584 -0.697 . . . . 1.0 109.25 179.809 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -34.71 -31.93 0.07 OUTLIER 'Trans proline' 0 N--CA 1.489 1.207 1 C-N-CA 125.588 4.192 . . . . 1.0 111.36 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 76.8 p -75.3 -50.22 16.71 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.475 -0.766 . . . . 1.0 109.872 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 38.0 mt-30 -61.57 -48.02 82.88 Favored 'General case' 0 N--CA 1.465 0.291 0 O-C-N 121.44 -0.788 . . . . 1.0 109.811 -179.86 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.9 t -64.69 -28.4 69.57 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.392 -0.818 . . . . 1.0 109.558 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -87.95 -4.96 58.77 Favored 'General case' 0 CA--C 1.534 0.353 0 O-C-N 121.57 -0.706 . . . . 1.0 110.012 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -75.01 -30.1 61.03 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.318 -0.864 . . . . 1.0 109.73 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.5 mmtp -102.82 -40.43 6.56 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.453 -0.779 . . . . 1.0 109.466 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 118.23 39.27 0.75 Allowed Glycine 0 CA--C 1.529 0.944 0 N-CA-C 109.419 -1.472 . . . . 1.0 109.419 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 48.7 m -101.94 139.7 37.22 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.567 -0.96 . . . . 1.0 109.189 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 84.6 m -65.37 116.51 6.76 Favored 'General case' 0 N--CA 1.464 0.255 0 O-C-N 121.523 -0.736 . . . . 1.0 109.927 -179.374 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 34.2 t80 -92.74 121.14 33.84 Favored 'General case' 0 C--N 1.333 -0.141 0 N-CA-C 109.042 -0.725 . . . . 1.0 109.042 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 26.8 t0 -134.15 118.48 17.72 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.391 -0.818 . . . . 1.0 109.518 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.441 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 7.0 p-10 -110.91 64.55 0.61 Allowed 'General case' 0 CA--C 1.533 0.298 0 O-C-N 121.526 -0.734 . . . . 1.0 109.236 179.866 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 27.0 p -114.26 -49.71 2.83 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.392 -0.817 . . . . 1.0 109.489 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.3 t -100.22 133.6 42.69 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 O-C-N 121.404 -0.81 . . . . 1.0 109.507 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.404 ' HG3' ' H ' ' A' ' 40' ' ' GLY . 2.3 tpt180 -85.13 176.17 8.55 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.571 -0.706 . . . . 1.0 109.553 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.404 ' H ' ' HG3' ' A' ' 39' ' ' ARG . . . 80.89 -48.43 3.74 Favored Glycine 0 CA--C 1.529 0.908 0 N-CA-C 109.447 -1.461 . . . . 1.0 109.447 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.3 m -81.4 169.75 17.86 Favored Pre-proline 0 CA--C 1.536 0.437 0 O-C-N 121.511 -0.993 . . . . 1.0 109.215 179.806 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -86.55 124.37 2.3 Favored 'Trans proline' 0 C--N 1.35 0.628 0 C-N-CA 124.757 3.638 . . . . 1.0 110.157 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.441 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 16.9 m0 -67.28 -37.61 83.7 Favored 'General case' 0 CA--C 1.53 0.192 0 O-C-N 121.554 -0.716 . . . . 1.0 109.522 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 11.1 t -87.86 109.25 19.62 Favored 'General case' 0 C--O 1.233 0.195 0 O-C-N 121.399 -0.813 . . . . 1.0 108.961 179.486 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.434 ' CE2' ' O ' ' A' ' 7' ' ' CYS . 1.3 p90 -149.3 178.44 8.76 Favored 'General case' 0 CA--C 1.537 0.454 0 O-C-N 121.454 -0.779 . . . . 1.0 109.832 -179.512 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 29.8 m-85 -83.78 170.28 14.59 Favored Pre-proline 0 CA--C 1.538 0.498 0 O-C-N 121.485 -0.759 . . . . 1.0 109.942 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -93.83 -168.32 0.18 Allowed 'Trans proline' 0 C--N 1.35 0.641 1 C-N-CA 125.357 4.038 . . . . 1.0 111.39 -179.45 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.5 m120 . . . . . 0 C--N 1.33 -0.241 0 N-CA-C 107.902 -1.148 . . . . 1.0 107.902 179.364 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.069 HG22 HG22 ' A' ' 8' ' ' THR . 0.6 OUTLIER . . . . . 0 CA--C 1.53 0.208 0 CA-C-O 121.139 0.495 . . . . 1.0 109.733 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 80.6 m -97.31 45.84 1.04 Allowed 'General case' 0 CA--C 1.532 0.287 0 O-C-N 121.51 -0.743 . . . . 1.0 108.998 179.445 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' THR . . . . . 1.069 HG22 HG22 ' A' ' 6' ' ' THR . 4.6 t -123.79 83.5 2.15 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.178 -0.951 . . . . 1.0 109.848 -179.616 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.619 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.2 t -109.5 172.03 2.46 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 N-CA-C 108.85 -0.796 . . . . 1.0 108.85 179.449 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.619 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -73.15 131.76 83.04 Favored Pre-proline 0 CA--C 1.541 0.597 0 O-C-N 121.323 -0.861 . . . . 1.0 109.272 -179.781 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -36.87 -38.75 0.39 Allowed 'Trans proline' 0 N--CA 1.488 1.156 0 C-N-CA 125.103 3.869 . . . . 1.0 111.351 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.7 mpp_? -82.01 -40.28 22.34 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 121.433 -0.792 . . . . 1.0 109.944 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.548 ' O ' HG11 ' A' ' 9' ' ' VAL . 29.6 mt-10 -86.24 42.68 1.01 Allowed 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.277 -0.89 . . . . 1.0 109.671 -179.657 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 37.9 mtt180 -101.51 151.34 22.08 Favored 'General case' 0 N--CA 1.464 0.232 0 O-C-N 121.409 -0.807 . . . . 1.0 109.627 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -104.68 105.6 15.76 Favored 'General case' 0 N--CA 1.462 0.172 0 O-C-N 121.345 -0.847 . . . . 1.0 109.06 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 61.5 t30 -57.32 118.69 5.38 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 121.235 -0.916 . . . . 1.0 110.305 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -94.13 -18.85 21.35 Favored 'General case' 0 CA--C 1.534 0.348 0 O-C-N 121.515 -0.741 . . . . 1.0 109.345 179.672 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -171.88 176.82 44.9 Favored Glycine 0 CA--C 1.53 1.017 0 N-CA-C 109.059 -1.616 . . . . 1.0 109.059 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.58 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.3 p90 -66.12 167.16 12.91 Favored Pre-proline 0 CA--C 1.539 0.526 0 O-C-N 121.374 -1.074 . . . . 1.0 108.815 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.97 -30.16 1.41 Allowed 'Trans proline' 0 N--CA 1.482 0.828 0 C-N-CA 124.537 3.491 . . . . 1.0 110.906 -178.604 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -57.8 -11.86 9.12 Favored Glycine 0 CA--C 1.536 1.39 0 N-CA-C 110.323 -1.111 . . . . 1.0 110.323 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.58 HG22 ' O ' ' A' ' 19' ' ' PHE . 20.9 m -61.06 -172.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 O-C-N 121.302 -1.116 . . . . 1.0 109.932 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.557 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 59.9 p -145.15 157.64 53.21 Favored Pre-proline 0 CA--C 1.535 0.37 0 N-CA-C 108.913 -0.773 . . . . 1.0 108.913 179.709 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -35.07 -39.75 0.22 Allowed 'Trans proline' 0 N--CA 1.489 1.212 1 C-N-CA 125.484 4.123 . . . . 1.0 111.378 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.1 p -74.08 -46.63 41.77 Favored 'General case' 0 CA--C 1.532 0.288 0 O-C-N 121.462 -0.774 . . . . 1.0 109.903 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLN . . . . . 0.557 ' HB2' ' H ' ' A' ' 23' ' ' THR . 32.4 mt-30 -61.26 -53.07 61.49 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 121.447 -0.783 . . . . 1.0 109.975 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 23.1 t -61.66 -26.41 68.0 Favored 'General case' 0 CA--C 1.533 0.322 0 O-C-N 121.298 -0.877 . . . . 1.0 109.719 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -90.01 -6.69 55.33 Favored 'General case' 0 CA--C 1.535 0.386 0 O-C-N 121.504 -0.748 . . . . 1.0 110.08 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 15.5 t-20 -78.96 -45.38 20.49 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.29 -0.882 . . . . 1.0 109.535 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.1 mtmm -72.36 -45.85 58.03 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.483 -0.761 . . . . 1.0 109.526 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 125.26 27.03 1.25 Allowed Glycine 0 CA--C 1.529 0.939 0 N-CA-C 109.197 -1.561 . . . . 1.0 109.197 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 26.4 m -99.52 145.29 27.65 Favored 'General case' 0 CA--C 1.532 0.276 0 O-C-N 121.685 -0.891 . . . . 1.0 108.696 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 35.9 m -68.58 128.92 38.35 Favored 'General case' 0 N--CA 1.465 0.321 0 O-C-N 121.307 -0.871 . . . . 1.0 109.42 -179.682 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -97.82 138.09 35.69 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.511 -0.743 . . . . 1.0 109.067 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 13.6 t0 -157.63 89.25 1.02 Allowed 'General case' 0 N--CA 1.463 0.183 0 O-C-N 121.521 -0.737 . . . . 1.0 109.512 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.424 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 38.2 p-10 -103.05 78.68 1.67 Allowed 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.539 -0.725 . . . . 1.0 109.472 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 76.6 p -113.85 -23.15 9.79 Favored 'General case' 0 CA--C 1.534 0.334 0 O-C-N 121.383 -0.823 . . . . 1.0 109.709 -179.801 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.537 HG12 ' N ' ' A' ' 39' ' ' ARG . 33.8 t -127.6 165.54 26.35 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 O-C-N 121.451 -0.78 . . . . 1.0 109.645 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.537 ' N ' HG12 ' A' ' 38' ' ' VAL . 0.0 OUTLIER -107.03 175.05 5.63 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 109.097 -0.705 . . . . 1.0 109.097 179.812 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.436 ' H ' ' CD ' ' A' ' 39' ' ' ARG . . . 72.17 -8.07 7.13 Favored Glycine 0 CA--C 1.533 1.173 0 N-CA-C 109.954 -1.258 . . . . 1.0 109.954 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.9 m -121.52 170.08 8.12 Favored Pre-proline 0 CA--C 1.537 0.461 0 O-C-N 121.317 -1.108 . . . . 1.0 109.051 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -86.53 127.75 2.85 Favored 'Trans proline' 0 N--CA 1.48 0.694 0 C-N-CA 124.585 3.523 . . . . 1.0 110.209 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.424 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.4 m0 -82.49 -39.36 22.57 Favored 'General case' 0 N--CA 1.464 0.264 0 O-C-N 121.586 -0.696 . . . . 1.0 109.28 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.1 t -88.14 117.49 27.06 Favored 'General case' 0 N--CA 1.466 0.329 0 O-C-N 121.508 -0.745 . . . . 1.0 109.113 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.419 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 5.2 p90 -145.18 173.14 12.19 Favored 'General case' 0 CA--C 1.537 0.463 0 O-C-N 121.328 -0.857 . . . . 1.0 110.34 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.408 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 14.3 m-85 -79.53 172.78 9.0 Favored Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 121.473 -0.767 . . . . 1.0 109.496 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo -90.37 160.53 4.54 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 125.087 3.858 . . . . 1.0 110.252 179.672 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.529 ' ND2' HG21 ' A' ' 9' ' ' VAL . 8.2 m-20 . . . . . 0 CA--C 1.53 0.195 0 O-C-N 121.485 -0.759 . . . . 1.0 109.492 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.447 HG22 HG22 ' A' ' 8' ' ' THR . 1.1 m . . . . . 0 CA--C 1.532 0.256 0 N-CA-C 109.502 -0.555 . . . . 1.0 109.502 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 63.9 m -105.61 -20.56 13.43 Favored 'General case' 0 CA--C 1.533 0.316 0 O-C-N 121.601 -0.687 . . . . 1.0 109.478 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.576 HG23 ' O ' ' A' ' 8' ' ' THR . 3.8 t -70.05 104.78 2.66 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.322 -0.861 . . . . 1.0 109.538 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.613 HG12 ' N ' ' A' ' 10' ' ' ALA . 36.2 t -131.66 170.66 19.39 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 O-C-N 121.607 -0.683 . . . . 1.0 109.186 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.613 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -65.77 126.52 91.86 Favored Pre-proline 0 CA--C 1.539 0.535 0 O-C-N 121.448 -0.782 . . . . 1.0 109.22 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_exo -37.74 -40.02 0.88 Allowed 'Trans proline' 0 N--CA 1.49 1.268 0 C-N-CA 124.926 3.751 . . . . 1.0 111.126 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.9 mtm-85 -76.6 -41.73 45.08 Favored 'General case' 0 CA--C 1.532 0.254 0 O-C-N 121.4 -0.812 . . . . 1.0 109.886 -179.425 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -81.88 40.52 0.61 Allowed 'General case' 0 C--N 1.331 -0.213 0 O-C-N 121.451 -0.78 . . . . 1.0 109.561 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 55.3 mtt180 -108.09 133.49 52.31 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.47 -0.769 . . . . 1.0 109.556 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 22.6 mm-40 -90.65 117.71 29.52 Favored 'General case' 0 N--CA 1.464 0.227 0 O-C-N 121.438 -0.789 . . . . 1.0 109.367 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -61.31 115.36 3.78 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.453 -0.779 . . . . 1.0 109.992 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.4 t -93.47 -20.39 20.33 Favored 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.605 -0.685 . . . . 1.0 109.324 179.614 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.52 170.58 37.19 Favored Glycine 0 CA--C 1.529 0.958 0 N-CA-C 109.494 -1.442 . . . . 1.0 109.494 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.73 ' O ' HG22 ' A' ' 22' ' ' VAL . 19.8 p90 -64.85 148.77 97.14 Favored Pre-proline 0 CA--C 1.538 0.505 0 O-C-N 121.435 -1.038 . . . . 1.0 109.263 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -65.43 -28.69 54.07 Favored 'Trans proline' 0 N--CA 1.489 1.232 0 C-N-CA 124.053 3.169 . . . . 1.0 110.704 -178.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -55.04 -15.62 7.1 Favored Glycine 0 CA--C 1.536 1.355 0 N-CA-C 110.649 -0.981 . . . . 1.0 110.649 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.73 HG22 ' O ' ' A' ' 19' ' ' PHE . 30.2 m -64.01 178.26 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 O-C-N 121.389 -1.065 . . . . 1.0 109.505 179.816 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.1 p -132.03 156.4 80.15 Favored Pre-proline 0 CA--C 1.536 0.427 0 O-C-N 121.543 -0.723 . . . . 1.0 109.313 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -34.49 -33.03 0.07 OUTLIER 'Trans proline' 0 N--CA 1.489 1.206 1 C-N-CA 125.587 4.192 . . . . 1.0 111.293 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 2.6 m -71.83 -49.96 33.83 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.472 -0.767 . . . . 1.0 109.962 -179.554 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 13.2 mm-40 -63.39 -49.93 71.89 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.403 -0.81 . . . . 1.0 109.73 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.6 t -63.16 -21.34 66.14 Favored 'General case' 0 CA--C 1.533 0.306 0 O-C-N 121.518 -0.739 . . . . 1.0 109.829 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.0 -11.06 27.06 Favored 'General case' 0 CA--C 1.535 0.399 0 O-C-N 121.416 -0.802 . . . . 1.0 109.916 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -71.38 -35.96 71.27 Favored 'General case' 0 N--CA 1.463 0.205 0 O-C-N 121.331 -0.856 . . . . 1.0 109.56 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.8 tttp -92.07 -42.68 9.82 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.44 -0.787 . . . . 1.0 109.447 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 122.33 38.05 0.61 Allowed Glycine 0 CA--C 1.528 0.849 0 N-CA-C 109.526 -1.43 . . . . 1.0 109.526 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.8 m -105.59 145.34 31.12 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.493 -1.004 . . . . 1.0 109.114 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 61.4 m -68.5 127.48 33.14 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.557 -0.714 . . . . 1.0 109.54 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 51.1 t80 -104.12 109.39 21.16 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 121.507 -0.746 . . . . 1.0 109.25 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -120.81 102.98 8.74 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.575 -0.703 . . . . 1.0 109.564 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.443 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.8 p-10 -108.08 59.49 0.61 Allowed 'General case' 0 CA--C 1.532 0.267 0 O-C-N 121.527 -0.733 . . . . 1.0 109.291 179.742 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.5 p -112.28 -42.1 3.78 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.364 -0.835 . . . . 1.0 109.454 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.2 t -96.71 155.09 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 O-C-N 121.481 -0.762 . . . . 1.0 109.483 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -108.03 165.05 11.75 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.529 -0.732 . . . . 1.0 109.449 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.4 -32.6 2.82 Favored Glycine 0 CA--C 1.53 1.009 0 N-CA-C 109.096 -1.602 . . . . 1.0 109.096 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.423 ' H ' HG22 ' A' ' 41' ' ' VAL . 26.8 m -91.34 171.85 7.45 Favored Pre-proline 0 CA--C 1.538 0.502 0 O-C-N 121.619 -0.93 . . . . 1.0 109.041 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' PRO . . . . . 0.413 ' CD ' ' HB ' ' A' ' 41' ' ' VAL . 11.4 Cg_endo -85.97 138.68 6.01 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 124.411 3.407 . . . . 1.0 109.706 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.443 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 30.6 m0 -87.36 -46.06 10.0 Favored 'General case' 0 CA--C 1.531 0.239 0 O-C-N 121.481 -0.762 . . . . 1.0 110.466 -179.004 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 14.9 t -89.04 109.51 20.34 Favored 'General case' 0 CA--C 1.532 0.276 0 O-C-N 121.242 -0.911 . . . . 1.0 109.953 -179.503 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.415 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 5.6 p90 -137.38 -178.97 5.46 Favored 'General case' 0 CA--C 1.537 0.474 0 O-C-N 121.387 -0.821 . . . . 1.0 109.448 179.365 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.415 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 43.9 m-85 -90.48 165.27 23.74 Favored Pre-proline 0 CA--C 1.536 0.422 0 O-C-N 121.328 -0.857 . . . . 1.0 109.512 -179.798 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -90.86 175.59 2.49 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 124.95 3.767 . . . . 1.0 110.502 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 26.2 m120 . . . . . 0 CA--C 1.529 0.165 0 N-CA-C 109.291 -0.633 . . . . 1.0 109.291 179.866 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.703 HG22 ' O ' ' A' ' 48' ' ' ASN . 4.7 t . . . . . 0 CA--C 1.532 0.265 0 N-CA-C 109.316 -0.624 . . . . 1.0 109.316 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 72.2 m -108.43 -20.97 12.94 Favored 'General case' 0 CA--C 1.534 0.345 0 O-C-N 121.46 -0.775 . . . . 1.0 109.644 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.57 HG23 ' O ' ' A' ' 8' ' ' THR . 3.5 t -70.03 102.98 2.15 Favored 'General case' 0 CA--C 1.53 0.211 0 O-C-N 121.489 -0.757 . . . . 1.0 109.892 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.617 HG12 ' N ' ' A' ' 10' ' ' ALA . 40.0 t -114.53 171.44 4.32 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 O-C-N 121.346 -0.846 . . . . 1.0 108.936 179.488 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.617 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -78.39 119.5 77.54 Favored Pre-proline 0 CA--C 1.541 0.622 0 O-C-N 121.417 -0.802 . . . . 1.0 109.542 -179.608 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.642 ' HB3' HG11 ' A' ' 41' ' ' VAL . 18.8 Cg_exo -37.93 -38.84 0.77 Allowed 'Trans proline' 0 N--CA 1.489 1.258 0 C-N-CA 124.757 3.638 . . . . 1.0 111.205 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 18.6 mmm-85 -77.01 -42.65 37.76 Favored 'General case' 0 N--CA 1.464 0.237 0 O-C-N 121.494 -0.754 . . . . 1.0 109.889 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -102.53 50.03 0.83 Allowed 'General case' 0 CA--C 1.532 0.286 0 O-C-N 121.375 -0.828 . . . . 1.0 109.508 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 26.7 mtt180 -94.04 147.77 22.81 Favored 'General case' 0 N--CA 1.463 0.223 0 O-C-N 121.379 -0.826 . . . . 1.0 109.704 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 54.1 mm-40 -91.6 107.26 19.09 Favored 'General case' 0 CA--C 1.53 0.196 0 O-C-N 121.474 -0.766 . . . . 1.0 109.166 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 30.2 t-20 -63.76 123.06 17.92 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 121.513 -0.742 . . . . 1.0 109.819 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 38.1 t -100.9 -18.34 16.4 Favored 'General case' 0 CA--C 1.534 0.329 0 O-C-N 121.53 -0.731 . . . . 1.0 109.505 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 175.94 -177.13 47.67 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 109.276 -1.53 . . . . 1.0 109.276 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.573 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.1 p90 -65.73 167.87 10.13 Favored Pre-proline 0 CA--C 1.538 0.492 0 O-C-N 121.395 -1.062 . . . . 1.0 108.822 179.732 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.81 -30.4 1.39 Allowed 'Trans proline' 0 N--CA 1.483 0.888 0 C-N-CA 124.374 3.383 . . . . 1.0 110.794 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -56.96 -12.58 7.23 Favored Glycine 0 CA--C 1.537 1.458 0 N-CA-C 110.357 -1.097 . . . . 1.0 110.357 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 19' ' ' PHE . 23.0 m -61.05 170.37 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 O-C-N 121.3 -1.117 . . . . 1.0 109.627 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.7 p -133.97 154.51 80.33 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.555 -0.716 . . . . 1.0 109.172 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.419 ' HD3' ' CZ ' ' A' ' 34' ' ' PHE . 16.8 Cg_exo -34.58 -31.87 0.06 OUTLIER 'Trans proline' 0 N--CA 1.488 1.195 1 C-N-CA 125.594 4.196 . . . . 1.0 111.355 179.956 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.6 m -75.53 -51.24 13.39 Favored 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.439 -0.788 . . . . 1.0 109.608 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 15.6 mt-30 -62.79 -43.37 98.98 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.427 -0.796 . . . . 1.0 109.721 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 10.1 t -64.54 -29.14 70.17 Favored 'General case' 0 N--CA 1.464 0.235 0 O-C-N 121.474 -0.766 . . . . 1.0 109.422 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.98 -11.15 56.13 Favored 'General case' 0 CA--C 1.533 0.315 0 O-C-N 121.604 -0.685 . . . . 1.0 109.756 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -88.24 -26.04 22.55 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.359 -0.838 . . . . 1.0 109.531 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 9.6 tttp -89.39 -32.06 17.46 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.419 -0.801 . . . . 1.0 109.407 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.41 43.43 1.36 Allowed Glycine 0 CA--C 1.53 0.985 0 N-CA-C 109.633 -1.387 . . . . 1.0 109.633 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.9 m -129.46 150.36 50.84 Favored 'General case' 0 CA--C 1.53 0.191 0 O-C-N 121.47 -1.018 . . . . 1.0 109.461 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.44 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 62.5 m -72.91 134.77 44.92 Favored 'General case' 0 CA--C 1.529 0.173 0 O-C-N 121.412 -0.805 . . . . 1.0 109.5 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.419 ' CZ ' ' HD3' ' A' ' 24' ' ' PRO . 57.1 t80 -107.87 125.13 51.1 Favored 'General case' 0 CA--C 1.53 0.175 0 O-C-N 121.488 -0.758 . . . . 1.0 109.233 179.689 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 16.2 t0 -138.54 117.84 12.77 Favored 'General case' 0 CA--C 1.53 0.179 0 O-C-N 121.457 -0.777 . . . . 1.0 109.527 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.431 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 14.1 p30 -113.55 66.06 0.66 Allowed 'General case' 0 N--CA 1.464 0.256 0 O-C-N 121.547 -0.721 . . . . 1.0 109.368 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.9 p -97.62 -69.82 0.74 Allowed 'General case' 0 CA--C 1.531 0.235 0 O-C-N 121.358 -0.839 . . . . 1.0 109.522 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 38.2 t -96.46 155.19 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 O-C-N 121.458 -0.776 . . . . 1.0 109.452 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.443 ' CG ' ' H ' ' A' ' 40' ' ' GLY . 13.7 ttp-105 -93.9 178.34 5.7 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 121.504 -0.748 . . . . 1.0 109.395 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.443 ' H ' ' CG ' ' A' ' 39' ' ' ARG . . . 81.3 -43.62 2.92 Favored Glycine 0 CA--C 1.529 0.918 0 N-CA-C 109.472 -1.451 . . . . 1.0 109.472 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.642 HG11 ' HB3' ' A' ' 11' ' ' PRO . 29.2 m -85.52 169.66 15.31 Favored Pre-proline 0 CA--C 1.537 0.444 0 O-C-N 121.538 -0.978 . . . . 1.0 109.197 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -87.22 136.46 4.06 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 124.77 3.647 . . . . 1.0 110.139 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.431 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 11.6 m0 -86.72 -50.55 6.69 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.526 -0.734 . . . . 1.0 109.569 -179.742 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.2 t -77.28 103.69 7.36 Favored 'General case' 0 N--CA 1.463 0.224 0 O-C-N 121.488 -0.758 . . . . 1.0 109.505 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.44 ' CE1' ' HB2' ' A' ' 33' ' ' CYS . 4.8 p90 -135.82 -178.99 5.38 Favored 'General case' 0 N--CA 1.465 0.316 0 O-C-N 121.489 -0.757 . . . . 1.0 109.523 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 65.1 m-85 -93.75 164.31 21.23 Favored Pre-proline 0 CA--C 1.534 0.357 0 O-C-N 121.436 -0.79 . . . . 1.0 109.652 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -91.11 -165.34 0.16 Allowed 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 125.045 3.83 . . . . 1.0 110.406 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.703 ' O ' HG22 ' A' ' 6' ' ' THR . 17.9 m-80 . . . . . 0 CA--C 1.53 0.207 0 O-C-N 121.505 -0.747 . . . . 1.0 109.441 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 CA--C 1.53 0.191 0 N-CA-C 109.303 -0.629 . . . . 1.0 109.303 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.9 m -105.21 28.87 6.88 Favored 'General case' 0 C--N 1.33 -0.249 0 O-C-N 121.611 -0.681 . . . . 1.0 109.316 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.53 HG23 ' O ' ' A' ' 8' ' ' THR . 5.2 t -80.51 118.29 21.98 Favored 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.406 -0.809 . . . . 1.0 109.508 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 36.4 t -149.47 154.18 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 O-C-N 121.57 -0.706 . . . . 1.0 109.349 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.605 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -83.1 146.38 51.41 Favored Pre-proline 0 CA--C 1.537 0.472 0 O-C-N 121.472 -0.768 . . . . 1.0 109.353 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_exo -34.48 -62.19 0.21 Allowed 'Trans proline' 0 N--CA 1.489 1.235 1 C-N-CA 125.571 4.18 . . . . 1.0 111.388 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.52 -29.88 65.29 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.383 -0.823 . . . . 1.0 109.856 -179.649 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.605 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 28.4 mt-10 -80.62 3.7 21.06 Favored 'General case' 0 CA--C 1.535 0.39 0 O-C-N 121.394 -0.816 . . . . 1.0 109.932 -179.812 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 48.8 mtt180 -73.86 129.71 38.45 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.396 -0.815 . . . . 1.0 109.56 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.4 mm-40 -88.08 108.98 19.51 Favored 'General case' 0 N--CA 1.463 0.212 0 N-CA-C 109.03 -0.73 . . . . 1.0 109.03 179.535 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 32.9 t-20 -59.22 105.8 0.37 Allowed 'General case' 0 CA--C 1.534 0.328 0 O-C-N 121.396 -0.815 . . . . 1.0 110.391 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.434 ' H ' ' HA ' ' A' ' 45' ' ' PHE . 1.7 t -85.53 -15.22 43.43 Favored 'General case' 0 CA--C 1.535 0.391 0 O-C-N 121.489 -0.757 . . . . 1.0 109.02 179.361 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 178.57 165.28 32.89 Favored Glycine 0 CA--C 1.529 0.96 0 N-CA-C 108.99 -1.644 . . . . 1.0 108.99 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.487 ' O ' HG22 ' A' ' 22' ' ' VAL . 7.1 p90 -59.41 168.91 1.49 Allowed Pre-proline 0 CA--C 1.541 0.634 0 O-C-N 121.355 -1.085 . . . . 1.0 109.276 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 19' ' ' PHE . 10.5 Cg_endo -80.51 -30.93 1.74 Allowed 'Trans proline' 0 N--CA 1.482 0.834 0 C-N-CA 124.112 3.208 . . . . 1.0 110.662 -178.677 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.43 -6.33 7.93 Favored Glycine 0 CA--C 1.537 1.408 0 N-CA-C 110.05 -1.22 . . . . 1.0 110.05 179.332 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.487 HG22 ' O ' ' A' ' 19' ' ' PHE . 24.7 m -59.71 -172.79 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 O-C-N 121.079 -1.248 . . . . 1.0 109.894 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.1 p -143.63 152.79 57.21 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.639 -0.663 . . . . 1.0 109.298 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -34.98 -33.31 0.08 OUTLIER 'Trans proline' 0 N--CA 1.488 1.174 1 C-N-CA 125.396 4.064 . . . . 1.0 111.437 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 9.3 t -76.37 -48.99 18.0 Favored 'General case' 0 CA--C 1.532 0.282 0 O-C-N 121.451 -0.781 . . . . 1.0 109.865 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 23.8 mt-30 -62.71 -41.17 99.0 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.45 -0.781 . . . . 1.0 109.782 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.3 t -69.09 -27.61 65.75 Favored 'General case' 0 CA--C 1.532 0.25 0 O-C-N 121.468 -0.77 . . . . 1.0 109.465 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.48 -5.77 53.7 Favored 'General case' 0 CA--C 1.536 0.424 0 O-C-N 121.546 -0.721 . . . . 1.0 109.941 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -63.03 -51.12 67.97 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.351 -0.843 . . . . 1.0 109.617 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.83 -40.54 13.07 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.466 -0.771 . . . . 1.0 109.403 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 126.91 21.44 1.72 Allowed Glycine 0 CA--C 1.531 1.074 0 N-CA-C 109.806 -1.318 . . . . 1.0 109.806 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 14.9 m -75.93 136.65 40.08 Favored 'General case' 0 N--CA 1.464 0.268 0 O-C-N 121.466 -1.02 . . . . 1.0 108.76 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 62.0 m -65.2 141.0 58.81 Favored 'General case' 0 CA--C 1.531 0.213 0 O-C-N 121.375 -0.828 . . . . 1.0 109.444 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 35' ' ' ASP . 15.2 t80 -111.22 143.17 42.4 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.448 -0.782 . . . . 1.0 109.17 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.443 ' N ' ' CD1' ' A' ' 34' ' ' PHE . 24.8 t70 -162.21 116.19 1.82 Allowed 'General case' 0 CA--C 1.531 0.242 0 O-C-N 121.392 -0.818 . . . . 1.0 109.62 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.444 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 16.0 p30 -105.71 63.17 0.67 Allowed 'General case' 0 CA--C 1.533 0.295 0 O-C-N 121.574 -0.704 . . . . 1.0 109.478 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.6 p -87.19 -58.18 2.68 Favored 'General case' 0 CA--C 1.531 0.242 0 O-C-N 121.417 -0.802 . . . . 1.0 109.512 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 37.5 t -119.74 146.56 24.3 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 O-C-N 121.496 -0.753 . . . . 1.0 109.427 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 1.4 ptm180 -84.15 -174.94 5.56 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 121.496 -0.752 . . . . 1.0 109.358 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.89 -42.93 2.55 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 109.213 -1.555 . . . . 1.0 109.213 -179.706 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.7 m -91.23 170.08 10.35 Favored Pre-proline 0 CA--C 1.534 0.354 0 O-C-N 121.489 -1.006 . . . . 1.0 108.981 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_endo -86.64 119.51 1.64 Allowed 'Trans proline' 0 C--N 1.35 0.621 0 C-N-CA 124.479 3.453 . . . . 1.0 110.049 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.444 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.9 m0 -72.69 -29.25 63.24 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 109.173 -0.677 . . . . 1.0 109.173 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 12.6 t -89.66 99.38 12.39 Favored 'General case' 0 CA--C 1.533 0.31 0 N-CA-C 109.158 -0.682 . . . . 1.0 109.158 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.434 ' HA ' ' H ' ' A' ' 17' ' ' CYS . 4.3 p90 -128.91 173.99 9.9 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 121.241 -0.912 . . . . 1.0 110.083 -179.619 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.402 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 19.8 m-85 -78.67 170.91 14.05 Favored Pre-proline 0 CA--C 1.536 0.424 0 O-C-N 121.415 -0.803 . . . . 1.0 109.543 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -89.81 -178.63 1.67 Allowed 'Trans proline' 0 C--N 1.351 0.662 0 C-N-CA 125.137 3.891 . . . . 1.0 110.304 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.8 m120 . . . . . 0 CA--C 1.531 0.243 0 O-C-N 121.441 -0.787 . . . . 1.0 109.303 179.957 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.432 HG22 HG22 ' A' ' 8' ' ' THR . 3.0 m . . . . . 0 CA--C 1.531 0.233 0 CA-C-O 121.243 0.544 . . . . 1.0 109.76 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.2 m -119.67 46.07 2.01 Favored 'General case' 0 CA--C 1.532 0.273 0 O-C-N 121.528 -0.733 . . . . 1.0 109.131 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.547 HG23 ' O ' ' A' ' 8' ' ' THR . 3.3 t -128.79 80.85 1.99 Allowed 'General case' 0 CA--C 1.532 0.269 0 O-C-N 121.423 -0.798 . . . . 1.0 109.469 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.614 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.0 t -102.42 170.16 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 O-C-N 121.367 -0.833 . . . . 1.0 109.332 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.614 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -71.79 134.99 83.43 Favored Pre-proline 0 CA--C 1.539 0.547 0 O-C-N 121.52 -0.738 . . . . 1.0 109.202 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_exo -35.87 -31.13 0.08 OUTLIER 'Trans proline' 0 N--CA 1.489 1.226 0 C-N-CA 125.202 3.934 . . . . 1.0 111.554 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.464 ' H ' ' HG2' ' A' ' 12' ' ' ARG . 10.5 ptp180 -84.25 -44.75 13.57 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.392 -0.817 . . . . 1.0 110.171 -179.402 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.466 ' O ' HG11 ' A' ' 9' ' ' VAL . 5.5 mt-10 -79.07 39.81 0.39 Allowed 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.357 -0.839 . . . . 1.0 109.653 -179.616 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 63.9 mtt180 -111.22 121.46 45.33 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.391 -0.818 . . . . 1.0 109.754 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.462 ' CD ' ' H ' ' A' ' 15' ' ' GLN . 0.3 OUTLIER -90.16 125.21 35.38 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.488 -0.757 . . . . 1.0 108.993 179.391 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -65.0 127.56 32.1 Favored 'General case' 0 CA--C 1.534 0.347 0 O-C-N 121.454 -0.779 . . . . 1.0 110.7 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -98.16 -26.67 14.49 Favored 'General case' 0 CA--C 1.534 0.335 0 N-CA-C 108.371 -0.974 . . . . 1.0 108.371 178.714 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -165.47 171.62 40.78 Favored Glycine 0 CA--C 1.53 1.012 0 N-CA-C 108.701 -1.76 . . . . 1.0 108.701 179.791 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.577 ' O ' HG22 ' A' ' 22' ' ' VAL . 7.9 p90 -62.73 167.62 5.54 Favored Pre-proline 0 CA--C 1.54 0.586 0 O-C-N 121.174 -1.192 . . . . 1.0 109.153 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.21 -30.86 1.44 Allowed 'Trans proline' 0 N--CA 1.483 0.875 0 C-N-CA 124.375 3.384 . . . . 1.0 110.771 -178.642 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.28 -9.91 9.29 Favored Glycine 0 CA--C 1.538 1.479 0 N-CA-C 110.104 -1.198 . . . . 1.0 110.104 179.443 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 19' ' ' PHE . 23.4 m -60.09 169.66 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 O-C-N 121.282 -1.128 . . . . 1.0 109.721 179.802 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.543 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 38.1 p -128.55 157.89 73.56 Favored Pre-proline 0 CA--C 1.536 0.409 0 N-CA-C 109.083 -0.71 . . . . 1.0 109.083 179.608 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -36.03 -34.03 0.13 Allowed 'Trans proline' 0 N--CA 1.488 1.157 1 C-N-CA 125.364 4.042 . . . . 1.0 111.176 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 33.7 p -79.25 -45.81 19.04 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.442 -0.786 . . . . 1.0 109.965 -179.599 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLN . . . . . 0.543 ' HB2' ' H ' ' A' ' 23' ' ' THR . 7.4 mt-30 -62.42 -52.5 63.32 Favored 'General case' 0 N--CA 1.465 0.304 0 O-C-N 121.476 -0.765 . . . . 1.0 109.853 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 10.4 t -62.0 -33.97 75.32 Favored 'General case' 0 CA--C 1.533 0.311 0 O-C-N 121.483 -0.761 . . . . 1.0 109.765 -179.77 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.6 -3.13 58.31 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.336 -0.852 . . . . 1.0 110.03 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -79.08 -46.65 17.64 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.319 -0.863 . . . . 1.0 109.834 -179.593 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.2 tttt -78.82 -48.5 14.64 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 121.431 -0.793 . . . . 1.0 109.544 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 132.58 21.41 0.92 Allowed Glycine 0 CA--C 1.531 1.052 0 N-CA-C 110.281 -1.127 . . . . 1.0 110.281 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 39.9 m -91.48 138.74 31.33 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 121.246 -1.149 . . . . 1.0 108.746 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.7 m -65.17 128.04 34.19 Favored 'General case' 0 N--CA 1.464 0.242 0 O-C-N 121.303 -0.873 . . . . 1.0 109.729 -179.676 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 64.4 t80 -97.57 143.3 28.4 Favored 'General case' 0 C--O 1.234 0.266 0 O-C-N 121.541 -0.724 . . . . 1.0 109.155 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -152.72 103.54 2.79 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 121.363 -0.836 . . . . 1.0 109.645 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.431 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 9.5 p-10 -109.02 82.56 1.61 Allowed 'General case' 0 CA--C 1.531 0.216 0 O-C-N 121.55 -0.719 . . . . 1.0 109.426 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 49.1 p -118.63 -35.03 3.82 Favored 'General case' 0 N--CA 1.463 0.218 0 O-C-N 121.421 -0.799 . . . . 1.0 109.601 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.6 t -128.97 150.15 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 O-C-N 121.458 -0.776 . . . . 1.0 109.396 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 22.3 ttt180 -87.08 168.18 13.52 Favored 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.468 -0.77 . . . . 1.0 109.384 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.43 -52.03 4.58 Favored Glycine 0 CA--C 1.529 0.907 0 N-CA-C 109.529 -1.428 . . . . 1.0 109.529 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 27.6 m -74.14 169.2 20.21 Favored Pre-proline 0 CA--C 1.536 0.419 0 O-C-N 121.551 -0.97 . . . . 1.0 109.324 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_endo -88.92 130.43 2.15 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 124.883 3.722 . . . . 1.0 110.219 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.431 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 7.7 m0 -87.95 -36.44 17.09 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.423 -0.798 . . . . 1.0 109.509 -179.652 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 8.0 t -89.44 102.96 15.63 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 109.144 -0.687 . . . . 1.0 109.144 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.406 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 3.6 p90 -134.55 174.23 10.78 Favored 'General case' 0 CA--C 1.538 0.497 0 O-C-N 121.304 -0.873 . . . . 1.0 110.083 -179.414 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.406 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 45.3 m-85 -76.6 170.5 15.87 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 121.435 -0.791 . . . . 1.0 109.495 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_endo -90.18 161.83 4.73 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 124.928 3.752 . . . . 1.0 110.454 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 . . . . . 0 N--CA 1.463 0.194 0 O-C-N 121.569 -0.707 . . . . 1.0 109.384 179.974 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 31.7 m . . . . . 0 CA--C 1.531 0.248 0 N-CA-C 109.193 -0.669 . . . . 1.0 109.193 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.3 m -124.67 -6.23 7.48 Favored 'General case' 0 CA--C 1.535 0.393 0 O-C-N 121.446 -0.783 . . . . 1.0 109.92 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.405 ' O ' HG23 ' A' ' 8' ' ' THR . 3.6 t -70.17 126.94 31.11 Favored 'General case' 0 N--CA 1.463 0.215 0 O-C-N 121.215 -0.928 . . . . 1.0 109.434 179.713 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.636 HG12 ' N ' ' A' ' 10' ' ' ALA . 26.0 t -142.34 173.64 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 O-C-N 121.513 -0.742 . . . . 1.0 109.37 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.636 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -77.96 136.84 61.89 Favored Pre-proline 0 CA--C 1.54 0.595 0 O-C-N 121.477 -0.764 . . . . 1.0 109.566 -179.788 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_exo -36.0 -38.24 0.27 Allowed 'Trans proline' 0 N--CA 1.489 1.216 1 C-N-CA 125.314 4.01 . . . . 1.0 111.442 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 40.4 mtp85 -85.11 -39.97 17.31 Favored 'General case' 0 N--CA 1.465 0.321 0 O-C-N 121.362 -0.836 . . . . 1.0 110.02 -179.282 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.63 ' O ' HG11 ' A' ' 9' ' ' VAL . 11.6 mt-10 -79.11 39.67 0.39 Allowed 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.427 -0.795 . . . . 1.0 109.671 -179.624 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 39.3 mtt180 -107.8 125.91 52.0 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.464 -0.772 . . . . 1.0 109.672 179.817 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.0 mp0 -94.76 113.13 24.86 Favored 'General case' 0 CA--C 1.532 0.284 0 O-C-N 121.472 -0.768 . . . . 1.0 109.224 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -59.74 126.17 26.53 Favored 'General case' 0 CA--C 1.533 0.314 0 O-C-N 121.411 -0.805 . . . . 1.0 110.252 -179.728 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -98.58 -18.63 18.03 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 121.565 -0.71 . . . . 1.0 109.094 179.582 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -173.21 176.67 45.89 Favored Glycine 0 CA--C 1.529 0.935 0 N-CA-C 108.834 -1.706 . . . . 1.0 108.834 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.568 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.4 p90 -65.87 167.34 11.83 Favored Pre-proline 0 CA--C 1.538 0.491 0 O-C-N 121.289 -1.124 . . . . 1.0 108.923 179.771 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.55 -29.46 1.83 Allowed 'Trans proline' 0 N--CA 1.483 0.894 0 C-N-CA 124.492 3.461 . . . . 1.0 110.897 -178.528 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.43 -11.58 10.34 Favored Glycine 0 CA--C 1.538 1.474 0 N-CA-C 110.192 -1.163 . . . . 1.0 110.192 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.568 HG22 ' O ' ' A' ' 19' ' ' PHE . 22.7 m -61.06 -171.8 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 O-C-N 121.354 -1.086 . . . . 1.0 109.72 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 43.3 p -147.1 152.52 43.59 Favored Pre-proline 0 CA--C 1.535 0.393 0 O-C-N 121.527 -0.733 . . . . 1.0 109.168 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_exo -35.15 -31.43 0.07 OUTLIER 'Trans proline' 0 N--CA 1.488 1.187 1 C-N-CA 125.575 4.183 . . . . 1.0 111.224 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 78.9 p -77.21 -51.21 11.33 Favored 'General case' 0 CA--C 1.532 0.271 0 O-C-N 121.491 -0.756 . . . . 1.0 109.752 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 68.8 mt-30 -63.08 -46.93 85.11 Favored 'General case' 0 N--CA 1.464 0.252 0 O-C-N 121.493 -0.755 . . . . 1.0 109.97 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 13.1 t -62.36 -33.15 74.15 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 121.419 -0.8 . . . . 1.0 109.82 -179.709 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.84 -3.96 58.61 Favored 'General case' 0 CA--C 1.534 0.346 0 O-C-N 121.444 -0.785 . . . . 1.0 110.056 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -79.73 -39.31 31.4 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.37 -0.831 . . . . 1.0 109.809 -179.534 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 35.4 mtmt -85.18 -46.58 10.95 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.396 -0.815 . . . . 1.0 109.938 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 137.91 11.58 0.93 Allowed Glycine 0 CA--C 1.533 1.174 0 N-CA-C 110.246 -1.141 . . . . 1.0 110.246 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 35.0 m -86.91 136.88 32.79 Favored 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.353 -1.086 . . . . 1.0 108.71 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.6 m -69.7 126.08 28.64 Favored 'General case' 0 N--CA 1.465 0.302 0 O-C-N 121.249 -0.907 . . . . 1.0 109.924 -179.704 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.451 ' CE1' ' HB2' ' A' ' 43' ' ' TRP . 50.3 t80 -94.79 147.34 23.44 Favored 'General case' 0 CA--C 1.531 0.22 0 N-CA-C 109.156 -0.683 . . . . 1.0 109.156 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -154.04 96.31 1.94 Allowed 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.454 -0.779 . . . . 1.0 109.631 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.421 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 6.7 p-10 -104.48 70.64 0.96 Allowed 'General case' 0 CA--C 1.533 0.299 0 O-C-N 121.523 -0.736 . . . . 1.0 109.25 179.821 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 18.2 p -117.64 -42.47 2.86 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.356 -0.84 . . . . 1.0 109.407 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.431 HG12 ' N ' ' A' ' 39' ' ' ARG . 37.4 t -111.2 159.23 11.32 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 O-C-N 121.438 -0.789 . . . . 1.0 109.415 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.431 ' N ' HG12 ' A' ' 38' ' ' VAL . 16.4 ttp-105 -100.33 170.37 8.47 Favored 'General case' 0 C--O 1.233 0.201 0 O-C-N 121.412 -0.805 . . . . 1.0 109.425 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.46 -58.29 5.0 Favored Glycine 0 CA--C 1.529 0.922 0 N-CA-C 109.511 -1.436 . . . . 1.0 109.511 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.5 m -70.23 169.25 14.13 Favored Pre-proline 0 CA--C 1.537 0.448 0 O-C-N 121.491 -1.006 . . . . 1.0 109.233 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -87.39 127.11 2.38 Favored 'Trans proline' 0 C--N 1.352 0.72 0 C-N-CA 124.721 3.614 . . . . 1.0 110.15 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.451 ' HB2' ' CE1' ' A' ' 34' ' ' PHE . 11.2 m0 -73.62 -43.45 59.55 Favored 'General case' 0 N--CA 1.464 0.248 0 O-C-N 121.593 -0.692 . . . . 1.0 109.603 -179.665 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 12.3 t -88.3 110.99 21.2 Favored 'General case' 0 CA--C 1.535 0.382 0 O-C-N 121.452 -0.78 . . . . 1.0 109.578 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.401 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 4.2 p90 -141.89 175.9 9.36 Favored 'General case' 0 CA--C 1.538 0.507 0 O-C-N 121.353 -0.842 . . . . 1.0 109.974 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.401 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 18.1 m-85 -74.83 171.43 11.63 Favored Pre-proline 0 CA--C 1.536 0.432 0 O-C-N 121.472 -0.767 . . . . 1.0 109.889 -179.788 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -94.42 -178.82 0.64 Allowed 'Trans proline' 0 C--N 1.351 0.691 1 C-N-CA 125.336 4.024 . . . . 1.0 110.919 -179.647 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.457 HD22 ' CG2' ' A' ' 9' ' ' VAL . 19.4 m-20 . . . . . 0 CA--C 1.531 0.222 0 O-C-N 121.602 -0.687 . . . . 1.0 109.214 179.832 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.461 HG22 HG22 ' A' ' 8' ' ' THR . 1.6 m . . . . . 0 C--O 1.233 0.191 0 N-CA-C 109.574 -0.528 . . . . 1.0 109.574 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 77.6 m -110.51 34.68 3.81 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.523 -0.736 . . . . 1.0 109.229 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.461 HG22 HG22 ' A' ' 6' ' ' THR . 5.0 t -91.96 125.64 36.73 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.507 -0.745 . . . . 1.0 109.677 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.499 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.7 t -146.88 163.7 8.02 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 109.085 -0.709 . . . . 1.0 109.085 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.788 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -78.59 136.59 59.46 Favored Pre-proline 0 CA--C 1.541 0.624 0 O-C-N 121.467 -0.771 . . . . 1.0 109.233 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_exo -34.74 -57.81 0.4 Allowed 'Trans proline' 0 N--CA 1.488 1.196 1 C-N-CA 125.457 4.105 . . . . 1.0 111.416 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.2 mmt180 -74.49 -32.28 62.49 Favored 'General case' 0 N--CA 1.463 0.194 0 O-C-N 121.488 -0.758 . . . . 1.0 109.895 -179.616 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.788 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 9.5 mt-10 -83.05 21.93 1.01 Allowed 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.348 -0.845 . . . . 1.0 109.73 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 69.0 mtt180 -89.98 126.03 35.6 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.444 -0.785 . . . . 1.0 109.418 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -89.01 121.42 31.35 Favored 'General case' 0 CA--C 1.53 0.197 0 O-C-N 121.52 -0.738 . . . . 1.0 109.092 179.643 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -69.04 118.61 12.16 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.421 -0.799 . . . . 1.0 109.484 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -88.29 -24.16 23.26 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.48 -0.762 . . . . 1.0 109.065 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -169.74 173.79 43.95 Favored Glycine 0 CA--C 1.529 0.914 0 N-CA-C 109.085 -1.606 . . . . 1.0 109.085 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.559 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.5 p90 -66.5 167.59 12.57 Favored Pre-proline 0 CA--C 1.538 0.493 0 O-C-N 121.439 -1.036 . . . . 1.0 108.924 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -82.09 -30.21 1.35 Allowed 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 124.441 3.427 . . . . 1.0 110.801 -178.719 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.05 -11.33 8.57 Favored Glycine 0 CA--C 1.537 1.46 0 N-CA-C 110.329 -1.108 . . . . 1.0 110.329 179.593 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 19' ' ' PHE . 22.3 m -60.73 -169.98 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 O-C-N 121.334 -1.098 . . . . 1.0 109.702 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.506 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 12.8 p -140.85 156.13 68.83 Favored Pre-proline 0 CA--C 1.534 0.356 0 N-CA-C 109.096 -0.705 . . . . 1.0 109.096 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_exo -38.16 -36.23 0.49 Allowed 'Trans proline' 0 N--CA 1.487 1.143 0 C-N-CA 125.14 3.893 . . . . 1.0 110.998 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.3 t -75.98 -41.46 51.29 Favored 'General case' 0 CA--C 1.532 0.273 0 O-C-N 121.557 -0.714 . . . . 1.0 110.141 -179.473 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLN . . . . . 0.506 ' HB2' ' H ' ' A' ' 23' ' ' THR . 5.1 mt-30 -65.2 -50.79 64.51 Favored 'General case' 0 CA--C 1.532 0.261 0 O-C-N 121.431 -0.793 . . . . 1.0 110.002 -179.638 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 11.4 t -61.67 -32.3 72.47 Favored 'General case' 0 CA--C 1.533 0.319 0 O-C-N 121.335 -0.853 . . . . 1.0 109.914 -179.66 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -89.18 -3.93 58.42 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 121.497 -0.752 . . . . 1.0 110.109 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 41.6 t-20 -73.8 -53.55 10.01 Favored 'General case' 0 N--CA 1.464 0.245 0 O-C-N 121.392 -0.818 . . . . 1.0 109.523 -179.692 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.2 mttt -73.19 -48.09 38.18 Favored 'General case' 0 C--N 1.332 -0.182 0 O-C-N 121.515 -0.74 . . . . 1.0 109.375 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 136.8 15.67 0.82 Allowed Glycine 0 CA--C 1.532 1.119 0 N-CA-C 109.647 -1.381 . . . . 1.0 109.647 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 36.4 m -82.12 140.61 33.7 Favored 'General case' 0 N--CA 1.463 0.218 0 O-C-N 121.345 -1.091 . . . . 1.0 108.731 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 69.3 m -71.5 123.27 22.05 Favored 'General case' 0 C--N 1.332 -0.189 0 O-C-N 121.368 -0.833 . . . . 1.0 109.66 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 37.0 t80 -94.71 142.72 27.13 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.46 -0.775 . . . . 1.0 109.169 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -160.45 98.96 1.28 Allowed 'General case' 0 C--O 1.233 0.194 0 O-C-N 121.513 -0.742 . . . . 1.0 109.47 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.447 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.0 p-10 -107.44 76.28 1.07 Allowed 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.457 -0.777 . . . . 1.0 109.486 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 70.1 p -120.15 -38.54 2.91 Favored 'General case' 0 CA--C 1.533 0.291 0 O-C-N 121.468 -0.77 . . . . 1.0 109.654 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.8 t -110.75 144.5 18.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 O-C-N 121.397 -0.815 . . . . 1.0 109.7 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.2 mmt180 -88.69 177.16 6.82 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.547 -0.721 . . . . 1.0 109.487 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.71 -62.57 4.36 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 109.092 -1.603 . . . . 1.0 109.092 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 28.7 m -73.1 170.23 14.61 Favored Pre-proline 0 CA--C 1.536 0.406 0 O-C-N 121.63 -0.924 . . . . 1.0 109.096 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -84.34 150.76 11.95 Favored 'Trans proline' 0 C--N 1.351 0.662 0 C-N-CA 124.366 3.377 . . . . 1.0 109.901 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.447 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 7.8 m0 -94.68 -40.58 9.73 Favored 'General case' 0 N--CA 1.465 0.284 0 O-C-N 121.545 -0.722 . . . . 1.0 109.639 -179.218 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 22.7 t -90.29 105.55 17.89 Favored 'General case' 0 CA--C 1.534 0.364 0 O-C-N 121.416 -0.802 . . . . 1.0 109.448 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.433 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 4.9 p90 -128.99 179.26 5.84 Favored 'General case' 0 CA--C 1.534 0.338 0 O-C-N 121.395 -0.816 . . . . 1.0 109.9 -179.863 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.401 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 17.8 m-85 -80.97 170.71 14.48 Favored Pre-proline 0 CA--C 1.538 0.482 0 O-C-N 121.391 -0.818 . . . . 1.0 109.835 -179.596 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -90.58 169.6 3.83 Favored 'Trans proline' 0 C--N 1.352 0.736 0 C-N-CA 124.981 3.787 . . . . 1.0 110.58 179.798 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.2 m120 . . . . . 0 CA--C 1.531 0.215 0 O-C-N 121.469 -0.77 . . . . 1.0 109.011 179.726 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.941 HG22 HG22 ' A' ' 8' ' ' THR . 2.3 m . . . . . 0 CA--C 1.531 0.249 0 CA-C-O 121.19 0.519 . . . . 1.0 109.625 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 75.8 m -110.73 13.67 22.37 Favored 'General case' 0 CA--C 1.534 0.346 0 O-C-N 121.482 -0.761 . . . . 1.0 109.623 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.941 HG22 HG22 ' A' ' 6' ' ' THR . 4.4 t -93.97 104.69 16.73 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.444 -0.785 . . . . 1.0 109.565 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.515 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.6 t -123.4 164.43 21.11 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 O-C-N 121.557 -0.714 . . . . 1.0 109.29 179.798 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.515 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -69.4 121.96 83.92 Favored Pre-proline 0 CA--C 1.54 0.569 0 O-C-N 121.434 -0.791 . . . . 1.0 109.155 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.479 ' HB3' HG11 ' A' ' 41' ' ' VAL . 17.6 Cg_exo -38.36 -28.22 0.12 Allowed 'Trans proline' 0 N--CA 1.49 1.29 0 C-N-CA 124.749 3.633 . . . . 1.0 111.357 -179.653 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 64.8 mtt180 -84.25 -41.26 17.09 Favored 'General case' 0 CA--C 1.533 0.292 0 O-C-N 121.37 -0.831 . . . . 1.0 110.171 -179.252 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 15.0 mm-40 -92.43 44.88 1.17 Allowed 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.45 -0.781 . . . . 1.0 109.748 -179.74 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.408 ' HD3' ' CD2' ' A' ' 45' ' ' PHE . 19.3 mtt180 -106.81 141.63 37.73 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.332 -0.855 . . . . 1.0 109.603 179.767 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 16.5 mt-30 -111.11 126.67 55.08 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 108.918 -0.771 . . . . 1.0 108.918 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -67.73 117.32 9.49 Favored 'General case' 0 CA--C 1.532 0.285 0 O-C-N 121.427 -0.796 . . . . 1.0 110.673 -178.947 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.482 ' H ' ' HA ' ' A' ' 45' ' ' PHE . 3.0 t -72.64 -31.32 65.03 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 108.665 -0.865 . . . . 1.0 108.665 178.855 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -152.88 178.92 29.73 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 109.306 -1.517 . . . . 1.0 109.306 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.534 ' O ' HG22 ' A' ' 22' ' ' VAL . 6.6 p90 -62.03 169.28 2.89 Favored Pre-proline 0 CA--C 1.541 0.634 0 O-C-N 121.387 -1.067 . . . . 1.0 108.889 179.674 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 19' ' ' PHE . 10.6 Cg_endo -80.43 -31.92 1.44 Allowed 'Trans proline' 0 N--CA 1.482 0.838 0 C-N-CA 124.044 3.163 . . . . 1.0 110.762 -178.845 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.2 -3.21 6.24 Favored Glycine 0 CA--C 1.537 1.423 0 N-CA-C 110.196 -1.161 . . . . 1.0 110.196 179.704 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.534 HG22 ' O ' ' A' ' 19' ' ' PHE . 21.9 m -62.82 170.73 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 O-C-N 121.148 -1.207 . . . . 1.0 109.686 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.8 p -130.21 155.72 80.41 Favored Pre-proline 0 CA--C 1.534 0.361 0 N-CA-C 108.962 -0.755 . . . . 1.0 108.962 179.714 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -35.95 -38.7 0.28 Allowed 'Trans proline' 0 N--CA 1.488 1.18 0 C-N-CA 125.254 3.969 . . . . 1.0 111.188 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 79.4 p -70.9 -46.23 62.91 Favored 'General case' 0 CA--C 1.533 0.291 0 O-C-N 121.447 -0.783 . . . . 1.0 110.043 -179.583 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -62.19 -49.1 77.12 Favored 'General case' 0 N--CA 1.465 0.321 0 O-C-N 121.366 -0.834 . . . . 1.0 110.024 -179.656 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 7.2 t -62.54 -25.12 67.88 Favored 'General case' 0 CA--C 1.533 0.297 0 O-C-N 121.407 -0.808 . . . . 1.0 109.808 -179.715 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -95.95 -5.32 41.62 Favored 'General case' 0 CA--C 1.534 0.363 0 O-C-N 121.391 -0.818 . . . . 1.0 110.309 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -98.11 -23.39 15.75 Favored 'General case' 0 N--CA 1.465 0.281 0 O-C-N 121.223 -0.923 . . . . 1.0 109.726 -179.619 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.1 mmtm -91.41 -15.2 29.29 Favored 'General case' 0 CA--C 1.533 0.289 0 O-C-N 121.311 -0.868 . . . . 1.0 109.736 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.99 14.81 41.29 Favored Glycine 0 CA--C 1.532 1.143 0 N-CA-C 109.988 -1.245 . . . . 1.0 109.988 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 56.3 m -94.3 148.52 22.13 Favored 'General case' 0 N--CA 1.465 0.298 0 O-C-N 121.402 -1.058 . . . . 1.0 108.808 179.843 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.454 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 58.4 m -80.7 126.71 31.63 Favored 'General case' 0 CA--C 1.532 0.267 0 O-C-N 121.343 -0.848 . . . . 1.0 109.713 -179.638 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -98.84 128.13 44.96 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 108.799 -0.815 . . . . 1.0 108.799 179.334 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -141.38 117.32 10.5 Favored 'General case' 0 N--CA 1.464 0.256 0 O-C-N 121.465 -0.772 . . . . 1.0 109.864 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.438 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 7.2 p-10 -112.14 72.92 0.79 Allowed 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.594 -0.691 . . . . 1.0 109.21 179.513 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.1 p -104.08 -61.92 1.38 Allowed 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.368 -0.832 . . . . 1.0 109.619 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.6 t -103.5 154.72 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 O-C-N 121.451 -0.781 . . . . 1.0 109.415 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.94 171.85 8.85 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.479 -0.763 . . . . 1.0 109.487 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.08 -49.64 4.15 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 109.477 -1.449 . . . . 1.0 109.477 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.479 HG11 ' HB3' ' A' ' 11' ' ' PRO . 29.7 m -73.81 169.36 19.06 Favored Pre-proline 0 CA--C 1.536 0.422 0 O-C-N 121.553 -0.969 . . . . 1.0 109.333 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_endo -89.08 127.1 1.74 Allowed 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 124.838 3.692 . . . . 1.0 109.901 179.732 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.438 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 13.6 m0 -77.27 -51.5 10.8 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.51 -0.744 . . . . 1.0 109.367 -179.719 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 5.2 t -74.88 111.63 10.28 Favored 'General case' 0 CA--C 1.531 0.241 0 N-CA-C 108.616 -0.883 . . . . 1.0 108.616 179.496 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.482 ' HA ' ' H ' ' A' ' 17' ' ' CYS . 2.3 p90 -140.86 175.32 9.71 Favored 'General case' 0 N--CA 1.468 0.429 0 O-C-N 121.449 -0.782 . . . . 1.0 110.185 -179.686 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 41.7 m-85 -74.17 160.55 81.3 Favored Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 121.405 -0.81 . . . . 1.0 110.128 -179.243 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -90.03 174.32 3.23 Favored 'Trans proline' 0 C--N 1.352 0.74 0 C-N-CA 124.96 3.774 . . . . 1.0 110.401 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 4.0 m120 . . . . . 0 CA--C 1.53 0.203 0 O-C-N 121.541 -0.724 . . . . 1.0 109.491 179.867 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.479 ' HB ' HG22 ' A' ' 8' ' ' THR . 1.7 m . . . . . 0 CA--C 1.53 0.209 0 N-CA-C 109.402 -0.592 . . . . 1.0 109.402 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 73.1 m -86.95 11.97 12.27 Favored 'General case' 0 CA--C 1.534 0.35 0 O-C-N 121.544 -0.722 . . . . 1.0 109.641 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.535 HG23 ' O ' ' A' ' 8' ' ' THR . 5.4 t -85.41 117.96 24.65 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.257 -0.902 . . . . 1.0 109.677 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 10' ' ' ALA . 37.7 t -140.95 168.24 16.5 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 O-C-N 121.419 -0.8 . . . . 1.0 109.126 179.649 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.579 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -84.42 138.32 38.82 Favored Pre-proline 0 CA--C 1.538 0.487 0 O-C-N 121.351 -0.843 . . . . 1.0 109.439 -179.908 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_exo -34.75 -40.38 0.22 Allowed 'Trans proline' 0 N--CA 1.489 1.222 1 C-N-CA 125.511 4.141 . . . . 1.0 111.276 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 25.7 mtt85 -85.26 -46.57 10.9 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.472 -0.767 . . . . 1.0 109.699 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -67.31 -5.0 12.33 Favored 'General case' 0 CA--C 1.534 0.328 0 O-C-N 121.505 -0.747 . . . . 1.0 110.023 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.8 mtt180 -70.38 126.11 28.72 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.36 -0.838 . . . . 1.0 109.52 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 11.2 mm100 -87.07 123.09 31.76 Favored 'General case' 0 C--N 1.332 -0.168 0 O-C-N 121.478 -0.764 . . . . 1.0 109.252 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -65.7 111.39 3.18 Favored 'General case' 0 N--CA 1.464 0.238 0 O-C-N 121.559 -0.713 . . . . 1.0 109.745 -179.709 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 41.8 t -82.04 -16.42 50.23 Favored 'General case' 0 CA--C 1.534 0.351 0 O-C-N 121.431 -0.793 . . . . 1.0 109.339 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.59 179.08 44.01 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 109.061 -1.615 . . . . 1.0 109.061 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.551 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.2 p90 -65.04 167.73 9.01 Favored Pre-proline 0 CA--C 1.539 0.548 0 O-C-N 121.306 -1.114 . . . . 1.0 108.838 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.54 -30.59 1.42 Allowed 'Trans proline' 0 N--CA 1.482 0.814 0 C-N-CA 124.39 3.393 . . . . 1.0 110.881 -178.658 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.62 -8.77 7.9 Favored Glycine 0 CA--C 1.537 1.441 0 N-CA-C 110.25 -1.14 . . . . 1.0 110.25 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.551 HG22 ' O ' ' A' ' 19' ' ' PHE . 20.0 m -61.16 177.24 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 O-C-N 121.228 -1.16 . . . . 1.0 109.669 179.766 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.0 p -138.89 156.24 72.73 Favored Pre-proline 0 CA--C 1.535 0.389 0 O-C-N 121.54 -0.725 . . . . 1.0 109.225 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -34.91 -32.04 0.07 OUTLIER 'Trans proline' 0 N--CA 1.487 1.12 1 C-N-CA 125.56 4.174 . . . . 1.0 111.171 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 1.8 m -72.12 -51.94 19.08 Favored 'General case' 0 CA--C 1.532 0.281 0 O-C-N 121.419 -0.801 . . . . 1.0 109.614 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 52.3 mt-30 -62.78 -46.01 90.0 Favored 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.47 -0.769 . . . . 1.0 109.772 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.2 t -64.59 -23.8 67.38 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.401 -0.812 . . . . 1.0 109.563 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -94.12 -7.12 43.37 Favored 'General case' 0 CA--C 1.535 0.399 0 O-C-N 121.383 -0.823 . . . . 1.0 109.881 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -73.38 -39.26 65.27 Favored 'General case' 0 CA--C 1.532 0.281 0 O-C-N 121.269 -0.895 . . . . 1.0 109.418 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -92.49 -38.39 11.98 Favored 'General case' 0 N--CA 1.462 0.171 0 O-C-N 121.523 -0.736 . . . . 1.0 109.425 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 113.95 37.93 1.21 Allowed Glycine 0 CA--C 1.53 1.024 0 N-CA-C 109.631 -1.388 . . . . 1.0 109.631 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.8 m -97.52 145.01 26.65 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.472 -1.017 . . . . 1.0 109.273 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.404 ' O ' ' CD1' ' A' ' 45' ' ' PHE . 58.4 m -68.28 119.56 13.02 Favored 'General case' 0 CA--C 1.532 0.267 0 O-C-N 121.398 -0.814 . . . . 1.0 109.426 -179.677 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 43.7 t80 -92.02 146.85 23.41 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.386 -0.821 . . . . 1.0 109.258 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 10.6 t0 -162.12 110.43 1.41 Allowed 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.353 -0.842 . . . . 1.0 109.537 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.435 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 13.6 p30 -110.63 70.77 0.73 Allowed 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.501 -0.749 . . . . 1.0 109.442 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.8 p -111.82 -53.31 2.72 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.403 -0.811 . . . . 1.0 109.737 -179.789 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.437 HG12 ' N ' ' A' ' 39' ' ' ARG . 35.6 t -96.3 159.38 2.98 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 O-C-N 121.341 -0.849 . . . . 1.0 109.639 -179.692 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.437 ' N ' HG12 ' A' ' 38' ' ' VAL . 2.2 mmm180 -103.82 169.13 8.69 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 121.473 -0.767 . . . . 1.0 109.263 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.75 -42.63 2.49 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 109.355 -1.498 . . . . 1.0 109.355 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.4 m -80.34 169.68 18.77 Favored Pre-proline 0 CA--C 1.537 0.466 0 O-C-N 121.538 -0.978 . . . . 1.0 109.082 179.768 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -87.3 131.77 3.05 Favored 'Trans proline' 0 C--N 1.351 0.682 0 C-N-CA 124.712 3.608 . . . . 1.0 110.011 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.435 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 15.3 m0 -80.15 -39.45 29.34 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.46 -0.775 . . . . 1.0 109.738 -179.482 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 16.0 t -90.01 107.78 19.32 Favored 'General case' 0 CA--C 1.534 0.338 0 O-C-N 121.412 -0.805 . . . . 1.0 109.486 179.841 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.423 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 5.6 p90 -133.52 175.9 9.01 Favored 'General case' 0 CA--C 1.536 0.412 0 O-C-N 121.452 -0.78 . . . . 1.0 109.757 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.406 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 31.9 m-85 -85.34 170.84 12.09 Favored Pre-proline 0 CA--C 1.537 0.462 0 O-C-N 121.532 -0.73 . . . . 1.0 109.351 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -90.96 177.06 2.15 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 124.968 3.779 . . . . 1.0 110.39 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.2 m120 . . . . . 0 CA--C 1.53 0.188 0 O-C-N 121.569 -0.707 . . . . 1.0 109.597 179.953 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.463 0.175 0 N-CA-C 109.327 -0.62 . . . . 1.0 109.327 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 62.3 m -114.9 28.24 8.85 Favored 'General case' 0 C--O 1.232 0.15 0 O-C-N 121.496 -0.752 . . . . 1.0 109.326 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.481 HG23 ' O ' ' A' ' 8' ' ' THR . 5.6 t -95.39 122.82 38.51 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.362 -0.836 . . . . 1.0 109.586 -179.89 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.56 HG12 ' N ' ' A' ' 10' ' ' ALA . 40.3 t -147.11 167.67 5.5 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.198 0 O-C-N 121.5 -0.75 . . . . 1.0 109.283 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.573 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -76.66 124.97 87.83 Favored Pre-proline 0 CA--C 1.541 0.609 0 O-C-N 121.438 -0.789 . . . . 1.0 109.354 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.401 ' HD2' ' HA ' ' A' ' 10' ' ' ALA . 19.4 Cg_exo -36.87 -50.37 1.45 Allowed 'Trans proline' 0 N--CA 1.49 1.302 0 C-N-CA 124.922 3.748 . . . . 1.0 111.242 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.6 mtp180 -70.21 -49.12 53.38 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.458 -0.776 . . . . 1.0 109.652 -179.742 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.573 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 25.0 mt-10 -82.61 40.36 0.66 Allowed 'General case' 0 CA--C 1.53 0.211 0 O-C-N 121.46 -0.775 . . . . 1.0 109.52 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 26.2 mtt180 -92.4 139.34 30.7 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.473 -0.767 . . . . 1.0 109.476 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -85.46 108.48 17.91 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.522 -0.736 . . . . 1.0 109.162 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -64.59 120.48 12.43 Favored 'General case' 0 CA--C 1.532 0.275 0 O-C-N 121.485 -0.759 . . . . 1.0 109.668 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 28.2 t -95.75 -19.48 19.63 Favored 'General case' 0 CA--C 1.534 0.327 0 O-C-N 121.586 -0.696 . . . . 1.0 109.456 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 175.3 -179.03 46.79 Favored Glycine 0 CA--C 1.528 0.871 0 N-CA-C 109.232 -1.547 . . . . 1.0 109.232 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.561 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.1 p90 -65.72 167.97 9.84 Favored Pre-proline 0 CA--C 1.537 0.455 0 O-C-N 121.369 -1.077 . . . . 1.0 108.929 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.68 -30.15 1.53 Allowed 'Trans proline' 0 N--CA 1.483 0.902 0 C-N-CA 124.418 3.412 . . . . 1.0 110.809 -178.713 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -57.16 -12.16 7.4 Favored Glycine 0 CA--C 1.536 1.401 0 N-CA-C 110.401 -1.079 . . . . 1.0 110.401 179.597 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.561 HG22 ' O ' ' A' ' 19' ' ' PHE . 24.2 m -61.3 162.92 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 O-C-N 121.253 -1.145 . . . . 1.0 109.641 179.694 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.4 p -121.6 154.75 60.05 Favored Pre-proline 0 CA--C 1.534 0.35 0 O-C-N 121.505 -0.747 . . . . 1.0 109.311 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.0 Cg_exo -35.8 -38.75 0.27 Allowed 'Trans proline' 0 N--CA 1.487 1.119 1 C-N-CA 125.479 4.12 . . . . 1.0 111.258 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 1.9 p -69.91 -48.08 59.97 Favored 'General case' 0 N--CA 1.463 0.213 0 O-C-N 121.511 -0.743 . . . . 1.0 109.791 -179.826 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -62.72 -46.15 89.42 Favored 'General case' 0 CA--C 1.533 0.322 0 O-C-N 121.4 -0.813 . . . . 1.0 109.749 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 17.3 t -64.59 -26.79 68.56 Favored 'General case' 0 CA--C 1.531 0.213 0 O-C-N 121.431 -0.793 . . . . 1.0 109.368 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.56 -8.85 54.06 Favored 'General case' 0 CA--C 1.532 0.271 0 O-C-N 121.562 -0.711 . . . . 1.0 109.811 179.708 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -77.94 -38.42 45.46 Favored 'General case' 0 CA--C 1.53 0.18 0 O-C-N 121.245 -0.91 . . . . 1.0 109.373 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.4 mmtt -83.69 -41.44 17.72 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 121.429 -0.794 . . . . 1.0 109.41 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 118.07 38.45 0.81 Allowed Glycine 0 CA--C 1.531 1.055 0 N-CA-C 109.569 -1.412 . . . . 1.0 109.569 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.7 m -112.61 147.97 35.56 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.606 -0.938 . . . . 1.0 109.485 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 66.4 m -69.5 125.14 25.82 Favored 'General case' 0 CA--C 1.529 0.163 0 O-C-N 121.477 -0.765 . . . . 1.0 109.36 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -99.1 143.13 29.71 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.508 -0.745 . . . . 1.0 109.367 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -157.0 113.9 3.06 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 121.529 -0.732 . . . . 1.0 109.503 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.423 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.9 p-10 -111.54 60.27 0.62 Allowed 'General case' 0 CA--C 1.533 0.321 0 O-C-N 121.492 -0.755 . . . . 1.0 109.39 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 67.7 p -99.8 -56.64 2.33 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.356 -0.84 . . . . 1.0 109.569 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.484 HG12 ' N ' ' A' ' 39' ' ' ARG . 36.5 t -98.23 161.88 2.87 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.22 0 O-C-N 121.485 -0.76 . . . . 1.0 109.425 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.484 ' N ' HG12 ' A' ' 38' ' ' VAL . 4.0 mpt_? -104.95 173.59 6.24 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.506 -0.746 . . . . 1.0 109.448 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.31 -45.53 3.06 Favored Glycine 0 CA--C 1.529 0.936 0 N-CA-C 109.477 -1.449 . . . . 1.0 109.477 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.6 m -79.37 169.52 20.01 Favored Pre-proline 0 CA--C 1.536 0.413 0 O-C-N 121.56 -0.965 . . . . 1.0 109.321 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -87.42 127.84 2.47 Favored 'Trans proline' 0 C--N 1.35 0.657 0 C-N-CA 124.805 3.67 . . . . 1.0 109.987 179.743 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.423 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 16.6 m0 -74.6 -38.54 62.58 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.457 -0.777 . . . . 1.0 109.918 -179.439 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 8.3 t -89.59 109.15 20.13 Favored 'General case' 0 CA--C 1.533 0.318 0 O-C-N 121.352 -0.842 . . . . 1.0 109.609 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.419 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 4.9 p90 -135.65 -178.69 5.24 Favored 'General case' 0 CA--C 1.535 0.397 0 O-C-N 121.415 -0.803 . . . . 1.0 109.463 179.708 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.402 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 18.6 m-85 -90.68 167.1 17.17 Favored Pre-proline 0 CA--C 1.536 0.426 0 O-C-N 121.487 -0.758 . . . . 1.0 109.592 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -91.23 148.65 3.66 Favored 'Trans proline' 0 C--N 1.35 0.628 0 C-N-CA 124.998 3.799 . . . . 1.0 110.461 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.6 m120 . . . . . 0 C--N 1.332 -0.173 0 N-CA-C 109.126 -0.694 . . . . 1.0 109.126 179.664 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.531 0.247 0 N-CA-C 109.53 -0.545 . . . . 1.0 109.53 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 74.0 m -107.04 19.98 19.67 Favored 'General case' 0 CA--C 1.532 0.277 0 O-C-N 121.539 -0.725 . . . . 1.0 109.548 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.611 HG23 ' O ' ' A' ' 8' ' ' THR . 4.8 t -82.89 94.87 7.79 Favored 'General case' 0 CA--C 1.532 0.286 0 O-C-N 121.456 -0.777 . . . . 1.0 109.749 -179.628 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.599 HG11 ' O ' ' A' ' 13' ' ' GLU . 39.8 t -122.16 155.04 26.95 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 O-C-N 121.526 -0.734 . . . . 1.0 109.035 179.639 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -81.23 137.49 49.08 Favored Pre-proline 0 CA--C 1.539 0.533 0 O-C-N 121.387 -0.82 . . . . 1.0 109.378 -179.731 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.456 ' HB3' HG11 ' A' ' 41' ' ' VAL . 18.4 Cg_exo -35.39 -36.41 0.15 Allowed 'Trans proline' 0 N--CA 1.488 1.159 1 C-N-CA 125.398 4.065 . . . . 1.0 111.266 -179.957 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 19.6 mtp180 -74.47 -49.91 20.4 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.529 -0.732 . . . . 1.0 109.674 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.599 ' O ' HG11 ' A' ' 9' ' ' VAL . 7.7 mm-40 -81.38 27.64 0.41 Allowed 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.481 -0.762 . . . . 1.0 109.808 -179.756 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 32.2 mtt180 -100.73 146.31 27.38 Favored 'General case' 0 N--CA 1.464 0.23 0 O-C-N 121.433 -0.792 . . . . 1.0 109.418 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 16.7 mt-30 -120.38 154.76 34.65 Favored 'General case' 0 C--N 1.332 -0.194 0 O-C-N 121.518 -0.739 . . . . 1.0 109.297 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ASN . . . . . 0.421 ' ND2' ' O ' ' A' ' 18' ' ' GLY . 8.1 t30 -80.32 125.15 29.53 Favored 'General case' 0 CA--C 1.53 0.197 0 O-C-N 121.498 -0.751 . . . . 1.0 109.132 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -98.62 -23.71 15.37 Favored 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.455 -0.778 . . . . 1.0 109.303 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.421 ' O ' ' ND2' ' A' ' 16' ' ' ASN . . . -167.13 -179.81 40.35 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 109.021 -1.632 . . . . 1.0 109.021 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.647 ' O ' HG22 ' A' ' 22' ' ' VAL . 7.8 p90 -67.68 167.17 17.31 Favored Pre-proline 0 CA--C 1.537 0.471 0 O-C-N 121.348 -1.09 . . . . 1.0 108.826 179.81 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -82.31 -29.57 1.48 Allowed 'Trans proline' 0 N--CA 1.483 0.908 0 C-N-CA 124.551 3.501 . . . . 1.0 110.914 -178.576 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -55.6 -15.34 8.52 Favored Glycine 0 CA--C 1.535 1.324 0 N-CA-C 110.35 -1.1 . . . . 1.0 110.35 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.647 HG22 ' O ' ' A' ' 19' ' ' PHE . 22.6 m -63.22 151.55 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 O-C-N 121.326 -1.103 . . . . 1.0 109.543 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.59 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 73.0 p -99.7 154.64 37.16 Favored Pre-proline 0 CA--C 1.536 0.422 0 N-CA-C 108.99 -0.745 . . . . 1.0 108.99 179.311 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -33.18 -55.68 0.38 Allowed 'Trans proline' 0 N--CA 1.487 1.113 1 C-N-CA 125.797 4.332 . . . . 1.0 111.862 -179.454 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 67.6 m -80.12 -27.38 39.15 Favored 'General case' 0 N--CA 1.464 0.245 0 O-C-N 121.43 -0.793 . . . . 1.0 110.565 -179.041 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLN . . . . . 0.59 ' HB2' ' H ' ' A' ' 23' ' ' THR . 10.5 mt-30 -61.46 -54.51 42.44 Favored 'General case' 0 N--CA 1.466 0.353 0 O-C-N 121.287 -0.883 . . . . 1.0 110.332 -179.47 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -77.5 -27.2 51.77 Favored 'General case' 0 CA--C 1.534 0.333 0 O-C-N 121.393 -0.817 . . . . 1.0 109.886 -179.261 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.72 -5.01 57.73 Favored 'General case' 0 CA--C 1.534 0.365 0 O-C-N 121.422 -0.799 . . . . 1.0 110.113 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -106.8 -4.39 19.36 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.316 -0.865 . . . . 1.0 109.8 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.1 tttt -89.9 -46.69 8.37 Favored 'General case' 0 CA--C 1.533 0.289 0 O-C-N 121.269 -0.895 . . . . 1.0 109.196 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 151.22 19.14 0.06 OUTLIER Glycine 0 CA--C 1.531 1.054 0 N-CA-C 109.528 -1.429 . . . . 1.0 109.528 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 85.6 m -119.17 148.96 42.51 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.423 -1.045 . . . . 1.0 109.285 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 55.9 m -77.49 115.63 17.41 Favored 'General case' 0 N--CA 1.463 0.221 0 O-C-N 121.557 -0.715 . . . . 1.0 109.083 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.436 ' CD1' ' N ' ' A' ' 35' ' ' ASP . 46.5 t80 -89.95 152.37 21.24 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.446 -0.784 . . . . 1.0 109.722 -179.618 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.436 ' N ' ' CD1' ' A' ' 34' ' ' PHE . 28.5 t70 -165.29 118.7 1.21 Allowed 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.589 -0.694 . . . . 1.0 109.309 179.724 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -120.34 51.54 1.21 Allowed 'General case' 0 CA--C 1.534 0.329 0 O-C-N 121.532 -0.73 . . . . 1.0 109.547 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -99.77 -15.59 18.4 Favored 'General case' 0 CA--C 1.533 0.317 0 O-C-N 121.308 -0.87 . . . . 1.0 109.937 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.463 HG12 ' N ' ' A' ' 39' ' ' ARG . 37.3 t -129.71 161.02 40.1 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.222 0 O-C-N 121.335 -0.853 . . . . 1.0 109.625 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.463 ' N ' HG12 ' A' ' 38' ' ' VAL . 79.5 mtt85 -111.89 166.96 10.75 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.516 -0.74 . . . . 1.0 109.379 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.55 -41.99 2.38 Favored Glycine 0 CA--C 1.53 0.986 0 N-CA-C 109.234 -1.546 . . . . 1.0 109.234 -179.818 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.456 HG11 ' HB3' ' A' ' 11' ' ' PRO . 28.9 m -81.1 170.63 14.75 Favored Pre-proline 0 CA--C 1.537 0.478 0 O-C-N 121.587 -0.949 . . . . 1.0 109.049 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' PRO . . . . . 0.405 ' CD ' ' HB ' ' A' ' 41' ' ' VAL . 11.7 Cg_endo -85.87 126.31 2.89 Favored 'Trans proline' 0 C--N 1.352 0.744 0 C-N-CA 124.539 3.493 . . . . 1.0 110.018 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' TRP . . . . . . . . . . . . . 33.8 m0 -75.41 -37.6 60.35 Favored 'General case' 0 N--CA 1.462 0.169 0 O-C-N 121.429 -0.794 . . . . 1.0 109.91 -179.536 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 6.5 t -90.08 113.99 25.82 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.415 -0.803 . . . . 1.0 109.539 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.416 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 5.7 p90 -140.02 170.91 14.98 Favored 'General case' 0 CA--C 1.536 0.424 0 O-C-N 121.388 -0.82 . . . . 1.0 110.025 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 61.8 m-85 -77.06 170.59 15.6 Favored Pre-proline 0 CA--C 1.537 0.443 0 O-C-N 121.674 -0.641 . . . . 1.0 109.419 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -88.18 173.12 4.92 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 124.829 3.686 . . . . 1.0 110.415 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.5 m120 . . . . . 0 CA--C 1.531 0.215 0 O-C-N 121.664 -0.647 . . . . 1.0 109.346 179.905 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.7 m . . . . . 0 C--O 1.233 0.198 0 CA-C-O 121.302 0.572 . . . . 1.0 109.953 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 86.2 m -108.07 -18.53 13.76 Favored 'General case' 0 CA--C 1.534 0.336 0 O-C-N 121.444 -0.785 . . . . 1.0 109.216 179.337 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.551 HG23 ' O ' ' A' ' 8' ' ' THR . 3.1 t -68.78 101.42 1.33 Allowed 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.201 -0.937 . . . . 1.0 109.521 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.612 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.6 t -121.82 171.16 11.02 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 O-C-N 121.575 -0.703 . . . . 1.0 109.233 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.612 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -67.99 129.17 93.25 Favored Pre-proline 0 CA--C 1.539 0.541 0 O-C-N 121.355 -0.84 . . . . 1.0 109.483 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -36.95 -50.21 1.48 Allowed 'Trans proline' 0 N--CA 1.49 1.281 0 C-N-CA 125.027 3.818 . . . . 1.0 111.227 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.413 ' HD2' ' H ' ' A' ' 12' ' ' ARG . 1.2 mpt_? -70.75 -39.55 73.21 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.502 -0.749 . . . . 1.0 109.833 -179.591 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -81.42 29.24 0.37 Allowed 'General case' 0 CA--C 1.532 0.254 0 O-C-N 121.529 -0.732 . . . . 1.0 109.716 -179.72 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 37.9 mtt180 -101.41 120.63 40.57 Favored 'General case' 0 N--CA 1.464 0.248 0 O-C-N 121.417 -0.802 . . . . 1.0 109.368 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 -79.86 121.43 25.4 Favored 'General case' 0 CA--C 1.531 0.216 0 O-C-N 121.491 -0.756 . . . . 1.0 109.261 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -63.91 121.4 13.98 Favored 'General case' 0 CA--C 1.532 0.261 0 O-C-N 121.517 -0.74 . . . . 1.0 109.911 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.3 t -93.73 -20.33 20.23 Favored 'General case' 0 CA--C 1.534 0.351 0 O-C-N 121.562 -0.711 . . . . 1.0 109.272 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 179.57 177.23 47.71 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 109.178 -1.569 . . . . 1.0 109.178 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.533 ' CD2' HG13 ' A' ' 22' ' ' VAL . 8.8 p90 -65.01 167.7 9.0 Favored Pre-proline 0 CA--C 1.538 0.516 0 O-C-N 121.446 -1.032 . . . . 1.0 108.885 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.58 -30.67 1.38 Allowed 'Trans proline' 0 N--CA 1.481 0.777 0 C-N-CA 124.45 3.433 . . . . 1.0 110.802 -178.845 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.46 -10.04 7.22 Favored Glycine 0 CA--C 1.537 1.454 0 N-CA-C 110.307 -1.117 . . . . 1.0 110.307 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.533 HG13 ' CD2' ' A' ' 19' ' ' PHE . 24.2 m -60.66 -174.74 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 O-C-N 121.231 -1.158 . . . . 1.0 109.531 179.763 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.42 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 4.1 p -143.74 153.72 58.28 Favored Pre-proline 0 CA--C 1.537 0.45 0 O-C-N 121.515 -0.741 . . . . 1.0 109.285 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -35.85 -36.97 0.2 Allowed 'Trans proline' 0 N--CA 1.487 1.134 1 C-N-CA 125.32 4.013 . . . . 1.0 111.382 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.6 t -73.73 -47.34 40.04 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.442 -0.786 . . . . 1.0 109.756 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLN . . . . . 0.42 ' HB2' ' H ' ' A' ' 23' ' ' THR . 45.0 mt-30 -61.65 -44.73 96.42 Favored 'General case' 0 N--CA 1.466 0.327 0 O-C-N 121.436 -0.79 . . . . 1.0 109.674 -179.831 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 8.5 t -65.34 -32.63 74.37 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 121.486 -0.758 . . . . 1.0 109.382 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.6 -4.16 59.08 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 121.615 -0.678 . . . . 1.0 109.938 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -86.22 -23.55 26.39 Favored 'General case' 0 N--CA 1.464 0.258 0 O-C-N 121.218 -0.926 . . . . 1.0 109.636 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.3 tppp? -101.41 -34.94 9.38 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.379 -0.826 . . . . 1.0 109.315 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 111.49 53.62 0.52 Allowed Glycine 0 CA--C 1.529 0.955 0 N-CA-C 109.414 -1.475 . . . . 1.0 109.414 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.7 m -128.7 139.24 52.33 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.544 -0.974 . . . . 1.0 109.363 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.425 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 56.0 m -61.47 119.8 9.27 Favored 'General case' 0 N--CA 1.468 0.448 0 O-C-N 121.462 -0.774 . . . . 1.0 109.964 -179.344 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -101.51 121.56 42.19 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.423 -0.798 . . . . 1.0 109.192 179.623 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.443 ' OD1' HG23 ' A' ' 37' ' ' THR . 22.5 t0 -134.6 114.24 12.57 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.493 -0.754 . . . . 1.0 109.61 -179.783 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.424 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 5.8 p-10 -112.0 54.82 0.69 Allowed 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.503 -0.748 . . . . 1.0 109.156 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.443 HG23 ' OD1' ' A' ' 35' ' ' ASP . 39.3 p -104.01 -31.27 9.79 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.377 -0.827 . . . . 1.0 109.61 -179.724 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.41 ' HB ' HG21 ' A' ' 41' ' ' VAL . 34.9 t -114.88 151.76 16.58 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 O-C-N 121.406 -0.809 . . . . 1.0 109.478 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 21.7 mtm-85 -101.77 165.65 11.09 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 121.497 -0.752 . . . . 1.0 109.471 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.54 -33.79 2.52 Favored Glycine 0 CA--C 1.53 1.017 0 N-CA-C 109.457 -1.457 . . . . 1.0 109.457 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.41 HG21 ' HB ' ' A' ' 38' ' ' VAL . 28.5 m -88.13 169.99 12.52 Favored Pre-proline 0 CA--C 1.537 0.473 0 O-C-N 121.521 -0.988 . . . . 1.0 109.222 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -86.63 123.57 2.15 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 124.724 3.616 . . . . 1.0 110.04 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.424 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 23.9 m0 -75.3 -43.93 48.34 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.555 -0.716 . . . . 1.0 109.873 -179.515 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.6 t -88.8 109.11 19.91 Favored 'General case' 0 CA--C 1.535 0.365 0 O-C-N 121.328 -0.857 . . . . 1.0 109.915 -179.841 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.428 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 7.1 p90 -138.9 177.33 7.97 Favored 'General case' 0 CA--C 1.537 0.453 0 O-C-N 121.461 -0.775 . . . . 1.0 109.547 179.259 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.428 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 70.6 m-85 -78.78 169.32 21.22 Favored Pre-proline 0 CA--C 1.537 0.463 0 O-C-N 121.271 -0.893 . . . . 1.0 109.975 -179.568 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -92.34 167.69 2.86 Favored 'Trans proline' 0 C--N 1.352 0.711 0 C-N-CA 125.047 3.831 . . . . 1.0 110.582 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.512 HD22 HG21 ' A' ' 9' ' ' VAL . 23.1 m-20 . . . . . 0 N--CA 1.463 0.222 0 O-C-N 121.466 -0.771 . . . . 1.0 109.273 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.868 HG22 HG22 ' A' ' 8' ' ' THR . 0.9 OUTLIER . . . . . 0 CA--C 1.53 0.208 0 CA-C-O 121.148 0.499 . . . . 1.0 109.667 . . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.5 m -117.18 46.18 1.74 Allowed 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.463 -0.773 . . . . 1.0 109.314 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.868 HG22 HG22 ' A' ' 6' ' ' THR . 4.9 t -131.01 106.89 8.7 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.517 -0.739 . . . . 1.0 109.369 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.639 HG12 ' H ' ' A' ' 10' ' ' ALA . 21.7 t -125.09 174.09 9.82 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 O-C-N 121.369 -0.832 . . . . 1.0 109.34 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.639 ' H ' HG12 ' A' ' 9' ' ' VAL . . . -74.92 140.33 74.0 Favored Pre-proline 0 CA--C 1.538 0.508 0 O-C-N 121.479 -0.763 . . . . 1.0 109.57 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_exo -34.81 -61.24 0.25 Allowed 'Trans proline' 0 N--CA 1.488 1.171 1 C-N-CA 125.484 4.122 . . . . 1.0 111.566 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -69.93 -29.95 67.22 Favored 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.476 -0.765 . . . . 1.0 110.107 -179.287 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.541 ' O ' HG11 ' A' ' 9' ' ' VAL . 13.1 mt-10 -85.29 36.62 0.64 Allowed 'General case' 0 N--CA 1.464 0.252 0 O-C-N 121.289 -0.882 . . . . 1.0 109.642 -179.736 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.403 HH12 ' HB3' ' A' ' 35' ' ' ASP . 50.4 mtt180 -108.1 142.94 37.54 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.508 -0.745 . . . . 1.0 109.435 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -102.35 115.02 29.71 Favored 'General case' 0 N--CA 1.463 0.195 0 O-C-N 121.547 -0.721 . . . . 1.0 109.399 179.813 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 48.9 t30 -61.06 118.7 7.1 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 121.391 -0.818 . . . . 1.0 109.784 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 t -94.51 -18.85 21.06 Favored 'General case' 0 CA--C 1.534 0.352 0 O-C-N 121.463 -0.773 . . . . 1.0 109.247 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.43 178.2 47.8 Favored Glycine 0 CA--C 1.53 0.976 0 N-CA-C 108.967 -1.653 . . . . 1.0 108.967 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.58 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.5 p90 -65.92 167.81 10.68 Favored Pre-proline 0 CA--C 1.539 0.542 0 O-C-N 121.369 -1.077 . . . . 1.0 108.799 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -82.12 -30.09 1.38 Allowed 'Trans proline' 0 N--CA 1.483 0.855 0 C-N-CA 124.38 3.387 . . . . 1.0 110.992 -178.71 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -56.62 -13.73 8.33 Favored Glycine 0 CA--C 1.536 1.358 0 N-CA-C 110.36 -1.096 . . . . 1.0 110.36 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.58 HG22 ' O ' ' A' ' 19' ' ' PHE . 20.4 m -60.7 173.54 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 O-C-N 121.239 -1.153 . . . . 1.0 109.768 179.849 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 73.6 p -131.84 155.7 81.06 Favored Pre-proline 0 CA--C 1.534 0.339 0 O-C-N 121.524 -0.735 . . . . 1.0 109.143 179.773 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -35.74 -33.82 0.12 Allowed 'Trans proline' 0 N--CA 1.49 1.267 1 C-N-CA 125.354 4.036 . . . . 1.0 111.233 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 39.7 m -75.68 -47.74 24.98 Favored 'General case' 0 CA--C 1.532 0.253 0 O-C-N 121.396 -0.815 . . . . 1.0 109.956 -179.622 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -65.3 -47.25 77.25 Favored 'General case' 0 CA--C 1.533 0.307 0 O-C-N 121.468 -0.77 . . . . 1.0 109.85 -179.689 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 11.2 t -62.48 -29.86 70.84 Favored 'General case' 0 N--CA 1.464 0.269 0 O-C-N 121.408 -0.808 . . . . 1.0 109.796 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -90.52 -9.79 45.95 Favored 'General case' 0 N--CA 1.465 0.281 0 O-C-N 121.464 -0.772 . . . . 1.0 110.098 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -93.03 -5.09 51.33 Favored 'General case' 0 CA--C 1.534 0.34 0 O-C-N 121.224 -0.923 . . . . 1.0 110.028 -179.762 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 51.9 mttp -109.52 -27.28 9.51 Favored 'General case' 0 N--CA 1.464 0.246 0 O-C-N 121.337 -0.852 . . . . 1.0 109.544 -179.794 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.08 22.66 5.83 Favored Glycine 0 CA--C 1.53 0.993 0 N-CA-C 109.568 -1.413 . . . . 1.0 109.568 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 22.8 m -112.74 137.21 51.38 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.469 -1.018 . . . . 1.0 108.564 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.6 m -72.85 133.87 44.62 Favored 'General case' 0 N--CA 1.463 0.222 0 O-C-N 121.316 -0.865 . . . . 1.0 109.735 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -101.68 139.63 37.07 Favored 'General case' 0 C--O 1.232 0.163 0 O-C-N 121.626 -0.671 . . . . 1.0 109.223 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.403 ' HB3' HH12 ' A' ' 14' ' ' ARG . 9.9 t0 -148.62 102.39 3.3 Favored 'General case' 0 N--CA 1.463 0.202 0 O-C-N 121.306 -0.871 . . . . 1.0 109.591 -179.785 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.435 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 7.0 p-10 -104.9 73.93 1.1 Allowed 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.525 -0.735 . . . . 1.0 109.294 179.83 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 30.6 p -118.66 -43.6 2.68 Favored 'General case' 0 CA--C 1.53 0.177 0 O-C-N 121.43 -0.794 . . . . 1.0 109.494 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 38.2 t -110.81 153.06 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 O-C-N 121.467 -0.771 . . . . 1.0 109.287 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 7.8 mtt-85 -101.11 172.51 6.97 Favored 'General case' 0 CA--C 1.532 0.271 0 O-C-N 121.545 -0.722 . . . . 1.0 109.337 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.72 -31.14 3.06 Favored Glycine 0 CA--C 1.529 0.917 0 N-CA-C 109.501 -1.44 . . . . 1.0 109.501 -179.884 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.404 ' HB ' ' CD ' ' A' ' 42' ' ' PRO . 29.6 m -99.83 170.55 6.61 Favored Pre-proline 0 CA--C 1.537 0.478 0 O-C-N 121.501 -1.0 . . . . 1.0 109.129 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' PRO . . . . . 0.404 ' CD ' ' HB ' ' A' ' 41' ' ' VAL . 11.2 Cg_endo -85.64 126.41 3.01 Favored 'Trans proline' 0 N--CA 1.479 0.654 0 C-N-CA 124.506 3.471 . . . . 1.0 110.036 179.745 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.435 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 10.0 m0 -77.64 -38.89 46.91 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.555 -0.715 . . . . 1.0 109.837 -179.356 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 28.1 t -89.44 103.84 16.45 Favored 'General case' 0 CA--C 1.534 0.357 0 O-C-N 121.385 -0.822 . . . . 1.0 109.566 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.406 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 5.1 p90 -132.87 177.42 7.66 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.259 -0.901 . . . . 1.0 109.881 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' TYR . . . . . 0.406 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 32.2 m-85 -74.1 169.81 17.44 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 121.61 -0.681 . . . . 1.0 109.684 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -93.35 173.16 1.85 Allowed 'Trans proline' 0 C--N 1.35 0.643 0 C-N-CA 125.217 3.944 . . . . 1.0 110.612 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 8.2 m120 . . . . . 0 CA--C 1.531 0.241 0 O-C-N 121.54 -0.725 . . . . 1.0 109.38 179.989 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 . . . . . 0 CA--C 1.531 0.232 0 N-CA-C 109.414 -0.587 . . . . 1.0 109.414 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -165.0 166.45 19.33 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.495 -0.753 . . . . 1.0 109.535 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -110.56 171.26 7.56 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.487 -0.758 . . . . 1.0 109.385 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 15.6 p -132.31 144.09 50.33 Favored 'General case' 0 CA--C 1.529 0.165 0 O-C-N 121.531 -0.73 . . . . 1.0 109.56 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -84.41 137.5 33.35 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.559 -0.713 . . . . 1.0 109.141 179.757 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.1 m -149.62 124.34 9.83 Favored 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.575 -0.703 . . . . 1.0 109.715 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 75.1 m -113.22 -14.19 12.89 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.498 -0.751 . . . . 1.0 109.594 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.548 HG23 ' O ' ' A' ' 8' ' ' THR . 2.8 t -71.19 96.44 1.38 Allowed 'General case' 0 CA--C 1.53 0.211 0 O-C-N 121.286 -0.884 . . . . 1.0 109.658 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.584 HG12 ' N ' ' A' ' 10' ' ' ALA . 39.4 t -119.35 168.98 11.01 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 O-C-N 121.465 -0.772 . . . . 1.0 109.074 179.7 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.891 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -65.21 121.27 73.53 Favored Pre-proline 0 CA--C 1.542 0.65 0 O-C-N 121.386 -0.821 . . . . 1.0 109.17 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.419 ' HD2' ' HA ' ' A' ' 10' ' ' ALA . 19.1 Cg_exo -36.95 -47.43 1.46 Allowed 'Trans proline' 0 N--CA 1.49 1.281 0 C-N-CA 124.917 3.745 . . . . 1.0 111.334 -179.559 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -75.88 -39.44 56.44 Favored 'General case' 0 N--CA 1.463 0.208 0 O-C-N 121.466 -0.771 . . . . 1.0 109.745 -179.775 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.891 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 28.0 mt-10 -84.33 38.38 0.67 Allowed 'General case' 0 N--CA 1.462 0.162 0 O-C-N 121.399 -0.813 . . . . 1.0 109.565 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 18.6 mtt180 -104.82 145.64 30.1 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.446 -0.784 . . . . 1.0 109.407 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 10.1 mp0 -94.69 120.6 35.17 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 121.542 -0.724 . . . . 1.0 109.36 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 62.7 t30 -63.63 120.34 11.59 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.457 -0.777 . . . . 1.0 109.817 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.42 ' HA ' ' CE2' ' A' ' 46' ' ' TYR . 44.3 t -94.65 -17.77 21.97 Favored 'General case' 0 CA--C 1.535 0.385 0 O-C-N 121.574 -0.704 . . . . 1.0 109.329 179.716 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 177.15 175.44 44.43 Favored Glycine 0 CA--C 1.529 0.939 0 N-CA-C 109.404 -1.479 . . . . 1.0 109.404 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.567 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.5 p90 -64.61 167.95 7.84 Favored Pre-proline 0 CA--C 1.538 0.512 0 O-C-N 121.383 -1.069 . . . . 1.0 109.063 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.33 -31.36 1.25 Allowed 'Trans proline' 0 N--CA 1.483 0.905 0 C-N-CA 124.341 3.361 . . . . 1.0 110.643 -178.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.75 -7.91 6.95 Favored Glycine 0 CA--C 1.537 1.438 0 N-CA-C 110.294 -1.122 . . . . 1.0 110.294 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.567 HG22 ' O ' ' A' ' 19' ' ' PHE . 17.4 m -60.17 -178.97 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 O-C-N 121.208 -1.172 . . . . 1.0 109.742 179.762 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.433 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 12.0 p -138.5 155.08 73.88 Favored Pre-proline 0 CA--C 1.536 0.43 0 O-C-N 121.513 -0.742 . . . . 1.0 109.276 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -36.05 -36.45 0.2 Allowed 'Trans proline' 0 N--CA 1.488 1.187 1 C-N-CA 125.368 4.045 . . . . 1.0 111.316 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 42.1 t -73.99 -46.07 46.1 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.405 -0.809 . . . . 1.0 109.874 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLN . . . . . 0.433 ' HB2' ' H ' ' A' ' 23' ' ' THR . 38.0 mt-30 -60.57 -48.63 80.91 Favored 'General case' 0 N--CA 1.464 0.258 0 O-C-N 121.468 -0.77 . . . . 1.0 109.988 -179.808 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.7 t -65.11 -27.73 68.95 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.409 -0.807 . . . . 1.0 109.497 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.34 -5.26 58.42 Favored 'General case' 0 CA--C 1.535 0.38 0 O-C-N 121.547 -0.721 . . . . 1.0 109.846 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.0 t-20 -70.83 -49.45 46.17 Favored 'General case' 0 N--CA 1.463 0.181 0 O-C-N 121.408 -0.808 . . . . 1.0 109.363 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.441 ' HG2' ' H ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -83.64 -44.7 14.27 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.534 -0.729 . . . . 1.0 109.432 179.889 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.441 ' H ' ' HG2' ' A' ' 30' ' ' LYS . . . 125.65 32.45 0.76 Allowed Glycine 0 CA--C 1.531 1.075 0 N-CA-C 109.958 -1.257 . . . . 1.0 109.958 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.5 m -92.26 144.7 25.13 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.43 -1.041 . . . . 1.0 109.301 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.402 ' O ' ' CD1' ' A' ' 45' ' ' PHE . 60.0 m -66.51 115.4 6.35 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.462 -0.774 . . . . 1.0 109.516 -179.814 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -94.6 132.01 39.76 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.38 -0.825 . . . . 1.0 109.33 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -144.2 111.12 5.74 Favored 'General case' 0 CA--C 1.53 0.19 0 O-C-N 121.425 -0.797 . . . . 1.0 109.481 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.434 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.0 p-10 -115.34 70.42 0.74 Allowed 'General case' 0 CA--C 1.534 0.334 0 O-C-N 121.509 -0.745 . . . . 1.0 109.414 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 43.9 p -114.45 -39.35 3.84 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.429 -0.794 . . . . 1.0 109.471 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.577 HG12 ' N ' ' A' ' 39' ' ' ARG . 39.9 t -111.95 167.93 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 O-C-N 121.519 -0.738 . . . . 1.0 109.401 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.577 ' N ' HG12 ' A' ' 38' ' ' VAL . 4.9 ttm180 -113.31 175.99 5.22 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.432 -0.793 . . . . 1.0 109.432 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.51 -37.33 2.25 Favored Glycine 0 CA--C 1.53 0.996 0 N-CA-C 109.41 -1.476 . . . . 1.0 109.41 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 28.9 m -94.66 170.39 8.16 Favored Pre-proline 0 CA--C 1.536 0.431 0 O-C-N 121.571 -0.958 . . . . 1.0 109.174 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_endo -85.68 139.31 6.57 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 124.628 3.552 . . . . 1.0 109.937 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.434 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 11.2 m0 -89.22 -41.05 12.44 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 121.502 -0.749 . . . . 1.0 110.028 -179.304 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 18.5 t -89.31 107.43 19.06 Favored 'General case' 0 N--CA 1.465 0.309 0 O-C-N 121.426 -0.797 . . . . 1.0 109.719 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.417 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 9.5 p90 -135.05 173.81 11.31 Favored 'General case' 0 CA--C 1.537 0.479 0 O-C-N 121.346 -0.846 . . . . 1.0 109.633 179.59 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.42 ' CE2' ' HA ' ' A' ' 17' ' ' CYS . 90.8 m-85 -82.11 167.38 31.04 Favored Pre-proline 0 CA--C 1.536 0.419 0 O-C-N 121.493 -0.755 . . . . 1.0 109.716 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -89.65 161.52 5.26 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 124.998 3.799 . . . . 1.0 110.424 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -136.62 100.09 4.24 Favored 'General case' 0 CA--C 1.531 0.216 0 O-C-N 121.549 -0.719 . . . . 1.0 109.388 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 41.3 p -77.68 116.04 17.91 Favored 'General case' 0 CA--C 1.53 0.209 0 O-C-N 121.503 -0.748 . . . . 1.0 109.476 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 60.2 mt -98.82 144.49 11.66 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 O-C-N 121.527 -0.733 . . . . 1.0 109.374 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -80.94 130.05 34.84 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.479 -0.763 . . . . 1.0 109.528 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.607 HG23 ' O ' ' A' ' 52' ' ' VAL . 27.9 m -126.85 79.38 72.44 Favored Pre-proline 0 CA--C 1.539 0.532 0 O-C-N 121.421 -0.799 . . . . 1.0 109.456 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.434 ' N ' ' CD ' ' A' ' 54' ' ' PRO . 16.7 Cg_exo -34.85 -46.59 0.59 Allowed 'Trans proline' 0 N--CA 1.487 1.127 0 C-N-CA 125.214 3.943 . . . . 1.0 111.862 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.434 ' CD ' ' N ' ' A' ' 53' ' ' PRO . 19.3 Cg_endo -91.28 121.43 0.68 Allowed 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 124.737 3.625 . . . . 1.0 110.418 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.0 tt0 -80.26 141.59 35.4 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.457 -0.777 . . . . 1.0 109.412 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -103.09 175.08 5.59 Favored 'General case' 0 N--CA 1.463 0.199 0 O-C-N 121.499 -0.751 . . . . 1.0 109.463 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -108.76 141.96 40.0 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.569 -0.707 . . . . 1.0 109.452 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.7 p -134.46 179.32 6.35 Favored 'General case' 0 CA--C 1.53 0.189 0 O-C-N 121.526 -0.734 . . . . 1.0 109.473 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -76.47 137.7 39.83 Favored 'General case' 0 N--CA 1.463 0.177 0 O-C-N 121.501 -0.749 . . . . 1.0 109.455 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 25.9 t80 . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.983 -1.008 . . . . 1.0 109.417 -179.964 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 . . . . . 0 CA--C 1.529 0.162 0 N-CA-C 109.419 -0.585 . . . . 1.0 109.419 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -158.79 33.69 0.22 Allowed 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.392 -0.818 . . . . 1.0 109.491 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 9.7 mp0 -85.67 102.66 13.79 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.497 -0.752 . . . . 1.0 109.5 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 17.0 p -146.83 -168.2 2.97 Favored 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.575 -0.703 . . . . 1.0 109.404 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -86.39 137.24 32.72 Favored 'General case' 0 CA--C 1.531 0.213 0 O-C-N 121.462 -0.774 . . . . 1.0 109.441 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.569 HG22 HG22 ' A' ' 8' ' ' THR . 0.8 OUTLIER -128.11 146.74 50.6 Favored 'General case' 0 CA--C 1.53 0.181 0 O-C-N 121.544 -0.722 . . . . 1.0 109.383 179.832 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.411 ' HB3' ' CZ ' ' A' ' 45' ' ' PHE . 62.8 m -125.91 31.49 5.46 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.488 -0.758 . . . . 1.0 109.022 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.569 HG22 HG22 ' A' ' 6' ' ' THR . 5.1 t -96.08 118.9 33.58 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.657 -0.652 . . . . 1.0 109.556 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.435 HG11 ' O ' ' A' ' 13' ' ' GLU . 34.2 t -149.92 156.21 7.24 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.206 0 O-C-N 121.495 -0.753 . . . . 1.0 109.236 179.828 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -74.07 136.72 76.04 Favored Pre-proline 0 CA--C 1.54 0.59 0 O-C-N 121.482 -0.761 . . . . 1.0 109.308 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -35.05 -41.05 0.28 Allowed 'Trans proline' 0 N--CA 1.488 1.171 1 C-N-CA 125.361 4.041 . . . . 1.0 111.305 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.7 mtt180 -80.95 -44.61 17.95 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.543 -0.723 . . . . 1.0 109.759 -179.784 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.435 ' O ' HG11 ' A' ' 9' ' ' VAL . 19.9 mt-10 -74.56 10.46 1.34 Allowed 'General case' 0 CA--C 1.533 0.326 0 O-C-N 121.417 -0.802 . . . . 1.0 109.975 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 24.2 mtt180 -81.25 124.37 29.26 Favored 'General case' 0 CA--C 1.529 0.164 0 O-C-N 121.34 -0.85 . . . . 1.0 109.361 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 25.5 mm100 -92.56 126.76 37.79 Favored 'General case' 0 N--CA 1.463 0.197 0 O-C-N 121.463 -0.773 . . . . 1.0 109.025 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.2 t-20 -72.23 116.68 12.95 Favored 'General case' 0 CA--C 1.532 0.286 0 O-C-N 121.604 -0.685 . . . . 1.0 109.942 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -83.55 -6.97 59.6 Favored 'General case' 0 CA--C 1.537 0.447 0 O-C-N 121.53 -0.731 . . . . 1.0 109.208 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.84 170.0 37.42 Favored Glycine 0 CA--C 1.532 1.097 0 N-CA-C 108.353 -1.899 . . . . 1.0 108.353 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.442 ' O ' HG22 ' A' ' 22' ' ' VAL . 7.5 p90 -62.52 168.33 4.35 Favored Pre-proline 0 CA--C 1.54 0.56 0 O-C-N 121.208 -1.172 . . . . 1.0 109.043 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -81.36 -30.25 1.61 Allowed 'Trans proline' 0 N--CA 1.481 0.785 0 C-N-CA 124.304 3.336 . . . . 1.0 110.677 -178.648 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.23 -6.82 8.12 Favored Glycine 0 CA--C 1.536 1.374 0 N-CA-C 110.052 -1.219 . . . . 1.0 110.052 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.442 HG22 ' O ' ' A' ' 19' ' ' PHE . 29.2 m -60.25 -176.31 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 O-C-N 121.157 -1.202 . . . . 1.0 109.816 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.419 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 10.6 p -137.38 155.95 75.36 Favored Pre-proline 0 CA--C 1.535 0.368 0 O-C-N 121.51 -0.744 . . . . 1.0 109.13 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_exo -37.47 -42.24 1.08 Allowed 'Trans proline' 0 N--CA 1.488 1.176 0 C-N-CA 125.188 3.926 . . . . 1.0 111.001 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 80.3 p -69.45 -42.76 74.51 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.524 -0.735 . . . . 1.0 110.118 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLN . . . . . 0.419 ' HB2' ' H ' ' A' ' 23' ' ' THR . 13.9 mm100 -65.61 -53.92 34.91 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.401 -0.812 . . . . 1.0 109.909 -179.562 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 18.9 t -62.04 -19.71 63.17 Favored 'General case' 0 CA--C 1.534 0.357 0 O-C-N 121.409 -0.807 . . . . 1.0 109.934 -179.687 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -100.54 -3.56 30.41 Favored 'General case' 0 CA--C 1.535 0.378 0 O-C-N 121.356 -0.84 . . . . 1.0 110.154 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -73.78 -44.07 57.09 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.395 -0.815 . . . . 1.0 109.855 -179.476 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.9 tttm -86.26 -41.39 14.64 Favored 'General case' 0 N--CA 1.462 0.154 0 O-C-N 121.43 -0.794 . . . . 1.0 109.662 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 127.27 19.71 1.88 Allowed Glycine 0 CA--C 1.53 1.031 0 N-CA-C 109.473 -1.451 . . . . 1.0 109.473 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 60.8 m -77.39 140.42 39.91 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.43 -1.041 . . . . 1.0 109.028 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 84.5 m -66.87 123.09 19.2 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.414 -0.803 . . . . 1.0 109.647 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -96.51 147.78 23.49 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.439 -0.788 . . . . 1.0 109.162 179.653 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -161.72 135.12 6.38 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.384 -0.822 . . . . 1.0 109.486 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -133.17 38.24 3.34 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.515 -0.741 . . . . 1.0 109.471 179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 59.9 p -72.05 -58.7 3.22 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.48 -0.763 . . . . 1.0 109.541 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.0 t -110.07 138.12 39.26 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 O-C-N 121.429 -0.794 . . . . 1.0 109.408 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -83.62 178.03 8.15 Favored 'General case' 0 CA--C 1.53 0.19 0 O-C-N 121.496 -0.752 . . . . 1.0 109.247 179.808 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.56 -45.73 3.15 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 109.339 -1.504 . . . . 1.0 109.339 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.414 HG22 ' H ' ' A' ' 41' ' ' VAL . 26.7 m -84.43 157.33 61.84 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.647 -0.914 . . . . 1.0 109.325 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -59.63 129.24 30.06 Favored 'Trans proline' 0 N--CA 1.488 1.164 0 C-N-CA 124.164 3.243 . . . . 1.0 110.308 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' TRP . . . . . . . . . . . . . 40.4 m0 -87.27 -45.87 10.22 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.521 -0.737 . . . . 1.0 109.173 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 27.4 t -89.92 110.42 21.37 Favored 'General case' 0 CA--C 1.534 0.338 0 O-C-N 121.493 -0.755 . . . . 1.0 108.978 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.433 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 5.2 p90 -134.1 175.87 9.09 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 121.302 -0.874 . . . . 1.0 110.257 -179.371 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.41 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 21.5 m-85 -82.18 171.33 12.18 Favored Pre-proline 0 CA--C 1.537 0.47 0 O-C-N 121.523 -0.735 . . . . 1.0 109.522 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -90.84 -166.39 0.19 Allowed 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 124.939 3.759 . . . . 1.0 110.102 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -158.42 100.51 1.66 Allowed 'General case' 0 N--CA 1.463 0.192 0 O-C-N 121.478 -0.763 . . . . 1.0 109.509 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 33.5 p -80.7 97.89 7.48 Favored 'General case' 0 CA--C 1.532 0.265 0 O-C-N 121.429 -0.795 . . . . 1.0 109.306 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.526 HG22 ' N ' ' A' ' 51' ' ' ASP . 63.4 mt -136.92 165.08 28.89 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 O-C-N 121.443 -0.786 . . . . 1.0 109.374 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.526 ' N ' HG22 ' A' ' 50' ' ' ILE . 2.2 t0 -107.29 -166.66 1.18 Allowed 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.433 -0.792 . . . . 1.0 109.443 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.1 m -130.8 160.36 66.89 Favored Pre-proline 0 CA--C 1.536 0.427 0 O-C-N 121.502 -0.749 . . . . 1.0 109.379 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -91.59 154.46 3.54 Favored 'Trans proline' 0 CA--C 1.537 0.642 0 C-N-CA 124.956 3.77 . . . . 1.0 110.359 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -34.47 -46.33 0.52 Allowed 'Trans proline' 0 N--CA 1.489 1.234 1 C-N-CA 125.567 4.178 . . . . 1.0 111.18 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -134.63 165.73 24.56 Favored 'General case' 0 CA--C 1.53 0.209 0 O-C-N 121.532 -0.73 . . . . 1.0 109.382 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -111.46 117.47 33.12 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.436 -0.79 . . . . 1.0 109.37 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -143.84 108.13 4.79 Favored 'General case' 0 N--CA 1.463 0.215 0 O-C-N 121.47 -0.769 . . . . 1.0 109.409 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.7 m -141.7 122.23 14.16 Favored 'General case' 0 CA--C 1.53 0.196 0 O-C-N 121.521 -0.737 . . . . 1.0 109.466 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 20.2 tp10 -128.08 110.43 12.47 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.455 -0.778 . . . . 1.0 109.501 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 41.8 t80 . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.018 -0.991 . . . . 1.0 109.412 -179.964 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 . . . . . 0 CA--C 1.53 0.182 0 N-CA-C 109.478 -0.564 . . . . 1.0 109.478 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -117.49 88.42 2.91 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 121.483 -0.76 . . . . 1.0 109.507 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 2.5 mp0 -82.0 165.08 21.0 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.52 -0.737 . . . . 1.0 109.352 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.13 157.44 43.12 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.486 -0.759 . . . . 1.0 109.409 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -75.37 171.29 14.49 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 121.494 -0.754 . . . . 1.0 109.459 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.7 m -150.27 93.79 2.04 Favored 'General case' 0 CA--C 1.532 0.263 0 O-C-N 121.51 -0.744 . . . . 1.0 109.763 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 90.5 m -89.62 -15.82 31.91 Favored 'General case' 0 CA--C 1.533 0.326 0 O-C-N 121.311 -0.868 . . . . 1.0 109.493 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.56 HG23 ' O ' ' A' ' 8' ' ' THR . 4.8 t -71.31 112.45 7.45 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.429 -0.795 . . . . 1.0 109.907 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.552 HG12 ' N ' ' A' ' 10' ' ' ALA . 42.0 t -127.87 167.33 23.08 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.264 0 N-CA-C 108.84 -0.8 . . . . 1.0 108.84 179.626 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.758 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -71.67 125.41 91.7 Favored Pre-proline 0 CA--C 1.542 0.644 0 O-C-N 121.36 -0.838 . . . . 1.0 109.118 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.425 ' HB3' HG11 ' A' ' 41' ' ' VAL . 18.7 Cg_exo -36.84 -50.36 1.43 Allowed 'Trans proline' 0 N--CA 1.489 1.263 0 C-N-CA 124.899 3.732 . . . . 1.0 111.209 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.401 ' H ' ' HG2' ' A' ' 12' ' ' ARG . 18.7 ptt180 -73.8 -38.86 64.48 Favored 'General case' 0 N--CA 1.463 0.195 0 O-C-N 121.487 -0.758 . . . . 1.0 109.763 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.758 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 20.3 mt-10 -92.29 43.03 1.12 Allowed 'General case' 0 CA--C 1.532 0.253 0 O-C-N 121.405 -0.81 . . . . 1.0 109.574 -179.689 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 15.0 mtt180 -105.71 131.98 52.4 Favored 'General case' 0 CA--C 1.531 0.235 0 O-C-N 121.405 -0.81 . . . . 1.0 109.437 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -79.57 107.64 12.5 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 108.557 -0.905 . . . . 1.0 108.557 179.456 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 29.5 t30 -61.98 108.54 1.06 Allowed 'General case' 0 N--CA 1.464 0.245 0 O-C-N 121.557 -0.714 . . . . 1.0 110.085 -179.336 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.461 ' H ' ' HA ' ' A' ' 45' ' ' PHE . 49.5 t -76.78 -21.75 54.71 Favored 'General case' 0 CA--C 1.533 0.318 0 O-C-N 121.5 -0.75 . . . . 1.0 109.229 179.426 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -175.46 179.56 46.6 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 109.145 -1.582 . . . . 1.0 109.145 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.528 ' CD2' HG13 ' A' ' 22' ' ' VAL . 8.9 p90 -64.81 167.49 9.13 Favored Pre-proline 0 CA--C 1.538 0.489 0 O-C-N 121.398 -1.06 . . . . 1.0 109.0 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -81.19 -30.93 1.42 Allowed 'Trans proline' 0 N--CA 1.482 0.806 0 C-N-CA 124.351 3.367 . . . . 1.0 110.715 -178.75 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.84 -8.41 7.89 Favored Glycine 0 CA--C 1.537 1.457 0 N-CA-C 110.305 -1.118 . . . . 1.0 110.305 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.528 HG13 ' CD2' ' A' ' 19' ' ' PHE . 25.7 m -60.62 -171.21 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 O-C-N 121.194 -1.18 . . . . 1.0 109.864 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.51 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 19.9 p -150.09 157.27 37.64 Favored Pre-proline 0 CA--C 1.534 0.361 0 N-CA-C 109.18 -0.674 . . . . 1.0 109.18 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_exo -34.91 -36.37 0.12 Allowed 'Trans proline' 0 N--CA 1.488 1.193 1 C-N-CA 125.599 4.199 . . . . 1.0 111.383 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.4 t -76.41 -47.21 23.93 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.434 -0.791 . . . . 1.0 109.865 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLN . . . . . 0.51 ' HB2' ' H ' ' A' ' 23' ' ' THR . 2.2 mm100 -60.93 -44.05 97.76 Favored 'General case' 0 N--CA 1.465 0.293 0 O-C-N 121.433 -0.792 . . . . 1.0 109.925 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 7.5 t -64.72 -33.4 75.87 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.443 -0.786 . . . . 1.0 109.346 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.48 -5.55 59.28 Favored 'General case' 0 CA--C 1.534 0.358 0 O-C-N 121.556 -0.715 . . . . 1.0 109.935 179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 12.2 t-20 -64.84 -32.6 74.37 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.32 -0.862 . . . . 1.0 109.618 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.3 mtmm -105.79 -39.52 6.02 Favored 'General case' 0 C--N 1.332 -0.183 0 O-C-N 121.456 -0.777 . . . . 1.0 109.403 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 125.6 27.55 1.16 Allowed Glycine 0 CA--C 1.53 1.012 0 N-CA-C 109.862 -1.295 . . . . 1.0 109.862 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.8 m -91.09 147.69 22.89 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.326 -1.103 . . . . 1.0 109.16 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.455 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 57.4 m -70.33 139.6 52.06 Favored 'General case' 0 CA--C 1.532 0.266 0 O-C-N 121.371 -0.831 . . . . 1.0 109.333 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -119.21 119.7 34.87 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.463 -0.773 . . . . 1.0 109.332 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -132.67 120.1 21.29 Favored 'General case' 0 CA--C 1.529 0.167 0 O-C-N 121.533 -0.729 . . . . 1.0 109.667 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.419 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.0 p-10 -116.32 77.27 1.08 Allowed 'General case' 0 N--CA 1.463 0.197 0 O-C-N 121.442 -0.786 . . . . 1.0 109.233 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 82.2 p -114.54 -38.37 4.05 Favored 'General case' 0 CA--C 1.53 0.183 0 O-C-N 121.446 -0.784 . . . . 1.0 109.543 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 38.3 t -117.36 148.51 20.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.205 0 O-C-N 121.442 -0.786 . . . . 1.0 109.411 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 22.5 mtp180 -94.65 -179.08 4.76 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.5 -0.75 . . . . 1.0 109.5 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.07 6.71 13.89 Favored Glycine 0 CA--C 1.532 1.149 0 N-CA-C 109.992 -1.243 . . . . 1.0 109.992 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.425 HG11 ' HB3' ' A' ' 11' ' ' PRO . 30.0 m -130.59 169.35 13.81 Favored Pre-proline 0 CA--C 1.536 0.415 0 O-C-N 121.359 -1.083 . . . . 1.0 109.203 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -87.74 130.03 2.63 Favored 'Trans proline' 0 N--CA 1.48 0.708 0 C-N-CA 124.693 3.595 . . . . 1.0 110.117 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.419 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.3 m0 -91.95 -47.83 7.09 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.505 -0.747 . . . . 1.0 109.733 -179.567 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 18.6 t -78.07 107.81 10.9 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 121.527 -0.733 . . . . 1.0 109.646 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.461 ' HA ' ' H ' ' A' ' 17' ' ' CYS . 3.3 p90 -139.42 -175.93 4.36 Favored 'General case' 0 N--CA 1.465 0.314 0 O-C-N 121.515 -0.74 . . . . 1.0 109.393 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -91.57 163.85 26.68 Favored Pre-proline 0 CA--C 1.537 0.477 0 O-C-N 121.411 -0.806 . . . . 1.0 110.029 -179.404 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -90.18 172.84 3.5 Favored 'Trans proline' 0 C--N 1.352 0.744 0 C-N-CA 124.97 3.78 . . . . 1.0 110.718 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -143.35 86.38 1.9 Allowed 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.433 -0.792 . . . . 1.0 109.412 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 34.2 p -67.43 131.59 45.99 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.465 -0.772 . . . . 1.0 109.417 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 54.7 mt -118.8 140.36 42.86 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 O-C-N 121.412 -0.805 . . . . 1.0 109.306 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -143.08 166.62 24.17 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.443 -0.786 . . . . 1.0 109.518 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.573 HG23 ' O ' ' A' ' 52' ' ' VAL . 30.8 m -69.79 111.07 7.79 Favored Pre-proline 0 CA--C 1.539 0.546 0 O-C-N 121.543 -0.723 . . . . 1.0 109.462 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -93.3 176.88 1.39 Allowed 'Trans proline' 0 C--N 1.353 0.768 0 C-N-CA 124.755 3.637 . . . . 1.0 110.44 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.411 ' HD2' ' H ' ' A' ' 55' ' ' GLU . 18.7 Cg_endo -92.11 -54.77 0.02 OUTLIER 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 125.177 3.918 . . . . 1.0 110.175 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.411 ' H ' ' HD2' ' A' ' 54' ' ' PRO . 1.1 mt-10 -137.71 101.68 4.53 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.547 -0.721 . . . . 1.0 109.331 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -88.45 108.17 19.24 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.487 -0.758 . . . . 1.0 109.59 -179.813 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 -147.16 134.35 20.52 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.567 -0.708 . . . . 1.0 109.271 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 72.6 m -137.1 172.82 12.43 Favored 'General case' 0 N--CA 1.464 0.228 0 O-C-N 121.542 -0.724 . . . . 1.0 109.461 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 14.6 tm-20 -96.6 119.79 35.73 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.499 -0.751 . . . . 1.0 109.43 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.929 -1.034 . . . . 1.0 109.495 179.909 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 . . . . . 0 CA--C 1.531 0.216 0 N-CA-C 109.498 -0.556 . . . . 1.0 109.498 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -155.65 37.59 0.37 Allowed 'General case' 0 N--CA 1.463 0.195 0 O-C-N 121.479 -0.763 . . . . 1.0 109.581 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 14.9 mp0 -84.33 113.76 21.37 Favored 'General case' 0 CA--C 1.53 0.175 0 O-C-N 121.351 -0.843 . . . . 1.0 109.347 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 75.8 p -108.94 133.51 52.85 Favored 'General case' 0 C--N 1.332 -0.189 0 O-C-N 121.449 -0.782 . . . . 1.0 109.563 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -85.59 133.43 34.05 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.863 -0.792 . . . . 1.0 108.863 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.4 m -150.23 114.1 5.05 Favored 'General case' 0 CA--C 1.53 0.176 0 O-C-N 121.469 -0.769 . . . . 1.0 110.161 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 96.2 m -108.54 -18.14 13.8 Favored 'General case' 0 CA--C 1.536 0.408 0 O-C-N 121.503 -0.748 . . . . 1.0 109.184 179.136 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.596 HG23 ' O ' ' A' ' 8' ' ' THR . 5.2 t -70.15 108.35 4.09 Favored 'General case' 0 CA--C 1.533 0.297 0 O-C-N 121.106 -0.996 . . . . 1.0 109.329 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.632 HG12 ' N ' ' A' ' 10' ' ' ALA . 26.7 t -132.99 173.46 14.8 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.248 0 O-C-N 121.334 -0.854 . . . . 1.0 109.323 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.632 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -69.14 122.81 86.62 Favored Pre-proline 0 CA--C 1.539 0.542 0 O-C-N 121.461 -0.774 . . . . 1.0 109.235 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.559 ' HB3' HG11 ' A' ' 41' ' ' VAL . 18.3 Cg_exo -37.62 -33.92 0.24 Allowed 'Trans proline' 0 N--CA 1.488 1.198 0 C-N-CA 124.774 3.65 . . . . 1.0 111.229 -179.799 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 15.2 ptt180 -78.55 -46.88 18.42 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.469 -0.769 . . . . 1.0 109.766 -179.703 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 21.0 mm-40 -82.73 40.97 0.7 Allowed 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.405 -0.809 . . . . 1.0 109.434 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 54.0 mtt180 -104.1 142.95 33.57 Favored 'General case' 0 C--N 1.331 -0.214 0 O-C-N 121.526 -0.734 . . . . 1.0 109.569 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 12.2 mm100 -92.59 111.33 22.88 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.426 -0.796 . . . . 1.0 109.195 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -60.33 110.34 1.22 Allowed 'General case' 0 CA--C 1.533 0.303 0 O-C-N 121.362 -0.836 . . . . 1.0 110.121 -179.704 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.4 t -86.65 -16.4 36.74 Favored 'General case' 0 CA--C 1.533 0.323 0 O-C-N 121.485 -0.76 . . . . 1.0 109.442 179.763 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.64 179.28 44.19 Favored Glycine 0 CA--C 1.531 1.075 0 N-CA-C 109.506 -1.438 . . . . 1.0 109.506 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.592 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.6 p90 -65.13 168.0 8.56 Favored Pre-proline 0 CA--C 1.538 0.492 0 O-C-N 121.468 -1.019 . . . . 1.0 109.018 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.43 -30.98 1.32 Allowed 'Trans proline' 0 N--CA 1.484 0.918 0 C-N-CA 124.4 3.4 . . . . 1.0 110.671 -178.714 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.42 -10.28 7.51 Favored Glycine 0 CA--C 1.537 1.41 0 N-CA-C 110.356 -1.098 . . . . 1.0 110.356 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.592 HG22 ' O ' ' A' ' 19' ' ' PHE . 18.0 m -60.74 169.71 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 O-C-N 121.205 -1.174 . . . . 1.0 109.611 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 29.2 p -128.35 155.45 78.45 Favored Pre-proline 0 CA--C 1.535 0.387 0 O-C-N 121.517 -0.739 . . . . 1.0 109.38 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_exo -36.33 -37.35 0.26 Allowed 'Trans proline' 0 N--CA 1.489 1.237 1 C-N-CA 125.341 4.027 . . . . 1.0 111.186 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 4.5 m -69.91 -47.38 62.69 Favored 'General case' 0 N--CA 1.463 0.206 0 O-C-N 121.351 -0.843 . . . . 1.0 109.79 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 7.5 mm100 -61.49 -49.88 75.0 Favored 'General case' 0 CA--C 1.533 0.302 0 O-C-N 121.41 -0.806 . . . . 1.0 109.842 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.8 t -64.97 -27.49 68.87 Favored 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.431 -0.793 . . . . 1.0 109.439 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.29 -8.91 57.38 Favored 'General case' 0 CA--C 1.534 0.344 0 O-C-N 121.5 -0.75 . . . . 1.0 109.821 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -91.38 -28.0 17.98 Favored 'General case' 0 CA--C 1.529 0.14 0 O-C-N 121.37 -0.831 . . . . 1.0 109.405 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -89.65 -29.15 19.0 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.471 -0.768 . . . . 1.0 109.441 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.04 45.64 2.02 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 109.771 -1.332 . . . . 1.0 109.771 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 2.0 m -121.42 142.95 49.52 Favored 'General case' 0 N--CA 1.465 0.29 0 O-C-N 121.496 -1.002 . . . . 1.0 109.303 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 46.8 m -63.32 113.66 3.35 Favored 'General case' 0 N--CA 1.466 0.332 0 O-C-N 121.4 -0.812 . . . . 1.0 109.39 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 48.7 t80 -90.36 137.19 32.55 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.43 -0.794 . . . . 1.0 109.126 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -151.02 106.86 3.41 Favored 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.47 -0.769 . . . . 1.0 109.676 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.435 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 2.1 p30 -107.09 48.55 0.83 Allowed 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.491 -0.756 . . . . 1.0 109.245 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 16.8 p -81.34 -52.28 7.46 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.519 -0.738 . . . . 1.0 109.361 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.8 t -114.14 145.39 20.03 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 O-C-N 121.589 -0.694 . . . . 1.0 109.383 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -88.35 179.66 6.29 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.539 -0.726 . . . . 1.0 109.449 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.45 -49.91 4.12 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 109.278 -1.529 . . . . 1.0 109.278 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.559 HG11 ' HB3' ' A' ' 11' ' ' PRO . 27.6 m -79.79 171.16 13.15 Favored Pre-proline 0 CA--C 1.538 0.502 0 O-C-N 121.588 -0.948 . . . . 1.0 109.041 179.632 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' PRO . . . . . 0.409 ' CD ' ' HB ' ' A' ' 41' ' ' VAL . 11.2 Cg_endo -84.17 127.41 3.99 Favored 'Trans proline' 0 N--CA 1.48 0.724 0 C-N-CA 124.383 3.389 . . . . 1.0 110.003 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.435 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 11.0 m0 -82.83 -39.85 21.12 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.594 -0.691 . . . . 1.0 110.104 -179.129 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.5 t -89.46 108.38 19.61 Favored 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.325 -0.859 . . . . 1.0 109.597 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.426 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 15.0 p90 -135.92 175.9 9.17 Favored 'General case' 0 CA--C 1.538 0.496 0 O-C-N 121.438 -0.789 . . . . 1.0 109.58 179.647 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.426 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 37.5 m-85 -84.61 166.99 29.45 Favored Pre-proline 0 CA--C 1.536 0.422 0 O-C-N 121.274 -0.891 . . . . 1.0 110.061 -179.539 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -88.92 159.7 6.01 Favored 'Trans proline' 0 C--N 1.353 0.779 0 C-N-CA 124.868 3.712 . . . . 1.0 110.538 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 19.9 m120 -132.77 84.85 2.17 Favored 'General case' 0 CA--C 1.531 0.242 0 O-C-N 121.525 -0.734 . . . . 1.0 109.406 -179.883 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.4 p -88.64 122.57 32.22 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.508 -0.745 . . . . 1.0 109.377 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 64.7 mt -94.54 145.01 8.6 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 O-C-N 121.472 -0.767 . . . . 1.0 109.264 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -155.14 173.27 16.84 Favored 'General case' 0 CA--C 1.529 0.171 0 O-C-N 121.546 -0.721 . . . . 1.0 109.494 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.598 HG23 ' O ' ' A' ' 52' ' ' VAL . 28.2 m -139.18 88.02 13.41 Favored Pre-proline 0 CA--C 1.535 0.366 0 O-C-N 121.559 -0.713 . . . . 1.0 109.573 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -91.42 169.03 3.32 Favored 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 125.139 3.892 . . . . 1.0 110.283 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.447 ' HD2' ' H ' ' A' ' 55' ' ' GLU . 19.1 Cg_endo -91.39 -23.75 0.44 Allowed 'Trans proline' 0 C--N 1.349 0.602 0 C-N-CA 125.123 3.882 . . . . 1.0 110.305 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.447 ' H ' ' HD2' ' A' ' 54' ' ' PRO . 15.2 mt-10 -131.93 178.47 6.75 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.482 -0.761 . . . . 1.0 109.472 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -125.77 153.08 44.51 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 121.463 -0.773 . . . . 1.0 109.445 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -146.14 120.55 9.66 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.515 -0.74 . . . . 1.0 109.421 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -96.93 152.18 18.96 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.511 -0.743 . . . . 1.0 109.392 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -100.39 153.56 19.23 Favored 'General case' 0 CA--C 1.53 0.189 0 O-C-N 121.449 -0.782 . . . . 1.0 109.456 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 41.9 p90 . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.894 -1.05 . . . . 1.0 109.516 180.0 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 . . . . . 0 CA--C 1.531 0.216 0 N-CA-C 109.465 -0.569 . . . . 1.0 109.465 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -160.2 84.75 0.72 Allowed 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.558 -0.714 . . . . 1.0 109.475 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.695 ' O ' HG23 ' A' ' 4' ' ' THR . 23.9 mt-30 -91.29 101.15 13.86 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.57 -0.706 . . . . 1.0 109.442 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.695 HG23 ' O ' ' A' ' 3' ' ' GLN . 0.7 OUTLIER -165.15 -170.06 1.81 Allowed 'General case' 0 N--CA 1.465 0.278 0 O-C-N 121.472 -0.767 . . . . 1.0 109.602 -179.979 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLU . . . . . 0.469 ' HG2' HG22 ' A' ' 49' ' ' THR . 7.0 mt-10 -91.29 152.92 20.29 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.511 -0.743 . . . . 1.0 109.226 179.787 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.774 HG22 HG22 ' A' ' 8' ' ' THR . 1.5 m -150.5 125.45 9.86 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.42 -0.8 . . . . 1.0 110.016 -179.808 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 98.6 m -104.02 45.33 0.97 Allowed 'General case' 0 CA--C 1.534 0.358 0 O-C-N 121.429 -0.794 . . . . 1.0 108.934 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.774 HG22 HG22 ' A' ' 6' ' ' THR . 5.8 t -110.83 108.98 18.99 Favored 'General case' 0 CA--C 1.532 0.262 0 O-C-N 121.19 -0.944 . . . . 1.0 109.877 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.46 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.5 t -135.39 160.9 40.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 O-C-N 121.441 -0.787 . . . . 1.0 109.114 179.802 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.46 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -79.55 115.59 54.54 Favored Pre-proline 0 CA--C 1.541 0.606 0 O-C-N 121.434 -0.791 . . . . 1.0 109.382 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -38.23 -28.79 0.13 Allowed 'Trans proline' 0 N--CA 1.49 1.277 0 C-N-CA 124.664 3.576 . . . . 1.0 111.108 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 -66.94 -64.92 0.75 Allowed 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.489 -0.757 . . . . 1.0 109.691 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -90.56 44.4 1.2 Allowed 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.499 -0.751 . . . . 1.0 109.542 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 21.7 mtt180 -86.11 143.16 28.19 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.476 -0.765 . . . . 1.0 109.516 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -92.87 108.1 19.73 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 109.021 -0.733 . . . . 1.0 109.021 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -62.49 122.59 16.15 Favored 'General case' 0 CA--C 1.532 0.278 0 O-C-N 121.517 -0.739 . . . . 1.0 109.984 -179.709 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 t -88.94 -13.33 39.25 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 109.06 -0.718 . . . . 1.0 109.06 179.434 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 177.28 177.54 46.25 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 108.645 -1.782 . . . . 1.0 108.645 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.6 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.2 p90 -64.35 167.62 8.08 Favored Pre-proline 0 CA--C 1.54 0.585 0 O-C-N 121.24 -1.153 . . . . 1.0 109.064 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -81.22 -30.38 1.62 Allowed 'Trans proline' 0 N--CA 1.483 0.858 0 C-N-CA 124.347 3.365 . . . . 1.0 110.84 -178.684 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.92 -10.16 8.28 Favored Glycine 0 CA--C 1.537 1.423 0 N-CA-C 110.192 -1.163 . . . . 1.0 110.192 179.528 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.6 HG22 ' O ' ' A' ' 19' ' ' PHE . 23.6 m -62.01 169.14 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 O-C-N 121.257 -1.143 . . . . 1.0 109.727 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 71.8 p -127.41 157.52 72.52 Favored Pre-proline 0 CA--C 1.534 0.361 0 N-CA-C 108.702 -0.851 . . . . 1.0 108.702 179.553 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -34.88 -36.12 0.12 Allowed 'Trans proline' 0 N--CA 1.489 1.255 1 C-N-CA 125.364 4.043 . . . . 1.0 111.315 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.7 p -72.83 -48.37 38.3 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.469 -0.769 . . . . 1.0 109.931 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 53.1 mt-30 -65.17 -44.01 89.89 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.542 -0.724 . . . . 1.0 110.07 -179.634 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 9.1 t -61.3 -31.85 71.7 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 121.303 -0.873 . . . . 1.0 109.855 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.19 -1.5 48.17 Favored 'General case' 0 CA--C 1.535 0.373 0 O-C-N 121.433 -0.792 . . . . 1.0 110.137 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -69.95 -28.49 65.61 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 121.349 -0.845 . . . . 1.0 110.255 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.29 -36.9 5.68 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 121.249 -0.907 . . . . 1.0 109.857 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 126.76 55.71 0.14 Allowed Glycine 0 CA--C 1.531 1.057 0 N-CA-C 109.959 -1.256 . . . . 1.0 109.959 179.826 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 36.9 m -120.98 137.3 54.7 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.398 -1.06 . . . . 1.0 108.725 179.701 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 53.0 m -69.42 122.75 19.58 Favored 'General case' 0 N--CA 1.466 0.374 0 O-C-N 121.326 -0.859 . . . . 1.0 109.418 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 34.9 t80 -93.48 140.1 29.97 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.493 -0.754 . . . . 1.0 109.002 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -152.76 112.4 3.91 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.379 -0.825 . . . . 1.0 109.737 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.44 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 11.5 p30 -113.76 76.12 0.96 Allowed 'General case' 0 N--CA 1.464 0.253 0 O-C-N 121.474 -0.766 . . . . 1.0 109.446 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.8 p -115.39 -29.95 6.39 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.507 -0.746 . . . . 1.0 109.635 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.4 t -124.44 154.43 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 O-C-N 121.503 -0.748 . . . . 1.0 109.501 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 41.8 mtm-85 -99.29 178.95 4.74 Favored 'General case' 0 CA--C 1.53 0.184 0 O-C-N 121.532 -0.73 . . . . 1.0 109.357 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 62.14 11.21 31.41 Favored Glycine 0 CA--C 1.533 1.206 0 N-CA-C 109.919 -1.272 . . . . 1.0 109.919 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.9 m -134.64 169.27 14.3 Favored Pre-proline 0 CA--C 1.535 0.404 0 O-C-N 121.357 -1.084 . . . . 1.0 109.182 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -87.64 122.44 1.69 Allowed 'Trans proline' 0 C--N 1.351 0.692 0 C-N-CA 124.825 3.683 . . . . 1.0 110.213 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.44 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.7 m0 -82.71 -32.68 27.89 Favored 'General case' 0 N--CA 1.463 0.216 0 O-C-N 121.478 -0.764 . . . . 1.0 109.44 -179.618 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 11.0 t -89.36 107.97 19.37 Favored 'General case' 0 CA--C 1.535 0.372 0 O-C-N 121.532 -0.73 . . . . 1.0 109.207 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.413 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 4.7 p90 -137.4 -179.32 5.66 Favored 'General case' 0 CA--C 1.539 0.524 0 O-C-N 121.263 -0.898 . . . . 1.0 110.33 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.409 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 10.5 m-85 -84.41 169.32 17.11 Favored Pre-proline 0 CA--C 1.539 0.524 0 O-C-N 121.519 -0.738 . . . . 1.0 110.097 -179.539 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_endo -90.89 170.23 3.46 Favored 'Trans proline' 0 C--N 1.353 0.767 0 C-N-CA 125.204 3.936 . . . . 1.0 110.888 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -132.44 79.75 1.87 Allowed 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 108.445 -0.946 . . . . 1.0 108.445 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.469 HG22 ' HG2' ' A' ' 5' ' ' GLU . 56.5 p -72.19 145.61 47.91 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.526 -0.734 . . . . 1.0 110.322 -179.061 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 42.5 mt -121.41 146.28 26.69 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 N-CA-C 108.764 -0.828 . . . . 1.0 108.764 179.402 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -154.51 -168.19 2.84 Favored 'General case' 0 N--CA 1.464 0.242 0 O-C-N 121.453 -0.779 . . . . 1.0 109.684 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.4 m -84.5 160.78 55.85 Favored Pre-proline 0 CA--C 1.536 0.421 0 O-C-N 121.589 -0.694 . . . . 1.0 109.348 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -90.72 106.85 0.31 Allowed 'Trans proline' 0 CA--C 1.539 0.734 0 C-N-CA 124.943 3.762 . . . . 1.0 110.151 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_endo -89.19 -160.32 0.1 OUTLIER 'Trans proline' 0 C--N 1.353 0.778 0 C-N-CA 124.734 3.623 . . . . 1.0 110.344 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 -78.14 135.52 37.68 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.428 -0.795 . . . . 1.0 109.586 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -107.28 117.08 33.14 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.508 -0.745 . . . . 1.0 109.369 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -108.18 157.64 18.14 Favored 'General case' 0 CA--C 1.53 0.205 0 O-C-N 121.529 -0.732 . . . . 1.0 109.498 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.0 p -139.18 109.27 6.39 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.547 -0.721 . . . . 1.0 109.348 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 11.9 mm-40 -132.63 106.49 7.83 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.553 -0.717 . . . . 1.0 109.418 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 8.7 t80 . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.032 -0.985 . . . . 1.0 109.412 -179.995 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 . . . . . 0 CA--C 1.532 0.281 0 N-CA-C 109.369 -0.604 . . . . 1.0 109.369 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.609 ' HB1' ' CD1' ' A' ' 50' ' ' ILE . . . -166.59 70.61 0.12 Allowed 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.494 -0.754 . . . . 1.0 109.367 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.72 ' O ' HG23 ' A' ' 4' ' ' THR . 10.9 mp0 -147.02 94.36 2.4 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.384 -0.823 . . . . 1.0 109.3 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.72 HG23 ' O ' ' A' ' 3' ' ' GLN . 0.2 OUTLIER -171.77 -165.75 0.39 Allowed 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.447 -0.783 . . . . 1.0 109.321 -179.945 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -108.97 124.43 50.68 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.489 -0.757 . . . . 1.0 109.145 179.523 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.688 HG22 HG22 ' A' ' 8' ' ' THR . 1.2 m -139.39 147.39 41.41 Favored 'General case' 0 CA--C 1.53 0.185 0 O-C-N 121.518 -0.739 . . . . 1.0 109.485 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.434 ' O ' ' CE2' ' A' ' 45' ' ' PHE . 11.2 m -111.05 -24.57 10.26 Favored 'General case' 0 C--N 1.332 -0.16 0 O-C-N 121.544 -0.723 . . . . 1.0 109.449 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.688 HG22 HG22 ' A' ' 6' ' ' THR . 3.9 t -68.9 146.31 52.92 Favored 'General case' 0 N--CA 1.464 0.24 0 O-C-N 121.475 -0.766 . . . . 1.0 110.739 -178.745 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.738 HG12 ' H ' ' A' ' 10' ' ' ALA . 25.2 t -140.32 178.9 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 108.308 -0.997 . . . . 1.0 108.308 179.616 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.738 ' H ' HG12 ' A' ' 9' ' ' VAL . . . -61.95 110.54 3.32 Favored Pre-proline 0 CA--C 1.541 0.603 0 O-C-N 121.216 -0.927 . . . . 1.0 109.717 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -39.75 -31.32 0.43 Allowed 'Trans proline' 0 N--CA 1.489 1.222 0 C-N-CA 124.607 3.538 . . . . 1.0 111.194 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 8.7 mtt-85 -84.19 -39.61 19.16 Favored 'General case' 0 N--CA 1.464 0.273 0 O-C-N 121.39 -0.819 . . . . 1.0 109.979 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -103.58 50.82 0.8 Allowed 'General case' 0 CA--C 1.532 0.282 0 O-C-N 121.385 -0.822 . . . . 1.0 109.348 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 50.0 mtt180 -91.35 136.39 33.14 Favored 'General case' 0 N--CA 1.464 0.239 0 O-C-N 121.457 -0.777 . . . . 1.0 109.726 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -79.92 104.21 10.34 Favored 'General case' 0 CA--C 1.53 0.182 0 O-C-N 121.586 -0.696 . . . . 1.0 109.249 179.724 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 11.5 t-20 -62.84 116.5 5.31 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.48 -0.763 . . . . 1.0 109.899 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.0 t -92.55 -9.97 39.29 Favored 'General case' 0 CA--C 1.536 0.422 0 O-C-N 121.555 -0.716 . . . . 1.0 109.521 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.91 173.57 33.69 Favored Glycine 0 CA--C 1.529 0.957 0 N-CA-C 109.206 -1.557 . . . . 1.0 109.206 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.557 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.9 p90 -65.51 167.74 9.99 Favored Pre-proline 0 CA--C 1.539 0.544 0 O-C-N 121.43 -1.041 . . . . 1.0 108.971 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.67 -30.37 1.45 Allowed 'Trans proline' 0 N--CA 1.484 0.922 0 C-N-CA 124.305 3.337 . . . . 1.0 110.832 -178.774 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.29 -10.71 7.83 Favored Glycine 0 CA--C 1.537 1.441 0 N-CA-C 110.324 -1.11 . . . . 1.0 110.324 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.557 HG22 ' O ' ' A' ' 19' ' ' PHE . 20.3 m -60.54 -171.94 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 O-C-N 121.294 -1.121 . . . . 1.0 109.723 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -146.63 157.25 48.2 Favored Pre-proline 0 CA--C 1.535 0.379 0 O-C-N 121.584 -0.697 . . . . 1.0 109.25 179.809 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -34.71 -31.93 0.07 OUTLIER 'Trans proline' 0 N--CA 1.489 1.207 1 C-N-CA 125.588 4.192 . . . . 1.0 111.36 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 76.8 p -75.3 -50.22 16.71 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.475 -0.766 . . . . 1.0 109.872 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 38.0 mt-30 -61.57 -48.02 82.88 Favored 'General case' 0 N--CA 1.465 0.291 0 O-C-N 121.44 -0.788 . . . . 1.0 109.811 -179.86 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.9 t -64.69 -28.4 69.57 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.392 -0.818 . . . . 1.0 109.558 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -87.95 -4.96 58.77 Favored 'General case' 0 CA--C 1.534 0.353 0 O-C-N 121.57 -0.706 . . . . 1.0 110.012 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -75.01 -30.1 61.03 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.318 -0.864 . . . . 1.0 109.73 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.5 mmtp -102.82 -40.43 6.56 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.453 -0.779 . . . . 1.0 109.466 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 118.23 39.27 0.75 Allowed Glycine 0 CA--C 1.529 0.944 0 N-CA-C 109.419 -1.472 . . . . 1.0 109.419 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 48.7 m -101.94 139.7 37.22 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.567 -0.96 . . . . 1.0 109.189 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 84.6 m -65.37 116.51 6.76 Favored 'General case' 0 N--CA 1.464 0.255 0 O-C-N 121.523 -0.736 . . . . 1.0 109.927 -179.374 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 34.2 t80 -92.74 121.14 33.84 Favored 'General case' 0 C--N 1.333 -0.141 0 N-CA-C 109.042 -0.725 . . . . 1.0 109.042 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 26.8 t0 -134.15 118.48 17.72 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.391 -0.818 . . . . 1.0 109.518 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.441 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 7.0 p-10 -110.91 64.55 0.61 Allowed 'General case' 0 CA--C 1.533 0.298 0 O-C-N 121.526 -0.734 . . . . 1.0 109.236 179.866 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 27.0 p -114.26 -49.71 2.83 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.392 -0.817 . . . . 1.0 109.489 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.3 t -100.22 133.6 42.69 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 O-C-N 121.404 -0.81 . . . . 1.0 109.507 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.404 ' HG3' ' H ' ' A' ' 40' ' ' GLY . 2.3 tpt180 -85.13 176.17 8.55 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.571 -0.706 . . . . 1.0 109.553 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.404 ' H ' ' HG3' ' A' ' 39' ' ' ARG . . . 80.89 -48.43 3.74 Favored Glycine 0 CA--C 1.529 0.908 0 N-CA-C 109.447 -1.461 . . . . 1.0 109.447 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.3 m -81.4 169.75 17.86 Favored Pre-proline 0 CA--C 1.536 0.437 0 O-C-N 121.511 -0.993 . . . . 1.0 109.215 179.806 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -86.55 124.37 2.3 Favored 'Trans proline' 0 C--N 1.35 0.628 0 C-N-CA 124.757 3.638 . . . . 1.0 110.157 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.441 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 16.9 m0 -67.28 -37.61 83.7 Favored 'General case' 0 CA--C 1.53 0.192 0 O-C-N 121.554 -0.716 . . . . 1.0 109.522 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 11.1 t -87.86 109.25 19.62 Favored 'General case' 0 C--O 1.233 0.195 0 O-C-N 121.399 -0.813 . . . . 1.0 108.961 179.486 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.434 ' CE2' ' O ' ' A' ' 7' ' ' CYS . 1.3 p90 -149.3 178.44 8.76 Favored 'General case' 0 CA--C 1.537 0.454 0 O-C-N 121.454 -0.779 . . . . 1.0 109.832 -179.512 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 29.8 m-85 -83.78 170.28 14.59 Favored Pre-proline 0 CA--C 1.538 0.498 0 O-C-N 121.485 -0.759 . . . . 1.0 109.942 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -93.83 -168.32 0.18 Allowed 'Trans proline' 0 C--N 1.35 0.641 1 C-N-CA 125.357 4.038 . . . . 1.0 111.39 -179.45 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -168.79 79.22 0.13 Allowed 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 107.902 -1.148 . . . . 1.0 107.902 179.364 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.589 HG22 ' H ' ' A' ' 6' ' ' THR . 48.4 p -98.5 137.29 37.39 Favored 'General case' 0 C--N 1.33 -0.247 0 O-C-N 121.641 -0.662 . . . . 1.0 110.004 -178.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.609 ' CD1' ' HB1' ' A' ' 2' ' ' ALA . 30.3 mt -90.5 170.23 1.26 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 108.275 -1.009 . . . . 1.0 108.275 179.5 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.508 ' N ' HG22 ' A' ' 50' ' ' ILE . 2.2 m-20 -80.13 175.41 10.67 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.265 -0.897 . . . . 1.0 110.062 -179.363 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 29.1 m -121.78 157.94 55.83 Favored Pre-proline 0 CA--C 1.537 0.451 0 O-C-N 121.598 -0.689 . . . . 1.0 109.793 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.455 ' N ' ' HD2' ' A' ' 54' ' ' PRO . 3.0 Cg_exo -38.47 -60.18 0.5 Allowed 'Trans proline' 0 N--CA 1.486 1.049 0 C-N-CA 125.186 3.924 . . . . 1.0 111.311 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.455 ' HD2' ' N ' ' A' ' 53' ' ' PRO . 22.7 Cg_exo -33.63 128.05 0.15 Allowed 'Trans proline' 0 N--CA 1.491 1.347 0 C-N-CA 125.261 3.974 . . . . 1.0 111.511 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -76.62 135.32 39.17 Favored 'General case' 0 N--CA 1.462 0.162 0 O-C-N 121.566 -0.709 . . . . 1.0 109.511 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -122.96 147.94 46.05 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.433 -0.792 . . . . 1.0 109.422 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -102.09 139.9 37.1 Favored 'General case' 0 CA--C 1.532 0.27 0 O-C-N 121.465 -0.772 . . . . 1.0 109.52 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 7.9 m -72.06 122.98 21.85 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.558 -0.714 . . . . 1.0 109.409 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 -146.94 117.76 7.62 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.474 -0.766 . . . . 1.0 109.537 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 117.976 -1.012 . . . . 1.0 109.228 179.942 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 . . . . . 0 CA--C 1.531 0.217 0 N-CA-C 109.458 -0.571 . . . . 1.0 109.458 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -85.82 108.49 18.14 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.481 -0.762 . . . . 1.0 109.52 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 25.0 mt-30 -145.5 127.73 15.75 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.455 -0.778 . . . . 1.0 109.341 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.8 p -126.22 172.95 9.63 Favored 'General case' 0 N--CA 1.464 0.232 0 O-C-N 121.422 -0.798 . . . . 1.0 109.621 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -89.27 133.92 34.26 Favored 'General case' 0 N--CA 1.462 0.153 0 O-C-N 121.497 -0.752 . . . . 1.0 109.367 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.069 HG22 HG22 ' A' ' 8' ' ' THR . 0.6 OUTLIER -146.76 108.26 4.29 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.514 -0.742 . . . . 1.0 109.733 -179.807 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 80.6 m -97.31 45.84 1.04 Allowed 'General case' 0 CA--C 1.532 0.287 0 O-C-N 121.51 -0.743 . . . . 1.0 108.998 179.445 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' THR . . . . . 1.069 HG22 HG22 ' A' ' 6' ' ' THR . 4.6 t -123.79 83.5 2.15 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.178 -0.951 . . . . 1.0 109.848 -179.616 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.619 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.2 t -109.5 172.03 2.46 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 N-CA-C 108.85 -0.796 . . . . 1.0 108.85 179.449 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.619 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -73.15 131.76 83.04 Favored Pre-proline 0 CA--C 1.541 0.597 0 O-C-N 121.323 -0.861 . . . . 1.0 109.272 -179.781 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -36.87 -38.75 0.39 Allowed 'Trans proline' 0 N--CA 1.488 1.156 0 C-N-CA 125.103 3.869 . . . . 1.0 111.351 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.7 mpp_? -82.01 -40.28 22.34 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 121.433 -0.792 . . . . 1.0 109.944 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.548 ' O ' HG11 ' A' ' 9' ' ' VAL . 29.6 mt-10 -86.24 42.68 1.01 Allowed 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.277 -0.89 . . . . 1.0 109.671 -179.657 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 37.9 mtt180 -101.51 151.34 22.08 Favored 'General case' 0 N--CA 1.464 0.232 0 O-C-N 121.409 -0.807 . . . . 1.0 109.627 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -104.68 105.6 15.76 Favored 'General case' 0 N--CA 1.462 0.172 0 O-C-N 121.345 -0.847 . . . . 1.0 109.06 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 61.5 t30 -57.32 118.69 5.38 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 121.235 -0.916 . . . . 1.0 110.305 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -94.13 -18.85 21.35 Favored 'General case' 0 CA--C 1.534 0.348 0 O-C-N 121.515 -0.741 . . . . 1.0 109.345 179.672 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -171.88 176.82 44.9 Favored Glycine 0 CA--C 1.53 1.017 0 N-CA-C 109.059 -1.616 . . . . 1.0 109.059 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.58 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.3 p90 -66.12 167.16 12.91 Favored Pre-proline 0 CA--C 1.539 0.526 0 O-C-N 121.374 -1.074 . . . . 1.0 108.815 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.97 -30.16 1.41 Allowed 'Trans proline' 0 N--CA 1.482 0.828 0 C-N-CA 124.537 3.491 . . . . 1.0 110.906 -178.604 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -57.8 -11.86 9.12 Favored Glycine 0 CA--C 1.536 1.39 0 N-CA-C 110.323 -1.111 . . . . 1.0 110.323 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.58 HG22 ' O ' ' A' ' 19' ' ' PHE . 20.9 m -61.06 -172.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 O-C-N 121.302 -1.116 . . . . 1.0 109.932 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.557 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 59.9 p -145.15 157.64 53.21 Favored Pre-proline 0 CA--C 1.535 0.37 0 N-CA-C 108.913 -0.773 . . . . 1.0 108.913 179.709 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -35.07 -39.75 0.22 Allowed 'Trans proline' 0 N--CA 1.489 1.212 1 C-N-CA 125.484 4.123 . . . . 1.0 111.378 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.1 p -74.08 -46.63 41.77 Favored 'General case' 0 CA--C 1.532 0.288 0 O-C-N 121.462 -0.774 . . . . 1.0 109.903 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLN . . . . . 0.557 ' HB2' ' H ' ' A' ' 23' ' ' THR . 32.4 mt-30 -61.26 -53.07 61.49 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 121.447 -0.783 . . . . 1.0 109.975 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 23.1 t -61.66 -26.41 68.0 Favored 'General case' 0 CA--C 1.533 0.322 0 O-C-N 121.298 -0.877 . . . . 1.0 109.719 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -90.01 -6.69 55.33 Favored 'General case' 0 CA--C 1.535 0.386 0 O-C-N 121.504 -0.748 . . . . 1.0 110.08 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 15.5 t-20 -78.96 -45.38 20.49 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.29 -0.882 . . . . 1.0 109.535 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.1 mtmm -72.36 -45.85 58.03 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.483 -0.761 . . . . 1.0 109.526 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 125.26 27.03 1.25 Allowed Glycine 0 CA--C 1.529 0.939 0 N-CA-C 109.197 -1.561 . . . . 1.0 109.197 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 26.4 m -99.52 145.29 27.65 Favored 'General case' 0 CA--C 1.532 0.276 0 O-C-N 121.685 -0.891 . . . . 1.0 108.696 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 35.9 m -68.58 128.92 38.35 Favored 'General case' 0 N--CA 1.465 0.321 0 O-C-N 121.307 -0.871 . . . . 1.0 109.42 -179.682 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -97.82 138.09 35.69 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.511 -0.743 . . . . 1.0 109.067 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 13.6 t0 -157.63 89.25 1.02 Allowed 'General case' 0 N--CA 1.463 0.183 0 O-C-N 121.521 -0.737 . . . . 1.0 109.512 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.424 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 38.2 p-10 -103.05 78.68 1.67 Allowed 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.539 -0.725 . . . . 1.0 109.472 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 76.6 p -113.85 -23.15 9.79 Favored 'General case' 0 CA--C 1.534 0.334 0 O-C-N 121.383 -0.823 . . . . 1.0 109.709 -179.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.537 HG12 ' N ' ' A' ' 39' ' ' ARG . 33.8 t -127.6 165.54 26.35 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 O-C-N 121.451 -0.78 . . . . 1.0 109.645 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.537 ' N ' HG12 ' A' ' 38' ' ' VAL . 0.0 OUTLIER -107.03 175.05 5.63 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 109.097 -0.705 . . . . 1.0 109.097 179.812 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.436 ' H ' ' CD ' ' A' ' 39' ' ' ARG . . . 72.17 -8.07 7.13 Favored Glycine 0 CA--C 1.533 1.173 0 N-CA-C 109.954 -1.258 . . . . 1.0 109.954 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.9 m -121.52 170.08 8.12 Favored Pre-proline 0 CA--C 1.537 0.461 0 O-C-N 121.317 -1.108 . . . . 1.0 109.051 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -86.53 127.75 2.85 Favored 'Trans proline' 0 N--CA 1.48 0.694 0 C-N-CA 124.585 3.523 . . . . 1.0 110.209 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.424 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.4 m0 -82.49 -39.36 22.57 Favored 'General case' 0 N--CA 1.464 0.264 0 O-C-N 121.586 -0.696 . . . . 1.0 109.28 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.1 t -88.14 117.49 27.06 Favored 'General case' 0 N--CA 1.466 0.329 0 O-C-N 121.508 -0.745 . . . . 1.0 109.113 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.419 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 5.2 p90 -145.18 173.14 12.19 Favored 'General case' 0 CA--C 1.537 0.463 0 O-C-N 121.328 -0.857 . . . . 1.0 110.34 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.408 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 14.3 m-85 -79.53 172.78 9.0 Favored Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 121.473 -0.767 . . . . 1.0 109.496 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo -90.37 160.53 4.54 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 125.087 3.858 . . . . 1.0 110.252 179.672 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.529 ' ND2' HG21 ' A' ' 9' ' ' VAL . 8.2 m-20 -135.57 106.11 6.48 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.485 -0.759 . . . . 1.0 109.492 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 65.0 p -86.9 88.24 7.65 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 121.457 -0.777 . . . . 1.0 109.535 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 62.6 mt -104.18 155.69 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 O-C-N 121.461 -0.774 . . . . 1.0 109.257 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -82.69 137.45 34.44 Favored 'General case' 0 CA--C 1.53 0.202 0 O-C-N 121.497 -0.752 . . . . 1.0 109.482 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.588 HG23 ' O ' ' A' ' 52' ' ' VAL . 31.0 m -114.12 79.69 5.1 Favored Pre-proline 0 CA--C 1.537 0.461 0 O-C-N 121.509 -0.744 . . . . 1.0 109.411 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.458 ' N ' ' HD2' ' A' ' 54' ' ' PRO . 7.2 Cg_exo -37.34 -59.68 0.47 Allowed 'Trans proline' 0 N--CA 1.486 1.086 0 C-N-CA 125.128 3.885 . . . . 1.0 111.345 -179.845 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.458 ' HD2' ' N ' ' A' ' 53' ' ' PRO . 15.3 Cg_exo -37.47 154.6 0.03 OUTLIER 'Trans proline' 0 N--CA 1.49 1.291 0 C-N-CA 124.785 3.657 . . . . 1.0 111.014 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -77.86 156.31 30.47 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.489 -0.757 . . . . 1.0 109.408 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -69.88 144.66 52.43 Favored 'General case' 0 CA--C 1.53 0.202 0 O-C-N 121.417 -0.802 . . . . 1.0 109.42 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 30.8 mt-10 -145.21 108.68 4.64 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 121.472 -0.768 . . . . 1.0 109.473 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 22.9 t -118.49 119.93 36.01 Favored 'General case' 0 N--CA 1.463 0.186 0 O-C-N 121.46 -0.775 . . . . 1.0 109.388 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -87.37 101.61 13.73 Favored 'General case' 0 N--CA 1.463 0.202 0 O-C-N 121.44 -0.787 . . . . 1.0 109.523 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 40.5 t80 . . . . . 0 C--O 1.221 -0.408 0 CA-C-O 117.965 -1.017 . . . . 1.0 109.386 -179.954 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.531 0.212 0 N-CA-C 109.413 -0.588 . . . . 1.0 109.413 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -81.28 23.32 0.61 Allowed 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.545 -0.722 . . . . 1.0 109.578 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -102.37 111.3 23.54 Favored 'General case' 0 CA--C 1.53 0.196 0 O-C-N 121.441 -0.787 . . . . 1.0 109.478 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.4 p -92.88 174.83 7.04 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.456 -0.778 . . . . 1.0 109.503 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 -77.7 145.01 36.85 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.46 -0.775 . . . . 1.0 109.459 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.447 HG22 HG22 ' A' ' 8' ' ' THR . 1.1 m -143.09 125.12 15.25 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.528 -0.733 . . . . 1.0 109.502 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 63.9 m -105.61 -20.56 13.43 Favored 'General case' 0 CA--C 1.533 0.316 0 O-C-N 121.601 -0.687 . . . . 1.0 109.478 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.576 HG23 ' O ' ' A' ' 8' ' ' THR . 3.8 t -70.05 104.78 2.66 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.322 -0.861 . . . . 1.0 109.538 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.613 HG12 ' N ' ' A' ' 10' ' ' ALA . 36.2 t -131.66 170.66 19.39 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 O-C-N 121.607 -0.683 . . . . 1.0 109.186 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.613 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -65.77 126.52 91.86 Favored Pre-proline 0 CA--C 1.539 0.535 0 O-C-N 121.448 -0.782 . . . . 1.0 109.22 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_exo -37.74 -40.02 0.88 Allowed 'Trans proline' 0 N--CA 1.49 1.268 0 C-N-CA 124.926 3.751 . . . . 1.0 111.126 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.9 mtm-85 -76.6 -41.73 45.08 Favored 'General case' 0 CA--C 1.532 0.254 0 O-C-N 121.4 -0.812 . . . . 1.0 109.886 -179.425 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -81.88 40.52 0.61 Allowed 'General case' 0 C--N 1.331 -0.213 0 O-C-N 121.451 -0.78 . . . . 1.0 109.561 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 55.3 mtt180 -108.09 133.49 52.31 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.47 -0.769 . . . . 1.0 109.556 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 22.6 mm-40 -90.65 117.71 29.52 Favored 'General case' 0 N--CA 1.464 0.227 0 O-C-N 121.438 -0.789 . . . . 1.0 109.367 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -61.31 115.36 3.78 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.453 -0.779 . . . . 1.0 109.992 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.4 t -93.47 -20.39 20.33 Favored 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.605 -0.685 . . . . 1.0 109.324 179.614 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.52 170.58 37.19 Favored Glycine 0 CA--C 1.529 0.958 0 N-CA-C 109.494 -1.442 . . . . 1.0 109.494 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.73 ' O ' HG22 ' A' ' 22' ' ' VAL . 19.8 p90 -64.85 148.77 97.14 Favored Pre-proline 0 CA--C 1.538 0.505 0 O-C-N 121.435 -1.038 . . . . 1.0 109.263 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -65.43 -28.69 54.07 Favored 'Trans proline' 0 N--CA 1.489 1.232 0 C-N-CA 124.053 3.169 . . . . 1.0 110.704 -178.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -55.04 -15.62 7.1 Favored Glycine 0 CA--C 1.536 1.355 0 N-CA-C 110.649 -0.981 . . . . 1.0 110.649 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.73 HG22 ' O ' ' A' ' 19' ' ' PHE . 30.2 m -64.01 178.26 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 O-C-N 121.389 -1.065 . . . . 1.0 109.505 179.816 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.1 p -132.03 156.4 80.15 Favored Pre-proline 0 CA--C 1.536 0.427 0 O-C-N 121.543 -0.723 . . . . 1.0 109.313 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -34.49 -33.03 0.07 OUTLIER 'Trans proline' 0 N--CA 1.489 1.206 1 C-N-CA 125.587 4.192 . . . . 1.0 111.293 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 2.6 m -71.83 -49.96 33.83 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.472 -0.767 . . . . 1.0 109.962 -179.554 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 13.2 mm-40 -63.39 -49.93 71.89 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.403 -0.81 . . . . 1.0 109.73 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.6 t -63.16 -21.34 66.14 Favored 'General case' 0 CA--C 1.533 0.306 0 O-C-N 121.518 -0.739 . . . . 1.0 109.829 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.0 -11.06 27.06 Favored 'General case' 0 CA--C 1.535 0.399 0 O-C-N 121.416 -0.802 . . . . 1.0 109.916 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -71.38 -35.96 71.27 Favored 'General case' 0 N--CA 1.463 0.205 0 O-C-N 121.331 -0.856 . . . . 1.0 109.56 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.8 tttp -92.07 -42.68 9.82 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.44 -0.787 . . . . 1.0 109.447 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 122.33 38.05 0.61 Allowed Glycine 0 CA--C 1.528 0.849 0 N-CA-C 109.526 -1.43 . . . . 1.0 109.526 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.8 m -105.59 145.34 31.12 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.493 -1.004 . . . . 1.0 109.114 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 61.4 m -68.5 127.48 33.14 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.557 -0.714 . . . . 1.0 109.54 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 51.1 t80 -104.12 109.39 21.16 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 121.507 -0.746 . . . . 1.0 109.25 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -120.81 102.98 8.74 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.575 -0.703 . . . . 1.0 109.564 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.443 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.8 p-10 -108.08 59.49 0.61 Allowed 'General case' 0 CA--C 1.532 0.267 0 O-C-N 121.527 -0.733 . . . . 1.0 109.291 179.742 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.5 p -112.28 -42.1 3.78 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.364 -0.835 . . . . 1.0 109.454 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.2 t -96.71 155.09 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 O-C-N 121.481 -0.762 . . . . 1.0 109.483 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -108.03 165.05 11.75 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.529 -0.732 . . . . 1.0 109.449 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.4 -32.6 2.82 Favored Glycine 0 CA--C 1.53 1.009 0 N-CA-C 109.096 -1.602 . . . . 1.0 109.096 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.423 ' H ' HG22 ' A' ' 41' ' ' VAL . 26.8 m -91.34 171.85 7.45 Favored Pre-proline 0 CA--C 1.538 0.502 0 O-C-N 121.619 -0.93 . . . . 1.0 109.041 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' PRO . . . . . 0.413 ' CD ' ' HB ' ' A' ' 41' ' ' VAL . 11.4 Cg_endo -85.97 138.68 6.01 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 124.411 3.407 . . . . 1.0 109.706 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.443 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 30.6 m0 -87.36 -46.06 10.0 Favored 'General case' 0 CA--C 1.531 0.239 0 O-C-N 121.481 -0.762 . . . . 1.0 110.466 -179.004 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 14.9 t -89.04 109.51 20.34 Favored 'General case' 0 CA--C 1.532 0.276 0 O-C-N 121.242 -0.911 . . . . 1.0 109.953 -179.503 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.415 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 5.6 p90 -137.38 -178.97 5.46 Favored 'General case' 0 CA--C 1.537 0.474 0 O-C-N 121.387 -0.821 . . . . 1.0 109.448 179.365 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.415 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 43.9 m-85 -90.48 165.27 23.74 Favored Pre-proline 0 CA--C 1.536 0.422 0 O-C-N 121.328 -0.857 . . . . 1.0 109.512 -179.798 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -90.86 175.59 2.49 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 124.95 3.767 . . . . 1.0 110.502 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 26.2 m120 -153.1 105.19 2.88 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 109.291 -0.633 . . . . 1.0 109.291 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 30.7 p -65.9 92.89 0.17 Allowed 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.479 -0.763 . . . . 1.0 109.349 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.488 HG22 ' N ' ' A' ' 51' ' ' ASP . 63.2 mt -139.87 162.43 25.62 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 O-C-N 121.561 -0.712 . . . . 1.0 109.315 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.488 ' N ' HG22 ' A' ' 50' ' ' ILE . 3.5 t0 -101.82 130.82 48.36 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.459 -0.776 . . . . 1.0 109.36 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.9 m -144.56 155.59 56.83 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.548 -0.72 . . . . 1.0 109.446 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -38.85 162.27 0.02 OUTLIER 'Trans proline' 0 N--CA 1.488 1.152 0 C-N-CA 125.249 3.966 . . . . 1.0 110.852 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -90.68 -72.91 0.0 OUTLIER 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 124.888 3.725 . . . . 1.0 110.311 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 65.5 mt-10 -78.08 127.8 32.86 Favored 'General case' 0 CA--C 1.532 0.26 0 O-C-N 121.599 -0.688 . . . . 1.0 109.383 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -86.2 129.91 34.69 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 121.595 -0.69 . . . . 1.0 109.413 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.432 ' HG2' ' H ' ' A' ' 58' ' ' SER . 8.2 tt0 -76.78 164.41 25.87 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.522 -0.736 . . . . 1.0 109.405 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.432 ' H ' ' HG2' ' A' ' 57' ' ' GLU . 57.8 m -145.75 159.63 42.9 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.462 -0.774 . . . . 1.0 109.44 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 28.3 mm-40 -105.31 146.2 29.7 Favored 'General case' 0 CA--C 1.532 0.254 0 O-C-N 121.538 -0.726 . . . . 1.0 109.474 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 117.986 -1.007 . . . . 1.0 109.43 -179.97 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.531 0.243 0 N-CA-C 109.531 -0.544 . . . . 1.0 109.531 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -149.47 85.51 1.45 Allowed 'General case' 0 CA--C 1.531 0.213 0 O-C-N 121.42 -0.8 . . . . 1.0 109.394 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 -124.38 118.56 26.97 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.51 -0.744 . . . . 1.0 109.459 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -87.4 172.94 9.45 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.528 -0.732 . . . . 1.0 109.489 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.8 mt-10 -93.55 144.94 24.9 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.477 -0.764 . . . . 1.0 109.64 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.703 HG22 ' O ' ' A' ' 48' ' ' ASN . 4.7 t -115.74 148.02 40.26 Favored 'General case' 0 CA--C 1.532 0.265 0 O-C-N 121.549 -0.72 . . . . 1.0 109.316 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 72.2 m -108.43 -20.97 12.94 Favored 'General case' 0 CA--C 1.534 0.345 0 O-C-N 121.46 -0.775 . . . . 1.0 109.644 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.57 HG23 ' O ' ' A' ' 8' ' ' THR . 3.5 t -70.03 102.98 2.15 Favored 'General case' 0 CA--C 1.53 0.211 0 O-C-N 121.489 -0.757 . . . . 1.0 109.892 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.617 HG12 ' N ' ' A' ' 10' ' ' ALA . 40.0 t -114.53 171.44 4.32 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 O-C-N 121.346 -0.846 . . . . 1.0 108.936 179.488 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.617 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -78.39 119.5 77.54 Favored Pre-proline 0 CA--C 1.541 0.622 0 O-C-N 121.417 -0.802 . . . . 1.0 109.542 -179.608 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.642 ' HB3' HG11 ' A' ' 41' ' ' VAL . 18.8 Cg_exo -37.93 -38.84 0.77 Allowed 'Trans proline' 0 N--CA 1.489 1.258 0 C-N-CA 124.757 3.638 . . . . 1.0 111.205 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 18.6 mmm-85 -77.01 -42.65 37.76 Favored 'General case' 0 N--CA 1.464 0.237 0 O-C-N 121.494 -0.754 . . . . 1.0 109.889 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -102.53 50.03 0.83 Allowed 'General case' 0 CA--C 1.532 0.286 0 O-C-N 121.375 -0.828 . . . . 1.0 109.508 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 26.7 mtt180 -94.04 147.77 22.81 Favored 'General case' 0 N--CA 1.463 0.223 0 O-C-N 121.379 -0.826 . . . . 1.0 109.704 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 54.1 mm-40 -91.6 107.26 19.09 Favored 'General case' 0 CA--C 1.53 0.196 0 O-C-N 121.474 -0.766 . . . . 1.0 109.166 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 30.2 t-20 -63.76 123.06 17.92 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 121.513 -0.742 . . . . 1.0 109.819 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 38.1 t -100.9 -18.34 16.4 Favored 'General case' 0 CA--C 1.534 0.329 0 O-C-N 121.53 -0.731 . . . . 1.0 109.505 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 175.94 -177.13 47.67 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 109.276 -1.53 . . . . 1.0 109.276 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.573 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.1 p90 -65.73 167.87 10.13 Favored Pre-proline 0 CA--C 1.538 0.492 0 O-C-N 121.395 -1.062 . . . . 1.0 108.822 179.732 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.81 -30.4 1.39 Allowed 'Trans proline' 0 N--CA 1.483 0.888 0 C-N-CA 124.374 3.383 . . . . 1.0 110.794 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -56.96 -12.58 7.23 Favored Glycine 0 CA--C 1.537 1.458 0 N-CA-C 110.357 -1.097 . . . . 1.0 110.357 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 19' ' ' PHE . 23.0 m -61.05 170.37 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 O-C-N 121.3 -1.117 . . . . 1.0 109.627 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.7 p -133.97 154.51 80.33 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.555 -0.716 . . . . 1.0 109.172 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.419 ' HD3' ' CZ ' ' A' ' 34' ' ' PHE . 16.8 Cg_exo -34.58 -31.87 0.06 OUTLIER 'Trans proline' 0 N--CA 1.488 1.195 1 C-N-CA 125.594 4.196 . . . . 1.0 111.355 179.956 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.6 m -75.53 -51.24 13.39 Favored 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.439 -0.788 . . . . 1.0 109.608 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 15.6 mt-30 -62.79 -43.37 98.98 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.427 -0.796 . . . . 1.0 109.721 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 10.1 t -64.54 -29.14 70.17 Favored 'General case' 0 N--CA 1.464 0.235 0 O-C-N 121.474 -0.766 . . . . 1.0 109.422 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.98 -11.15 56.13 Favored 'General case' 0 CA--C 1.533 0.315 0 O-C-N 121.604 -0.685 . . . . 1.0 109.756 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -88.24 -26.04 22.55 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.359 -0.838 . . . . 1.0 109.531 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 9.6 tttp -89.39 -32.06 17.46 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.419 -0.801 . . . . 1.0 109.407 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.41 43.43 1.36 Allowed Glycine 0 CA--C 1.53 0.985 0 N-CA-C 109.633 -1.387 . . . . 1.0 109.633 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.9 m -129.46 150.36 50.84 Favored 'General case' 0 CA--C 1.53 0.191 0 O-C-N 121.47 -1.018 . . . . 1.0 109.461 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.44 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 62.5 m -72.91 134.77 44.92 Favored 'General case' 0 CA--C 1.529 0.173 0 O-C-N 121.412 -0.805 . . . . 1.0 109.5 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.419 ' CZ ' ' HD3' ' A' ' 24' ' ' PRO . 57.1 t80 -107.87 125.13 51.1 Favored 'General case' 0 CA--C 1.53 0.175 0 O-C-N 121.488 -0.758 . . . . 1.0 109.233 179.689 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 16.2 t0 -138.54 117.84 12.77 Favored 'General case' 0 CA--C 1.53 0.179 0 O-C-N 121.457 -0.777 . . . . 1.0 109.527 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.431 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 14.1 p30 -113.55 66.06 0.66 Allowed 'General case' 0 N--CA 1.464 0.256 0 O-C-N 121.547 -0.721 . . . . 1.0 109.368 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.9 p -97.62 -69.82 0.74 Allowed 'General case' 0 CA--C 1.531 0.235 0 O-C-N 121.358 -0.839 . . . . 1.0 109.522 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 38.2 t -96.46 155.19 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 O-C-N 121.458 -0.776 . . . . 1.0 109.452 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.443 ' CG ' ' H ' ' A' ' 40' ' ' GLY . 13.7 ttp-105 -93.9 178.34 5.7 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 121.504 -0.748 . . . . 1.0 109.395 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.443 ' H ' ' CG ' ' A' ' 39' ' ' ARG . . . 81.3 -43.62 2.92 Favored Glycine 0 CA--C 1.529 0.918 0 N-CA-C 109.472 -1.451 . . . . 1.0 109.472 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.642 HG11 ' HB3' ' A' ' 11' ' ' PRO . 29.2 m -85.52 169.66 15.31 Favored Pre-proline 0 CA--C 1.537 0.444 0 O-C-N 121.538 -0.978 . . . . 1.0 109.197 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -87.22 136.46 4.06 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 124.77 3.647 . . . . 1.0 110.139 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.431 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 11.6 m0 -86.72 -50.55 6.69 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.526 -0.734 . . . . 1.0 109.569 -179.742 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.2 t -77.28 103.69 7.36 Favored 'General case' 0 N--CA 1.463 0.224 0 O-C-N 121.488 -0.758 . . . . 1.0 109.505 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.44 ' CE1' ' HB2' ' A' ' 33' ' ' CYS . 4.8 p90 -135.82 -178.99 5.38 Favored 'General case' 0 N--CA 1.465 0.316 0 O-C-N 121.489 -0.757 . . . . 1.0 109.523 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 65.1 m-85 -93.75 164.31 21.23 Favored Pre-proline 0 CA--C 1.534 0.357 0 O-C-N 121.436 -0.79 . . . . 1.0 109.652 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -91.11 -165.34 0.16 Allowed 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 125.045 3.83 . . . . 1.0 110.406 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.703 ' O ' HG22 ' A' ' 6' ' ' THR . 17.9 m-80 -157.5 118.51 3.57 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.505 -0.747 . . . . 1.0 109.441 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 1.3 p -66.8 96.61 0.42 Allowed 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.454 -0.779 . . . . 1.0 109.51 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.614 HG22 ' N ' ' A' ' 51' ' ' ASP . 60.8 mt -129.04 170.21 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 O-C-N 121.463 -0.773 . . . . 1.0 109.285 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.614 ' N ' HG22 ' A' ' 50' ' ' ILE . 7.6 p-10 -74.86 -173.1 1.78 Allowed 'General case' 0 CA--C 1.53 0.209 0 O-C-N 121.504 -0.747 . . . . 1.0 109.292 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.2 m -88.09 143.12 32.51 Favored Pre-proline 0 CA--C 1.538 0.487 0 O-C-N 121.433 -0.792 . . . . 1.0 109.443 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_exo -35.65 154.03 0.02 OUTLIER 'Trans proline' 0 N--CA 1.489 1.215 1 C-N-CA 125.38 4.053 . . . . 1.0 111.083 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -34.7 -53.46 0.63 Allowed 'Trans proline' 0 N--CA 1.487 1.101 1 C-N-CA 125.646 4.231 . . . . 1.0 111.133 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -127.36 155.31 43.79 Favored 'General case' 0 CA--C 1.53 0.182 0 O-C-N 121.544 -0.723 . . . . 1.0 109.368 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -97.04 101.44 13.02 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.478 -0.764 . . . . 1.0 109.459 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -148.53 104.16 3.47 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.535 -0.728 . . . . 1.0 109.418 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.4 p -144.86 138.89 27.32 Favored 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.553 -0.717 . . . . 1.0 109.456 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.419 ' H ' ' HG2' ' A' ' 59' ' ' GLU . 9.8 pt-20 -105.6 153.43 21.8 Favored 'General case' 0 CA--C 1.53 0.202 0 O-C-N 121.542 -0.724 . . . . 1.0 109.437 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.02 -0.991 . . . . 1.0 109.439 179.958 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 . . . . . 0 CA--C 1.53 0.206 0 N-CA-C 109.419 -0.585 . . . . 1.0 109.419 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -166.25 39.26 0.05 Allowed 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.508 -0.745 . . . . 1.0 109.429 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -105.34 138.17 41.97 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.436 -0.79 . . . . 1.0 109.495 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 20.7 p -142.54 174.77 10.33 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.518 -0.739 . . . . 1.0 109.531 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 6.5 mm-40 -87.6 142.68 27.66 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.518 -0.739 . . . . 1.0 109.414 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.3 m -135.68 134.63 39.36 Favored 'General case' 0 CA--C 1.53 0.191 0 O-C-N 121.565 -0.709 . . . . 1.0 109.303 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.9 m -105.21 28.87 6.88 Favored 'General case' 0 C--N 1.33 -0.249 0 O-C-N 121.611 -0.681 . . . . 1.0 109.316 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.53 HG23 ' O ' ' A' ' 8' ' ' THR . 5.2 t -80.51 118.29 21.98 Favored 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.406 -0.809 . . . . 1.0 109.508 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 36.4 t -149.47 154.18 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 O-C-N 121.57 -0.706 . . . . 1.0 109.349 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.605 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -83.1 146.38 51.41 Favored Pre-proline 0 CA--C 1.537 0.472 0 O-C-N 121.472 -0.768 . . . . 1.0 109.353 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_exo -34.48 -62.19 0.21 Allowed 'Trans proline' 0 N--CA 1.489 1.235 1 C-N-CA 125.571 4.18 . . . . 1.0 111.388 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.52 -29.88 65.29 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.383 -0.823 . . . . 1.0 109.856 -179.649 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.605 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 28.4 mt-10 -80.62 3.7 21.06 Favored 'General case' 0 CA--C 1.535 0.39 0 O-C-N 121.394 -0.816 . . . . 1.0 109.932 -179.812 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 48.8 mtt180 -73.86 129.71 38.45 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.396 -0.815 . . . . 1.0 109.56 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.4 mm-40 -88.08 108.98 19.51 Favored 'General case' 0 N--CA 1.463 0.212 0 N-CA-C 109.03 -0.73 . . . . 1.0 109.03 179.535 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 32.9 t-20 -59.22 105.8 0.37 Allowed 'General case' 0 CA--C 1.534 0.328 0 O-C-N 121.396 -0.815 . . . . 1.0 110.391 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.434 ' H ' ' HA ' ' A' ' 45' ' ' PHE . 1.7 t -85.53 -15.22 43.43 Favored 'General case' 0 CA--C 1.535 0.391 0 O-C-N 121.489 -0.757 . . . . 1.0 109.02 179.361 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 178.57 165.28 32.89 Favored Glycine 0 CA--C 1.529 0.96 0 N-CA-C 108.99 -1.644 . . . . 1.0 108.99 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.487 ' O ' HG22 ' A' ' 22' ' ' VAL . 7.1 p90 -59.41 168.91 1.49 Allowed Pre-proline 0 CA--C 1.541 0.634 0 O-C-N 121.355 -1.085 . . . . 1.0 109.276 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 19' ' ' PHE . 10.5 Cg_endo -80.51 -30.93 1.74 Allowed 'Trans proline' 0 N--CA 1.482 0.834 0 C-N-CA 124.112 3.208 . . . . 1.0 110.662 -178.677 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.43 -6.33 7.93 Favored Glycine 0 CA--C 1.537 1.408 0 N-CA-C 110.05 -1.22 . . . . 1.0 110.05 179.332 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.487 HG22 ' O ' ' A' ' 19' ' ' PHE . 24.7 m -59.71 -172.79 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 O-C-N 121.079 -1.248 . . . . 1.0 109.894 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.1 p -143.63 152.79 57.21 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.639 -0.663 . . . . 1.0 109.298 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -34.98 -33.31 0.08 OUTLIER 'Trans proline' 0 N--CA 1.488 1.174 1 C-N-CA 125.396 4.064 . . . . 1.0 111.437 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 9.3 t -76.37 -48.99 18.0 Favored 'General case' 0 CA--C 1.532 0.282 0 O-C-N 121.451 -0.781 . . . . 1.0 109.865 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 23.8 mt-30 -62.71 -41.17 99.0 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.45 -0.781 . . . . 1.0 109.782 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.3 t -69.09 -27.61 65.75 Favored 'General case' 0 CA--C 1.532 0.25 0 O-C-N 121.468 -0.77 . . . . 1.0 109.465 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.48 -5.77 53.7 Favored 'General case' 0 CA--C 1.536 0.424 0 O-C-N 121.546 -0.721 . . . . 1.0 109.941 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -63.03 -51.12 67.97 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.351 -0.843 . . . . 1.0 109.617 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.83 -40.54 13.07 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.466 -0.771 . . . . 1.0 109.403 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 126.91 21.44 1.72 Allowed Glycine 0 CA--C 1.531 1.074 0 N-CA-C 109.806 -1.318 . . . . 1.0 109.806 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 14.9 m -75.93 136.65 40.08 Favored 'General case' 0 N--CA 1.464 0.268 0 O-C-N 121.466 -1.02 . . . . 1.0 108.76 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 62.0 m -65.2 141.0 58.81 Favored 'General case' 0 CA--C 1.531 0.213 0 O-C-N 121.375 -0.828 . . . . 1.0 109.444 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 35' ' ' ASP . 15.2 t80 -111.22 143.17 42.4 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.448 -0.782 . . . . 1.0 109.17 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.443 ' N ' ' CD1' ' A' ' 34' ' ' PHE . 24.8 t70 -162.21 116.19 1.82 Allowed 'General case' 0 CA--C 1.531 0.242 0 O-C-N 121.392 -0.818 . . . . 1.0 109.62 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.444 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 16.0 p30 -105.71 63.17 0.67 Allowed 'General case' 0 CA--C 1.533 0.295 0 O-C-N 121.574 -0.704 . . . . 1.0 109.478 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.6 p -87.19 -58.18 2.68 Favored 'General case' 0 CA--C 1.531 0.242 0 O-C-N 121.417 -0.802 . . . . 1.0 109.512 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 37.5 t -119.74 146.56 24.3 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 O-C-N 121.496 -0.753 . . . . 1.0 109.427 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 1.4 ptm180 -84.15 -174.94 5.56 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 121.496 -0.752 . . . . 1.0 109.358 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.89 -42.93 2.55 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 109.213 -1.555 . . . . 1.0 109.213 -179.706 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.7 m -91.23 170.08 10.35 Favored Pre-proline 0 CA--C 1.534 0.354 0 O-C-N 121.489 -1.006 . . . . 1.0 108.981 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_endo -86.64 119.51 1.64 Allowed 'Trans proline' 0 C--N 1.35 0.621 0 C-N-CA 124.479 3.453 . . . . 1.0 110.049 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.444 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.9 m0 -72.69 -29.25 63.24 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 109.173 -0.677 . . . . 1.0 109.173 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 12.6 t -89.66 99.38 12.39 Favored 'General case' 0 CA--C 1.533 0.31 0 N-CA-C 109.158 -0.682 . . . . 1.0 109.158 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.434 ' HA ' ' H ' ' A' ' 17' ' ' CYS . 4.3 p90 -128.91 173.99 9.9 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 121.241 -0.912 . . . . 1.0 110.083 -179.619 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.402 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 19.8 m-85 -78.67 170.91 14.05 Favored Pre-proline 0 CA--C 1.536 0.424 0 O-C-N 121.415 -0.803 . . . . 1.0 109.543 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -89.81 -178.63 1.67 Allowed 'Trans proline' 0 C--N 1.351 0.662 0 C-N-CA 125.137 3.891 . . . . 1.0 110.304 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -143.85 108.64 4.91 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.441 -0.787 . . . . 1.0 109.303 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 1.3 p -76.88 104.27 7.28 Favored 'General case' 0 N--CA 1.464 0.263 0 O-C-N 121.53 -0.731 . . . . 1.0 109.533 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 62.4 mt -127.47 150.54 33.4 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.222 0 O-C-N 121.502 -0.749 . . . . 1.0 109.298 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -80.73 175.44 10.67 Favored 'General case' 0 CA--C 1.53 0.181 0 O-C-N 121.484 -0.76 . . . . 1.0 109.428 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.613 HG23 ' O ' ' A' ' 52' ' ' VAL . 30.3 m -140.75 90.65 9.61 Favored Pre-proline 0 CA--C 1.535 0.394 0 O-C-N 121.509 -0.744 . . . . 1.0 109.503 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -91.55 163.93 3.52 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 125.118 3.879 . . . . 1.0 110.305 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.448 ' HD2' ' H ' ' A' ' 55' ' ' GLU . 21.8 Cg_endo -92.79 -21.28 0.44 Allowed 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 125.054 3.836 . . . . 1.0 110.359 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.448 ' H ' ' HD2' ' A' ' 54' ' ' PRO . 0.5 OUTLIER -98.84 150.49 21.82 Favored 'General case' 0 N--CA 1.463 0.211 0 O-C-N 121.52 -0.738 . . . . 1.0 109.571 -179.944 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 2.5 pm0 -112.34 148.69 33.71 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.577 -0.702 . . . . 1.0 109.358 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -90.13 165.23 14.1 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.461 -0.774 . . . . 1.0 109.465 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 7.9 m -75.0 111.3 10.07 Favored 'General case' 0 C--O 1.233 0.198 0 O-C-N 121.482 -0.761 . . . . 1.0 109.401 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 -118.56 166.78 12.29 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.5 -0.75 . . . . 1.0 109.416 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.047 -0.978 . . . . 1.0 109.417 179.986 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 46.9 mm-40 . . . . . 0 CA--C 1.531 0.221 0 N-CA-C 109.397 -0.594 . . . . 1.0 109.397 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -116.48 111.92 20.66 Favored 'General case' 0 N--CA 1.462 0.172 0 O-C-N 121.503 -0.748 . . . . 1.0 109.554 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 25.2 mt-30 -89.89 158.0 17.63 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.399 -0.813 . . . . 1.0 109.482 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 55.8 p -112.78 177.62 4.57 Favored 'General case' 0 CA--C 1.531 0.235 0 O-C-N 121.516 -0.74 . . . . 1.0 109.314 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -86.02 129.68 34.76 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.508 -0.745 . . . . 1.0 109.26 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.432 HG22 HG22 ' A' ' 8' ' ' THR . 3.0 m -149.23 113.69 5.28 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.45 -0.781 . . . . 1.0 109.76 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.2 m -119.67 46.07 2.01 Favored 'General case' 0 CA--C 1.532 0.273 0 O-C-N 121.528 -0.733 . . . . 1.0 109.131 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.547 HG23 ' O ' ' A' ' 8' ' ' THR . 3.3 t -128.79 80.85 1.99 Allowed 'General case' 0 CA--C 1.532 0.269 0 O-C-N 121.423 -0.798 . . . . 1.0 109.469 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.614 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.0 t -102.42 170.16 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 O-C-N 121.367 -0.833 . . . . 1.0 109.332 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.614 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -71.79 134.99 83.43 Favored Pre-proline 0 CA--C 1.539 0.547 0 O-C-N 121.52 -0.738 . . . . 1.0 109.202 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_exo -35.87 -31.13 0.08 OUTLIER 'Trans proline' 0 N--CA 1.489 1.226 0 C-N-CA 125.202 3.934 . . . . 1.0 111.554 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.464 ' H ' ' HG2' ' A' ' 12' ' ' ARG . 10.5 ptp180 -84.25 -44.75 13.57 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.392 -0.817 . . . . 1.0 110.171 -179.402 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.466 ' O ' HG11 ' A' ' 9' ' ' VAL . 5.5 mt-10 -79.07 39.81 0.39 Allowed 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.357 -0.839 . . . . 1.0 109.653 -179.616 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 63.9 mtt180 -111.22 121.46 45.33 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.391 -0.818 . . . . 1.0 109.754 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.462 ' CD ' ' H ' ' A' ' 15' ' ' GLN . 0.3 OUTLIER -90.16 125.21 35.38 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.488 -0.757 . . . . 1.0 108.993 179.391 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -65.0 127.56 32.1 Favored 'General case' 0 CA--C 1.534 0.347 0 O-C-N 121.454 -0.779 . . . . 1.0 110.7 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -98.16 -26.67 14.49 Favored 'General case' 0 CA--C 1.534 0.335 0 N-CA-C 108.371 -0.974 . . . . 1.0 108.371 178.714 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -165.47 171.62 40.78 Favored Glycine 0 CA--C 1.53 1.012 0 N-CA-C 108.701 -1.76 . . . . 1.0 108.701 179.791 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.577 ' O ' HG22 ' A' ' 22' ' ' VAL . 7.9 p90 -62.73 167.62 5.54 Favored Pre-proline 0 CA--C 1.54 0.586 0 O-C-N 121.174 -1.192 . . . . 1.0 109.153 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.21 -30.86 1.44 Allowed 'Trans proline' 0 N--CA 1.483 0.875 0 C-N-CA 124.375 3.384 . . . . 1.0 110.771 -178.642 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.28 -9.91 9.29 Favored Glycine 0 CA--C 1.538 1.479 0 N-CA-C 110.104 -1.198 . . . . 1.0 110.104 179.443 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 19' ' ' PHE . 23.4 m -60.09 169.66 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 O-C-N 121.282 -1.128 . . . . 1.0 109.721 179.802 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.543 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 38.1 p -128.55 157.89 73.56 Favored Pre-proline 0 CA--C 1.536 0.409 0 N-CA-C 109.083 -0.71 . . . . 1.0 109.083 179.608 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -36.03 -34.03 0.13 Allowed 'Trans proline' 0 N--CA 1.488 1.157 1 C-N-CA 125.364 4.042 . . . . 1.0 111.176 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 33.7 p -79.25 -45.81 19.04 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.442 -0.786 . . . . 1.0 109.965 -179.599 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLN . . . . . 0.543 ' HB2' ' H ' ' A' ' 23' ' ' THR . 7.4 mt-30 -62.42 -52.5 63.32 Favored 'General case' 0 N--CA 1.465 0.304 0 O-C-N 121.476 -0.765 . . . . 1.0 109.853 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 10.4 t -62.0 -33.97 75.32 Favored 'General case' 0 CA--C 1.533 0.311 0 O-C-N 121.483 -0.761 . . . . 1.0 109.765 -179.77 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.6 -3.13 58.31 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.336 -0.852 . . . . 1.0 110.03 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -79.08 -46.65 17.64 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.319 -0.863 . . . . 1.0 109.834 -179.593 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.2 tttt -78.82 -48.5 14.64 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 121.431 -0.793 . . . . 1.0 109.544 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 132.58 21.41 0.92 Allowed Glycine 0 CA--C 1.531 1.052 0 N-CA-C 110.281 -1.127 . . . . 1.0 110.281 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 39.9 m -91.48 138.74 31.33 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 121.246 -1.149 . . . . 1.0 108.746 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.7 m -65.17 128.04 34.19 Favored 'General case' 0 N--CA 1.464 0.242 0 O-C-N 121.303 -0.873 . . . . 1.0 109.729 -179.676 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 64.4 t80 -97.57 143.3 28.4 Favored 'General case' 0 C--O 1.234 0.266 0 O-C-N 121.541 -0.724 . . . . 1.0 109.155 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -152.72 103.54 2.79 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 121.363 -0.836 . . . . 1.0 109.645 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.431 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 9.5 p-10 -109.02 82.56 1.61 Allowed 'General case' 0 CA--C 1.531 0.216 0 O-C-N 121.55 -0.719 . . . . 1.0 109.426 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 49.1 p -118.63 -35.03 3.82 Favored 'General case' 0 N--CA 1.463 0.218 0 O-C-N 121.421 -0.799 . . . . 1.0 109.601 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.6 t -128.97 150.15 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 O-C-N 121.458 -0.776 . . . . 1.0 109.396 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 22.3 ttt180 -87.08 168.18 13.52 Favored 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.468 -0.77 . . . . 1.0 109.384 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.43 -52.03 4.58 Favored Glycine 0 CA--C 1.529 0.907 0 N-CA-C 109.529 -1.428 . . . . 1.0 109.529 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 27.6 m -74.14 169.2 20.21 Favored Pre-proline 0 CA--C 1.536 0.419 0 O-C-N 121.551 -0.97 . . . . 1.0 109.324 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_endo -88.92 130.43 2.15 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 124.883 3.722 . . . . 1.0 110.219 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.431 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 7.7 m0 -87.95 -36.44 17.09 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.423 -0.798 . . . . 1.0 109.509 -179.652 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 8.0 t -89.44 102.96 15.63 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 109.144 -0.687 . . . . 1.0 109.144 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.406 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 3.6 p90 -134.55 174.23 10.78 Favored 'General case' 0 CA--C 1.538 0.497 0 O-C-N 121.304 -0.873 . . . . 1.0 110.083 -179.414 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.406 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 45.3 m-85 -76.6 170.5 15.87 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 121.435 -0.791 . . . . 1.0 109.495 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_endo -90.18 161.83 4.73 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 124.928 3.752 . . . . 1.0 110.454 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -136.16 107.43 6.82 Favored 'General case' 0 N--CA 1.463 0.194 0 O-C-N 121.569 -0.707 . . . . 1.0 109.384 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 62.4 p -81.71 107.45 14.46 Favored 'General case' 0 C--N 1.332 -0.182 0 O-C-N 121.504 -0.747 . . . . 1.0 109.444 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 57.9 mt -128.34 155.76 40.21 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 O-C-N 121.412 -0.805 . . . . 1.0 109.307 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -78.14 107.93 11.07 Favored 'General case' 0 CA--C 1.53 0.209 0 O-C-N 121.41 -0.806 . . . . 1.0 109.524 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.8 m -131.24 147.96 68.27 Favored Pre-proline 0 CA--C 1.537 0.475 0 O-C-N 121.514 -0.741 . . . . 1.0 109.537 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.466 ' N ' ' HD2' ' A' ' 54' ' ' PRO . 6.6 Cg_exo -37.54 -59.72 0.48 Allowed 'Trans proline' 0 N--CA 1.486 1.051 0 C-N-CA 125.218 3.945 . . . . 1.0 111.374 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.466 ' HD2' ' N ' ' A' ' 53' ' ' PRO . 21.1 Cg_exo -33.76 131.14 0.15 Allowed 'Trans proline' 0 C--N 1.363 1.329 0 C-N-CA 125.228 3.952 . . . . 1.0 111.547 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -76.22 175.09 9.34 Favored 'General case' 0 CA--C 1.532 0.27 0 O-C-N 121.523 -0.736 . . . . 1.0 109.496 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.419 ' H ' ' HG3' ' A' ' 56' ' ' GLU . 0.0 OUTLIER -115.17 161.49 18.34 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.528 -0.733 . . . . 1.0 109.487 179.863 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 20.4 mm-40 -108.01 118.42 36.7 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.474 -0.766 . . . . 1.0 109.537 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 60.3 p -103.77 134.32 47.28 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.519 -0.738 . . . . 1.0 109.407 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -95.0 151.01 19.53 Favored 'General case' 0 N--CA 1.463 0.214 0 O-C-N 121.517 -0.74 . . . . 1.0 109.436 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.952 -1.023 . . . . 1.0 109.389 179.95 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 . . . . . 0 C--O 1.232 0.173 0 N-CA-C 109.485 -0.561 . . . . 1.0 109.485 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -144.41 48.62 1.35 Allowed 'General case' 0 CA--C 1.533 0.31 0 O-C-N 121.485 -0.759 . . . . 1.0 109.266 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.595 ' O ' HG23 ' A' ' 4' ' ' THR . 4.3 mp0 -100.76 96.85 7.59 Favored 'General case' 0 C--N 1.331 -0.215 0 O-C-N 121.521 -0.737 . . . . 1.0 109.378 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.595 HG23 ' O ' ' A' ' 3' ' ' GLN . 0.8 OUTLIER -160.01 -177.37 6.26 Favored 'General case' 0 CA--C 1.532 0.25 0 O-C-N 121.414 -0.804 . . . . 1.0 109.482 -179.923 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -89.55 135.21 33.73 Favored 'General case' 0 CA--C 1.531 0.242 0 O-C-N 121.482 -0.761 . . . . 1.0 109.549 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 31.7 m -127.97 132.73 49.17 Favored 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.479 -0.763 . . . . 1.0 109.193 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.3 m -124.67 -6.23 7.48 Favored 'General case' 0 CA--C 1.535 0.393 0 O-C-N 121.446 -0.783 . . . . 1.0 109.92 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.405 ' O ' HG23 ' A' ' 8' ' ' THR . 3.6 t -70.17 126.94 31.11 Favored 'General case' 0 N--CA 1.463 0.215 0 O-C-N 121.215 -0.928 . . . . 1.0 109.434 179.713 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.636 HG12 ' N ' ' A' ' 10' ' ' ALA . 26.0 t -142.34 173.64 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 O-C-N 121.513 -0.742 . . . . 1.0 109.37 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.636 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -77.96 136.84 61.89 Favored Pre-proline 0 CA--C 1.54 0.595 0 O-C-N 121.477 -0.764 . . . . 1.0 109.566 -179.788 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_exo -36.0 -38.24 0.27 Allowed 'Trans proline' 0 N--CA 1.489 1.216 1 C-N-CA 125.314 4.01 . . . . 1.0 111.442 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 40.4 mtp85 -85.11 -39.97 17.31 Favored 'General case' 0 N--CA 1.465 0.321 0 O-C-N 121.362 -0.836 . . . . 1.0 110.02 -179.282 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.63 ' O ' HG11 ' A' ' 9' ' ' VAL . 11.6 mt-10 -79.11 39.67 0.39 Allowed 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.427 -0.795 . . . . 1.0 109.671 -179.624 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 39.3 mtt180 -107.8 125.91 52.0 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.464 -0.772 . . . . 1.0 109.672 179.817 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.0 mp0 -94.76 113.13 24.86 Favored 'General case' 0 CA--C 1.532 0.284 0 O-C-N 121.472 -0.768 . . . . 1.0 109.224 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -59.74 126.17 26.53 Favored 'General case' 0 CA--C 1.533 0.314 0 O-C-N 121.411 -0.805 . . . . 1.0 110.252 -179.728 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -98.58 -18.63 18.03 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 121.565 -0.71 . . . . 1.0 109.094 179.582 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -173.21 176.67 45.89 Favored Glycine 0 CA--C 1.529 0.935 0 N-CA-C 108.834 -1.706 . . . . 1.0 108.834 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.568 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.4 p90 -65.87 167.34 11.83 Favored Pre-proline 0 CA--C 1.538 0.491 0 O-C-N 121.289 -1.124 . . . . 1.0 108.923 179.771 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.55 -29.46 1.83 Allowed 'Trans proline' 0 N--CA 1.483 0.894 0 C-N-CA 124.492 3.461 . . . . 1.0 110.897 -178.528 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.43 -11.58 10.34 Favored Glycine 0 CA--C 1.538 1.474 0 N-CA-C 110.192 -1.163 . . . . 1.0 110.192 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.568 HG22 ' O ' ' A' ' 19' ' ' PHE . 22.7 m -61.06 -171.8 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 O-C-N 121.354 -1.086 . . . . 1.0 109.72 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 43.3 p -147.1 152.52 43.59 Favored Pre-proline 0 CA--C 1.535 0.393 0 O-C-N 121.527 -0.733 . . . . 1.0 109.168 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_exo -35.15 -31.43 0.07 OUTLIER 'Trans proline' 0 N--CA 1.488 1.187 1 C-N-CA 125.575 4.183 . . . . 1.0 111.224 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 78.9 p -77.21 -51.21 11.33 Favored 'General case' 0 CA--C 1.532 0.271 0 O-C-N 121.491 -0.756 . . . . 1.0 109.752 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 68.8 mt-30 -63.08 -46.93 85.11 Favored 'General case' 0 N--CA 1.464 0.252 0 O-C-N 121.493 -0.755 . . . . 1.0 109.97 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 13.1 t -62.36 -33.15 74.15 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 121.419 -0.8 . . . . 1.0 109.82 -179.709 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.84 -3.96 58.61 Favored 'General case' 0 CA--C 1.534 0.346 0 O-C-N 121.444 -0.785 . . . . 1.0 110.056 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -79.73 -39.31 31.4 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.37 -0.831 . . . . 1.0 109.809 -179.534 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 35.4 mtmt -85.18 -46.58 10.95 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.396 -0.815 . . . . 1.0 109.938 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 137.91 11.58 0.93 Allowed Glycine 0 CA--C 1.533 1.174 0 N-CA-C 110.246 -1.141 . . . . 1.0 110.246 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 35.0 m -86.91 136.88 32.79 Favored 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.353 -1.086 . . . . 1.0 108.71 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.6 m -69.7 126.08 28.64 Favored 'General case' 0 N--CA 1.465 0.302 0 O-C-N 121.249 -0.907 . . . . 1.0 109.924 -179.704 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.451 ' CE1' ' HB2' ' A' ' 43' ' ' TRP . 50.3 t80 -94.79 147.34 23.44 Favored 'General case' 0 CA--C 1.531 0.22 0 N-CA-C 109.156 -0.683 . . . . 1.0 109.156 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -154.04 96.31 1.94 Allowed 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.454 -0.779 . . . . 1.0 109.631 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.421 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 6.7 p-10 -104.48 70.64 0.96 Allowed 'General case' 0 CA--C 1.533 0.299 0 O-C-N 121.523 -0.736 . . . . 1.0 109.25 179.821 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 18.2 p -117.64 -42.47 2.86 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.356 -0.84 . . . . 1.0 109.407 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.431 HG12 ' N ' ' A' ' 39' ' ' ARG . 37.4 t -111.2 159.23 11.32 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 O-C-N 121.438 -0.789 . . . . 1.0 109.415 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.431 ' N ' HG12 ' A' ' 38' ' ' VAL . 16.4 ttp-105 -100.33 170.37 8.47 Favored 'General case' 0 C--O 1.233 0.201 0 O-C-N 121.412 -0.805 . . . . 1.0 109.425 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.46 -58.29 5.0 Favored Glycine 0 CA--C 1.529 0.922 0 N-CA-C 109.511 -1.436 . . . . 1.0 109.511 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.5 m -70.23 169.25 14.13 Favored Pre-proline 0 CA--C 1.537 0.448 0 O-C-N 121.491 -1.006 . . . . 1.0 109.233 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -87.39 127.11 2.38 Favored 'Trans proline' 0 C--N 1.352 0.72 0 C-N-CA 124.721 3.614 . . . . 1.0 110.15 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.451 ' HB2' ' CE1' ' A' ' 34' ' ' PHE . 11.2 m0 -73.62 -43.45 59.55 Favored 'General case' 0 N--CA 1.464 0.248 0 O-C-N 121.593 -0.692 . . . . 1.0 109.603 -179.665 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 12.3 t -88.3 110.99 21.2 Favored 'General case' 0 CA--C 1.535 0.382 0 O-C-N 121.452 -0.78 . . . . 1.0 109.578 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.401 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 4.2 p90 -141.89 175.9 9.36 Favored 'General case' 0 CA--C 1.538 0.507 0 O-C-N 121.353 -0.842 . . . . 1.0 109.974 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.401 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 18.1 m-85 -74.83 171.43 11.63 Favored Pre-proline 0 CA--C 1.536 0.432 0 O-C-N 121.472 -0.767 . . . . 1.0 109.889 -179.788 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -94.42 -178.82 0.64 Allowed 'Trans proline' 0 C--N 1.351 0.691 1 C-N-CA 125.336 4.024 . . . . 1.0 110.919 -179.647 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.457 HD22 ' CG2' ' A' ' 9' ' ' VAL . 19.4 m-20 -158.29 82.84 0.84 Allowed 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.602 -0.687 . . . . 1.0 109.214 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 56.4 p -76.67 135.09 39.11 Favored 'General case' 0 N--CA 1.464 0.231 0 O-C-N 121.416 -0.803 . . . . 1.0 109.582 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.409 HG22 ' N ' ' A' ' 51' ' ' ASP . 38.1 mt -121.85 157.5 25.87 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 O-C-N 121.511 -0.743 . . . . 1.0 109.345 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.409 ' N ' HG22 ' A' ' 50' ' ' ILE . 3.7 p30 -164.82 151.25 10.53 Favored 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.53 -0.731 . . . . 1.0 109.285 179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 29.5 m -80.35 140.54 52.52 Favored Pre-proline 0 CA--C 1.537 0.463 0 O-C-N 121.38 -0.825 . . . . 1.0 109.439 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -34.83 91.09 0.01 OUTLIER 'Trans proline' 0 N--CA 1.487 1.143 1 C-N-CA 125.485 4.124 . . . . 1.0 111.325 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -92.2 -67.66 0.01 OUTLIER 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 125.094 3.862 . . . . 1.0 110.297 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -147.15 128.98 15.31 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.486 -0.759 . . . . 1.0 109.378 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -82.19 164.18 21.41 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.485 -0.759 . . . . 1.0 109.428 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 1.8 tp10 -127.7 103.72 7.46 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.439 -0.788 . . . . 1.0 109.493 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.5 p -97.41 126.8 42.89 Favored 'General case' 0 CA--C 1.53 0.191 0 O-C-N 121.539 -0.725 . . . . 1.0 109.387 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -136.02 106.81 6.59 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.399 -0.813 . . . . 1.0 109.367 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.419 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 20.5 p90 . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 117.996 -1.002 . . . . 1.0 109.507 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 . . . . . 0 CA--C 1.531 0.216 0 N-CA-C 109.329 -0.619 . . . . 1.0 109.329 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -146.93 83.72 1.59 Allowed 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.522 -0.736 . . . . 1.0 109.371 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -136.87 101.82 4.7 Favored 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.521 -0.737 . . . . 1.0 109.394 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 61.8 p -124.55 140.96 52.46 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 121.506 -0.746 . . . . 1.0 109.494 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 9.8 mp0 -109.73 139.88 44.26 Favored 'General case' 0 CA--C 1.531 0.246 0 O-C-N 121.565 -0.709 . . . . 1.0 109.422 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.461 HG22 HG22 ' A' ' 8' ' ' THR . 1.6 m -150.01 137.07 19.51 Favored 'General case' 0 C--O 1.233 0.191 0 O-C-N 121.543 -0.723 . . . . 1.0 109.574 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 77.6 m -110.51 34.68 3.81 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.523 -0.736 . . . . 1.0 109.229 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.461 HG22 HG22 ' A' ' 6' ' ' THR . 5.0 t -91.96 125.64 36.73 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.507 -0.745 . . . . 1.0 109.677 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.499 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.7 t -146.88 163.7 8.02 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 109.085 -0.709 . . . . 1.0 109.085 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.788 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -78.59 136.59 59.46 Favored Pre-proline 0 CA--C 1.541 0.624 0 O-C-N 121.467 -0.771 . . . . 1.0 109.233 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_exo -34.74 -57.81 0.4 Allowed 'Trans proline' 0 N--CA 1.488 1.196 1 C-N-CA 125.457 4.105 . . . . 1.0 111.416 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.2 mmt180 -74.49 -32.28 62.49 Favored 'General case' 0 N--CA 1.463 0.194 0 O-C-N 121.488 -0.758 . . . . 1.0 109.895 -179.616 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.788 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 9.5 mt-10 -83.05 21.93 1.01 Allowed 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.348 -0.845 . . . . 1.0 109.73 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 69.0 mtt180 -89.98 126.03 35.6 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.444 -0.785 . . . . 1.0 109.418 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -89.01 121.42 31.35 Favored 'General case' 0 CA--C 1.53 0.197 0 O-C-N 121.52 -0.738 . . . . 1.0 109.092 179.643 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -69.04 118.61 12.16 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.421 -0.799 . . . . 1.0 109.484 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -88.29 -24.16 23.26 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.48 -0.762 . . . . 1.0 109.065 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -169.74 173.79 43.95 Favored Glycine 0 CA--C 1.529 0.914 0 N-CA-C 109.085 -1.606 . . . . 1.0 109.085 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.559 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.5 p90 -66.5 167.59 12.57 Favored Pre-proline 0 CA--C 1.538 0.493 0 O-C-N 121.439 -1.036 . . . . 1.0 108.924 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -82.09 -30.21 1.35 Allowed 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 124.441 3.427 . . . . 1.0 110.801 -178.719 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.05 -11.33 8.57 Favored Glycine 0 CA--C 1.537 1.46 0 N-CA-C 110.329 -1.108 . . . . 1.0 110.329 179.593 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 19' ' ' PHE . 22.3 m -60.73 -169.98 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 O-C-N 121.334 -1.098 . . . . 1.0 109.702 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.506 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 12.8 p -140.85 156.13 68.83 Favored Pre-proline 0 CA--C 1.534 0.356 0 N-CA-C 109.096 -0.705 . . . . 1.0 109.096 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_exo -38.16 -36.23 0.49 Allowed 'Trans proline' 0 N--CA 1.487 1.143 0 C-N-CA 125.14 3.893 . . . . 1.0 110.998 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.3 t -75.98 -41.46 51.29 Favored 'General case' 0 CA--C 1.532 0.273 0 O-C-N 121.557 -0.714 . . . . 1.0 110.141 -179.473 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLN . . . . . 0.506 ' HB2' ' H ' ' A' ' 23' ' ' THR . 5.1 mt-30 -65.2 -50.79 64.51 Favored 'General case' 0 CA--C 1.532 0.261 0 O-C-N 121.431 -0.793 . . . . 1.0 110.002 -179.638 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 11.4 t -61.67 -32.3 72.47 Favored 'General case' 0 CA--C 1.533 0.319 0 O-C-N 121.335 -0.853 . . . . 1.0 109.914 -179.66 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -89.18 -3.93 58.42 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 121.497 -0.752 . . . . 1.0 110.109 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 41.6 t-20 -73.8 -53.55 10.01 Favored 'General case' 0 N--CA 1.464 0.245 0 O-C-N 121.392 -0.818 . . . . 1.0 109.523 -179.692 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.2 mttt -73.19 -48.09 38.18 Favored 'General case' 0 C--N 1.332 -0.182 0 O-C-N 121.515 -0.74 . . . . 1.0 109.375 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 136.8 15.67 0.82 Allowed Glycine 0 CA--C 1.532 1.119 0 N-CA-C 109.647 -1.381 . . . . 1.0 109.647 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 36.4 m -82.12 140.61 33.7 Favored 'General case' 0 N--CA 1.463 0.218 0 O-C-N 121.345 -1.091 . . . . 1.0 108.731 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 69.3 m -71.5 123.27 22.05 Favored 'General case' 0 C--N 1.332 -0.189 0 O-C-N 121.368 -0.833 . . . . 1.0 109.66 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 37.0 t80 -94.71 142.72 27.13 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.46 -0.775 . . . . 1.0 109.169 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -160.45 98.96 1.28 Allowed 'General case' 0 C--O 1.233 0.194 0 O-C-N 121.513 -0.742 . . . . 1.0 109.47 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.447 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.0 p-10 -107.44 76.28 1.07 Allowed 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.457 -0.777 . . . . 1.0 109.486 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 70.1 p -120.15 -38.54 2.91 Favored 'General case' 0 CA--C 1.533 0.291 0 O-C-N 121.468 -0.77 . . . . 1.0 109.654 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.8 t -110.75 144.5 18.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 O-C-N 121.397 -0.815 . . . . 1.0 109.7 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.2 mmt180 -88.69 177.16 6.82 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.547 -0.721 . . . . 1.0 109.487 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.71 -62.57 4.36 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 109.092 -1.603 . . . . 1.0 109.092 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 28.7 m -73.1 170.23 14.61 Favored Pre-proline 0 CA--C 1.536 0.406 0 O-C-N 121.63 -0.924 . . . . 1.0 109.096 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -84.34 150.76 11.95 Favored 'Trans proline' 0 C--N 1.351 0.662 0 C-N-CA 124.366 3.377 . . . . 1.0 109.901 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.447 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 7.8 m0 -94.68 -40.58 9.73 Favored 'General case' 0 N--CA 1.465 0.284 0 O-C-N 121.545 -0.722 . . . . 1.0 109.639 -179.218 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 22.7 t -90.29 105.55 17.89 Favored 'General case' 0 CA--C 1.534 0.364 0 O-C-N 121.416 -0.802 . . . . 1.0 109.448 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.433 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 4.9 p90 -128.99 179.26 5.84 Favored 'General case' 0 CA--C 1.534 0.338 0 O-C-N 121.395 -0.816 . . . . 1.0 109.9 -179.863 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.401 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 17.8 m-85 -80.97 170.71 14.48 Favored Pre-proline 0 CA--C 1.538 0.482 0 O-C-N 121.391 -0.818 . . . . 1.0 109.835 -179.596 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -90.58 169.6 3.83 Favored 'Trans proline' 0 C--N 1.352 0.736 0 C-N-CA 124.981 3.787 . . . . 1.0 110.58 179.798 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -141.3 79.77 1.7 Allowed 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.469 -0.77 . . . . 1.0 109.011 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 68.5 p -88.65 140.68 29.2 Favored 'General case' 0 CA--C 1.529 0.168 0 O-C-N 121.479 -0.763 . . . . 1.0 109.702 -179.676 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 41.9 mt -100.17 149.58 5.89 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 N-CA-C 108.963 -0.754 . . . . 1.0 108.963 179.718 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -136.14 172.88 12.36 Favored 'General case' 0 CA--C 1.53 0.179 0 O-C-N 121.397 -0.815 . . . . 1.0 109.888 -179.762 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 52' ' ' VAL . 31.6 m -108.67 79.77 1.1 Allowed Pre-proline 0 CA--C 1.538 0.507 0 O-C-N 121.619 -0.676 . . . . 1.0 109.344 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.474 ' N ' ' HD2' ' A' ' 54' ' ' PRO . 9.8 Cg_exo -35.56 -59.14 0.39 Allowed 'Trans proline' 0 N--CA 1.487 1.137 0 C-N-CA 125.234 3.956 . . . . 1.0 111.583 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.474 ' HD2' ' N ' ' A' ' 53' ' ' PRO . 20.9 Cg_exo -33.83 -51.89 0.54 Allowed 'Trans proline' 0 N--CA 1.49 1.277 0 C-N-CA 125.253 3.969 . . . . 1.0 111.479 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -107.53 118.43 36.7 Favored 'General case' 0 N--CA 1.463 0.203 0 O-C-N 121.501 -0.749 . . . . 1.0 109.394 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -138.76 109.49 6.66 Favored 'General case' 0 N--CA 1.464 0.226 0 O-C-N 121.472 -0.768 . . . . 1.0 109.414 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -141.18 150.53 42.85 Favored 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.527 -0.733 . . . . 1.0 109.33 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 16.5 p -141.27 152.68 44.71 Favored 'General case' 0 CA--C 1.531 0.246 0 O-C-N 121.547 -0.721 . . . . 1.0 109.445 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 9.1 tt0 -75.11 166.92 22.9 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.527 -0.733 . . . . 1.0 109.438 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 4.6 t80 . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.934 -1.031 . . . . 1.0 109.462 -179.995 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 . . . . . 0 CA--C 1.532 0.256 0 CA-C-O 121.353 0.597 . . . . 1.0 109.406 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -120.72 -169.46 1.82 Allowed 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.349 -0.844 . . . . 1.0 109.381 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.481 ' O ' HG23 ' A' ' 4' ' ' THR . 26.0 mt-30 -111.87 99.3 8.01 Favored 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.432 -0.793 . . . . 1.0 109.447 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.481 HG23 ' O ' ' A' ' 3' ' ' GLN . 15.3 p -155.56 158.73 38.9 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.444 -0.785 . . . . 1.0 109.367 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -67.1 146.59 54.13 Favored 'General case' 0 C--N 1.331 -0.201 0 O-C-N 121.568 -0.708 . . . . 1.0 109.393 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.941 HG22 HG22 ' A' ' 8' ' ' THR . 2.3 m -132.24 124.64 29.34 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.462 -0.774 . . . . 1.0 109.625 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 75.8 m -110.73 13.67 22.37 Favored 'General case' 0 CA--C 1.534 0.346 0 O-C-N 121.482 -0.761 . . . . 1.0 109.623 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.941 HG22 HG22 ' A' ' 6' ' ' THR . 4.4 t -93.97 104.69 16.73 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.444 -0.785 . . . . 1.0 109.565 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.515 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.6 t -123.4 164.43 21.11 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 O-C-N 121.557 -0.714 . . . . 1.0 109.29 179.798 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.515 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -69.4 121.96 83.92 Favored Pre-proline 0 CA--C 1.54 0.569 0 O-C-N 121.434 -0.791 . . . . 1.0 109.155 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.479 ' HB3' HG11 ' A' ' 41' ' ' VAL . 17.6 Cg_exo -38.36 -28.22 0.12 Allowed 'Trans proline' 0 N--CA 1.49 1.29 0 C-N-CA 124.749 3.633 . . . . 1.0 111.357 -179.653 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 64.8 mtt180 -84.25 -41.26 17.09 Favored 'General case' 0 CA--C 1.533 0.292 0 O-C-N 121.37 -0.831 . . . . 1.0 110.171 -179.252 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 15.0 mm-40 -92.43 44.88 1.17 Allowed 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.45 -0.781 . . . . 1.0 109.748 -179.74 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.408 ' HD3' ' CD2' ' A' ' 45' ' ' PHE . 19.3 mtt180 -106.81 141.63 37.73 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.332 -0.855 . . . . 1.0 109.603 179.767 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 16.5 mt-30 -111.11 126.67 55.08 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 108.918 -0.771 . . . . 1.0 108.918 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -67.73 117.32 9.49 Favored 'General case' 0 CA--C 1.532 0.285 0 O-C-N 121.427 -0.796 . . . . 1.0 110.673 -178.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.482 ' H ' ' HA ' ' A' ' 45' ' ' PHE . 3.0 t -72.64 -31.32 65.03 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 108.665 -0.865 . . . . 1.0 108.665 178.855 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -152.88 178.92 29.73 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 109.306 -1.517 . . . . 1.0 109.306 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.534 ' O ' HG22 ' A' ' 22' ' ' VAL . 6.6 p90 -62.03 169.28 2.89 Favored Pre-proline 0 CA--C 1.541 0.634 0 O-C-N 121.387 -1.067 . . . . 1.0 108.889 179.674 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 19' ' ' PHE . 10.6 Cg_endo -80.43 -31.92 1.44 Allowed 'Trans proline' 0 N--CA 1.482 0.838 0 C-N-CA 124.044 3.163 . . . . 1.0 110.762 -178.845 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.2 -3.21 6.24 Favored Glycine 0 CA--C 1.537 1.423 0 N-CA-C 110.196 -1.161 . . . . 1.0 110.196 179.704 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.534 HG22 ' O ' ' A' ' 19' ' ' PHE . 21.9 m -62.82 170.73 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 O-C-N 121.148 -1.207 . . . . 1.0 109.686 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.8 p -130.21 155.72 80.41 Favored Pre-proline 0 CA--C 1.534 0.361 0 N-CA-C 108.962 -0.755 . . . . 1.0 108.962 179.714 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -35.95 -38.7 0.28 Allowed 'Trans proline' 0 N--CA 1.488 1.18 0 C-N-CA 125.254 3.969 . . . . 1.0 111.188 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 79.4 p -70.9 -46.23 62.91 Favored 'General case' 0 CA--C 1.533 0.291 0 O-C-N 121.447 -0.783 . . . . 1.0 110.043 -179.583 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -62.19 -49.1 77.12 Favored 'General case' 0 N--CA 1.465 0.321 0 O-C-N 121.366 -0.834 . . . . 1.0 110.024 -179.656 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 7.2 t -62.54 -25.12 67.88 Favored 'General case' 0 CA--C 1.533 0.297 0 O-C-N 121.407 -0.808 . . . . 1.0 109.808 -179.715 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -95.95 -5.32 41.62 Favored 'General case' 0 CA--C 1.534 0.363 0 O-C-N 121.391 -0.818 . . . . 1.0 110.309 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -98.11 -23.39 15.75 Favored 'General case' 0 N--CA 1.465 0.281 0 O-C-N 121.223 -0.923 . . . . 1.0 109.726 -179.619 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.1 mmtm -91.41 -15.2 29.29 Favored 'General case' 0 CA--C 1.533 0.289 0 O-C-N 121.311 -0.868 . . . . 1.0 109.736 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.99 14.81 41.29 Favored Glycine 0 CA--C 1.532 1.143 0 N-CA-C 109.988 -1.245 . . . . 1.0 109.988 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 56.3 m -94.3 148.52 22.13 Favored 'General case' 0 N--CA 1.465 0.298 0 O-C-N 121.402 -1.058 . . . . 1.0 108.808 179.843 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.454 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 58.4 m -80.7 126.71 31.63 Favored 'General case' 0 CA--C 1.532 0.267 0 O-C-N 121.343 -0.848 . . . . 1.0 109.713 -179.638 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -98.84 128.13 44.96 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 108.799 -0.815 . . . . 1.0 108.799 179.334 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -141.38 117.32 10.5 Favored 'General case' 0 N--CA 1.464 0.256 0 O-C-N 121.465 -0.772 . . . . 1.0 109.864 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.438 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 7.2 p-10 -112.14 72.92 0.79 Allowed 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.594 -0.691 . . . . 1.0 109.21 179.513 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.1 p -104.08 -61.92 1.38 Allowed 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.368 -0.832 . . . . 1.0 109.619 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.6 t -103.5 154.72 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 O-C-N 121.451 -0.781 . . . . 1.0 109.415 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.94 171.85 8.85 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.479 -0.763 . . . . 1.0 109.487 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.08 -49.64 4.15 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 109.477 -1.449 . . . . 1.0 109.477 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.479 HG11 ' HB3' ' A' ' 11' ' ' PRO . 29.7 m -73.81 169.36 19.06 Favored Pre-proline 0 CA--C 1.536 0.422 0 O-C-N 121.553 -0.969 . . . . 1.0 109.333 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_endo -89.08 127.1 1.74 Allowed 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 124.838 3.692 . . . . 1.0 109.901 179.732 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.438 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 13.6 m0 -77.27 -51.5 10.8 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.51 -0.744 . . . . 1.0 109.367 -179.719 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 5.2 t -74.88 111.63 10.28 Favored 'General case' 0 CA--C 1.531 0.241 0 N-CA-C 108.616 -0.883 . . . . 1.0 108.616 179.496 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.482 ' HA ' ' H ' ' A' ' 17' ' ' CYS . 2.3 p90 -140.86 175.32 9.71 Favored 'General case' 0 N--CA 1.468 0.429 0 O-C-N 121.449 -0.782 . . . . 1.0 110.185 -179.686 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 41.7 m-85 -74.17 160.55 81.3 Favored Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 121.405 -0.81 . . . . 1.0 110.128 -179.243 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -90.03 174.32 3.23 Favored 'Trans proline' 0 C--N 1.352 0.74 0 C-N-CA 124.96 3.774 . . . . 1.0 110.401 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -132.82 92.18 3.01 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 121.541 -0.724 . . . . 1.0 109.491 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 12.0 p -86.55 94.99 9.59 Favored 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.449 -0.782 . . . . 1.0 109.259 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 36.1 mt -118.66 146.52 23.14 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 O-C-N 121.475 -0.765 . . . . 1.0 109.394 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -110.3 154.78 22.99 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 121.465 -0.772 . . . . 1.0 109.404 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.587 HG23 ' O ' ' A' ' 52' ' ' VAL . 28.0 m -139.84 92.44 9.94 Favored Pre-proline 0 CA--C 1.537 0.455 0 O-C-N 121.446 -0.784 . . . . 1.0 109.479 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -91.48 175.06 2.33 Favored 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 125.059 3.84 . . . . 1.0 110.299 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -91.47 -4.48 4.17 Favored 'Trans proline' 0 C--N 1.35 0.645 0 C-N-CA 125.006 3.804 . . . . 1.0 110.616 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 22.0 mt-10 -113.77 114.93 27.0 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.432 -0.792 . . . . 1.0 109.422 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -86.83 110.04 19.69 Favored 'General case' 0 C--N 1.332 -0.178 0 O-C-N 121.465 -0.772 . . . . 1.0 109.484 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -141.38 173.99 10.97 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 121.433 -0.792 . . . . 1.0 109.474 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.5 m -79.31 116.88 19.83 Favored 'General case' 0 CA--C 1.531 0.216 0 O-C-N 121.534 -0.729 . . . . 1.0 109.451 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -146.49 159.77 42.97 Favored 'General case' 0 N--CA 1.463 0.204 0 O-C-N 121.602 -0.686 . . . . 1.0 109.418 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.053 -0.975 . . . . 1.0 109.465 179.97 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 . . . . . 0 CA--C 1.529 0.171 0 N-CA-C 109.382 -0.599 . . . . 1.0 109.382 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -155.89 20.55 0.38 Allowed 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.423 -0.798 . . . . 1.0 109.68 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.659 ' O ' HG23 ' A' ' 4' ' ' THR . 62.0 mm-40 -146.52 95.56 2.62 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.384 -0.822 . . . . 1.0 109.395 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.659 HG23 ' O ' ' A' ' 3' ' ' GLN . 0.9 OUTLIER -161.52 -165.38 1.28 Allowed 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.556 -0.715 . . . . 1.0 109.492 -179.966 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -103.0 132.13 49.48 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.536 -0.727 . . . . 1.0 109.2 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.479 ' HB ' HG22 ' A' ' 8' ' ' THR . 1.7 m -150.26 146.13 26.61 Favored 'General case' 0 CA--C 1.53 0.209 0 O-C-N 121.403 -0.811 . . . . 1.0 109.402 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 73.1 m -86.95 11.97 12.27 Favored 'General case' 0 CA--C 1.534 0.35 0 O-C-N 121.544 -0.722 . . . . 1.0 109.641 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.535 HG23 ' O ' ' A' ' 8' ' ' THR . 5.4 t -85.41 117.96 24.65 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.257 -0.902 . . . . 1.0 109.677 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 10' ' ' ALA . 37.7 t -140.95 168.24 16.5 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 O-C-N 121.419 -0.8 . . . . 1.0 109.126 179.649 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.579 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -84.42 138.32 38.82 Favored Pre-proline 0 CA--C 1.538 0.487 0 O-C-N 121.351 -0.843 . . . . 1.0 109.439 -179.908 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_exo -34.75 -40.38 0.22 Allowed 'Trans proline' 0 N--CA 1.489 1.222 1 C-N-CA 125.511 4.141 . . . . 1.0 111.276 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 25.7 mtt85 -85.26 -46.57 10.9 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.472 -0.767 . . . . 1.0 109.699 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -67.31 -5.0 12.33 Favored 'General case' 0 CA--C 1.534 0.328 0 O-C-N 121.505 -0.747 . . . . 1.0 110.023 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.8 mtt180 -70.38 126.11 28.72 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.36 -0.838 . . . . 1.0 109.52 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 11.2 mm100 -87.07 123.09 31.76 Favored 'General case' 0 C--N 1.332 -0.168 0 O-C-N 121.478 -0.764 . . . . 1.0 109.252 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -65.7 111.39 3.18 Favored 'General case' 0 N--CA 1.464 0.238 0 O-C-N 121.559 -0.713 . . . . 1.0 109.745 -179.709 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 41.8 t -82.04 -16.42 50.23 Favored 'General case' 0 CA--C 1.534 0.351 0 O-C-N 121.431 -0.793 . . . . 1.0 109.339 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.59 179.08 44.01 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 109.061 -1.615 . . . . 1.0 109.061 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.551 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.2 p90 -65.04 167.73 9.01 Favored Pre-proline 0 CA--C 1.539 0.548 0 O-C-N 121.306 -1.114 . . . . 1.0 108.838 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.54 -30.59 1.42 Allowed 'Trans proline' 0 N--CA 1.482 0.814 0 C-N-CA 124.39 3.393 . . . . 1.0 110.881 -178.658 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.62 -8.77 7.9 Favored Glycine 0 CA--C 1.537 1.441 0 N-CA-C 110.25 -1.14 . . . . 1.0 110.25 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.551 HG22 ' O ' ' A' ' 19' ' ' PHE . 20.0 m -61.16 177.24 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 O-C-N 121.228 -1.16 . . . . 1.0 109.669 179.766 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.0 p -138.89 156.24 72.73 Favored Pre-proline 0 CA--C 1.535 0.389 0 O-C-N 121.54 -0.725 . . . . 1.0 109.225 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -34.91 -32.04 0.07 OUTLIER 'Trans proline' 0 N--CA 1.487 1.12 1 C-N-CA 125.56 4.174 . . . . 1.0 111.171 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 1.8 m -72.12 -51.94 19.08 Favored 'General case' 0 CA--C 1.532 0.281 0 O-C-N 121.419 -0.801 . . . . 1.0 109.614 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 52.3 mt-30 -62.78 -46.01 90.0 Favored 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.47 -0.769 . . . . 1.0 109.772 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.2 t -64.59 -23.8 67.38 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.401 -0.812 . . . . 1.0 109.563 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -94.12 -7.12 43.37 Favored 'General case' 0 CA--C 1.535 0.399 0 O-C-N 121.383 -0.823 . . . . 1.0 109.881 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -73.38 -39.26 65.27 Favored 'General case' 0 CA--C 1.532 0.281 0 O-C-N 121.269 -0.895 . . . . 1.0 109.418 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -92.49 -38.39 11.98 Favored 'General case' 0 N--CA 1.462 0.171 0 O-C-N 121.523 -0.736 . . . . 1.0 109.425 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 113.95 37.93 1.21 Allowed Glycine 0 CA--C 1.53 1.024 0 N-CA-C 109.631 -1.388 . . . . 1.0 109.631 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.8 m -97.52 145.01 26.65 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.472 -1.017 . . . . 1.0 109.273 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.404 ' O ' ' CD1' ' A' ' 45' ' ' PHE . 58.4 m -68.28 119.56 13.02 Favored 'General case' 0 CA--C 1.532 0.267 0 O-C-N 121.398 -0.814 . . . . 1.0 109.426 -179.677 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 43.7 t80 -92.02 146.85 23.41 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.386 -0.821 . . . . 1.0 109.258 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 10.6 t0 -162.12 110.43 1.41 Allowed 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.353 -0.842 . . . . 1.0 109.537 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.435 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 13.6 p30 -110.63 70.77 0.73 Allowed 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.501 -0.749 . . . . 1.0 109.442 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.8 p -111.82 -53.31 2.72 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.403 -0.811 . . . . 1.0 109.737 -179.789 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.437 HG12 ' N ' ' A' ' 39' ' ' ARG . 35.6 t -96.3 159.38 2.98 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 O-C-N 121.341 -0.849 . . . . 1.0 109.639 -179.692 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.437 ' N ' HG12 ' A' ' 38' ' ' VAL . 2.2 mmm180 -103.82 169.13 8.69 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 121.473 -0.767 . . . . 1.0 109.263 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.75 -42.63 2.49 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 109.355 -1.498 . . . . 1.0 109.355 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.4 m -80.34 169.68 18.77 Favored Pre-proline 0 CA--C 1.537 0.466 0 O-C-N 121.538 -0.978 . . . . 1.0 109.082 179.768 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -87.3 131.77 3.05 Favored 'Trans proline' 0 C--N 1.351 0.682 0 C-N-CA 124.712 3.608 . . . . 1.0 110.011 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.435 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 15.3 m0 -80.15 -39.45 29.34 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.46 -0.775 . . . . 1.0 109.738 -179.482 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 16.0 t -90.01 107.78 19.32 Favored 'General case' 0 CA--C 1.534 0.338 0 O-C-N 121.412 -0.805 . . . . 1.0 109.486 179.841 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.423 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 5.6 p90 -133.52 175.9 9.01 Favored 'General case' 0 CA--C 1.536 0.412 0 O-C-N 121.452 -0.78 . . . . 1.0 109.757 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.406 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 31.9 m-85 -85.34 170.84 12.09 Favored Pre-proline 0 CA--C 1.537 0.462 0 O-C-N 121.532 -0.73 . . . . 1.0 109.351 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -90.96 177.06 2.15 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 124.968 3.779 . . . . 1.0 110.39 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -123.08 99.92 6.61 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.569 -0.707 . . . . 1.0 109.597 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 55.3 p -105.36 92.36 4.17 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.461 -0.775 . . . . 1.0 109.393 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 57.3 mt -111.27 141.46 26.57 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.276 0 O-C-N 121.496 -0.752 . . . . 1.0 109.365 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -155.2 128.84 8.54 Favored 'General case' 0 CA--C 1.53 0.179 0 O-C-N 121.566 -0.709 . . . . 1.0 109.461 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 52' ' ' VAL . 30.9 m -150.22 79.58 7.47 Favored Pre-proline 0 CA--C 1.536 0.438 0 O-C-N 121.506 -0.746 . . . . 1.0 109.54 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.438 ' N ' ' CD ' ' A' ' 54' ' ' PRO . 16.8 Cg_exo -35.0 -46.56 0.61 Allowed 'Trans proline' 0 N--CA 1.487 1.14 1 C-N-CA 125.355 4.036 . . . . 1.0 111.795 179.972 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.438 ' CD ' ' N ' ' A' ' 53' ' ' PRO . 17.3 Cg_endo -90.6 -160.23 0.09 OUTLIER 'Trans proline' 0 C--N 1.354 0.843 0 C-N-CA 124.593 3.529 . . . . 1.0 110.427 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.424 ' CD ' ' H ' ' A' ' 55' ' ' GLU . 0.9 OUTLIER -69.96 162.61 27.74 Favored 'General case' 0 N--CA 1.465 0.276 0 O-C-N 121.469 -0.77 . . . . 1.0 109.503 -179.967 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -72.14 -179.85 3.01 Favored 'General case' 0 CA--C 1.529 0.166 0 O-C-N 121.527 -0.733 . . . . 1.0 109.571 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 13.9 pm0 -110.71 153.03 25.85 Favored 'General case' 0 C--O 1.233 0.209 0 O-C-N 121.464 -0.773 . . . . 1.0 109.438 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 6.0 m -99.01 164.45 12.17 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.449 -0.782 . . . . 1.0 109.377 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -81.2 104.16 11.48 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.436 -0.79 . . . . 1.0 109.475 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 54.8 m-85 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.003 -0.999 . . . . 1.0 109.417 -179.964 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 11.0 pm0 . . . . . 0 CA--C 1.53 0.187 0 N-CA-C 109.379 -0.601 . . . . 1.0 109.379 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.78 77.07 1.05 Allowed 'General case' 0 CA--C 1.531 0.226 0 O-C-N 121.52 -0.737 . . . . 1.0 109.491 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 9.9 mp0 -143.45 170.79 15.13 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.477 -0.765 . . . . 1.0 109.346 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -147.94 176.21 10.35 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.519 -0.738 . . . . 1.0 109.395 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -90.51 139.38 30.75 Favored 'General case' 0 CA--C 1.529 0.153 0 O-C-N 121.564 -0.71 . . . . 1.0 109.41 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.66 155.33 48.38 Favored 'General case' 0 N--CA 1.463 0.175 0 O-C-N 121.495 -0.753 . . . . 1.0 109.327 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 62.3 m -114.9 28.24 8.85 Favored 'General case' 0 C--O 1.232 0.15 0 O-C-N 121.496 -0.752 . . . . 1.0 109.326 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.481 HG23 ' O ' ' A' ' 8' ' ' THR . 5.6 t -95.39 122.82 38.51 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.362 -0.836 . . . . 1.0 109.586 -179.89 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.56 HG12 ' N ' ' A' ' 10' ' ' ALA . 40.3 t -147.11 167.67 5.5 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.198 0 O-C-N 121.5 -0.75 . . . . 1.0 109.283 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.573 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -76.66 124.97 87.83 Favored Pre-proline 0 CA--C 1.541 0.609 0 O-C-N 121.438 -0.789 . . . . 1.0 109.354 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.401 ' HD2' ' HA ' ' A' ' 10' ' ' ALA . 19.4 Cg_exo -36.87 -50.37 1.45 Allowed 'Trans proline' 0 N--CA 1.49 1.302 0 C-N-CA 124.922 3.748 . . . . 1.0 111.242 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.6 mtp180 -70.21 -49.12 53.38 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.458 -0.776 . . . . 1.0 109.652 -179.742 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.573 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 25.0 mt-10 -82.61 40.36 0.66 Allowed 'General case' 0 CA--C 1.53 0.211 0 O-C-N 121.46 -0.775 . . . . 1.0 109.52 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 26.2 mtt180 -92.4 139.34 30.7 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.473 -0.767 . . . . 1.0 109.476 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -85.46 108.48 17.91 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.522 -0.736 . . . . 1.0 109.162 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -64.59 120.48 12.43 Favored 'General case' 0 CA--C 1.532 0.275 0 O-C-N 121.485 -0.759 . . . . 1.0 109.668 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 28.2 t -95.75 -19.48 19.63 Favored 'General case' 0 CA--C 1.534 0.327 0 O-C-N 121.586 -0.696 . . . . 1.0 109.456 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 175.3 -179.03 46.79 Favored Glycine 0 CA--C 1.528 0.871 0 N-CA-C 109.232 -1.547 . . . . 1.0 109.232 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.561 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.1 p90 -65.72 167.97 9.84 Favored Pre-proline 0 CA--C 1.537 0.455 0 O-C-N 121.369 -1.077 . . . . 1.0 108.929 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.68 -30.15 1.53 Allowed 'Trans proline' 0 N--CA 1.483 0.902 0 C-N-CA 124.418 3.412 . . . . 1.0 110.809 -178.713 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -57.16 -12.16 7.4 Favored Glycine 0 CA--C 1.536 1.401 0 N-CA-C 110.401 -1.079 . . . . 1.0 110.401 179.597 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.561 HG22 ' O ' ' A' ' 19' ' ' PHE . 24.2 m -61.3 162.92 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 O-C-N 121.253 -1.145 . . . . 1.0 109.641 179.694 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.4 p -121.6 154.75 60.05 Favored Pre-proline 0 CA--C 1.534 0.35 0 O-C-N 121.505 -0.747 . . . . 1.0 109.311 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.0 Cg_exo -35.8 -38.75 0.27 Allowed 'Trans proline' 0 N--CA 1.487 1.119 1 C-N-CA 125.479 4.12 . . . . 1.0 111.258 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 1.9 p -69.91 -48.08 59.97 Favored 'General case' 0 N--CA 1.463 0.213 0 O-C-N 121.511 -0.743 . . . . 1.0 109.791 -179.826 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -62.72 -46.15 89.42 Favored 'General case' 0 CA--C 1.533 0.322 0 O-C-N 121.4 -0.813 . . . . 1.0 109.749 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 17.3 t -64.59 -26.79 68.56 Favored 'General case' 0 CA--C 1.531 0.213 0 O-C-N 121.431 -0.793 . . . . 1.0 109.368 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.56 -8.85 54.06 Favored 'General case' 0 CA--C 1.532 0.271 0 O-C-N 121.562 -0.711 . . . . 1.0 109.811 179.708 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -77.94 -38.42 45.46 Favored 'General case' 0 CA--C 1.53 0.18 0 O-C-N 121.245 -0.91 . . . . 1.0 109.373 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.4 mmtt -83.69 -41.44 17.72 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 121.429 -0.794 . . . . 1.0 109.41 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 118.07 38.45 0.81 Allowed Glycine 0 CA--C 1.531 1.055 0 N-CA-C 109.569 -1.412 . . . . 1.0 109.569 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.7 m -112.61 147.97 35.56 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.606 -0.938 . . . . 1.0 109.485 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 66.4 m -69.5 125.14 25.82 Favored 'General case' 0 CA--C 1.529 0.163 0 O-C-N 121.477 -0.765 . . . . 1.0 109.36 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -99.1 143.13 29.71 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.508 -0.745 . . . . 1.0 109.367 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -157.0 113.9 3.06 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 121.529 -0.732 . . . . 1.0 109.503 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.423 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.9 p-10 -111.54 60.27 0.62 Allowed 'General case' 0 CA--C 1.533 0.321 0 O-C-N 121.492 -0.755 . . . . 1.0 109.39 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 67.7 p -99.8 -56.64 2.33 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.356 -0.84 . . . . 1.0 109.569 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.484 HG12 ' N ' ' A' ' 39' ' ' ARG . 36.5 t -98.23 161.88 2.87 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.22 0 O-C-N 121.485 -0.76 . . . . 1.0 109.425 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.484 ' N ' HG12 ' A' ' 38' ' ' VAL . 4.0 mpt_? -104.95 173.59 6.24 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.506 -0.746 . . . . 1.0 109.448 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.31 -45.53 3.06 Favored Glycine 0 CA--C 1.529 0.936 0 N-CA-C 109.477 -1.449 . . . . 1.0 109.477 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.6 m -79.37 169.52 20.01 Favored Pre-proline 0 CA--C 1.536 0.413 0 O-C-N 121.56 -0.965 . . . . 1.0 109.321 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -87.42 127.84 2.47 Favored 'Trans proline' 0 C--N 1.35 0.657 0 C-N-CA 124.805 3.67 . . . . 1.0 109.987 179.743 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.423 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 16.6 m0 -74.6 -38.54 62.58 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.457 -0.777 . . . . 1.0 109.918 -179.439 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 8.3 t -89.59 109.15 20.13 Favored 'General case' 0 CA--C 1.533 0.318 0 O-C-N 121.352 -0.842 . . . . 1.0 109.609 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.419 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 4.9 p90 -135.65 -178.69 5.24 Favored 'General case' 0 CA--C 1.535 0.397 0 O-C-N 121.415 -0.803 . . . . 1.0 109.463 179.708 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.402 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 18.6 m-85 -90.68 167.1 17.17 Favored Pre-proline 0 CA--C 1.536 0.426 0 O-C-N 121.487 -0.758 . . . . 1.0 109.592 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -91.23 148.65 3.66 Favored 'Trans proline' 0 C--N 1.35 0.628 0 C-N-CA 124.998 3.799 . . . . 1.0 110.461 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -123.77 101.2 7.15 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 109.126 -0.694 . . . . 1.0 109.126 179.664 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.4 p -61.94 98.3 0.1 Allowed 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.409 -0.807 . . . . 1.0 109.856 -179.635 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 48.1 mt -131.46 156.24 42.47 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 O-C-N 121.554 -0.716 . . . . 1.0 109.158 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -127.7 151.59 48.78 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.388 -0.82 . . . . 1.0 109.537 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.4 m -131.11 147.36 65.96 Favored Pre-proline 0 CA--C 1.534 0.364 0 O-C-N 121.584 -0.697 . . . . 1.0 109.465 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.449 ' N ' ' HD2' ' A' ' 54' ' ' PRO . 4.7 Cg_exo -38.17 -60.17 0.48 Allowed 'Trans proline' 0 N--CA 1.486 1.038 0 C-N-CA 125.172 3.915 . . . . 1.0 111.233 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.449 ' HD2' ' N ' ' A' ' 53' ' ' PRO . 14.6 Cg_exo -37.31 157.31 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.378 0 C-N-CA 124.892 3.728 . . . . 1.0 111.02 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -114.2 145.87 41.12 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.504 -0.748 . . . . 1.0 109.381 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -107.01 118.06 35.69 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 121.547 -0.72 . . . . 1.0 109.416 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -138.65 151.2 47.01 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.46 -0.775 . . . . 1.0 109.415 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.5 p -76.02 130.79 38.93 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.39 -0.819 . . . . 1.0 109.453 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -142.85 153.79 43.52 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.508 -0.745 . . . . 1.0 109.468 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 7.5 t80 . . . . . 0 C--O 1.221 -0.412 0 CA-C-O 118.019 -0.991 . . . . 1.0 109.47 179.997 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 . . . . . 0 CA--C 1.53 0.194 0 N-CA-C 109.433 -0.58 . . . . 1.0 109.433 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -96.84 99.49 11.06 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 121.533 -0.729 . . . . 1.0 109.438 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 14.5 mm100 -137.31 131.34 32.09 Favored 'General case' 0 CA--C 1.53 0.189 0 O-C-N 121.482 -0.761 . . . . 1.0 109.436 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.3 p -144.3 -179.3 6.44 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.442 -0.786 . . . . 1.0 109.433 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -110.06 127.39 54.82 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 121.481 -0.762 . . . . 1.0 109.44 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.31 144.0 25.26 Favored 'General case' 0 CA--C 1.531 0.247 0 O-C-N 121.446 -0.784 . . . . 1.0 109.53 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 74.0 m -107.04 19.98 19.67 Favored 'General case' 0 CA--C 1.532 0.277 0 O-C-N 121.539 -0.725 . . . . 1.0 109.548 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.611 HG23 ' O ' ' A' ' 8' ' ' THR . 4.8 t -82.89 94.87 7.79 Favored 'General case' 0 CA--C 1.532 0.286 0 O-C-N 121.456 -0.777 . . . . 1.0 109.749 -179.628 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.599 HG11 ' O ' ' A' ' 13' ' ' GLU . 39.8 t -122.16 155.04 26.95 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 O-C-N 121.526 -0.734 . . . . 1.0 109.035 179.639 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -81.23 137.49 49.08 Favored Pre-proline 0 CA--C 1.539 0.533 0 O-C-N 121.387 -0.82 . . . . 1.0 109.378 -179.731 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.456 ' HB3' HG11 ' A' ' 41' ' ' VAL . 18.4 Cg_exo -35.39 -36.41 0.15 Allowed 'Trans proline' 0 N--CA 1.488 1.159 1 C-N-CA 125.398 4.065 . . . . 1.0 111.266 -179.957 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 19.6 mtp180 -74.47 -49.91 20.4 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.529 -0.732 . . . . 1.0 109.674 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.599 ' O ' HG11 ' A' ' 9' ' ' VAL . 7.7 mm-40 -81.38 27.64 0.41 Allowed 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.481 -0.762 . . . . 1.0 109.808 -179.756 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 32.2 mtt180 -100.73 146.31 27.38 Favored 'General case' 0 N--CA 1.464 0.23 0 O-C-N 121.433 -0.792 . . . . 1.0 109.418 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 16.7 mt-30 -120.38 154.76 34.65 Favored 'General case' 0 C--N 1.332 -0.194 0 O-C-N 121.518 -0.739 . . . . 1.0 109.297 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.421 ' ND2' ' O ' ' A' ' 18' ' ' GLY . 8.1 t30 -80.32 125.15 29.53 Favored 'General case' 0 CA--C 1.53 0.197 0 O-C-N 121.498 -0.751 . . . . 1.0 109.132 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -98.62 -23.71 15.37 Favored 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.455 -0.778 . . . . 1.0 109.303 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.421 ' O ' ' ND2' ' A' ' 16' ' ' ASN . . . -167.13 -179.81 40.35 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 109.021 -1.632 . . . . 1.0 109.021 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.647 ' O ' HG22 ' A' ' 22' ' ' VAL . 7.8 p90 -67.68 167.17 17.31 Favored Pre-proline 0 CA--C 1.537 0.471 0 O-C-N 121.348 -1.09 . . . . 1.0 108.826 179.81 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -82.31 -29.57 1.48 Allowed 'Trans proline' 0 N--CA 1.483 0.908 0 C-N-CA 124.551 3.501 . . . . 1.0 110.914 -178.576 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -55.6 -15.34 8.52 Favored Glycine 0 CA--C 1.535 1.324 0 N-CA-C 110.35 -1.1 . . . . 1.0 110.35 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.647 HG22 ' O ' ' A' ' 19' ' ' PHE . 22.6 m -63.22 151.55 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 O-C-N 121.326 -1.103 . . . . 1.0 109.543 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.59 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 73.0 p -99.7 154.64 37.16 Favored Pre-proline 0 CA--C 1.536 0.422 0 N-CA-C 108.99 -0.745 . . . . 1.0 108.99 179.311 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -33.18 -55.68 0.38 Allowed 'Trans proline' 0 N--CA 1.487 1.113 1 C-N-CA 125.797 4.332 . . . . 1.0 111.862 -179.454 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 67.6 m -80.12 -27.38 39.15 Favored 'General case' 0 N--CA 1.464 0.245 0 O-C-N 121.43 -0.793 . . . . 1.0 110.565 -179.041 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLN . . . . . 0.59 ' HB2' ' H ' ' A' ' 23' ' ' THR . 10.5 mt-30 -61.46 -54.51 42.44 Favored 'General case' 0 N--CA 1.466 0.353 0 O-C-N 121.287 -0.883 . . . . 1.0 110.332 -179.47 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -77.5 -27.2 51.77 Favored 'General case' 0 CA--C 1.534 0.333 0 O-C-N 121.393 -0.817 . . . . 1.0 109.886 -179.261 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.72 -5.01 57.73 Favored 'General case' 0 CA--C 1.534 0.365 0 O-C-N 121.422 -0.799 . . . . 1.0 110.113 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -106.8 -4.39 19.36 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.316 -0.865 . . . . 1.0 109.8 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.1 tttt -89.9 -46.69 8.37 Favored 'General case' 0 CA--C 1.533 0.289 0 O-C-N 121.269 -0.895 . . . . 1.0 109.196 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 151.22 19.14 0.06 OUTLIER Glycine 0 CA--C 1.531 1.054 0 N-CA-C 109.528 -1.429 . . . . 1.0 109.528 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 85.6 m -119.17 148.96 42.51 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.423 -1.045 . . . . 1.0 109.285 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 55.9 m -77.49 115.63 17.41 Favored 'General case' 0 N--CA 1.463 0.221 0 O-C-N 121.557 -0.715 . . . . 1.0 109.083 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.436 ' CD1' ' N ' ' A' ' 35' ' ' ASP . 46.5 t80 -89.95 152.37 21.24 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.446 -0.784 . . . . 1.0 109.722 -179.618 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.436 ' N ' ' CD1' ' A' ' 34' ' ' PHE . 28.5 t70 -165.29 118.7 1.21 Allowed 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.589 -0.694 . . . . 1.0 109.309 179.724 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -120.34 51.54 1.21 Allowed 'General case' 0 CA--C 1.534 0.329 0 O-C-N 121.532 -0.73 . . . . 1.0 109.547 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -99.77 -15.59 18.4 Favored 'General case' 0 CA--C 1.533 0.317 0 O-C-N 121.308 -0.87 . . . . 1.0 109.937 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.463 HG12 ' N ' ' A' ' 39' ' ' ARG . 37.3 t -129.71 161.02 40.1 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.222 0 O-C-N 121.335 -0.853 . . . . 1.0 109.625 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.463 ' N ' HG12 ' A' ' 38' ' ' VAL . 79.5 mtt85 -111.89 166.96 10.75 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.516 -0.74 . . . . 1.0 109.379 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.55 -41.99 2.38 Favored Glycine 0 CA--C 1.53 0.986 0 N-CA-C 109.234 -1.546 . . . . 1.0 109.234 -179.818 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.456 HG11 ' HB3' ' A' ' 11' ' ' PRO . 28.9 m -81.1 170.63 14.75 Favored Pre-proline 0 CA--C 1.537 0.478 0 O-C-N 121.587 -0.949 . . . . 1.0 109.049 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' PRO . . . . . 0.405 ' CD ' ' HB ' ' A' ' 41' ' ' VAL . 11.7 Cg_endo -85.87 126.31 2.89 Favored 'Trans proline' 0 C--N 1.352 0.744 0 C-N-CA 124.539 3.493 . . . . 1.0 110.018 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' TRP . . . . . . . . . . . . . 33.8 m0 -75.41 -37.6 60.35 Favored 'General case' 0 N--CA 1.462 0.169 0 O-C-N 121.429 -0.794 . . . . 1.0 109.91 -179.536 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 6.5 t -90.08 113.99 25.82 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.415 -0.803 . . . . 1.0 109.539 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.416 ' N ' ' CD1' ' A' ' 45' ' ' PHE . 5.7 p90 -140.02 170.91 14.98 Favored 'General case' 0 CA--C 1.536 0.424 0 O-C-N 121.388 -0.82 . . . . 1.0 110.025 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 61.8 m-85 -77.06 170.59 15.6 Favored Pre-proline 0 CA--C 1.537 0.443 0 O-C-N 121.674 -0.641 . . . . 1.0 109.419 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -88.18 173.12 4.92 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 124.829 3.686 . . . . 1.0 110.415 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -148.09 107.11 3.85 Favored 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.664 -0.647 . . . . 1.0 109.346 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 24.2 p -77.05 84.73 3.56 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.483 -0.76 . . . . 1.0 109.485 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.585 HG22 ' N ' ' A' ' 51' ' ' ASP . 48.0 mt -96.91 168.71 1.54 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 O-C-N 121.523 -0.735 . . . . 1.0 109.298 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.585 ' N ' HG22 ' A' ' 50' ' ' ILE . 3.9 p-10 -75.39 -177.91 3.78 Favored 'General case' 0 N--CA 1.463 0.179 0 O-C-N 121.473 -0.767 . . . . 1.0 109.422 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.618 HG23 ' O ' ' A' ' 52' ' ' VAL . 30.0 m -148.71 100.31 3.51 Favored Pre-proline 0 CA--C 1.539 0.543 0 O-C-N 121.451 -0.781 . . . . 1.0 109.538 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -49.66 -178.43 0.01 OUTLIER 'Trans proline' 0 N--CA 1.488 1.181 0 C-N-CA 123.948 3.099 . . . . 1.0 110.209 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -87.42 42.88 0.85 Allowed 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 124.729 3.619 . . . . 1.0 110.281 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 32.3 mt-10 -112.75 118.65 35.57 Favored 'General case' 0 CA--C 1.53 0.202 0 O-C-N 121.479 -0.763 . . . . 1.0 109.265 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 51.0 mt-10 -126.73 135.91 51.73 Favored 'General case' 0 N--CA 1.463 0.193 0 O-C-N 121.475 -0.765 . . . . 1.0 109.617 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 33.3 mt-10 -148.78 110.5 4.51 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.536 -0.727 . . . . 1.0 109.364 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 90.8 p -80.96 110.37 16.43 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 121.443 -0.786 . . . . 1.0 109.531 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 13.3 tt0 -139.86 169.04 18.45 Favored 'General case' 0 N--CA 1.463 0.198 0 O-C-N 121.515 -0.741 . . . . 1.0 109.39 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.954 -1.022 . . . . 1.0 109.374 -179.934 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 13.5 tt0 . . . . . 0 CA--C 1.53 0.211 0 N-CA-C 109.413 -0.588 . . . . 1.0 109.413 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -115.23 139.57 49.83 Favored 'General case' 0 CA--C 1.531 0.223 0 O-C-N 121.454 -0.779 . . . . 1.0 109.553 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.413 ' O ' HG23 ' A' ' 4' ' ' THR . 0.8 OUTLIER -123.25 108.93 13.33 Favored 'General case' 0 N--CA 1.463 0.211 0 O-C-N 121.483 -0.76 . . . . 1.0 109.442 179.935 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.413 HG23 ' O ' ' A' ' 3' ' ' GLN . 30.7 p -155.1 161.71 41.2 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.563 -0.711 . . . . 1.0 109.57 -179.885 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -67.57 156.87 35.73 Favored 'General case' 0 CA--C 1.53 0.184 0 O-C-N 121.425 -0.797 . . . . 1.0 109.005 179.654 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.7 m -149.28 116.36 6.03 Favored 'General case' 0 C--O 1.233 0.198 0 O-C-N 121.404 -0.81 . . . . 1.0 109.953 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 86.2 m -108.07 -18.53 13.76 Favored 'General case' 0 CA--C 1.534 0.336 0 O-C-N 121.444 -0.785 . . . . 1.0 109.216 179.337 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.551 HG23 ' O ' ' A' ' 8' ' ' THR . 3.1 t -68.78 101.42 1.33 Allowed 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.201 -0.937 . . . . 1.0 109.521 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.612 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.6 t -121.82 171.16 11.02 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 O-C-N 121.575 -0.703 . . . . 1.0 109.233 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.612 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -67.99 129.17 93.25 Favored Pre-proline 0 CA--C 1.539 0.541 0 O-C-N 121.355 -0.84 . . . . 1.0 109.483 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -36.95 -50.21 1.48 Allowed 'Trans proline' 0 N--CA 1.49 1.281 0 C-N-CA 125.027 3.818 . . . . 1.0 111.227 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.413 ' HD2' ' H ' ' A' ' 12' ' ' ARG . 1.2 mpt_? -70.75 -39.55 73.21 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.502 -0.749 . . . . 1.0 109.833 -179.591 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -81.42 29.24 0.37 Allowed 'General case' 0 CA--C 1.532 0.254 0 O-C-N 121.529 -0.732 . . . . 1.0 109.716 -179.72 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 37.9 mtt180 -101.41 120.63 40.57 Favored 'General case' 0 N--CA 1.464 0.248 0 O-C-N 121.417 -0.802 . . . . 1.0 109.368 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 -79.86 121.43 25.4 Favored 'General case' 0 CA--C 1.531 0.216 0 O-C-N 121.491 -0.756 . . . . 1.0 109.261 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -63.91 121.4 13.98 Favored 'General case' 0 CA--C 1.532 0.261 0 O-C-N 121.517 -0.74 . . . . 1.0 109.911 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.3 t -93.73 -20.33 20.23 Favored 'General case' 0 CA--C 1.534 0.351 0 O-C-N 121.562 -0.711 . . . . 1.0 109.272 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 179.57 177.23 47.71 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 109.178 -1.569 . . . . 1.0 109.178 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.533 ' CD2' HG13 ' A' ' 22' ' ' VAL . 8.8 p90 -65.01 167.7 9.0 Favored Pre-proline 0 CA--C 1.538 0.516 0 O-C-N 121.446 -1.032 . . . . 1.0 108.885 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.58 -30.67 1.38 Allowed 'Trans proline' 0 N--CA 1.481 0.777 0 C-N-CA 124.45 3.433 . . . . 1.0 110.802 -178.845 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.46 -10.04 7.22 Favored Glycine 0 CA--C 1.537 1.454 0 N-CA-C 110.307 -1.117 . . . . 1.0 110.307 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.533 HG13 ' CD2' ' A' ' 19' ' ' PHE . 24.2 m -60.66 -174.74 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 O-C-N 121.231 -1.158 . . . . 1.0 109.531 179.763 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.42 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 4.1 p -143.74 153.72 58.28 Favored Pre-proline 0 CA--C 1.537 0.45 0 O-C-N 121.515 -0.741 . . . . 1.0 109.285 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -35.85 -36.97 0.2 Allowed 'Trans proline' 0 N--CA 1.487 1.134 1 C-N-CA 125.32 4.013 . . . . 1.0 111.382 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.6 t -73.73 -47.34 40.04 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.442 -0.786 . . . . 1.0 109.756 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLN . . . . . 0.42 ' HB2' ' H ' ' A' ' 23' ' ' THR . 45.0 mt-30 -61.65 -44.73 96.42 Favored 'General case' 0 N--CA 1.466 0.327 0 O-C-N 121.436 -0.79 . . . . 1.0 109.674 -179.831 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 8.5 t -65.34 -32.63 74.37 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 121.486 -0.758 . . . . 1.0 109.382 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.6 -4.16 59.08 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 121.615 -0.678 . . . . 1.0 109.938 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -86.22 -23.55 26.39 Favored 'General case' 0 N--CA 1.464 0.258 0 O-C-N 121.218 -0.926 . . . . 1.0 109.636 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.3 tppp? -101.41 -34.94 9.38 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.379 -0.826 . . . . 1.0 109.315 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 111.49 53.62 0.52 Allowed Glycine 0 CA--C 1.529 0.955 0 N-CA-C 109.414 -1.475 . . . . 1.0 109.414 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.7 m -128.7 139.24 52.33 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.544 -0.974 . . . . 1.0 109.363 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.425 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 56.0 m -61.47 119.8 9.27 Favored 'General case' 0 N--CA 1.468 0.448 0 O-C-N 121.462 -0.774 . . . . 1.0 109.964 -179.344 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -101.51 121.56 42.19 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.423 -0.798 . . . . 1.0 109.192 179.623 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.443 ' OD1' HG23 ' A' ' 37' ' ' THR . 22.5 t0 -134.6 114.24 12.57 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.493 -0.754 . . . . 1.0 109.61 -179.783 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.424 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 5.8 p-10 -112.0 54.82 0.69 Allowed 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.503 -0.748 . . . . 1.0 109.156 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.443 HG23 ' OD1' ' A' ' 35' ' ' ASP . 39.3 p -104.01 -31.27 9.79 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.377 -0.827 . . . . 1.0 109.61 -179.724 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.41 ' HB ' HG21 ' A' ' 41' ' ' VAL . 34.9 t -114.88 151.76 16.58 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 O-C-N 121.406 -0.809 . . . . 1.0 109.478 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 21.7 mtm-85 -101.77 165.65 11.09 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 121.497 -0.752 . . . . 1.0 109.471 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.54 -33.79 2.52 Favored Glycine 0 CA--C 1.53 1.017 0 N-CA-C 109.457 -1.457 . . . . 1.0 109.457 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.41 HG21 ' HB ' ' A' ' 38' ' ' VAL . 28.5 m -88.13 169.99 12.52 Favored Pre-proline 0 CA--C 1.537 0.473 0 O-C-N 121.521 -0.988 . . . . 1.0 109.222 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -86.63 123.57 2.15 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 124.724 3.616 . . . . 1.0 110.04 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.424 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 23.9 m0 -75.3 -43.93 48.34 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.555 -0.716 . . . . 1.0 109.873 -179.515 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.6 t -88.8 109.11 19.91 Favored 'General case' 0 CA--C 1.535 0.365 0 O-C-N 121.328 -0.857 . . . . 1.0 109.915 -179.841 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.428 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 7.1 p90 -138.9 177.33 7.97 Favored 'General case' 0 CA--C 1.537 0.453 0 O-C-N 121.461 -0.775 . . . . 1.0 109.547 179.259 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.428 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 70.6 m-85 -78.78 169.32 21.22 Favored Pre-proline 0 CA--C 1.537 0.463 0 O-C-N 121.271 -0.893 . . . . 1.0 109.975 -179.568 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -92.34 167.69 2.86 Favored 'Trans proline' 0 C--N 1.352 0.711 0 C-N-CA 125.047 3.831 . . . . 1.0 110.582 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.512 HD22 HG21 ' A' ' 9' ' ' VAL . 23.1 m-20 -146.99 80.75 1.54 Allowed 'General case' 0 N--CA 1.463 0.222 0 O-C-N 121.466 -0.771 . . . . 1.0 109.273 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 17.8 p -75.09 121.37 21.94 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 121.377 -0.827 . . . . 1.0 109.683 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 58.7 mt -99.93 141.56 16.84 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 O-C-N 121.484 -0.76 . . . . 1.0 109.201 179.806 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -163.52 173.72 12.73 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.51 -0.744 . . . . 1.0 109.591 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.8 m -78.23 152.03 78.75 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.509 -0.744 . . . . 1.0 109.42 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -34.38 91.07 0.01 OUTLIER 'Trans proline' 0 N--CA 1.489 1.235 1 C-N-CA 125.568 4.179 . . . . 1.0 111.201 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -91.63 -159.34 0.08 OUTLIER 'Trans proline' 0 C--N 1.351 0.67 0 C-N-CA 125.038 3.825 . . . . 1.0 110.272 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -103.99 161.79 13.68 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.453 -0.78 . . . . 1.0 109.471 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -97.73 120.83 38.81 Favored 'General case' 0 CA--C 1.529 0.158 0 O-C-N 121.505 -0.747 . . . . 1.0 109.462 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -137.62 175.52 9.52 Favored 'General case' 0 N--CA 1.462 0.162 0 O-C-N 121.427 -0.795 . . . . 1.0 109.467 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.1 m -134.17 150.9 51.12 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.493 -0.754 . . . . 1.0 109.351 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -147.17 175.6 10.6 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.509 -0.744 . . . . 1.0 109.362 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 40.4 m-85 . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 117.997 -1.002 . . . . 1.0 109.467 179.996 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 . . . . . 0 CA--C 1.53 0.208 0 N-CA-C 109.358 -0.608 . . . . 1.0 109.358 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -144.33 175.76 9.86 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.484 -0.76 . . . . 1.0 109.448 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -102.23 119.38 38.71 Favored 'General case' 0 CA--C 1.53 0.205 0 O-C-N 121.503 -0.748 . . . . 1.0 109.536 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.7 p -143.37 -169.39 3.04 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.491 -0.756 . . . . 1.0 109.435 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -65.02 148.53 51.49 Favored 'General case' 0 CA--C 1.532 0.263 0 O-C-N 121.413 -0.804 . . . . 1.0 109.267 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.868 HG22 HG22 ' A' ' 8' ' ' THR . 0.9 OUTLIER -137.01 126.19 24.64 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.515 -0.74 . . . . 1.0 109.667 -179.809 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.5 m -117.18 46.18 1.74 Allowed 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.463 -0.773 . . . . 1.0 109.314 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.868 HG22 HG22 ' A' ' 6' ' ' THR . 4.9 t -131.01 106.89 8.7 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.517 -0.739 . . . . 1.0 109.369 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.639 HG12 ' H ' ' A' ' 10' ' ' ALA . 21.7 t -125.09 174.09 9.82 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 O-C-N 121.369 -0.832 . . . . 1.0 109.34 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.639 ' H ' HG12 ' A' ' 9' ' ' VAL . . . -74.92 140.33 74.0 Favored Pre-proline 0 CA--C 1.538 0.508 0 O-C-N 121.479 -0.763 . . . . 1.0 109.57 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_exo -34.81 -61.24 0.25 Allowed 'Trans proline' 0 N--CA 1.488 1.171 1 C-N-CA 125.484 4.122 . . . . 1.0 111.566 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -69.93 -29.95 67.22 Favored 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.476 -0.765 . . . . 1.0 110.107 -179.287 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.541 ' O ' HG11 ' A' ' 9' ' ' VAL . 13.1 mt-10 -85.29 36.62 0.64 Allowed 'General case' 0 N--CA 1.464 0.252 0 O-C-N 121.289 -0.882 . . . . 1.0 109.642 -179.736 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.403 HH12 ' HB3' ' A' ' 35' ' ' ASP . 50.4 mtt180 -108.1 142.94 37.54 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.508 -0.745 . . . . 1.0 109.435 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -102.35 115.02 29.71 Favored 'General case' 0 N--CA 1.463 0.195 0 O-C-N 121.547 -0.721 . . . . 1.0 109.399 179.813 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 48.9 t30 -61.06 118.7 7.1 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 121.391 -0.818 . . . . 1.0 109.784 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 t -94.51 -18.85 21.06 Favored 'General case' 0 CA--C 1.534 0.352 0 O-C-N 121.463 -0.773 . . . . 1.0 109.247 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.43 178.2 47.8 Favored Glycine 0 CA--C 1.53 0.976 0 N-CA-C 108.967 -1.653 . . . . 1.0 108.967 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.58 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.5 p90 -65.92 167.81 10.68 Favored Pre-proline 0 CA--C 1.539 0.542 0 O-C-N 121.369 -1.077 . . . . 1.0 108.799 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -82.12 -30.09 1.38 Allowed 'Trans proline' 0 N--CA 1.483 0.855 0 C-N-CA 124.38 3.387 . . . . 1.0 110.992 -178.71 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -56.62 -13.73 8.33 Favored Glycine 0 CA--C 1.536 1.358 0 N-CA-C 110.36 -1.096 . . . . 1.0 110.36 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.58 HG22 ' O ' ' A' ' 19' ' ' PHE . 20.4 m -60.7 173.54 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 O-C-N 121.239 -1.153 . . . . 1.0 109.768 179.849 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 73.6 p -131.84 155.7 81.06 Favored Pre-proline 0 CA--C 1.534 0.339 0 O-C-N 121.524 -0.735 . . . . 1.0 109.143 179.773 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -35.74 -33.82 0.12 Allowed 'Trans proline' 0 N--CA 1.49 1.267 1 C-N-CA 125.354 4.036 . . . . 1.0 111.233 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 39.7 m -75.68 -47.74 24.98 Favored 'General case' 0 CA--C 1.532 0.253 0 O-C-N 121.396 -0.815 . . . . 1.0 109.956 -179.622 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -65.3 -47.25 77.25 Favored 'General case' 0 CA--C 1.533 0.307 0 O-C-N 121.468 -0.77 . . . . 1.0 109.85 -179.689 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 11.2 t -62.48 -29.86 70.84 Favored 'General case' 0 N--CA 1.464 0.269 0 O-C-N 121.408 -0.808 . . . . 1.0 109.796 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -90.52 -9.79 45.95 Favored 'General case' 0 N--CA 1.465 0.281 0 O-C-N 121.464 -0.772 . . . . 1.0 110.098 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -93.03 -5.09 51.33 Favored 'General case' 0 CA--C 1.534 0.34 0 O-C-N 121.224 -0.923 . . . . 1.0 110.028 -179.762 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 51.9 mttp -109.52 -27.28 9.51 Favored 'General case' 0 N--CA 1.464 0.246 0 O-C-N 121.337 -0.852 . . . . 1.0 109.544 -179.794 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.08 22.66 5.83 Favored Glycine 0 CA--C 1.53 0.993 0 N-CA-C 109.568 -1.413 . . . . 1.0 109.568 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 22.8 m -112.74 137.21 51.38 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.469 -1.018 . . . . 1.0 108.564 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.6 m -72.85 133.87 44.62 Favored 'General case' 0 N--CA 1.463 0.222 0 O-C-N 121.316 -0.865 . . . . 1.0 109.735 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -101.68 139.63 37.07 Favored 'General case' 0 C--O 1.232 0.163 0 O-C-N 121.626 -0.671 . . . . 1.0 109.223 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.403 ' HB3' HH12 ' A' ' 14' ' ' ARG . 9.9 t0 -148.62 102.39 3.3 Favored 'General case' 0 N--CA 1.463 0.202 0 O-C-N 121.306 -0.871 . . . . 1.0 109.591 -179.785 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.435 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 7.0 p-10 -104.9 73.93 1.1 Allowed 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.525 -0.735 . . . . 1.0 109.294 179.83 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 30.6 p -118.66 -43.6 2.68 Favored 'General case' 0 CA--C 1.53 0.177 0 O-C-N 121.43 -0.794 . . . . 1.0 109.494 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 38.2 t -110.81 153.06 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 O-C-N 121.467 -0.771 . . . . 1.0 109.287 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 7.8 mtt-85 -101.11 172.51 6.97 Favored 'General case' 0 CA--C 1.532 0.271 0 O-C-N 121.545 -0.722 . . . . 1.0 109.337 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.72 -31.14 3.06 Favored Glycine 0 CA--C 1.529 0.917 0 N-CA-C 109.501 -1.44 . . . . 1.0 109.501 -179.884 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.404 ' HB ' ' CD ' ' A' ' 42' ' ' PRO . 29.6 m -99.83 170.55 6.61 Favored Pre-proline 0 CA--C 1.537 0.478 0 O-C-N 121.501 -1.0 . . . . 1.0 109.129 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' PRO . . . . . 0.404 ' CD ' ' HB ' ' A' ' 41' ' ' VAL . 11.2 Cg_endo -85.64 126.41 3.01 Favored 'Trans proline' 0 N--CA 1.479 0.654 0 C-N-CA 124.506 3.471 . . . . 1.0 110.036 179.745 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.435 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 10.0 m0 -77.64 -38.89 46.91 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.555 -0.715 . . . . 1.0 109.837 -179.356 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 28.1 t -89.44 103.84 16.45 Favored 'General case' 0 CA--C 1.534 0.357 0 O-C-N 121.385 -0.822 . . . . 1.0 109.566 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.406 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 5.1 p90 -132.87 177.42 7.66 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.259 -0.901 . . . . 1.0 109.881 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' TYR . . . . . 0.406 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 32.2 m-85 -74.1 169.81 17.44 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 121.61 -0.681 . . . . 1.0 109.684 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -93.35 173.16 1.85 Allowed 'Trans proline' 0 C--N 1.35 0.643 0 C-N-CA 125.217 3.944 . . . . 1.0 110.612 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -141.51 95.04 2.76 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.54 -0.725 . . . . 1.0 109.38 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 77.7 p -76.72 132.87 39.56 Favored 'General case' 0 CA--C 1.53 0.191 0 O-C-N 121.47 -0.769 . . . . 1.0 109.452 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 63.0 mt -128.26 142.29 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 O-C-N 121.361 -0.837 . . . . 1.0 109.323 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -162.12 -177.26 5.63 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.456 -0.777 . . . . 1.0 109.421 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 29.8 m -93.01 141.41 24.06 Favored Pre-proline 0 CA--C 1.537 0.46 0 O-C-N 121.522 -0.737 . . . . 1.0 109.302 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.451 ' N ' ' HD2' ' A' ' 54' ' ' PRO . 3.0 Cg_exo -39.13 -60.39 0.51 Allowed 'Trans proline' 0 N--CA 1.488 1.172 0 C-N-CA 124.96 3.773 . . . . 1.0 111.179 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.451 ' HD2' ' N ' ' A' ' 53' ' ' PRO . 16.0 Cg_exo -36.36 -69.77 0.07 OUTLIER 'Trans proline' 0 N--CA 1.49 1.294 0 C-N-CA 124.95 3.767 . . . . 1.0 111.215 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -73.46 167.16 21.86 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 121.473 -0.767 . . . . 1.0 109.494 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -140.81 135.92 31.92 Favored 'General case' 0 CA--C 1.53 0.176 0 O-C-N 121.495 -0.753 . . . . 1.0 109.404 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -102.72 132.47 48.84 Favored 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.527 -0.733 . . . . 1.0 109.467 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 13.8 p -92.16 156.69 17.16 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 121.45 -0.781 . . . . 1.0 109.444 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -130.6 136.06 48.5 Favored 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.518 -0.739 . . . . 1.0 109.491 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 44.1 t80 . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.976 -1.011 . . . . 1.0 109.443 -179.964 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.1 m . . . . . 0 CA--C 1.531 0.248 0 CA-C-O 121.139 0.495 . . . . 1.0 109.715 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 75.1 m -113.22 -14.19 12.89 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.498 -0.751 . . . . 1.0 109.594 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.548 HG23 ' O ' ' A' ' 8' ' ' THR . 2.8 t -71.19 96.44 1.38 Allowed 'General case' 0 CA--C 1.53 0.211 0 O-C-N 121.286 -0.884 . . . . 1.0 109.658 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.584 HG12 ' N ' ' A' ' 10' ' ' ALA . 39.4 t -119.35 168.98 11.01 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 O-C-N 121.465 -0.772 . . . . 1.0 109.074 179.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.891 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -65.21 121.27 73.53 Favored Pre-proline 0 CA--C 1.542 0.65 0 O-C-N 121.386 -0.821 . . . . 1.0 109.17 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.419 ' HD2' ' HA ' ' A' ' 10' ' ' ALA . 19.1 Cg_exo -36.95 -47.43 1.46 Allowed 'Trans proline' 0 N--CA 1.49 1.281 0 C-N-CA 124.917 3.745 . . . . 1.0 111.334 -179.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -75.88 -39.44 56.44 Favored 'General case' 0 N--CA 1.463 0.208 0 O-C-N 121.466 -0.771 . . . . 1.0 109.745 -179.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.891 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 28.0 mt-10 -84.33 38.38 0.67 Allowed 'General case' 0 N--CA 1.462 0.162 0 O-C-N 121.399 -0.813 . . . . 1.0 109.565 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 18.6 mtt180 -104.82 145.64 30.1 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.446 -0.784 . . . . 1.0 109.407 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 10.1 mp0 -94.69 120.6 35.17 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 121.542 -0.724 . . . . 1.0 109.36 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -63.63 120.34 11.59 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.457 -0.777 . . . . 1.0 109.817 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.42 ' HA ' ' CE2' ' A' ' 46' ' ' TYR . 44.3 t -94.65 -17.77 21.97 Favored 'General case' 0 CA--C 1.535 0.385 0 O-C-N 121.574 -0.704 . . . . 1.0 109.329 179.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 177.15 175.44 44.43 Favored Glycine 0 CA--C 1.529 0.939 0 N-CA-C 109.404 -1.479 . . . . 1.0 109.404 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.567 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.5 p90 -64.61 167.95 7.84 Favored Pre-proline 0 CA--C 1.538 0.512 0 O-C-N 121.383 -1.069 . . . . 1.0 109.063 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.33 -31.36 1.25 Allowed 'Trans proline' 0 N--CA 1.483 0.905 0 C-N-CA 124.341 3.361 . . . . 1.0 110.643 -178.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.75 -7.91 6.95 Favored Glycine 0 CA--C 1.537 1.438 0 N-CA-C 110.294 -1.122 . . . . 1.0 110.294 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.567 HG22 ' O ' ' A' ' 19' ' ' PHE . 17.4 m -60.17 -178.97 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 O-C-N 121.208 -1.172 . . . . 1.0 109.742 179.762 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.433 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 12.0 p -138.5 155.08 73.88 Favored Pre-proline 0 CA--C 1.536 0.43 0 O-C-N 121.513 -0.742 . . . . 1.0 109.276 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -36.05 -36.45 0.2 Allowed 'Trans proline' 0 N--CA 1.488 1.187 1 C-N-CA 125.368 4.045 . . . . 1.0 111.316 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 42.1 t -73.99 -46.07 46.1 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.405 -0.809 . . . . 1.0 109.874 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLN . . . . . 0.433 ' HB2' ' H ' ' A' ' 23' ' ' THR . 38.0 mt-30 -60.57 -48.63 80.91 Favored 'General case' 0 N--CA 1.464 0.258 0 O-C-N 121.468 -0.77 . . . . 1.0 109.988 -179.808 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.7 t -65.11 -27.73 68.95 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.409 -0.807 . . . . 1.0 109.497 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.34 -5.26 58.42 Favored 'General case' 0 CA--C 1.535 0.38 0 O-C-N 121.547 -0.721 . . . . 1.0 109.846 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.0 t-20 -70.83 -49.45 46.17 Favored 'General case' 0 N--CA 1.463 0.181 0 O-C-N 121.408 -0.808 . . . . 1.0 109.363 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.441 ' HG2' ' H ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -83.64 -44.7 14.27 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.534 -0.729 . . . . 1.0 109.432 179.889 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.441 ' H ' ' HG2' ' A' ' 30' ' ' LYS . . . 125.65 32.45 0.76 Allowed Glycine 0 CA--C 1.531 1.075 0 N-CA-C 109.958 -1.257 . . . . 1.0 109.958 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.5 m -92.26 144.7 25.13 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.43 -1.041 . . . . 1.0 109.301 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.402 ' O ' ' CD1' ' A' ' 45' ' ' PHE . 60.0 m -66.51 115.4 6.35 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.462 -0.774 . . . . 1.0 109.516 -179.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -94.6 132.01 39.76 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.38 -0.825 . . . . 1.0 109.33 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -144.2 111.12 5.74 Favored 'General case' 0 CA--C 1.53 0.19 0 O-C-N 121.425 -0.797 . . . . 1.0 109.481 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.434 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.0 p-10 -115.34 70.42 0.74 Allowed 'General case' 0 CA--C 1.534 0.334 0 O-C-N 121.509 -0.745 . . . . 1.0 109.414 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 43.9 p -114.45 -39.35 3.84 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.429 -0.794 . . . . 1.0 109.471 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.577 HG12 ' N ' ' A' ' 39' ' ' ARG . 39.9 t -111.95 167.93 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 O-C-N 121.519 -0.738 . . . . 1.0 109.401 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.577 ' N ' HG12 ' A' ' 38' ' ' VAL . 4.9 ttm180 -113.31 175.99 5.22 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.432 -0.793 . . . . 1.0 109.432 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.51 -37.33 2.25 Favored Glycine 0 CA--C 1.53 0.996 0 N-CA-C 109.41 -1.476 . . . . 1.0 109.41 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 28.9 m -94.66 170.39 8.16 Favored Pre-proline 0 CA--C 1.536 0.431 0 O-C-N 121.571 -0.958 . . . . 1.0 109.174 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_endo -85.68 139.31 6.57 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 124.628 3.552 . . . . 1.0 109.937 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.434 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 11.2 m0 -89.22 -41.05 12.44 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 121.502 -0.749 . . . . 1.0 110.028 -179.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 18.5 t -89.31 107.43 19.06 Favored 'General case' 0 N--CA 1.465 0.309 0 O-C-N 121.426 -0.797 . . . . 1.0 109.719 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.417 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 9.5 p90 -135.05 173.81 11.31 Favored 'General case' 0 CA--C 1.537 0.479 0 O-C-N 121.346 -0.846 . . . . 1.0 109.633 179.59 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.42 ' CE2' ' HA ' ' A' ' 17' ' ' CYS . 90.8 m-85 -82.11 167.38 31.04 Favored Pre-proline 0 CA--C 1.536 0.419 0 O-C-N 121.493 -0.755 . . . . 1.0 109.716 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -89.65 161.52 5.26 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 124.998 3.799 . . . . 1.0 110.424 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 . . . . . 0 CA--C 1.531 0.216 0 O-C-N 121.549 -0.719 . . . . 1.0 109.388 179.949 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.569 HG22 HG22 ' A' ' 8' ' ' THR . 0.8 OUTLIER . . . . . 0 CA--C 1.53 0.181 0 N-CA-C 109.383 -0.599 . . . . 1.0 109.383 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.411 ' HB3' ' CZ ' ' A' ' 45' ' ' PHE . 62.8 m -125.91 31.49 5.46 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.488 -0.758 . . . . 1.0 109.022 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.569 HG22 HG22 ' A' ' 6' ' ' THR . 5.1 t -96.08 118.9 33.58 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.657 -0.652 . . . . 1.0 109.556 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.435 HG11 ' O ' ' A' ' 13' ' ' GLU . 34.2 t -149.92 156.21 7.24 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.206 0 O-C-N 121.495 -0.753 . . . . 1.0 109.236 179.828 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -74.07 136.72 76.04 Favored Pre-proline 0 CA--C 1.54 0.59 0 O-C-N 121.482 -0.761 . . . . 1.0 109.308 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -35.05 -41.05 0.28 Allowed 'Trans proline' 0 N--CA 1.488 1.171 1 C-N-CA 125.361 4.041 . . . . 1.0 111.305 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.7 mtt180 -80.95 -44.61 17.95 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.543 -0.723 . . . . 1.0 109.759 -179.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.435 ' O ' HG11 ' A' ' 9' ' ' VAL . 19.9 mt-10 -74.56 10.46 1.34 Allowed 'General case' 0 CA--C 1.533 0.326 0 O-C-N 121.417 -0.802 . . . . 1.0 109.975 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 24.2 mtt180 -81.25 124.37 29.26 Favored 'General case' 0 CA--C 1.529 0.164 0 O-C-N 121.34 -0.85 . . . . 1.0 109.361 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 25.5 mm100 -92.56 126.76 37.79 Favored 'General case' 0 N--CA 1.463 0.197 0 O-C-N 121.463 -0.773 . . . . 1.0 109.025 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.2 t-20 -72.23 116.68 12.95 Favored 'General case' 0 CA--C 1.532 0.286 0 O-C-N 121.604 -0.685 . . . . 1.0 109.942 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -83.55 -6.97 59.6 Favored 'General case' 0 CA--C 1.537 0.447 0 O-C-N 121.53 -0.731 . . . . 1.0 109.208 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.84 170.0 37.42 Favored Glycine 0 CA--C 1.532 1.097 0 N-CA-C 108.353 -1.899 . . . . 1.0 108.353 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.442 ' O ' HG22 ' A' ' 22' ' ' VAL . 7.5 p90 -62.52 168.33 4.35 Favored Pre-proline 0 CA--C 1.54 0.56 0 O-C-N 121.208 -1.172 . . . . 1.0 109.043 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -81.36 -30.25 1.61 Allowed 'Trans proline' 0 N--CA 1.481 0.785 0 C-N-CA 124.304 3.336 . . . . 1.0 110.677 -178.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.23 -6.82 8.12 Favored Glycine 0 CA--C 1.536 1.374 0 N-CA-C 110.052 -1.219 . . . . 1.0 110.052 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.442 HG22 ' O ' ' A' ' 19' ' ' PHE . 29.2 m -60.25 -176.31 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 O-C-N 121.157 -1.202 . . . . 1.0 109.816 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.419 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 10.6 p -137.38 155.95 75.36 Favored Pre-proline 0 CA--C 1.535 0.368 0 O-C-N 121.51 -0.744 . . . . 1.0 109.13 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_exo -37.47 -42.24 1.08 Allowed 'Trans proline' 0 N--CA 1.488 1.176 0 C-N-CA 125.188 3.926 . . . . 1.0 111.001 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 80.3 p -69.45 -42.76 74.51 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.524 -0.735 . . . . 1.0 110.118 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLN . . . . . 0.419 ' HB2' ' H ' ' A' ' 23' ' ' THR . 13.9 mm100 -65.61 -53.92 34.91 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.401 -0.812 . . . . 1.0 109.909 -179.562 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 18.9 t -62.04 -19.71 63.17 Favored 'General case' 0 CA--C 1.534 0.357 0 O-C-N 121.409 -0.807 . . . . 1.0 109.934 -179.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -100.54 -3.56 30.41 Favored 'General case' 0 CA--C 1.535 0.378 0 O-C-N 121.356 -0.84 . . . . 1.0 110.154 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -73.78 -44.07 57.09 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.395 -0.815 . . . . 1.0 109.855 -179.476 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.9 tttm -86.26 -41.39 14.64 Favored 'General case' 0 N--CA 1.462 0.154 0 O-C-N 121.43 -0.794 . . . . 1.0 109.662 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 127.27 19.71 1.88 Allowed Glycine 0 CA--C 1.53 1.031 0 N-CA-C 109.473 -1.451 . . . . 1.0 109.473 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 60.8 m -77.39 140.42 39.91 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.43 -1.041 . . . . 1.0 109.028 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 84.5 m -66.87 123.09 19.2 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.414 -0.803 . . . . 1.0 109.647 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -96.51 147.78 23.49 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.439 -0.788 . . . . 1.0 109.162 179.653 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -161.72 135.12 6.38 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.384 -0.822 . . . . 1.0 109.486 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -133.17 38.24 3.34 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.515 -0.741 . . . . 1.0 109.471 179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 59.9 p -72.05 -58.7 3.22 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.48 -0.763 . . . . 1.0 109.541 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.0 t -110.07 138.12 39.26 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 O-C-N 121.429 -0.794 . . . . 1.0 109.408 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -83.62 178.03 8.15 Favored 'General case' 0 CA--C 1.53 0.19 0 O-C-N 121.496 -0.752 . . . . 1.0 109.247 179.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.56 -45.73 3.15 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 109.339 -1.504 . . . . 1.0 109.339 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.414 HG22 ' H ' ' A' ' 41' ' ' VAL . 26.7 m -84.43 157.33 61.84 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.647 -0.914 . . . . 1.0 109.325 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -59.63 129.24 30.06 Favored 'Trans proline' 0 N--CA 1.488 1.164 0 C-N-CA 124.164 3.243 . . . . 1.0 110.308 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . . . . . . . . . 40.4 m0 -87.27 -45.87 10.22 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.521 -0.737 . . . . 1.0 109.173 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 27.4 t -89.92 110.42 21.37 Favored 'General case' 0 CA--C 1.534 0.338 0 O-C-N 121.493 -0.755 . . . . 1.0 108.978 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.433 ' CD1' ' N ' ' A' ' 45' ' ' PHE . 5.2 p90 -134.1 175.87 9.09 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 121.302 -0.874 . . . . 1.0 110.257 -179.371 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.41 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 21.5 m-85 -82.18 171.33 12.18 Favored Pre-proline 0 CA--C 1.537 0.47 0 O-C-N 121.523 -0.735 . . . . 1.0 109.522 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -90.84 -166.39 0.19 Allowed 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 124.939 3.759 . . . . 1.0 110.102 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.4 m120 . . . . . 0 N--CA 1.463 0.192 0 O-C-N 121.478 -0.763 . . . . 1.0 109.509 179.943 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.7 m . . . . . 0 CA--C 1.532 0.263 0 N-CA-C 109.763 -0.458 . . . . 1.0 109.763 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 90.5 m -89.62 -15.82 31.91 Favored 'General case' 0 CA--C 1.533 0.326 0 O-C-N 121.311 -0.868 . . . . 1.0 109.493 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.56 HG23 ' O ' ' A' ' 8' ' ' THR . 4.8 t -71.31 112.45 7.45 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.429 -0.795 . . . . 1.0 109.907 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.552 HG12 ' N ' ' A' ' 10' ' ' ALA . 42.0 t -127.87 167.33 23.08 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.264 0 N-CA-C 108.84 -0.8 . . . . 1.0 108.84 179.626 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.758 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -71.67 125.41 91.7 Favored Pre-proline 0 CA--C 1.542 0.644 0 O-C-N 121.36 -0.838 . . . . 1.0 109.118 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.425 ' HB3' HG11 ' A' ' 41' ' ' VAL . 18.7 Cg_exo -36.84 -50.36 1.43 Allowed 'Trans proline' 0 N--CA 1.489 1.263 0 C-N-CA 124.899 3.732 . . . . 1.0 111.209 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.401 ' H ' ' HG2' ' A' ' 12' ' ' ARG . 18.7 ptt180 -73.8 -38.86 64.48 Favored 'General case' 0 N--CA 1.463 0.195 0 O-C-N 121.487 -0.758 . . . . 1.0 109.763 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.758 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 20.3 mt-10 -92.29 43.03 1.12 Allowed 'General case' 0 CA--C 1.532 0.253 0 O-C-N 121.405 -0.81 . . . . 1.0 109.574 -179.689 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 15.0 mtt180 -105.71 131.98 52.4 Favored 'General case' 0 CA--C 1.531 0.235 0 O-C-N 121.405 -0.81 . . . . 1.0 109.437 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -79.57 107.64 12.5 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 108.557 -0.905 . . . . 1.0 108.557 179.456 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 29.5 t30 -61.98 108.54 1.06 Allowed 'General case' 0 N--CA 1.464 0.245 0 O-C-N 121.557 -0.714 . . . . 1.0 110.085 -179.336 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.461 ' H ' ' HA ' ' A' ' 45' ' ' PHE . 49.5 t -76.78 -21.75 54.71 Favored 'General case' 0 CA--C 1.533 0.318 0 O-C-N 121.5 -0.75 . . . . 1.0 109.229 179.426 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -175.46 179.56 46.6 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 109.145 -1.582 . . . . 1.0 109.145 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.528 ' CD2' HG13 ' A' ' 22' ' ' VAL . 8.9 p90 -64.81 167.49 9.13 Favored Pre-proline 0 CA--C 1.538 0.489 0 O-C-N 121.398 -1.06 . . . . 1.0 109.0 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -81.19 -30.93 1.42 Allowed 'Trans proline' 0 N--CA 1.482 0.806 0 C-N-CA 124.351 3.367 . . . . 1.0 110.715 -178.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.84 -8.41 7.89 Favored Glycine 0 CA--C 1.537 1.457 0 N-CA-C 110.305 -1.118 . . . . 1.0 110.305 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.528 HG13 ' CD2' ' A' ' 19' ' ' PHE . 25.7 m -60.62 -171.21 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 O-C-N 121.194 -1.18 . . . . 1.0 109.864 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.51 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 19.9 p -150.09 157.27 37.64 Favored Pre-proline 0 CA--C 1.534 0.361 0 N-CA-C 109.18 -0.674 . . . . 1.0 109.18 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_exo -34.91 -36.37 0.12 Allowed 'Trans proline' 0 N--CA 1.488 1.193 1 C-N-CA 125.599 4.199 . . . . 1.0 111.383 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.4 t -76.41 -47.21 23.93 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.434 -0.791 . . . . 1.0 109.865 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLN . . . . . 0.51 ' HB2' ' H ' ' A' ' 23' ' ' THR . 2.2 mm100 -60.93 -44.05 97.76 Favored 'General case' 0 N--CA 1.465 0.293 0 O-C-N 121.433 -0.792 . . . . 1.0 109.925 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 7.5 t -64.72 -33.4 75.87 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.443 -0.786 . . . . 1.0 109.346 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.48 -5.55 59.28 Favored 'General case' 0 CA--C 1.534 0.358 0 O-C-N 121.556 -0.715 . . . . 1.0 109.935 179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 12.2 t-20 -64.84 -32.6 74.37 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.32 -0.862 . . . . 1.0 109.618 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.3 mtmm -105.79 -39.52 6.02 Favored 'General case' 0 C--N 1.332 -0.183 0 O-C-N 121.456 -0.777 . . . . 1.0 109.403 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 125.6 27.55 1.16 Allowed Glycine 0 CA--C 1.53 1.012 0 N-CA-C 109.862 -1.295 . . . . 1.0 109.862 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.8 m -91.09 147.69 22.89 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.326 -1.103 . . . . 1.0 109.16 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.455 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 57.4 m -70.33 139.6 52.06 Favored 'General case' 0 CA--C 1.532 0.266 0 O-C-N 121.371 -0.831 . . . . 1.0 109.333 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -119.21 119.7 34.87 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.463 -0.773 . . . . 1.0 109.332 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -132.67 120.1 21.29 Favored 'General case' 0 CA--C 1.529 0.167 0 O-C-N 121.533 -0.729 . . . . 1.0 109.667 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.419 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.0 p-10 -116.32 77.27 1.08 Allowed 'General case' 0 N--CA 1.463 0.197 0 O-C-N 121.442 -0.786 . . . . 1.0 109.233 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 82.2 p -114.54 -38.37 4.05 Favored 'General case' 0 CA--C 1.53 0.183 0 O-C-N 121.446 -0.784 . . . . 1.0 109.543 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 38.3 t -117.36 148.51 20.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.205 0 O-C-N 121.442 -0.786 . . . . 1.0 109.411 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 22.5 mtp180 -94.65 -179.08 4.76 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.5 -0.75 . . . . 1.0 109.5 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.07 6.71 13.89 Favored Glycine 0 CA--C 1.532 1.149 0 N-CA-C 109.992 -1.243 . . . . 1.0 109.992 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.425 HG11 ' HB3' ' A' ' 11' ' ' PRO . 30.0 m -130.59 169.35 13.81 Favored Pre-proline 0 CA--C 1.536 0.415 0 O-C-N 121.359 -1.083 . . . . 1.0 109.203 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -87.74 130.03 2.63 Favored 'Trans proline' 0 N--CA 1.48 0.708 0 C-N-CA 124.693 3.595 . . . . 1.0 110.117 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.419 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.3 m0 -91.95 -47.83 7.09 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.505 -0.747 . . . . 1.0 109.733 -179.567 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 18.6 t -78.07 107.81 10.9 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 121.527 -0.733 . . . . 1.0 109.646 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.461 ' HA ' ' H ' ' A' ' 17' ' ' CYS . 3.3 p90 -139.42 -175.93 4.36 Favored 'General case' 0 N--CA 1.465 0.314 0 O-C-N 121.515 -0.74 . . . . 1.0 109.393 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -91.57 163.85 26.68 Favored Pre-proline 0 CA--C 1.537 0.477 0 O-C-N 121.411 -0.806 . . . . 1.0 110.029 -179.404 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -90.18 172.84 3.5 Favored 'Trans proline' 0 C--N 1.352 0.744 0 C-N-CA 124.97 3.78 . . . . 1.0 110.718 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 . . . . . 0 CA--C 1.531 0.217 0 O-C-N 121.433 -0.792 . . . . 1.0 109.412 179.944 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.4 m . . . . . 0 CA--C 1.53 0.176 0 CA-C-O 121.153 0.501 . . . . 1.0 110.161 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 96.2 m -108.54 -18.14 13.8 Favored 'General case' 0 CA--C 1.536 0.408 0 O-C-N 121.503 -0.748 . . . . 1.0 109.184 179.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.596 HG23 ' O ' ' A' ' 8' ' ' THR . 5.2 t -70.15 108.35 4.09 Favored 'General case' 0 CA--C 1.533 0.297 0 O-C-N 121.106 -0.996 . . . . 1.0 109.329 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.733 HG21 HD22 ' A' ' 48' ' ' ASN . 26.7 t -132.99 173.46 14.8 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.248 0 O-C-N 121.334 -0.854 . . . . 1.0 109.323 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.632 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -69.14 122.81 86.62 Favored Pre-proline 0 CA--C 1.539 0.542 0 O-C-N 121.461 -0.774 . . . . 1.0 109.235 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.559 ' HB3' HG11 ' A' ' 41' ' ' VAL . 18.3 Cg_exo -37.62 -33.92 0.24 Allowed 'Trans proline' 0 N--CA 1.488 1.198 0 C-N-CA 124.774 3.65 . . . . 1.0 111.229 -179.799 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 15.2 ptt180 -78.55 -46.88 18.42 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.469 -0.769 . . . . 1.0 109.766 -179.703 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 21.0 mm-40 -82.73 40.97 0.7 Allowed 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.405 -0.809 . . . . 1.0 109.434 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 54.0 mtt180 -104.1 142.95 33.57 Favored 'General case' 0 C--N 1.331 -0.214 0 O-C-N 121.526 -0.734 . . . . 1.0 109.569 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 mm-40 -92.59 111.33 22.88 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.426 -0.796 . . . . 1.0 109.195 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -60.33 110.34 1.22 Allowed 'General case' 0 CA--C 1.533 0.303 0 O-C-N 121.362 -0.836 . . . . 1.0 110.121 -179.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.4 t -86.65 -16.4 36.74 Favored 'General case' 0 CA--C 1.533 0.323 0 O-C-N 121.485 -0.76 . . . . 1.0 109.442 179.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.64 179.28 44.19 Favored Glycine 0 CA--C 1.531 1.075 0 N-CA-C 109.506 -1.438 . . . . 1.0 109.506 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.592 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.6 p90 -65.13 168.0 8.56 Favored Pre-proline 0 CA--C 1.538 0.492 0 O-C-N 121.468 -1.019 . . . . 1.0 109.018 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.43 -30.98 1.32 Allowed 'Trans proline' 0 N--CA 1.484 0.918 0 C-N-CA 124.4 3.4 . . . . 1.0 110.671 -178.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.42 -10.28 7.51 Favored Glycine 0 CA--C 1.537 1.41 0 N-CA-C 110.356 -1.098 . . . . 1.0 110.356 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.592 HG22 ' O ' ' A' ' 19' ' ' PHE . 18.0 m -60.74 169.71 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 O-C-N 121.205 -1.174 . . . . 1.0 109.611 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 29.2 p -128.35 155.45 78.45 Favored Pre-proline 0 CA--C 1.535 0.387 0 O-C-N 121.517 -0.739 . . . . 1.0 109.38 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_exo -36.33 -37.35 0.26 Allowed 'Trans proline' 0 N--CA 1.489 1.237 1 C-N-CA 125.341 4.027 . . . . 1.0 111.186 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 4.5 m -69.91 -47.38 62.69 Favored 'General case' 0 N--CA 1.463 0.206 0 O-C-N 121.351 -0.843 . . . . 1.0 109.79 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 7.5 mm100 -61.49 -49.88 75.0 Favored 'General case' 0 CA--C 1.533 0.302 0 O-C-N 121.41 -0.806 . . . . 1.0 109.842 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.8 t -64.97 -27.49 68.87 Favored 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.431 -0.793 . . . . 1.0 109.439 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.29 -8.91 57.38 Favored 'General case' 0 CA--C 1.534 0.344 0 O-C-N 121.5 -0.75 . . . . 1.0 109.821 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -91.38 -28.0 17.98 Favored 'General case' 0 CA--C 1.529 0.14 0 O-C-N 121.37 -0.831 . . . . 1.0 109.405 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -89.65 -29.15 19.0 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.471 -0.768 . . . . 1.0 109.441 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.04 45.64 2.02 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 109.771 -1.332 . . . . 1.0 109.771 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 2.0 m -121.42 142.95 49.52 Favored 'General case' 0 N--CA 1.465 0.29 0 O-C-N 121.496 -1.002 . . . . 1.0 109.303 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 46.8 m -63.32 113.66 3.35 Favored 'General case' 0 N--CA 1.466 0.332 0 O-C-N 121.4 -0.812 . . . . 1.0 109.39 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 48.7 t80 -90.36 137.19 32.55 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.43 -0.794 . . . . 1.0 109.126 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -151.02 106.86 3.41 Favored 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.47 -0.769 . . . . 1.0 109.676 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.435 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 2.1 p30 -107.09 48.55 0.83 Allowed 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.491 -0.756 . . . . 1.0 109.245 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 16.8 p -81.34 -52.28 7.46 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.519 -0.738 . . . . 1.0 109.361 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.8 t -114.14 145.39 20.03 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 O-C-N 121.589 -0.694 . . . . 1.0 109.383 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -88.35 179.66 6.29 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.539 -0.726 . . . . 1.0 109.449 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.45 -49.91 4.12 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 109.278 -1.529 . . . . 1.0 109.278 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.559 HG11 ' HB3' ' A' ' 11' ' ' PRO . 27.6 m -79.79 171.16 13.15 Favored Pre-proline 0 CA--C 1.538 0.502 0 O-C-N 121.588 -0.948 . . . . 1.0 109.041 179.632 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . 0.409 ' CD ' ' HB ' ' A' ' 41' ' ' VAL . 11.2 Cg_endo -84.17 127.41 3.99 Favored 'Trans proline' 0 N--CA 1.48 0.724 0 C-N-CA 124.383 3.389 . . . . 1.0 110.003 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.435 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 11.0 m0 -82.83 -39.85 21.12 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.594 -0.691 . . . . 1.0 110.104 -179.129 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.5 t -89.46 108.38 19.61 Favored 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.325 -0.859 . . . . 1.0 109.597 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.426 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 15.0 p90 -135.92 175.9 9.17 Favored 'General case' 0 CA--C 1.538 0.496 0 O-C-N 121.438 -0.789 . . . . 1.0 109.58 179.647 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.426 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 37.5 m-85 -84.61 166.99 29.45 Favored Pre-proline 0 CA--C 1.536 0.422 0 O-C-N 121.274 -0.891 . . . . 1.0 110.061 -179.539 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -88.92 159.7 6.01 Favored 'Trans proline' 0 C--N 1.353 0.779 0 C-N-CA 124.868 3.712 . . . . 1.0 110.538 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.733 HD22 HG21 ' A' ' 9' ' ' VAL . 59.7 m-80 . . . . . 0 CA--C 1.531 0.242 0 O-C-N 121.525 -0.734 . . . . 1.0 109.406 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.774 HG22 HG22 ' A' ' 8' ' ' THR . 1.5 m . . . . . 0 CA--C 1.531 0.219 0 CA-C-O 121.184 0.516 . . . . 1.0 110.016 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 98.6 m -104.02 45.33 0.97 Allowed 'General case' 0 CA--C 1.534 0.358 0 O-C-N 121.429 -0.794 . . . . 1.0 108.934 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.774 HG22 HG22 ' A' ' 6' ' ' THR . 5.8 t -110.83 108.98 18.99 Favored 'General case' 0 CA--C 1.532 0.262 0 O-C-N 121.19 -0.944 . . . . 1.0 109.877 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.46 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.5 t -135.39 160.9 40.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 O-C-N 121.441 -0.787 . . . . 1.0 109.114 179.802 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.46 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -79.55 115.59 54.54 Favored Pre-proline 0 CA--C 1.541 0.606 0 O-C-N 121.434 -0.791 . . . . 1.0 109.382 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -38.23 -28.79 0.13 Allowed 'Trans proline' 0 N--CA 1.49 1.277 0 C-N-CA 124.664 3.576 . . . . 1.0 111.108 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 -66.94 -64.92 0.75 Allowed 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.489 -0.757 . . . . 1.0 109.691 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -90.56 44.4 1.2 Allowed 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.499 -0.751 . . . . 1.0 109.542 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 21.7 mtt180 -86.11 143.16 28.19 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.476 -0.765 . . . . 1.0 109.516 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -92.87 108.1 19.73 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 109.021 -0.733 . . . . 1.0 109.021 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -62.49 122.59 16.15 Favored 'General case' 0 CA--C 1.532 0.278 0 O-C-N 121.517 -0.739 . . . . 1.0 109.984 -179.709 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 t -88.94 -13.33 39.25 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 109.06 -0.718 . . . . 1.0 109.06 179.434 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 177.28 177.54 46.25 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 108.645 -1.782 . . . . 1.0 108.645 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.6 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.2 p90 -64.35 167.62 8.08 Favored Pre-proline 0 CA--C 1.54 0.585 0 O-C-N 121.24 -1.153 . . . . 1.0 109.064 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -81.22 -30.38 1.62 Allowed 'Trans proline' 0 N--CA 1.483 0.858 0 C-N-CA 124.347 3.365 . . . . 1.0 110.84 -178.684 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.92 -10.16 8.28 Favored Glycine 0 CA--C 1.537 1.423 0 N-CA-C 110.192 -1.163 . . . . 1.0 110.192 179.528 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.6 HG22 ' O ' ' A' ' 19' ' ' PHE . 23.6 m -62.01 169.14 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 O-C-N 121.257 -1.143 . . . . 1.0 109.727 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 71.8 p -127.41 157.52 72.52 Favored Pre-proline 0 CA--C 1.534 0.361 0 N-CA-C 108.702 -0.851 . . . . 1.0 108.702 179.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -34.88 -36.12 0.12 Allowed 'Trans proline' 0 N--CA 1.489 1.255 1 C-N-CA 125.364 4.043 . . . . 1.0 111.315 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.7 p -72.83 -48.37 38.3 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.469 -0.769 . . . . 1.0 109.931 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 53.1 mt-30 -65.17 -44.01 89.89 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.542 -0.724 . . . . 1.0 110.07 -179.634 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 9.1 t -61.3 -31.85 71.7 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 121.303 -0.873 . . . . 1.0 109.855 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.19 -1.5 48.17 Favored 'General case' 0 CA--C 1.535 0.373 0 O-C-N 121.433 -0.792 . . . . 1.0 110.137 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -69.95 -28.49 65.61 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 121.349 -0.845 . . . . 1.0 110.255 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.29 -36.9 5.68 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 121.249 -0.907 . . . . 1.0 109.857 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 126.76 55.71 0.14 Allowed Glycine 0 CA--C 1.531 1.057 0 N-CA-C 109.959 -1.256 . . . . 1.0 109.959 179.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 36.9 m -120.98 137.3 54.7 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.398 -1.06 . . . . 1.0 108.725 179.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 53.0 m -69.42 122.75 19.58 Favored 'General case' 0 N--CA 1.466 0.374 0 O-C-N 121.326 -0.859 . . . . 1.0 109.418 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 34.9 t80 -93.48 140.1 29.97 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.493 -0.754 . . . . 1.0 109.002 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -152.76 112.4 3.91 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.379 -0.825 . . . . 1.0 109.737 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.44 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 11.5 p30 -113.76 76.12 0.96 Allowed 'General case' 0 N--CA 1.464 0.253 0 O-C-N 121.474 -0.766 . . . . 1.0 109.446 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.8 p -115.39 -29.95 6.39 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.507 -0.746 . . . . 1.0 109.635 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.4 t -124.44 154.43 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 O-C-N 121.503 -0.748 . . . . 1.0 109.501 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 41.8 mtm-85 -99.29 178.95 4.74 Favored 'General case' 0 CA--C 1.53 0.184 0 O-C-N 121.532 -0.73 . . . . 1.0 109.357 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 62.14 11.21 31.41 Favored Glycine 0 CA--C 1.533 1.206 0 N-CA-C 109.919 -1.272 . . . . 1.0 109.919 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.9 m -134.64 169.27 14.3 Favored Pre-proline 0 CA--C 1.535 0.404 0 O-C-N 121.357 -1.084 . . . . 1.0 109.182 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -87.64 122.44 1.69 Allowed 'Trans proline' 0 C--N 1.351 0.692 0 C-N-CA 124.825 3.683 . . . . 1.0 110.213 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.44 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.7 m0 -82.71 -32.68 27.89 Favored 'General case' 0 N--CA 1.463 0.216 0 O-C-N 121.478 -0.764 . . . . 1.0 109.44 -179.618 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 11.0 t -89.36 107.97 19.37 Favored 'General case' 0 CA--C 1.535 0.372 0 O-C-N 121.532 -0.73 . . . . 1.0 109.207 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.413 ' CD1' ' N ' ' A' ' 45' ' ' PHE . 4.7 p90 -137.4 -179.32 5.66 Favored 'General case' 0 CA--C 1.539 0.524 0 O-C-N 121.263 -0.898 . . . . 1.0 110.33 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.409 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 10.5 m-85 -84.41 169.32 17.11 Favored Pre-proline 0 CA--C 1.539 0.524 0 O-C-N 121.519 -0.738 . . . . 1.0 110.097 -179.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_endo -90.89 170.23 3.46 Favored 'Trans proline' 0 C--N 1.353 0.767 0 C-N-CA 125.204 3.936 . . . . 1.0 110.888 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.6 m120 . . . . . 0 CA--C 1.531 0.249 0 N-CA-C 108.445 -0.946 . . . . 1.0 108.445 179.224 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.688 HG22 HG22 ' A' ' 8' ' ' THR . 1.2 m . . . . . 0 CA--C 1.53 0.185 0 CA-C-O 121.283 0.563 . . . . 1.0 109.485 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.434 ' O ' ' CE2' ' A' ' 45' ' ' PHE . 11.2 m -111.05 -24.57 10.26 Favored 'General case' 0 C--N 1.332 -0.16 0 O-C-N 121.544 -0.723 . . . . 1.0 109.449 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.688 HG22 HG22 ' A' ' 6' ' ' THR . 3.9 t -68.9 146.31 52.92 Favored 'General case' 0 N--CA 1.464 0.24 0 O-C-N 121.475 -0.766 . . . . 1.0 110.739 -178.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.738 HG12 ' H ' ' A' ' 10' ' ' ALA . 25.2 t -140.32 178.9 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 108.308 -0.997 . . . . 1.0 108.308 179.616 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.738 ' H ' HG12 ' A' ' 9' ' ' VAL . . . -61.95 110.54 3.32 Favored Pre-proline 0 CA--C 1.541 0.603 0 O-C-N 121.216 -0.927 . . . . 1.0 109.717 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -39.75 -31.32 0.43 Allowed 'Trans proline' 0 N--CA 1.489 1.222 0 C-N-CA 124.607 3.538 . . . . 1.0 111.194 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 8.7 mtt-85 -84.19 -39.61 19.16 Favored 'General case' 0 N--CA 1.464 0.273 0 O-C-N 121.39 -0.819 . . . . 1.0 109.979 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -103.58 50.82 0.8 Allowed 'General case' 0 CA--C 1.532 0.282 0 O-C-N 121.385 -0.822 . . . . 1.0 109.348 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 50.0 mtt180 -91.35 136.39 33.14 Favored 'General case' 0 N--CA 1.464 0.239 0 O-C-N 121.457 -0.777 . . . . 1.0 109.726 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -79.92 104.21 10.34 Favored 'General case' 0 CA--C 1.53 0.182 0 O-C-N 121.586 -0.696 . . . . 1.0 109.249 179.724 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 11.5 t-20 -62.84 116.5 5.31 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.48 -0.763 . . . . 1.0 109.899 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.0 t -92.55 -9.97 39.29 Favored 'General case' 0 CA--C 1.536 0.422 0 O-C-N 121.555 -0.716 . . . . 1.0 109.521 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.91 173.57 33.69 Favored Glycine 0 CA--C 1.529 0.957 0 N-CA-C 109.206 -1.557 . . . . 1.0 109.206 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.557 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.9 p90 -65.51 167.74 9.99 Favored Pre-proline 0 CA--C 1.539 0.544 0 O-C-N 121.43 -1.041 . . . . 1.0 108.971 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.67 -30.37 1.45 Allowed 'Trans proline' 0 N--CA 1.484 0.922 0 C-N-CA 124.305 3.337 . . . . 1.0 110.832 -178.774 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.29 -10.71 7.83 Favored Glycine 0 CA--C 1.537 1.441 0 N-CA-C 110.324 -1.11 . . . . 1.0 110.324 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.557 HG22 ' O ' ' A' ' 19' ' ' PHE . 20.3 m -60.54 -171.94 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 O-C-N 121.294 -1.121 . . . . 1.0 109.723 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -146.63 157.25 48.2 Favored Pre-proline 0 CA--C 1.535 0.379 0 O-C-N 121.584 -0.697 . . . . 1.0 109.25 179.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -34.71 -31.93 0.07 OUTLIER 'Trans proline' 0 N--CA 1.489 1.207 1 C-N-CA 125.588 4.192 . . . . 1.0 111.36 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 76.8 p -75.3 -50.22 16.71 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.475 -0.766 . . . . 1.0 109.872 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 38.0 mt-30 -61.57 -48.02 82.88 Favored 'General case' 0 N--CA 1.465 0.291 0 O-C-N 121.44 -0.788 . . . . 1.0 109.811 -179.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.9 t -64.69 -28.4 69.57 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.392 -0.818 . . . . 1.0 109.558 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -87.95 -4.96 58.77 Favored 'General case' 0 CA--C 1.534 0.353 0 O-C-N 121.57 -0.706 . . . . 1.0 110.012 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -75.01 -30.1 61.03 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.318 -0.864 . . . . 1.0 109.73 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.5 mmtp -102.82 -40.43 6.56 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.453 -0.779 . . . . 1.0 109.466 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 118.23 39.27 0.75 Allowed Glycine 0 CA--C 1.529 0.944 0 N-CA-C 109.419 -1.472 . . . . 1.0 109.419 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 48.7 m -101.94 139.7 37.22 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.567 -0.96 . . . . 1.0 109.189 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 84.6 m -65.37 116.51 6.76 Favored 'General case' 0 N--CA 1.464 0.255 0 O-C-N 121.523 -0.736 . . . . 1.0 109.927 -179.374 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 34.2 t80 -92.74 121.14 33.84 Favored 'General case' 0 C--N 1.333 -0.141 0 N-CA-C 109.042 -0.725 . . . . 1.0 109.042 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 26.8 t0 -134.15 118.48 17.72 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.391 -0.818 . . . . 1.0 109.518 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.441 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 7.0 p-10 -110.91 64.55 0.61 Allowed 'General case' 0 CA--C 1.533 0.298 0 O-C-N 121.526 -0.734 . . . . 1.0 109.236 179.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 27.0 p -114.26 -49.71 2.83 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.392 -0.817 . . . . 1.0 109.489 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.3 t -100.22 133.6 42.69 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 O-C-N 121.404 -0.81 . . . . 1.0 109.507 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.404 ' HG3' ' H ' ' A' ' 40' ' ' GLY . 2.3 tpt180 -85.13 176.17 8.55 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.571 -0.706 . . . . 1.0 109.553 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.404 ' H ' ' HG3' ' A' ' 39' ' ' ARG . . . 80.89 -48.43 3.74 Favored Glycine 0 CA--C 1.529 0.908 0 N-CA-C 109.447 -1.461 . . . . 1.0 109.447 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.3 m -81.4 169.75 17.86 Favored Pre-proline 0 CA--C 1.536 0.437 0 O-C-N 121.511 -0.993 . . . . 1.0 109.215 179.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -86.55 124.37 2.3 Favored 'Trans proline' 0 C--N 1.35 0.628 0 C-N-CA 124.757 3.638 . . . . 1.0 110.157 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.441 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 16.9 m0 -67.28 -37.61 83.7 Favored 'General case' 0 CA--C 1.53 0.192 0 O-C-N 121.554 -0.716 . . . . 1.0 109.522 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 11.1 t -87.86 109.25 19.62 Favored 'General case' 0 C--O 1.233 0.195 0 O-C-N 121.399 -0.813 . . . . 1.0 108.961 179.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.434 ' CE2' ' O ' ' A' ' 7' ' ' CYS . 1.3 p90 -149.3 178.44 8.76 Favored 'General case' 0 CA--C 1.537 0.454 0 O-C-N 121.454 -0.779 . . . . 1.0 109.832 -179.512 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 29.8 m-85 -83.78 170.28 14.59 Favored Pre-proline 0 CA--C 1.538 0.498 0 O-C-N 121.485 -0.759 . . . . 1.0 109.942 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -93.83 -168.32 0.18 Allowed 'Trans proline' 0 C--N 1.35 0.641 1 C-N-CA 125.357 4.038 . . . . 1.0 111.39 -179.45 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.5 m120 . . . . . 0 C--N 1.33 -0.241 0 N-CA-C 107.902 -1.148 . . . . 1.0 107.902 179.364 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.069 HG22 HG22 ' A' ' 8' ' ' THR . 0.6 OUTLIER . . . . . 0 CA--C 1.53 0.208 0 CA-C-O 121.139 0.495 . . . . 1.0 109.733 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 80.6 m -97.31 45.84 1.04 Allowed 'General case' 0 CA--C 1.532 0.287 0 O-C-N 121.51 -0.743 . . . . 1.0 108.998 179.445 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 1.069 HG22 HG22 ' A' ' 6' ' ' THR . 4.6 t -123.79 83.5 2.15 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.178 -0.951 . . . . 1.0 109.848 -179.616 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.619 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.2 t -109.5 172.03 2.46 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 N-CA-C 108.85 -0.796 . . . . 1.0 108.85 179.449 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.619 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -73.15 131.76 83.04 Favored Pre-proline 0 CA--C 1.541 0.597 0 O-C-N 121.323 -0.861 . . . . 1.0 109.272 -179.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -36.87 -38.75 0.39 Allowed 'Trans proline' 0 N--CA 1.488 1.156 0 C-N-CA 125.103 3.869 . . . . 1.0 111.351 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.7 mpp_? -82.01 -40.28 22.34 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 121.433 -0.792 . . . . 1.0 109.944 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.548 ' O ' HG11 ' A' ' 9' ' ' VAL . 29.6 mt-10 -86.24 42.68 1.01 Allowed 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.277 -0.89 . . . . 1.0 109.671 -179.657 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 37.9 mtt180 -101.51 151.34 22.08 Favored 'General case' 0 N--CA 1.464 0.232 0 O-C-N 121.409 -0.807 . . . . 1.0 109.627 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -104.68 105.6 15.76 Favored 'General case' 0 N--CA 1.462 0.172 0 O-C-N 121.345 -0.847 . . . . 1.0 109.06 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -57.32 118.69 5.38 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 121.235 -0.916 . . . . 1.0 110.305 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -94.13 -18.85 21.35 Favored 'General case' 0 CA--C 1.534 0.348 0 O-C-N 121.515 -0.741 . . . . 1.0 109.345 179.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -171.88 176.82 44.9 Favored Glycine 0 CA--C 1.53 1.017 0 N-CA-C 109.059 -1.616 . . . . 1.0 109.059 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.58 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.3 p90 -66.12 167.16 12.91 Favored Pre-proline 0 CA--C 1.539 0.526 0 O-C-N 121.374 -1.074 . . . . 1.0 108.815 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.97 -30.16 1.41 Allowed 'Trans proline' 0 N--CA 1.482 0.828 0 C-N-CA 124.537 3.491 . . . . 1.0 110.906 -178.604 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -57.8 -11.86 9.12 Favored Glycine 0 CA--C 1.536 1.39 0 N-CA-C 110.323 -1.111 . . . . 1.0 110.323 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.58 HG22 ' O ' ' A' ' 19' ' ' PHE . 20.9 m -61.06 -172.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 O-C-N 121.302 -1.116 . . . . 1.0 109.932 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.557 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 59.9 p -145.15 157.64 53.21 Favored Pre-proline 0 CA--C 1.535 0.37 0 N-CA-C 108.913 -0.773 . . . . 1.0 108.913 179.709 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -35.07 -39.75 0.22 Allowed 'Trans proline' 0 N--CA 1.489 1.212 1 C-N-CA 125.484 4.123 . . . . 1.0 111.378 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.1 p -74.08 -46.63 41.77 Favored 'General case' 0 CA--C 1.532 0.288 0 O-C-N 121.462 -0.774 . . . . 1.0 109.903 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLN . . . . . 0.557 ' HB2' ' H ' ' A' ' 23' ' ' THR . 32.4 mt-30 -61.26 -53.07 61.49 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 121.447 -0.783 . . . . 1.0 109.975 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 23.1 t -61.66 -26.41 68.0 Favored 'General case' 0 CA--C 1.533 0.322 0 O-C-N 121.298 -0.877 . . . . 1.0 109.719 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -90.01 -6.69 55.33 Favored 'General case' 0 CA--C 1.535 0.386 0 O-C-N 121.504 -0.748 . . . . 1.0 110.08 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 15.5 t-20 -78.96 -45.38 20.49 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.29 -0.882 . . . . 1.0 109.535 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.1 mtmm -72.36 -45.85 58.03 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.483 -0.761 . . . . 1.0 109.526 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 125.26 27.03 1.25 Allowed Glycine 0 CA--C 1.529 0.939 0 N-CA-C 109.197 -1.561 . . . . 1.0 109.197 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 26.4 m -99.52 145.29 27.65 Favored 'General case' 0 CA--C 1.532 0.276 0 O-C-N 121.685 -0.891 . . . . 1.0 108.696 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 35.9 m -68.58 128.92 38.35 Favored 'General case' 0 N--CA 1.465 0.321 0 O-C-N 121.307 -0.871 . . . . 1.0 109.42 -179.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -97.82 138.09 35.69 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.511 -0.743 . . . . 1.0 109.067 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 13.6 t0 -157.63 89.25 1.02 Allowed 'General case' 0 N--CA 1.463 0.183 0 O-C-N 121.521 -0.737 . . . . 1.0 109.512 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.424 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 38.2 p-10 -103.05 78.68 1.67 Allowed 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.539 -0.725 . . . . 1.0 109.472 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 76.6 p -113.85 -23.15 9.79 Favored 'General case' 0 CA--C 1.534 0.334 0 O-C-N 121.383 -0.823 . . . . 1.0 109.709 -179.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.537 HG12 ' N ' ' A' ' 39' ' ' ARG . 33.8 t -127.6 165.54 26.35 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 O-C-N 121.451 -0.78 . . . . 1.0 109.645 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.537 ' N ' HG12 ' A' ' 38' ' ' VAL . 0.0 OUTLIER -107.03 175.05 5.63 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 109.097 -0.705 . . . . 1.0 109.097 179.812 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.436 ' H ' ' CD ' ' A' ' 39' ' ' ARG . . . 72.17 -8.07 7.13 Favored Glycine 0 CA--C 1.533 1.173 0 N-CA-C 109.954 -1.258 . . . . 1.0 109.954 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.9 m -121.52 170.08 8.12 Favored Pre-proline 0 CA--C 1.537 0.461 0 O-C-N 121.317 -1.108 . . . . 1.0 109.051 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -86.53 127.75 2.85 Favored 'Trans proline' 0 N--CA 1.48 0.694 0 C-N-CA 124.585 3.523 . . . . 1.0 110.209 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.424 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.4 m0 -82.49 -39.36 22.57 Favored 'General case' 0 N--CA 1.464 0.264 0 O-C-N 121.586 -0.696 . . . . 1.0 109.28 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.1 t -88.14 117.49 27.06 Favored 'General case' 0 N--CA 1.466 0.329 0 O-C-N 121.508 -0.745 . . . . 1.0 109.113 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.419 ' CD1' ' N ' ' A' ' 45' ' ' PHE . 5.2 p90 -145.18 173.14 12.19 Favored 'General case' 0 CA--C 1.537 0.463 0 O-C-N 121.328 -0.857 . . . . 1.0 110.34 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.408 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 14.3 m-85 -79.53 172.78 9.0 Favored Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 121.473 -0.767 . . . . 1.0 109.496 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo -90.37 160.53 4.54 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 125.087 3.858 . . . . 1.0 110.252 179.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.529 ' ND2' HG21 ' A' ' 9' ' ' VAL . 8.2 m-20 . . . . . 0 CA--C 1.53 0.195 0 O-C-N 121.485 -0.759 . . . . 1.0 109.492 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.447 HG22 HG22 ' A' ' 8' ' ' THR . 1.1 m . . . . . 0 CA--C 1.532 0.256 0 N-CA-C 109.502 -0.555 . . . . 1.0 109.502 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 63.9 m -105.61 -20.56 13.43 Favored 'General case' 0 CA--C 1.533 0.316 0 O-C-N 121.601 -0.687 . . . . 1.0 109.478 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.576 HG23 ' O ' ' A' ' 8' ' ' THR . 3.8 t -70.05 104.78 2.66 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.322 -0.861 . . . . 1.0 109.538 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.613 HG12 ' N ' ' A' ' 10' ' ' ALA . 36.2 t -131.66 170.66 19.39 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 O-C-N 121.607 -0.683 . . . . 1.0 109.186 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.613 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -65.77 126.52 91.86 Favored Pre-proline 0 CA--C 1.539 0.535 0 O-C-N 121.448 -0.782 . . . . 1.0 109.22 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_exo -37.74 -40.02 0.88 Allowed 'Trans proline' 0 N--CA 1.49 1.268 0 C-N-CA 124.926 3.751 . . . . 1.0 111.126 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.9 mtm-85 -76.6 -41.73 45.08 Favored 'General case' 0 CA--C 1.532 0.254 0 O-C-N 121.4 -0.812 . . . . 1.0 109.886 -179.425 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -81.88 40.52 0.61 Allowed 'General case' 0 C--N 1.331 -0.213 0 O-C-N 121.451 -0.78 . . . . 1.0 109.561 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 55.3 mtt180 -108.09 133.49 52.31 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.47 -0.769 . . . . 1.0 109.556 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 22.6 mm-40 -90.65 117.71 29.52 Favored 'General case' 0 N--CA 1.464 0.227 0 O-C-N 121.438 -0.789 . . . . 1.0 109.367 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -61.31 115.36 3.78 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.453 -0.779 . . . . 1.0 109.992 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.4 t -93.47 -20.39 20.33 Favored 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.605 -0.685 . . . . 1.0 109.324 179.614 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.52 170.58 37.19 Favored Glycine 0 CA--C 1.529 0.958 0 N-CA-C 109.494 -1.442 . . . . 1.0 109.494 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.73 ' O ' HG22 ' A' ' 22' ' ' VAL . 19.8 p90 -64.85 148.77 97.14 Favored Pre-proline 0 CA--C 1.538 0.505 0 O-C-N 121.435 -1.038 . . . . 1.0 109.263 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -65.43 -28.69 54.07 Favored 'Trans proline' 0 N--CA 1.489 1.232 0 C-N-CA 124.053 3.169 . . . . 1.0 110.704 -178.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -55.04 -15.62 7.1 Favored Glycine 0 CA--C 1.536 1.355 0 N-CA-C 110.649 -0.981 . . . . 1.0 110.649 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.73 HG22 ' O ' ' A' ' 19' ' ' PHE . 30.2 m -64.01 178.26 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 O-C-N 121.389 -1.065 . . . . 1.0 109.505 179.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.1 p -132.03 156.4 80.15 Favored Pre-proline 0 CA--C 1.536 0.427 0 O-C-N 121.543 -0.723 . . . . 1.0 109.313 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -34.49 -33.03 0.07 OUTLIER 'Trans proline' 0 N--CA 1.489 1.206 1 C-N-CA 125.587 4.192 . . . . 1.0 111.293 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 2.6 m -71.83 -49.96 33.83 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.472 -0.767 . . . . 1.0 109.962 -179.554 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 13.2 mm-40 -63.39 -49.93 71.89 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.403 -0.81 . . . . 1.0 109.73 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.6 t -63.16 -21.34 66.14 Favored 'General case' 0 CA--C 1.533 0.306 0 O-C-N 121.518 -0.739 . . . . 1.0 109.829 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.0 -11.06 27.06 Favored 'General case' 0 CA--C 1.535 0.399 0 O-C-N 121.416 -0.802 . . . . 1.0 109.916 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -71.38 -35.96 71.27 Favored 'General case' 0 N--CA 1.463 0.205 0 O-C-N 121.331 -0.856 . . . . 1.0 109.56 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.8 tttp -92.07 -42.68 9.82 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.44 -0.787 . . . . 1.0 109.447 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 122.33 38.05 0.61 Allowed Glycine 0 CA--C 1.528 0.849 0 N-CA-C 109.526 -1.43 . . . . 1.0 109.526 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.8 m -105.59 145.34 31.12 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.493 -1.004 . . . . 1.0 109.114 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 61.4 m -68.5 127.48 33.14 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.557 -0.714 . . . . 1.0 109.54 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 51.1 t80 -104.12 109.39 21.16 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 121.507 -0.746 . . . . 1.0 109.25 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -120.81 102.98 8.74 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.575 -0.703 . . . . 1.0 109.564 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.443 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.8 p-10 -108.08 59.49 0.61 Allowed 'General case' 0 CA--C 1.532 0.267 0 O-C-N 121.527 -0.733 . . . . 1.0 109.291 179.742 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.5 p -112.28 -42.1 3.78 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.364 -0.835 . . . . 1.0 109.454 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.2 t -96.71 155.09 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 O-C-N 121.481 -0.762 . . . . 1.0 109.483 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -108.03 165.05 11.75 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.529 -0.732 . . . . 1.0 109.449 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.4 -32.6 2.82 Favored Glycine 0 CA--C 1.53 1.009 0 N-CA-C 109.096 -1.602 . . . . 1.0 109.096 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.423 HG22 ' H ' ' A' ' 41' ' ' VAL . 26.8 m -91.34 171.85 7.45 Favored Pre-proline 0 CA--C 1.538 0.502 0 O-C-N 121.619 -0.93 . . . . 1.0 109.041 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . 0.413 ' CD ' ' HB ' ' A' ' 41' ' ' VAL . 11.4 Cg_endo -85.97 138.68 6.01 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 124.411 3.407 . . . . 1.0 109.706 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.443 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 30.6 m0 -87.36 -46.06 10.0 Favored 'General case' 0 CA--C 1.531 0.239 0 O-C-N 121.481 -0.762 . . . . 1.0 110.466 -179.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 14.9 t -89.04 109.51 20.34 Favored 'General case' 0 CA--C 1.532 0.276 0 O-C-N 121.242 -0.911 . . . . 1.0 109.953 -179.503 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.415 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 5.6 p90 -137.38 -178.97 5.46 Favored 'General case' 0 CA--C 1.537 0.474 0 O-C-N 121.387 -0.821 . . . . 1.0 109.448 179.365 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.415 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 43.9 m-85 -90.48 165.27 23.74 Favored Pre-proline 0 CA--C 1.536 0.422 0 O-C-N 121.328 -0.857 . . . . 1.0 109.512 -179.798 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -90.86 175.59 2.49 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 124.95 3.767 . . . . 1.0 110.502 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.595 HD22 HG21 ' A' ' 9' ' ' VAL . 67.8 m-80 . . . . . 0 CA--C 1.529 0.165 0 N-CA-C 109.291 -0.633 . . . . 1.0 109.291 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.703 HG22 ' O ' ' A' ' 48' ' ' ASN . 4.7 t . . . . . 0 CA--C 1.532 0.265 0 N-CA-C 109.316 -0.624 . . . . 1.0 109.316 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 72.2 m -108.43 -20.97 12.94 Favored 'General case' 0 CA--C 1.534 0.345 0 O-C-N 121.46 -0.775 . . . . 1.0 109.644 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.57 HG23 ' O ' ' A' ' 8' ' ' THR . 3.5 t -70.03 102.98 2.15 Favored 'General case' 0 CA--C 1.53 0.211 0 O-C-N 121.489 -0.757 . . . . 1.0 109.892 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.617 HG12 ' N ' ' A' ' 10' ' ' ALA . 40.0 t -114.53 171.44 4.32 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 O-C-N 121.346 -0.846 . . . . 1.0 108.936 179.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.617 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -78.39 119.5 77.54 Favored Pre-proline 0 CA--C 1.541 0.622 0 O-C-N 121.417 -0.802 . . . . 1.0 109.542 -179.608 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.642 ' HB3' HG11 ' A' ' 41' ' ' VAL . 18.8 Cg_exo -37.93 -38.84 0.77 Allowed 'Trans proline' 0 N--CA 1.489 1.258 0 C-N-CA 124.757 3.638 . . . . 1.0 111.205 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 18.6 mmm-85 -77.01 -42.65 37.76 Favored 'General case' 0 N--CA 1.464 0.237 0 O-C-N 121.494 -0.754 . . . . 1.0 109.889 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -102.53 50.03 0.83 Allowed 'General case' 0 CA--C 1.532 0.286 0 O-C-N 121.375 -0.828 . . . . 1.0 109.508 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 26.7 mtt180 -94.04 147.77 22.81 Favored 'General case' 0 N--CA 1.463 0.223 0 O-C-N 121.379 -0.826 . . . . 1.0 109.704 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 54.1 mm-40 -91.6 107.26 19.09 Favored 'General case' 0 CA--C 1.53 0.196 0 O-C-N 121.474 -0.766 . . . . 1.0 109.166 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 30.2 t-20 -63.76 123.06 17.92 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 121.513 -0.742 . . . . 1.0 109.819 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 38.1 t -100.9 -18.34 16.4 Favored 'General case' 0 CA--C 1.534 0.329 0 O-C-N 121.53 -0.731 . . . . 1.0 109.505 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 175.94 -177.13 47.67 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 109.276 -1.53 . . . . 1.0 109.276 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.573 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.1 p90 -65.73 167.87 10.13 Favored Pre-proline 0 CA--C 1.538 0.492 0 O-C-N 121.395 -1.062 . . . . 1.0 108.822 179.732 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.81 -30.4 1.39 Allowed 'Trans proline' 0 N--CA 1.483 0.888 0 C-N-CA 124.374 3.383 . . . . 1.0 110.794 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -56.96 -12.58 7.23 Favored Glycine 0 CA--C 1.537 1.458 0 N-CA-C 110.357 -1.097 . . . . 1.0 110.357 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 19' ' ' PHE . 23.0 m -61.05 170.37 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 O-C-N 121.3 -1.117 . . . . 1.0 109.627 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.7 p -133.97 154.51 80.33 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.555 -0.716 . . . . 1.0 109.172 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.419 ' HD3' ' CZ ' ' A' ' 34' ' ' PHE . 16.8 Cg_exo -34.58 -31.87 0.06 OUTLIER 'Trans proline' 0 N--CA 1.488 1.195 1 C-N-CA 125.594 4.196 . . . . 1.0 111.355 179.956 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.6 m -75.53 -51.24 13.39 Favored 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.439 -0.788 . . . . 1.0 109.608 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 15.6 mt-30 -62.79 -43.37 98.98 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.427 -0.796 . . . . 1.0 109.721 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 10.1 t -64.54 -29.14 70.17 Favored 'General case' 0 N--CA 1.464 0.235 0 O-C-N 121.474 -0.766 . . . . 1.0 109.422 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.98 -11.15 56.13 Favored 'General case' 0 CA--C 1.533 0.315 0 O-C-N 121.604 -0.685 . . . . 1.0 109.756 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -88.24 -26.04 22.55 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.359 -0.838 . . . . 1.0 109.531 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 9.6 tttp -89.39 -32.06 17.46 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.419 -0.801 . . . . 1.0 109.407 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.41 43.43 1.36 Allowed Glycine 0 CA--C 1.53 0.985 0 N-CA-C 109.633 -1.387 . . . . 1.0 109.633 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.9 m -129.46 150.36 50.84 Favored 'General case' 0 CA--C 1.53 0.191 0 O-C-N 121.47 -1.018 . . . . 1.0 109.461 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.44 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 62.5 m -72.91 134.77 44.92 Favored 'General case' 0 CA--C 1.529 0.173 0 O-C-N 121.412 -0.805 . . . . 1.0 109.5 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.419 ' CZ ' ' HD3' ' A' ' 24' ' ' PRO . 57.1 t80 -107.87 125.13 51.1 Favored 'General case' 0 CA--C 1.53 0.175 0 O-C-N 121.488 -0.758 . . . . 1.0 109.233 179.689 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 16.2 t0 -138.54 117.84 12.77 Favored 'General case' 0 CA--C 1.53 0.179 0 O-C-N 121.457 -0.777 . . . . 1.0 109.527 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.431 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 14.1 p30 -113.55 66.06 0.66 Allowed 'General case' 0 N--CA 1.464 0.256 0 O-C-N 121.547 -0.721 . . . . 1.0 109.368 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.9 p -97.62 -69.82 0.74 Allowed 'General case' 0 CA--C 1.531 0.235 0 O-C-N 121.358 -0.839 . . . . 1.0 109.522 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 38.2 t -96.46 155.19 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 O-C-N 121.458 -0.776 . . . . 1.0 109.452 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.443 ' CG ' ' H ' ' A' ' 40' ' ' GLY . 13.7 ttp-105 -93.9 178.34 5.7 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 121.504 -0.748 . . . . 1.0 109.395 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.443 ' H ' ' CG ' ' A' ' 39' ' ' ARG . . . 81.3 -43.62 2.92 Favored Glycine 0 CA--C 1.529 0.918 0 N-CA-C 109.472 -1.451 . . . . 1.0 109.472 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.642 HG11 ' HB3' ' A' ' 11' ' ' PRO . 29.2 m -85.52 169.66 15.31 Favored Pre-proline 0 CA--C 1.537 0.444 0 O-C-N 121.538 -0.978 . . . . 1.0 109.197 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -87.22 136.46 4.06 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 124.77 3.647 . . . . 1.0 110.139 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.431 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 11.6 m0 -86.72 -50.55 6.69 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.526 -0.734 . . . . 1.0 109.569 -179.742 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.2 t -77.28 103.69 7.36 Favored 'General case' 0 N--CA 1.463 0.224 0 O-C-N 121.488 -0.758 . . . . 1.0 109.505 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.44 ' CE1' ' HB2' ' A' ' 33' ' ' CYS . 4.8 p90 -135.82 -178.99 5.38 Favored 'General case' 0 N--CA 1.465 0.316 0 O-C-N 121.489 -0.757 . . . . 1.0 109.523 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 65.1 m-85 -93.75 164.31 21.23 Favored Pre-proline 0 CA--C 1.534 0.357 0 O-C-N 121.436 -0.79 . . . . 1.0 109.652 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -91.11 -165.34 0.16 Allowed 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 125.045 3.83 . . . . 1.0 110.406 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.703 ' O ' HG22 ' A' ' 6' ' ' THR . 17.9 m-80 . . . . . 0 CA--C 1.53 0.207 0 O-C-N 121.505 -0.747 . . . . 1.0 109.441 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 CA--C 1.53 0.191 0 N-CA-C 109.303 -0.629 . . . . 1.0 109.303 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.9 m -105.21 28.87 6.88 Favored 'General case' 0 C--N 1.33 -0.249 0 O-C-N 121.611 -0.681 . . . . 1.0 109.316 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.53 HG23 ' O ' ' A' ' 8' ' ' THR . 5.2 t -80.51 118.29 21.98 Favored 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.406 -0.809 . . . . 1.0 109.508 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 36.4 t -149.47 154.18 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 O-C-N 121.57 -0.706 . . . . 1.0 109.349 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.605 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -83.1 146.38 51.41 Favored Pre-proline 0 CA--C 1.537 0.472 0 O-C-N 121.472 -0.768 . . . . 1.0 109.353 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_exo -34.48 -62.19 0.21 Allowed 'Trans proline' 0 N--CA 1.489 1.235 1 C-N-CA 125.571 4.18 . . . . 1.0 111.388 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.52 -29.88 65.29 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.383 -0.823 . . . . 1.0 109.856 -179.649 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.605 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 28.4 mt-10 -80.62 3.7 21.06 Favored 'General case' 0 CA--C 1.535 0.39 0 O-C-N 121.394 -0.816 . . . . 1.0 109.932 -179.812 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 48.8 mtt180 -73.86 129.71 38.45 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.396 -0.815 . . . . 1.0 109.56 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.4 mm-40 -88.08 108.98 19.51 Favored 'General case' 0 N--CA 1.463 0.212 0 N-CA-C 109.03 -0.73 . . . . 1.0 109.03 179.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 32.9 t-20 -59.22 105.8 0.37 Allowed 'General case' 0 CA--C 1.534 0.328 0 O-C-N 121.396 -0.815 . . . . 1.0 110.391 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.434 ' H ' ' HA ' ' A' ' 45' ' ' PHE . 1.7 t -85.53 -15.22 43.43 Favored 'General case' 0 CA--C 1.535 0.391 0 O-C-N 121.489 -0.757 . . . . 1.0 109.02 179.361 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 178.57 165.28 32.89 Favored Glycine 0 CA--C 1.529 0.96 0 N-CA-C 108.99 -1.644 . . . . 1.0 108.99 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.487 ' O ' HG22 ' A' ' 22' ' ' VAL . 7.1 p90 -59.41 168.91 1.49 Allowed Pre-proline 0 CA--C 1.541 0.634 0 O-C-N 121.355 -1.085 . . . . 1.0 109.276 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 19' ' ' PHE . 10.5 Cg_endo -80.51 -30.93 1.74 Allowed 'Trans proline' 0 N--CA 1.482 0.834 0 C-N-CA 124.112 3.208 . . . . 1.0 110.662 -178.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.43 -6.33 7.93 Favored Glycine 0 CA--C 1.537 1.408 0 N-CA-C 110.05 -1.22 . . . . 1.0 110.05 179.332 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.487 HG22 ' O ' ' A' ' 19' ' ' PHE . 24.7 m -59.71 -172.79 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 O-C-N 121.079 -1.248 . . . . 1.0 109.894 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.1 p -143.63 152.79 57.21 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.639 -0.663 . . . . 1.0 109.298 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -34.98 -33.31 0.08 OUTLIER 'Trans proline' 0 N--CA 1.488 1.174 1 C-N-CA 125.396 4.064 . . . . 1.0 111.437 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 9.3 t -76.37 -48.99 18.0 Favored 'General case' 0 CA--C 1.532 0.282 0 O-C-N 121.451 -0.781 . . . . 1.0 109.865 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 66.2 mt-30 -62.71 -41.17 99.0 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.45 -0.781 . . . . 1.0 109.782 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.3 t -69.09 -27.61 65.75 Favored 'General case' 0 CA--C 1.532 0.25 0 O-C-N 121.468 -0.77 . . . . 1.0 109.465 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.48 -5.77 53.7 Favored 'General case' 0 CA--C 1.536 0.424 0 O-C-N 121.546 -0.721 . . . . 1.0 109.941 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -63.03 -51.12 67.97 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.351 -0.843 . . . . 1.0 109.617 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.83 -40.54 13.07 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.466 -0.771 . . . . 1.0 109.403 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 126.91 21.44 1.72 Allowed Glycine 0 CA--C 1.531 1.074 0 N-CA-C 109.806 -1.318 . . . . 1.0 109.806 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 14.9 m -75.93 136.65 40.08 Favored 'General case' 0 N--CA 1.464 0.268 0 O-C-N 121.466 -1.02 . . . . 1.0 108.76 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 62.0 m -65.2 141.0 58.81 Favored 'General case' 0 CA--C 1.531 0.213 0 O-C-N 121.375 -0.828 . . . . 1.0 109.444 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 35' ' ' ASP . 15.2 t80 -111.22 143.17 42.4 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.448 -0.782 . . . . 1.0 109.17 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.443 ' N ' ' CD1' ' A' ' 34' ' ' PHE . 24.8 t70 -162.21 116.19 1.82 Allowed 'General case' 0 CA--C 1.531 0.242 0 O-C-N 121.392 -0.818 . . . . 1.0 109.62 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.444 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 16.0 p30 -105.71 63.17 0.67 Allowed 'General case' 0 CA--C 1.533 0.295 0 O-C-N 121.574 -0.704 . . . . 1.0 109.478 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.6 p -87.19 -58.18 2.68 Favored 'General case' 0 CA--C 1.531 0.242 0 O-C-N 121.417 -0.802 . . . . 1.0 109.512 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 37.5 t -119.74 146.56 24.3 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 O-C-N 121.496 -0.753 . . . . 1.0 109.427 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 1.4 ptm180 -84.15 -174.94 5.56 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 121.496 -0.752 . . . . 1.0 109.358 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.89 -42.93 2.55 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 109.213 -1.555 . . . . 1.0 109.213 -179.706 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.7 m -91.23 170.08 10.35 Favored Pre-proline 0 CA--C 1.534 0.354 0 O-C-N 121.489 -1.006 . . . . 1.0 108.981 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_endo -86.64 119.51 1.64 Allowed 'Trans proline' 0 C--N 1.35 0.621 0 C-N-CA 124.479 3.453 . . . . 1.0 110.049 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.444 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.9 m0 -72.69 -29.25 63.24 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 109.173 -0.677 . . . . 1.0 109.173 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 12.6 t -89.66 99.38 12.39 Favored 'General case' 0 CA--C 1.533 0.31 0 N-CA-C 109.158 -0.682 . . . . 1.0 109.158 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.434 ' HA ' ' H ' ' A' ' 17' ' ' CYS . 4.3 p90 -128.91 173.99 9.9 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 121.241 -0.912 . . . . 1.0 110.083 -179.619 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.402 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 19.8 m-85 -78.67 170.91 14.05 Favored Pre-proline 0 CA--C 1.536 0.424 0 O-C-N 121.415 -0.803 . . . . 1.0 109.543 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -89.81 -178.63 1.67 Allowed 'Trans proline' 0 C--N 1.351 0.662 0 C-N-CA 125.137 3.891 . . . . 1.0 110.304 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.8 m120 . . . . . 0 CA--C 1.531 0.243 0 O-C-N 121.441 -0.787 . . . . 1.0 109.303 179.957 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.432 HG22 HG22 ' A' ' 8' ' ' THR . 3.0 m . . . . . 0 CA--C 1.531 0.233 0 CA-C-O 121.243 0.544 . . . . 1.0 109.76 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.2 m -119.67 46.07 2.01 Favored 'General case' 0 CA--C 1.532 0.273 0 O-C-N 121.528 -0.733 . . . . 1.0 109.131 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.547 HG23 ' O ' ' A' ' 8' ' ' THR . 3.3 t -128.79 80.85 1.99 Allowed 'General case' 0 CA--C 1.532 0.269 0 O-C-N 121.423 -0.798 . . . . 1.0 109.469 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.614 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.0 t -102.42 170.16 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 O-C-N 121.367 -0.833 . . . . 1.0 109.332 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.614 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -71.79 134.99 83.43 Favored Pre-proline 0 CA--C 1.539 0.547 0 O-C-N 121.52 -0.738 . . . . 1.0 109.202 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_exo -35.87 -31.13 0.08 OUTLIER 'Trans proline' 0 N--CA 1.489 1.226 0 C-N-CA 125.202 3.934 . . . . 1.0 111.554 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.464 ' H ' ' HG2' ' A' ' 12' ' ' ARG . 10.5 ptp180 -84.25 -44.75 13.57 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.392 -0.817 . . . . 1.0 110.171 -179.402 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.466 ' O ' HG11 ' A' ' 9' ' ' VAL . 5.5 mt-10 -79.07 39.81 0.39 Allowed 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.357 -0.839 . . . . 1.0 109.653 -179.616 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 63.9 mtt180 -111.22 121.46 45.33 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.391 -0.818 . . . . 1.0 109.754 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.533 ' NE2' ' H ' ' A' ' 15' ' ' GLN . 1.3 pm0 -90.16 125.21 35.38 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.488 -0.757 . . . . 1.0 108.993 179.391 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -65.0 127.56 32.1 Favored 'General case' 0 CA--C 1.534 0.347 0 O-C-N 121.454 -0.779 . . . . 1.0 110.7 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -98.16 -26.67 14.49 Favored 'General case' 0 CA--C 1.534 0.335 0 N-CA-C 108.371 -0.974 . . . . 1.0 108.371 178.714 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -165.47 171.62 40.78 Favored Glycine 0 CA--C 1.53 1.012 0 N-CA-C 108.701 -1.76 . . . . 1.0 108.701 179.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.577 ' O ' HG22 ' A' ' 22' ' ' VAL . 7.9 p90 -62.73 167.62 5.54 Favored Pre-proline 0 CA--C 1.54 0.586 0 O-C-N 121.174 -1.192 . . . . 1.0 109.153 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.21 -30.86 1.44 Allowed 'Trans proline' 0 N--CA 1.483 0.875 0 C-N-CA 124.375 3.384 . . . . 1.0 110.771 -178.642 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.28 -9.91 9.29 Favored Glycine 0 CA--C 1.538 1.479 0 N-CA-C 110.104 -1.198 . . . . 1.0 110.104 179.443 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 19' ' ' PHE . 23.4 m -60.09 169.66 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 O-C-N 121.282 -1.128 . . . . 1.0 109.721 179.802 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.543 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 38.1 p -128.55 157.89 73.56 Favored Pre-proline 0 CA--C 1.536 0.409 0 N-CA-C 109.083 -0.71 . . . . 1.0 109.083 179.608 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -36.03 -34.03 0.13 Allowed 'Trans proline' 0 N--CA 1.488 1.157 1 C-N-CA 125.364 4.042 . . . . 1.0 111.176 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 33.7 p -79.25 -45.81 19.04 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.442 -0.786 . . . . 1.0 109.965 -179.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLN . . . . . 0.543 ' HB2' ' H ' ' A' ' 23' ' ' THR . 25.7 mt-30 -62.42 -52.5 63.32 Favored 'General case' 0 N--CA 1.465 0.304 0 O-C-N 121.476 -0.765 . . . . 1.0 109.853 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 10.4 t -62.0 -33.97 75.32 Favored 'General case' 0 CA--C 1.533 0.311 0 O-C-N 121.483 -0.761 . . . . 1.0 109.765 -179.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.6 -3.13 58.31 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.336 -0.852 . . . . 1.0 110.03 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -79.08 -46.65 17.64 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.319 -0.863 . . . . 1.0 109.834 -179.593 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.2 tttt -78.82 -48.5 14.64 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 121.431 -0.793 . . . . 1.0 109.544 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 132.58 21.41 0.92 Allowed Glycine 0 CA--C 1.531 1.052 0 N-CA-C 110.281 -1.127 . . . . 1.0 110.281 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 39.9 m -91.48 138.74 31.33 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 121.246 -1.149 . . . . 1.0 108.746 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.7 m -65.17 128.04 34.19 Favored 'General case' 0 N--CA 1.464 0.242 0 O-C-N 121.303 -0.873 . . . . 1.0 109.729 -179.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 64.4 t80 -97.57 143.3 28.4 Favored 'General case' 0 C--O 1.234 0.266 0 O-C-N 121.541 -0.724 . . . . 1.0 109.155 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -152.72 103.54 2.79 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 121.363 -0.836 . . . . 1.0 109.645 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.431 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 9.5 p-10 -109.02 82.56 1.61 Allowed 'General case' 0 CA--C 1.531 0.216 0 O-C-N 121.55 -0.719 . . . . 1.0 109.426 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 49.1 p -118.63 -35.03 3.82 Favored 'General case' 0 N--CA 1.463 0.218 0 O-C-N 121.421 -0.799 . . . . 1.0 109.601 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.6 t -128.97 150.15 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 O-C-N 121.458 -0.776 . . . . 1.0 109.396 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 22.3 ttt180 -87.08 168.18 13.52 Favored 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.468 -0.77 . . . . 1.0 109.384 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.43 -52.03 4.58 Favored Glycine 0 CA--C 1.529 0.907 0 N-CA-C 109.529 -1.428 . . . . 1.0 109.529 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 27.6 m -74.14 169.2 20.21 Favored Pre-proline 0 CA--C 1.536 0.419 0 O-C-N 121.551 -0.97 . . . . 1.0 109.324 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_endo -88.92 130.43 2.15 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 124.883 3.722 . . . . 1.0 110.219 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.431 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 7.7 m0 -87.95 -36.44 17.09 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.423 -0.798 . . . . 1.0 109.509 -179.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 8.0 t -89.44 102.96 15.63 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 109.144 -0.687 . . . . 1.0 109.144 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.406 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 3.6 p90 -134.55 174.23 10.78 Favored 'General case' 0 CA--C 1.538 0.497 0 O-C-N 121.304 -0.873 . . . . 1.0 110.083 -179.414 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.406 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 45.3 m-85 -76.6 170.5 15.87 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 121.435 -0.791 . . . . 1.0 109.495 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_endo -90.18 161.83 4.73 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 124.928 3.752 . . . . 1.0 110.454 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 . . . . . 0 N--CA 1.463 0.194 0 O-C-N 121.569 -0.707 . . . . 1.0 109.384 179.974 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 31.7 m . . . . . 0 CA--C 1.531 0.248 0 N-CA-C 109.193 -0.669 . . . . 1.0 109.193 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.3 m -124.67 -6.23 7.48 Favored 'General case' 0 CA--C 1.535 0.393 0 O-C-N 121.446 -0.783 . . . . 1.0 109.92 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.405 ' O ' HG23 ' A' ' 8' ' ' THR . 3.6 t -70.17 126.94 31.11 Favored 'General case' 0 N--CA 1.463 0.215 0 O-C-N 121.215 -0.928 . . . . 1.0 109.434 179.713 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.636 HG12 ' N ' ' A' ' 10' ' ' ALA . 26.0 t -142.34 173.64 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 O-C-N 121.513 -0.742 . . . . 1.0 109.37 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.636 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -77.96 136.84 61.89 Favored Pre-proline 0 CA--C 1.54 0.595 0 O-C-N 121.477 -0.764 . . . . 1.0 109.566 -179.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_exo -36.0 -38.24 0.27 Allowed 'Trans proline' 0 N--CA 1.489 1.216 1 C-N-CA 125.314 4.01 . . . . 1.0 111.442 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 40.4 mtp85 -85.11 -39.97 17.31 Favored 'General case' 0 N--CA 1.465 0.321 0 O-C-N 121.362 -0.836 . . . . 1.0 110.02 -179.282 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.63 ' O ' HG11 ' A' ' 9' ' ' VAL . 11.6 mt-10 -79.11 39.67 0.39 Allowed 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.427 -0.795 . . . . 1.0 109.671 -179.624 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 39.3 mtt180 -107.8 125.91 52.0 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.464 -0.772 . . . . 1.0 109.672 179.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.0 mp0 -94.76 113.13 24.86 Favored 'General case' 0 CA--C 1.532 0.284 0 O-C-N 121.472 -0.768 . . . . 1.0 109.224 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -59.74 126.17 26.53 Favored 'General case' 0 CA--C 1.533 0.314 0 O-C-N 121.411 -0.805 . . . . 1.0 110.252 -179.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -98.58 -18.63 18.03 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 121.565 -0.71 . . . . 1.0 109.094 179.582 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -173.21 176.67 45.89 Favored Glycine 0 CA--C 1.529 0.935 0 N-CA-C 108.834 -1.706 . . . . 1.0 108.834 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.568 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.4 p90 -65.87 167.34 11.83 Favored Pre-proline 0 CA--C 1.538 0.491 0 O-C-N 121.289 -1.124 . . . . 1.0 108.923 179.771 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.55 -29.46 1.83 Allowed 'Trans proline' 0 N--CA 1.483 0.894 0 C-N-CA 124.492 3.461 . . . . 1.0 110.897 -178.528 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.43 -11.58 10.34 Favored Glycine 0 CA--C 1.538 1.474 0 N-CA-C 110.192 -1.163 . . . . 1.0 110.192 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.568 HG22 ' O ' ' A' ' 19' ' ' PHE . 22.7 m -61.06 -171.8 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 O-C-N 121.354 -1.086 . . . . 1.0 109.72 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 43.3 p -147.1 152.52 43.59 Favored Pre-proline 0 CA--C 1.535 0.393 0 O-C-N 121.527 -0.733 . . . . 1.0 109.168 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_exo -35.15 -31.43 0.07 OUTLIER 'Trans proline' 0 N--CA 1.488 1.187 1 C-N-CA 125.575 4.183 . . . . 1.0 111.224 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 78.9 p -77.21 -51.21 11.33 Favored 'General case' 0 CA--C 1.532 0.271 0 O-C-N 121.491 -0.756 . . . . 1.0 109.752 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 68.8 mt-30 -63.08 -46.93 85.11 Favored 'General case' 0 N--CA 1.464 0.252 0 O-C-N 121.493 -0.755 . . . . 1.0 109.97 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 13.1 t -62.36 -33.15 74.15 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 121.419 -0.8 . . . . 1.0 109.82 -179.709 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.84 -3.96 58.61 Favored 'General case' 0 CA--C 1.534 0.346 0 O-C-N 121.444 -0.785 . . . . 1.0 110.056 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -79.73 -39.31 31.4 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.37 -0.831 . . . . 1.0 109.809 -179.534 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 35.4 mtmt -85.18 -46.58 10.95 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.396 -0.815 . . . . 1.0 109.938 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 137.91 11.58 0.93 Allowed Glycine 0 CA--C 1.533 1.174 0 N-CA-C 110.246 -1.141 . . . . 1.0 110.246 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 35.0 m -86.91 136.88 32.79 Favored 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.353 -1.086 . . . . 1.0 108.71 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.6 m -69.7 126.08 28.64 Favored 'General case' 0 N--CA 1.465 0.302 0 O-C-N 121.249 -0.907 . . . . 1.0 109.924 -179.704 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.451 ' CE1' ' HB2' ' A' ' 43' ' ' TRP . 50.3 t80 -94.79 147.34 23.44 Favored 'General case' 0 CA--C 1.531 0.22 0 N-CA-C 109.156 -0.683 . . . . 1.0 109.156 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -154.04 96.31 1.94 Allowed 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.454 -0.779 . . . . 1.0 109.631 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.421 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 6.7 p-10 -104.48 70.64 0.96 Allowed 'General case' 0 CA--C 1.533 0.299 0 O-C-N 121.523 -0.736 . . . . 1.0 109.25 179.821 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 18.2 p -117.64 -42.47 2.86 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.356 -0.84 . . . . 1.0 109.407 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.431 HG12 ' N ' ' A' ' 39' ' ' ARG . 37.4 t -111.2 159.23 11.32 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 O-C-N 121.438 -0.789 . . . . 1.0 109.415 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.431 ' N ' HG12 ' A' ' 38' ' ' VAL . 16.4 ttp-105 -100.33 170.37 8.47 Favored 'General case' 0 C--O 1.233 0.201 0 O-C-N 121.412 -0.805 . . . . 1.0 109.425 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.46 -58.29 5.0 Favored Glycine 0 CA--C 1.529 0.922 0 N-CA-C 109.511 -1.436 . . . . 1.0 109.511 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.5 m -70.23 169.25 14.13 Favored Pre-proline 0 CA--C 1.537 0.448 0 O-C-N 121.491 -1.006 . . . . 1.0 109.233 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -87.39 127.11 2.38 Favored 'Trans proline' 0 C--N 1.352 0.72 0 C-N-CA 124.721 3.614 . . . . 1.0 110.15 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.451 ' HB2' ' CE1' ' A' ' 34' ' ' PHE . 11.2 m0 -73.62 -43.45 59.55 Favored 'General case' 0 N--CA 1.464 0.248 0 O-C-N 121.593 -0.692 . . . . 1.0 109.603 -179.665 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 12.3 t -88.3 110.99 21.2 Favored 'General case' 0 CA--C 1.535 0.382 0 O-C-N 121.452 -0.78 . . . . 1.0 109.578 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.401 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 4.2 p90 -141.89 175.9 9.36 Favored 'General case' 0 CA--C 1.538 0.507 0 O-C-N 121.353 -0.842 . . . . 1.0 109.974 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.401 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 18.1 m-85 -74.83 171.43 11.63 Favored Pre-proline 0 CA--C 1.536 0.432 0 O-C-N 121.472 -0.767 . . . . 1.0 109.889 -179.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -94.42 -178.82 0.64 Allowed 'Trans proline' 0 C--N 1.351 0.691 1 C-N-CA 125.336 4.024 . . . . 1.0 110.919 -179.647 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.457 HD22 ' CG2' ' A' ' 9' ' ' VAL . 19.4 m-20 . . . . . 0 CA--C 1.531 0.222 0 O-C-N 121.602 -0.687 . . . . 1.0 109.214 179.832 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.461 HG22 HG22 ' A' ' 8' ' ' THR . 1.6 m . . . . . 0 C--O 1.233 0.191 0 N-CA-C 109.574 -0.528 . . . . 1.0 109.574 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 77.6 m -110.51 34.68 3.81 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.523 -0.736 . . . . 1.0 109.229 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.461 HG22 HG22 ' A' ' 6' ' ' THR . 5.0 t -91.96 125.64 36.73 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.507 -0.745 . . . . 1.0 109.677 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.499 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.7 t -146.88 163.7 8.02 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 109.085 -0.709 . . . . 1.0 109.085 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.788 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -78.59 136.59 59.46 Favored Pre-proline 0 CA--C 1.541 0.624 0 O-C-N 121.467 -0.771 . . . . 1.0 109.233 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_exo -34.74 -57.81 0.4 Allowed 'Trans proline' 0 N--CA 1.488 1.196 1 C-N-CA 125.457 4.105 . . . . 1.0 111.416 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.2 mmt180 -74.49 -32.28 62.49 Favored 'General case' 0 N--CA 1.463 0.194 0 O-C-N 121.488 -0.758 . . . . 1.0 109.895 -179.616 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.788 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 9.5 mt-10 -83.05 21.93 1.01 Allowed 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.348 -0.845 . . . . 1.0 109.73 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 69.0 mtt180 -89.98 126.03 35.6 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.444 -0.785 . . . . 1.0 109.418 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -89.01 121.42 31.35 Favored 'General case' 0 CA--C 1.53 0.197 0 O-C-N 121.52 -0.738 . . . . 1.0 109.092 179.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -69.04 118.61 12.16 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.421 -0.799 . . . . 1.0 109.484 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -88.29 -24.16 23.26 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.48 -0.762 . . . . 1.0 109.065 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -169.74 173.79 43.95 Favored Glycine 0 CA--C 1.529 0.914 0 N-CA-C 109.085 -1.606 . . . . 1.0 109.085 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.559 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.5 p90 -66.5 167.59 12.57 Favored Pre-proline 0 CA--C 1.538 0.493 0 O-C-N 121.439 -1.036 . . . . 1.0 108.924 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -82.09 -30.21 1.35 Allowed 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 124.441 3.427 . . . . 1.0 110.801 -178.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.05 -11.33 8.57 Favored Glycine 0 CA--C 1.537 1.46 0 N-CA-C 110.329 -1.108 . . . . 1.0 110.329 179.593 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 19' ' ' PHE . 22.3 m -60.73 -169.98 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 O-C-N 121.334 -1.098 . . . . 1.0 109.702 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.506 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 12.8 p -140.85 156.13 68.83 Favored Pre-proline 0 CA--C 1.534 0.356 0 N-CA-C 109.096 -0.705 . . . . 1.0 109.096 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_exo -38.16 -36.23 0.49 Allowed 'Trans proline' 0 N--CA 1.487 1.143 0 C-N-CA 125.14 3.893 . . . . 1.0 110.998 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.3 t -75.98 -41.46 51.29 Favored 'General case' 0 CA--C 1.532 0.273 0 O-C-N 121.557 -0.714 . . . . 1.0 110.141 -179.473 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLN . . . . . 0.506 ' HB2' ' H ' ' A' ' 23' ' ' THR . 5.1 mt-30 -65.2 -50.79 64.51 Favored 'General case' 0 CA--C 1.532 0.261 0 O-C-N 121.431 -0.793 . . . . 1.0 110.002 -179.638 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 11.4 t -61.67 -32.3 72.47 Favored 'General case' 0 CA--C 1.533 0.319 0 O-C-N 121.335 -0.853 . . . . 1.0 109.914 -179.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -89.18 -3.93 58.42 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 121.497 -0.752 . . . . 1.0 110.109 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 41.6 t-20 -73.8 -53.55 10.01 Favored 'General case' 0 N--CA 1.464 0.245 0 O-C-N 121.392 -0.818 . . . . 1.0 109.523 -179.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.2 mttt -73.19 -48.09 38.18 Favored 'General case' 0 C--N 1.332 -0.182 0 O-C-N 121.515 -0.74 . . . . 1.0 109.375 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 136.8 15.67 0.82 Allowed Glycine 0 CA--C 1.532 1.119 0 N-CA-C 109.647 -1.381 . . . . 1.0 109.647 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 36.4 m -82.12 140.61 33.7 Favored 'General case' 0 N--CA 1.463 0.218 0 O-C-N 121.345 -1.091 . . . . 1.0 108.731 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 69.3 m -71.5 123.27 22.05 Favored 'General case' 0 C--N 1.332 -0.189 0 O-C-N 121.368 -0.833 . . . . 1.0 109.66 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 37.0 t80 -94.71 142.72 27.13 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.46 -0.775 . . . . 1.0 109.169 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -160.45 98.96 1.28 Allowed 'General case' 0 C--O 1.233 0.194 0 O-C-N 121.513 -0.742 . . . . 1.0 109.47 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.447 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.0 p-10 -107.44 76.28 1.07 Allowed 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.457 -0.777 . . . . 1.0 109.486 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 70.1 p -120.15 -38.54 2.91 Favored 'General case' 0 CA--C 1.533 0.291 0 O-C-N 121.468 -0.77 . . . . 1.0 109.654 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.8 t -110.75 144.5 18.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 O-C-N 121.397 -0.815 . . . . 1.0 109.7 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.2 mmt180 -88.69 177.16 6.82 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.547 -0.721 . . . . 1.0 109.487 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.71 -62.57 4.36 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 109.092 -1.603 . . . . 1.0 109.092 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 28.7 m -73.1 170.23 14.61 Favored Pre-proline 0 CA--C 1.536 0.406 0 O-C-N 121.63 -0.924 . . . . 1.0 109.096 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -84.34 150.76 11.95 Favored 'Trans proline' 0 C--N 1.351 0.662 0 C-N-CA 124.366 3.377 . . . . 1.0 109.901 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.447 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 7.8 m0 -94.68 -40.58 9.73 Favored 'General case' 0 N--CA 1.465 0.284 0 O-C-N 121.545 -0.722 . . . . 1.0 109.639 -179.218 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 22.7 t -90.29 105.55 17.89 Favored 'General case' 0 CA--C 1.534 0.364 0 O-C-N 121.416 -0.802 . . . . 1.0 109.448 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.433 ' CD1' ' N ' ' A' ' 45' ' ' PHE . 4.9 p90 -128.99 179.26 5.84 Favored 'General case' 0 CA--C 1.534 0.338 0 O-C-N 121.395 -0.816 . . . . 1.0 109.9 -179.863 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.401 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 17.8 m-85 -80.97 170.71 14.48 Favored Pre-proline 0 CA--C 1.538 0.482 0 O-C-N 121.391 -0.818 . . . . 1.0 109.835 -179.596 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -90.58 169.6 3.83 Favored 'Trans proline' 0 C--N 1.352 0.736 0 C-N-CA 124.981 3.787 . . . . 1.0 110.58 179.798 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.2 m120 . . . . . 0 CA--C 1.531 0.215 0 O-C-N 121.469 -0.77 . . . . 1.0 109.011 179.726 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.941 HG22 HG22 ' A' ' 8' ' ' THR . 2.3 m . . . . . 0 CA--C 1.531 0.249 0 CA-C-O 121.19 0.519 . . . . 1.0 109.625 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 75.8 m -110.73 13.67 22.37 Favored 'General case' 0 CA--C 1.534 0.346 0 O-C-N 121.482 -0.761 . . . . 1.0 109.623 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.941 HG22 HG22 ' A' ' 6' ' ' THR . 4.4 t -93.97 104.69 16.73 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.444 -0.785 . . . . 1.0 109.565 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.515 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.6 t -123.4 164.43 21.11 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 O-C-N 121.557 -0.714 . . . . 1.0 109.29 179.798 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.515 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -69.4 121.96 83.92 Favored Pre-proline 0 CA--C 1.54 0.569 0 O-C-N 121.434 -0.791 . . . . 1.0 109.155 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.479 ' HB3' HG11 ' A' ' 41' ' ' VAL . 17.6 Cg_exo -38.36 -28.22 0.12 Allowed 'Trans proline' 0 N--CA 1.49 1.29 0 C-N-CA 124.749 3.633 . . . . 1.0 111.357 -179.653 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 64.8 mtt180 -84.25 -41.26 17.09 Favored 'General case' 0 CA--C 1.533 0.292 0 O-C-N 121.37 -0.831 . . . . 1.0 110.171 -179.252 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 15.0 mm-40 -92.43 44.88 1.17 Allowed 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.45 -0.781 . . . . 1.0 109.748 -179.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.408 ' HD3' ' CD2' ' A' ' 45' ' ' PHE . 19.3 mtt180 -106.81 141.63 37.73 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.332 -0.855 . . . . 1.0 109.603 179.767 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 16.5 mt-30 -111.11 126.67 55.08 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 108.918 -0.771 . . . . 1.0 108.918 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -67.73 117.32 9.49 Favored 'General case' 0 CA--C 1.532 0.285 0 O-C-N 121.427 -0.796 . . . . 1.0 110.673 -178.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.482 ' H ' ' HA ' ' A' ' 45' ' ' PHE . 3.0 t -72.64 -31.32 65.03 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 108.665 -0.865 . . . . 1.0 108.665 178.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -152.88 178.92 29.73 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 109.306 -1.517 . . . . 1.0 109.306 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.534 ' O ' HG22 ' A' ' 22' ' ' VAL . 6.6 p90 -62.03 169.28 2.89 Favored Pre-proline 0 CA--C 1.541 0.634 0 O-C-N 121.387 -1.067 . . . . 1.0 108.889 179.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 19' ' ' PHE . 10.6 Cg_endo -80.43 -31.92 1.44 Allowed 'Trans proline' 0 N--CA 1.482 0.838 0 C-N-CA 124.044 3.163 . . . . 1.0 110.762 -178.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.2 -3.21 6.24 Favored Glycine 0 CA--C 1.537 1.423 0 N-CA-C 110.196 -1.161 . . . . 1.0 110.196 179.704 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.534 HG22 ' O ' ' A' ' 19' ' ' PHE . 21.9 m -62.82 170.73 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 O-C-N 121.148 -1.207 . . . . 1.0 109.686 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.8 p -130.21 155.72 80.41 Favored Pre-proline 0 CA--C 1.534 0.361 0 N-CA-C 108.962 -0.755 . . . . 1.0 108.962 179.714 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -35.95 -38.7 0.28 Allowed 'Trans proline' 0 N--CA 1.488 1.18 0 C-N-CA 125.254 3.969 . . . . 1.0 111.188 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 79.4 p -70.9 -46.23 62.91 Favored 'General case' 0 CA--C 1.533 0.291 0 O-C-N 121.447 -0.783 . . . . 1.0 110.043 -179.583 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -62.19 -49.1 77.12 Favored 'General case' 0 N--CA 1.465 0.321 0 O-C-N 121.366 -0.834 . . . . 1.0 110.024 -179.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 7.2 t -62.54 -25.12 67.88 Favored 'General case' 0 CA--C 1.533 0.297 0 O-C-N 121.407 -0.808 . . . . 1.0 109.808 -179.715 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -95.95 -5.32 41.62 Favored 'General case' 0 CA--C 1.534 0.363 0 O-C-N 121.391 -0.818 . . . . 1.0 110.309 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -98.11 -23.39 15.75 Favored 'General case' 0 N--CA 1.465 0.281 0 O-C-N 121.223 -0.923 . . . . 1.0 109.726 -179.619 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.1 mmtm -91.41 -15.2 29.29 Favored 'General case' 0 CA--C 1.533 0.289 0 O-C-N 121.311 -0.868 . . . . 1.0 109.736 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.99 14.81 41.29 Favored Glycine 0 CA--C 1.532 1.143 0 N-CA-C 109.988 -1.245 . . . . 1.0 109.988 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 56.3 m -94.3 148.52 22.13 Favored 'General case' 0 N--CA 1.465 0.298 0 O-C-N 121.402 -1.058 . . . . 1.0 108.808 179.843 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.454 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 58.4 m -80.7 126.71 31.63 Favored 'General case' 0 CA--C 1.532 0.267 0 O-C-N 121.343 -0.848 . . . . 1.0 109.713 -179.638 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -98.84 128.13 44.96 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 108.799 -0.815 . . . . 1.0 108.799 179.334 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -141.38 117.32 10.5 Favored 'General case' 0 N--CA 1.464 0.256 0 O-C-N 121.465 -0.772 . . . . 1.0 109.864 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.438 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 7.2 p-10 -112.14 72.92 0.79 Allowed 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.594 -0.691 . . . . 1.0 109.21 179.513 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.1 p -104.08 -61.92 1.38 Allowed 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.368 -0.832 . . . . 1.0 109.619 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.6 t -103.5 154.72 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 O-C-N 121.451 -0.781 . . . . 1.0 109.415 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.94 171.85 8.85 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.479 -0.763 . . . . 1.0 109.487 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.08 -49.64 4.15 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 109.477 -1.449 . . . . 1.0 109.477 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.479 HG11 ' HB3' ' A' ' 11' ' ' PRO . 29.7 m -73.81 169.36 19.06 Favored Pre-proline 0 CA--C 1.536 0.422 0 O-C-N 121.553 -0.969 . . . . 1.0 109.333 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_endo -89.08 127.1 1.74 Allowed 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 124.838 3.692 . . . . 1.0 109.901 179.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.438 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 13.6 m0 -77.27 -51.5 10.8 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.51 -0.744 . . . . 1.0 109.367 -179.719 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 5.2 t -74.88 111.63 10.28 Favored 'General case' 0 CA--C 1.531 0.241 0 N-CA-C 108.616 -0.883 . . . . 1.0 108.616 179.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.482 ' HA ' ' H ' ' A' ' 17' ' ' CYS . 2.3 p90 -140.86 175.32 9.71 Favored 'General case' 0 N--CA 1.468 0.429 0 O-C-N 121.449 -0.782 . . . . 1.0 110.185 -179.686 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 41.7 m-85 -74.17 160.55 81.3 Favored Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 121.405 -0.81 . . . . 1.0 110.128 -179.243 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -90.03 174.32 3.23 Favored 'Trans proline' 0 C--N 1.352 0.74 0 C-N-CA 124.96 3.774 . . . . 1.0 110.401 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 4.0 m120 . . . . . 0 CA--C 1.53 0.203 0 O-C-N 121.541 -0.724 . . . . 1.0 109.491 179.867 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.479 ' HB ' HG22 ' A' ' 8' ' ' THR . 1.7 m . . . . . 0 CA--C 1.53 0.209 0 N-CA-C 109.402 -0.592 . . . . 1.0 109.402 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 73.1 m -86.95 11.97 12.27 Favored 'General case' 0 CA--C 1.534 0.35 0 O-C-N 121.544 -0.722 . . . . 1.0 109.641 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.535 HG23 ' O ' ' A' ' 8' ' ' THR . 5.4 t -85.41 117.96 24.65 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.257 -0.902 . . . . 1.0 109.677 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 10' ' ' ALA . 37.7 t -140.95 168.24 16.5 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 O-C-N 121.419 -0.8 . . . . 1.0 109.126 179.649 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.579 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -84.42 138.32 38.82 Favored Pre-proline 0 CA--C 1.538 0.487 0 O-C-N 121.351 -0.843 . . . . 1.0 109.439 -179.908 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_exo -34.75 -40.38 0.22 Allowed 'Trans proline' 0 N--CA 1.489 1.222 1 C-N-CA 125.511 4.141 . . . . 1.0 111.276 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 25.7 mtt85 -85.26 -46.57 10.9 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.472 -0.767 . . . . 1.0 109.699 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -67.31 -5.0 12.33 Favored 'General case' 0 CA--C 1.534 0.328 0 O-C-N 121.505 -0.747 . . . . 1.0 110.023 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.8 mtt180 -70.38 126.11 28.72 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.36 -0.838 . . . . 1.0 109.52 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 11.2 mm100 -87.07 123.09 31.76 Favored 'General case' 0 C--N 1.332 -0.168 0 O-C-N 121.478 -0.764 . . . . 1.0 109.252 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -65.7 111.39 3.18 Favored 'General case' 0 N--CA 1.464 0.238 0 O-C-N 121.559 -0.713 . . . . 1.0 109.745 -179.709 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 41.8 t -82.04 -16.42 50.23 Favored 'General case' 0 CA--C 1.534 0.351 0 O-C-N 121.431 -0.793 . . . . 1.0 109.339 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.59 179.08 44.01 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 109.061 -1.615 . . . . 1.0 109.061 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.551 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.2 p90 -65.04 167.73 9.01 Favored Pre-proline 0 CA--C 1.539 0.548 0 O-C-N 121.306 -1.114 . . . . 1.0 108.838 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.54 -30.59 1.42 Allowed 'Trans proline' 0 N--CA 1.482 0.814 0 C-N-CA 124.39 3.393 . . . . 1.0 110.881 -178.658 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.62 -8.77 7.9 Favored Glycine 0 CA--C 1.537 1.441 0 N-CA-C 110.25 -1.14 . . . . 1.0 110.25 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.551 HG22 ' O ' ' A' ' 19' ' ' PHE . 20.0 m -61.16 177.24 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 O-C-N 121.228 -1.16 . . . . 1.0 109.669 179.766 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.0 p -138.89 156.24 72.73 Favored Pre-proline 0 CA--C 1.535 0.389 0 O-C-N 121.54 -0.725 . . . . 1.0 109.225 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -34.91 -32.04 0.07 OUTLIER 'Trans proline' 0 N--CA 1.487 1.12 1 C-N-CA 125.56 4.174 . . . . 1.0 111.171 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 1.8 m -72.12 -51.94 19.08 Favored 'General case' 0 CA--C 1.532 0.281 0 O-C-N 121.419 -0.801 . . . . 1.0 109.614 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 52.3 mt-30 -62.78 -46.01 90.0 Favored 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.47 -0.769 . . . . 1.0 109.772 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.2 t -64.59 -23.8 67.38 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.401 -0.812 . . . . 1.0 109.563 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -94.12 -7.12 43.37 Favored 'General case' 0 CA--C 1.535 0.399 0 O-C-N 121.383 -0.823 . . . . 1.0 109.881 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -73.38 -39.26 65.27 Favored 'General case' 0 CA--C 1.532 0.281 0 O-C-N 121.269 -0.895 . . . . 1.0 109.418 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -92.49 -38.39 11.98 Favored 'General case' 0 N--CA 1.462 0.171 0 O-C-N 121.523 -0.736 . . . . 1.0 109.425 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 113.95 37.93 1.21 Allowed Glycine 0 CA--C 1.53 1.024 0 N-CA-C 109.631 -1.388 . . . . 1.0 109.631 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.8 m -97.52 145.01 26.65 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.472 -1.017 . . . . 1.0 109.273 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.404 ' O ' ' CD1' ' A' ' 45' ' ' PHE . 58.4 m -68.28 119.56 13.02 Favored 'General case' 0 CA--C 1.532 0.267 0 O-C-N 121.398 -0.814 . . . . 1.0 109.426 -179.677 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 43.7 t80 -92.02 146.85 23.41 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.386 -0.821 . . . . 1.0 109.258 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 10.6 t0 -162.12 110.43 1.41 Allowed 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.353 -0.842 . . . . 1.0 109.537 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.435 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 13.6 p30 -110.63 70.77 0.73 Allowed 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.501 -0.749 . . . . 1.0 109.442 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.8 p -111.82 -53.31 2.72 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.403 -0.811 . . . . 1.0 109.737 -179.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.437 HG12 ' N ' ' A' ' 39' ' ' ARG . 35.6 t -96.3 159.38 2.98 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 O-C-N 121.341 -0.849 . . . . 1.0 109.639 -179.692 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.437 ' N ' HG12 ' A' ' 38' ' ' VAL . 2.2 mmm180 -103.82 169.13 8.69 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 121.473 -0.767 . . . . 1.0 109.263 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.75 -42.63 2.49 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 109.355 -1.498 . . . . 1.0 109.355 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.4 m -80.34 169.68 18.77 Favored Pre-proline 0 CA--C 1.537 0.466 0 O-C-N 121.538 -0.978 . . . . 1.0 109.082 179.768 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -87.3 131.77 3.05 Favored 'Trans proline' 0 C--N 1.351 0.682 0 C-N-CA 124.712 3.608 . . . . 1.0 110.011 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.435 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 15.3 m0 -80.15 -39.45 29.34 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.46 -0.775 . . . . 1.0 109.738 -179.482 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 16.0 t -90.01 107.78 19.32 Favored 'General case' 0 CA--C 1.534 0.338 0 O-C-N 121.412 -0.805 . . . . 1.0 109.486 179.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.423 ' CD1' ' N ' ' A' ' 45' ' ' PHE . 5.6 p90 -133.52 175.9 9.01 Favored 'General case' 0 CA--C 1.536 0.412 0 O-C-N 121.452 -0.78 . . . . 1.0 109.757 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.406 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 31.9 m-85 -85.34 170.84 12.09 Favored Pre-proline 0 CA--C 1.537 0.462 0 O-C-N 121.532 -0.73 . . . . 1.0 109.351 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -90.96 177.06 2.15 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 124.968 3.779 . . . . 1.0 110.39 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.2 m120 . . . . . 0 CA--C 1.53 0.188 0 O-C-N 121.569 -0.707 . . . . 1.0 109.597 179.953 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.463 0.175 0 N-CA-C 109.327 -0.62 . . . . 1.0 109.327 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 62.3 m -114.9 28.24 8.85 Favored 'General case' 0 C--O 1.232 0.15 0 O-C-N 121.496 -0.752 . . . . 1.0 109.326 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.481 HG23 ' O ' ' A' ' 8' ' ' THR . 5.6 t -95.39 122.82 38.51 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.362 -0.836 . . . . 1.0 109.586 -179.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.56 HG12 ' N ' ' A' ' 10' ' ' ALA . 40.3 t -147.11 167.67 5.5 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.198 0 O-C-N 121.5 -0.75 . . . . 1.0 109.283 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.573 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -76.66 124.97 87.83 Favored Pre-proline 0 CA--C 1.541 0.609 0 O-C-N 121.438 -0.789 . . . . 1.0 109.354 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.401 ' HD2' ' HA ' ' A' ' 10' ' ' ALA . 19.4 Cg_exo -36.87 -50.37 1.45 Allowed 'Trans proline' 0 N--CA 1.49 1.302 0 C-N-CA 124.922 3.748 . . . . 1.0 111.242 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.6 mtp180 -70.21 -49.12 53.38 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.458 -0.776 . . . . 1.0 109.652 -179.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.573 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 25.0 mt-10 -82.61 40.36 0.66 Allowed 'General case' 0 CA--C 1.53 0.211 0 O-C-N 121.46 -0.775 . . . . 1.0 109.52 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 26.2 mtt180 -92.4 139.34 30.7 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.473 -0.767 . . . . 1.0 109.476 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -85.46 108.48 17.91 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.522 -0.736 . . . . 1.0 109.162 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -64.59 120.48 12.43 Favored 'General case' 0 CA--C 1.532 0.275 0 O-C-N 121.485 -0.759 . . . . 1.0 109.668 -179.72 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 28.2 t -95.75 -19.48 19.63 Favored 'General case' 0 CA--C 1.534 0.327 0 O-C-N 121.586 -0.696 . . . . 1.0 109.456 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 175.3 -179.03 46.79 Favored Glycine 0 CA--C 1.528 0.871 0 N-CA-C 109.232 -1.547 . . . . 1.0 109.232 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.561 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.1 p90 -65.72 167.97 9.84 Favored Pre-proline 0 CA--C 1.537 0.455 0 O-C-N 121.369 -1.077 . . . . 1.0 108.929 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.68 -30.15 1.53 Allowed 'Trans proline' 0 N--CA 1.483 0.902 0 C-N-CA 124.418 3.412 . . . . 1.0 110.809 -178.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -57.16 -12.16 7.4 Favored Glycine 0 CA--C 1.536 1.401 0 N-CA-C 110.401 -1.079 . . . . 1.0 110.401 179.597 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.561 HG22 ' O ' ' A' ' 19' ' ' PHE . 24.2 m -61.3 162.92 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 O-C-N 121.253 -1.145 . . . . 1.0 109.641 179.694 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.4 p -121.6 154.75 60.05 Favored Pre-proline 0 CA--C 1.534 0.35 0 O-C-N 121.505 -0.747 . . . . 1.0 109.311 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.0 Cg_exo -35.8 -38.75 0.27 Allowed 'Trans proline' 0 N--CA 1.487 1.119 1 C-N-CA 125.479 4.12 . . . . 1.0 111.258 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 1.9 p -69.91 -48.08 59.97 Favored 'General case' 0 N--CA 1.463 0.213 0 O-C-N 121.511 -0.743 . . . . 1.0 109.791 -179.826 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -62.72 -46.15 89.42 Favored 'General case' 0 CA--C 1.533 0.322 0 O-C-N 121.4 -0.813 . . . . 1.0 109.749 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 17.3 t -64.59 -26.79 68.56 Favored 'General case' 0 CA--C 1.531 0.213 0 O-C-N 121.431 -0.793 . . . . 1.0 109.368 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.56 -8.85 54.06 Favored 'General case' 0 CA--C 1.532 0.271 0 O-C-N 121.562 -0.711 . . . . 1.0 109.811 179.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -77.94 -38.42 45.46 Favored 'General case' 0 CA--C 1.53 0.18 0 O-C-N 121.245 -0.91 . . . . 1.0 109.373 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.4 mmtt -83.69 -41.44 17.72 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 121.429 -0.794 . . . . 1.0 109.41 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 118.07 38.45 0.81 Allowed Glycine 0 CA--C 1.531 1.055 0 N-CA-C 109.569 -1.412 . . . . 1.0 109.569 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.7 m -112.61 147.97 35.56 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.606 -0.938 . . . . 1.0 109.485 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 66.4 m -69.5 125.14 25.82 Favored 'General case' 0 CA--C 1.529 0.163 0 O-C-N 121.477 -0.765 . . . . 1.0 109.36 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -99.1 143.13 29.71 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.508 -0.745 . . . . 1.0 109.367 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -157.0 113.9 3.06 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 121.529 -0.732 . . . . 1.0 109.503 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.423 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.9 p-10 -111.54 60.27 0.62 Allowed 'General case' 0 CA--C 1.533 0.321 0 O-C-N 121.492 -0.755 . . . . 1.0 109.39 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 67.7 p -99.8 -56.64 2.33 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.356 -0.84 . . . . 1.0 109.569 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.484 HG12 ' N ' ' A' ' 39' ' ' ARG . 36.5 t -98.23 161.88 2.87 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.22 0 O-C-N 121.485 -0.76 . . . . 1.0 109.425 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.484 ' N ' HG12 ' A' ' 38' ' ' VAL . 4.0 mpt_? -104.95 173.59 6.24 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.506 -0.746 . . . . 1.0 109.448 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.31 -45.53 3.06 Favored Glycine 0 CA--C 1.529 0.936 0 N-CA-C 109.477 -1.449 . . . . 1.0 109.477 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.6 m -79.37 169.52 20.01 Favored Pre-proline 0 CA--C 1.536 0.413 0 O-C-N 121.56 -0.965 . . . . 1.0 109.321 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -87.42 127.84 2.47 Favored 'Trans proline' 0 C--N 1.35 0.657 0 C-N-CA 124.805 3.67 . . . . 1.0 109.987 179.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.423 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 16.6 m0 -74.6 -38.54 62.58 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.457 -0.777 . . . . 1.0 109.918 -179.439 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 8.3 t -89.59 109.15 20.13 Favored 'General case' 0 CA--C 1.533 0.318 0 O-C-N 121.352 -0.842 . . . . 1.0 109.609 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.419 ' CD1' ' N ' ' A' ' 45' ' ' PHE . 4.9 p90 -135.65 -178.69 5.24 Favored 'General case' 0 CA--C 1.535 0.397 0 O-C-N 121.415 -0.803 . . . . 1.0 109.463 179.708 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.402 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 18.6 m-85 -90.68 167.1 17.17 Favored Pre-proline 0 CA--C 1.536 0.426 0 O-C-N 121.487 -0.758 . . . . 1.0 109.592 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -91.23 148.65 3.66 Favored 'Trans proline' 0 C--N 1.35 0.628 0 C-N-CA 124.998 3.799 . . . . 1.0 110.461 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.6 m120 . . . . . 0 C--N 1.332 -0.173 0 N-CA-C 109.126 -0.694 . . . . 1.0 109.126 179.664 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.531 0.247 0 N-CA-C 109.53 -0.545 . . . . 1.0 109.53 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 74.0 m -107.04 19.98 19.67 Favored 'General case' 0 CA--C 1.532 0.277 0 O-C-N 121.539 -0.725 . . . . 1.0 109.548 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.611 HG23 ' O ' ' A' ' 8' ' ' THR . 4.8 t -82.89 94.87 7.79 Favored 'General case' 0 CA--C 1.532 0.286 0 O-C-N 121.456 -0.777 . . . . 1.0 109.749 -179.628 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.599 HG11 ' O ' ' A' ' 13' ' ' GLU . 39.8 t -122.16 155.04 26.95 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 O-C-N 121.526 -0.734 . . . . 1.0 109.035 179.639 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -81.23 137.49 49.08 Favored Pre-proline 0 CA--C 1.539 0.533 0 O-C-N 121.387 -0.82 . . . . 1.0 109.378 -179.731 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.456 ' HB3' HG11 ' A' ' 41' ' ' VAL . 18.4 Cg_exo -35.39 -36.41 0.15 Allowed 'Trans proline' 0 N--CA 1.488 1.159 1 C-N-CA 125.398 4.065 . . . . 1.0 111.266 -179.957 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 19.6 mtp180 -74.47 -49.91 20.4 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.529 -0.732 . . . . 1.0 109.674 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.599 ' O ' HG11 ' A' ' 9' ' ' VAL . 7.7 mm-40 -81.38 27.64 0.41 Allowed 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.481 -0.762 . . . . 1.0 109.808 -179.756 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 32.2 mtt180 -100.73 146.31 27.38 Favored 'General case' 0 N--CA 1.464 0.23 0 O-C-N 121.433 -0.792 . . . . 1.0 109.418 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 16.7 mt-30 -120.38 154.76 34.65 Favored 'General case' 0 C--N 1.332 -0.194 0 O-C-N 121.518 -0.739 . . . . 1.0 109.297 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -80.32 125.15 29.53 Favored 'General case' 0 CA--C 1.53 0.197 0 O-C-N 121.498 -0.751 . . . . 1.0 109.132 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -98.62 -23.71 15.37 Favored 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.455 -0.778 . . . . 1.0 109.303 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -167.13 -179.81 40.35 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 109.021 -1.632 . . . . 1.0 109.021 179.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.647 ' O ' HG22 ' A' ' 22' ' ' VAL . 7.8 p90 -67.68 167.17 17.31 Favored Pre-proline 0 CA--C 1.537 0.471 0 O-C-N 121.348 -1.09 . . . . 1.0 108.826 179.81 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -82.31 -29.57 1.48 Allowed 'Trans proline' 0 N--CA 1.483 0.908 0 C-N-CA 124.551 3.501 . . . . 1.0 110.914 -178.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -55.6 -15.34 8.52 Favored Glycine 0 CA--C 1.535 1.324 0 N-CA-C 110.35 -1.1 . . . . 1.0 110.35 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.647 HG22 ' O ' ' A' ' 19' ' ' PHE . 22.6 m -63.22 151.55 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 O-C-N 121.326 -1.103 . . . . 1.0 109.543 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.59 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 73.0 p -99.7 154.64 37.16 Favored Pre-proline 0 CA--C 1.536 0.422 0 N-CA-C 108.99 -0.745 . . . . 1.0 108.99 179.311 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -33.18 -55.68 0.38 Allowed 'Trans proline' 0 N--CA 1.487 1.113 1 C-N-CA 125.797 4.332 . . . . 1.0 111.862 -179.454 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 67.6 m -80.12 -27.38 39.15 Favored 'General case' 0 N--CA 1.464 0.245 0 O-C-N 121.43 -0.793 . . . . 1.0 110.565 -179.041 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLN . . . . . 0.59 ' HB2' ' H ' ' A' ' 23' ' ' THR . 10.5 mt-30 -61.46 -54.51 42.44 Favored 'General case' 0 N--CA 1.466 0.353 0 O-C-N 121.287 -0.883 . . . . 1.0 110.332 -179.47 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -77.5 -27.2 51.77 Favored 'General case' 0 CA--C 1.534 0.333 0 O-C-N 121.393 -0.817 . . . . 1.0 109.886 -179.261 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.72 -5.01 57.73 Favored 'General case' 0 CA--C 1.534 0.365 0 O-C-N 121.422 -0.799 . . . . 1.0 110.113 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -106.8 -4.39 19.36 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.316 -0.865 . . . . 1.0 109.8 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.1 tttt -89.9 -46.69 8.37 Favored 'General case' 0 CA--C 1.533 0.289 0 O-C-N 121.269 -0.895 . . . . 1.0 109.196 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 151.22 19.14 0.06 OUTLIER Glycine 0 CA--C 1.531 1.054 0 N-CA-C 109.528 -1.429 . . . . 1.0 109.528 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 85.6 m -119.17 148.96 42.51 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.423 -1.045 . . . . 1.0 109.285 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 55.9 m -77.49 115.63 17.41 Favored 'General case' 0 N--CA 1.463 0.221 0 O-C-N 121.557 -0.715 . . . . 1.0 109.083 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.436 ' CD1' ' N ' ' A' ' 35' ' ' ASP . 46.5 t80 -89.95 152.37 21.24 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.446 -0.784 . . . . 1.0 109.722 -179.618 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.436 ' N ' ' CD1' ' A' ' 34' ' ' PHE . 28.5 t70 -165.29 118.7 1.21 Allowed 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.589 -0.694 . . . . 1.0 109.309 179.724 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -120.34 51.54 1.21 Allowed 'General case' 0 CA--C 1.534 0.329 0 O-C-N 121.532 -0.73 . . . . 1.0 109.547 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -99.77 -15.59 18.4 Favored 'General case' 0 CA--C 1.533 0.317 0 O-C-N 121.308 -0.87 . . . . 1.0 109.937 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.463 HG12 ' N ' ' A' ' 39' ' ' ARG . 37.3 t -129.71 161.02 40.1 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.222 0 O-C-N 121.335 -0.853 . . . . 1.0 109.625 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.463 ' N ' HG12 ' A' ' 38' ' ' VAL . 79.5 mtt85 -111.89 166.96 10.75 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.516 -0.74 . . . . 1.0 109.379 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.55 -41.99 2.38 Favored Glycine 0 CA--C 1.53 0.986 0 N-CA-C 109.234 -1.546 . . . . 1.0 109.234 -179.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.456 HG11 ' HB3' ' A' ' 11' ' ' PRO . 28.9 m -81.1 170.63 14.75 Favored Pre-proline 0 CA--C 1.537 0.478 0 O-C-N 121.587 -0.949 . . . . 1.0 109.049 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . 0.405 ' CD ' ' HB ' ' A' ' 41' ' ' VAL . 11.7 Cg_endo -85.87 126.31 2.89 Favored 'Trans proline' 0 C--N 1.352 0.744 0 C-N-CA 124.539 3.493 . . . . 1.0 110.018 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . . . . . . . . . 33.8 m0 -75.41 -37.6 60.35 Favored 'General case' 0 N--CA 1.462 0.169 0 O-C-N 121.429 -0.794 . . . . 1.0 109.91 -179.536 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 6.5 t -90.08 113.99 25.82 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.415 -0.803 . . . . 1.0 109.539 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.416 ' CD1' ' N ' ' A' ' 45' ' ' PHE . 5.7 p90 -140.02 170.91 14.98 Favored 'General case' 0 CA--C 1.536 0.424 0 O-C-N 121.388 -0.82 . . . . 1.0 110.025 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 61.8 m-85 -77.06 170.59 15.6 Favored Pre-proline 0 CA--C 1.537 0.443 0 O-C-N 121.674 -0.641 . . . . 1.0 109.419 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -88.18 173.12 4.92 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 124.829 3.686 . . . . 1.0 110.415 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.5 m120 . . . . . 0 CA--C 1.531 0.215 0 O-C-N 121.664 -0.647 . . . . 1.0 109.346 179.905 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.7 m . . . . . 0 C--O 1.233 0.198 0 CA-C-O 121.302 0.572 . . . . 1.0 109.953 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 86.2 m -108.07 -18.53 13.76 Favored 'General case' 0 CA--C 1.534 0.336 0 O-C-N 121.444 -0.785 . . . . 1.0 109.216 179.337 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.551 HG23 ' O ' ' A' ' 8' ' ' THR . 3.1 t -68.78 101.42 1.33 Allowed 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.201 -0.937 . . . . 1.0 109.521 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.612 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.6 t -121.82 171.16 11.02 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 O-C-N 121.575 -0.703 . . . . 1.0 109.233 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.612 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -67.99 129.17 93.25 Favored Pre-proline 0 CA--C 1.539 0.541 0 O-C-N 121.355 -0.84 . . . . 1.0 109.483 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -36.95 -50.21 1.48 Allowed 'Trans proline' 0 N--CA 1.49 1.281 0 C-N-CA 125.027 3.818 . . . . 1.0 111.227 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.413 ' HD2' ' H ' ' A' ' 12' ' ' ARG . 1.2 mpt_? -70.75 -39.55 73.21 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.502 -0.749 . . . . 1.0 109.833 -179.591 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -81.42 29.24 0.37 Allowed 'General case' 0 CA--C 1.532 0.254 0 O-C-N 121.529 -0.732 . . . . 1.0 109.716 -179.72 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 37.9 mtt180 -101.41 120.63 40.57 Favored 'General case' 0 N--CA 1.464 0.248 0 O-C-N 121.417 -0.802 . . . . 1.0 109.368 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 -79.86 121.43 25.4 Favored 'General case' 0 CA--C 1.531 0.216 0 O-C-N 121.491 -0.756 . . . . 1.0 109.261 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -63.91 121.4 13.98 Favored 'General case' 0 CA--C 1.532 0.261 0 O-C-N 121.517 -0.74 . . . . 1.0 109.911 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.3 t -93.73 -20.33 20.23 Favored 'General case' 0 CA--C 1.534 0.351 0 O-C-N 121.562 -0.711 . . . . 1.0 109.272 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 179.57 177.23 47.71 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 109.178 -1.569 . . . . 1.0 109.178 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.533 ' CD2' HG13 ' A' ' 22' ' ' VAL . 8.8 p90 -65.01 167.7 9.0 Favored Pre-proline 0 CA--C 1.538 0.516 0 O-C-N 121.446 -1.032 . . . . 1.0 108.885 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.58 -30.67 1.38 Allowed 'Trans proline' 0 N--CA 1.481 0.777 0 C-N-CA 124.45 3.433 . . . . 1.0 110.802 -178.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.46 -10.04 7.22 Favored Glycine 0 CA--C 1.537 1.454 0 N-CA-C 110.307 -1.117 . . . . 1.0 110.307 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.533 HG13 ' CD2' ' A' ' 19' ' ' PHE . 24.2 m -60.66 -174.74 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 O-C-N 121.231 -1.158 . . . . 1.0 109.531 179.763 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.42 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 4.1 p -143.74 153.72 58.28 Favored Pre-proline 0 CA--C 1.537 0.45 0 O-C-N 121.515 -0.741 . . . . 1.0 109.285 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -35.85 -36.97 0.2 Allowed 'Trans proline' 0 N--CA 1.487 1.134 1 C-N-CA 125.32 4.013 . . . . 1.0 111.382 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.6 t -73.73 -47.34 40.04 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.442 -0.786 . . . . 1.0 109.756 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLN . . . . . 0.42 ' HB2' ' H ' ' A' ' 23' ' ' THR . 45.0 mt-30 -61.65 -44.73 96.42 Favored 'General case' 0 N--CA 1.466 0.327 0 O-C-N 121.436 -0.79 . . . . 1.0 109.674 -179.831 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 8.5 t -65.34 -32.63 74.37 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 121.486 -0.758 . . . . 1.0 109.382 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.6 -4.16 59.08 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 121.615 -0.678 . . . . 1.0 109.938 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -86.22 -23.55 26.39 Favored 'General case' 0 N--CA 1.464 0.258 0 O-C-N 121.218 -0.926 . . . . 1.0 109.636 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.3 tppp? -101.41 -34.94 9.38 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.379 -0.826 . . . . 1.0 109.315 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 111.49 53.62 0.52 Allowed Glycine 0 CA--C 1.529 0.955 0 N-CA-C 109.414 -1.475 . . . . 1.0 109.414 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.7 m -128.7 139.24 52.33 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.544 -0.974 . . . . 1.0 109.363 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.425 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 56.0 m -61.47 119.8 9.27 Favored 'General case' 0 N--CA 1.468 0.448 0 O-C-N 121.462 -0.774 . . . . 1.0 109.964 -179.344 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -101.51 121.56 42.19 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.423 -0.798 . . . . 1.0 109.192 179.623 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.443 ' OD1' HG23 ' A' ' 37' ' ' THR . 22.5 t0 -134.6 114.24 12.57 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.493 -0.754 . . . . 1.0 109.61 -179.783 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.424 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 5.8 p-10 -112.0 54.82 0.69 Allowed 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.503 -0.748 . . . . 1.0 109.156 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.443 HG23 ' OD1' ' A' ' 35' ' ' ASP . 39.3 p -104.01 -31.27 9.79 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.377 -0.827 . . . . 1.0 109.61 -179.724 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.41 ' HB ' HG21 ' A' ' 41' ' ' VAL . 34.9 t -114.88 151.76 16.58 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 O-C-N 121.406 -0.809 . . . . 1.0 109.478 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 21.7 mtm-85 -101.77 165.65 11.09 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 121.497 -0.752 . . . . 1.0 109.471 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.54 -33.79 2.52 Favored Glycine 0 CA--C 1.53 1.017 0 N-CA-C 109.457 -1.457 . . . . 1.0 109.457 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.41 HG21 ' HB ' ' A' ' 38' ' ' VAL . 28.5 m -88.13 169.99 12.52 Favored Pre-proline 0 CA--C 1.537 0.473 0 O-C-N 121.521 -0.988 . . . . 1.0 109.222 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -86.63 123.57 2.15 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 124.724 3.616 . . . . 1.0 110.04 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.424 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 23.9 m0 -75.3 -43.93 48.34 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.555 -0.716 . . . . 1.0 109.873 -179.515 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.6 t -88.8 109.11 19.91 Favored 'General case' 0 CA--C 1.535 0.365 0 O-C-N 121.328 -0.857 . . . . 1.0 109.915 -179.841 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.428 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 7.1 p90 -138.9 177.33 7.97 Favored 'General case' 0 CA--C 1.537 0.453 0 O-C-N 121.461 -0.775 . . . . 1.0 109.547 179.259 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.428 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 70.6 m-85 -78.78 169.32 21.22 Favored Pre-proline 0 CA--C 1.537 0.463 0 O-C-N 121.271 -0.893 . . . . 1.0 109.975 -179.568 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -92.34 167.69 2.86 Favored 'Trans proline' 0 C--N 1.352 0.711 0 C-N-CA 125.047 3.831 . . . . 1.0 110.582 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.512 HD22 HG21 ' A' ' 9' ' ' VAL . 23.1 m-20 . . . . . 0 N--CA 1.463 0.222 0 O-C-N 121.466 -0.771 . . . . 1.0 109.273 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.868 HG22 HG22 ' A' ' 8' ' ' THR . 0.9 OUTLIER . . . . . 0 CA--C 1.53 0.208 0 CA-C-O 121.148 0.499 . . . . 1.0 109.667 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.5 m -117.18 46.18 1.74 Allowed 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.463 -0.773 . . . . 1.0 109.314 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.868 HG22 HG22 ' A' ' 6' ' ' THR . 4.9 t -131.01 106.89 8.7 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.517 -0.739 . . . . 1.0 109.369 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.639 HG12 ' H ' ' A' ' 10' ' ' ALA . 21.7 t -125.09 174.09 9.82 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 O-C-N 121.369 -0.832 . . . . 1.0 109.34 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.639 ' H ' HG12 ' A' ' 9' ' ' VAL . . . -74.92 140.33 74.0 Favored Pre-proline 0 CA--C 1.538 0.508 0 O-C-N 121.479 -0.763 . . . . 1.0 109.57 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_exo -34.81 -61.24 0.25 Allowed 'Trans proline' 0 N--CA 1.488 1.171 1 C-N-CA 125.484 4.122 . . . . 1.0 111.566 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -69.93 -29.95 67.22 Favored 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.476 -0.765 . . . . 1.0 110.107 -179.287 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.541 ' O ' HG11 ' A' ' 9' ' ' VAL . 13.1 mt-10 -85.29 36.62 0.64 Allowed 'General case' 0 N--CA 1.464 0.252 0 O-C-N 121.289 -0.882 . . . . 1.0 109.642 -179.736 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.403 HH12 ' HB3' ' A' ' 35' ' ' ASP . 50.4 mtt180 -108.1 142.94 37.54 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.508 -0.745 . . . . 1.0 109.435 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -102.35 115.02 29.71 Favored 'General case' 0 N--CA 1.463 0.195 0 O-C-N 121.547 -0.721 . . . . 1.0 109.399 179.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 48.9 t30 -61.06 118.7 7.1 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 121.391 -0.818 . . . . 1.0 109.784 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 t -94.51 -18.85 21.06 Favored 'General case' 0 CA--C 1.534 0.352 0 O-C-N 121.463 -0.773 . . . . 1.0 109.247 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.43 178.2 47.8 Favored Glycine 0 CA--C 1.53 0.976 0 N-CA-C 108.967 -1.653 . . . . 1.0 108.967 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.58 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.5 p90 -65.92 167.81 10.68 Favored Pre-proline 0 CA--C 1.539 0.542 0 O-C-N 121.369 -1.077 . . . . 1.0 108.799 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -82.12 -30.09 1.38 Allowed 'Trans proline' 0 N--CA 1.483 0.855 0 C-N-CA 124.38 3.387 . . . . 1.0 110.992 -178.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -56.62 -13.73 8.33 Favored Glycine 0 CA--C 1.536 1.358 0 N-CA-C 110.36 -1.096 . . . . 1.0 110.36 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.58 HG22 ' O ' ' A' ' 19' ' ' PHE . 20.4 m -60.7 173.54 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 O-C-N 121.239 -1.153 . . . . 1.0 109.768 179.849 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 73.6 p -131.84 155.7 81.06 Favored Pre-proline 0 CA--C 1.534 0.339 0 O-C-N 121.524 -0.735 . . . . 1.0 109.143 179.773 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -35.74 -33.82 0.12 Allowed 'Trans proline' 0 N--CA 1.49 1.267 1 C-N-CA 125.354 4.036 . . . . 1.0 111.233 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 39.7 m -75.68 -47.74 24.98 Favored 'General case' 0 CA--C 1.532 0.253 0 O-C-N 121.396 -0.815 . . . . 1.0 109.956 -179.622 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -65.3 -47.25 77.25 Favored 'General case' 0 CA--C 1.533 0.307 0 O-C-N 121.468 -0.77 . . . . 1.0 109.85 -179.689 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 11.2 t -62.48 -29.86 70.84 Favored 'General case' 0 N--CA 1.464 0.269 0 O-C-N 121.408 -0.808 . . . . 1.0 109.796 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -90.52 -9.79 45.95 Favored 'General case' 0 N--CA 1.465 0.281 0 O-C-N 121.464 -0.772 . . . . 1.0 110.098 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -93.03 -5.09 51.33 Favored 'General case' 0 CA--C 1.534 0.34 0 O-C-N 121.224 -0.923 . . . . 1.0 110.028 -179.762 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 51.9 mttp -109.52 -27.28 9.51 Favored 'General case' 0 N--CA 1.464 0.246 0 O-C-N 121.337 -0.852 . . . . 1.0 109.544 -179.794 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.08 22.66 5.83 Favored Glycine 0 CA--C 1.53 0.993 0 N-CA-C 109.568 -1.413 . . . . 1.0 109.568 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 22.8 m -112.74 137.21 51.38 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.469 -1.018 . . . . 1.0 108.564 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.6 m -72.85 133.87 44.62 Favored 'General case' 0 N--CA 1.463 0.222 0 O-C-N 121.316 -0.865 . . . . 1.0 109.735 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -101.68 139.63 37.07 Favored 'General case' 0 C--O 1.232 0.163 0 O-C-N 121.626 -0.671 . . . . 1.0 109.223 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.403 ' HB3' HH12 ' A' ' 14' ' ' ARG . 9.9 t0 -148.62 102.39 3.3 Favored 'General case' 0 N--CA 1.463 0.202 0 O-C-N 121.306 -0.871 . . . . 1.0 109.591 -179.785 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.435 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 7.0 p-10 -104.9 73.93 1.1 Allowed 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.525 -0.735 . . . . 1.0 109.294 179.83 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 30.6 p -118.66 -43.6 2.68 Favored 'General case' 0 CA--C 1.53 0.177 0 O-C-N 121.43 -0.794 . . . . 1.0 109.494 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 38.2 t -110.81 153.06 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 O-C-N 121.467 -0.771 . . . . 1.0 109.287 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 7.8 mtt-85 -101.11 172.51 6.97 Favored 'General case' 0 CA--C 1.532 0.271 0 O-C-N 121.545 -0.722 . . . . 1.0 109.337 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.72 -31.14 3.06 Favored Glycine 0 CA--C 1.529 0.917 0 N-CA-C 109.501 -1.44 . . . . 1.0 109.501 -179.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.404 ' HB ' ' CD ' ' A' ' 42' ' ' PRO . 29.6 m -99.83 170.55 6.61 Favored Pre-proline 0 CA--C 1.537 0.478 0 O-C-N 121.501 -1.0 . . . . 1.0 109.129 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . 0.404 ' CD ' ' HB ' ' A' ' 41' ' ' VAL . 11.2 Cg_endo -85.64 126.41 3.01 Favored 'Trans proline' 0 N--CA 1.479 0.654 0 C-N-CA 124.506 3.471 . . . . 1.0 110.036 179.745 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.435 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 10.0 m0 -77.64 -38.89 46.91 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.555 -0.715 . . . . 1.0 109.837 -179.356 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 28.1 t -89.44 103.84 16.45 Favored 'General case' 0 CA--C 1.534 0.357 0 O-C-N 121.385 -0.822 . . . . 1.0 109.566 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.406 ' CD1' ' N ' ' A' ' 45' ' ' PHE . 5.1 p90 -132.87 177.42 7.66 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.259 -0.901 . . . . 1.0 109.881 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' TYR . . . . . 0.406 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 32.2 m-85 -74.1 169.81 17.44 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 121.61 -0.681 . . . . 1.0 109.684 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -93.35 173.16 1.85 Allowed 'Trans proline' 0 C--N 1.35 0.643 0 C-N-CA 125.217 3.944 . . . . 1.0 110.612 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 . . . . . 0 CA--C 1.531 0.241 0 O-C-N 121.54 -0.725 . . . . 1.0 109.38 179.989 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 . . . . . 0 CA--C 1.531 0.232 0 N-CA-C 109.414 -0.587 . . . . 1.0 109.414 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -165.0 166.45 19.33 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.495 -0.753 . . . . 1.0 109.535 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -110.56 171.26 7.56 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.487 -0.758 . . . . 1.0 109.385 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 15.6 p -132.31 144.09 50.33 Favored 'General case' 0 CA--C 1.529 0.165 0 O-C-N 121.531 -0.73 . . . . 1.0 109.56 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -84.41 137.5 33.35 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.559 -0.713 . . . . 1.0 109.141 179.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.1 m -149.62 124.34 9.83 Favored 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.575 -0.703 . . . . 1.0 109.715 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 75.1 m -113.22 -14.19 12.89 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.498 -0.751 . . . . 1.0 109.594 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.548 HG23 ' O ' ' A' ' 8' ' ' THR . 2.8 t -71.19 96.44 1.38 Allowed 'General case' 0 CA--C 1.53 0.211 0 O-C-N 121.286 -0.884 . . . . 1.0 109.658 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.584 HG12 ' N ' ' A' ' 10' ' ' ALA . 39.4 t -119.35 168.98 11.01 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 O-C-N 121.465 -0.772 . . . . 1.0 109.074 179.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.891 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -65.21 121.27 73.53 Favored Pre-proline 0 CA--C 1.542 0.65 0 O-C-N 121.386 -0.821 . . . . 1.0 109.17 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.419 ' HD2' ' HA ' ' A' ' 10' ' ' ALA . 19.1 Cg_exo -36.95 -47.43 1.46 Allowed 'Trans proline' 0 N--CA 1.49 1.281 0 C-N-CA 124.917 3.745 . . . . 1.0 111.334 -179.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -75.88 -39.44 56.44 Favored 'General case' 0 N--CA 1.463 0.208 0 O-C-N 121.466 -0.771 . . . . 1.0 109.745 -179.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.891 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 28.0 mt-10 -84.33 38.38 0.67 Allowed 'General case' 0 N--CA 1.462 0.162 0 O-C-N 121.399 -0.813 . . . . 1.0 109.565 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 18.6 mtt180 -104.82 145.64 30.1 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.446 -0.784 . . . . 1.0 109.407 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 10.1 mp0 -94.69 120.6 35.17 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 121.542 -0.724 . . . . 1.0 109.36 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -63.63 120.34 11.59 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.457 -0.777 . . . . 1.0 109.817 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.42 ' HA ' ' CE2' ' A' ' 46' ' ' TYR . 44.3 t -94.65 -17.77 21.97 Favored 'General case' 0 CA--C 1.535 0.385 0 O-C-N 121.574 -0.704 . . . . 1.0 109.329 179.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 177.15 175.44 44.43 Favored Glycine 0 CA--C 1.529 0.939 0 N-CA-C 109.404 -1.479 . . . . 1.0 109.404 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.567 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.5 p90 -64.61 167.95 7.84 Favored Pre-proline 0 CA--C 1.538 0.512 0 O-C-N 121.383 -1.069 . . . . 1.0 109.063 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.33 -31.36 1.25 Allowed 'Trans proline' 0 N--CA 1.483 0.905 0 C-N-CA 124.341 3.361 . . . . 1.0 110.643 -178.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.75 -7.91 6.95 Favored Glycine 0 CA--C 1.537 1.438 0 N-CA-C 110.294 -1.122 . . . . 1.0 110.294 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.567 HG22 ' O ' ' A' ' 19' ' ' PHE . 17.4 m -60.17 -178.97 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 O-C-N 121.208 -1.172 . . . . 1.0 109.742 179.762 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.433 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 12.0 p -138.5 155.08 73.88 Favored Pre-proline 0 CA--C 1.536 0.43 0 O-C-N 121.513 -0.742 . . . . 1.0 109.276 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -36.05 -36.45 0.2 Allowed 'Trans proline' 0 N--CA 1.488 1.187 1 C-N-CA 125.368 4.045 . . . . 1.0 111.316 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 42.1 t -73.99 -46.07 46.1 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.405 -0.809 . . . . 1.0 109.874 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLN . . . . . 0.433 ' HB2' ' H ' ' A' ' 23' ' ' THR . 38.0 mt-30 -60.57 -48.63 80.91 Favored 'General case' 0 N--CA 1.464 0.258 0 O-C-N 121.468 -0.77 . . . . 1.0 109.988 -179.808 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.7 t -65.11 -27.73 68.95 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.409 -0.807 . . . . 1.0 109.497 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.34 -5.26 58.42 Favored 'General case' 0 CA--C 1.535 0.38 0 O-C-N 121.547 -0.721 . . . . 1.0 109.846 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.0 t-20 -70.83 -49.45 46.17 Favored 'General case' 0 N--CA 1.463 0.181 0 O-C-N 121.408 -0.808 . . . . 1.0 109.363 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.441 ' HG2' ' H ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -83.64 -44.7 14.27 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.534 -0.729 . . . . 1.0 109.432 179.889 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.441 ' H ' ' HG2' ' A' ' 30' ' ' LYS . . . 125.65 32.45 0.76 Allowed Glycine 0 CA--C 1.531 1.075 0 N-CA-C 109.958 -1.257 . . . . 1.0 109.958 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.5 m -92.26 144.7 25.13 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.43 -1.041 . . . . 1.0 109.301 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.402 ' O ' ' CD1' ' A' ' 45' ' ' PHE . 60.0 m -66.51 115.4 6.35 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.462 -0.774 . . . . 1.0 109.516 -179.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -94.6 132.01 39.76 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.38 -0.825 . . . . 1.0 109.33 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -144.2 111.12 5.74 Favored 'General case' 0 CA--C 1.53 0.19 0 O-C-N 121.425 -0.797 . . . . 1.0 109.481 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.434 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.0 p-10 -115.34 70.42 0.74 Allowed 'General case' 0 CA--C 1.534 0.334 0 O-C-N 121.509 -0.745 . . . . 1.0 109.414 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 43.9 p -114.45 -39.35 3.84 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.429 -0.794 . . . . 1.0 109.471 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.577 HG12 ' N ' ' A' ' 39' ' ' ARG . 39.9 t -111.95 167.93 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 O-C-N 121.519 -0.738 . . . . 1.0 109.401 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.577 ' N ' HG12 ' A' ' 38' ' ' VAL . 4.9 ttm180 -113.31 175.99 5.22 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.432 -0.793 . . . . 1.0 109.432 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.51 -37.33 2.25 Favored Glycine 0 CA--C 1.53 0.996 0 N-CA-C 109.41 -1.476 . . . . 1.0 109.41 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 28.9 m -94.66 170.39 8.16 Favored Pre-proline 0 CA--C 1.536 0.431 0 O-C-N 121.571 -0.958 . . . . 1.0 109.174 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_endo -85.68 139.31 6.57 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 124.628 3.552 . . . . 1.0 109.937 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.434 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 11.2 m0 -89.22 -41.05 12.44 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 121.502 -0.749 . . . . 1.0 110.028 -179.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 18.5 t -89.31 107.43 19.06 Favored 'General case' 0 N--CA 1.465 0.309 0 O-C-N 121.426 -0.797 . . . . 1.0 109.719 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.417 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 9.5 p90 -135.05 173.81 11.31 Favored 'General case' 0 CA--C 1.537 0.479 0 O-C-N 121.346 -0.846 . . . . 1.0 109.633 179.59 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.42 ' CE2' ' HA ' ' A' ' 17' ' ' CYS . 90.8 m-85 -82.11 167.38 31.04 Favored Pre-proline 0 CA--C 1.536 0.419 0 O-C-N 121.493 -0.755 . . . . 1.0 109.716 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -89.65 161.52 5.26 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 124.998 3.799 . . . . 1.0 110.424 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -136.62 100.09 4.24 Favored 'General case' 0 CA--C 1.531 0.216 0 O-C-N 121.549 -0.719 . . . . 1.0 109.388 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 41.3 p -77.68 116.04 17.91 Favored 'General case' 0 CA--C 1.53 0.209 0 O-C-N 121.503 -0.748 . . . . 1.0 109.476 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 60.2 mt -98.82 144.49 11.66 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 O-C-N 121.527 -0.733 . . . . 1.0 109.374 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -80.94 130.05 34.84 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.479 -0.763 . . . . 1.0 109.528 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.607 HG23 ' O ' ' A' ' 52' ' ' VAL . 27.9 m -126.85 79.38 72.44 Favored Pre-proline 0 CA--C 1.539 0.532 0 O-C-N 121.421 -0.799 . . . . 1.0 109.456 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.434 ' N ' ' CD ' ' A' ' 54' ' ' PRO . 16.7 Cg_exo -34.85 -46.59 0.59 Allowed 'Trans proline' 0 N--CA 1.487 1.127 0 C-N-CA 125.214 3.943 . . . . 1.0 111.862 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.434 ' CD ' ' N ' ' A' ' 53' ' ' PRO . 19.3 Cg_endo -91.28 121.43 0.68 Allowed 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 124.737 3.625 . . . . 1.0 110.418 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.0 tt0 -80.26 141.59 35.4 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.457 -0.777 . . . . 1.0 109.412 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -103.09 175.08 5.59 Favored 'General case' 0 N--CA 1.463 0.199 0 O-C-N 121.499 -0.751 . . . . 1.0 109.463 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -108.76 141.96 40.0 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.569 -0.707 . . . . 1.0 109.452 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.7 p -134.46 179.32 6.35 Favored 'General case' 0 CA--C 1.53 0.189 0 O-C-N 121.526 -0.734 . . . . 1.0 109.473 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -76.47 137.7 39.83 Favored 'General case' 0 N--CA 1.463 0.177 0 O-C-N 121.501 -0.749 . . . . 1.0 109.455 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 25.9 t80 . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.983 -1.008 . . . . 1.0 109.417 -179.964 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 . . . . . 0 CA--C 1.529 0.162 0 N-CA-C 109.419 -0.585 . . . . 1.0 109.419 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -158.79 33.69 0.22 Allowed 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.392 -0.818 . . . . 1.0 109.491 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 9.7 mp0 -85.67 102.66 13.79 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.497 -0.752 . . . . 1.0 109.5 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 17.0 p -146.83 -168.2 2.97 Favored 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.575 -0.703 . . . . 1.0 109.404 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -86.39 137.24 32.72 Favored 'General case' 0 CA--C 1.531 0.213 0 O-C-N 121.462 -0.774 . . . . 1.0 109.441 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.569 HG22 HG22 ' A' ' 8' ' ' THR . 0.8 OUTLIER -128.11 146.74 50.6 Favored 'General case' 0 CA--C 1.53 0.181 0 O-C-N 121.544 -0.722 . . . . 1.0 109.383 179.832 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.411 ' HB3' ' CZ ' ' A' ' 45' ' ' PHE . 62.8 m -125.91 31.49 5.46 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.488 -0.758 . . . . 1.0 109.022 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.569 HG22 HG22 ' A' ' 6' ' ' THR . 5.1 t -96.08 118.9 33.58 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.657 -0.652 . . . . 1.0 109.556 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.435 HG11 ' O ' ' A' ' 13' ' ' GLU . 34.2 t -149.92 156.21 7.24 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.206 0 O-C-N 121.495 -0.753 . . . . 1.0 109.236 179.828 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -74.07 136.72 76.04 Favored Pre-proline 0 CA--C 1.54 0.59 0 O-C-N 121.482 -0.761 . . . . 1.0 109.308 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -35.05 -41.05 0.28 Allowed 'Trans proline' 0 N--CA 1.488 1.171 1 C-N-CA 125.361 4.041 . . . . 1.0 111.305 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 41.7 mtt180 -80.95 -44.61 17.95 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.543 -0.723 . . . . 1.0 109.759 -179.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.435 ' O ' HG11 ' A' ' 9' ' ' VAL . 19.9 mt-10 -74.56 10.46 1.34 Allowed 'General case' 0 CA--C 1.533 0.326 0 O-C-N 121.417 -0.802 . . . . 1.0 109.975 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 24.2 mtt180 -81.25 124.37 29.26 Favored 'General case' 0 CA--C 1.529 0.164 0 O-C-N 121.34 -0.85 . . . . 1.0 109.361 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 25.5 mm100 -92.56 126.76 37.79 Favored 'General case' 0 N--CA 1.463 0.197 0 O-C-N 121.463 -0.773 . . . . 1.0 109.025 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.2 t-20 -72.23 116.68 12.95 Favored 'General case' 0 CA--C 1.532 0.286 0 O-C-N 121.604 -0.685 . . . . 1.0 109.942 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -83.55 -6.97 59.6 Favored 'General case' 0 CA--C 1.537 0.447 0 O-C-N 121.53 -0.731 . . . . 1.0 109.208 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.84 170.0 37.42 Favored Glycine 0 CA--C 1.532 1.097 0 N-CA-C 108.353 -1.899 . . . . 1.0 108.353 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.442 ' O ' HG22 ' A' ' 22' ' ' VAL . 7.5 p90 -62.52 168.33 4.35 Favored Pre-proline 0 CA--C 1.54 0.56 0 O-C-N 121.208 -1.172 . . . . 1.0 109.043 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -81.36 -30.25 1.61 Allowed 'Trans proline' 0 N--CA 1.481 0.785 0 C-N-CA 124.304 3.336 . . . . 1.0 110.677 -178.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.23 -6.82 8.12 Favored Glycine 0 CA--C 1.536 1.374 0 N-CA-C 110.052 -1.219 . . . . 1.0 110.052 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.442 HG22 ' O ' ' A' ' 19' ' ' PHE . 29.2 m -60.25 -176.31 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 O-C-N 121.157 -1.202 . . . . 1.0 109.816 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.419 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 10.6 p -137.38 155.95 75.36 Favored Pre-proline 0 CA--C 1.535 0.368 0 O-C-N 121.51 -0.744 . . . . 1.0 109.13 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_exo -37.47 -42.24 1.08 Allowed 'Trans proline' 0 N--CA 1.488 1.176 0 C-N-CA 125.188 3.926 . . . . 1.0 111.001 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 80.3 p -69.45 -42.76 74.51 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.524 -0.735 . . . . 1.0 110.118 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLN . . . . . 0.419 ' HB2' ' H ' ' A' ' 23' ' ' THR . 13.9 mm100 -65.61 -53.92 34.91 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.401 -0.812 . . . . 1.0 109.909 -179.562 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 18.9 t -62.04 -19.71 63.17 Favored 'General case' 0 CA--C 1.534 0.357 0 O-C-N 121.409 -0.807 . . . . 1.0 109.934 -179.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -100.54 -3.56 30.41 Favored 'General case' 0 CA--C 1.535 0.378 0 O-C-N 121.356 -0.84 . . . . 1.0 110.154 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -73.78 -44.07 57.09 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.395 -0.815 . . . . 1.0 109.855 -179.476 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.9 tttm -86.26 -41.39 14.64 Favored 'General case' 0 N--CA 1.462 0.154 0 O-C-N 121.43 -0.794 . . . . 1.0 109.662 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 127.27 19.71 1.88 Allowed Glycine 0 CA--C 1.53 1.031 0 N-CA-C 109.473 -1.451 . . . . 1.0 109.473 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 60.8 m -77.39 140.42 39.91 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.43 -1.041 . . . . 1.0 109.028 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 84.5 m -66.87 123.09 19.2 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.414 -0.803 . . . . 1.0 109.647 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -96.51 147.78 23.49 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.439 -0.788 . . . . 1.0 109.162 179.653 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -161.72 135.12 6.38 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.384 -0.822 . . . . 1.0 109.486 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -133.17 38.24 3.34 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.515 -0.741 . . . . 1.0 109.471 179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 59.9 p -72.05 -58.7 3.22 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.48 -0.763 . . . . 1.0 109.541 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.0 t -110.07 138.12 39.26 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 O-C-N 121.429 -0.794 . . . . 1.0 109.408 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -83.62 178.03 8.15 Favored 'General case' 0 CA--C 1.53 0.19 0 O-C-N 121.496 -0.752 . . . . 1.0 109.247 179.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.56 -45.73 3.15 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 109.339 -1.504 . . . . 1.0 109.339 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.414 HG22 ' H ' ' A' ' 41' ' ' VAL . 26.7 m -84.43 157.33 61.84 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.647 -0.914 . . . . 1.0 109.325 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -59.63 129.24 30.06 Favored 'Trans proline' 0 N--CA 1.488 1.164 0 C-N-CA 124.164 3.243 . . . . 1.0 110.308 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . . . . . . . . . 40.4 m0 -87.27 -45.87 10.22 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.521 -0.737 . . . . 1.0 109.173 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 27.4 t -89.92 110.42 21.37 Favored 'General case' 0 CA--C 1.534 0.338 0 O-C-N 121.493 -0.755 . . . . 1.0 108.978 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.433 ' CD1' ' N ' ' A' ' 45' ' ' PHE . 5.2 p90 -134.1 175.87 9.09 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 121.302 -0.874 . . . . 1.0 110.257 -179.371 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.41 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 21.5 m-85 -82.18 171.33 12.18 Favored Pre-proline 0 CA--C 1.537 0.47 0 O-C-N 121.523 -0.735 . . . . 1.0 109.522 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -90.84 -166.39 0.19 Allowed 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 124.939 3.759 . . . . 1.0 110.102 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -158.42 100.51 1.66 Allowed 'General case' 0 N--CA 1.463 0.192 0 O-C-N 121.478 -0.763 . . . . 1.0 109.509 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 33.5 p -80.7 97.89 7.48 Favored 'General case' 0 CA--C 1.532 0.265 0 O-C-N 121.429 -0.795 . . . . 1.0 109.306 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.526 HG22 ' N ' ' A' ' 51' ' ' ASP . 63.4 mt -136.92 165.08 28.89 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 O-C-N 121.443 -0.786 . . . . 1.0 109.374 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.526 ' N ' HG22 ' A' ' 50' ' ' ILE . 2.2 t0 -107.29 -166.66 1.18 Allowed 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.433 -0.792 . . . . 1.0 109.443 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.1 m -130.8 160.36 66.89 Favored Pre-proline 0 CA--C 1.536 0.427 0 O-C-N 121.502 -0.749 . . . . 1.0 109.379 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -91.59 154.46 3.54 Favored 'Trans proline' 0 CA--C 1.537 0.642 0 C-N-CA 124.956 3.77 . . . . 1.0 110.359 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -34.47 -46.33 0.52 Allowed 'Trans proline' 0 N--CA 1.489 1.234 1 C-N-CA 125.567 4.178 . . . . 1.0 111.18 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -134.63 165.73 24.56 Favored 'General case' 0 CA--C 1.53 0.209 0 O-C-N 121.532 -0.73 . . . . 1.0 109.382 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -111.46 117.47 33.12 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.436 -0.79 . . . . 1.0 109.37 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -143.84 108.13 4.79 Favored 'General case' 0 N--CA 1.463 0.215 0 O-C-N 121.47 -0.769 . . . . 1.0 109.409 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.7 m -141.7 122.23 14.16 Favored 'General case' 0 CA--C 1.53 0.196 0 O-C-N 121.521 -0.737 . . . . 1.0 109.466 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 20.2 tp10 -128.08 110.43 12.47 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.455 -0.778 . . . . 1.0 109.501 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 41.8 t80 . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.018 -0.991 . . . . 1.0 109.412 -179.964 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 . . . . . 0 CA--C 1.53 0.182 0 N-CA-C 109.478 -0.564 . . . . 1.0 109.478 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -117.49 88.42 2.91 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 121.483 -0.76 . . . . 1.0 109.507 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 2.5 mp0 -82.0 165.08 21.0 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.52 -0.737 . . . . 1.0 109.352 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.13 157.44 43.12 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.486 -0.759 . . . . 1.0 109.409 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -75.37 171.29 14.49 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 121.494 -0.754 . . . . 1.0 109.459 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.7 m -150.27 93.79 2.04 Favored 'General case' 0 CA--C 1.532 0.263 0 O-C-N 121.51 -0.744 . . . . 1.0 109.763 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 90.5 m -89.62 -15.82 31.91 Favored 'General case' 0 CA--C 1.533 0.326 0 O-C-N 121.311 -0.868 . . . . 1.0 109.493 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.56 HG23 ' O ' ' A' ' 8' ' ' THR . 4.8 t -71.31 112.45 7.45 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.429 -0.795 . . . . 1.0 109.907 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.552 HG12 ' N ' ' A' ' 10' ' ' ALA . 42.0 t -127.87 167.33 23.08 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.264 0 N-CA-C 108.84 -0.8 . . . . 1.0 108.84 179.626 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.758 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -71.67 125.41 91.7 Favored Pre-proline 0 CA--C 1.542 0.644 0 O-C-N 121.36 -0.838 . . . . 1.0 109.118 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.425 ' HB3' HG11 ' A' ' 41' ' ' VAL . 18.7 Cg_exo -36.84 -50.36 1.43 Allowed 'Trans proline' 0 N--CA 1.489 1.263 0 C-N-CA 124.899 3.732 . . . . 1.0 111.209 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.401 ' H ' ' HG2' ' A' ' 12' ' ' ARG . 18.7 ptt180 -73.8 -38.86 64.48 Favored 'General case' 0 N--CA 1.463 0.195 0 O-C-N 121.487 -0.758 . . . . 1.0 109.763 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.758 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 20.3 mt-10 -92.29 43.03 1.12 Allowed 'General case' 0 CA--C 1.532 0.253 0 O-C-N 121.405 -0.81 . . . . 1.0 109.574 -179.689 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 15.0 mtt180 -105.71 131.98 52.4 Favored 'General case' 0 CA--C 1.531 0.235 0 O-C-N 121.405 -0.81 . . . . 1.0 109.437 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -79.57 107.64 12.5 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 108.557 -0.905 . . . . 1.0 108.557 179.456 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 29.5 t30 -61.98 108.54 1.06 Allowed 'General case' 0 N--CA 1.464 0.245 0 O-C-N 121.557 -0.714 . . . . 1.0 110.085 -179.336 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.461 ' H ' ' HA ' ' A' ' 45' ' ' PHE . 49.5 t -76.78 -21.75 54.71 Favored 'General case' 0 CA--C 1.533 0.318 0 O-C-N 121.5 -0.75 . . . . 1.0 109.229 179.426 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -175.46 179.56 46.6 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 109.145 -1.582 . . . . 1.0 109.145 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.528 ' CD2' HG13 ' A' ' 22' ' ' VAL . 8.9 p90 -64.81 167.49 9.13 Favored Pre-proline 0 CA--C 1.538 0.489 0 O-C-N 121.398 -1.06 . . . . 1.0 109.0 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -81.19 -30.93 1.42 Allowed 'Trans proline' 0 N--CA 1.482 0.806 0 C-N-CA 124.351 3.367 . . . . 1.0 110.715 -178.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.84 -8.41 7.89 Favored Glycine 0 CA--C 1.537 1.457 0 N-CA-C 110.305 -1.118 . . . . 1.0 110.305 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.528 HG13 ' CD2' ' A' ' 19' ' ' PHE . 25.7 m -60.62 -171.21 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 O-C-N 121.194 -1.18 . . . . 1.0 109.864 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.51 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 19.9 p -150.09 157.27 37.64 Favored Pre-proline 0 CA--C 1.534 0.361 0 N-CA-C 109.18 -0.674 . . . . 1.0 109.18 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_exo -34.91 -36.37 0.12 Allowed 'Trans proline' 0 N--CA 1.488 1.193 1 C-N-CA 125.599 4.199 . . . . 1.0 111.383 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.4 t -76.41 -47.21 23.93 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.434 -0.791 . . . . 1.0 109.865 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLN . . . . . 0.51 ' HB2' ' H ' ' A' ' 23' ' ' THR . 2.2 mm100 -60.93 -44.05 97.76 Favored 'General case' 0 N--CA 1.465 0.293 0 O-C-N 121.433 -0.792 . . . . 1.0 109.925 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 7.5 t -64.72 -33.4 75.87 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.443 -0.786 . . . . 1.0 109.346 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.48 -5.55 59.28 Favored 'General case' 0 CA--C 1.534 0.358 0 O-C-N 121.556 -0.715 . . . . 1.0 109.935 179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 12.2 t-20 -64.84 -32.6 74.37 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.32 -0.862 . . . . 1.0 109.618 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.3 mtmm -105.79 -39.52 6.02 Favored 'General case' 0 C--N 1.332 -0.183 0 O-C-N 121.456 -0.777 . . . . 1.0 109.403 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 125.6 27.55 1.16 Allowed Glycine 0 CA--C 1.53 1.012 0 N-CA-C 109.862 -1.295 . . . . 1.0 109.862 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.8 m -91.09 147.69 22.89 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.326 -1.103 . . . . 1.0 109.16 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.455 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 57.4 m -70.33 139.6 52.06 Favored 'General case' 0 CA--C 1.532 0.266 0 O-C-N 121.371 -0.831 . . . . 1.0 109.333 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -119.21 119.7 34.87 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.463 -0.773 . . . . 1.0 109.332 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -132.67 120.1 21.29 Favored 'General case' 0 CA--C 1.529 0.167 0 O-C-N 121.533 -0.729 . . . . 1.0 109.667 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.419 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.0 p-10 -116.32 77.27 1.08 Allowed 'General case' 0 N--CA 1.463 0.197 0 O-C-N 121.442 -0.786 . . . . 1.0 109.233 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 82.2 p -114.54 -38.37 4.05 Favored 'General case' 0 CA--C 1.53 0.183 0 O-C-N 121.446 -0.784 . . . . 1.0 109.543 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 38.3 t -117.36 148.51 20.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.205 0 O-C-N 121.442 -0.786 . . . . 1.0 109.411 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 22.5 mtp180 -94.65 -179.08 4.76 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.5 -0.75 . . . . 1.0 109.5 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.07 6.71 13.89 Favored Glycine 0 CA--C 1.532 1.149 0 N-CA-C 109.992 -1.243 . . . . 1.0 109.992 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.425 HG11 ' HB3' ' A' ' 11' ' ' PRO . 30.0 m -130.59 169.35 13.81 Favored Pre-proline 0 CA--C 1.536 0.415 0 O-C-N 121.359 -1.083 . . . . 1.0 109.203 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -87.74 130.03 2.63 Favored 'Trans proline' 0 N--CA 1.48 0.708 0 C-N-CA 124.693 3.595 . . . . 1.0 110.117 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.419 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.3 m0 -91.95 -47.83 7.09 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.505 -0.747 . . . . 1.0 109.733 -179.567 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 18.6 t -78.07 107.81 10.9 Favored 'General case' 0 CA--C 1.531 0.225 0 O-C-N 121.527 -0.733 . . . . 1.0 109.646 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.461 ' HA ' ' H ' ' A' ' 17' ' ' CYS . 3.3 p90 -139.42 -175.93 4.36 Favored 'General case' 0 N--CA 1.465 0.314 0 O-C-N 121.515 -0.74 . . . . 1.0 109.393 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -91.57 163.85 26.68 Favored Pre-proline 0 CA--C 1.537 0.477 0 O-C-N 121.411 -0.806 . . . . 1.0 110.029 -179.404 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -90.18 172.84 3.5 Favored 'Trans proline' 0 C--N 1.352 0.744 0 C-N-CA 124.97 3.78 . . . . 1.0 110.718 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -143.35 86.38 1.9 Allowed 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.433 -0.792 . . . . 1.0 109.412 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 34.2 p -67.43 131.59 45.99 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.465 -0.772 . . . . 1.0 109.417 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 54.7 mt -118.8 140.36 42.86 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 O-C-N 121.412 -0.805 . . . . 1.0 109.306 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -143.08 166.62 24.17 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.443 -0.786 . . . . 1.0 109.518 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.573 HG23 ' O ' ' A' ' 52' ' ' VAL . 30.8 m -69.79 111.07 7.79 Favored Pre-proline 0 CA--C 1.539 0.546 0 O-C-N 121.543 -0.723 . . . . 1.0 109.462 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -93.3 176.88 1.39 Allowed 'Trans proline' 0 C--N 1.353 0.768 0 C-N-CA 124.755 3.637 . . . . 1.0 110.44 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.411 ' HD2' ' H ' ' A' ' 55' ' ' GLU . 18.7 Cg_endo -92.11 -54.77 0.02 OUTLIER 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 125.177 3.918 . . . . 1.0 110.175 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.411 ' H ' ' HD2' ' A' ' 54' ' ' PRO . 1.1 mt-10 -137.71 101.68 4.53 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.547 -0.721 . . . . 1.0 109.331 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -88.45 108.17 19.24 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.487 -0.758 . . . . 1.0 109.59 -179.813 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 -147.16 134.35 20.52 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.567 -0.708 . . . . 1.0 109.271 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 72.6 m -137.1 172.82 12.43 Favored 'General case' 0 N--CA 1.464 0.228 0 O-C-N 121.542 -0.724 . . . . 1.0 109.461 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 14.6 tm-20 -96.6 119.79 35.73 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.499 -0.751 . . . . 1.0 109.43 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.929 -1.034 . . . . 1.0 109.495 179.909 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 . . . . . 0 CA--C 1.531 0.216 0 N-CA-C 109.498 -0.556 . . . . 1.0 109.498 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -155.65 37.59 0.37 Allowed 'General case' 0 N--CA 1.463 0.195 0 O-C-N 121.479 -0.763 . . . . 1.0 109.581 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 14.9 mp0 -84.33 113.76 21.37 Favored 'General case' 0 CA--C 1.53 0.175 0 O-C-N 121.351 -0.843 . . . . 1.0 109.347 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 75.8 p -108.94 133.51 52.85 Favored 'General case' 0 C--N 1.332 -0.189 0 O-C-N 121.449 -0.782 . . . . 1.0 109.563 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -85.59 133.43 34.05 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.863 -0.792 . . . . 1.0 108.863 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.4 m -150.23 114.1 5.05 Favored 'General case' 0 CA--C 1.53 0.176 0 O-C-N 121.469 -0.769 . . . . 1.0 110.161 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 96.2 m -108.54 -18.14 13.8 Favored 'General case' 0 CA--C 1.536 0.408 0 O-C-N 121.503 -0.748 . . . . 1.0 109.184 179.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.596 HG23 ' O ' ' A' ' 8' ' ' THR . 5.2 t -70.15 108.35 4.09 Favored 'General case' 0 CA--C 1.533 0.297 0 O-C-N 121.106 -0.996 . . . . 1.0 109.329 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.733 HG21 HD22 ' A' ' 48' ' ' ASN . 26.7 t -132.99 173.46 14.8 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.248 0 O-C-N 121.334 -0.854 . . . . 1.0 109.323 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.632 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -69.14 122.81 86.62 Favored Pre-proline 0 CA--C 1.539 0.542 0 O-C-N 121.461 -0.774 . . . . 1.0 109.235 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.559 ' HB3' HG11 ' A' ' 41' ' ' VAL . 18.3 Cg_exo -37.62 -33.92 0.24 Allowed 'Trans proline' 0 N--CA 1.488 1.198 0 C-N-CA 124.774 3.65 . . . . 1.0 111.229 -179.799 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 15.2 ptt180 -78.55 -46.88 18.42 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.469 -0.769 . . . . 1.0 109.766 -179.703 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 21.0 mm-40 -82.73 40.97 0.7 Allowed 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.405 -0.809 . . . . 1.0 109.434 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 54.0 mtt180 -104.1 142.95 33.57 Favored 'General case' 0 C--N 1.331 -0.214 0 O-C-N 121.526 -0.734 . . . . 1.0 109.569 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 mm-40 -92.59 111.33 22.88 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.426 -0.796 . . . . 1.0 109.195 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -60.33 110.34 1.22 Allowed 'General case' 0 CA--C 1.533 0.303 0 O-C-N 121.362 -0.836 . . . . 1.0 110.121 -179.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.4 t -86.65 -16.4 36.74 Favored 'General case' 0 CA--C 1.533 0.323 0 O-C-N 121.485 -0.76 . . . . 1.0 109.442 179.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.64 179.28 44.19 Favored Glycine 0 CA--C 1.531 1.075 0 N-CA-C 109.506 -1.438 . . . . 1.0 109.506 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.592 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.6 p90 -65.13 168.0 8.56 Favored Pre-proline 0 CA--C 1.538 0.492 0 O-C-N 121.468 -1.019 . . . . 1.0 109.018 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.43 -30.98 1.32 Allowed 'Trans proline' 0 N--CA 1.484 0.918 0 C-N-CA 124.4 3.4 . . . . 1.0 110.671 -178.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.42 -10.28 7.51 Favored Glycine 0 CA--C 1.537 1.41 0 N-CA-C 110.356 -1.098 . . . . 1.0 110.356 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.592 HG22 ' O ' ' A' ' 19' ' ' PHE . 18.0 m -60.74 169.71 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 O-C-N 121.205 -1.174 . . . . 1.0 109.611 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 29.2 p -128.35 155.45 78.45 Favored Pre-proline 0 CA--C 1.535 0.387 0 O-C-N 121.517 -0.739 . . . . 1.0 109.38 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_exo -36.33 -37.35 0.26 Allowed 'Trans proline' 0 N--CA 1.489 1.237 1 C-N-CA 125.341 4.027 . . . . 1.0 111.186 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 4.5 m -69.91 -47.38 62.69 Favored 'General case' 0 N--CA 1.463 0.206 0 O-C-N 121.351 -0.843 . . . . 1.0 109.79 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 7.5 mm100 -61.49 -49.88 75.0 Favored 'General case' 0 CA--C 1.533 0.302 0 O-C-N 121.41 -0.806 . . . . 1.0 109.842 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.8 t -64.97 -27.49 68.87 Favored 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.431 -0.793 . . . . 1.0 109.439 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.29 -8.91 57.38 Favored 'General case' 0 CA--C 1.534 0.344 0 O-C-N 121.5 -0.75 . . . . 1.0 109.821 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -91.38 -28.0 17.98 Favored 'General case' 0 CA--C 1.529 0.14 0 O-C-N 121.37 -0.831 . . . . 1.0 109.405 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -89.65 -29.15 19.0 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.471 -0.768 . . . . 1.0 109.441 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.04 45.64 2.02 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 109.771 -1.332 . . . . 1.0 109.771 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 2.0 m -121.42 142.95 49.52 Favored 'General case' 0 N--CA 1.465 0.29 0 O-C-N 121.496 -1.002 . . . . 1.0 109.303 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 46.8 m -63.32 113.66 3.35 Favored 'General case' 0 N--CA 1.466 0.332 0 O-C-N 121.4 -0.812 . . . . 1.0 109.39 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 48.7 t80 -90.36 137.19 32.55 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.43 -0.794 . . . . 1.0 109.126 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -151.02 106.86 3.41 Favored 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.47 -0.769 . . . . 1.0 109.676 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.435 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 2.1 p30 -107.09 48.55 0.83 Allowed 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.491 -0.756 . . . . 1.0 109.245 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 16.8 p -81.34 -52.28 7.46 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.519 -0.738 . . . . 1.0 109.361 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.8 t -114.14 145.39 20.03 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 O-C-N 121.589 -0.694 . . . . 1.0 109.383 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -88.35 179.66 6.29 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.539 -0.726 . . . . 1.0 109.449 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.45 -49.91 4.12 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 109.278 -1.529 . . . . 1.0 109.278 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.559 HG11 ' HB3' ' A' ' 11' ' ' PRO . 27.6 m -79.79 171.16 13.15 Favored Pre-proline 0 CA--C 1.538 0.502 0 O-C-N 121.588 -0.948 . . . . 1.0 109.041 179.632 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . 0.409 ' CD ' ' HB ' ' A' ' 41' ' ' VAL . 11.2 Cg_endo -84.17 127.41 3.99 Favored 'Trans proline' 0 N--CA 1.48 0.724 0 C-N-CA 124.383 3.389 . . . . 1.0 110.003 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.435 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 11.0 m0 -82.83 -39.85 21.12 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.594 -0.691 . . . . 1.0 110.104 -179.129 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.5 t -89.46 108.38 19.61 Favored 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.325 -0.859 . . . . 1.0 109.597 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.426 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 15.0 p90 -135.92 175.9 9.17 Favored 'General case' 0 CA--C 1.538 0.496 0 O-C-N 121.438 -0.789 . . . . 1.0 109.58 179.647 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.426 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 37.5 m-85 -84.61 166.99 29.45 Favored Pre-proline 0 CA--C 1.536 0.422 0 O-C-N 121.274 -0.891 . . . . 1.0 110.061 -179.539 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -88.92 159.7 6.01 Favored 'Trans proline' 0 C--N 1.353 0.779 0 C-N-CA 124.868 3.712 . . . . 1.0 110.538 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.733 HD22 HG21 ' A' ' 9' ' ' VAL . 59.7 m-80 -132.77 84.85 2.17 Favored 'General case' 0 CA--C 1.531 0.242 0 O-C-N 121.525 -0.734 . . . . 1.0 109.406 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.4 p -88.64 122.57 32.22 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.508 -0.745 . . . . 1.0 109.377 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 64.7 mt -94.54 145.01 8.6 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 O-C-N 121.472 -0.767 . . . . 1.0 109.264 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -155.14 173.27 16.84 Favored 'General case' 0 CA--C 1.529 0.171 0 O-C-N 121.546 -0.721 . . . . 1.0 109.494 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.598 HG23 ' O ' ' A' ' 52' ' ' VAL . 28.2 m -139.18 88.02 13.41 Favored Pre-proline 0 CA--C 1.535 0.366 0 O-C-N 121.559 -0.713 . . . . 1.0 109.573 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -91.42 169.03 3.32 Favored 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 125.139 3.892 . . . . 1.0 110.283 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.447 ' HD2' ' H ' ' A' ' 55' ' ' GLU . 19.1 Cg_endo -91.39 -23.75 0.44 Allowed 'Trans proline' 0 C--N 1.349 0.602 0 C-N-CA 125.123 3.882 . . . . 1.0 110.305 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.447 ' H ' ' HD2' ' A' ' 54' ' ' PRO . 15.2 mt-10 -131.93 178.47 6.75 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.482 -0.761 . . . . 1.0 109.472 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -125.77 153.08 44.51 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 121.463 -0.773 . . . . 1.0 109.445 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -146.14 120.55 9.66 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.515 -0.74 . . . . 1.0 109.421 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -96.93 152.18 18.96 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.511 -0.743 . . . . 1.0 109.392 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -100.39 153.56 19.23 Favored 'General case' 0 CA--C 1.53 0.189 0 O-C-N 121.449 -0.782 . . . . 1.0 109.456 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 41.9 p90 . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.894 -1.05 . . . . 1.0 109.516 180.0 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 . . . . . 0 CA--C 1.531 0.216 0 N-CA-C 109.465 -0.569 . . . . 1.0 109.465 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -160.2 84.75 0.72 Allowed 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.558 -0.714 . . . . 1.0 109.475 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.695 ' O ' HG23 ' A' ' 4' ' ' THR . 23.9 mt-30 -91.29 101.15 13.86 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.57 -0.706 . . . . 1.0 109.442 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.695 HG23 ' O ' ' A' ' 3' ' ' GLN . 0.7 OUTLIER -165.15 -170.06 1.81 Allowed 'General case' 0 N--CA 1.465 0.278 0 O-C-N 121.472 -0.767 . . . . 1.0 109.602 -179.979 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . 0.469 ' HG2' HG22 ' A' ' 49' ' ' THR . 7.0 mt-10 -91.29 152.92 20.29 Favored 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.511 -0.743 . . . . 1.0 109.226 179.787 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.774 HG22 HG22 ' A' ' 8' ' ' THR . 1.5 m -150.5 125.45 9.86 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.42 -0.8 . . . . 1.0 110.016 -179.808 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 98.6 m -104.02 45.33 0.97 Allowed 'General case' 0 CA--C 1.534 0.358 0 O-C-N 121.429 -0.794 . . . . 1.0 108.934 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.774 HG22 HG22 ' A' ' 6' ' ' THR . 5.8 t -110.83 108.98 18.99 Favored 'General case' 0 CA--C 1.532 0.262 0 O-C-N 121.19 -0.944 . . . . 1.0 109.877 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.46 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.5 t -135.39 160.9 40.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 O-C-N 121.441 -0.787 . . . . 1.0 109.114 179.802 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.46 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -79.55 115.59 54.54 Favored Pre-proline 0 CA--C 1.541 0.606 0 O-C-N 121.434 -0.791 . . . . 1.0 109.382 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -38.23 -28.79 0.13 Allowed 'Trans proline' 0 N--CA 1.49 1.277 0 C-N-CA 124.664 3.576 . . . . 1.0 111.108 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 -66.94 -64.92 0.75 Allowed 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.489 -0.757 . . . . 1.0 109.691 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -90.56 44.4 1.2 Allowed 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.499 -0.751 . . . . 1.0 109.542 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 21.7 mtt180 -86.11 143.16 28.19 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.476 -0.765 . . . . 1.0 109.516 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -92.87 108.1 19.73 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 109.021 -0.733 . . . . 1.0 109.021 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -62.49 122.59 16.15 Favored 'General case' 0 CA--C 1.532 0.278 0 O-C-N 121.517 -0.739 . . . . 1.0 109.984 -179.709 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 t -88.94 -13.33 39.25 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 109.06 -0.718 . . . . 1.0 109.06 179.434 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 177.28 177.54 46.25 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 108.645 -1.782 . . . . 1.0 108.645 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.6 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.2 p90 -64.35 167.62 8.08 Favored Pre-proline 0 CA--C 1.54 0.585 0 O-C-N 121.24 -1.153 . . . . 1.0 109.064 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -81.22 -30.38 1.62 Allowed 'Trans proline' 0 N--CA 1.483 0.858 0 C-N-CA 124.347 3.365 . . . . 1.0 110.84 -178.684 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.92 -10.16 8.28 Favored Glycine 0 CA--C 1.537 1.423 0 N-CA-C 110.192 -1.163 . . . . 1.0 110.192 179.528 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.6 HG22 ' O ' ' A' ' 19' ' ' PHE . 23.6 m -62.01 169.14 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 O-C-N 121.257 -1.143 . . . . 1.0 109.727 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 71.8 p -127.41 157.52 72.52 Favored Pre-proline 0 CA--C 1.534 0.361 0 N-CA-C 108.702 -0.851 . . . . 1.0 108.702 179.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -34.88 -36.12 0.12 Allowed 'Trans proline' 0 N--CA 1.489 1.255 1 C-N-CA 125.364 4.043 . . . . 1.0 111.315 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.7 p -72.83 -48.37 38.3 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.469 -0.769 . . . . 1.0 109.931 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 53.1 mt-30 -65.17 -44.01 89.89 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.542 -0.724 . . . . 1.0 110.07 -179.634 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 9.1 t -61.3 -31.85 71.7 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 121.303 -0.873 . . . . 1.0 109.855 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.19 -1.5 48.17 Favored 'General case' 0 CA--C 1.535 0.373 0 O-C-N 121.433 -0.792 . . . . 1.0 110.137 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -69.95 -28.49 65.61 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 121.349 -0.845 . . . . 1.0 110.255 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.29 -36.9 5.68 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 121.249 -0.907 . . . . 1.0 109.857 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 126.76 55.71 0.14 Allowed Glycine 0 CA--C 1.531 1.057 0 N-CA-C 109.959 -1.256 . . . . 1.0 109.959 179.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 36.9 m -120.98 137.3 54.7 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.398 -1.06 . . . . 1.0 108.725 179.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 53.0 m -69.42 122.75 19.58 Favored 'General case' 0 N--CA 1.466 0.374 0 O-C-N 121.326 -0.859 . . . . 1.0 109.418 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 34.9 t80 -93.48 140.1 29.97 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.493 -0.754 . . . . 1.0 109.002 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -152.76 112.4 3.91 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.379 -0.825 . . . . 1.0 109.737 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.44 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 11.5 p30 -113.76 76.12 0.96 Allowed 'General case' 0 N--CA 1.464 0.253 0 O-C-N 121.474 -0.766 . . . . 1.0 109.446 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.8 p -115.39 -29.95 6.39 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.507 -0.746 . . . . 1.0 109.635 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.4 t -124.44 154.43 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 O-C-N 121.503 -0.748 . . . . 1.0 109.501 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 41.8 mtm-85 -99.29 178.95 4.74 Favored 'General case' 0 CA--C 1.53 0.184 0 O-C-N 121.532 -0.73 . . . . 1.0 109.357 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 62.14 11.21 31.41 Favored Glycine 0 CA--C 1.533 1.206 0 N-CA-C 109.919 -1.272 . . . . 1.0 109.919 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.9 m -134.64 169.27 14.3 Favored Pre-proline 0 CA--C 1.535 0.404 0 O-C-N 121.357 -1.084 . . . . 1.0 109.182 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -87.64 122.44 1.69 Allowed 'Trans proline' 0 C--N 1.351 0.692 0 C-N-CA 124.825 3.683 . . . . 1.0 110.213 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.44 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.7 m0 -82.71 -32.68 27.89 Favored 'General case' 0 N--CA 1.463 0.216 0 O-C-N 121.478 -0.764 . . . . 1.0 109.44 -179.618 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 11.0 t -89.36 107.97 19.37 Favored 'General case' 0 CA--C 1.535 0.372 0 O-C-N 121.532 -0.73 . . . . 1.0 109.207 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.413 ' CD1' ' N ' ' A' ' 45' ' ' PHE . 4.7 p90 -137.4 -179.32 5.66 Favored 'General case' 0 CA--C 1.539 0.524 0 O-C-N 121.263 -0.898 . . . . 1.0 110.33 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.409 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 10.5 m-85 -84.41 169.32 17.11 Favored Pre-proline 0 CA--C 1.539 0.524 0 O-C-N 121.519 -0.738 . . . . 1.0 110.097 -179.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_endo -90.89 170.23 3.46 Favored 'Trans proline' 0 C--N 1.353 0.767 0 C-N-CA 125.204 3.936 . . . . 1.0 110.888 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -132.44 79.75 1.87 Allowed 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 108.445 -0.946 . . . . 1.0 108.445 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.469 HG22 ' HG2' ' A' ' 5' ' ' GLU . 56.5 p -72.19 145.61 47.91 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.526 -0.734 . . . . 1.0 110.322 -179.061 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 42.5 mt -121.41 146.28 26.69 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 N-CA-C 108.764 -0.828 . . . . 1.0 108.764 179.402 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -154.51 -168.19 2.84 Favored 'General case' 0 N--CA 1.464 0.242 0 O-C-N 121.453 -0.779 . . . . 1.0 109.684 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.4 m -84.5 160.78 55.85 Favored Pre-proline 0 CA--C 1.536 0.421 0 O-C-N 121.589 -0.694 . . . . 1.0 109.348 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -90.72 106.85 0.31 Allowed 'Trans proline' 0 CA--C 1.539 0.734 0 C-N-CA 124.943 3.762 . . . . 1.0 110.151 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_endo -89.19 -160.32 0.1 OUTLIER 'Trans proline' 0 C--N 1.353 0.778 0 C-N-CA 124.734 3.623 . . . . 1.0 110.344 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 -78.14 135.52 37.68 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.428 -0.795 . . . . 1.0 109.586 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -107.28 117.08 33.14 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.508 -0.745 . . . . 1.0 109.369 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -108.18 157.64 18.14 Favored 'General case' 0 CA--C 1.53 0.205 0 O-C-N 121.529 -0.732 . . . . 1.0 109.498 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.0 p -139.18 109.27 6.39 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.547 -0.721 . . . . 1.0 109.348 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 11.9 mm-40 -132.63 106.49 7.83 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.553 -0.717 . . . . 1.0 109.418 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 8.7 t80 . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.032 -0.985 . . . . 1.0 109.412 -179.995 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 . . . . . 0 CA--C 1.532 0.281 0 N-CA-C 109.369 -0.604 . . . . 1.0 109.369 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.609 ' HB1' ' CD1' ' A' ' 50' ' ' ILE . . . -166.59 70.61 0.12 Allowed 'General case' 0 CA--C 1.532 0.279 0 O-C-N 121.494 -0.754 . . . . 1.0 109.367 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.72 ' O ' HG23 ' A' ' 4' ' ' THR . 10.9 mp0 -147.02 94.36 2.4 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.384 -0.823 . . . . 1.0 109.3 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.72 HG23 ' O ' ' A' ' 3' ' ' GLN . 0.2 OUTLIER -171.77 -165.75 0.39 Allowed 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.447 -0.783 . . . . 1.0 109.321 -179.945 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -108.97 124.43 50.68 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.489 -0.757 . . . . 1.0 109.145 179.523 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.688 HG22 HG22 ' A' ' 8' ' ' THR . 1.2 m -139.39 147.39 41.41 Favored 'General case' 0 CA--C 1.53 0.185 0 O-C-N 121.518 -0.739 . . . . 1.0 109.485 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.434 ' O ' ' CE2' ' A' ' 45' ' ' PHE . 11.2 m -111.05 -24.57 10.26 Favored 'General case' 0 C--N 1.332 -0.16 0 O-C-N 121.544 -0.723 . . . . 1.0 109.449 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.688 HG22 HG22 ' A' ' 6' ' ' THR . 3.9 t -68.9 146.31 52.92 Favored 'General case' 0 N--CA 1.464 0.24 0 O-C-N 121.475 -0.766 . . . . 1.0 110.739 -178.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.738 HG12 ' H ' ' A' ' 10' ' ' ALA . 25.2 t -140.32 178.9 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 108.308 -0.997 . . . . 1.0 108.308 179.616 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.738 ' H ' HG12 ' A' ' 9' ' ' VAL . . . -61.95 110.54 3.32 Favored Pre-proline 0 CA--C 1.541 0.603 0 O-C-N 121.216 -0.927 . . . . 1.0 109.717 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -39.75 -31.32 0.43 Allowed 'Trans proline' 0 N--CA 1.489 1.222 0 C-N-CA 124.607 3.538 . . . . 1.0 111.194 -179.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 8.7 mtt-85 -84.19 -39.61 19.16 Favored 'General case' 0 N--CA 1.464 0.273 0 O-C-N 121.39 -0.819 . . . . 1.0 109.979 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -103.58 50.82 0.8 Allowed 'General case' 0 CA--C 1.532 0.282 0 O-C-N 121.385 -0.822 . . . . 1.0 109.348 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 50.0 mtt180 -91.35 136.39 33.14 Favored 'General case' 0 N--CA 1.464 0.239 0 O-C-N 121.457 -0.777 . . . . 1.0 109.726 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -79.92 104.21 10.34 Favored 'General case' 0 CA--C 1.53 0.182 0 O-C-N 121.586 -0.696 . . . . 1.0 109.249 179.724 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 11.5 t-20 -62.84 116.5 5.31 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.48 -0.763 . . . . 1.0 109.899 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.0 t -92.55 -9.97 39.29 Favored 'General case' 0 CA--C 1.536 0.422 0 O-C-N 121.555 -0.716 . . . . 1.0 109.521 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.91 173.57 33.69 Favored Glycine 0 CA--C 1.529 0.957 0 N-CA-C 109.206 -1.557 . . . . 1.0 109.206 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.557 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.9 p90 -65.51 167.74 9.99 Favored Pre-proline 0 CA--C 1.539 0.544 0 O-C-N 121.43 -1.041 . . . . 1.0 108.971 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.67 -30.37 1.45 Allowed 'Trans proline' 0 N--CA 1.484 0.922 0 C-N-CA 124.305 3.337 . . . . 1.0 110.832 -178.774 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.29 -10.71 7.83 Favored Glycine 0 CA--C 1.537 1.441 0 N-CA-C 110.324 -1.11 . . . . 1.0 110.324 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.557 HG22 ' O ' ' A' ' 19' ' ' PHE . 20.3 m -60.54 -171.94 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 O-C-N 121.294 -1.121 . . . . 1.0 109.723 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -146.63 157.25 48.2 Favored Pre-proline 0 CA--C 1.535 0.379 0 O-C-N 121.584 -0.697 . . . . 1.0 109.25 179.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -34.71 -31.93 0.07 OUTLIER 'Trans proline' 0 N--CA 1.489 1.207 1 C-N-CA 125.588 4.192 . . . . 1.0 111.36 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 76.8 p -75.3 -50.22 16.71 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.475 -0.766 . . . . 1.0 109.872 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 38.0 mt-30 -61.57 -48.02 82.88 Favored 'General case' 0 N--CA 1.465 0.291 0 O-C-N 121.44 -0.788 . . . . 1.0 109.811 -179.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.9 t -64.69 -28.4 69.57 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.392 -0.818 . . . . 1.0 109.558 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -87.95 -4.96 58.77 Favored 'General case' 0 CA--C 1.534 0.353 0 O-C-N 121.57 -0.706 . . . . 1.0 110.012 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -75.01 -30.1 61.03 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.318 -0.864 . . . . 1.0 109.73 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.5 mmtp -102.82 -40.43 6.56 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.453 -0.779 . . . . 1.0 109.466 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 118.23 39.27 0.75 Allowed Glycine 0 CA--C 1.529 0.944 0 N-CA-C 109.419 -1.472 . . . . 1.0 109.419 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 48.7 m -101.94 139.7 37.22 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.567 -0.96 . . . . 1.0 109.189 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 84.6 m -65.37 116.51 6.76 Favored 'General case' 0 N--CA 1.464 0.255 0 O-C-N 121.523 -0.736 . . . . 1.0 109.927 -179.374 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 34.2 t80 -92.74 121.14 33.84 Favored 'General case' 0 C--N 1.333 -0.141 0 N-CA-C 109.042 -0.725 . . . . 1.0 109.042 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 26.8 t0 -134.15 118.48 17.72 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.391 -0.818 . . . . 1.0 109.518 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.441 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 7.0 p-10 -110.91 64.55 0.61 Allowed 'General case' 0 CA--C 1.533 0.298 0 O-C-N 121.526 -0.734 . . . . 1.0 109.236 179.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 27.0 p -114.26 -49.71 2.83 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.392 -0.817 . . . . 1.0 109.489 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.3 t -100.22 133.6 42.69 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 O-C-N 121.404 -0.81 . . . . 1.0 109.507 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.404 ' HG3' ' H ' ' A' ' 40' ' ' GLY . 2.3 tpt180 -85.13 176.17 8.55 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.571 -0.706 . . . . 1.0 109.553 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.404 ' H ' ' HG3' ' A' ' 39' ' ' ARG . . . 80.89 -48.43 3.74 Favored Glycine 0 CA--C 1.529 0.908 0 N-CA-C 109.447 -1.461 . . . . 1.0 109.447 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.3 m -81.4 169.75 17.86 Favored Pre-proline 0 CA--C 1.536 0.437 0 O-C-N 121.511 -0.993 . . . . 1.0 109.215 179.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -86.55 124.37 2.3 Favored 'Trans proline' 0 C--N 1.35 0.628 0 C-N-CA 124.757 3.638 . . . . 1.0 110.157 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.441 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 16.9 m0 -67.28 -37.61 83.7 Favored 'General case' 0 CA--C 1.53 0.192 0 O-C-N 121.554 -0.716 . . . . 1.0 109.522 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 11.1 t -87.86 109.25 19.62 Favored 'General case' 0 C--O 1.233 0.195 0 O-C-N 121.399 -0.813 . . . . 1.0 108.961 179.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.434 ' CE2' ' O ' ' A' ' 7' ' ' CYS . 1.3 p90 -149.3 178.44 8.76 Favored 'General case' 0 CA--C 1.537 0.454 0 O-C-N 121.454 -0.779 . . . . 1.0 109.832 -179.512 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 29.8 m-85 -83.78 170.28 14.59 Favored Pre-proline 0 CA--C 1.538 0.498 0 O-C-N 121.485 -0.759 . . . . 1.0 109.942 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -93.83 -168.32 0.18 Allowed 'Trans proline' 0 C--N 1.35 0.641 1 C-N-CA 125.357 4.038 . . . . 1.0 111.39 -179.45 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -168.79 79.22 0.13 Allowed 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 107.902 -1.148 . . . . 1.0 107.902 179.364 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.589 HG22 ' H ' ' A' ' 6' ' ' THR . 48.4 p -98.5 137.29 37.39 Favored 'General case' 0 C--N 1.33 -0.247 0 O-C-N 121.641 -0.662 . . . . 1.0 110.004 -178.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.609 ' CD1' ' HB1' ' A' ' 2' ' ' ALA . 30.3 mt -90.5 170.23 1.26 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 108.275 -1.009 . . . . 1.0 108.275 179.5 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.508 ' N ' HG22 ' A' ' 50' ' ' ILE . 2.2 m-20 -80.13 175.41 10.67 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.265 -0.897 . . . . 1.0 110.062 -179.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 29.1 m -121.78 157.94 55.83 Favored Pre-proline 0 CA--C 1.537 0.451 0 O-C-N 121.598 -0.689 . . . . 1.0 109.793 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.455 ' N ' ' HD2' ' A' ' 54' ' ' PRO . 3.0 Cg_exo -38.47 -60.18 0.5 Allowed 'Trans proline' 0 N--CA 1.486 1.049 0 C-N-CA 125.186 3.924 . . . . 1.0 111.311 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.455 ' HD2' ' N ' ' A' ' 53' ' ' PRO . 22.7 Cg_exo -33.63 128.05 0.15 Allowed 'Trans proline' 0 N--CA 1.491 1.347 0 C-N-CA 125.261 3.974 . . . . 1.0 111.511 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -76.62 135.32 39.17 Favored 'General case' 0 N--CA 1.462 0.162 0 O-C-N 121.566 -0.709 . . . . 1.0 109.511 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -122.96 147.94 46.05 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.433 -0.792 . . . . 1.0 109.422 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -102.09 139.9 37.1 Favored 'General case' 0 CA--C 1.532 0.27 0 O-C-N 121.465 -0.772 . . . . 1.0 109.52 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 7.9 m -72.06 122.98 21.85 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.558 -0.714 . . . . 1.0 109.409 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 -146.94 117.76 7.62 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.474 -0.766 . . . . 1.0 109.537 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 117.976 -1.012 . . . . 1.0 109.228 179.942 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 . . . . . 0 CA--C 1.531 0.217 0 N-CA-C 109.458 -0.571 . . . . 1.0 109.458 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -85.82 108.49 18.14 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.481 -0.762 . . . . 1.0 109.52 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 25.0 mt-30 -145.5 127.73 15.75 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.455 -0.778 . . . . 1.0 109.341 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.8 p -126.22 172.95 9.63 Favored 'General case' 0 N--CA 1.464 0.232 0 O-C-N 121.422 -0.798 . . . . 1.0 109.621 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -89.27 133.92 34.26 Favored 'General case' 0 N--CA 1.462 0.153 0 O-C-N 121.497 -0.752 . . . . 1.0 109.367 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.069 HG22 HG22 ' A' ' 8' ' ' THR . 0.6 OUTLIER -146.76 108.26 4.29 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.514 -0.742 . . . . 1.0 109.733 -179.807 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 80.6 m -97.31 45.84 1.04 Allowed 'General case' 0 CA--C 1.532 0.287 0 O-C-N 121.51 -0.743 . . . . 1.0 108.998 179.445 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 1.069 HG22 HG22 ' A' ' 6' ' ' THR . 4.6 t -123.79 83.5 2.15 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.178 -0.951 . . . . 1.0 109.848 -179.616 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.619 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.2 t -109.5 172.03 2.46 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 N-CA-C 108.85 -0.796 . . . . 1.0 108.85 179.449 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.619 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -73.15 131.76 83.04 Favored Pre-proline 0 CA--C 1.541 0.597 0 O-C-N 121.323 -0.861 . . . . 1.0 109.272 -179.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -36.87 -38.75 0.39 Allowed 'Trans proline' 0 N--CA 1.488 1.156 0 C-N-CA 125.103 3.869 . . . . 1.0 111.351 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.7 mpp_? -82.01 -40.28 22.34 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 121.433 -0.792 . . . . 1.0 109.944 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.548 ' O ' HG11 ' A' ' 9' ' ' VAL . 29.6 mt-10 -86.24 42.68 1.01 Allowed 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.277 -0.89 . . . . 1.0 109.671 -179.657 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 37.9 mtt180 -101.51 151.34 22.08 Favored 'General case' 0 N--CA 1.464 0.232 0 O-C-N 121.409 -0.807 . . . . 1.0 109.627 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -104.68 105.6 15.76 Favored 'General case' 0 N--CA 1.462 0.172 0 O-C-N 121.345 -0.847 . . . . 1.0 109.06 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -57.32 118.69 5.38 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 121.235 -0.916 . . . . 1.0 110.305 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -94.13 -18.85 21.35 Favored 'General case' 0 CA--C 1.534 0.348 0 O-C-N 121.515 -0.741 . . . . 1.0 109.345 179.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -171.88 176.82 44.9 Favored Glycine 0 CA--C 1.53 1.017 0 N-CA-C 109.059 -1.616 . . . . 1.0 109.059 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.58 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.3 p90 -66.12 167.16 12.91 Favored Pre-proline 0 CA--C 1.539 0.526 0 O-C-N 121.374 -1.074 . . . . 1.0 108.815 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.97 -30.16 1.41 Allowed 'Trans proline' 0 N--CA 1.482 0.828 0 C-N-CA 124.537 3.491 . . . . 1.0 110.906 -178.604 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -57.8 -11.86 9.12 Favored Glycine 0 CA--C 1.536 1.39 0 N-CA-C 110.323 -1.111 . . . . 1.0 110.323 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.58 HG22 ' O ' ' A' ' 19' ' ' PHE . 20.9 m -61.06 -172.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 O-C-N 121.302 -1.116 . . . . 1.0 109.932 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.557 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 59.9 p -145.15 157.64 53.21 Favored Pre-proline 0 CA--C 1.535 0.37 0 N-CA-C 108.913 -0.773 . . . . 1.0 108.913 179.709 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -35.07 -39.75 0.22 Allowed 'Trans proline' 0 N--CA 1.489 1.212 1 C-N-CA 125.484 4.123 . . . . 1.0 111.378 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.1 p -74.08 -46.63 41.77 Favored 'General case' 0 CA--C 1.532 0.288 0 O-C-N 121.462 -0.774 . . . . 1.0 109.903 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLN . . . . . 0.557 ' HB2' ' H ' ' A' ' 23' ' ' THR . 32.4 mt-30 -61.26 -53.07 61.49 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 121.447 -0.783 . . . . 1.0 109.975 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 23.1 t -61.66 -26.41 68.0 Favored 'General case' 0 CA--C 1.533 0.322 0 O-C-N 121.298 -0.877 . . . . 1.0 109.719 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -90.01 -6.69 55.33 Favored 'General case' 0 CA--C 1.535 0.386 0 O-C-N 121.504 -0.748 . . . . 1.0 110.08 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 15.5 t-20 -78.96 -45.38 20.49 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.29 -0.882 . . . . 1.0 109.535 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.1 mtmm -72.36 -45.85 58.03 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.483 -0.761 . . . . 1.0 109.526 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 125.26 27.03 1.25 Allowed Glycine 0 CA--C 1.529 0.939 0 N-CA-C 109.197 -1.561 . . . . 1.0 109.197 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 26.4 m -99.52 145.29 27.65 Favored 'General case' 0 CA--C 1.532 0.276 0 O-C-N 121.685 -0.891 . . . . 1.0 108.696 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 35.9 m -68.58 128.92 38.35 Favored 'General case' 0 N--CA 1.465 0.321 0 O-C-N 121.307 -0.871 . . . . 1.0 109.42 -179.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -97.82 138.09 35.69 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.511 -0.743 . . . . 1.0 109.067 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 13.6 t0 -157.63 89.25 1.02 Allowed 'General case' 0 N--CA 1.463 0.183 0 O-C-N 121.521 -0.737 . . . . 1.0 109.512 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.424 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 38.2 p-10 -103.05 78.68 1.67 Allowed 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.539 -0.725 . . . . 1.0 109.472 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 76.6 p -113.85 -23.15 9.79 Favored 'General case' 0 CA--C 1.534 0.334 0 O-C-N 121.383 -0.823 . . . . 1.0 109.709 -179.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.537 HG12 ' N ' ' A' ' 39' ' ' ARG . 33.8 t -127.6 165.54 26.35 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 O-C-N 121.451 -0.78 . . . . 1.0 109.645 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.537 ' N ' HG12 ' A' ' 38' ' ' VAL . 0.0 OUTLIER -107.03 175.05 5.63 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 109.097 -0.705 . . . . 1.0 109.097 179.812 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.436 ' H ' ' CD ' ' A' ' 39' ' ' ARG . . . 72.17 -8.07 7.13 Favored Glycine 0 CA--C 1.533 1.173 0 N-CA-C 109.954 -1.258 . . . . 1.0 109.954 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.9 m -121.52 170.08 8.12 Favored Pre-proline 0 CA--C 1.537 0.461 0 O-C-N 121.317 -1.108 . . . . 1.0 109.051 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -86.53 127.75 2.85 Favored 'Trans proline' 0 N--CA 1.48 0.694 0 C-N-CA 124.585 3.523 . . . . 1.0 110.209 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.424 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.4 m0 -82.49 -39.36 22.57 Favored 'General case' 0 N--CA 1.464 0.264 0 O-C-N 121.586 -0.696 . . . . 1.0 109.28 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.1 t -88.14 117.49 27.06 Favored 'General case' 0 N--CA 1.466 0.329 0 O-C-N 121.508 -0.745 . . . . 1.0 109.113 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.419 ' CD1' ' N ' ' A' ' 45' ' ' PHE . 5.2 p90 -145.18 173.14 12.19 Favored 'General case' 0 CA--C 1.537 0.463 0 O-C-N 121.328 -0.857 . . . . 1.0 110.34 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.408 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 14.3 m-85 -79.53 172.78 9.0 Favored Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 121.473 -0.767 . . . . 1.0 109.496 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo -90.37 160.53 4.54 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 125.087 3.858 . . . . 1.0 110.252 179.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.529 ' ND2' HG21 ' A' ' 9' ' ' VAL . 8.2 m-20 -135.57 106.11 6.48 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.485 -0.759 . . . . 1.0 109.492 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 65.0 p -86.9 88.24 7.65 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 121.457 -0.777 . . . . 1.0 109.535 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 62.6 mt -104.18 155.69 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 O-C-N 121.461 -0.774 . . . . 1.0 109.257 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -82.69 137.45 34.44 Favored 'General case' 0 CA--C 1.53 0.202 0 O-C-N 121.497 -0.752 . . . . 1.0 109.482 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.588 HG23 ' O ' ' A' ' 52' ' ' VAL . 31.0 m -114.12 79.69 5.1 Favored Pre-proline 0 CA--C 1.537 0.461 0 O-C-N 121.509 -0.744 . . . . 1.0 109.411 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.458 ' N ' ' HD2' ' A' ' 54' ' ' PRO . 7.2 Cg_exo -37.34 -59.68 0.47 Allowed 'Trans proline' 0 N--CA 1.486 1.086 0 C-N-CA 125.128 3.885 . . . . 1.0 111.345 -179.845 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.458 ' HD2' ' N ' ' A' ' 53' ' ' PRO . 15.3 Cg_exo -37.47 154.6 0.03 OUTLIER 'Trans proline' 0 N--CA 1.49 1.291 0 C-N-CA 124.785 3.657 . . . . 1.0 111.014 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -77.86 156.31 30.47 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.489 -0.757 . . . . 1.0 109.408 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -69.88 144.66 52.43 Favored 'General case' 0 CA--C 1.53 0.202 0 O-C-N 121.417 -0.802 . . . . 1.0 109.42 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 30.8 mt-10 -145.21 108.68 4.64 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 121.472 -0.768 . . . . 1.0 109.473 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 22.9 t -118.49 119.93 36.01 Favored 'General case' 0 N--CA 1.463 0.186 0 O-C-N 121.46 -0.775 . . . . 1.0 109.388 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -87.37 101.61 13.73 Favored 'General case' 0 N--CA 1.463 0.202 0 O-C-N 121.44 -0.787 . . . . 1.0 109.523 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 40.5 t80 . . . . . 0 C--O 1.221 -0.408 0 CA-C-O 117.965 -1.017 . . . . 1.0 109.386 -179.954 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.531 0.212 0 N-CA-C 109.413 -0.588 . . . . 1.0 109.413 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -81.28 23.32 0.61 Allowed 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.545 -0.722 . . . . 1.0 109.578 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -102.37 111.3 23.54 Favored 'General case' 0 CA--C 1.53 0.196 0 O-C-N 121.441 -0.787 . . . . 1.0 109.478 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 2.4 p -92.88 174.83 7.04 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.456 -0.778 . . . . 1.0 109.503 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 -77.7 145.01 36.85 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.46 -0.775 . . . . 1.0 109.459 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.447 HG22 HG22 ' A' ' 8' ' ' THR . 1.1 m -143.09 125.12 15.25 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.528 -0.733 . . . . 1.0 109.502 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 63.9 m -105.61 -20.56 13.43 Favored 'General case' 0 CA--C 1.533 0.316 0 O-C-N 121.601 -0.687 . . . . 1.0 109.478 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.576 HG23 ' O ' ' A' ' 8' ' ' THR . 3.8 t -70.05 104.78 2.66 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.322 -0.861 . . . . 1.0 109.538 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.613 HG12 ' N ' ' A' ' 10' ' ' ALA . 36.2 t -131.66 170.66 19.39 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 O-C-N 121.607 -0.683 . . . . 1.0 109.186 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.613 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -65.77 126.52 91.86 Favored Pre-proline 0 CA--C 1.539 0.535 0 O-C-N 121.448 -0.782 . . . . 1.0 109.22 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_exo -37.74 -40.02 0.88 Allowed 'Trans proline' 0 N--CA 1.49 1.268 0 C-N-CA 124.926 3.751 . . . . 1.0 111.126 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.9 mtm-85 -76.6 -41.73 45.08 Favored 'General case' 0 CA--C 1.532 0.254 0 O-C-N 121.4 -0.812 . . . . 1.0 109.886 -179.425 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -81.88 40.52 0.61 Allowed 'General case' 0 C--N 1.331 -0.213 0 O-C-N 121.451 -0.78 . . . . 1.0 109.561 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 55.3 mtt180 -108.09 133.49 52.31 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.47 -0.769 . . . . 1.0 109.556 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 22.6 mm-40 -90.65 117.71 29.52 Favored 'General case' 0 N--CA 1.464 0.227 0 O-C-N 121.438 -0.789 . . . . 1.0 109.367 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -61.31 115.36 3.78 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.453 -0.779 . . . . 1.0 109.992 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.4 t -93.47 -20.39 20.33 Favored 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.605 -0.685 . . . . 1.0 109.324 179.614 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.52 170.58 37.19 Favored Glycine 0 CA--C 1.529 0.958 0 N-CA-C 109.494 -1.442 . . . . 1.0 109.494 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.73 ' O ' HG22 ' A' ' 22' ' ' VAL . 19.8 p90 -64.85 148.77 97.14 Favored Pre-proline 0 CA--C 1.538 0.505 0 O-C-N 121.435 -1.038 . . . . 1.0 109.263 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -65.43 -28.69 54.07 Favored 'Trans proline' 0 N--CA 1.489 1.232 0 C-N-CA 124.053 3.169 . . . . 1.0 110.704 -178.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -55.04 -15.62 7.1 Favored Glycine 0 CA--C 1.536 1.355 0 N-CA-C 110.649 -0.981 . . . . 1.0 110.649 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.73 HG22 ' O ' ' A' ' 19' ' ' PHE . 30.2 m -64.01 178.26 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 O-C-N 121.389 -1.065 . . . . 1.0 109.505 179.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.1 p -132.03 156.4 80.15 Favored Pre-proline 0 CA--C 1.536 0.427 0 O-C-N 121.543 -0.723 . . . . 1.0 109.313 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -34.49 -33.03 0.07 OUTLIER 'Trans proline' 0 N--CA 1.489 1.206 1 C-N-CA 125.587 4.192 . . . . 1.0 111.293 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 2.6 m -71.83 -49.96 33.83 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.472 -0.767 . . . . 1.0 109.962 -179.554 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 13.2 mm-40 -63.39 -49.93 71.89 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.403 -0.81 . . . . 1.0 109.73 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.6 t -63.16 -21.34 66.14 Favored 'General case' 0 CA--C 1.533 0.306 0 O-C-N 121.518 -0.739 . . . . 1.0 109.829 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -96.0 -11.06 27.06 Favored 'General case' 0 CA--C 1.535 0.399 0 O-C-N 121.416 -0.802 . . . . 1.0 109.916 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -71.38 -35.96 71.27 Favored 'General case' 0 N--CA 1.463 0.205 0 O-C-N 121.331 -0.856 . . . . 1.0 109.56 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.8 tttp -92.07 -42.68 9.82 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.44 -0.787 . . . . 1.0 109.447 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 122.33 38.05 0.61 Allowed Glycine 0 CA--C 1.528 0.849 0 N-CA-C 109.526 -1.43 . . . . 1.0 109.526 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.8 m -105.59 145.34 31.12 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.493 -1.004 . . . . 1.0 109.114 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 61.4 m -68.5 127.48 33.14 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.557 -0.714 . . . . 1.0 109.54 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 51.1 t80 -104.12 109.39 21.16 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 121.507 -0.746 . . . . 1.0 109.25 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -120.81 102.98 8.74 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.575 -0.703 . . . . 1.0 109.564 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.443 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.8 p-10 -108.08 59.49 0.61 Allowed 'General case' 0 CA--C 1.532 0.267 0 O-C-N 121.527 -0.733 . . . . 1.0 109.291 179.742 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.5 p -112.28 -42.1 3.78 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.364 -0.835 . . . . 1.0 109.454 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.2 t -96.71 155.09 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 O-C-N 121.481 -0.762 . . . . 1.0 109.483 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -108.03 165.05 11.75 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.529 -0.732 . . . . 1.0 109.449 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.4 -32.6 2.82 Favored Glycine 0 CA--C 1.53 1.009 0 N-CA-C 109.096 -1.602 . . . . 1.0 109.096 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.423 HG22 ' H ' ' A' ' 41' ' ' VAL . 26.8 m -91.34 171.85 7.45 Favored Pre-proline 0 CA--C 1.538 0.502 0 O-C-N 121.619 -0.93 . . . . 1.0 109.041 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . 0.413 ' CD ' ' HB ' ' A' ' 41' ' ' VAL . 11.4 Cg_endo -85.97 138.68 6.01 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 124.411 3.407 . . . . 1.0 109.706 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.443 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 30.6 m0 -87.36 -46.06 10.0 Favored 'General case' 0 CA--C 1.531 0.239 0 O-C-N 121.481 -0.762 . . . . 1.0 110.466 -179.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 14.9 t -89.04 109.51 20.34 Favored 'General case' 0 CA--C 1.532 0.276 0 O-C-N 121.242 -0.911 . . . . 1.0 109.953 -179.503 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.415 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 5.6 p90 -137.38 -178.97 5.46 Favored 'General case' 0 CA--C 1.537 0.474 0 O-C-N 121.387 -0.821 . . . . 1.0 109.448 179.365 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.415 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 43.9 m-85 -90.48 165.27 23.74 Favored Pre-proline 0 CA--C 1.536 0.422 0 O-C-N 121.328 -0.857 . . . . 1.0 109.512 -179.798 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -90.86 175.59 2.49 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 124.95 3.767 . . . . 1.0 110.502 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.595 HD22 HG21 ' A' ' 9' ' ' VAL . 67.8 m-80 -153.1 105.19 2.88 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 109.291 -0.633 . . . . 1.0 109.291 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 30.7 p -65.9 92.89 0.17 Allowed 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.479 -0.763 . . . . 1.0 109.349 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.488 HG22 ' N ' ' A' ' 51' ' ' ASP . 63.2 mt -139.87 162.43 25.62 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 O-C-N 121.561 -0.712 . . . . 1.0 109.315 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.488 ' N ' HG22 ' A' ' 50' ' ' ILE . 3.5 t0 -101.82 130.82 48.36 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.459 -0.776 . . . . 1.0 109.36 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.9 m -144.56 155.59 56.83 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.548 -0.72 . . . . 1.0 109.446 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -38.85 162.27 0.02 OUTLIER 'Trans proline' 0 N--CA 1.488 1.152 0 C-N-CA 125.249 3.966 . . . . 1.0 110.852 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -90.68 -72.91 0.0 OUTLIER 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 124.888 3.725 . . . . 1.0 110.311 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 65.5 mt-10 -78.08 127.8 32.86 Favored 'General case' 0 CA--C 1.532 0.26 0 O-C-N 121.599 -0.688 . . . . 1.0 109.383 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -86.2 129.91 34.69 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 121.595 -0.69 . . . . 1.0 109.413 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.432 ' HG2' ' H ' ' A' ' 58' ' ' SER . 8.2 tt0 -76.78 164.41 25.87 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.522 -0.736 . . . . 1.0 109.405 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.432 ' H ' ' HG2' ' A' ' 57' ' ' GLU . 57.8 m -145.75 159.63 42.9 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.462 -0.774 . . . . 1.0 109.44 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 28.3 mm-40 -105.31 146.2 29.7 Favored 'General case' 0 CA--C 1.532 0.254 0 O-C-N 121.538 -0.726 . . . . 1.0 109.474 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 117.986 -1.007 . . . . 1.0 109.43 -179.97 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.531 0.243 0 N-CA-C 109.531 -0.544 . . . . 1.0 109.531 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -149.47 85.51 1.45 Allowed 'General case' 0 CA--C 1.531 0.213 0 O-C-N 121.42 -0.8 . . . . 1.0 109.394 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 -124.38 118.56 26.97 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.51 -0.744 . . . . 1.0 109.459 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -87.4 172.94 9.45 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.528 -0.732 . . . . 1.0 109.489 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.8 mt-10 -93.55 144.94 24.9 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.477 -0.764 . . . . 1.0 109.64 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.703 HG22 ' O ' ' A' ' 48' ' ' ASN . 4.7 t -115.74 148.02 40.26 Favored 'General case' 0 CA--C 1.532 0.265 0 O-C-N 121.549 -0.72 . . . . 1.0 109.316 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 72.2 m -108.43 -20.97 12.94 Favored 'General case' 0 CA--C 1.534 0.345 0 O-C-N 121.46 -0.775 . . . . 1.0 109.644 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.57 HG23 ' O ' ' A' ' 8' ' ' THR . 3.5 t -70.03 102.98 2.15 Favored 'General case' 0 CA--C 1.53 0.211 0 O-C-N 121.489 -0.757 . . . . 1.0 109.892 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.617 HG12 ' N ' ' A' ' 10' ' ' ALA . 40.0 t -114.53 171.44 4.32 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 O-C-N 121.346 -0.846 . . . . 1.0 108.936 179.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.617 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -78.39 119.5 77.54 Favored Pre-proline 0 CA--C 1.541 0.622 0 O-C-N 121.417 -0.802 . . . . 1.0 109.542 -179.608 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.642 ' HB3' HG11 ' A' ' 41' ' ' VAL . 18.8 Cg_exo -37.93 -38.84 0.77 Allowed 'Trans proline' 0 N--CA 1.489 1.258 0 C-N-CA 124.757 3.638 . . . . 1.0 111.205 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 18.6 mmm-85 -77.01 -42.65 37.76 Favored 'General case' 0 N--CA 1.464 0.237 0 O-C-N 121.494 -0.754 . . . . 1.0 109.889 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -102.53 50.03 0.83 Allowed 'General case' 0 CA--C 1.532 0.286 0 O-C-N 121.375 -0.828 . . . . 1.0 109.508 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 26.7 mtt180 -94.04 147.77 22.81 Favored 'General case' 0 N--CA 1.463 0.223 0 O-C-N 121.379 -0.826 . . . . 1.0 109.704 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 54.1 mm-40 -91.6 107.26 19.09 Favored 'General case' 0 CA--C 1.53 0.196 0 O-C-N 121.474 -0.766 . . . . 1.0 109.166 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 30.2 t-20 -63.76 123.06 17.92 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 121.513 -0.742 . . . . 1.0 109.819 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 38.1 t -100.9 -18.34 16.4 Favored 'General case' 0 CA--C 1.534 0.329 0 O-C-N 121.53 -0.731 . . . . 1.0 109.505 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 175.94 -177.13 47.67 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 109.276 -1.53 . . . . 1.0 109.276 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.573 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.1 p90 -65.73 167.87 10.13 Favored Pre-proline 0 CA--C 1.538 0.492 0 O-C-N 121.395 -1.062 . . . . 1.0 108.822 179.732 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.81 -30.4 1.39 Allowed 'Trans proline' 0 N--CA 1.483 0.888 0 C-N-CA 124.374 3.383 . . . . 1.0 110.794 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -56.96 -12.58 7.23 Favored Glycine 0 CA--C 1.537 1.458 0 N-CA-C 110.357 -1.097 . . . . 1.0 110.357 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 19' ' ' PHE . 23.0 m -61.05 170.37 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 O-C-N 121.3 -1.117 . . . . 1.0 109.627 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.7 p -133.97 154.51 80.33 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.555 -0.716 . . . . 1.0 109.172 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.419 ' HD3' ' CZ ' ' A' ' 34' ' ' PHE . 16.8 Cg_exo -34.58 -31.87 0.06 OUTLIER 'Trans proline' 0 N--CA 1.488 1.195 1 C-N-CA 125.594 4.196 . . . . 1.0 111.355 179.956 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.6 m -75.53 -51.24 13.39 Favored 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.439 -0.788 . . . . 1.0 109.608 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 15.6 mt-30 -62.79 -43.37 98.98 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.427 -0.796 . . . . 1.0 109.721 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 10.1 t -64.54 -29.14 70.17 Favored 'General case' 0 N--CA 1.464 0.235 0 O-C-N 121.474 -0.766 . . . . 1.0 109.422 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.98 -11.15 56.13 Favored 'General case' 0 CA--C 1.533 0.315 0 O-C-N 121.604 -0.685 . . . . 1.0 109.756 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -88.24 -26.04 22.55 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.359 -0.838 . . . . 1.0 109.531 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 9.6 tttp -89.39 -32.06 17.46 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.419 -0.801 . . . . 1.0 109.407 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.41 43.43 1.36 Allowed Glycine 0 CA--C 1.53 0.985 0 N-CA-C 109.633 -1.387 . . . . 1.0 109.633 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.9 m -129.46 150.36 50.84 Favored 'General case' 0 CA--C 1.53 0.191 0 O-C-N 121.47 -1.018 . . . . 1.0 109.461 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.44 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 62.5 m -72.91 134.77 44.92 Favored 'General case' 0 CA--C 1.529 0.173 0 O-C-N 121.412 -0.805 . . . . 1.0 109.5 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.419 ' CZ ' ' HD3' ' A' ' 24' ' ' PRO . 57.1 t80 -107.87 125.13 51.1 Favored 'General case' 0 CA--C 1.53 0.175 0 O-C-N 121.488 -0.758 . . . . 1.0 109.233 179.689 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 16.2 t0 -138.54 117.84 12.77 Favored 'General case' 0 CA--C 1.53 0.179 0 O-C-N 121.457 -0.777 . . . . 1.0 109.527 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.431 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 14.1 p30 -113.55 66.06 0.66 Allowed 'General case' 0 N--CA 1.464 0.256 0 O-C-N 121.547 -0.721 . . . . 1.0 109.368 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.9 p -97.62 -69.82 0.74 Allowed 'General case' 0 CA--C 1.531 0.235 0 O-C-N 121.358 -0.839 . . . . 1.0 109.522 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 38.2 t -96.46 155.19 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 O-C-N 121.458 -0.776 . . . . 1.0 109.452 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.443 ' CG ' ' H ' ' A' ' 40' ' ' GLY . 13.7 ttp-105 -93.9 178.34 5.7 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 121.504 -0.748 . . . . 1.0 109.395 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.443 ' H ' ' CG ' ' A' ' 39' ' ' ARG . . . 81.3 -43.62 2.92 Favored Glycine 0 CA--C 1.529 0.918 0 N-CA-C 109.472 -1.451 . . . . 1.0 109.472 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.642 HG11 ' HB3' ' A' ' 11' ' ' PRO . 29.2 m -85.52 169.66 15.31 Favored Pre-proline 0 CA--C 1.537 0.444 0 O-C-N 121.538 -0.978 . . . . 1.0 109.197 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -87.22 136.46 4.06 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 124.77 3.647 . . . . 1.0 110.139 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.431 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 11.6 m0 -86.72 -50.55 6.69 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.526 -0.734 . . . . 1.0 109.569 -179.742 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.2 t -77.28 103.69 7.36 Favored 'General case' 0 N--CA 1.463 0.224 0 O-C-N 121.488 -0.758 . . . . 1.0 109.505 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.44 ' CE1' ' HB2' ' A' ' 33' ' ' CYS . 4.8 p90 -135.82 -178.99 5.38 Favored 'General case' 0 N--CA 1.465 0.316 0 O-C-N 121.489 -0.757 . . . . 1.0 109.523 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 65.1 m-85 -93.75 164.31 21.23 Favored Pre-proline 0 CA--C 1.534 0.357 0 O-C-N 121.436 -0.79 . . . . 1.0 109.652 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -91.11 -165.34 0.16 Allowed 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 125.045 3.83 . . . . 1.0 110.406 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.703 ' O ' HG22 ' A' ' 6' ' ' THR . 17.9 m-80 -157.5 118.51 3.57 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.505 -0.747 . . . . 1.0 109.441 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 1.3 p -66.8 96.61 0.42 Allowed 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.454 -0.779 . . . . 1.0 109.51 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.614 HG22 ' N ' ' A' ' 51' ' ' ASP . 60.8 mt -129.04 170.21 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 O-C-N 121.463 -0.773 . . . . 1.0 109.285 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.614 ' N ' HG22 ' A' ' 50' ' ' ILE . 7.6 p-10 -74.86 -173.1 1.78 Allowed 'General case' 0 CA--C 1.53 0.209 0 O-C-N 121.504 -0.747 . . . . 1.0 109.292 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.2 m -88.09 143.12 32.51 Favored Pre-proline 0 CA--C 1.538 0.487 0 O-C-N 121.433 -0.792 . . . . 1.0 109.443 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_exo -35.65 154.03 0.02 OUTLIER 'Trans proline' 0 N--CA 1.489 1.215 1 C-N-CA 125.38 4.053 . . . . 1.0 111.083 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -34.7 -53.46 0.63 Allowed 'Trans proline' 0 N--CA 1.487 1.101 1 C-N-CA 125.646 4.231 . . . . 1.0 111.133 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -127.36 155.31 43.79 Favored 'General case' 0 CA--C 1.53 0.182 0 O-C-N 121.544 -0.723 . . . . 1.0 109.368 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -97.04 101.44 13.02 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.478 -0.764 . . . . 1.0 109.459 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 15.4 tt0 -148.53 104.16 3.47 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.535 -0.728 . . . . 1.0 109.418 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 37.4 p -144.86 138.89 27.32 Favored 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.553 -0.717 . . . . 1.0 109.456 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.419 ' H ' ' HG2' ' A' ' 59' ' ' GLU . 9.8 pt-20 -105.6 153.43 21.8 Favored 'General case' 0 CA--C 1.53 0.202 0 O-C-N 121.542 -0.724 . . . . 1.0 109.437 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.02 -0.991 . . . . 1.0 109.439 179.958 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 . . . . . 0 CA--C 1.53 0.206 0 N-CA-C 109.419 -0.585 . . . . 1.0 109.419 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -166.25 39.26 0.05 Allowed 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.508 -0.745 . . . . 1.0 109.429 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -105.34 138.17 41.97 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.436 -0.79 . . . . 1.0 109.495 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 20.7 p -142.54 174.77 10.33 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.518 -0.739 . . . . 1.0 109.531 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 6.5 mm-40 -87.6 142.68 27.66 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.518 -0.739 . . . . 1.0 109.414 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.3 m -135.68 134.63 39.36 Favored 'General case' 0 CA--C 1.53 0.191 0 O-C-N 121.565 -0.709 . . . . 1.0 109.303 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.9 m -105.21 28.87 6.88 Favored 'General case' 0 C--N 1.33 -0.249 0 O-C-N 121.611 -0.681 . . . . 1.0 109.316 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.53 HG23 ' O ' ' A' ' 8' ' ' THR . 5.2 t -80.51 118.29 21.98 Favored 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.406 -0.809 . . . . 1.0 109.508 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 36.4 t -149.47 154.18 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 O-C-N 121.57 -0.706 . . . . 1.0 109.349 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.605 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -83.1 146.38 51.41 Favored Pre-proline 0 CA--C 1.537 0.472 0 O-C-N 121.472 -0.768 . . . . 1.0 109.353 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_exo -34.48 -62.19 0.21 Allowed 'Trans proline' 0 N--CA 1.489 1.235 1 C-N-CA 125.571 4.18 . . . . 1.0 111.388 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.52 -29.88 65.29 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.383 -0.823 . . . . 1.0 109.856 -179.649 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.605 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 28.4 mt-10 -80.62 3.7 21.06 Favored 'General case' 0 CA--C 1.535 0.39 0 O-C-N 121.394 -0.816 . . . . 1.0 109.932 -179.812 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 48.8 mtt180 -73.86 129.71 38.45 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.396 -0.815 . . . . 1.0 109.56 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.4 mm-40 -88.08 108.98 19.51 Favored 'General case' 0 N--CA 1.463 0.212 0 N-CA-C 109.03 -0.73 . . . . 1.0 109.03 179.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 32.9 t-20 -59.22 105.8 0.37 Allowed 'General case' 0 CA--C 1.534 0.328 0 O-C-N 121.396 -0.815 . . . . 1.0 110.391 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.434 ' H ' ' HA ' ' A' ' 45' ' ' PHE . 1.7 t -85.53 -15.22 43.43 Favored 'General case' 0 CA--C 1.535 0.391 0 O-C-N 121.489 -0.757 . . . . 1.0 109.02 179.361 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 178.57 165.28 32.89 Favored Glycine 0 CA--C 1.529 0.96 0 N-CA-C 108.99 -1.644 . . . . 1.0 108.99 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.487 ' O ' HG22 ' A' ' 22' ' ' VAL . 7.1 p90 -59.41 168.91 1.49 Allowed Pre-proline 0 CA--C 1.541 0.634 0 O-C-N 121.355 -1.085 . . . . 1.0 109.276 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 19' ' ' PHE . 10.5 Cg_endo -80.51 -30.93 1.74 Allowed 'Trans proline' 0 N--CA 1.482 0.834 0 C-N-CA 124.112 3.208 . . . . 1.0 110.662 -178.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.43 -6.33 7.93 Favored Glycine 0 CA--C 1.537 1.408 0 N-CA-C 110.05 -1.22 . . . . 1.0 110.05 179.332 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.487 HG22 ' O ' ' A' ' 19' ' ' PHE . 24.7 m -59.71 -172.79 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 O-C-N 121.079 -1.248 . . . . 1.0 109.894 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.1 p -143.63 152.79 57.21 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.639 -0.663 . . . . 1.0 109.298 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -34.98 -33.31 0.08 OUTLIER 'Trans proline' 0 N--CA 1.488 1.174 1 C-N-CA 125.396 4.064 . . . . 1.0 111.437 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 9.3 t -76.37 -48.99 18.0 Favored 'General case' 0 CA--C 1.532 0.282 0 O-C-N 121.451 -0.781 . . . . 1.0 109.865 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 66.2 mt-30 -62.71 -41.17 99.0 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.45 -0.781 . . . . 1.0 109.782 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.3 t -69.09 -27.61 65.75 Favored 'General case' 0 CA--C 1.532 0.25 0 O-C-N 121.468 -0.77 . . . . 1.0 109.465 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.48 -5.77 53.7 Favored 'General case' 0 CA--C 1.536 0.424 0 O-C-N 121.546 -0.721 . . . . 1.0 109.941 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -63.03 -51.12 67.97 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.351 -0.843 . . . . 1.0 109.617 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.83 -40.54 13.07 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.466 -0.771 . . . . 1.0 109.403 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 126.91 21.44 1.72 Allowed Glycine 0 CA--C 1.531 1.074 0 N-CA-C 109.806 -1.318 . . . . 1.0 109.806 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 14.9 m -75.93 136.65 40.08 Favored 'General case' 0 N--CA 1.464 0.268 0 O-C-N 121.466 -1.02 . . . . 1.0 108.76 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 62.0 m -65.2 141.0 58.81 Favored 'General case' 0 CA--C 1.531 0.213 0 O-C-N 121.375 -0.828 . . . . 1.0 109.444 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 35' ' ' ASP . 15.2 t80 -111.22 143.17 42.4 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.448 -0.782 . . . . 1.0 109.17 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.443 ' N ' ' CD1' ' A' ' 34' ' ' PHE . 24.8 t70 -162.21 116.19 1.82 Allowed 'General case' 0 CA--C 1.531 0.242 0 O-C-N 121.392 -0.818 . . . . 1.0 109.62 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.444 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 16.0 p30 -105.71 63.17 0.67 Allowed 'General case' 0 CA--C 1.533 0.295 0 O-C-N 121.574 -0.704 . . . . 1.0 109.478 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.6 p -87.19 -58.18 2.68 Favored 'General case' 0 CA--C 1.531 0.242 0 O-C-N 121.417 -0.802 . . . . 1.0 109.512 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 37.5 t -119.74 146.56 24.3 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 O-C-N 121.496 -0.753 . . . . 1.0 109.427 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 1.4 ptm180 -84.15 -174.94 5.56 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 121.496 -0.752 . . . . 1.0 109.358 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.89 -42.93 2.55 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 109.213 -1.555 . . . . 1.0 109.213 -179.706 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.7 m -91.23 170.08 10.35 Favored Pre-proline 0 CA--C 1.534 0.354 0 O-C-N 121.489 -1.006 . . . . 1.0 108.981 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_endo -86.64 119.51 1.64 Allowed 'Trans proline' 0 C--N 1.35 0.621 0 C-N-CA 124.479 3.453 . . . . 1.0 110.049 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.444 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 8.9 m0 -72.69 -29.25 63.24 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 109.173 -0.677 . . . . 1.0 109.173 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 12.6 t -89.66 99.38 12.39 Favored 'General case' 0 CA--C 1.533 0.31 0 N-CA-C 109.158 -0.682 . . . . 1.0 109.158 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.434 ' HA ' ' H ' ' A' ' 17' ' ' CYS . 4.3 p90 -128.91 173.99 9.9 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 121.241 -0.912 . . . . 1.0 110.083 -179.619 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.402 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 19.8 m-85 -78.67 170.91 14.05 Favored Pre-proline 0 CA--C 1.536 0.424 0 O-C-N 121.415 -0.803 . . . . 1.0 109.543 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -89.81 -178.63 1.67 Allowed 'Trans proline' 0 C--N 1.351 0.662 0 C-N-CA 125.137 3.891 . . . . 1.0 110.304 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -143.85 108.64 4.91 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.441 -0.787 . . . . 1.0 109.303 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 1.3 p -76.88 104.27 7.28 Favored 'General case' 0 N--CA 1.464 0.263 0 O-C-N 121.53 -0.731 . . . . 1.0 109.533 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 62.4 mt -127.47 150.54 33.4 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.222 0 O-C-N 121.502 -0.749 . . . . 1.0 109.298 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -80.73 175.44 10.67 Favored 'General case' 0 CA--C 1.53 0.181 0 O-C-N 121.484 -0.76 . . . . 1.0 109.428 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.613 HG23 ' O ' ' A' ' 52' ' ' VAL . 30.3 m -140.75 90.65 9.61 Favored Pre-proline 0 CA--C 1.535 0.394 0 O-C-N 121.509 -0.744 . . . . 1.0 109.503 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -91.55 163.93 3.52 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 125.118 3.879 . . . . 1.0 110.305 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.448 ' HD2' ' H ' ' A' ' 55' ' ' GLU . 21.8 Cg_endo -92.79 -21.28 0.44 Allowed 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 125.054 3.836 . . . . 1.0 110.359 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.448 ' H ' ' HD2' ' A' ' 54' ' ' PRO . 0.5 OUTLIER -98.84 150.49 21.82 Favored 'General case' 0 N--CA 1.463 0.211 0 O-C-N 121.52 -0.738 . . . . 1.0 109.571 -179.944 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 2.5 pm0 -112.34 148.69 33.71 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.577 -0.702 . . . . 1.0 109.358 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -90.13 165.23 14.1 Favored 'General case' 0 N--CA 1.463 0.196 0 O-C-N 121.461 -0.774 . . . . 1.0 109.465 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 7.9 m -75.0 111.3 10.07 Favored 'General case' 0 C--O 1.233 0.198 0 O-C-N 121.482 -0.761 . . . . 1.0 109.401 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 -118.56 166.78 12.29 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.5 -0.75 . . . . 1.0 109.416 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.047 -0.978 . . . . 1.0 109.417 179.986 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 46.9 mm-40 . . . . . 0 CA--C 1.531 0.221 0 N-CA-C 109.397 -0.594 . . . . 1.0 109.397 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -116.48 111.92 20.66 Favored 'General case' 0 N--CA 1.462 0.172 0 O-C-N 121.503 -0.748 . . . . 1.0 109.554 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 25.2 mt-30 -89.89 158.0 17.63 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.399 -0.813 . . . . 1.0 109.482 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 55.8 p -112.78 177.62 4.57 Favored 'General case' 0 CA--C 1.531 0.235 0 O-C-N 121.516 -0.74 . . . . 1.0 109.314 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -86.02 129.68 34.76 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.508 -0.745 . . . . 1.0 109.26 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.432 HG22 HG22 ' A' ' 8' ' ' THR . 3.0 m -149.23 113.69 5.28 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.45 -0.781 . . . . 1.0 109.76 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.2 m -119.67 46.07 2.01 Favored 'General case' 0 CA--C 1.532 0.273 0 O-C-N 121.528 -0.733 . . . . 1.0 109.131 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.547 HG23 ' O ' ' A' ' 8' ' ' THR . 3.3 t -128.79 80.85 1.99 Allowed 'General case' 0 CA--C 1.532 0.269 0 O-C-N 121.423 -0.798 . . . . 1.0 109.469 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.614 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.0 t -102.42 170.16 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 O-C-N 121.367 -0.833 . . . . 1.0 109.332 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.614 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -71.79 134.99 83.43 Favored Pre-proline 0 CA--C 1.539 0.547 0 O-C-N 121.52 -0.738 . . . . 1.0 109.202 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_exo -35.87 -31.13 0.08 OUTLIER 'Trans proline' 0 N--CA 1.489 1.226 0 C-N-CA 125.202 3.934 . . . . 1.0 111.554 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.464 ' H ' ' HG2' ' A' ' 12' ' ' ARG . 10.5 ptp180 -84.25 -44.75 13.57 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.392 -0.817 . . . . 1.0 110.171 -179.402 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.466 ' O ' HG11 ' A' ' 9' ' ' VAL . 5.5 mt-10 -79.07 39.81 0.39 Allowed 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.357 -0.839 . . . . 1.0 109.653 -179.616 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 63.9 mtt180 -111.22 121.46 45.33 Favored 'General case' 0 CA--C 1.531 0.232 0 O-C-N 121.391 -0.818 . . . . 1.0 109.754 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.533 ' NE2' ' H ' ' A' ' 15' ' ' GLN . 1.3 pm0 -90.16 125.21 35.38 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.488 -0.757 . . . . 1.0 108.993 179.391 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -65.0 127.56 32.1 Favored 'General case' 0 CA--C 1.534 0.347 0 O-C-N 121.454 -0.779 . . . . 1.0 110.7 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -98.16 -26.67 14.49 Favored 'General case' 0 CA--C 1.534 0.335 0 N-CA-C 108.371 -0.974 . . . . 1.0 108.371 178.714 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -165.47 171.62 40.78 Favored Glycine 0 CA--C 1.53 1.012 0 N-CA-C 108.701 -1.76 . . . . 1.0 108.701 179.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.577 ' O ' HG22 ' A' ' 22' ' ' VAL . 7.9 p90 -62.73 167.62 5.54 Favored Pre-proline 0 CA--C 1.54 0.586 0 O-C-N 121.174 -1.192 . . . . 1.0 109.153 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.21 -30.86 1.44 Allowed 'Trans proline' 0 N--CA 1.483 0.875 0 C-N-CA 124.375 3.384 . . . . 1.0 110.771 -178.642 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.28 -9.91 9.29 Favored Glycine 0 CA--C 1.538 1.479 0 N-CA-C 110.104 -1.198 . . . . 1.0 110.104 179.443 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 19' ' ' PHE . 23.4 m -60.09 169.66 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 O-C-N 121.282 -1.128 . . . . 1.0 109.721 179.802 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.543 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 38.1 p -128.55 157.89 73.56 Favored Pre-proline 0 CA--C 1.536 0.409 0 N-CA-C 109.083 -0.71 . . . . 1.0 109.083 179.608 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -36.03 -34.03 0.13 Allowed 'Trans proline' 0 N--CA 1.488 1.157 1 C-N-CA 125.364 4.042 . . . . 1.0 111.176 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 33.7 p -79.25 -45.81 19.04 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.442 -0.786 . . . . 1.0 109.965 -179.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLN . . . . . 0.543 ' HB2' ' H ' ' A' ' 23' ' ' THR . 25.7 mt-30 -62.42 -52.5 63.32 Favored 'General case' 0 N--CA 1.465 0.304 0 O-C-N 121.476 -0.765 . . . . 1.0 109.853 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 10.4 t -62.0 -33.97 75.32 Favored 'General case' 0 CA--C 1.533 0.311 0 O-C-N 121.483 -0.761 . . . . 1.0 109.765 -179.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.6 -3.13 58.31 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.336 -0.852 . . . . 1.0 110.03 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -79.08 -46.65 17.64 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.319 -0.863 . . . . 1.0 109.834 -179.593 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.2 tttt -78.82 -48.5 14.64 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 121.431 -0.793 . . . . 1.0 109.544 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 132.58 21.41 0.92 Allowed Glycine 0 CA--C 1.531 1.052 0 N-CA-C 110.281 -1.127 . . . . 1.0 110.281 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 39.9 m -91.48 138.74 31.33 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 121.246 -1.149 . . . . 1.0 108.746 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.7 m -65.17 128.04 34.19 Favored 'General case' 0 N--CA 1.464 0.242 0 O-C-N 121.303 -0.873 . . . . 1.0 109.729 -179.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 64.4 t80 -97.57 143.3 28.4 Favored 'General case' 0 C--O 1.234 0.266 0 O-C-N 121.541 -0.724 . . . . 1.0 109.155 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -152.72 103.54 2.79 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 121.363 -0.836 . . . . 1.0 109.645 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.431 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 9.5 p-10 -109.02 82.56 1.61 Allowed 'General case' 0 CA--C 1.531 0.216 0 O-C-N 121.55 -0.719 . . . . 1.0 109.426 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 49.1 p -118.63 -35.03 3.82 Favored 'General case' 0 N--CA 1.463 0.218 0 O-C-N 121.421 -0.799 . . . . 1.0 109.601 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.6 t -128.97 150.15 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 O-C-N 121.458 -0.776 . . . . 1.0 109.396 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 22.3 ttt180 -87.08 168.18 13.52 Favored 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.468 -0.77 . . . . 1.0 109.384 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.43 -52.03 4.58 Favored Glycine 0 CA--C 1.529 0.907 0 N-CA-C 109.529 -1.428 . . . . 1.0 109.529 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 27.6 m -74.14 169.2 20.21 Favored Pre-proline 0 CA--C 1.536 0.419 0 O-C-N 121.551 -0.97 . . . . 1.0 109.324 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_endo -88.92 130.43 2.15 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 124.883 3.722 . . . . 1.0 110.219 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.431 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 7.7 m0 -87.95 -36.44 17.09 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.423 -0.798 . . . . 1.0 109.509 -179.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 8.0 t -89.44 102.96 15.63 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 109.144 -0.687 . . . . 1.0 109.144 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.406 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 3.6 p90 -134.55 174.23 10.78 Favored 'General case' 0 CA--C 1.538 0.497 0 O-C-N 121.304 -0.873 . . . . 1.0 110.083 -179.414 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.406 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 45.3 m-85 -76.6 170.5 15.87 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 121.435 -0.791 . . . . 1.0 109.495 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_endo -90.18 161.83 4.73 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 124.928 3.752 . . . . 1.0 110.454 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -136.16 107.43 6.82 Favored 'General case' 0 N--CA 1.463 0.194 0 O-C-N 121.569 -0.707 . . . . 1.0 109.384 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 62.4 p -81.71 107.45 14.46 Favored 'General case' 0 C--N 1.332 -0.182 0 O-C-N 121.504 -0.747 . . . . 1.0 109.444 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 57.9 mt -128.34 155.76 40.21 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 O-C-N 121.412 -0.805 . . . . 1.0 109.307 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -78.14 107.93 11.07 Favored 'General case' 0 CA--C 1.53 0.209 0 O-C-N 121.41 -0.806 . . . . 1.0 109.524 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.8 m -131.24 147.96 68.27 Favored Pre-proline 0 CA--C 1.537 0.475 0 O-C-N 121.514 -0.741 . . . . 1.0 109.537 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.466 ' N ' ' HD2' ' A' ' 54' ' ' PRO . 6.6 Cg_exo -37.54 -59.72 0.48 Allowed 'Trans proline' 0 N--CA 1.486 1.051 0 C-N-CA 125.218 3.945 . . . . 1.0 111.374 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.466 ' HD2' ' N ' ' A' ' 53' ' ' PRO . 21.1 Cg_exo -33.76 131.14 0.15 Allowed 'Trans proline' 0 C--N 1.363 1.329 0 C-N-CA 125.228 3.952 . . . . 1.0 111.547 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -76.22 175.09 9.34 Favored 'General case' 0 CA--C 1.532 0.27 0 O-C-N 121.523 -0.736 . . . . 1.0 109.496 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.419 ' H ' ' HG3' ' A' ' 56' ' ' GLU . 0.0 OUTLIER -115.17 161.49 18.34 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.528 -0.733 . . . . 1.0 109.487 179.863 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 20.4 mm-40 -108.01 118.42 36.7 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.474 -0.766 . . . . 1.0 109.537 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 60.3 p -103.77 134.32 47.28 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.519 -0.738 . . . . 1.0 109.407 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -95.0 151.01 19.53 Favored 'General case' 0 N--CA 1.463 0.214 0 O-C-N 121.517 -0.74 . . . . 1.0 109.436 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.952 -1.023 . . . . 1.0 109.389 179.95 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 . . . . . 0 C--O 1.232 0.173 0 N-CA-C 109.485 -0.561 . . . . 1.0 109.485 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -144.41 48.62 1.35 Allowed 'General case' 0 CA--C 1.533 0.31 0 O-C-N 121.485 -0.759 . . . . 1.0 109.266 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.595 ' O ' HG23 ' A' ' 4' ' ' THR . 4.3 mp0 -100.76 96.85 7.59 Favored 'General case' 0 C--N 1.331 -0.215 0 O-C-N 121.521 -0.737 . . . . 1.0 109.378 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.595 HG23 ' O ' ' A' ' 3' ' ' GLN . 0.8 OUTLIER -160.01 -177.37 6.26 Favored 'General case' 0 CA--C 1.532 0.25 0 O-C-N 121.414 -0.804 . . . . 1.0 109.482 -179.923 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -89.55 135.21 33.73 Favored 'General case' 0 CA--C 1.531 0.242 0 O-C-N 121.482 -0.761 . . . . 1.0 109.549 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 31.7 m -127.97 132.73 49.17 Favored 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.479 -0.763 . . . . 1.0 109.193 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.3 m -124.67 -6.23 7.48 Favored 'General case' 0 CA--C 1.535 0.393 0 O-C-N 121.446 -0.783 . . . . 1.0 109.92 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.405 ' O ' HG23 ' A' ' 8' ' ' THR . 3.6 t -70.17 126.94 31.11 Favored 'General case' 0 N--CA 1.463 0.215 0 O-C-N 121.215 -0.928 . . . . 1.0 109.434 179.713 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.636 HG12 ' N ' ' A' ' 10' ' ' ALA . 26.0 t -142.34 173.64 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 O-C-N 121.513 -0.742 . . . . 1.0 109.37 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.636 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -77.96 136.84 61.89 Favored Pre-proline 0 CA--C 1.54 0.595 0 O-C-N 121.477 -0.764 . . . . 1.0 109.566 -179.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_exo -36.0 -38.24 0.27 Allowed 'Trans proline' 0 N--CA 1.489 1.216 1 C-N-CA 125.314 4.01 . . . . 1.0 111.442 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 40.4 mtp85 -85.11 -39.97 17.31 Favored 'General case' 0 N--CA 1.465 0.321 0 O-C-N 121.362 -0.836 . . . . 1.0 110.02 -179.282 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.63 ' O ' HG11 ' A' ' 9' ' ' VAL . 11.6 mt-10 -79.11 39.67 0.39 Allowed 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.427 -0.795 . . . . 1.0 109.671 -179.624 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 39.3 mtt180 -107.8 125.91 52.0 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.464 -0.772 . . . . 1.0 109.672 179.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.0 mp0 -94.76 113.13 24.86 Favored 'General case' 0 CA--C 1.532 0.284 0 O-C-N 121.472 -0.768 . . . . 1.0 109.224 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -59.74 126.17 26.53 Favored 'General case' 0 CA--C 1.533 0.314 0 O-C-N 121.411 -0.805 . . . . 1.0 110.252 -179.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -98.58 -18.63 18.03 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 121.565 -0.71 . . . . 1.0 109.094 179.582 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -173.21 176.67 45.89 Favored Glycine 0 CA--C 1.529 0.935 0 N-CA-C 108.834 -1.706 . . . . 1.0 108.834 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.568 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.4 p90 -65.87 167.34 11.83 Favored Pre-proline 0 CA--C 1.538 0.491 0 O-C-N 121.289 -1.124 . . . . 1.0 108.923 179.771 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.55 -29.46 1.83 Allowed 'Trans proline' 0 N--CA 1.483 0.894 0 C-N-CA 124.492 3.461 . . . . 1.0 110.897 -178.528 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.43 -11.58 10.34 Favored Glycine 0 CA--C 1.538 1.474 0 N-CA-C 110.192 -1.163 . . . . 1.0 110.192 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.568 HG22 ' O ' ' A' ' 19' ' ' PHE . 22.7 m -61.06 -171.8 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 O-C-N 121.354 -1.086 . . . . 1.0 109.72 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 43.3 p -147.1 152.52 43.59 Favored Pre-proline 0 CA--C 1.535 0.393 0 O-C-N 121.527 -0.733 . . . . 1.0 109.168 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_exo -35.15 -31.43 0.07 OUTLIER 'Trans proline' 0 N--CA 1.488 1.187 1 C-N-CA 125.575 4.183 . . . . 1.0 111.224 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 78.9 p -77.21 -51.21 11.33 Favored 'General case' 0 CA--C 1.532 0.271 0 O-C-N 121.491 -0.756 . . . . 1.0 109.752 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 68.8 mt-30 -63.08 -46.93 85.11 Favored 'General case' 0 N--CA 1.464 0.252 0 O-C-N 121.493 -0.755 . . . . 1.0 109.97 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 13.1 t -62.36 -33.15 74.15 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 121.419 -0.8 . . . . 1.0 109.82 -179.709 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.84 -3.96 58.61 Favored 'General case' 0 CA--C 1.534 0.346 0 O-C-N 121.444 -0.785 . . . . 1.0 110.056 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -79.73 -39.31 31.4 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.37 -0.831 . . . . 1.0 109.809 -179.534 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 35.4 mtmt -85.18 -46.58 10.95 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.396 -0.815 . . . . 1.0 109.938 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 137.91 11.58 0.93 Allowed Glycine 0 CA--C 1.533 1.174 0 N-CA-C 110.246 -1.141 . . . . 1.0 110.246 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 35.0 m -86.91 136.88 32.79 Favored 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.353 -1.086 . . . . 1.0 108.71 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.6 m -69.7 126.08 28.64 Favored 'General case' 0 N--CA 1.465 0.302 0 O-C-N 121.249 -0.907 . . . . 1.0 109.924 -179.704 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.451 ' CE1' ' HB2' ' A' ' 43' ' ' TRP . 50.3 t80 -94.79 147.34 23.44 Favored 'General case' 0 CA--C 1.531 0.22 0 N-CA-C 109.156 -0.683 . . . . 1.0 109.156 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -154.04 96.31 1.94 Allowed 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.454 -0.779 . . . . 1.0 109.631 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.421 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 6.7 p-10 -104.48 70.64 0.96 Allowed 'General case' 0 CA--C 1.533 0.299 0 O-C-N 121.523 -0.736 . . . . 1.0 109.25 179.821 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 18.2 p -117.64 -42.47 2.86 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.356 -0.84 . . . . 1.0 109.407 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.431 HG12 ' N ' ' A' ' 39' ' ' ARG . 37.4 t -111.2 159.23 11.32 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 O-C-N 121.438 -0.789 . . . . 1.0 109.415 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.431 ' N ' HG12 ' A' ' 38' ' ' VAL . 16.4 ttp-105 -100.33 170.37 8.47 Favored 'General case' 0 C--O 1.233 0.201 0 O-C-N 121.412 -0.805 . . . . 1.0 109.425 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.46 -58.29 5.0 Favored Glycine 0 CA--C 1.529 0.922 0 N-CA-C 109.511 -1.436 . . . . 1.0 109.511 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.5 m -70.23 169.25 14.13 Favored Pre-proline 0 CA--C 1.537 0.448 0 O-C-N 121.491 -1.006 . . . . 1.0 109.233 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -87.39 127.11 2.38 Favored 'Trans proline' 0 C--N 1.352 0.72 0 C-N-CA 124.721 3.614 . . . . 1.0 110.15 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.451 ' HB2' ' CE1' ' A' ' 34' ' ' PHE . 11.2 m0 -73.62 -43.45 59.55 Favored 'General case' 0 N--CA 1.464 0.248 0 O-C-N 121.593 -0.692 . . . . 1.0 109.603 -179.665 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 12.3 t -88.3 110.99 21.2 Favored 'General case' 0 CA--C 1.535 0.382 0 O-C-N 121.452 -0.78 . . . . 1.0 109.578 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.401 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 4.2 p90 -141.89 175.9 9.36 Favored 'General case' 0 CA--C 1.538 0.507 0 O-C-N 121.353 -0.842 . . . . 1.0 109.974 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.401 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 18.1 m-85 -74.83 171.43 11.63 Favored Pre-proline 0 CA--C 1.536 0.432 0 O-C-N 121.472 -0.767 . . . . 1.0 109.889 -179.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -94.42 -178.82 0.64 Allowed 'Trans proline' 0 C--N 1.351 0.691 1 C-N-CA 125.336 4.024 . . . . 1.0 110.919 -179.647 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.457 HD22 ' CG2' ' A' ' 9' ' ' VAL . 19.4 m-20 -158.29 82.84 0.84 Allowed 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.602 -0.687 . . . . 1.0 109.214 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 56.4 p -76.67 135.09 39.11 Favored 'General case' 0 N--CA 1.464 0.231 0 O-C-N 121.416 -0.803 . . . . 1.0 109.582 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.409 HG22 ' N ' ' A' ' 51' ' ' ASP . 38.1 mt -121.85 157.5 25.87 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 O-C-N 121.511 -0.743 . . . . 1.0 109.345 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.409 ' N ' HG22 ' A' ' 50' ' ' ILE . 3.7 p30 -164.82 151.25 10.53 Favored 'General case' 0 CA--C 1.531 0.237 0 O-C-N 121.53 -0.731 . . . . 1.0 109.285 179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 29.5 m -80.35 140.54 52.52 Favored Pre-proline 0 CA--C 1.537 0.463 0 O-C-N 121.38 -0.825 . . . . 1.0 109.439 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -34.83 91.09 0.01 OUTLIER 'Trans proline' 0 N--CA 1.487 1.143 1 C-N-CA 125.485 4.124 . . . . 1.0 111.325 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -92.2 -67.66 0.01 OUTLIER 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 125.094 3.862 . . . . 1.0 110.297 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -147.15 128.98 15.31 Favored 'General case' 0 CA--C 1.53 0.207 0 O-C-N 121.486 -0.759 . . . . 1.0 109.378 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -82.19 164.18 21.41 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.485 -0.759 . . . . 1.0 109.428 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 1.8 tp10 -127.7 103.72 7.46 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.439 -0.788 . . . . 1.0 109.493 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.5 p -97.41 126.8 42.89 Favored 'General case' 0 CA--C 1.53 0.191 0 O-C-N 121.539 -0.725 . . . . 1.0 109.387 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -136.02 106.81 6.59 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.399 -0.813 . . . . 1.0 109.367 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.419 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 20.5 p90 . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 117.996 -1.002 . . . . 1.0 109.507 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 . . . . . 0 CA--C 1.531 0.216 0 N-CA-C 109.329 -0.619 . . . . 1.0 109.329 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -146.93 83.72 1.59 Allowed 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.522 -0.736 . . . . 1.0 109.371 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -136.87 101.82 4.7 Favored 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.521 -0.737 . . . . 1.0 109.394 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 61.8 p -124.55 140.96 52.46 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 121.506 -0.746 . . . . 1.0 109.494 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 9.8 mp0 -109.73 139.88 44.26 Favored 'General case' 0 CA--C 1.531 0.246 0 O-C-N 121.565 -0.709 . . . . 1.0 109.422 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.461 HG22 HG22 ' A' ' 8' ' ' THR . 1.6 m -150.01 137.07 19.51 Favored 'General case' 0 C--O 1.233 0.191 0 O-C-N 121.543 -0.723 . . . . 1.0 109.574 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 77.6 m -110.51 34.68 3.81 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.523 -0.736 . . . . 1.0 109.229 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.461 HG22 HG22 ' A' ' 6' ' ' THR . 5.0 t -91.96 125.64 36.73 Favored 'General case' 0 CA--C 1.532 0.264 0 O-C-N 121.507 -0.745 . . . . 1.0 109.677 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.499 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.7 t -146.88 163.7 8.02 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 109.085 -0.709 . . . . 1.0 109.085 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.788 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -78.59 136.59 59.46 Favored Pre-proline 0 CA--C 1.541 0.624 0 O-C-N 121.467 -0.771 . . . . 1.0 109.233 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_exo -34.74 -57.81 0.4 Allowed 'Trans proline' 0 N--CA 1.488 1.196 1 C-N-CA 125.457 4.105 . . . . 1.0 111.416 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.2 mmt180 -74.49 -32.28 62.49 Favored 'General case' 0 N--CA 1.463 0.194 0 O-C-N 121.488 -0.758 . . . . 1.0 109.895 -179.616 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.788 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 9.5 mt-10 -83.05 21.93 1.01 Allowed 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.348 -0.845 . . . . 1.0 109.73 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 69.0 mtt180 -89.98 126.03 35.6 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.444 -0.785 . . . . 1.0 109.418 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -89.01 121.42 31.35 Favored 'General case' 0 CA--C 1.53 0.197 0 O-C-N 121.52 -0.738 . . . . 1.0 109.092 179.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -69.04 118.61 12.16 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.421 -0.799 . . . . 1.0 109.484 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -88.29 -24.16 23.26 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.48 -0.762 . . . . 1.0 109.065 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -169.74 173.79 43.95 Favored Glycine 0 CA--C 1.529 0.914 0 N-CA-C 109.085 -1.606 . . . . 1.0 109.085 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.559 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.5 p90 -66.5 167.59 12.57 Favored Pre-proline 0 CA--C 1.538 0.493 0 O-C-N 121.439 -1.036 . . . . 1.0 108.924 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -82.09 -30.21 1.35 Allowed 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 124.441 3.427 . . . . 1.0 110.801 -178.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.05 -11.33 8.57 Favored Glycine 0 CA--C 1.537 1.46 0 N-CA-C 110.329 -1.108 . . . . 1.0 110.329 179.593 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 19' ' ' PHE . 22.3 m -60.73 -169.98 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 O-C-N 121.334 -1.098 . . . . 1.0 109.702 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.506 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 12.8 p -140.85 156.13 68.83 Favored Pre-proline 0 CA--C 1.534 0.356 0 N-CA-C 109.096 -0.705 . . . . 1.0 109.096 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_exo -38.16 -36.23 0.49 Allowed 'Trans proline' 0 N--CA 1.487 1.143 0 C-N-CA 125.14 3.893 . . . . 1.0 110.998 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.3 t -75.98 -41.46 51.29 Favored 'General case' 0 CA--C 1.532 0.273 0 O-C-N 121.557 -0.714 . . . . 1.0 110.141 -179.473 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLN . . . . . 0.506 ' HB2' ' H ' ' A' ' 23' ' ' THR . 5.1 mt-30 -65.2 -50.79 64.51 Favored 'General case' 0 CA--C 1.532 0.261 0 O-C-N 121.431 -0.793 . . . . 1.0 110.002 -179.638 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 11.4 t -61.67 -32.3 72.47 Favored 'General case' 0 CA--C 1.533 0.319 0 O-C-N 121.335 -0.853 . . . . 1.0 109.914 -179.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -89.18 -3.93 58.42 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 121.497 -0.752 . . . . 1.0 110.109 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 41.6 t-20 -73.8 -53.55 10.01 Favored 'General case' 0 N--CA 1.464 0.245 0 O-C-N 121.392 -0.818 . . . . 1.0 109.523 -179.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.2 mttt -73.19 -48.09 38.18 Favored 'General case' 0 C--N 1.332 -0.182 0 O-C-N 121.515 -0.74 . . . . 1.0 109.375 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 136.8 15.67 0.82 Allowed Glycine 0 CA--C 1.532 1.119 0 N-CA-C 109.647 -1.381 . . . . 1.0 109.647 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 36.4 m -82.12 140.61 33.7 Favored 'General case' 0 N--CA 1.463 0.218 0 O-C-N 121.345 -1.091 . . . . 1.0 108.731 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 69.3 m -71.5 123.27 22.05 Favored 'General case' 0 C--N 1.332 -0.189 0 O-C-N 121.368 -0.833 . . . . 1.0 109.66 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 37.0 t80 -94.71 142.72 27.13 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.46 -0.775 . . . . 1.0 109.169 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -160.45 98.96 1.28 Allowed 'General case' 0 C--O 1.233 0.194 0 O-C-N 121.513 -0.742 . . . . 1.0 109.47 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.447 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.0 p-10 -107.44 76.28 1.07 Allowed 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.457 -0.777 . . . . 1.0 109.486 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 70.1 p -120.15 -38.54 2.91 Favored 'General case' 0 CA--C 1.533 0.291 0 O-C-N 121.468 -0.77 . . . . 1.0 109.654 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.8 t -110.75 144.5 18.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 O-C-N 121.397 -0.815 . . . . 1.0 109.7 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.2 mmt180 -88.69 177.16 6.82 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.547 -0.721 . . . . 1.0 109.487 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.71 -62.57 4.36 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 109.092 -1.603 . . . . 1.0 109.092 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 28.7 m -73.1 170.23 14.61 Favored Pre-proline 0 CA--C 1.536 0.406 0 O-C-N 121.63 -0.924 . . . . 1.0 109.096 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -84.34 150.76 11.95 Favored 'Trans proline' 0 C--N 1.351 0.662 0 C-N-CA 124.366 3.377 . . . . 1.0 109.901 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.447 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 7.8 m0 -94.68 -40.58 9.73 Favored 'General case' 0 N--CA 1.465 0.284 0 O-C-N 121.545 -0.722 . . . . 1.0 109.639 -179.218 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 22.7 t -90.29 105.55 17.89 Favored 'General case' 0 CA--C 1.534 0.364 0 O-C-N 121.416 -0.802 . . . . 1.0 109.448 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.433 ' CD1' ' N ' ' A' ' 45' ' ' PHE . 4.9 p90 -128.99 179.26 5.84 Favored 'General case' 0 CA--C 1.534 0.338 0 O-C-N 121.395 -0.816 . . . . 1.0 109.9 -179.863 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.401 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 17.8 m-85 -80.97 170.71 14.48 Favored Pre-proline 0 CA--C 1.538 0.482 0 O-C-N 121.391 -0.818 . . . . 1.0 109.835 -179.596 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -90.58 169.6 3.83 Favored 'Trans proline' 0 C--N 1.352 0.736 0 C-N-CA 124.981 3.787 . . . . 1.0 110.58 179.798 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -141.3 79.77 1.7 Allowed 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.469 -0.77 . . . . 1.0 109.011 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 68.5 p -88.65 140.68 29.2 Favored 'General case' 0 CA--C 1.529 0.168 0 O-C-N 121.479 -0.763 . . . . 1.0 109.702 -179.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 41.9 mt -100.17 149.58 5.89 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 N-CA-C 108.963 -0.754 . . . . 1.0 108.963 179.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -136.14 172.88 12.36 Favored 'General case' 0 CA--C 1.53 0.179 0 O-C-N 121.397 -0.815 . . . . 1.0 109.888 -179.762 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 52' ' ' VAL . 31.6 m -108.67 79.77 1.1 Allowed Pre-proline 0 CA--C 1.538 0.507 0 O-C-N 121.619 -0.676 . . . . 1.0 109.344 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.474 ' N ' ' HD2' ' A' ' 54' ' ' PRO . 9.8 Cg_exo -35.56 -59.14 0.39 Allowed 'Trans proline' 0 N--CA 1.487 1.137 0 C-N-CA 125.234 3.956 . . . . 1.0 111.583 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.474 ' HD2' ' N ' ' A' ' 53' ' ' PRO . 20.9 Cg_exo -33.83 -51.89 0.54 Allowed 'Trans proline' 0 N--CA 1.49 1.277 0 C-N-CA 125.253 3.969 . . . . 1.0 111.479 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -107.53 118.43 36.7 Favored 'General case' 0 N--CA 1.463 0.203 0 O-C-N 121.501 -0.749 . . . . 1.0 109.394 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -138.76 109.49 6.66 Favored 'General case' 0 N--CA 1.464 0.226 0 O-C-N 121.472 -0.768 . . . . 1.0 109.414 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -141.18 150.53 42.85 Favored 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.527 -0.733 . . . . 1.0 109.33 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 16.5 p -141.27 152.68 44.71 Favored 'General case' 0 CA--C 1.531 0.246 0 O-C-N 121.547 -0.721 . . . . 1.0 109.445 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 9.1 tt0 -75.11 166.92 22.9 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.527 -0.733 . . . . 1.0 109.438 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 4.6 t80 . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.934 -1.031 . . . . 1.0 109.462 -179.995 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 . . . . . 0 CA--C 1.532 0.256 0 CA-C-O 121.353 0.597 . . . . 1.0 109.406 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -120.72 -169.46 1.82 Allowed 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.349 -0.844 . . . . 1.0 109.381 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.481 ' O ' HG23 ' A' ' 4' ' ' THR . 26.0 mt-30 -111.87 99.3 8.01 Favored 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.432 -0.793 . . . . 1.0 109.447 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.481 HG23 ' O ' ' A' ' 3' ' ' GLN . 15.3 p -155.56 158.73 38.9 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.444 -0.785 . . . . 1.0 109.367 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -67.1 146.59 54.13 Favored 'General case' 0 C--N 1.331 -0.201 0 O-C-N 121.568 -0.708 . . . . 1.0 109.393 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.941 HG22 HG22 ' A' ' 8' ' ' THR . 2.3 m -132.24 124.64 29.34 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.462 -0.774 . . . . 1.0 109.625 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 75.8 m -110.73 13.67 22.37 Favored 'General case' 0 CA--C 1.534 0.346 0 O-C-N 121.482 -0.761 . . . . 1.0 109.623 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.941 HG22 HG22 ' A' ' 6' ' ' THR . 4.4 t -93.97 104.69 16.73 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.444 -0.785 . . . . 1.0 109.565 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.515 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.6 t -123.4 164.43 21.11 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 O-C-N 121.557 -0.714 . . . . 1.0 109.29 179.798 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.515 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -69.4 121.96 83.92 Favored Pre-proline 0 CA--C 1.54 0.569 0 O-C-N 121.434 -0.791 . . . . 1.0 109.155 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.479 ' HB3' HG11 ' A' ' 41' ' ' VAL . 17.6 Cg_exo -38.36 -28.22 0.12 Allowed 'Trans proline' 0 N--CA 1.49 1.29 0 C-N-CA 124.749 3.633 . . . . 1.0 111.357 -179.653 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 64.8 mtt180 -84.25 -41.26 17.09 Favored 'General case' 0 CA--C 1.533 0.292 0 O-C-N 121.37 -0.831 . . . . 1.0 110.171 -179.252 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 15.0 mm-40 -92.43 44.88 1.17 Allowed 'General case' 0 N--CA 1.464 0.257 0 O-C-N 121.45 -0.781 . . . . 1.0 109.748 -179.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.408 ' HD3' ' CD2' ' A' ' 45' ' ' PHE . 19.3 mtt180 -106.81 141.63 37.73 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.332 -0.855 . . . . 1.0 109.603 179.767 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 16.5 mt-30 -111.11 126.67 55.08 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 108.918 -0.771 . . . . 1.0 108.918 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -67.73 117.32 9.49 Favored 'General case' 0 CA--C 1.532 0.285 0 O-C-N 121.427 -0.796 . . . . 1.0 110.673 -178.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.482 ' H ' ' HA ' ' A' ' 45' ' ' PHE . 3.0 t -72.64 -31.32 65.03 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 108.665 -0.865 . . . . 1.0 108.665 178.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -152.88 178.92 29.73 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 109.306 -1.517 . . . . 1.0 109.306 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.534 ' O ' HG22 ' A' ' 22' ' ' VAL . 6.6 p90 -62.03 169.28 2.89 Favored Pre-proline 0 CA--C 1.541 0.634 0 O-C-N 121.387 -1.067 . . . . 1.0 108.889 179.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 19' ' ' PHE . 10.6 Cg_endo -80.43 -31.92 1.44 Allowed 'Trans proline' 0 N--CA 1.482 0.838 0 C-N-CA 124.044 3.163 . . . . 1.0 110.762 -178.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.2 -3.21 6.24 Favored Glycine 0 CA--C 1.537 1.423 0 N-CA-C 110.196 -1.161 . . . . 1.0 110.196 179.704 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.534 HG22 ' O ' ' A' ' 19' ' ' PHE . 21.9 m -62.82 170.73 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 O-C-N 121.148 -1.207 . . . . 1.0 109.686 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.8 p -130.21 155.72 80.41 Favored Pre-proline 0 CA--C 1.534 0.361 0 N-CA-C 108.962 -0.755 . . . . 1.0 108.962 179.714 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -35.95 -38.7 0.28 Allowed 'Trans proline' 0 N--CA 1.488 1.18 0 C-N-CA 125.254 3.969 . . . . 1.0 111.188 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 79.4 p -70.9 -46.23 62.91 Favored 'General case' 0 CA--C 1.533 0.291 0 O-C-N 121.447 -0.783 . . . . 1.0 110.043 -179.583 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -62.19 -49.1 77.12 Favored 'General case' 0 N--CA 1.465 0.321 0 O-C-N 121.366 -0.834 . . . . 1.0 110.024 -179.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 7.2 t -62.54 -25.12 67.88 Favored 'General case' 0 CA--C 1.533 0.297 0 O-C-N 121.407 -0.808 . . . . 1.0 109.808 -179.715 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -95.95 -5.32 41.62 Favored 'General case' 0 CA--C 1.534 0.363 0 O-C-N 121.391 -0.818 . . . . 1.0 110.309 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -98.11 -23.39 15.75 Favored 'General case' 0 N--CA 1.465 0.281 0 O-C-N 121.223 -0.923 . . . . 1.0 109.726 -179.619 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.1 mmtm -91.41 -15.2 29.29 Favored 'General case' 0 CA--C 1.533 0.289 0 O-C-N 121.311 -0.868 . . . . 1.0 109.736 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.99 14.81 41.29 Favored Glycine 0 CA--C 1.532 1.143 0 N-CA-C 109.988 -1.245 . . . . 1.0 109.988 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 56.3 m -94.3 148.52 22.13 Favored 'General case' 0 N--CA 1.465 0.298 0 O-C-N 121.402 -1.058 . . . . 1.0 108.808 179.843 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.454 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 58.4 m -80.7 126.71 31.63 Favored 'General case' 0 CA--C 1.532 0.267 0 O-C-N 121.343 -0.848 . . . . 1.0 109.713 -179.638 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -98.84 128.13 44.96 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 108.799 -0.815 . . . . 1.0 108.799 179.334 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -141.38 117.32 10.5 Favored 'General case' 0 N--CA 1.464 0.256 0 O-C-N 121.465 -0.772 . . . . 1.0 109.864 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.438 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 7.2 p-10 -112.14 72.92 0.79 Allowed 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.594 -0.691 . . . . 1.0 109.21 179.513 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 1.1 p -104.08 -61.92 1.38 Allowed 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.368 -0.832 . . . . 1.0 109.619 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.6 t -103.5 154.72 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 O-C-N 121.451 -0.781 . . . . 1.0 109.415 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.94 171.85 8.85 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 121.479 -0.763 . . . . 1.0 109.487 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.08 -49.64 4.15 Favored Glycine 0 CA--C 1.529 0.966 0 N-CA-C 109.477 -1.449 . . . . 1.0 109.477 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.479 HG11 ' HB3' ' A' ' 11' ' ' PRO . 29.7 m -73.81 169.36 19.06 Favored Pre-proline 0 CA--C 1.536 0.422 0 O-C-N 121.553 -0.969 . . . . 1.0 109.333 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_endo -89.08 127.1 1.74 Allowed 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 124.838 3.692 . . . . 1.0 109.901 179.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.438 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 13.6 m0 -77.27 -51.5 10.8 Favored 'General case' 0 CA--C 1.531 0.229 0 O-C-N 121.51 -0.744 . . . . 1.0 109.367 -179.719 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 5.2 t -74.88 111.63 10.28 Favored 'General case' 0 CA--C 1.531 0.241 0 N-CA-C 108.616 -0.883 . . . . 1.0 108.616 179.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.482 ' HA ' ' H ' ' A' ' 17' ' ' CYS . 2.3 p90 -140.86 175.32 9.71 Favored 'General case' 0 N--CA 1.468 0.429 0 O-C-N 121.449 -0.782 . . . . 1.0 110.185 -179.686 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 41.7 m-85 -74.17 160.55 81.3 Favored Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 121.405 -0.81 . . . . 1.0 110.128 -179.243 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -90.03 174.32 3.23 Favored 'Trans proline' 0 C--N 1.352 0.74 0 C-N-CA 124.96 3.774 . . . . 1.0 110.401 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -132.82 92.18 3.01 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 121.541 -0.724 . . . . 1.0 109.491 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 12.0 p -86.55 94.99 9.59 Favored 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.449 -0.782 . . . . 1.0 109.259 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 36.1 mt -118.66 146.52 23.14 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 O-C-N 121.475 -0.765 . . . . 1.0 109.394 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -110.3 154.78 22.99 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 121.465 -0.772 . . . . 1.0 109.404 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.587 HG23 ' O ' ' A' ' 52' ' ' VAL . 28.0 m -139.84 92.44 9.94 Favored Pre-proline 0 CA--C 1.537 0.455 0 O-C-N 121.446 -0.784 . . . . 1.0 109.479 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -91.48 175.06 2.33 Favored 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 125.059 3.84 . . . . 1.0 110.299 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -91.47 -4.48 4.17 Favored 'Trans proline' 0 C--N 1.35 0.645 0 C-N-CA 125.006 3.804 . . . . 1.0 110.616 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 22.0 mt-10 -113.77 114.93 27.0 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.432 -0.792 . . . . 1.0 109.422 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -86.83 110.04 19.69 Favored 'General case' 0 C--N 1.332 -0.178 0 O-C-N 121.465 -0.772 . . . . 1.0 109.484 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -141.38 173.99 10.97 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 121.433 -0.792 . . . . 1.0 109.474 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.5 m -79.31 116.88 19.83 Favored 'General case' 0 CA--C 1.531 0.216 0 O-C-N 121.534 -0.729 . . . . 1.0 109.451 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -146.49 159.77 42.97 Favored 'General case' 0 N--CA 1.463 0.204 0 O-C-N 121.602 -0.686 . . . . 1.0 109.418 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.053 -0.975 . . . . 1.0 109.465 179.97 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 . . . . . 0 CA--C 1.529 0.171 0 N-CA-C 109.382 -0.599 . . . . 1.0 109.382 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -155.89 20.55 0.38 Allowed 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.423 -0.798 . . . . 1.0 109.68 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.659 ' O ' HG23 ' A' ' 4' ' ' THR . 62.0 mm-40 -146.52 95.56 2.62 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.384 -0.822 . . . . 1.0 109.395 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.659 HG23 ' O ' ' A' ' 3' ' ' GLN . 0.9 OUTLIER -161.52 -165.38 1.28 Allowed 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.556 -0.715 . . . . 1.0 109.492 -179.966 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -103.0 132.13 49.48 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.536 -0.727 . . . . 1.0 109.2 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.479 ' HB ' HG22 ' A' ' 8' ' ' THR . 1.7 m -150.26 146.13 26.61 Favored 'General case' 0 CA--C 1.53 0.209 0 O-C-N 121.403 -0.811 . . . . 1.0 109.402 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 73.1 m -86.95 11.97 12.27 Favored 'General case' 0 CA--C 1.534 0.35 0 O-C-N 121.544 -0.722 . . . . 1.0 109.641 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.535 HG23 ' O ' ' A' ' 8' ' ' THR . 5.4 t -85.41 117.96 24.65 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.257 -0.902 . . . . 1.0 109.677 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 10' ' ' ALA . 37.7 t -140.95 168.24 16.5 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 O-C-N 121.419 -0.8 . . . . 1.0 109.126 179.649 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.579 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -84.42 138.32 38.82 Favored Pre-proline 0 CA--C 1.538 0.487 0 O-C-N 121.351 -0.843 . . . . 1.0 109.439 -179.908 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_exo -34.75 -40.38 0.22 Allowed 'Trans proline' 0 N--CA 1.489 1.222 1 C-N-CA 125.511 4.141 . . . . 1.0 111.276 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 25.7 mtt85 -85.26 -46.57 10.9 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.472 -0.767 . . . . 1.0 109.699 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -67.31 -5.0 12.33 Favored 'General case' 0 CA--C 1.534 0.328 0 O-C-N 121.505 -0.747 . . . . 1.0 110.023 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.8 mtt180 -70.38 126.11 28.72 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.36 -0.838 . . . . 1.0 109.52 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 11.2 mm100 -87.07 123.09 31.76 Favored 'General case' 0 C--N 1.332 -0.168 0 O-C-N 121.478 -0.764 . . . . 1.0 109.252 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -65.7 111.39 3.18 Favored 'General case' 0 N--CA 1.464 0.238 0 O-C-N 121.559 -0.713 . . . . 1.0 109.745 -179.709 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 41.8 t -82.04 -16.42 50.23 Favored 'General case' 0 CA--C 1.534 0.351 0 O-C-N 121.431 -0.793 . . . . 1.0 109.339 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.59 179.08 44.01 Favored Glycine 0 CA--C 1.528 0.855 0 N-CA-C 109.061 -1.615 . . . . 1.0 109.061 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.551 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.2 p90 -65.04 167.73 9.01 Favored Pre-proline 0 CA--C 1.539 0.548 0 O-C-N 121.306 -1.114 . . . . 1.0 108.838 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.54 -30.59 1.42 Allowed 'Trans proline' 0 N--CA 1.482 0.814 0 C-N-CA 124.39 3.393 . . . . 1.0 110.881 -178.658 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.62 -8.77 7.9 Favored Glycine 0 CA--C 1.537 1.441 0 N-CA-C 110.25 -1.14 . . . . 1.0 110.25 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.551 HG22 ' O ' ' A' ' 19' ' ' PHE . 20.0 m -61.16 177.24 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 O-C-N 121.228 -1.16 . . . . 1.0 109.669 179.766 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.0 p -138.89 156.24 72.73 Favored Pre-proline 0 CA--C 1.535 0.389 0 O-C-N 121.54 -0.725 . . . . 1.0 109.225 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -34.91 -32.04 0.07 OUTLIER 'Trans proline' 0 N--CA 1.487 1.12 1 C-N-CA 125.56 4.174 . . . . 1.0 111.171 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 1.8 m -72.12 -51.94 19.08 Favored 'General case' 0 CA--C 1.532 0.281 0 O-C-N 121.419 -0.801 . . . . 1.0 109.614 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 52.3 mt-30 -62.78 -46.01 90.0 Favored 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.47 -0.769 . . . . 1.0 109.772 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 5.2 t -64.59 -23.8 67.38 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.401 -0.812 . . . . 1.0 109.563 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -94.12 -7.12 43.37 Favored 'General case' 0 CA--C 1.535 0.399 0 O-C-N 121.383 -0.823 . . . . 1.0 109.881 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -73.38 -39.26 65.27 Favored 'General case' 0 CA--C 1.532 0.281 0 O-C-N 121.269 -0.895 . . . . 1.0 109.418 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -92.49 -38.39 11.98 Favored 'General case' 0 N--CA 1.462 0.171 0 O-C-N 121.523 -0.736 . . . . 1.0 109.425 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 113.95 37.93 1.21 Allowed Glycine 0 CA--C 1.53 1.024 0 N-CA-C 109.631 -1.388 . . . . 1.0 109.631 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.8 m -97.52 145.01 26.65 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.472 -1.017 . . . . 1.0 109.273 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.404 ' O ' ' CD1' ' A' ' 45' ' ' PHE . 58.4 m -68.28 119.56 13.02 Favored 'General case' 0 CA--C 1.532 0.267 0 O-C-N 121.398 -0.814 . . . . 1.0 109.426 -179.677 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 43.7 t80 -92.02 146.85 23.41 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 121.386 -0.821 . . . . 1.0 109.258 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 10.6 t0 -162.12 110.43 1.41 Allowed 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.353 -0.842 . . . . 1.0 109.537 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.435 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 13.6 p30 -110.63 70.77 0.73 Allowed 'General case' 0 CA--C 1.534 0.33 0 O-C-N 121.501 -0.749 . . . . 1.0 109.442 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.8 p -111.82 -53.31 2.72 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.403 -0.811 . . . . 1.0 109.737 -179.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.437 HG12 ' N ' ' A' ' 39' ' ' ARG . 35.6 t -96.3 159.38 2.98 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 O-C-N 121.341 -0.849 . . . . 1.0 109.639 -179.692 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.437 ' N ' HG12 ' A' ' 38' ' ' VAL . 2.2 mmm180 -103.82 169.13 8.69 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 121.473 -0.767 . . . . 1.0 109.263 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.75 -42.63 2.49 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 109.355 -1.498 . . . . 1.0 109.355 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.4 m -80.34 169.68 18.77 Favored Pre-proline 0 CA--C 1.537 0.466 0 O-C-N 121.538 -0.978 . . . . 1.0 109.082 179.768 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -87.3 131.77 3.05 Favored 'Trans proline' 0 C--N 1.351 0.682 0 C-N-CA 124.712 3.608 . . . . 1.0 110.011 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.435 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 15.3 m0 -80.15 -39.45 29.34 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.46 -0.775 . . . . 1.0 109.738 -179.482 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 16.0 t -90.01 107.78 19.32 Favored 'General case' 0 CA--C 1.534 0.338 0 O-C-N 121.412 -0.805 . . . . 1.0 109.486 179.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.423 ' CD1' ' N ' ' A' ' 45' ' ' PHE . 5.6 p90 -133.52 175.9 9.01 Favored 'General case' 0 CA--C 1.536 0.412 0 O-C-N 121.452 -0.78 . . . . 1.0 109.757 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.406 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 31.9 m-85 -85.34 170.84 12.09 Favored Pre-proline 0 CA--C 1.537 0.462 0 O-C-N 121.532 -0.73 . . . . 1.0 109.351 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -90.96 177.06 2.15 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 124.968 3.779 . . . . 1.0 110.39 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -123.08 99.92 6.61 Favored 'General case' 0 CA--C 1.53 0.188 0 O-C-N 121.569 -0.707 . . . . 1.0 109.597 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 55.3 p -105.36 92.36 4.17 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.461 -0.775 . . . . 1.0 109.393 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 57.3 mt -111.27 141.46 26.57 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.276 0 O-C-N 121.496 -0.752 . . . . 1.0 109.365 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -155.2 128.84 8.54 Favored 'General case' 0 CA--C 1.53 0.179 0 O-C-N 121.566 -0.709 . . . . 1.0 109.461 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 52' ' ' VAL . 30.9 m -150.22 79.58 7.47 Favored Pre-proline 0 CA--C 1.536 0.438 0 O-C-N 121.506 -0.746 . . . . 1.0 109.54 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.438 ' N ' ' CD ' ' A' ' 54' ' ' PRO . 16.8 Cg_exo -35.0 -46.56 0.61 Allowed 'Trans proline' 0 N--CA 1.487 1.14 1 C-N-CA 125.355 4.036 . . . . 1.0 111.795 179.972 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.438 ' CD ' ' N ' ' A' ' 53' ' ' PRO . 17.3 Cg_endo -90.6 -160.23 0.09 OUTLIER 'Trans proline' 0 C--N 1.354 0.843 0 C-N-CA 124.593 3.529 . . . . 1.0 110.427 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.424 ' H ' ' CD ' ' A' ' 55' ' ' GLU . 0.9 OUTLIER -69.96 162.61 27.74 Favored 'General case' 0 N--CA 1.465 0.276 0 O-C-N 121.469 -0.77 . . . . 1.0 109.503 -179.967 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -72.14 -179.85 3.01 Favored 'General case' 0 CA--C 1.529 0.166 0 O-C-N 121.527 -0.733 . . . . 1.0 109.571 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 13.9 pm0 -110.71 153.03 25.85 Favored 'General case' 0 C--O 1.233 0.209 0 O-C-N 121.464 -0.773 . . . . 1.0 109.438 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 6.0 m -99.01 164.45 12.17 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.449 -0.782 . . . . 1.0 109.377 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -81.2 104.16 11.48 Favored 'General case' 0 CA--C 1.53 0.199 0 O-C-N 121.436 -0.79 . . . . 1.0 109.475 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 54.8 m-85 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.003 -0.999 . . . . 1.0 109.417 -179.964 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 11.0 pm0 . . . . . 0 CA--C 1.53 0.187 0 N-CA-C 109.379 -0.601 . . . . 1.0 109.379 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.78 77.07 1.05 Allowed 'General case' 0 CA--C 1.531 0.226 0 O-C-N 121.52 -0.737 . . . . 1.0 109.491 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 9.9 mp0 -143.45 170.79 15.13 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.477 -0.765 . . . . 1.0 109.346 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -147.94 176.21 10.35 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.519 -0.738 . . . . 1.0 109.395 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -90.51 139.38 30.75 Favored 'General case' 0 CA--C 1.529 0.153 0 O-C-N 121.564 -0.71 . . . . 1.0 109.41 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.66 155.33 48.38 Favored 'General case' 0 N--CA 1.463 0.175 0 O-C-N 121.495 -0.753 . . . . 1.0 109.327 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 62.3 m -114.9 28.24 8.85 Favored 'General case' 0 C--O 1.232 0.15 0 O-C-N 121.496 -0.752 . . . . 1.0 109.326 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.481 HG23 ' O ' ' A' ' 8' ' ' THR . 5.6 t -95.39 122.82 38.51 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.362 -0.836 . . . . 1.0 109.586 -179.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.56 HG12 ' N ' ' A' ' 10' ' ' ALA . 40.3 t -147.11 167.67 5.5 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.198 0 O-C-N 121.5 -0.75 . . . . 1.0 109.283 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.573 ' HB3' ' HB2' ' A' ' 13' ' ' GLU . . . -76.66 124.97 87.83 Favored Pre-proline 0 CA--C 1.541 0.609 0 O-C-N 121.438 -0.789 . . . . 1.0 109.354 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.401 ' HD2' ' HA ' ' A' ' 10' ' ' ALA . 19.4 Cg_exo -36.87 -50.37 1.45 Allowed 'Trans proline' 0 N--CA 1.49 1.302 0 C-N-CA 124.922 3.748 . . . . 1.0 111.242 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.6 mtp180 -70.21 -49.12 53.38 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.458 -0.776 . . . . 1.0 109.652 -179.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.573 ' HB2' ' HB3' ' A' ' 10' ' ' ALA . 25.0 mt-10 -82.61 40.36 0.66 Allowed 'General case' 0 CA--C 1.53 0.211 0 O-C-N 121.46 -0.775 . . . . 1.0 109.52 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 26.2 mtt180 -92.4 139.34 30.7 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.473 -0.767 . . . . 1.0 109.476 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -85.46 108.48 17.91 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.522 -0.736 . . . . 1.0 109.162 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -64.59 120.48 12.43 Favored 'General case' 0 CA--C 1.532 0.275 0 O-C-N 121.485 -0.759 . . . . 1.0 109.668 -179.72 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 28.2 t -95.75 -19.48 19.63 Favored 'General case' 0 CA--C 1.534 0.327 0 O-C-N 121.586 -0.696 . . . . 1.0 109.456 179.735 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 175.3 -179.03 46.79 Favored Glycine 0 CA--C 1.528 0.871 0 N-CA-C 109.232 -1.547 . . . . 1.0 109.232 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.561 ' O ' HG22 ' A' ' 22' ' ' VAL . 9.1 p90 -65.72 167.97 9.84 Favored Pre-proline 0 CA--C 1.537 0.455 0 O-C-N 121.369 -1.077 . . . . 1.0 108.929 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -81.68 -30.15 1.53 Allowed 'Trans proline' 0 N--CA 1.483 0.902 0 C-N-CA 124.418 3.412 . . . . 1.0 110.809 -178.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -57.16 -12.16 7.4 Favored Glycine 0 CA--C 1.536 1.401 0 N-CA-C 110.401 -1.079 . . . . 1.0 110.401 179.597 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.561 HG22 ' O ' ' A' ' 19' ' ' PHE . 24.2 m -61.3 162.92 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 O-C-N 121.253 -1.145 . . . . 1.0 109.641 179.694 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.4 p -121.6 154.75 60.05 Favored Pre-proline 0 CA--C 1.534 0.35 0 O-C-N 121.505 -0.747 . . . . 1.0 109.311 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 16.0 Cg_exo -35.8 -38.75 0.27 Allowed 'Trans proline' 0 N--CA 1.487 1.119 1 C-N-CA 125.479 4.12 . . . . 1.0 111.258 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 1.9 p -69.91 -48.08 59.97 Favored 'General case' 0 N--CA 1.463 0.213 0 O-C-N 121.511 -0.743 . . . . 1.0 109.791 -179.826 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -62.72 -46.15 89.42 Favored 'General case' 0 CA--C 1.533 0.322 0 O-C-N 121.4 -0.813 . . . . 1.0 109.749 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 17.3 t -64.59 -26.79 68.56 Favored 'General case' 0 CA--C 1.531 0.213 0 O-C-N 121.431 -0.793 . . . . 1.0 109.368 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.56 -8.85 54.06 Favored 'General case' 0 CA--C 1.532 0.271 0 O-C-N 121.562 -0.711 . . . . 1.0 109.811 179.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -77.94 -38.42 45.46 Favored 'General case' 0 CA--C 1.53 0.18 0 O-C-N 121.245 -0.91 . . . . 1.0 109.373 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.4 mmtt -83.69 -41.44 17.72 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 121.429 -0.794 . . . . 1.0 109.41 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 118.07 38.45 0.81 Allowed Glycine 0 CA--C 1.531 1.055 0 N-CA-C 109.569 -1.412 . . . . 1.0 109.569 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.7 m -112.61 147.97 35.56 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.606 -0.938 . . . . 1.0 109.485 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 66.4 m -69.5 125.14 25.82 Favored 'General case' 0 CA--C 1.529 0.163 0 O-C-N 121.477 -0.765 . . . . 1.0 109.36 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -99.1 143.13 29.71 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.508 -0.745 . . . . 1.0 109.367 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -157.0 113.9 3.06 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 121.529 -0.732 . . . . 1.0 109.503 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.423 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 8.9 p-10 -111.54 60.27 0.62 Allowed 'General case' 0 CA--C 1.533 0.321 0 O-C-N 121.492 -0.755 . . . . 1.0 109.39 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 67.7 p -99.8 -56.64 2.33 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.356 -0.84 . . . . 1.0 109.569 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.484 HG12 ' N ' ' A' ' 39' ' ' ARG . 36.5 t -98.23 161.88 2.87 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.22 0 O-C-N 121.485 -0.76 . . . . 1.0 109.425 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.484 ' N ' HG12 ' A' ' 38' ' ' VAL . 4.0 mpt_? -104.95 173.59 6.24 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.506 -0.746 . . . . 1.0 109.448 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.31 -45.53 3.06 Favored Glycine 0 CA--C 1.529 0.936 0 N-CA-C 109.477 -1.449 . . . . 1.0 109.477 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.6 m -79.37 169.52 20.01 Favored Pre-proline 0 CA--C 1.536 0.413 0 O-C-N 121.56 -0.965 . . . . 1.0 109.321 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -87.42 127.84 2.47 Favored 'Trans proline' 0 C--N 1.35 0.657 0 C-N-CA 124.805 3.67 . . . . 1.0 109.987 179.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.423 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 16.6 m0 -74.6 -38.54 62.58 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.457 -0.777 . . . . 1.0 109.918 -179.439 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 8.3 t -89.59 109.15 20.13 Favored 'General case' 0 CA--C 1.533 0.318 0 O-C-N 121.352 -0.842 . . . . 1.0 109.609 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.419 ' CD1' ' N ' ' A' ' 45' ' ' PHE . 4.9 p90 -135.65 -178.69 5.24 Favored 'General case' 0 CA--C 1.535 0.397 0 O-C-N 121.415 -0.803 . . . . 1.0 109.463 179.708 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.402 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 18.6 m-85 -90.68 167.1 17.17 Favored Pre-proline 0 CA--C 1.536 0.426 0 O-C-N 121.487 -0.758 . . . . 1.0 109.592 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -91.23 148.65 3.66 Favored 'Trans proline' 0 C--N 1.35 0.628 0 C-N-CA 124.998 3.799 . . . . 1.0 110.461 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -123.77 101.2 7.15 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 109.126 -0.694 . . . . 1.0 109.126 179.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.4 p -61.94 98.3 0.1 Allowed 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.409 -0.807 . . . . 1.0 109.856 -179.635 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 48.1 mt -131.46 156.24 42.47 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 O-C-N 121.554 -0.716 . . . . 1.0 109.158 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -127.7 151.59 48.78 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 121.388 -0.82 . . . . 1.0 109.537 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.4 m -131.11 147.36 65.96 Favored Pre-proline 0 CA--C 1.534 0.364 0 O-C-N 121.584 -0.697 . . . . 1.0 109.465 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.449 ' N ' ' HD2' ' A' ' 54' ' ' PRO . 4.7 Cg_exo -38.17 -60.17 0.48 Allowed 'Trans proline' 0 N--CA 1.486 1.038 0 C-N-CA 125.172 3.915 . . . . 1.0 111.233 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.449 ' HD2' ' N ' ' A' ' 53' ' ' PRO . 14.6 Cg_exo -37.31 157.31 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.378 0 C-N-CA 124.892 3.728 . . . . 1.0 111.02 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -114.2 145.87 41.12 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.504 -0.748 . . . . 1.0 109.381 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -107.01 118.06 35.69 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 121.547 -0.72 . . . . 1.0 109.416 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -138.65 151.2 47.01 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.46 -0.775 . . . . 1.0 109.415 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.5 p -76.02 130.79 38.93 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 121.39 -0.819 . . . . 1.0 109.453 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -142.85 153.79 43.52 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.508 -0.745 . . . . 1.0 109.468 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 7.5 t80 . . . . . 0 C--O 1.221 -0.412 0 CA-C-O 118.019 -0.991 . . . . 1.0 109.47 179.997 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 . . . . . 0 CA--C 1.53 0.194 0 N-CA-C 109.433 -0.58 . . . . 1.0 109.433 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -96.84 99.49 11.06 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 121.533 -0.729 . . . . 1.0 109.438 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 7.9 mm-40 -137.31 131.34 32.09 Favored 'General case' 0 CA--C 1.53 0.189 0 O-C-N 121.482 -0.761 . . . . 1.0 109.436 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.3 p -144.3 -179.3 6.44 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.442 -0.786 . . . . 1.0 109.433 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -110.06 127.39 54.82 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 121.481 -0.762 . . . . 1.0 109.44 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.31 144.0 25.26 Favored 'General case' 0 CA--C 1.531 0.247 0 O-C-N 121.446 -0.784 . . . . 1.0 109.53 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 74.0 m -107.04 19.98 19.67 Favored 'General case' 0 CA--C 1.532 0.277 0 O-C-N 121.539 -0.725 . . . . 1.0 109.548 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.611 HG23 ' O ' ' A' ' 8' ' ' THR . 4.8 t -82.89 94.87 7.79 Favored 'General case' 0 CA--C 1.532 0.286 0 O-C-N 121.456 -0.777 . . . . 1.0 109.749 -179.628 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.599 HG11 ' O ' ' A' ' 13' ' ' GLU . 39.8 t -122.16 155.04 26.95 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 O-C-N 121.526 -0.734 . . . . 1.0 109.035 179.639 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -81.23 137.49 49.08 Favored Pre-proline 0 CA--C 1.539 0.533 0 O-C-N 121.387 -0.82 . . . . 1.0 109.378 -179.731 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.456 ' HB3' HG11 ' A' ' 41' ' ' VAL . 18.4 Cg_exo -35.39 -36.41 0.15 Allowed 'Trans proline' 0 N--CA 1.488 1.159 1 C-N-CA 125.398 4.065 . . . . 1.0 111.266 -179.957 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 19.6 mtp180 -74.47 -49.91 20.4 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.529 -0.732 . . . . 1.0 109.674 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.599 ' O ' HG11 ' A' ' 9' ' ' VAL . 7.7 mm-40 -81.38 27.64 0.41 Allowed 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.481 -0.762 . . . . 1.0 109.808 -179.756 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 32.2 mtt180 -100.73 146.31 27.38 Favored 'General case' 0 N--CA 1.464 0.23 0 O-C-N 121.433 -0.792 . . . . 1.0 109.418 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 16.7 mt-30 -120.38 154.76 34.65 Favored 'General case' 0 C--N 1.332 -0.194 0 O-C-N 121.518 -0.739 . . . . 1.0 109.297 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -80.32 125.15 29.53 Favored 'General case' 0 CA--C 1.53 0.197 0 O-C-N 121.498 -0.751 . . . . 1.0 109.132 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.8 t -98.62 -23.71 15.37 Favored 'General case' 0 CA--C 1.531 0.248 0 O-C-N 121.455 -0.778 . . . . 1.0 109.303 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -167.13 -179.81 40.35 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 109.021 -1.632 . . . . 1.0 109.021 179.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.647 ' O ' HG22 ' A' ' 22' ' ' VAL . 7.8 p90 -67.68 167.17 17.31 Favored Pre-proline 0 CA--C 1.537 0.471 0 O-C-N 121.348 -1.09 . . . . 1.0 108.826 179.81 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -82.31 -29.57 1.48 Allowed 'Trans proline' 0 N--CA 1.483 0.908 0 C-N-CA 124.551 3.501 . . . . 1.0 110.914 -178.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -55.6 -15.34 8.52 Favored Glycine 0 CA--C 1.535 1.324 0 N-CA-C 110.35 -1.1 . . . . 1.0 110.35 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.647 HG22 ' O ' ' A' ' 19' ' ' PHE . 22.6 m -63.22 151.55 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 O-C-N 121.326 -1.103 . . . . 1.0 109.543 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.59 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 73.0 p -99.7 154.64 37.16 Favored Pre-proline 0 CA--C 1.536 0.422 0 N-CA-C 108.99 -0.745 . . . . 1.0 108.99 179.311 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -33.18 -55.68 0.38 Allowed 'Trans proline' 0 N--CA 1.487 1.113 1 C-N-CA 125.797 4.332 . . . . 1.0 111.862 -179.454 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 67.6 m -80.12 -27.38 39.15 Favored 'General case' 0 N--CA 1.464 0.245 0 O-C-N 121.43 -0.793 . . . . 1.0 110.565 -179.041 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLN . . . . . 0.59 ' HB2' ' H ' ' A' ' 23' ' ' THR . 10.5 mt-30 -61.46 -54.51 42.44 Favored 'General case' 0 N--CA 1.466 0.353 0 O-C-N 121.287 -0.883 . . . . 1.0 110.332 -179.47 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -77.5 -27.2 51.77 Favored 'General case' 0 CA--C 1.534 0.333 0 O-C-N 121.393 -0.817 . . . . 1.0 109.886 -179.261 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.72 -5.01 57.73 Favored 'General case' 0 CA--C 1.534 0.365 0 O-C-N 121.422 -0.799 . . . . 1.0 110.113 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -106.8 -4.39 19.36 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.316 -0.865 . . . . 1.0 109.8 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.1 tttt -89.9 -46.69 8.37 Favored 'General case' 0 CA--C 1.533 0.289 0 O-C-N 121.269 -0.895 . . . . 1.0 109.196 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 151.22 19.14 0.06 OUTLIER Glycine 0 CA--C 1.531 1.054 0 N-CA-C 109.528 -1.429 . . . . 1.0 109.528 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 85.6 m -119.17 148.96 42.51 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.423 -1.045 . . . . 1.0 109.285 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 55.9 m -77.49 115.63 17.41 Favored 'General case' 0 N--CA 1.463 0.221 0 O-C-N 121.557 -0.715 . . . . 1.0 109.083 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.436 ' CD1' ' N ' ' A' ' 35' ' ' ASP . 46.5 t80 -89.95 152.37 21.24 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.446 -0.784 . . . . 1.0 109.722 -179.618 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.436 ' N ' ' CD1' ' A' ' 34' ' ' PHE . 28.5 t70 -165.29 118.7 1.21 Allowed 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.589 -0.694 . . . . 1.0 109.309 179.724 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -120.34 51.54 1.21 Allowed 'General case' 0 CA--C 1.534 0.329 0 O-C-N 121.532 -0.73 . . . . 1.0 109.547 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -99.77 -15.59 18.4 Favored 'General case' 0 CA--C 1.533 0.317 0 O-C-N 121.308 -0.87 . . . . 1.0 109.937 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.463 HG12 ' N ' ' A' ' 39' ' ' ARG . 37.3 t -129.71 161.02 40.1 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.222 0 O-C-N 121.335 -0.853 . . . . 1.0 109.625 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.463 ' N ' HG12 ' A' ' 38' ' ' VAL . 79.5 mtt85 -111.89 166.96 10.75 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 121.516 -0.74 . . . . 1.0 109.379 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.55 -41.99 2.38 Favored Glycine 0 CA--C 1.53 0.986 0 N-CA-C 109.234 -1.546 . . . . 1.0 109.234 -179.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.456 HG11 ' HB3' ' A' ' 11' ' ' PRO . 28.9 m -81.1 170.63 14.75 Favored Pre-proline 0 CA--C 1.537 0.478 0 O-C-N 121.587 -0.949 . . . . 1.0 109.049 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . 0.405 ' CD ' ' HB ' ' A' ' 41' ' ' VAL . 11.7 Cg_endo -85.87 126.31 2.89 Favored 'Trans proline' 0 C--N 1.352 0.744 0 C-N-CA 124.539 3.493 . . . . 1.0 110.018 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . . . . . . . . . 33.8 m0 -75.41 -37.6 60.35 Favored 'General case' 0 N--CA 1.462 0.169 0 O-C-N 121.429 -0.794 . . . . 1.0 109.91 -179.536 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 6.5 t -90.08 113.99 25.82 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.415 -0.803 . . . . 1.0 109.539 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.416 ' CD1' ' N ' ' A' ' 45' ' ' PHE . 5.7 p90 -140.02 170.91 14.98 Favored 'General case' 0 CA--C 1.536 0.424 0 O-C-N 121.388 -0.82 . . . . 1.0 110.025 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . . . . . . . . . 61.8 m-85 -77.06 170.59 15.6 Favored Pre-proline 0 CA--C 1.537 0.443 0 O-C-N 121.674 -0.641 . . . . 1.0 109.419 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -88.18 173.12 4.92 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 124.829 3.686 . . . . 1.0 110.415 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -148.09 107.11 3.85 Favored 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.664 -0.647 . . . . 1.0 109.346 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 24.2 p -77.05 84.73 3.56 Favored 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.483 -0.76 . . . . 1.0 109.485 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.585 HG22 ' N ' ' A' ' 51' ' ' ASP . 48.0 mt -96.91 168.71 1.54 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 O-C-N 121.523 -0.735 . . . . 1.0 109.298 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.585 ' N ' HG22 ' A' ' 50' ' ' ILE . 3.9 p-10 -75.39 -177.91 3.78 Favored 'General case' 0 N--CA 1.463 0.179 0 O-C-N 121.473 -0.767 . . . . 1.0 109.422 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.618 HG23 ' O ' ' A' ' 52' ' ' VAL . 30.0 m -148.71 100.31 3.51 Favored Pre-proline 0 CA--C 1.539 0.543 0 O-C-N 121.451 -0.781 . . . . 1.0 109.538 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -49.66 -178.43 0.01 OUTLIER 'Trans proline' 0 N--CA 1.488 1.181 0 C-N-CA 123.948 3.099 . . . . 1.0 110.209 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -87.42 42.88 0.85 Allowed 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 124.729 3.619 . . . . 1.0 110.281 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 32.3 mt-10 -112.75 118.65 35.57 Favored 'General case' 0 CA--C 1.53 0.202 0 O-C-N 121.479 -0.763 . . . . 1.0 109.265 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 51.0 mt-10 -126.73 135.91 51.73 Favored 'General case' 0 N--CA 1.463 0.193 0 O-C-N 121.475 -0.765 . . . . 1.0 109.617 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 33.3 mt-10 -148.78 110.5 4.51 Favored 'General case' 0 CA--C 1.53 0.186 0 O-C-N 121.536 -0.727 . . . . 1.0 109.364 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 90.8 p -80.96 110.37 16.43 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 121.443 -0.786 . . . . 1.0 109.531 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 13.3 tt0 -139.86 169.04 18.45 Favored 'General case' 0 N--CA 1.463 0.198 0 O-C-N 121.515 -0.741 . . . . 1.0 109.39 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.954 -1.022 . . . . 1.0 109.374 -179.934 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 13.5 tt0 . . . . . 0 CA--C 1.53 0.211 0 N-CA-C 109.413 -0.588 . . . . 1.0 109.413 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -115.23 139.57 49.83 Favored 'General case' 0 CA--C 1.531 0.223 0 O-C-N 121.454 -0.779 . . . . 1.0 109.553 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.413 ' O ' HG23 ' A' ' 4' ' ' THR . 0.8 OUTLIER -123.25 108.93 13.33 Favored 'General case' 0 N--CA 1.463 0.211 0 O-C-N 121.483 -0.76 . . . . 1.0 109.442 179.935 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.413 HG23 ' O ' ' A' ' 3' ' ' GLN . 30.7 p -155.1 161.71 41.2 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.563 -0.711 . . . . 1.0 109.57 -179.885 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -67.57 156.87 35.73 Favored 'General case' 0 CA--C 1.53 0.184 0 O-C-N 121.425 -0.797 . . . . 1.0 109.005 179.654 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.7 m -149.28 116.36 6.03 Favored 'General case' 0 C--O 1.233 0.198 0 O-C-N 121.404 -0.81 . . . . 1.0 109.953 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 86.2 m -108.07 -18.53 13.76 Favored 'General case' 0 CA--C 1.534 0.336 0 O-C-N 121.444 -0.785 . . . . 1.0 109.216 179.337 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.551 HG23 ' O ' ' A' ' 8' ' ' THR . 3.1 t -68.78 101.42 1.33 Allowed 'General case' 0 CA--C 1.531 0.212 0 O-C-N 121.201 -0.937 . . . . 1.0 109.521 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.612 HG12 ' N ' ' A' ' 10' ' ' ALA . 38.6 t -121.82 171.16 11.02 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 O-C-N 121.575 -0.703 . . . . 1.0 109.233 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.612 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -67.99 129.17 93.25 Favored Pre-proline 0 CA--C 1.539 0.541 0 O-C-N 121.355 -0.84 . . . . 1.0 109.483 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -36.95 -50.21 1.48 Allowed 'Trans proline' 0 N--CA 1.49 1.281 0 C-N-CA 125.027 3.818 . . . . 1.0 111.227 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.413 ' HD2' ' H ' ' A' ' 12' ' ' ARG . 1.2 mpt_? -70.75 -39.55 73.21 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 121.502 -0.749 . . . . 1.0 109.833 -179.591 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -81.42 29.24 0.37 Allowed 'General case' 0 CA--C 1.532 0.254 0 O-C-N 121.529 -0.732 . . . . 1.0 109.716 -179.72 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 37.9 mtt180 -101.41 120.63 40.57 Favored 'General case' 0 N--CA 1.464 0.248 0 O-C-N 121.417 -0.802 . . . . 1.0 109.368 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 -79.86 121.43 25.4 Favored 'General case' 0 CA--C 1.531 0.216 0 O-C-N 121.491 -0.756 . . . . 1.0 109.261 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -63.91 121.4 13.98 Favored 'General case' 0 CA--C 1.532 0.261 0 O-C-N 121.517 -0.74 . . . . 1.0 109.911 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.3 t -93.73 -20.33 20.23 Favored 'General case' 0 CA--C 1.534 0.351 0 O-C-N 121.562 -0.711 . . . . 1.0 109.272 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 179.57 177.23 47.71 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 109.178 -1.569 . . . . 1.0 109.178 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.533 ' CD2' HG13 ' A' ' 22' ' ' VAL . 8.8 p90 -65.01 167.7 9.0 Favored Pre-proline 0 CA--C 1.538 0.516 0 O-C-N 121.446 -1.032 . . . . 1.0 108.885 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -81.58 -30.67 1.38 Allowed 'Trans proline' 0 N--CA 1.481 0.777 0 C-N-CA 124.45 3.433 . . . . 1.0 110.802 -178.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.46 -10.04 7.22 Favored Glycine 0 CA--C 1.537 1.454 0 N-CA-C 110.307 -1.117 . . . . 1.0 110.307 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.533 HG13 ' CD2' ' A' ' 19' ' ' PHE . 24.2 m -60.66 -174.74 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 O-C-N 121.231 -1.158 . . . . 1.0 109.531 179.763 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.42 ' H ' ' HB2' ' A' ' 26' ' ' GLN . 4.1 p -143.74 153.72 58.28 Favored Pre-proline 0 CA--C 1.537 0.45 0 O-C-N 121.515 -0.741 . . . . 1.0 109.285 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -35.85 -36.97 0.2 Allowed 'Trans proline' 0 N--CA 1.487 1.134 1 C-N-CA 125.32 4.013 . . . . 1.0 111.382 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 8.6 t -73.73 -47.34 40.04 Favored 'General case' 0 CA--C 1.532 0.256 0 O-C-N 121.442 -0.786 . . . . 1.0 109.756 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLN . . . . . 0.42 ' HB2' ' H ' ' A' ' 23' ' ' THR . 45.0 mt-30 -61.65 -44.73 96.42 Favored 'General case' 0 N--CA 1.466 0.327 0 O-C-N 121.436 -0.79 . . . . 1.0 109.674 -179.831 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 8.5 t -65.34 -32.63 74.37 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 121.486 -0.758 . . . . 1.0 109.382 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.6 -4.16 59.08 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 121.615 -0.678 . . . . 1.0 109.938 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -86.22 -23.55 26.39 Favored 'General case' 0 N--CA 1.464 0.258 0 O-C-N 121.218 -0.926 . . . . 1.0 109.636 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.3 tppp? -101.41 -34.94 9.38 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.379 -0.826 . . . . 1.0 109.315 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 111.49 53.62 0.52 Allowed Glycine 0 CA--C 1.529 0.955 0 N-CA-C 109.414 -1.475 . . . . 1.0 109.414 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.7 m -128.7 139.24 52.33 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.544 -0.974 . . . . 1.0 109.363 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.425 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 56.0 m -61.47 119.8 9.27 Favored 'General case' 0 N--CA 1.468 0.448 0 O-C-N 121.462 -0.774 . . . . 1.0 109.964 -179.344 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -101.51 121.56 42.19 Favored 'General case' 0 CA--C 1.531 0.243 0 O-C-N 121.423 -0.798 . . . . 1.0 109.192 179.623 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.443 ' OD1' HG23 ' A' ' 37' ' ' THR . 22.5 t0 -134.6 114.24 12.57 Favored 'General case' 0 CA--C 1.531 0.221 0 O-C-N 121.493 -0.754 . . . . 1.0 109.61 -179.783 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.424 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 5.8 p-10 -112.0 54.82 0.69 Allowed 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.503 -0.748 . . . . 1.0 109.156 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.443 HG23 ' OD1' ' A' ' 35' ' ' ASP . 39.3 p -104.01 -31.27 9.79 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 121.377 -0.827 . . . . 1.0 109.61 -179.724 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.41 ' HB ' HG21 ' A' ' 41' ' ' VAL . 34.9 t -114.88 151.76 16.58 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 O-C-N 121.406 -0.809 . . . . 1.0 109.478 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 21.7 mtm-85 -101.77 165.65 11.09 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 121.497 -0.752 . . . . 1.0 109.471 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.54 -33.79 2.52 Favored Glycine 0 CA--C 1.53 1.017 0 N-CA-C 109.457 -1.457 . . . . 1.0 109.457 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.41 HG21 ' HB ' ' A' ' 38' ' ' VAL . 28.5 m -88.13 169.99 12.52 Favored Pre-proline 0 CA--C 1.537 0.473 0 O-C-N 121.521 -0.988 . . . . 1.0 109.222 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -86.63 123.57 2.15 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 124.724 3.616 . . . . 1.0 110.04 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.424 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 23.9 m0 -75.3 -43.93 48.34 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.555 -0.716 . . . . 1.0 109.873 -179.515 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 13.6 t -88.8 109.11 19.91 Favored 'General case' 0 CA--C 1.535 0.365 0 O-C-N 121.328 -0.857 . . . . 1.0 109.915 -179.841 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.428 ' CD2' ' O ' ' A' ' 46' ' ' TYR . 7.1 p90 -138.9 177.33 7.97 Favored 'General case' 0 CA--C 1.537 0.453 0 O-C-N 121.461 -0.775 . . . . 1.0 109.547 179.259 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.428 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 70.6 m-85 -78.78 169.32 21.22 Favored Pre-proline 0 CA--C 1.537 0.463 0 O-C-N 121.271 -0.893 . . . . 1.0 109.975 -179.568 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -92.34 167.69 2.86 Favored 'Trans proline' 0 C--N 1.352 0.711 0 C-N-CA 125.047 3.831 . . . . 1.0 110.582 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.512 HD22 HG21 ' A' ' 9' ' ' VAL . 23.1 m-20 -146.99 80.75 1.54 Allowed 'General case' 0 N--CA 1.463 0.222 0 O-C-N 121.466 -0.771 . . . . 1.0 109.273 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 17.8 p -75.09 121.37 21.94 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 121.377 -0.827 . . . . 1.0 109.683 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 58.7 mt -99.93 141.56 16.84 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 O-C-N 121.484 -0.76 . . . . 1.0 109.201 179.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -163.52 173.72 12.73 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.51 -0.744 . . . . 1.0 109.591 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.8 m -78.23 152.03 78.75 Favored Pre-proline 0 CA--C 1.536 0.41 0 O-C-N 121.509 -0.744 . . . . 1.0 109.42 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -34.38 91.07 0.01 OUTLIER 'Trans proline' 0 N--CA 1.489 1.235 1 C-N-CA 125.568 4.179 . . . . 1.0 111.201 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -91.63 -159.34 0.08 OUTLIER 'Trans proline' 0 C--N 1.351 0.67 0 C-N-CA 125.038 3.825 . . . . 1.0 110.272 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -103.99 161.79 13.68 Favored 'General case' 0 CA--C 1.531 0.218 0 O-C-N 121.453 -0.78 . . . . 1.0 109.471 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -97.73 120.83 38.81 Favored 'General case' 0 CA--C 1.529 0.158 0 O-C-N 121.505 -0.747 . . . . 1.0 109.462 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -137.62 175.52 9.52 Favored 'General case' 0 N--CA 1.462 0.162 0 O-C-N 121.427 -0.795 . . . . 1.0 109.467 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.1 m -134.17 150.9 51.12 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.493 -0.754 . . . . 1.0 109.351 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -147.17 175.6 10.6 Favored 'General case' 0 CA--C 1.531 0.23 0 O-C-N 121.509 -0.744 . . . . 1.0 109.362 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 40.4 m-85 . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 117.997 -1.002 . . . . 1.0 109.467 179.996 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 . . . . . 0 CA--C 1.53 0.208 0 N-CA-C 109.358 -0.608 . . . . 1.0 109.358 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -144.33 175.76 9.86 Favored 'General case' 0 CA--C 1.531 0.244 0 O-C-N 121.484 -0.76 . . . . 1.0 109.448 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 4.0 mp0 -102.23 119.38 38.71 Favored 'General case' 0 CA--C 1.53 0.205 0 O-C-N 121.503 -0.748 . . . . 1.0 109.536 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.7 p -143.37 -169.39 3.04 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.491 -0.756 . . . . 1.0 109.435 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -65.02 148.53 51.49 Favored 'General case' 0 CA--C 1.532 0.263 0 O-C-N 121.413 -0.804 . . . . 1.0 109.267 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.868 HG22 HG22 ' A' ' 8' ' ' THR . 0.9 OUTLIER -137.01 126.19 24.64 Favored 'General case' 0 CA--C 1.53 0.208 0 O-C-N 121.515 -0.74 . . . . 1.0 109.667 -179.809 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.5 m -117.18 46.18 1.74 Allowed 'General case' 0 CA--C 1.532 0.259 0 O-C-N 121.463 -0.773 . . . . 1.0 109.314 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.868 HG22 HG22 ' A' ' 6' ' ' THR . 4.9 t -131.01 106.89 8.7 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.517 -0.739 . . . . 1.0 109.369 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.639 HG12 ' H ' ' A' ' 10' ' ' ALA . 21.7 t -125.09 174.09 9.82 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 O-C-N 121.369 -0.832 . . . . 1.0 109.34 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.639 ' H ' HG12 ' A' ' 9' ' ' VAL . . . -74.92 140.33 74.0 Favored Pre-proline 0 CA--C 1.538 0.508 0 O-C-N 121.479 -0.763 . . . . 1.0 109.57 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_exo -34.81 -61.24 0.25 Allowed 'Trans proline' 0 N--CA 1.488 1.171 1 C-N-CA 125.484 4.122 . . . . 1.0 111.566 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -69.93 -29.95 67.22 Favored 'General case' 0 CA--C 1.532 0.268 0 O-C-N 121.476 -0.765 . . . . 1.0 110.107 -179.287 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.541 ' O ' HG11 ' A' ' 9' ' ' VAL . 13.1 mt-10 -85.29 36.62 0.64 Allowed 'General case' 0 N--CA 1.464 0.252 0 O-C-N 121.289 -0.882 . . . . 1.0 109.642 -179.736 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.403 HH12 ' HB3' ' A' ' 35' ' ' ASP . 50.4 mtt180 -108.1 142.94 37.54 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.508 -0.745 . . . . 1.0 109.435 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -102.35 115.02 29.71 Favored 'General case' 0 N--CA 1.463 0.195 0 O-C-N 121.547 -0.721 . . . . 1.0 109.399 179.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 48.9 t30 -61.06 118.7 7.1 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 121.391 -0.818 . . . . 1.0 109.784 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 t -94.51 -18.85 21.06 Favored 'General case' 0 CA--C 1.534 0.352 0 O-C-N 121.463 -0.773 . . . . 1.0 109.247 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.43 178.2 47.8 Favored Glycine 0 CA--C 1.53 0.976 0 N-CA-C 108.967 -1.653 . . . . 1.0 108.967 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.58 ' O ' HG22 ' A' ' 22' ' ' VAL . 8.5 p90 -65.92 167.81 10.68 Favored Pre-proline 0 CA--C 1.539 0.542 0 O-C-N 121.369 -1.077 . . . . 1.0 108.799 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -82.12 -30.09 1.38 Allowed 'Trans proline' 0 N--CA 1.483 0.855 0 C-N-CA 124.38 3.387 . . . . 1.0 110.992 -178.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -56.62 -13.73 8.33 Favored Glycine 0 CA--C 1.536 1.358 0 N-CA-C 110.36 -1.096 . . . . 1.0 110.36 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.58 HG22 ' O ' ' A' ' 19' ' ' PHE . 20.4 m -60.7 173.54 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 O-C-N 121.239 -1.153 . . . . 1.0 109.768 179.849 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 73.6 p -131.84 155.7 81.06 Favored Pre-proline 0 CA--C 1.534 0.339 0 O-C-N 121.524 -0.735 . . . . 1.0 109.143 179.773 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -35.74 -33.82 0.12 Allowed 'Trans proline' 0 N--CA 1.49 1.267 1 C-N-CA 125.354 4.036 . . . . 1.0 111.233 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 39.7 m -75.68 -47.74 24.98 Favored 'General case' 0 CA--C 1.532 0.253 0 O-C-N 121.396 -0.815 . . . . 1.0 109.956 -179.622 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -65.3 -47.25 77.25 Favored 'General case' 0 CA--C 1.533 0.307 0 O-C-N 121.468 -0.77 . . . . 1.0 109.85 -179.689 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 11.2 t -62.48 -29.86 70.84 Favored 'General case' 0 N--CA 1.464 0.269 0 O-C-N 121.408 -0.808 . . . . 1.0 109.796 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -90.52 -9.79 45.95 Favored 'General case' 0 N--CA 1.465 0.281 0 O-C-N 121.464 -0.772 . . . . 1.0 110.098 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -93.03 -5.09 51.33 Favored 'General case' 0 CA--C 1.534 0.34 0 O-C-N 121.224 -0.923 . . . . 1.0 110.028 -179.762 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 51.9 mttp -109.52 -27.28 9.51 Favored 'General case' 0 N--CA 1.464 0.246 0 O-C-N 121.337 -0.852 . . . . 1.0 109.544 -179.794 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.08 22.66 5.83 Favored Glycine 0 CA--C 1.53 0.993 0 N-CA-C 109.568 -1.413 . . . . 1.0 109.568 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 22.8 m -112.74 137.21 51.38 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.469 -1.018 . . . . 1.0 108.564 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.6 m -72.85 133.87 44.62 Favored 'General case' 0 N--CA 1.463 0.222 0 O-C-N 121.316 -0.865 . . . . 1.0 109.735 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -101.68 139.63 37.07 Favored 'General case' 0 C--O 1.232 0.163 0 O-C-N 121.626 -0.671 . . . . 1.0 109.223 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.403 ' HB3' HH12 ' A' ' 14' ' ' ARG . 9.9 t0 -148.62 102.39 3.3 Favored 'General case' 0 N--CA 1.463 0.202 0 O-C-N 121.306 -0.871 . . . . 1.0 109.591 -179.785 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.435 ' HA ' ' CD1' ' A' ' 43' ' ' TRP . 7.0 p-10 -104.9 73.93 1.1 Allowed 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.525 -0.735 . . . . 1.0 109.294 179.83 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 30.6 p -118.66 -43.6 2.68 Favored 'General case' 0 CA--C 1.53 0.177 0 O-C-N 121.43 -0.794 . . . . 1.0 109.494 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 38.2 t -110.81 153.06 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 O-C-N 121.467 -0.771 . . . . 1.0 109.287 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 7.8 mtt-85 -101.11 172.51 6.97 Favored 'General case' 0 CA--C 1.532 0.271 0 O-C-N 121.545 -0.722 . . . . 1.0 109.337 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.72 -31.14 3.06 Favored Glycine 0 CA--C 1.529 0.917 0 N-CA-C 109.501 -1.44 . . . . 1.0 109.501 -179.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.404 ' HB ' ' CD ' ' A' ' 42' ' ' PRO . 29.6 m -99.83 170.55 6.61 Favored Pre-proline 0 CA--C 1.537 0.478 0 O-C-N 121.501 -1.0 . . . . 1.0 109.129 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . 0.404 ' CD ' ' HB ' ' A' ' 41' ' ' VAL . 11.2 Cg_endo -85.64 126.41 3.01 Favored 'Trans proline' 0 N--CA 1.479 0.654 0 C-N-CA 124.506 3.471 . . . . 1.0 110.036 179.745 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.435 ' CD1' ' HA ' ' A' ' 36' ' ' ASP . 10.0 m0 -77.64 -38.89 46.91 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.555 -0.715 . . . . 1.0 109.837 -179.356 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 28.1 t -89.44 103.84 16.45 Favored 'General case' 0 CA--C 1.534 0.357 0 O-C-N 121.385 -0.822 . . . . 1.0 109.566 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.406 ' CD1' ' N ' ' A' ' 45' ' ' PHE . 5.1 p90 -132.87 177.42 7.66 Favored 'General case' 0 CA--C 1.536 0.423 0 O-C-N 121.259 -0.901 . . . . 1.0 109.881 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' TYR . . . . . 0.406 ' O ' ' CD2' ' A' ' 45' ' ' PHE . 32.2 m-85 -74.1 169.81 17.44 Favored Pre-proline 0 CA--C 1.536 0.423 0 O-C-N 121.61 -0.681 . . . . 1.0 109.684 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -93.35 173.16 1.85 Allowed 'Trans proline' 0 C--N 1.35 0.643 0 C-N-CA 125.217 3.944 . . . . 1.0 110.612 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -141.51 95.04 2.76 Favored 'General case' 0 CA--C 1.531 0.241 0 O-C-N 121.54 -0.725 . . . . 1.0 109.38 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 77.7 p -76.72 132.87 39.56 Favored 'General case' 0 CA--C 1.53 0.191 0 O-C-N 121.47 -0.769 . . . . 1.0 109.452 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 63.0 mt -128.26 142.29 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 O-C-N 121.361 -0.837 . . . . 1.0 109.323 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -162.12 -177.26 5.63 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 121.456 -0.777 . . . . 1.0 109.421 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 29.8 m -93.01 141.41 24.06 Favored Pre-proline 0 CA--C 1.537 0.46 0 O-C-N 121.522 -0.737 . . . . 1.0 109.302 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.451 ' N ' ' HD2' ' A' ' 54' ' ' PRO . 3.0 Cg_exo -39.13 -60.39 0.51 Allowed 'Trans proline' 0 N--CA 1.488 1.172 0 C-N-CA 124.96 3.773 . . . . 1.0 111.179 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.451 ' HD2' ' N ' ' A' ' 53' ' ' PRO . 16.0 Cg_exo -36.36 -69.77 0.07 OUTLIER 'Trans proline' 0 N--CA 1.49 1.294 0 C-N-CA 124.95 3.767 . . . . 1.0 111.215 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -73.46 167.16 21.86 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 121.473 -0.767 . . . . 1.0 109.494 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -140.81 135.92 31.92 Favored 'General case' 0 CA--C 1.53 0.176 0 O-C-N 121.495 -0.753 . . . . 1.0 109.404 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -102.72 132.47 48.84 Favored 'General case' 0 CA--C 1.531 0.215 0 O-C-N 121.527 -0.733 . . . . 1.0 109.467 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 13.8 p -92.16 156.69 17.16 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 121.45 -0.781 . . . . 1.0 109.444 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -130.6 136.06 48.5 Favored 'General case' 0 CA--C 1.531 0.217 0 O-C-N 121.518 -0.739 . . . . 1.0 109.491 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 44.1 t80 . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.976 -1.011 . . . . 1.0 109.443 -179.964 . . . . . . . . 0 0 . 1 stop_ save_